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SUMMARY.
"
Dengue"virus" (DENV)" is"a"health"burden"responsible"of"50\100"million"new"cases"and"22,000"
deaths"per"year"and" its" four"serotypes"are"worryingly"spreading"out"of" the"endemic"regions."
Current"therapy" is"symptomatic,"making"antiviral"research"on"DENV"an"unmet"need."Vaccine"
development" is"more" challenging" than"expected," so" the"development"of" anti\DENV"drugs" is"
particularly" important" for" infection" management." DENV" is" a" positive" sense" single" stranded"
RNA"virus"that"replicates"within"cells"exploiting"both"host"and"viral"enzymes"to"replicate.""
Based" on" the" hypothesis" that" DENV" infection" can" be" stopped"with" the" inhibition" of" one" or"
more"of"the"enzymes"that"are"fundamental"for"its"replication,"the"aims"of"the"studies"reported"
in" this" PhD" thesis" were" to:" identify" novel" targets" to" combat" DENV" infection," generate" new"
basic"knowledge"and"discover"potential"novel" chemical" leads"exploiting" those" targets."Novel"
approaches" combining" molecular" modelling" techniques," classical" Medicinal" Chemistry"
approaches," chemical" synthesis" and" in& vitro" assays" were" applied" to" four" essential" viral\
encoded" proteins:" the" capsid" (C)," the" NS3" NTPase/helicase" (NS3hel)," the" NS5"
methyltransferase"(NS5"MTase)"and"the"NS5"RNA\dependent"RNA"polymerase"(NS5"RdRp).""
Novel"understanding"of"the"3’\5’"translocation"mechanism"of"NS3hel"along"the"RNA"has"been"
hypothesised,"increasing"awareness"about"DENV\encoded"proteins."
Important" knowledge" on" the" mode" of" action" of" promising" antiviral" compounds" has" been"
acquired,"for"example"that"ST\148"stabilises"C"protein\protein"interactions"and"that"published"
N\sulphonylanthranilic"acid"RdRp"inhibitors"bind"to"a"unique"allosteric"site."
Novel" promising" DENV" inhibitor" scaffolds" have" also" been" developed" and" the" chemical"
synthesis" of" one" of" them" has" been" described," showing" that" the" adopted" drug" discovery"
approaches"are"suitable"starting"points"for"the"development"of"anti\DENV"medicines."
The"results"obtained"represent"a"significant"contribution"to"DENV"research"in"increasing"basic"
knowledge"and"in"identifying"good"chemical"leads"for"future"work."
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ADE" "Antibody\Dependent"
Enhancement"
ADME" Adsorption,"Distribution,"
Metabolism,"Excretion"
AFMB" Architecture"Et"Function"Des"
Macromolécules"Biologiques"
AMBER" Assisted"Model"Building"with"
Energy"Refinement"
aMD" Accelerated"Molecular"
Dynamics"
AMPPNP" Adenosine"5’\(β,γ\imido)"
Triphosphate"
anchC" Anchored"Capsid"Protein"
ATP" " Adenosine"Triphosphate"
!XII"
B" " Weighting"Factor"for"Eelec"
BDV" " Border"Disease"Virus"
BLAST" Basic"Load"Alignment"Search"
Tool"
BSA" " Bovine"Serum"Albumin"
BVDV" " Bovine"Viral"Diarrhoea"Virus"
c" " Weighting"Factor"for"Epair"
C" " Capsid"Protein"
CC" " Non\Infected"Cells"Control"
CC50" "Half"Maximum"Cytotoxic"
Concentration"
CDC" " Center"for"Disease"Control"
CG" " Conjugated"Gradient"
CH3COOH" Acetic"Acid"
CHCl3" " Chloroform""
cMD" Calssical"Molecular"Dynamics"
CPE" " Cytopathic"Effect"
CPU" " Central"Processing"Unit"
CS" " Consensus"Score"
CSFV" " Classical"Swine"Fever"Virus"
d" " Doublet"
D1" " Domain"1"
D2" " Domain"2"
D3" " Domain"3"
DALYs" " Disability\Adjusted"Life"Years"
DCM" " Dichloromethane"
DENV" " Dengue"Virus"
DENV1" " Dengue"Virus"Serotype"1"
DENV2" " Dengue"Virus"Serotype"2"
DENV3" " Dengue"Virus"Serotype"3"
DENV4" " Dengue"Virus"Serotype"4"
DENV5" " Dengue"Virus"Serotype"5"
DF" " Dengue"Fever"
DHF" " Dengue"Haemorrhagic"Fever"
DHODH" "Dihydroorotate"
Dehydrogenase"
DIHED" Average"Dihedral"Energy"
DIPEA" N,N\diisopropylethilamine"
DMSO" " Dimethyl"Sulfoxide""
DNA" " Deoxyribonucleic"Acid"
DTT" " Dithiothrethiol"
dsRNA" " Double"Stranded"RNA"
DSS" " Dengue"Shock"Syndrome"
E" " Envelope"Protein"
E" "Threshold"Energy"(in"aMD"
calculations"
Eattr" "Attractive"Energy"
Contribution"
Ebend" "Energy"Related"to"Angle"
Bending"
ECoul" Coulombic"Energy"
Edes" Desolvation"Energy"for"Each"
Ligand’s"Atom"
Edihed" Dihedral"Threshold"Energy"
Eelec" Electrostatic"Energy"
Contribution"
Eflex" Energy"Correlated"to"the"
Ligand’s"Loss"in"Flexibility"
Eh\bond" Energy"Associated"With"
Hydrogen"Bonds"
Emetal" Energy"Associated"With"Metal"
Interactions"
EMM" "Molecular"Mechanics"Related"
Energy"
Epair" Desolvation"Energy"
Contribution"
Epot" Potential"Threshold"Energy"
Erep" Repulsive"Energy"
Contribution"
Esol" " Solvation"Energy"
Estr" Energy"Related"to"Bond"
Stretching"
Etors" "Energy"Related"to"Dihedral"
Torsions"
Etot" Total"Energy"
EvdW" "Van"der"Waals"Energy"
EC50" "Half"maximum"Effective"
Concentration""
EDTA" Ethylenediaminetetracetic"
Acid"
EJC" " Exon"Junction"Complex"
ELISA" "Enzyme\Linked"
Immunosorbent"Assay"
EM" " Energy"Minimization"
ER" " Endoplasmic"Reticulum"
ESI" " Electrospray"Ionisation"
!XIII"
Et" " Ethyl"
EtOAc" " Ethyl"Acetate"
EtOH" " Ethanol"
F" " Force"
FBDD" " Fragment"Based"Drug"Design"
fCHEMPLP" CHEMPLP"Scoring"Function"
FIOCRUZ" Oswaldo"Cruz"Foundation"
FP" " Fluorescence"Polarisation"
fPLP" " PLP"Scoring"Function"
Gcomplex" " Complex"Free"Energy"
Gligand" " Ligand"Free"Energy"
Greceptor" " Receptor"Free"Energy"
GAFF" " General"Amber"Force"Field"
GAG" " Glycosaminoglycan"
GB" " Generalized\Born"
GI" " Gastrointestinal"
Glide" "Grid\Based"Ligand"Docking"
with"Energetics"
GDP" Guanosine"Diphosphate"
GMP" " Guanosine"Monophosphate"
GPU" " Graphics"Processing"Unit"
GROMACS" GROningen"Machine"for"
Chemical"Simulations"
GSK" "GlaxoSmithKline"
GTP" " Guanosine"Triphosphate"
h" " Hours"
H2SO4" " Sulphuric"Acid"
H3PO4" " Phosphoric"Acid"
HCl" " Hydrochloric"Acid"
HCV" " Hepatitis"C"Virus"
HIV" "Human"Immunodeficiency"
Virus"
HMG\CoA" 3\Hydroxy\3\Methylglutaryl\
Coenzyme"A"
HS" Heparan"Sulphate"
HSO3Cl" Chlorosulphonic"Acid"
HTS" " High"Throughput"Screening"
HTVS" "High"Throughput"Virtual"
Screening"
I" " Self"Volume"Overlap"
IC50" "Half"Maximal"Inhibitory"
Concentration""
ICAR" "International"Conference"On"
Antiviral"Research"
ICTV" "International"Committee"On"
Taxonomy"Viruses"
IFN\γ" " Interferon\γ"
IFN\α/β" " Interferon\α/β"
IgG" " Immunoglobulin"G"
IgM" " Immunoglobulin"M"
IMP" " Inosine"Monophosphate"
IMPDH" "Inosine"Monophosphate"
Dehydrogenase"
ISAR" "International"Society"for"
Antiviral"Research"
J" Coupling"Constant""
JEV" " Japanese"Encephalitis"Virus"
Kd" " Dissociation"Constant"
LAV" " Life"Attenuated"Vaccines"
LD" " Lipid"Droplet"
LDL" " Low"Density"Lipoprotein"
LGTV" " Langat"Virus"
LID" "Laboratory"of"Infectious"
Diseases"
M" " Envelope"Glycoprotein"M"
m" " Mass"
m" " Multiplet"(in"NMR"spectra)"
M\H+" "Molecular"Ion"Signal"Given"By"
The"Addition"Of"A"H+"Ion"
M\Na+" "Molecular"Ion"Signal"Given"By"
The"Addition"Of"A"Na+"Ion"
m/z" Mass"To"Charge"Ratio"
MD" " Molecular"Dynamics"
Me" " Methyl"
MeOH" " Methanol"
MM" " Molecular"Mechanics"
MMFF94x" Merck"Molecular"Force"Field"
(94x)"
MMGBSA" Molecular"Mechanics"
Generalized"Born"Surface"
Area"
MMPB(GB)SA" Molecular"Mechanics"
Poisson\Boltzmann"(and"
Generalized"Born)"Surface"
Area"
!XIV"
MMPBSA" Molecular"Mechanics"
Poisson\Boltzmann"Surface"
Area"
MODV" Modoc"Virus"
MOE" "Molecular"Operating"
Environment"
mRNA" " Messenger"RNA"
MTase" " Methyltransferase"
MVD" "Mavalonate(diphospho)"
Decarboxylase"
MW" " Molecular"weight"
NaOH" " Sodium"Hydroxide"
NCS" " Normalised"Consensus"Score"
ND" " Not"Determined"
NI" " Nucleoside"Inhibitor"
NIAID" "National"Institute"of"Allergy"
and"Infectious"Diseases"
NIH" " National"Institute"of"Health"
NITD" "Novartis"Institute"for"Tropical"
Disease"
NLS" "Nuclear"Localisation"
Sequence"
NME" New"Molecular"Entity"
NMR" " Nuclear"Magnetic"Resonance"
NMRC" "Naval"Medical"Research"
Center"
NNI" " Non\nucleoside"Inhibitor"
NPT" Constant"Number"of"Atoms,"
Pressure"and"Temperature"
Conditions"
NS" " Non"Structural"Protein"
NS1" " Non"Structural"Protein"1"
NS2A" " Non"Structural"Protein"2A"
NS2B" " Non"Structural"Protein"2B"
NS3hel" Non"structural"Protein"3"
Helicase"
NS3pro" Non"Structural"Protein"3"
Protease"
NS4A" Non"Structural"Protein"4A"
NS4B" Non"Structural"Protein"4B"
NS5"MTase" Non"Structural"Protein"5"
Methyltransferase"
NS5"RdRp" Non"Structural"Protein"5"
RdRp"
NSAIDS" Non\Steroidal"Anti\
Inflammatory"Drugs"
NTP" " Nucleoside"Triphosphate"
NTPase" " Nucleoside"Triphosphatase"
NVT" Constant"Number"of"Atoms,"
Volume"and"Temperature"
Conditions"
o" Offset"Constant"
Of,g" Orientation\Dependent"
Overlap"
OPLS" Optimized"Potential"for"
Liquid"Simulations"
ORF" " Open"Reading"Frame"
p." " Peptide"
P\loop" " Priming"Loop"
PB" " Poisson\Boltzmann""
PBC" " Periodic"Boundary"Conditions"
PC" " Principal"Component"
PCA" " Principal"Component"Analysis"
PCl5" " Phosphorous"Pentachloride"
PCR" "Polymerase"Chain"Reaction"
PDB" " Protein"Data"Bank"
PDB"ID" " PDB"Identification"
PIV" " Purified"Inactivated"Virus"
Pk" " Pharmacokinetics"
PLANTS" " Protein\Ligand"ANT"System"
PME" " Particle"Mesh"Ewald"
POCl3" " Phosphorous"Oxychloride"
polyU" " Poly\Uridine"
POT" " Average"Potential"Energy"
ppA\RNA" RNA"With"5’"Diphosphate"
Adenine"
PPI" " Protein\Protein"Interaction"
pppA\RNA" RNA"With"5’"Triphosphate"
Adenine"
PR\MD" Position"Restrain"Molecular"
Dynamics"
prM" " M"Protein"Precursor"
PV" " Powassan"Virus"
Py" " Pyridine"
q" " Quartet""
!XV"
Q1" " First"Quartile"
QM" " Quantum"Mechanics"
QSAR" Quantitative"Structure\
Activity"Relationships"
r.t." Room"Temperature"
R&D" Research"And"Development"
RC" " Replication"Complex"
RdRp" RNA"Dependent"RNA"
Polymerase"
RMSD" " Root"Mean"Square"Deviation"
RMSF" "Root"Mean"Square"
Fluctuation"
RNA" " Ribonucleic"Acid"
RNAse" " RNA"Triphosphatase"
(\)RNA" " Minus\Stranded"RNA"
S" " Entropy"
s" "Gain/Loss"of"the"Ligand"
Rotational"And"Translational"
Entropy"
s" Singlet"(in"NMR"spectra)"
s.m." " Small"Molecule"
Sf,g" Shape"Similarity"Between"
Two"Molecules"(f"and"g)"
SAH" " S\Adenosyl\Homocystein"
SAM" " S\Adenosyl\L\Methionine"
SAR" "Structure\Activity"
Relationship"
SASA" Solvent"Accessible"Surface"
Area"
SD" Steepest"Descend"
SF" " Superfamily"
SF2" " Superfamily"2"
SI" " Selectivity"Index"
SO" " SYPRO"ORANGE"
SO3H" " Sulphonate"
SP" " Standard"Precision"
ssRNA" " Single"Stranded"RNA"
(+)ssRNA" Positive"Sense"Single"
Stranded"RNA"
St."Dev." Standard"Deviation"
T" Temperature"
t" Triplet"
Tf,g" Tanimoto"Index"for"
Molecules"f"and"g"
Tm" Melting"Temperature"
TBEV" Tick\Borne"Encephalitis"Virus"
TEMED" Tetramethylethylendiamine"
TGN" " Trans\Golgi"Network"
TLC" " Thin"Layer"Chromatography"
TPSA" " Total"Polar"Surface"Area"
Tris" Tris(hydroxymethyl)aminoe\
thane"
TSA" " Thermal"Shift"Assay"
USA" " United"States"of"America"
UTR" " Untranslated"Region"
UV" " Ultraviolet"
V(r)" " Potential"
V*" " Modified"Potential"
VC" " Infected"Cells"Control"
VLDL" Very"Low"Density"
Lipoproteins"
VMD" " Visual"Molecular"Dynamics"
VS" " Virtual"Screening"
VSV" " Vesicle"Stomatitis"Virus"
WEEV" "Western"Equine"Encephalitis"
Virus"
WHO" " World"Health"Organization"
WNV" " West"Nile"Virus"
WRAIR" "Walter"Reed"Army"Institute"
of"Research"
WT" Wild"Type"
XMP" Xantosine"Monophosphate"
XP" " Extra"Precision"
YFV" " Yellow"fever"Virus"
"
"
"
!XVI"
AMINO'ACID'ABBREVIATIONS'
"
Ala" (A)" "Alanine"
Asn" (N)" Asparagine"
Asp" (D)" Aspartic"acid"
Arg" (R)" Arginine"
Cys" (C)" Cysteine"
Glu" (E)" Glutamic"acid"
Gln" (Q)" Glutamine"
Gly" (G)" Glycine"
His" (H)" Histidine"
HID" " His"with"H"on"the"Nδ"
HIE" " His"with"H"on"the"Nε"
HIP" " Positively"charged"His"
Ile" (I)" Isoleucine"
Leu" (L)" Leucine"
Lys" (K)" Lysine"
Met" (M)" Methionine"
Phe" (F)" Phenylalanine"
Pro" (P)" Proline"
Ser" (S)" Serine"
Thr" (T)" Threonine"
Trp" (W)" Tryptophan"
Tyr" (Y)" Tyrosine"
Val" (V)" Valine"
"
NUCLEOTIDE'ABBREVIATIONS'
"
A" Adenine"
C" Cytosine"
G" Guanine"
U" Uracil
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1.1.DENGUE.VIRUS..
"
EPIDEMIOLOGY'
"
In"the"last"50"years,"the"increasing"spread"of"dengue"virus"(DENV)"has"captured"the"attention"
of" the"Scientific"World" to" this"neglected,"emerging"and" life\threatening"pathogen."The"exact"
period" when" this" agent" first" affected" humans" is" not" certain," mainly" because" often" the"
symptoms" of" the" DENV" related" diseases" are" misinterpreted" and" records" are" not" accurate,"
making" evolutionary" epidemiology" studies" challenging.[1]" The" first" report" of" DENV\related"
diseases" in" human"derives" from"a" Chinese"medical" encyclopaedia"written" between" 265\420"
A.D." In" the" text," the" disease"was" defined" as" “water" poison”," from" the" association"with" the"
mosquito\vector,"which" is" a"water\related" insect.[2,3]" The" subsequent" reports" belong" only" to"
the" 17th" Century" and" documentation" asserts" that" by" the" 18th" century," DENV" was" causing"
epidemics," in"particular" in" two"continents,"Asia"and"America." In" the" following"two"centuries,"
sailing" ships" and" the" slave" trade" caused" the" virus" to" spread" widely," mainly" in" tropical" and"
subtropical"regions,"reaching"pandemic"proportions.[3,4]"Four"DENV"serotypes"(DENV1,"DENV2,"
DENV3," DENV4)" are" currently" infecting" humans" and" they" are" now" all" present" in" endemic"
regions.[5]"More"details"on"DENV"serotypes"are"in"the"TAXONOMY"chapter"of"this"introduction."
In"recent"decades"the"World"Health"Organisation"(WHO)"has"registered"a"worrying"increase"in"
the"number"of"new"cases"of"dengue"infection.[4]"For"example,"in"the"period"between"the"years"
2000\2004," the"accrued"cases" (925,896" infections)"were"almost"double"of" the"ones"between"
1990\1999" (479,848" infections).[5]" The" WHO" 2014" report" shows" a" 30\fold" increase" of" the"
incidence"in"the"last"50"years,"reaching"a"value"of"around"50\100"million"new"cases"per"year.[6]"
The"disease"is"endemic"in"over"100"tropical"and"sub\tropical"countries"worldwide"(Africa,"the"
Americas,"the"Eastern"Mediterranean,"South\East"Asia"and"the"Western"Pacific)"and"the"most"
seriously" affected" are" in" the" American," South\East" Asia" and" the"Western" Pacific" continents,"
where" between" 2008" and" 2010" the" number" of" cases" has" almost" doubled" (from" 1.2" to" 2.3"
million"cases).[6,7]""
Besides"imported"cases,"DENV"can"also"be"responsible"for"epidemic"outbreaks"that"have"been"
registered" also" outside" the" endemic" regions." In" the" last" five" years," outbreaks" have" been"
recorded"worldwide,"e.g."Yunnan,"Honduras,"Costa"Rica,"Mexico,"Laos,"Cook"Islands,"Malaysia,"
Fiji," Vanuatu" and" in" Singapore." The" latter" country" had"been" able" to" eradicate" the"mosquito"
vector"and"the"virus,"but"now"cases"are"currently"reappearing.[6]"Similarly,"the"disease"has"re\
emerged" in" Japan" after" 70" years,"with" novel" cases" of" “domestic\acquired”" infections.[8]" The"
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most" severe" outbreak" in" Europe" was" recorded" in" 2012" in" the" Madeira" Islands" (Portugal),"
where" more" than" 2000" cases" were" diagnosed." Local" DENV" transmission" was" recognised" in"
France"and"Croatia"in"2010.[6,9]"DENV"infections"were"also"recorded"in"the"USA,"in"Texas"and"in"
particular" in"Florida,"where"DENV" is"now"autochthonous.[9]"The"described"global"distribution"
and"outbreaks"of"signalled"DENV"infection"cases"are"represented"in"Figure"1.1.""
"
!
Figure'1.1..Geographic.distribution.of.DENV..
The"countries"where"DENV"is"endemic"are"coloured"in"red,"while"the"countries"where"DENV"is"absent"are"in"green."
Intermediate"situations"are"coloured"in"yellow"and"in"orange."The"approximate"location"of"the"tropics"is"shown"with"
blue"lines."The"outbreaks"cited"in"the"text"are"highlighted"with"black"stars..
All" this" puts" approximately" 40%"of" the"World’s" population" (2.5\3.5" billion" people)" at" risk" of"
infection."The"risk"applies" to"not"only"people" that" live" in" tropical"and"sub\tropical"areas,"but"
also"travellers"that"come"back"from"these"places:"for"this"class"of"people,"dengue"has"become"
the" most" common" cause" of" illness," beating" even" malaria" and" gastro\intestinal" diseases."
Statistics"have"shown"that"around"500,000"people"(children"in"particular)"need"hospitalization"
for"severe"dengue"every"year"and"that"2.5%"of"the"severely"affected"(about"22,000"people)"die"
every"year.[2,6,7,10]""
These"are"the"official"numbers,"but"the"calculation"of"incidence"cannot"be"considered"accurate"
for"more"than"one"reason."First"of"all,"primary"dengue"infections"are"sometimes"asymptomatic"
or"the"symptoms"are"misinterpreted"because"they"can"be"very"similar"to"other" illnesses," like"
influenza" (see" the" CLINICAL& FEATURES" chapter" of" this" introduction" for" a" more" accurate"
description" of" the" clinical" aspects" of" the" infection)." This" leads" to" a"miscounting" of" the" real"
cases" of" dengue" infection," in" particular" in" non\endemic" regions" where" there" is" lower"
familiarity"with"the"disease."Another"issue"is"that"some"Nations,"particularly" in"Africa,"do"not"
have" an" adequate" surveillance" system" for" the" detection" of" the" disease" cases" among" the"
population,"decreasing"the"information"about"the"exact"extent"of"the"disease.[9,11]"
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A"recent"systematic"search"of"published"literature"and"online"resources,"reported"an"evidence\
based"map"of"dengue"risk"and"estimated"worldwide"dengue\related"infections"on"the"basis"of"
the"population"of"2010.[12]" In"accordance"with"the"WHO"figures,"the"new"infection"estimates"
located"the"virus" in" the" tropical"and"subtropical"areas."The"actual"number"of" infections"was,"
however,"projected"to"be"about"three"times"higher"than"the"one"reported"by"the"WHO."This"
disparity"between"actual" (or"modelled)"and"reported" infection"numbers"has"been"explained,"
as"mentioned"above,"by" the" fact" that" there" is"a" low"proportion"of" infected"people" that"seek"
care"from"formal"health"facilities"and"that"often"misdiagnosis"leads"to"cases"miscalculation."
Similarly" to" other" tropical" diseases," including" tuberculosis," the" viral" infection" produces"
approximately"1,300"disability\adjusted" life" years" (DALYs)"per"million"people" in" the"endemic"
countries.[5]"Adding" this" to" the"official"number"of"cases"and"the"costs" for"hospitalisation"and"
therapies," it"has"been"estimated"that"the"global"annual"economic"burden"of"DENV"is"around"
1.7"billion"dollars.[13]"From"these"numbers,"it"is"clear"that"even"only"considering"the"WHO"case"
reports,"DENV"infection"has"a"high"health"and"economic"cost"that"needs"to"be"tackled."
"
TRANSMISSION'
"
All" four" DENV" serotypes" exist" in" two" possible" transmission" cycles" that" are" ecologically" and"
evolutionary"distinct:"sylvatic"and"human."In"both"cases"the"transmission"is"aided"by"mosquito"
vectors"belonging" to" the"Aedes" family,"but" from"different" species"according" to" the" reservoir"
hosts.[3]" Sylvatic" transmission" occurs"mainly" in" the" arboreal" areas" of"Malaysia" and" Senegal."
Human\to\human" DENV" transmission" has" a" more" worldwide" spread" and" is" generally"
predominant," apart" from" West" Africa" where" the" sylvatic" cycle" is" more" diffused.[14]" In" the"
sylvatic"cycle,"the"amplification"and"reservoir"hosts"are"non\human"primates"and"the"mosquito"
vectors"are"Aedes"species"that"live"in"arboreal"environments."In"the"human"transmission"cycle,"
the" only" amplification" and" reservoir" hosts" are" humans" and" the" mosquito" vectors," Aedes&
aegypti& and" Aedes& albopictus," have" adapted" to" live" in" domestic" and" peridomestic"
environments." Occasionally," arboreal" Aedes" mosquitoes" feed" on" humans" and" it" has" been"
hypothesised"that"this"behaviour"might"be"the"cause"of"occasional"transfers"of"DENV"from"the"
sylvatic" to" peridomestic" environments," as" well" as" the" origin" of" the" onset" of" human"
infections.[1,3]""
Aedes&aegypti"and"Aedes&albopictus"have"a"very"precise"phenotype:"they"are"small,"dark"with"
white"markings"and"with"banded"legs."Because"of"these"peculiar"features,"they"are"commonly"
called"“tiger"mosquitoes”."The"most"usual"vector"for"DENV"is"the"Africa"native"Aedes&aegypti,"a"
highly" adaptable" species" that" lives" closely"with" humans" and"within" human" habitations." The"
other"type"of"mosquito,"Aedes&albopictus,"is"originally"from"Southeast"Asia."It"is"less"common,"
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but"is"not"a"less"efficient"vector"as"its"habitat"is"related"to"the"peridomestic"environment."Both"
arthropod"larvae"have"been"found"not"only"in"natural"environments"like"tree"holes,"but"also"in"
artificial"and"occasional"containers"of"water,"such"as"water"jars"and"buckets,"or"even"discarded"
tyres.[2,14\16]"
The"viral"transmission"occurs"through"the"bite"of"a"female"mosquito"belonging"to"one"of"these"
two"species."The"mosquito"comes"in"contact"with"the"pathogenic"agent"in"consequence"of"its"
feeding"on"an"infected"person"during"the"person’s"period"of"viremia"and"after"a"brief"phase"of"
incubation" (7\10" days)" the" insect" probably" remains" infectious" for" the" rest" of" its" life"
(approximately"2"weeks).[11]"As"human"beings"are"the"major"host"for"DENV,"the"transmission"is"
usually" between" people" via" the" insect" vector." Other" methods" of" transmission," like"
transfusions,"are"rare.[2,4]""
There"is"a"clear"association"between"the"regions"with"a"high"incidence"of"DENV"infection"and"
the" large" presence" of" Aedes" infestations," as" the" climate," in" terms" of" temperature" and"
precipitations,"is"favourable"for"the"mosquitos’"survival."Figure"1.2"shows"how"mosquitoes"and"
DENV" infection" distributions" overlap" and" that" the" two" species" often" coexist" in" the" same"
regions." These" territories" are" frequently" characterized" by" high" grades" of" poverty" that"
translates"into"a"lack"of"suitable"treatment"and"prevention"of"the"disease,"contributing"to"the"
endemic"behaviour"of"the"infection.[2]""
"
!
Figure'1.2..Geographic.distribution.of.A.'albopictus.and.A.'aegypti..
The"countries"where"DENV"is"endemic"are"coloured"with"grey"shades,"where"the"darker"colour"corresponds"to"
higher"presence"of"DENV."The"presence"of"Aedes"mosquitoes"is"indicated"with"coloured"circles:"red"for"A.&albopictus"
and"green"for"A.&aegypti.""
The"increase"of"the"incidence"of"dengue\correlated"infections"is"associated"with"the"increase"
of"the"global"population,"in"particular"with"the"uncontrolled"growth"of"the"population"in"South"
East" Asia" and" Africa," and" it" is" also" linked" to" the" spread" of" the" virus" to" new," uninfected"
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countries." The" increasing" movement" of" people" and" goods" between" different" countries," in"
combination" with" the" drought\resistance" of" the" mosquito" eggs," has" allowed" egg"
transportation" and" consequent" settlement" of" the" Aedes" mosquito" in" countries" other" than"
their"native"ones"in"the"tropical"and"subtropical"areas"of"Africa"(A.&aegypti)"and"Southeast"Asia"
(A.&albopictus).[2,11,14,15]""
The" adaptation" of" the"mosquitoes" in" new" territories" depends" on" both" climatic" factors" and"
landscape"features."Climatic"factors"refer"mainly"to"winter"temperatures"and"precipitation,"as"
low" values" of" both" parameters" are" not" compatible" with" the" mosquito" survival." As" both" A.&
aegypti"and"A.&albopictus"are"weak"flyers,"the"proximity"with"humans"is"also"fundamental"and"
makes" land"utilization"another" important"parameter" in"vector"distribution.[14\17]"Not"all"areas"
where"either"mosquito"is"now"established"are"also"endemic"for"DENV"infection."However,"the"
presence" of" either" mosquito" increases" the" probability" of" the" establishment" of" DENV" as" an"
autochthonous" disease." In" a" first" instance," autochthonous" mosquitoes" could" then" become"
infected" from" infected" travellers;" alternatively," infected" mosquitoes" could" be" transported"
through"goods"merchandising.[9]"For"example,"in"some"European"countries"(e.g."Italy,"Greece,"
France),"newly"established"populations"of"Aedes&albopictus"have"been"observed,"and"most"of"
Europe"can"be"considered"a"favourable"habitat"for"this"arthropod."For"the"moment,"the"cases"
of" dengue" fever" in" Europe" have" been"diagnosed"mostly" in" returning" travellers."However," in"
particular"after"the"European"outbreaks,"it"is"expected"that"in"the"future"there"will"be"seen"a"
diffusion" of" the" infection" also" in" this" continent.[2,11,15,18]" Similarly," it" is" estimated" that" the"A.&
albopictus"distribution" in"North\eastern"USA"will"put"at"risk"of"DENV"infection"approximately"
30"million"people"that"inhabit"those"areas.[17]"
"
TAXONOMY'
"
Virology"is"a"very"young"branch"of"science"as"the"understanding"of"viral"agents"began"only"in"
the"late"19th"Century,"when"viruses"were"“infectious"living"fluids”"that"could"pass"the"bacteria\
retaining"filters"(with"0.3μm"pores)."Currently,"viruses"are"defined"as"pathogenic"entities"that"
pass" bacteria\retaining" filters" and" possess" a" DNA" or" RNA" genome" that" is" used" for" their"
multiplication."As"they"are"not"able"to"grow"and"undergo"binary"fusion,"to"produce"energy"and"
do" not" have" a" complete" translation"machinery," they" use" the" host" structures" and" therefore"
they"are"obligatory"parasites."The"definition"of"virus" is" in"continuous"evolution."For"example,"
the" recent" discovery" of" so" called" “giant" viruses”" (like" Mimi\," Mega\" and" Pandora\)" is"
introducing" the" possibility" of" the" existence" of" viruses" that" can" be" bigger" than" some" small"
bacteria," undermining" the" importance" of" particle" dimension" in" the" definition.[19,20]"
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Furthermore,"in"these"last"100"years"an"even"more"basic"question"than"the"definition"of"a"virus"
has"not"yet"been"resolved:"are"viruses"a"form"of"life"or"not?[20]""
Although" virology" is" a" young" science," and" major" issues" are" still" under" discussion," a" huge"
number"of"viruses"have"been"discovered," leading" to" the"need" to"categorize" them."However,"
the" lack" of" clarity" to" the" basic" question" above" renders" difficult" the" application" of" classical"
taxonomy" methods." For" this" reason," the" International& Committee& on& Taxonomy& of& Viruses"
(ICTV)[21]" has" established" a" specific" taxonomy" classification" for" viruses," composed" of:" order"
(not"for"all"the"viruses),"family,"genus"and"species.[20,21]""
Dengue"virus" is"classified"within"the"Flaviviridae" family."This" family" includes"several"different"
positive"sense"single"stranded"RNA"viruses"that"can"be"divided"into"3"genera,"all"of"which"have"
common" characteristics:" they" are" all" small" (approximately" 40\50nm)"enveloped" viruses"with"
the"same"general"replication"cycle.[22]"One"genus"is"Hepacivirus,"named"after"the"Greek"word"
“hepatos”"(liver)"because"the"most"famous"member"of"the"genus"is"the"hepatitis"C"virus"(HCV)"
that"targets"mainly"liver"cells."Another"genus"is"Pestivirus,"named"after"the"Latin"name"“pestis”"
(plague)" as" the" viruses" implicated" (bovine" viral" diarrhoea" virus," BVDV;" classical" swine" fever"
virus,"CSFV;"border"disease"virus,"BDV)"cause"economically"important"diseases"in"animals."The"
viruses" belonging" to" these" two" genera" do" not" use" arthropod" vectors" for" their" transmission,"
differing" from"DENV." For"example,"HCV" is" transmitted" though"direct"blood" contact"with" the"
virus,"possible" in"certain"circumstances," like"blood"transfusion"or"the"use"of" infected"medical"
equipment."The"third"genus"belonging"to"the"Flaviviridae"family"is"Flavivirus,"named"after"the"
Latin"word"“flavus”"(yellow)"as"the"first"discovered"virus"belonging"to"this"genus"is"the"yellow"
fever"virus"(YFV)"that"causes"very"high"fevers"and"in"some"cases" liver"damage"that" induces"a"
yellow" colouration" to" the" patient" (skin" and" eyes)." DENV," as" also" West" Nile" virus" (WNV),"
Japanese" encephalitis" virus" (JEV)" and" many" others" (at" least" 73" distinct" viruses" have" been"
determined"to"date),"belong"to"this"last"genus"and"several"of"them"are"human"pathogens.[22\24]""
In" human" infections," the" known" antigenically" distinct" serotypes" of" DENV," sharing" about" 65\
70%" of" sequence" homology," are" four" (DENV" 1\4)" and" they" coexist" in" the" same" geographic"
regions.[4,7,10]" A" fifth" DENV" serotype" (DENV5)" has" been" discovered" recently" in" Malaysia."
However,"to"date"it"has"only"been"observed"in"the"sylvatic"cycle"and"not"in"humans.[25]""
The" causes" of" the" serotypes" differentiation" are" still" not" clear," but" it" has" been" hypothesised"
that"each"serotype"has"evolved"from"a"different"sylvatic"progenitor"that"was"transmitted"from"
the"sylvatic"cycle"to"humans.[1,3]"From"a"clinical"point"of"view,"association"of"the"serotypes"with"
the"transmission"efficiency"and"with"disease"severity"are"still"not"clear.[2]"However,"a"severity"
increase"of"a"secondary"DENV"infection"has"been"observed"when"the"sequential"infections"are"
DENV1"and"then"DENV2"or"DENV3,"or"DENV3"and"then"DENV2.[5]""
"
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CLINICAL'FEATURES'
"
Independently" of" the" serotype," DENV" is" correlated" to" a" broad" spectrum" of" diseases," with"
different" grades" of" severity," from" asymptomatic" to" fatal." Infection"with"DENV" starts" after" a"
variable"period"of"incubation"(from"2"days"to"2"weeks)"following"viral"inoculation"from"a"vector"
bite.[2,7,26]" If" it" is" a" primary" infection," it" can" be" asymptomatic" or" cause" a" self\limiting" flu\like"
disease" called" dengue" fever" (DF)" that" can" give" many" different" clinical" responses." Children"
usually"are"affected"by"a"flu\like"fever"with"cough,"vomiting"and"abdominal"pain."Adults"usually"
present" a" 5" to" 6" days" long" fever" with" chills," headache" (especially" retro\orbital" or" frontal),"
lethargy," musculoskeletal" pains," exanthema," leukopenia," transaminase" elevation" and"
thrombocytopenia.[2,26,27]"It"has"commonly"been"observed"at"skin"and"mucosal"surfaces,"minor"
bleeding" and" rash" and" in" patients" with" peptic" ulcer" DF" worsens" the" patient" condition." The"
highest"viremia"titers"(between"105"and"106"units/ml)"can"be"found"during"the"febrile"period,"
after"which"the"values"drop."Sometimes,"even"if"the"infection"is"not"too"severe,"the"recovery"
can"be"complicated"by"fatigue"and"depression.[2,7,11,27]"
The" primary" infection," caused" by" any" of" the" four" serotypes" and"with" any" grade" of" severity,"
produces" a" lifelong" immunity" to" that" serotype," but" only" an" approximately" 6" months" long"
immunity" to" the" other" serotypes." After" this" period," a" secondary" infection" with" a" different"
serotype" to" the" primary" one," leads" to" more" serious" diseases:" dengue" haemorrhagic" fever"
(DHF)" and" dengue" shock" syndrome" (DSS)." Both" of" them" are" particularly" severe" in" young"
children." Additionally" to" fever" and" many" of" the" DF" symptoms," DHF" causes" an" increased"
vascular" permeability" with" leakage" of" plasma" into" the" interstitial" space," thrombocytopenia,"
leukopenia," altered" homeostasis" and" liver" damage." The" viremia" titers" are" usually" 10" to" 100"
fold"higher"that"in"DF."DSS"is"a"complication"of"DHF"caused"by"a"very"high"loss"of"liquid"in"the"
interstitial" space" that" produces" hypovolemic" shock," with" severe" and" continuous" abdominal"
pain," fainting," perspiration," persistent" vomiting" and" high" risk" of" circulatory" failure" and"
death.[2,5,26,27]"
The"fact"that"a"secondary"infection"is"more"severe"than"a"primary"infection"is"attributed"to"a"
mechanism" called" antibody\dependent" enhancement" (ADE)." In" this" situation," antibody"
particles"of"a"different"serotype"are"able"to"bind"viral"particles,"forming"a"complex,"without"the"
ability"of"neutralising"the"pathogen."This"complex"is"then"taken"up"into"cells"that"express"the"
Fc" receptor" (e.g." phagocytes)." This" produces" an" enhancement" of" the" non\neutralized" viral"
particle" entry" into" the" Fc" expressing" cells." Consequently," a" higher" number" of" viral" particles"
successfully"infect"cells,"leading"to"a"more"severe"disease,"like"DHF"and"DSS.[7,11,26\28]"
In" addition" to" the" virulence" of" the" virus" and" to" the" infection" history" (ADE)," the" severity" of"
DENV" infection" is" also" linked" to" age," gender," host" genotype" and" pre\existing" comorbidities."
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Probably"due"to"intrinsic"higher"endothelium"permeability,"children"have"been"found"to"have"a"
greater"prevalence"of"DHF"and"DSS"with" respect" to"adults." Interestingly,"girls"generally"have"
higher"DSS"and"death"cases"than"males."This"is"probably"due"to"physiologically"immunological"
differences"between"genders,"but"unfortunately"the"cultural"factor"of"difference"in"health\care"
seeking" behaviour" in" endemic" countries" cannot" be" excluded." Furthermore," DENV" interacts"
with"many"human" receptors" and" factors" (see"BIOLOGY" chapter)," therefore"mutations" in" the"
host"genotype"involving"these"structures"can"reduce"viral"susceptibility."Finally,"DENV"can"be"
life\threatening" (with" 70%" of" fatalities" in" some" cases)" in" individuals" with" pre\existing"
comorbidities."Examples"of"these"comorbidities"are"asthma"and"diabetes.[5,24]""
"
BIOLOGY'
" "
""""""""A" "B"
Figure'1.3..Images.of.a.DENV.mature.virion...
A).Virion.surface.(PDB.1K4R)..Each"envelope"protein"(E)"surface"is"represented"here."The"three"E"monomers"are"
differently"coloured"(red,"light"blue"and"green)"for"a"better"visualisation"of"the"homotrimeric"structure..B).
Schematic.representation.of.the.viral.structure..The"envelope"bilayer"membrane"that"encloses"the"virion"is"
represented"in"dark"and"light"pink."E"proteins"are"represented"in"green"and"membrane"(M)"proteins"are"in"white."
The"disordered"nucleocapsid"is"coloured"in"blue"and"the"viral"genome"is"indicated"with"the"orange"line"binding"to"
the"capsid"protein"(C)."
DENV" is" a" small" spherical" virus" with" a" diameter" of" approximately" 50nm" presenting" a"
nucleocapsid"(electron\dense"core"of"30nm)"surrounded"by"an"envelope."As"shown"in"panel"A"
of"Figure"1.3,"the"overall"shape"of"the"mature"viral"particle"is"smooth"and"it"resembles"a"golf"
ball.[22]" The" external" envelope" has" an" outer" shell" constituted" of" 180" copies" of" two"
glycoproteins:" envelope" (E)" and" membrane" (M)." The" internal" portion" of" the" envelope" is"
constituted"by"a"lipid"bilayer"that"is"derived"from"host"cells."The"nucleocapsid"is"a"disordered"
construct,"constituted"by"the"complex"of"one"(+)ssRNA"molecule"that" interacts"with"multiple"
copies"of"the"capsid"protein"(C).[29,30]"Panel"B"in"Figure"1.3"shows"a"schematic"representation"of"
the"structural"elements"composing"a"DENV"virion"particle."
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The" initial" interaction" between" the" virus" and" a" target" cell" occurs" between" E" and" a" cellular"
receptor." The" exact" cell" targets" for" DENV" are" poorly" known," as" the" diseases" caused" by" this"
pathogen"are"systemic."Nevertheless,"it"is"established"that"during"the"incubation"period,"DENV"
replicates" in" proximity" to" the" site" of" inoculation," in" dendritic" cells," in" macrophages" and" in"
lymphocytes." Through" this" route" the" virus" eventually" reaches" the" blood" stream" and" at" this"
point" it" is" thought" that" the"main"cells" targeted"by"DENV"are" serotype\specific"depending"on"
the" serotype\specific" E" glycoprotein.[7,23]" Consequently," a" variety" of" cell" targets" have" been"
identified,"like"hepatocytes,"lymphocytes,"endothelial"cells,"neuronal"cells"and"muscle"satellite"
cells.[31]"The"specific"cell"receptors"that"trigger"the"virus"clathrin\mediated"internalization"are"
not"known"to"date,"but"it"has"been"shown"that"carbohydrate"molecules"on"host"cell"surfaces"
can" aid" viral" attachment" through" interaction"with" E" with" the" function" of" concentrating" the"
pathogen" and" facilitating" the" interaction" with" the" specific" receptor.[30]" It" has" been"
demonstrated"that"highly"sulphated"heparan"sulphate"(HS)"is"one"of"these"binding"factors"and"
putative"binding"motifs"were"located"in"the"E"protein."Interestingly,"the"high"heterogeneity"of"
the"structure"of"HS"on"cells" from"different" tissues"could"drive" the"tropism"of"DENV" in" target"
cell"binding.[32]""
Viruses" are" “obligatory" intracellular" parasites”," meaning" that" they" replicate" exploiting" the"
cellular" structures" as" they" are" missing" part" of" the" molecular" machinery.[20]" The" general"
replication" stages" change" between" groups" of" viruses," but" all" viruses" belonging" to" the"
Flaviviridae" family" follow" the" phases" schematised" in" Figure" 1.4." The" first" step" of" the" viral"
replication"cycle"(the"adsorption"of"the"virus"to"the"cell"surface)"is"followed"by"the"interaction"
with" the" specific" receptor" that" triggers" viral" entry" into" the" host" cell" through" a" clathrin\
mediated" endocytosis.[22\24]" Once" the" clathrin\coated" vesicles" have" entered" the" cytoplasm,"
they" fuse" with" endosomes." The" consequent" endosomatic" pH" decrease" triggers" the"
rearrangement" of" the" E" glycoprotein" from" a" dimer" into" a" monomer" state" and" then" into" a"
“fusion\active"trimeric"state”."These"changes"in"conformation"of"E"allow"the"viral"envelope"to"
fuse"with"the"endosomal"membrane,"releasing"the"viral"RNA"into"the"cytoplasm.[22\24]""
The" viral" nucleic" acid" has" three" important" roles" in" the" viral" replication" cycle:" it" acts" as" a"
messenger"RNA"(mRNA)"for"the"synthesis"of"the"viral"encoded"proteins;"it"is"a"template"for"the"
synthesis"of"novel"viral"RNA;"it"is"enclosed"in"novel"viral"particles"as"their"genetic"material."An"
untranslated"region"(UTR)"at"the"5’"end"of"the"RNA"(see"later"in"this"chapter)"directs"the"viral"
genome"to"the"cellular"ribosome"for"the"translation"of"the"genome.[22\24]"The"first"step"of"this"
process" is" the" synthesis" of" a" polyprotein"precursor" that" is" then" inserted" in" the"endoplasmic"
reticulum" (ER)" membrane" and" co\" and" post\translationally" cleaved" and" processed" into" the"
mature" viral" protein" via" the" activity" of" a" viral" enzyme" (NS3" protease," NS3pro)" and" host"
proteases.[22\24]"The"viral"RNA"replication"is"operated"by"the"replication"complex"(RC)."The"RC"
contains" viral" encoded" proteins," RNA" and" probably" host" factors" and" is" located" in" a"
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membranous"system."These"structures"seem"to"be"major"rearrangements" in"host"subcellular"
organelles,"most"probably" rough"and" smooth"ER," that"host" the"viral" replication" steps.[23,24,33]"
RNA"replication"undergoes"two"main"steps,"both"of"which"are"accomplished"by"the"viral"NS5"
RNA\dependent" RNA" polymerase" (RdRp)." The" first" step" employs" the" synthesis" of" a"
complementary" (minus\strand)" copy" of" the" RNA." This" is" then" used" as" a" template" for" the"
synthesis"of"the"plus\strand"nucleic"acid"in"the"second"step."The"double"stranded"RNA"(dsRNA)"
that"is"produced"in"this"way"is"unwound"by"DENV"NS3"helicase"(NS3hel)"and"the"positive"sense"
RNA"5’"end"is"capped"by"the"viral"NS5"methyltransferase"(MTase)."The"final" (+)ssRNA"is"then"
used" as" mRNA," template" for" RNA" transcription" or" encapsulated" in" novel" virions" (or" viral"
particles).[22\24]""
"
!
Figure'1.4..DENV.replication.cycle.within.the.host.cell..
In"this"figure"are"demonstrated"the"main"steps"of"viral"replication"cycle"as"described"in"the"text."
The"assembly"of" the"virion"starts"with"the"association"of" the"nucleocapsid."At"this"stage," the"
precursor" of" the" nucleocapsid" protein" (C)" anchors" to" the" membrane," making" possible" its"
interaction"with"the"envelope"and"membrane"precursor"proteins"(E"and"prM)."Multiple"copies"
of"C"protein,"featured"by"positively"charged"residues,"bind"to"a"single"negatively"charged"RNA"
and" form" the" nucleocapsid.[22\24]" Usually," enveloped" viruses" gather" their" lipid" bilayer" when"
they"are"released"from"the"host"cell"into"the"extracellular"environment."This"is"not"the"case"for"
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DENV:" the" formation" of" the" envelope" comes" as" a" consequence" of" the" budding" from" the"
modified"membranous"system.[23,24,33]"
Viral" maturation" occurs" in" the" trans\Golgi" network" (TGN)" where" the" low" pH" induces" high"
rearrangement"of"the"structure"of"the"immature"virus.[30]"At"the"end"of"the"DENV"replication"
cycle," the"release"of"the"virus"occurs"via"exocytosis"through"fusion"of"vesicles"containing"the"
enveloped"mature"virus.[22\24,33]""
From" the"description"of" the" replication" cycle," it" is" clear" that"RNA"plays" a" central" role" in" the"
whole"process."DENV"genome"RNA"is"composed"of"approximately"10,800"base"pairs."At"the"5'"
end"there"is"a"type"I"7MeGpppA2’OMe"cap"structure"that"ensures"stability"to"the"nucleic"acid"and"
therefore"it"is"essential"for"viral"replication."The"cap"is"followed"by"a"short"UTR"(67\132"bases)"
responsible"for"genome"targeting"to"the"ribosomes"and"essential"for"the"synthesis"of"the"viral"
RNA." At" the" 3'" end," a" 114\585" nucleotide" long" segment" constitutes" another" UTR." Between"
these" sequences" there" is"a" single"open" reading" frame" (ORF)" that"encodes" for"approximately"
3,400"amino"acids"that"form"the"polyprotein"precursor"(schematized"in"Figure"1.5).[22,24,27,30]""
"
!
Figure'1.5..DENV.polyprotein.processing.and.cleavage.products...
The"structural"proteins"are"indicated"in"cyan"(C=nucleocapsid"protein;"prM=precursor"of"membrane"glycoprotein"
M;"E=envelope"glycoprotein);"the"non"structural"proteins"are"in"orange."Cleavage"sites"are"shown"by"symbols:"◊"
represents"cellular"peptidases"cleavage"sites,"the"↓"arrow"represents"the"NS3\2B"serine"protease"sites."In"
multifunctional"proteins,"the"activity"of"each"portion"is"shown:"“PROT”=protease,"“HEL”=helicase,"
“MTase”=methyltransferase,"“RdRp”=RNA\dependent"RNA"polymerase."
This"polyprotein" is" co\" and"post\transnationally" cleaved"by" viral" and"host"proteases" in" three"
structural"and"seven"non"structural"(NS)"proteins"(also"schematized"in"Figure"1.5)."The"host"cell"
enzymes" involved"are"endoplasmic" reticulum"signalases" (represented"by"◊" in" the" figure)"and"
they"control"the"cleavage"between"nucleocapsid"protein"(C)"and"the"precursor"of"the"envelope"
glycoprotein"M" (prM);" prM" and" envelope" glycoprotein" E;" E" and" non\structural" protein"NS1;"
NS1"and"NS2A;"NS4A"and"NS5."The"viral"protein"involved"in"the"polyprotein"processing"is"NS3"
serine"protease"(NS3pro)"in"the"presence"of"the"NS2B"cofactor."It"operates"the"cleavage"at"the"
level" of" C/prM," NS2A/NS2B," NS2B/NS3," NS3/NS4A," NS4A/NS4B" and" NS4B/NS5"
junctions.[22,24,34]""
The" polyprotein" precursor" has" transmembrane" motifs" that" allow" its" insertion" in" the" ER"
membrane."The"mature"viral"proteins"are"also"associated"with"the"same"membrane"according"
to"the"topology"reported"in"Figure"1.6.""
"
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Figure'1.6..Model.of.mature.viral.proteins.topology..
Here"is"schematized"the"endoplasmic"reticulum"(ER)"membrane"associated"with"the"viral"proteins."The"structural"
proteins"are"highlighted"in"cyan,"while"the"non\structural"ones"are"in"orange."It"is"possible"to"see"that"the"proteins"
adopt"different"distributions"with"respect"to"the"ER"membrane,"as"reported"in"text."
In" this"model," the"mature" viral" proteins" are" either" in" the" ER" lumen" side" of" the"membrane"
(prM,"E,"NS1),"transmembrane"(NS2A,"NS2B,"NS4A,"NS4B),"or"on"the"cytoplasmic"side"of"the"ER"
membrane"(C,"NS3"and"NS5)."Most"of"them"are"in"the"ER"lumen"side"of"the"membrane.[22,24,34]"
The"mature"viral"proteins"have"different"roles"and"on"this"basis"they"can"be"divided"in"to"two"
main"groups:"structural"and"non\structural"proteins."Structural"proteins"are"the"ones"involved"
in"the"structure"of"the"virion"itself."
Capsid" protein" C" is" a" small" protein" of" 120" residues" of" which" a" high" percentage" (25%)" is"
constituted" by" basic" residues" (15" Lys" and" 9" Arg)." This" enables" C" to" bind" the" RNA" via"
electrostatic" interactions" with" its" negative" charges" during" the" encapsidation," enclosing" the"
genome"into"the"virion."C"is"inserted"in"the"ER"membrane"through"a"small"C\terminal"sequence"
of" 20" residues" called" signal" sequence." In" this" form" the" protein" is" actually" the" C" protein"
precursor" (anchC" or" “anchored" C”)" that" becomes" C" after" the" cleavage" of" the" signal"
sequence.[22,24,34]"
prM" is" the" glycosylated" precursor" protein" of" the" membrane" protein" (M)." It" is" a" small" (75"
residues)"protein"with"a"C\terminal"transmembrane"anchor"that"forms"ion"channels"that"allow"
the"passage"of"ions"as"calcium,"sodium,"chloride"and"potassium."On"the"lumen"side"of"the"ER"
membrane," prM" forms" a" heterodimer"with" the" envelope" protein" (E)," protecting" E" from" the"
acidic"environment"of"Golgi"vesicles"during"virion"maturation."This"low"pH"is"similar"to"the"one"
in" the" endosomes" and" in" absence" of" prM" these" conditions" could" lead" to" a" premature"
conformational"change"of"E"and"to"a"consequent"fusion"of"the"envelope"with"the"membrane,"
with" a" similar" mechanism" to" the" one" described" earlier." The" proteolytic" processing" of" prM"
occurs" in" a" late" stage" of" the" virion"maturation," when" a" cellular" protease" cleaves" it" into"M,"
which"remains"intercalated"in"the"envelope"membrane,"close"to"E,"and"“pr”,"which"is"released"
into"the"extracellular"environment.[22,24,34]"
The"envelope"glycoprotein"(E)"is"associated"to"the"viral"envelope"and"it"mediates"host"receptor"
binding"and"consequent"viral"internalization"during"the"initial"phases"of"the"replication"cycle."E"
forms"homodimers"on"the"envelope"surface"that"undergo"irreversible"conformational"changes"
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(into" monomers" and" then" homotrimers)" in" the" low" pH" environment" of" the" endosome,"
allowing"the"fusion"of"the"envelope"with"the"endosome"and"the"consequent"viral"RNA"release"
into"the"host"cell.[22,24,34]"
Non\structural" (NS)" proteins" are" not" directly" involved" in" viral" morphology," but" they" are"
essential"factors"of"the"replication"cycle."
Non\structural" protein" 1" (NS1)" is" a" 45" kDa" water\soluble" protein" that" is" glycosylated" for"
correct" folding" and" released" in" the" ER" lumen." In" infected" cells" it" is" present" in" a" dimer" form"
when"associated"to"membranes"(e.g."on"cell"membrane"of"infected"cells)"and"as"a"hexamer"in"
solution,"also"in"the"extracellular"environment.[35]"Outside"the"infected"cell,"NS1"is"able"to"aid"
the" virus" to" elude" the" host" immune" system" as" it" produces" a" protective" humoral" immune"
response." At" the" same" time" it" has" been" observed" that" NS1" antibodies" are" associated" with"
cross\reaction"with"platelets"and"endothelial"cells."Therefore," it"has"been"suggested"that"the"
inflammatory"situation"in"DF"is"correlated"to"this"non\structural"protein"and"the"fact"that"anti\
NS1" antibodies" protect" against" DENV" infection" is" consistent" with" this" hypothesis." NS1" also"
plays"a"role"within"the"viral"replication"cycle,"but"its"interactions"with"other"viral"proteins"and"
the"molecular"mechanism"are"still"not"well"understood.[22,24,34]"
Non\structural" protein" 2" is" divided" in" two" parts:" NS2A" and" NS2B." The" first" one" (NS2A)" is" a"
22kDa"protein"that"contains"transmembrane"domains."It"has"been"localized"in"the"replication"
site" and" it" is" essential" for" viral" replication." It" is" able" to"bind"NS3,"NS5" and" the"3’UTR"of" the"
genome."For"these"reasons"it"has"been"associated"to"RNA"replication,"but"its"exact"role"is"not"
fully" known" to" date." NS2B" is" associated" with" the" membrane" as" it" has" several" membrane"
spanning"domains"and"only"a"40"residues" long" fragment"of"hydrophilic"amino"acids." It" is" the"
cofactor"for"NS3"serine"protease"as"it"stabilises"this"structure"in"solution,"allowing"the"correct"
function"of"this"enzyme.[22,24,30,34]"
Non\structural" protein" 3" (NS3)" is" a" multifunctional" enzyme." The" N\terminal" one\third" (170"
residues)"portion"of"NS3"is"a"serine"protease"(with"the"His51,"Asp75"and"Ser135"catalytic"triad)"
that"is"functional"only"if"bound"to"the"cofactor"NS2B."As"listed"previously"in"this"chapter,"NS3"
protease" is" responsible" of" the" cleavage" of" the" junction" between" C/prM," NS2A/NS2B,"
NS2B/NS3," NS3/NS4A," NS4A/NS4B" and"NS4B/NS5." The" C\terminal" portion" of" NS3" has" three"
enzymatic" activities:" helicase," nucleotide" triphosphatase" (NTPase)" and" RNA" triphosphatase"
(RNAse)." The" function" of" this" portion" of" polyprotein" (NS3hel)" is" to" unwind" in" an" NTP\
dependent"manner"double"strands"of"genomic"RNA"(dsRNA)"and"to"remove"the"γ\phosphate"
at"the"5’"end"of"the"viral"nucleic"acid"during"the"capping"process.[22,24,34]"
Two"peptides"belong"to"non\structural"protein"4:.NS4A"and"NS4B."The"function"of"these"two"
proteins" is"not"clear" to"date."NS4A"has"been"associated"with"ER"membrane"alteration,"while"
NS4B" appears" to" be" involved" in" the"modulation" of" viral" replication" through" the" interaction"
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with"NS3."It"has"been"shown"to"cause"the"displacement"of"the"NS3hel"from"ssRNA,"enhancing"
dsRNA"unwinding.[22,24,30,34]"
The" largest" and" most" conserved" non\structural" protein" is" NS5," another" multifunctional"
enzyme." Its" C\terminal" portion" (residues" from" 270" to" 900)" is" a" RNA\dependent" RNA"
polymerase"(RdRp)."The"main"function"of"this"portion"is"the"synthesis"of"viral"RNA"through"the"
synthesis"of"an"intermediate"minus\stranded"RNA"template."The"N\terminal"part"of"NS5"has"a"
S\adenosyl\L\methionine" (SAM)" dependent"methyltransferase" (MTase)" activity." The" reaction"
catalysed"in"this"case"is"the"transfer"of"two"methyl"groups"from"two"molecules"of"SAM"to"the"
last"two"5’"bases"(a"guanine,"G"and"an"adenine,"A)"of"the"viral"RNA"in"positions"N\7"of"G"and"2’\
O"of"A."These"are"two"of"the"four"steps"of"RNA"capping,"essential"for"RNA"stability.[22,24,34,36]"
"
DIAGNOSIS'AND'CURRENT'TREATMENT''
"
DENV" infection" diagnosis" is" usually" clinical," but" the" broad" spectrum" of" symptoms" of" DENV"
infections," makes" laboratory" diagnosis" often" crucial" for" DF" or" DHF/DSS" recognition," in"
particular" in" Nations" were" the" disease" is" not" common.[5]" The" main" available" laboratory"
methods" are" virus" isolation," serological" tests" and" nucleic" acid" amplification" tests." Virus"
isolation"in"cell"cultures"is"the"technique"that"provides"the"most"specific"result."However,"due"
to" its" high" cost" it" is" not" always" available." Easier" to" perform" and" much" less" expensive" are"
serological" tests." For" instance," the" detection" in" blood" samples" of" the" viral" non\structural"
protein"1"(NS1)"can"confirm"infection."Furthermore,"the"enzyme\linked"immunosorbent"assay"
(ELISA)"can"be"applied"for"the"recognition"of"two"DENV\specific"immunoglobulin"proteins"that"
are"produced"5\7"days"after"infection:"IgM"and"IgG."The"first"antibody"becomes"undetectable"
2\3"months" after" the" infection" and" can" be" used" as" an" indicator" for" on\going" infections." IgG"
remains" detectable" for" over" 60" years" after" infection" and" is" a" useful" indicator" of" passed"
infections." Interestingly,"the"IgM/IgG"ratio"can"be"used"to"discriminate"between"primary"and"
secondary"infections,"however"cut\offs"have"not"been"fully"calibrated"to"date."The"nucleic"acid"
amplification" tests" can" be" a" very" sensitive" and" rapid" tool" for" the" identification" and"
quantification" of" the" virus" during" the" high" viremia" phase." Importantly," they" can" also"
distinguish"between"serotypes,"but"to"date"the"tests"are"available"only"in"the"USA.[5,10]"
Once" the" infection" has" been" diagnosed," the" therapy" is" currently" only" symptomatic." WHO"
guidelines"for"the"treatment"of"patients"were"published"in"2009"and"completed"in"2012,"as"the"
“Handbook" for" clinical" management”.[37,38]" In" case" of" high" fever," the" administration" of"
paracetamol" is" usually" preferred" to" other" non\steroidal" anti\inflammatory" agents" (NSAIDS),"
such" as" acetylsalicylic" acid," as" they" can"worsen" gastric" ulcers" and" consequent" bleeding.[37,38]"
Two"of"the"common"antiviral"agents,"Ribavirin"and"interferon,"have"shown"no"efficacy"against"
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DENV"and"cannot"be"used"for"therapy.[10,23]"Most"cases"of"DF"are"self\limiting"and"paracetamol"
support" is" sufficient.[10,38]" Conversely," for" cases" of" DHF" and" DSS," hospitalization" is" required"
most" of" the" time" and" the" hypovolemia" is" treated" with" hydration" or" with" aggressive" fluid"
management"in"order"to"counteract"the"loss"of"plasma."This"can"be"performed"via"body"fluid"
replacement" or" with" colloid" solutions" (e.g." with" lactate," dextran," starch" or" crystalloid"
solutions)." In" the" worst" of" cases" with" severe" bleeding," blood" transfusion" might" also" be"
necessary.[11,23,28\38]""
"
PREVENTION'
"
Other" guidelines" presented" by" WHO" address" the" prevention" of" the" disease" that" can" be"
operationalized"in"two"ways:"vector"control"and"vaccine"production."Several"strategies"for"the"
decrease" of" Aedes" mosquito" populations" are" reported" in" the" “DENGUE" Guidelines" for"
diagnosis,"treatment,"prevention"and"control”"(e.g."the"use"of"insecticides"or"larvicidal"fishes,"
proper" water" supply" to" households," periodic" cleaning" of" water" containers" and" waste"
management).[37]"However,"to"date"they"have"mostly"not"been"effective" in"both"the"short"or"
the" long" term" for" several" reasons." First" of" all," after" an" initial" success" the" procedures" are"
generally"abandoned,"allowing"the"residual"populations"to"grow"again."This"is"due"to"an"over"
reliance"upon"the"chemical"agents"used"and"a"lack"of"monitoring"procedures"that"assure"that"
the" vector" has" effectively" been" removed." Secondly," not" all" of" the" countries" are" applying"
measures"for"vector"control."This,"added"to"increased"international"travel,"allows"the"vector"to"
be" easily" reintroduced" even" after" complete" eradication." These" issues" can" be" related" to"
inadequate"financial"and"human"resources"or"excessive"investment"requirements"for"involved"
Countries"that"often"are"underdeveloped"or"in"development.[11,14,18,39]""
Vaccine"development"is"the"second"strategy"for"DENV"infection"prevention,"but"it"has"proven"
to" be" challenging" for" several" reasons." First," the" pathogenesis" of" the" virus" is" still" not" fully"
understood."It"has"been"found"that"human"antibodies"mostly"target"the"membrane"precursor"
(prM)"and"envelope" (E)" structural"proteins"and"non\structural"protein"NS1" (described" in" the"
BIOLOGY"chapter"of"this"introduction)."However,"studies"to"find"the"best"epitope"are"currently"
continuing."The"lack"of"complete"comprehension"of"the"antibody\enhanced"(ADE)"mechanism"
is" also" an" issue" for" vaccine" development." A" monovalent" vaccine" could" cause" severe" cross\
reaction"in"case"of"DENV"infection," in"the"same"way"as"a"primarily" infection"does."Therefore,"
current" knowledge" suggests" it" is" necessary" to" develop" a" tetravalent" vaccine.[40,41]" A" second"
obstacle" has" been" the" lack" of" suitable" animal"models" for" research" and"development.[41,42]" A"
third" complication" in" vaccine" development" has" been" to" obtain" antibody" titers" sufficient" for"
long\lasting" (life\long)"protection."ADE"will"always"be"a"worry"even"with"tetravalent"vaccines"
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and" therefore" vaccine" clinical" trials" must" address" this" issue" with" long\term" follow\up"
phases.[43]"Last,"there"are"other"criteria"that"a"vaccine"must"fulfil,"especially"for"developing"and"
third" world" countries:" immunisation" must" occur" with" no" significant" disease" symptom"
manifestation;" a" full" protection"must" be" obtained"with" a"maximum"of" two" injections;" there"
must"be"a"reduced"transmissibility"and"the"cost"of"the"vaccine"must"be"low.[7,11,42,44]""
To"date"there"are"no"vaccines"on"the"market"against"DENV,"but"some"candidates"are"in"clinical"
trials,"as"reported"in"Table"A1.1"of"APPENDIX&1."The"most"common"strategies"applied"to"date"
for" vaccine" development" have" been:" in& vitro& passaged" life\attenuated" virus" (LAV)" vaccines,"
recombinant" life\attenuated" virus" vaccines," chimeric" life\attenuated" virus" vaccines," purified"
inactivated"viruses"(PIV),"DNA"vaccines"and"recombinant"subunits."[7,11,41,43]"The"most"advanced"
vaccine" is" the"Sanofi"Pasteur" live"chimeric"vaccine"(CYD\TDV)," in"which"the" licensed"YFV"17D"
vaccine" is" used" as" a" backbone" for" the" expression" of" all" four" DENV" serotypes" prM" and" E"
proteins."It"reached"clinical"trial"phase"III"and"it"was"expected"to"be"launched"in"the"market"in"
2015.[45]"However,"phase"IIb"clinical"trial"results"showed"only"a"30%"efficacy"and"immunisation"
only"for"serotypes"1,"3"and"4,"creating"disappointment"in"the"vaccine"strategy.[41,43]"Aiming"to"
gain" stronger" statistical" analysis" and" to" conclusively" asses" the" CYD\TDV" efficacy" on" larger"
populations,"clinical" III" trials"have"been"begun" in"Asia"and" in"Latin"America." In"July"2014,"the"
results"of"the"Asian"study"were"disclosed."The"study"was"performed"administering"three"doses"
(at"0,"at"6"and"at"12"months)"of"the"vaccine"or"of"a"placebo"to"approximately"10,000"children,"
with" a" follow\up" of" two" years." The" vaccine" showed" a" 56%" reduction" of" the" disease" with" a"
limited"protection"against"DENV2."Inexplicably,"it"worked"best"against"severe"dengue"disease"
in"people"who"had"already"been"infected"in"the"past"(88.5%"protection).[46,47]"The"results"of"the"
second"study"on"approximately"20,000"children"in"Latin"America"were"published"in"September"
2014"and"have"been"found"to"be"in"line"with"the"previous"trial.[48]"The"positive"finding"of"cross\
trial"consistency"is"however"weakened"by"the"low"efficacy"in"dengue\naïve"people"that"seems"
to"preclude"its"use"in"non\endemic"areas"and"for"travellers.[47]""
"
FUTURE'POTENTIAL'TREATEMENTS'
"
THERAPEUTIC.STRATEGIES.
"
The"previous"chapter"has"described"how"DENV"prevention"has"proven"to"be"challenging"and"
the"approaches"tried"so"far"have"given"poor"results."In"summary,"vector"control"has"shown"to"
be" unrealistic," while" vaccine" development" to" date" has" not" given" the" required" efficacy." A"
simulation"of"the"effect"of"the"introduction"of"a"vaccine"in"the"market"was"recently"conducted"
for"the"analysis"of"the"potential"drug"market"for"this"virus.[13]"According"to"this"work,"even" if"
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the"Sanofi"Pasteur"vaccine"was"to"reach"the"market"in"2015,"the"clinical"cases"of"dengue"fever"
will"not"decrease"below"the"values"of"2006"before"2033"and"even"then," it"will"be"very" likely"
that" the" vaccinated" population" will" only" be" around" 16%.[13]" This" is" due" to" the" vaccine"
production" time"and" to" the" fact" that" it"might"not"be"possible" to"vaccinate"people" that"have"
been"already"infected"once"with"DENV."The"consequence"of"this"analysis"is"that,"even"should"a"
vaccine" become" available" therapeutic" drugs" will" have" a" fundamental" role" for" dengue" virus"
management." Furthermore," anti\DENV" agents" would" not" only" increase" the" early" search" for"
medical" treatment," reducing"dramatically" the" incidence"of"DHF"and"DSS,"but" they"could"also"
be"used"prophylactically"in"geographical"areas"of"high"infection,"preventing"a"further"spread"of"
the"pathogen.[49]""
Despite" the" pressure" to" find" an" antiviral" therapy," there" are" currently" no" approved" specific"
treatments"and"there"is"therefore"a"great"need"for"research"in"this"field."Very"similarly"to"the"
ideal"vaccine,"an"ideal"drug"should"meet"some"basic"pharmacological"criteria:"it"should"have"a"
good" bio\availability" through" oral" administration;" have" a" low" frequency" of" administration"
(maximum" 3" times" per" day);" cause" a" low" genetic" resistance;" be" safe" also" in" paediatric"
patients.[50]"As"well"as"these"features,"it"is"important"to"remember"that"the"countries"with"the"
highest" prevalence" of" DENV" are" in" tropical" and" subtropical" regions" and" that" they" are" low\
income" countries." Consequent," the" ideal" drug" should" also:" have" an" easy" and" “low\cost”"
synthesis" and" preparation;" have" a" good" thermal" stability" and" good" hygroscopic"
characteristics.[31,50]" A" significant" concern" on" DENV" antiviral" therapy" is" the" rapidity" of" the"
viremia" decline" during" the" infection," making" the" rapidity" of" action" a" key" factor" in" drug"
development,"in"conjunction"with"the"optimisation"and"spread"of"reliable"diagnostic"tools.[49]"
Even" though" the"pathogenesis" of"DENV" is" not" fully" understood," the" knowledge" acquired"on"
DENV" suggests" three" strategies" for" the" development" of" novel" treatments:" to" reduce" the"
viremia" during" the" early" stages" of" infection," to" block" viral" replication" by" inhibiting" a" viral"
encoded" target," or" to" control" the" host" response" to" the" disease" (important," in" particular" for"
DHF"and"DSS).[31,51]"
A"relevant"issue"in"the"development"of"drugs"against"DENV"has"been"the"absence"of"suitable"
animal"models"in"which"the"disease"phenotype"is"similar"to"humans"and"that"can"therefore"be"
used" for" pre\clinical" tests" of" compounds." Non\human" primates" have" been" investigated," but"
the" absence" of" clinical" signs" after" DENV" infection" has" made" these" models" not" suitable" for"
antiviral" research." The" availability" of" genetic" tools" has" made" possible" the" manipulation" of"
several" cheaper"and" smaller"animals," like"mice,"making" them"susceptible" to"DENV" infection."
However,"a"model"that"simultaneously"resembles"all"disease"features"has"not"been"created"to"
date"and"the"choice"of"the"model" is" therefore" linked"to"the"study" itself.[31,52]"Great"utility" for"
antiviral" research"has"been"demonstrated"by" the"AG129"mouse"model," lacking"both" IFN\α/β"
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and"IFN\γ,"as"it"can"reproduce"mild"and"severe"disease"models"as"well"as"ADE"according"to"the"
experimental"setup.[52,53]"
Given"the"difficulties"in"the"development"of"an"in&vivo"model,"several"in&vitro"approaches"were"
developed" for" the" assessment" of" compound" activity." Cell\based" assays" currently" available"
consist"of"live\virus,"viral"replicon"and"virus\like"particle"assays."The"most"common"used"test"is"
the" cytopathic" effect" inhibition" assay" (CPE)" that" assesses" the" ability" of" potential" drugs" to"
inhibit" viral\induced" cell" death" using" staining" procedures" that" respond" only" to" alive" cells." It"
requires" live" infected" cells,"with"biosafety" containment" issues,"but" it"has"been"proven" to"be"
reliable."Another"live\cell"assay"is"an"ELISA"test"that"detects"and"quantifies"the"production"of"E"
protein" in" DENV" infected" cells." The" viral" replicon" assay" consists" of" a" luciferase\based"
subgenomic"replicon"system"in"which"a"luciferase"reporter"replaces"DENV"structural"proteins."
No" biosafety" containments" are" necessary," but" this" test" can" only" be" performed" with" viral"
replication" inhibitors" and" false" positives" can" occur" as" compounds" might" interact" with" the"
luciferase" reporter" directly." The" co\transfection" of" a" viral" replicon"with" a" vector" expressing"
DENV"structural"proteins"gives"a"virus\like"particle."As"for"viral"replicon"assays,"assays"that"use"
virus\like"particles"do"not"need"biosafety"containment"and"have"a"high" rate"of" false"positive"
results." However," they" can" be" used" to" test" both" replication" and" entry" inhibitors.[51]" As" a"
compound"might" interact"with"several"cellular"pathways,"the"use"of"a"cell\based"assay" is"not"
always"useful"for"structure\activity"relationship"studies."For"this"reason"and"as"for"pre\clinical"
development"it"is"important"to"know"the"drug"target,"several"protein\specific"assays"have"also"
been"developed"for"compound"assessment."In"particular,"commonly"used"DENV"proteins"are:"
the"protease,"the"helicase,"the"methyltransferase"and"the"polymerase.[49,51]""
" "
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VIRAL.TARGET.DRUG.DESIGN.
"
In" a" viral\based" drug" design" approach," the" main" aim" is" to" block" viral" functions" that" are"
essential" at" any" stage" of" its" replication" cycle." The" rationale" behind" the" direct" antiviral"
approach"relies"on"the"awareness"that"virus"titers"are"directly"correlated"to"the"severity"of"the"
disease" and," consequently," the" reduction" of" viral" levels" should" prevent" or" reduce" the"
progression"to"DHF"and"DSS.[49]"For" this" reason"and"based"on"available"knowledge," the"main"
viral" targets" studied" to" date" to" find" an" anti\DENV" molecule" are" the" structural" proteins"
(envelope,"E"and"capsid,"C)"and" the"non" structural" (NS)"protein"NS3\2B" serine"protease," the"
NS3" helicase," NS4B," the" NS5" methyltransferase" (MTase)" and" NS5" RNA\dependent" RNA"
polymerase"(RdRp)"(see"BIOLOGY"chapter"for"viral"protein"description).[31,34,51]"A"detailed"list"of"
potential"inhibitors"is"reported"in"Table"A1.2"of"APPENDIX&1,"while"only"the"general"aspects"of"
drug"design"approaches"against"viral"targets"is"discussed"here."
The" inhibition" of" viral" entry" into" the" cell" is" an" antiviral" strategy" that" has" proven" to" be"
successful"for"other"viruses,"such"as"HIV.[49]"As"explained"in"the"BIOLOGY"chapter,"dengue"virus"
entry" in" the" host" cell" is" mediated" by" the" envelope. protein" (E)" that" undergoes" major"
conformational" changes"upon"change"of"environmental"pH."A" range"of" techniques"has"been"
applied"for"the"discovery"of"novel"compounds"that"interact"with"E"and"therefore"disrupt"the"E\
host"receptor"interaction."Molecules"have"been"selected"through"in&silico"approaches"such"as"
virtual"screening"of"compound"libraries"or"docking."In"both"cases,"compounds"were"aimed"to"
bind" to" a" hydrophobic" pocket" of" E," identified" by" β\N\octyl\glucoside" (βOG)" that" was" co\
crystallised"with" the"structural"protein."The"hypothesis"behind"this"strategy" is" that" inhibitors"
targeting"this"cleft"would"disrupt"pH\dependent"conformational"changes" in"E."Unfortunately,"
none" of" the" compounds" were" promising" enough" for" further" development.[49,54]" Peptides"
derived" from" a" portion" of" the" E" protein" inhibited" DENV" in" cells" and" some" of" them" were"
computationally" optimised." However," their" intrinsic" short" shelf\life" and" the" need" of"
intravenous" administration" has" reduced" the" interest" in" this" class" of" molecules.[49,54]" High"
throughput"screenings"(HTS)"of"compound"libraries"with"DENV"infection"assays"have"identified"
two" classes" of" antibiotic\derivatives" that" inhibit" DENV" entry," but" their"mechanism"of" action"
has" not" yet" been" defined." Preclinical" studies" are" currently" on\going" for" the" doxorubicin"
analogues.[49,54]"One"of" them" is"exemplified" in"panel"A"of"Figure"1.7.[55,56]"As"described" in" the"
BIOLOGY" chapter" of" this" introduction," DENV" E" protein" binds" the" cells" polysaccharide"
glycosamminoglycan" heparan" sulphate." For" this" reason," this" scaffold," shown" in" panel" B" of"
Figure"1.7,"has"also"been"used"for"the"design"of"antivirals"that"interact"with"E,"but"no"follow"up"
studies"have"been"reported.[49,54]""
"
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"
A"
"
B"
Figure'1.7..Chemical.structures.and.scaffolds.of.entry.inhibitors...
A).Antibiotic.SAF17."The"chemical"structure"of"this"doxorubicin"derivative"is"reported"here."The"doxorubicin"scaffold"
is"in"black,"while"the"novel"part"of"the"molecule"is"in"red."B).Heparan.sulphate.scaffold."The"polysaccharide"scaffold"
is"formed"by"“n”"repetitions"of"the"disaccharide"reported"here."Different"heparan"sulphate"molecules"are"
differently"sulphonated."Therefore"R"can"be"either"hydrogen"or"a"SO3"group."
A"further"target"for"DENV"is"the"capsid"(C)"structural"protein."Its"main"function"is"to"complex"
the"viral"RNA"through"electrostatic"interactions"and"to"form"the"nucleocapsid."Through"a"HTS"
strategy" that" analysed" compounds" belonging" to" a" library" and" their" ability" to" inhibit" the"
infection"in"cells,"a"compound,"ST\148"(Figure"1.8),"was"identified"that"is"active"against"all"four"
DENV"serotypes."Mutations"in"resistant"viral"strains"showed"that"the"molecule"binds"to"the"C"
protein." In" vivo" studies" confirmed" the" compound’s" activity" and" further" developments" are"
currently"in"progress.[49,57]"The"mode"of"action"of"this"compound"was"recently"published"and"it"
will"be"further"discussed"in"this"thesis"(in"the"CAPSID&AS&A&DRUG&TARGET"section).[58]"
"
!
Figure'1.8..STF148..
DENV"NS3.serine.protease"(NS3pro)"belongs"to"the"trypsin"family"and,"as"all"viral"proteases,"it"
contributes"to"viral"polyprotein"processing."As"this" is"an"essential"step"in"the"viral"replication"
cycle" it" is" considered" a" valid" antiviral" target." It" needs" the" cofactor" NS2B" that" actively"
participates"in"the"formation"of"the"active"site"which"results" in"being"flat"and"composed"of"a"
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high"percentage"of"negative"charged"residues"for"an"easier"binding"to"basic"residues"(Arg"and"
Lys).[34,49]"To"date,"three"approaches"have"been"used"to"find"inhibitors"of"this"protein:"designed"
peptidomimetics," library"HTS" and" in& silico" drug" design.[31,34,49,51]" The" selection" of" peptides" as"
inhibitors"aimed"to"maximise"the"interaction"with"the"protease"active"site"and"therefore"basic"
residues"are"used"as"a"scaffold."However," inserting"positive"charges"on"the"molecule"creates"
cell"permeability" issues."Furthermore," this"approach" requires"complex" (and" therefore"costly)"
chemical"synthesis,"representing"an"issue"for"a"disease"of"the"developing"world.[34,49,"54]"Several"
HTS" were" performed," using" mainly" a" construct" of" NS3\2B" protease" and" several" compound"
series"were"identified."Both"natural"products"and"small"molecules"have"been"recognised"to"be"
active" on" the" enzyme." They" often" present" positively" charged" groups" in" their" structure" that"
retain"the"cell"permeability"issues"(e.g."guanidines,"as"in"compound"166347"reported"in"panel"
A"of"Figure"1.9).[49,51,54,59]"Ring"rich"compounds"were"found" in&silico"to"fit"the"flat"and"shallow"
binding" site.[49,60]" From" these," anthracene\based" derivatives," obtained" from" compound"
ARDP0006"(panel"B"in"Figure"1.9)"modifications"were"used"for"structure\activity"relationships"
(SAR)" evaluations," but" no" further" studies" showing" the" activity" of" these" compounds" in" cells"
have"been"reported"to"date.[61]"
"
"
"
A" B"
Figure'1.9..Protease.inhibitors...
A).Compound.166347..This"is"an"example"of"guanidine"rich"inhibitor"selected"through"HTS."B).Compound.
ARDO0006..This"anthracene\based"molecule"is"an"example"of"inhibitors"identified"in&silico."
NS3. helicase/NTPase" (NS3hel)"participates" in" the"DENV" replication" cycle"by"using"energy" to"
unwind"double"stranded"nucleic"acid,"making"the"single"strand"available"to"protein"synthesis"
machinery"and"for"virion"formation."Like"helicases"from"other"(+)ssRNA"viruses"(e.g."HCV)"also"
NS3hel" is" a" promising" antiviral" drug" target.[54,62]" As" well" as" dsRNA" unwinding," NS3hel" has"
nucleoside" triphosphatase" (NTPase)" and" RNA" triphosphatase" (RNAse)" functions." The" two"
binding"pockets" (one" for"RNA"and"one" for"NTP)"have"proven"to"be"not"suitable" for"effective"
drug" design:" the" first" one" is" very" shallow" and" the" second" one" is" not" specific" for" any"
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nucleobase," making" selective" inhibitors" a" challenge.[51]" Attempts" to" overcome" these" issues"
were"performed"within"this"project"and"are"described"in"the"NS3&HELICASE&AS&A&DRUG&TARGET"
section." Other" research" groups" have" employed" other" strategies" and" two" compounds" were"
discovered"through"in&silico&docking"and"an"enzymatic"assay"(ivermectin)"and"through"HTS"(ST\
610).[49]"The"first"compound,"reported"in"panel"A"of"Figure"1.10,"is"a"broad"spectrum"flavivirus"
helicase" and" protease" inhibitor," but" in" cells" it" is" more" active" against" WNV" and" YFV" than"
DENV.[63\65]" ST\610," in" panel" B" of" Figure" 1.10," is" a" promising" panserotypic" DENV" NS3hel"
inhibitor,"active"both" in"cell\based"and"biochemical"assays"and" in&vivo" (in"the"AG\129"mouse"
model)."As"it"does"not"inhibit"the"ATPase"activity"and"it"induces"A263T"resistance"mutation"it"
probably"binds"to"the"RNA"binding"site.[66]"
"
"
A"
"
B"
Figure'1.10..Helicase.inhibitors...
A).Ivermectin..This"is"an"example"of"inhibitor"identified"in&silico."B).STF610."This"is"an"example"of"inhibitor"identified"
with"HTS."
NS4B" is" a" hydrophobic" transmembrane" protein" that" associates" to" NS3hel." It" probably"
participates"in"the"association"of"the"replication"complex"(RC)"to"membranes."Even"if"very"little"
is"known"about"its"precise"function"within"the"DENV"replication"cycle,"a"few"compounds"have"
been"shown"to" inhibit"DENV"infection"through" interaction"with"NS4B."These"small"molecules"
have" been" identified" through" HTS" campaigns," screening" libraries" against" DENV" replicon."
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Compound" interaction"with"NS4B"was" then"confirmed"by"mutations" found" in" this"protein" in"
resistant"viruses.[49]"
The"N\terminal"portion"of"NS5" is"a"methyltransferase" (NS5.MTase)," an"essential"enzyme" for"
RNA" capping" It" is" responsible" for" two" (N\7" and" 2’\O)" methylations" in" a" S\adenosyl\L\
methionine" (SAM)\dependent"manner." Host"methyltransferases" are" localised" in" the" nucleus"
and" cannot"mediate" these" reactions,"making"NS5"MTase" essential" for"DENV" replication" and"
therefore"a"promising"drug"target.[31,34,51]"Structural" information"about"the"enzyme"in"several"
complexes"is"available."Three"identified"binding"sites"have"been"used"for"structure\based"drug"
design"studies:"one"for"SAM,"one"for"the"cap"G"base"(also"called"“GTP"binding"site”"because"it"
was" first" seen" when" the" protein" was" crystallised" with" GTP)" and" a" shallow" highly" positively"
charged" area" that" connects" the" two" pockets" and" is" supposed" to" interact" with" the" RNA"
strand.[36]" Unfortunately," none" of" the" designed" compound"were" found" to" be" neither" highly"
active" nor" specific.[49]" S\adenosyl\homocysteine" (SAH)" was" rationally" modified" into" an"
analogue" (panel" A" in" Figure" 1.11)" that"was" confirmed" by" crystallography" to" inhibit" the"NS5"
MTase"though"binding"to"the"SAM"cleft."However,"this"molecule"was"not"selective"for"DENV.[67]"
Structural"data"confirmed"also"that"ribavirin"(panel"B"of"Figure"1.11)"binds"to"the"GTP"binding"
site,"but"it"is"not"active"in"patients.[51]"For"the"RNA"binding"site,"a"compound"(ATA,"in"panel"C"of"
Figure" 1.11)" was" identified" through" virtual" screening," but" no" follow" up" studies" have" been"
reported.[68]""
"
"
A"
"
"
B" C"
Figure'1.11..Methyltransferase.inhibitors...
A).SAH.analogue..Example"of"inhibitor"rationally"designed"to"bind"SAM"cleft..B).Ribavirin."Example"of"inhibitor"
binding"the"FTP"cleft..C).ATA."Example"of"inhibitor"identified"in&silico"to"bind"the"RNA"site."
Furthermore," a" fragment" based" drug" discovery" (FBDD)" approach" was" applied" within" this"
current"project"and"details"are"reported"in"the"NS5&MTASE&AS&A&DRUG&TARGET"section"of"this"
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thesis." Novartis" Institute" for" Tropical" Diseases" (NITD)" also" performed" HTS" with" biochemical"
assays,"but"failed"to"identify"putative"NS5"MTase"inhibitors.[49]"
The"C\terminal" portion"of"NS5" is" the"RNA\dependent"RNA"polymerase" (NS5. RdRp)." It" is" the"
most"conserved"DENV"protein"and"it"is"responsible"for"RNA"synthesis,"an"essential"step"within"
the" DENV" replication" cycle." For" these" reasons" it" represents" one" of" the" most" popular" drug"
targets" in" antiviral" research.[54,69]" RdRp" inhibitors" are" commonly" classified" in" two" categories:"
nucleoside/nucleotide"analogue" inhibitors" (NI)" and"non\nucleoside" inhibitors" (NNI)." The" first"
class"represents"probably"the" largest"group"of"drugs" in"antiviral"therapy.[49]"An"example"NI" is"
compound"NITD203"(panel"A"of"Figure"1.12),"that"has"shown"good"in&vitro"and"in&vivo"activity."
It"is"a"prodrug,"as"the"original"compound"(NITD449,"in"black"in"the"figure)"had"cell"permeability"
issues.[70]"The"popularity"of"NI"as"a"drug"strategy"resides"in"the"fact"that"molecules"target"the"
NS5"RdRp"active"site,"which"has"a"low"resistance"emergence"rate"as"it" is"the"most"conserved"
portion"of"the"enzyme."Furthermore,"this"region"is"conserved"also"among"different"serotypes,"
genotypes" and" viruses," allowing" the" possibility" of" development" of" broad\spectrum"
compounds."However,"NIs"present"also" important"challenges," in"addition"to"cell"permeation."
First" of" all," as" several" host" cell" enzymes" are" involved" in" NI" activity," structure\activity"
relationship" determination" is" almost" impossible" and" therefore" it" is" difficult" to" apply" the"
classical"medicinal"chemistry"methodology"to"this"class"of"compounds."Secondly,"as"they"are"
nucleoside/nucleotide" analogues," they" can" interfere" with" cell" processes," giving" off\target"
toxicity" problems.[13,54]" NITD203" development" was" indeed" interrupted" for" toxicity" issues.[70]"
This"challenge"is"less"important"for"NNI"compounds"as"they"are"usually"highly"specific"as"they"
do" not" target" directly" the" active" site." NNIs" are" non\competitive" molecules" that" exert" their"
function"by" binding" to" specific" clefts," blocking" changes" in"NS5"RdRp" conformations" that" are"
necessary" for" the" enzyme" in" order" to" accomplish" its" function." The" disadvantages" of" this"
strategy"are"mainly"related"to"the"choice"of"the"binding"pocket:"it"should"be"well"conserved"for"
cross\serotype"activity"and"for"the"reduction"of"resistance"onset.[31,34,49,51]"Crystal"structures"of"
NS5" RdRp" closed" conformation" have" been" solved," but" often" allosteric" binding" sites" are" not"
defined"in"this"state."For"this"reason,"HTS"has"been"a"more"successful"tool"for"the"identification"
of"NNIs"with"respect"to"structure"based"drug"design.[13]"N\sulphonylanthranilic"acid"derivatives"
(like"NITD2" in" panel" B" of" Figure" 1.12)"were" identified"with"HTS," but" their" development"was"
interrupted"for"poor"CPE"activity.[71\73]"Even"if"more"challenging,"some"putative"NS5"RdRp"NNIs"
have"been"identified"in&silico"through"virtual"screening"and"are"described"in"the"NS5&RDRP&AS&
DRUG&TARGET"section"of"this"thesis.""
"
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"
A" B"
Figure'1.12..Polymerase.inhibitors...
A).NITD203."Example"of"NI."It"is"the"prodrug"of"NITD449"and"the"groups"cleaved"by"host"cells"are"coloured"in"red..B).
NITD2."Example"of"NNI."
"
HOST.TARGET.DRUG.DESIGN.
"
As"for"all"viruses,"also"DENV"is"an"obligated"parasite"that"relies"on"host"factors"for"key"steps"in"
its" replication" cycle." For" this" reason," targeting" the" required" host" cell" factors" is" another"
therapeutic" strategy" that" can"be"pursued" for"antiviral"drug"development." This" approach"has"
the"advantages" to"be" less" serotype\dependent" and" to"decrease" resistance\related" issues," as"
more" viral" mutations" would" be" required" in" order" to" overcome" the" loss" of" a" host" cofactor."
Additionally," it" is"easier"to"develop"broad\spectrum"compounds,"as"several"viruses"share"the"
same" host" cofactor." The" disadvantages" of" targeting" host" factors" are" mainly" linked" to" the"
higher" rate"of" toxic" effects" that"might" develop."However," as"DENV" is" an" acute"disease," side"
effects"might"be"less"problematic"than"in"the"case"of"chronic"diseases."Consequently,"antiviral"
research"has"also"moved"in"this"direction.[31,49,51,74]"
Host" cofactors" that" are" necessary" in" the" DENV" replication" cycle" and" that" could" be" used" as"
potential" targets" are" several" (e.g." proteases," dihydroorotate" dehydrogenase," glucosidases,"
kinases" and" factors" of" the" cholesterol\biosynthesis" pathway).[49,51,74]" Some" inhibitors" that"
target"these"host"factors"are"reported"in"Table"A1.3"of"APPENDIX&1."Only"a"general"overview"of"
host"target"drug"design"is"presented"here."
Furin"and"signal.proteases"are"responsible"for"the"cleavage"of"the"viral"polyprotein"precursor"
together"with"NS3\2B"serine"protease"and"hence,"their"inhibition"would"have"the"same"effect"
as"the"inhibition"of"NS3\2B"protease"itself"in"infected"cells.[31,51]"Unfortunately,"small\molecule"
inhibitors"of" Furin"have"proven" to"be"challenging;"while" targeting" the" signal"protease"would"
give"too"many"side"effects"as"it"is"involved"in"several"other"cellular"functions.[31,51]"Compounds"
that" inhibit" selectively" flavivirus" RNA" translation" have," however," been" discovered" through"
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HTS."These"molecules"inhibit"host"factors,"but"the"identity"of"the"target"protein"has"yet"to"be"
determined.[49]"
For"viral"RNA"synthesis,"the"availability"of"ribonucleic"acid"bases"is"fundamental."Consequently,"
the" synthesis"of"purine"and"pyrimidine"bases"plays"an" important" role" in" the"viral" replication"
cycle.[49]"This"was"confirmed"by"the"fact"that"screening"campaigns"have"identified"compounds"
that" have" antiviral" effect" by" inhibiting" either" the" mitochondrial" protein" dihydroorotate"
dehydrogenase" (DHODH)" or" the" inosine"monophosphate" dehydrogenase" (IMPDH)." The" first"
enzyme" is" responsible" for" one" of" the" steps" required" for" de" novo" pyrimidine" synthesis" (e.g."
uridine,"U),"while"the"second"one"is"responsible"of"the"conversion"of"inosine"monophosphate"
(IMP)" to" xanthosine" monophosphate" (XMP)," precursor" of" GMP." However," to" show" in& vivo"
efficacy"of"these"compounds"is"a"challenge"as"pyrimidine"bases"(as"U)"and"GMP"levels"can"be"
restored"through"the"diet.[49,75,76]"
Host" kinases" are" responsible" for" nucleosides" phosphorylation," an" essential" step" for" RNA"
synthesis.[31,51]" Thus," these" proteins" constitute" another" potential" host" target." However," the"
biological" activity" profile" of" these" enzymes" is" often" not" fully" understood," making" drug"
discovery" challenging.[31,51]" For" example," known" kinase" inhibitors" (AZD0530" and" dasatinib" in"
panel"A"and"B"of"Figure"1.13" respectively)"were"also" found" to"be"host"Fyn"kinase" inhibitors."
Further"in&vitro"studies"have"shown"that"this"enzyme"is"critical"in"viral"RNA"replication"through"
interaction"with"NS4B"rather"than"nucleoside"phosphorylation."This"was"demonstrated"by"the"
fact"that"drug"resistant"viruses"presented"mutations"in"the"viral"protein"NS4B.[77]"
"
" ! "
A" B"
Figure'1.13..Fyn.kinase.inhibitors...
A).AZD0530..B).Dasatinib..
Three" of" the" viral" proteins" (prM," E" and" NS1)" have" to" be" glycosylated" for" correct" folding."
Misfolding" produces" protein"malfunction" and" the" arrest" of" the" viral" replication" cycle.[49,51,74]"
Consequently," the" inhibition" of" glucosidases," in" particular" α\glucosidases," is" a" promising"
therapeutic" strategy" as" these" enzymes" are" responsible" for" the" mentioned" viral" proteins"
glycosylation.[49,51,74]"They"seem"particularly"successful"targets"as"one"drug"candidate"that"has"
recently"finished"clinical"Phase"Ib"trial"for"DENV"is"Celgosivir"(Figure"1.14),"an"oral"pro\drug"of"
castanospermine," a" natural" product" from"Castanospermum&australae." It" is" a"α\glucosidase" I"
and" II" inhibitor"whose"effect" reflects" in"particular"on"NS1"unfolding." It" is"active"both" in&vitro"
and" in& vivo" in" the" AG129" mouse" model.[78,79,80]" Unfortunately" the" efficacy" data" on" DENV"
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patients"was"not"as"good"as"expected."Future"clinical"trials"will"be"improved,"adjusting"doses"
treatment"frequency"and"duration.[81]""
"
!
Figure'1.14..Celgosivir..
Both" endogenous" and" exogenous" cholesterol" have" been" found" necessary" for" DENV"
infection.[49]" The" exact" role" of" cholesterol" has" yet" to" be" fully" understood," but" it" has" been"
hypothesised" that" plasma" membrane" cholesterol" relocalization," in" particular" near" viral"
proteins,"could"affect"membrane"flexibility"and/or"stabilise"the"DENV"replication"complex."The"
inhibition" of" factors" involved" in" cholesterol" biosynthesis" and" transport" have" indeed" been"
shown" to" have" an" antiviral" effect" and" could" be" therefore" interesting" for" anti\DENV"
therapeutics" development.[49,51,82]" In" particular," enzymes" involved" in" the" cholesterol"
biosynthesis" pathway" whose" inhibition" prompts" an" antiviral" response" are" mevalonate"
(diphospho)" decarboxylase" (MVD)," HMGFCoA. synthase" and" squalene. synthase." These"
enzymes"could"be"used"as"drug"targets.[82]""
The"most"severe"DENV\related"clinical" features,"DHF"and"DSS,"have"been"associated"with"an"
antibody\dependent" enhancement" (ADE).[49]" For" this" reason," modulation" of" the" immune"
system" could"help" to" overcome" the" illness." Patients"with" severe"disease"have"high" levels" of"
cytokines,"chemokines"and" IFNFγ "and"consequently" these"factors"have"been"correlated"with"
disease" severity." For" this" reason" these" factors" have" been" considered" as" potential" host" drug"
targets." However," ADE" and" its" molecular" pathways" has" not" been" fully" elucidated" and"
consequently"this"approach"has"not"been"yet"explored.[31,49,51]""
"
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1.2.MOLECULAR.MODELLING..
"
MOLECULAR'MODELING'AND'DRUG'DISCOVERY'
"
Drugs"discovered"by"pharmaceutical" research"have"made"a"great" contribution" increasing" life"
expectancy"by"an"average"of"2"months"each"year"and"improving"quality"of"life"by"transforming"
many"life"threatening"diseases"to"almost"negligible"problems.[83\85]"The"process"that"leads"to"a"
new"molecular" entity" (NME)"becoming"available"on" the"market" for" an"efficacious" therapy" is"
long," costly" and"most" of" the" times" unpredictable." The" discovery" of" each" novel" drug" has" it’s"
own"peculiar"“story”,"but"the"overall"process"can"be"generalised."It"commonly"takes"between"
8" to" 14" years" and" costs" an" average" of" 1.3" billion" dollars" to" develop" a"NME.[83,86]" Everything"
starts"with" the"choice"of" the"disease"and," if" known,"of" the"molecular" target."Many"scientific"
factors,"in"particular"the"understanding"of"the"biological"processes"involved,"play"a"role"in"this"
decision."However,"also"economic"aspects"are"of"great" importance"at"this"stage," in"particular"
in"pharmaceutical"industries."It"is"fundamental"for"them"to"estimate"the"potential"return"that"
the"drug" could" give"when" it" reaches" the"market" and"evaluate" if" this" is" enough" to" cover" the"
costs"and"gain"money"for"future"investments"in"research"and"development"(R&D)."After"having"
identified" the" target," it" is" necessary" to" identify" a" lead" molecule" that" is" able" to" produce" a"
selective" therapeutic" effect." The" discovery" of" these" compounds" can" be" achieved" in" several"
ways" (e.g." from" natural" products," from" HTS" campaigns" or" from" rational" drug" design)," but"
usually"the"first"identified"molecule"is"not"suitable"for"progressing"through"drug"development"
and"eventually"for"human"administration."It"has"to"be"optimised"in"order"to"improve"both"its"
pharmacodynamics"and"pharmacokinetics"properties."Many"analogue"molecules"are"generally"
synthesised"and"evaluated"at"this"stage."The"most"attractive"compounds"are"then"tested"with"
in" vitro" and" in" vivo" models." This" constitutes" the" preclinical" phase," where" absorption,"
distribution,"metabolism"and"excretion" (ADME)"properties"are"also"evaluated,"as"well"as" the"
toxicology"profile."The"aim"at" this" stage" is" to"understand"whether" the"compound(s)"are"safe"
enough" to" be" tested" in" humans" and" to" have" an" estimate" of" the" initial" dose" that" should" be"
used."The"reliability"of"the"models"used"is"therefore"crucial"at"this"stage"in"order"to"obtain"the"
correct"toxicology"profile."Molecules"that"prove"to"be"safe"are"then"tested"in"human"through"
clinical"trials"that"can"be"divided"into"three"phases."Phase"I"represents"the"first"time"that"the"
compound" is" tested" in" humans." It" is" carried" out" on"healthy" volunteers"with" ascending" dose"
regimens" with" the" aim" of" evaluating" the" safety," tolerability" pharmacokinetics" and"
bioavailability"properties"of"the"potential"drug."Efficacy"can"be"evaluated"in"a"second"Phase"Ib"
trial" if" human" volunteers" are" a" suitable" population" for" the" putative"medicine." For" example,"
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potential" hypnotics" are" often" first" evaluated" for" efficacy" at" this" stage."However," usually" the"
candidate"molecule"is"first"evaluated"in"a"phase"II"clinical"trial"involving"between"100"and"300"
patients" depending" on" the" complexity" of" the" trial" design." The" tested" compound" efficacy" is"
usually"compared"to"placebo"and,"when"possible,"to"the"gold"standard"marketed"therapy."The"
last"clinical"studies" (phase" III"clinical" trial)"before"the"registration"of" the"drug"are"on"a" larger"
scale"(exposing"thousands"of"patients)"with"the"aim"of"confirming"what"has"been"observed"in"
phase"II,"but"with"a"stronger"statistics."These"trials"also"look"for"unwanted"effects"that"are"only"
apparent"when" large"patient"populations"are"exposed"to"the"drug."Drug"evaluation"does"not"
stop," though," with" the" approval" to" commercialisation." As" the" compound" has" never" been"
tested" on" a" large" scale" as" the"World" population," it" is" important" to" continue" to"monitor" its"
effects" also" after" reaching" the" market" through" pharmacosurvaillance.[83]" Figure" 1.15"
schematises"the"drug"discovery"pipeline"described"in"the"text."
"
"
Figure'1.15..Drug.discovery.pipeline.
Schematic"representation"of"the"drug"discovery"process."See"text"for"description"of"the"steps.""
Abbreviations:"ADME="Adsorption,"Distribution,"Metabolism"and"Excretion."
From" 1950," 1365" NMEs," most" of" which" are" small" molecules," were" approved" for"
commercialisation.[85,87]" Apart" from" a" temporary" peak" between" 1995" and" 1999" and" the"
unusually"high"number" in"2012"(39"NMEs)," the"trend"for"the"numbers"of"NMEs"reaching"the"
market"each"year" is" flat,"with"an"average"of"24"NMEs/year."Conversely," the" required"overall"
expenditure" to" get" these" NMEs" to" the"market" has" been" exponentially" growing" at" a" rate" of"
12.3%" per" year," whilst" the" sales" growth" is" flattening." This" “pharmaceutical" crisis”" scenario"
could"be"related"to"the"fact"that"the"“easy”"targets"have"already"been"tackled,"to"the"failure"
rate" of" 80%," to" the" continuous" increase" of" regulation," to" the" requirement" of" significant"
expected" improvement" in" respect" to" available" therapy," to" competition" and" to" difficulties" in"
innovation.[85]""
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In" order" to" improve" the" situation" and" since" “time" is" money”," industry" has" been" applying"
techniques" to" speed" up" the" drug" R&D" process." For" instance" combinatorial" chemistry" for"
analogue"synthesis"during"the"lead"optimisation"step"has"been"greatly"applied"as"it" is"a"rapid"
method"for"parallel"synthesis"of"a" large"collection"of"compounds.[83,88]"Another"way"to"speed"
up" the" process" is" the" development" of" automated" HTS" assays" to" screen" huge" compound"
libraries" for" a" faster" lead" discovery." This" technique," an" essential" facilitator" of" combinatorial"
chemistry,"has"been"shown"to"be"able" to" identify" leads"with"a" success" rate"between"50"and"
60%,"which" is" lower" than" the" initial" forecasts." This" is"mainly"because" it" relies"greatly"on" the"
quality"of"the"screened"libraries"and"on"the"strength"of"the"screening"assay."Additionally,"the"
equipment"is"very"costly"and"the"screening"of"big"compound"libraries"sometimes"takes"a"long"
time,"differently"from"a"more"focused"approach."Attempts"on"HTS"improvement,"in"particular"
on"the"quality"and"chemical"diversity"of"the"library,"are"being"carried"out,"but"the"cost"of"this"
technique"is"still"a"big"issue.[89]""
As"it"is"based"on"using"information"technology,"an"important"aid"in"greatly"reducing"time"and"
costs" of" R&D" can" be" given" by" molecular" modelling," whose" popularity" is" indeed" increasing."
Molecular"modelling"is"a"scientific"field"that"exploits"computational"techniques"(this"is"why"it"is"
often" described" as" synonymous" to" computational" chemistry)" in" order" to" explain" complex"
chemical" systems" in" terms" of" models." In" general" terms," a" model" is" heuristic," a" simplified"
description"of" a" system" that" has" the" goal" to" enable" understanding" and"predict"macroscopic"
properties,"starting"from"knowledge"on"an"atomic"scale."This"can"be"achieved"either"exploiting"
experimental" data" or" using" a" theoretical" model" or" combining" the" two" strategies.[90,91]" Drug"
activity" is" strictly" correlated" to" molecular" recognition" and" consequent" binding" to" biological"
targets," like"enzymes,"nucleic"acid,"glycoproteins"or" receptors."This" recognition" relies"on" the"
formation"of"specific"attractive"interactions"between"molecules,"like"hydrophobic"interactions"
or" hydrogen" bonds." Therefore," the" comprehension" of" the" characteristics" that" an" ideal" drug"
molecule"should"have"in"order"to"achieve"these"interactions"is"fundamental"for"efficient"drug"
design." In" a" live" organism" a" molecule" also" undergoes" a" series" of" processes" (adsorption,"
distribution,"metabolism"and"excretion)" and" consequently" the" compound" structure"must" be"
optimized"to"enhance"the"opportunity"for"the"molecule"to"interact"with"the"molecular"target."
Molecular" modelling" can" be" used" to" help" to" consider" all" of" these" aspects" through" virtual"
experiments" that" are" intrinsically" cheaper," faster" and" safer" than" real" experiments." In& silico"
results"can"help"scientists"to"select"compounds,"removing"those"that"do"not"have"the"correct"
profile," improving"the"probability"of"success"at" lower"costs."The"continued"development"and"
improvement"of"the"computers’"processing"capacity"and"of"the"molecular"modelling"programs"
themselves" are" contributing" notably" to" the" reliability" of" the" results" obtained" with"
computational" techniques" and" for" all" these" reasons," the" drug" discovery" process" has"
increasingly"involved"computational"chemistry"in"recent"years.[84,92]"
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Computer"aided"drug"design"is"generally"divided"into"two"major"categories:"ligandAbased"drug"
design"and" structureAbased" drug"design.[93]"StructureAbased" drug"design"aims" to" identify" and"
optimize"drug" target" interactions"and" is"based"on" the" lock"and"key"metaphor."However," the"
availability"or"the"possibility"to"construct"the"three\dimensional"structures"of"these"molecules"
is"an"absolute"requirement.[94]"If"structural"data"is"not"present"or"cannot"be"produced,"ligandA
based" drug" design" represents" a" valid" alternative." This" approach" is" based" on" the" analysis" of"
various" descriptors" of" a" set" of" ligands" of" a" biological" target" for" which" experimental" data" is"
available,"in"order"to"predict"and"optimize"biological"properties"of"compounds.[93]""
Computational" chemistry" can" also" be" seen" as" the" knowledge" derived" from" two" main" and"
different" computer\based" methods:" Molecular" Mechanics" (MM)" and" Quantum" Mechanics"
(QM)." Molecular" Mechanics" is" defined" as" the" application" of" classical" mechanics" to" the"
modelling" of" molecular" systems." Several" simplifications" to" the" physical" and" mathematical"
description" of"molecules" are" adopted," lowering" the" complexity" of" the" problem." Differently,"
Quantum"Mechanics"considers"electrons"as"separate"entities"and"in"this"manner"it"calculates"
all"of"those"properties"that"depend"on"electronic"distribution,"in"particular"chemical"reactions"
in"which"bonds"are"broken.[91]"
QUANTUM'MECHANICS'
"
Quantum"mechanics"(QM)"is"mainly"based"on"the"molecular"orbital"theory"and"Schrödinger’s"
equation.[92,95]"In"a"molecular"system,"its"properties"derive"from"the"description"of"the"particles"
(e.g."electrons"and"protons)"that"construct"each"atom"that"is"obtained"through"the"evaluation"
of" the" wave" function" associated" with" these" particles." Schrödinger’s" equation" is" the" most"
accurate" way" to" obtain" these" wave" functions," using" mathematical" variables" (quantum"
numbers)."The"partial"differential"equation"is"very"complex"and"can"be"analytically"solved"only"
in"very"simple"systems."Theoretically,"this"is"the"most"correct"approach"that"could"be"used"in"
molecular"modelling"studies,"but"the"complexity"of"the"calculations"described"above,"limits"its"
application" only" to" small" molecular" systems." Therefore," before" using" QM" methodology" to"
solve" problems" of" interest," it" is" important" to" assess" whether" this" grade" of" accuracy" is"
necessary."Usually,"problems" that"exploit"QM"calculations" regard"properties" that"depend"on"
electronic"distribution,"like"electron"density"studies"and"chemical"reactions"in"which"bonds"are"
broken"or"formed.[92,95]"
"
"
"
Section"1:"INTRODUCTION" 1.2&MOLECULAR&MODELLING"!
33!
MOLECULAR'MECHANICS'
"
Molecular" mechanics" (MM)" methods" apply" Newton’s" classical" mechanics" to" molecular"
systems." Bigger" approximations" than" in" QM" are" applied" and" the" electronic" motions" are"
ignored." In" fact," energies" in" the" system" are" calculated" as" a" function" of" the" atom’s" nuclear"
position"and"electrons"are"considered"to"be"always"in"their"ground"state."This"reduces"greatly"
the"amount"of"calculation"needed"and"allows"calculations"on"systems"with"a"large"number"of"
atoms.[92,96]"
The" approximations" made" are" several." The" most" important" ones" are" that:" molecules" are"
treated" as" balls\and\spring" systems," atoms" are" handled" as" solid" spheres"with" fixed" Van" der"
Waals"radius"and"charge,"atoms"differ"among"themselves"by"atom\type,"bonds"are"considered"
unbreakable" springs" and" electrons" and" nuclei" are" not" studied" as" separated" entities" in" the"
calculations." Atom\types" do" not" only" contain" information" about" the" atomic" number" of" the"
nuclei,"but"they"also"specify"the"hybridization"of"the"atom"and"therefore"the"geometry"(normal"
bond" lengths,"angles"and"dihedral" values)"of" the" system"concerning" the"atom"of" interest." In"
this"way," a"molecule" is" translated" into"a" series"of" atom" types"and"bonding" lists," considering"
each" atom" as" a" separate" entity." A" series" of"mathematical" equations" are" then" employed" to"
compute" the" descriptors" of" the" molecular" system." The" collection" of" the" mathematical"
equations"and"the"atom"parameters"is"defined"as"force"fields.[92,96,97]"
FORCE.FIELDS.
"
Force"fields"are"sets"of"mathematical"equations"and"parameters"that"allow"the"description,"as"
accurately" as" possible," of" the" intra\" and" inter\" molecular" interactions" within" a" molecular"
system."The"mathematical"equations"give"the"possibility"to"generate"the"potential"energy"of"a"
system," within" molecular" mechanics" approximations," and" their" derivatives," the" forces." The"
equation" forms" vary" between" different" force" fields," but" a" general" procedure" for" the"
calculation" of" the" potential" energy" of" a" system" is" the" sum" of" the" different" components" of"
bonded"and"non\bonded"interaction"for"each"atom,"as"reported"in"Equation"1.1.""
" !!"! = !!"# + !!"#$ + !!"#$ + !!"#$ + !!"# + !""#$#%&'(!!"#$"
Equation'1.1..General.equation.used.by.force.fields.[96].
The"potential"energy"is"calculated"as"the"sum"of"different"energy"components."Some"of"them"calculate"the"energy"
correlated"to"bonded"interactions:"bond"stretching"(Estr),"angle"bending"(Ebend),"dihedral"torsion"(Etors)."Others"
calculate"the"energy"correlated"to"non\bonded"interactions:"electrostatic"(ECoul)"and"van"der"Waals"(EvdW)"
interactions."Some"force"fields"use"also"an"additional"term."
Within"the"bonded"interactions"(bond"stretching"Estr,"angle"bending"Ebend"and"dihedral"torsions"
Etors," as" indicated" in" the" equation)," each" energy" component" is" calculated" in" respect" to" a"
reference" value" that" represents" the" “unrestrained”" or" “equilibrium”" value" of" bond" length,"
Section"1:"INTRODUCTION" 1.2&MOLECULAR&MODELLING"!
34!
angle" and" dihedral." These" values" represent" the" value" that" the" bond/angle/dihedral" adopts"
when"all"the"other"terms"in"the"force"field"equation"are"set"to"zero."The"deviation"from"them"is"
translated"in"terms"of"energy"penalties,"calculated"using"an"empirically"determined"constant,"
as"it"will"be"more"specifically"illustrated"in"the"description"of"Equation"1.2."All"the"equilibrium"
values" and" the" constants" constitute" the" parameters" of" a" force" field.[92,96,97]" Non\bonded"
interactions" are" usually" described" in" terms" of" electrostatic" and" van" der"Waals" interactions"
(Lennard\Jones" interaction)." More" sophisticated" force" fields" have" also" additional" terms" in"
order"to"give"more"accuracy"to"the"energy"calculation.[90,92,96,97]"
Looking"at"the"energy"calculation"in"more"detail,"one"common"functional"form"of"a"force"field"
is" reported" in" Equation" 1.2." In" order" to" simplify" calculations" for" calculation" rapidity"
enhancement,"bond"stretching"and"angle"bending"are"approximated"to"harmonic"systems"that"
follow"Hooke’s"law."The"energy"contribution"derives"consequently"from"the"cubic"difference"of"
the"bond"length/angle"value"to"the"reference"value,"multiplied"by"an"empirical"constant."This"
approximation" is"more" accurate" if" the" system" is" near" its" equilibrium." The" equation" is"more"
complex" for" the" calculation"of" the"dihedral" contribution" to" the" total" energy."Different" force"
fields"adopt"different"functions,"but"the"dihedral"contribution"often"follows"a"cosine"trend."As"
often" some" specific" torsion" angles" are" preferred" to" others," force" field" parameters" also"
consider"an"additional"empirical"term"in"the"dihedral"energy"contribution"to"describe"correctly"
the"geometry"of"the"molecules."Van"der"Waals"forces"are"taken"into"account"with"an"empirical"
expression" called" the" Lennard\Jones" function." This" function" relates" both" attractive" and"
repulsive" coefficients" between" pairs" of" atoms" to" their" distance." For" the" calculation" of" the"
electrostatic" properties" of" the"molecule," the" atom" partial" charges" are" placed" in" the" atom’s"
nuclei"and"the"electrostatic"energies"and"forces"are"then"calculated"with"Coulomb’s"law."Both"
of" the" non\bonded" interactions" are" considered" pair\additive," which" means" that" energy"
contributions" are" calculated" for" one" pair" of" interacting" atoms" at" the" time." In" reality" these"
energy" interactions"are"not"pair\additive"and"this"approximation,"that"simplifies"calculations,"
might"introduce"some"errors.[90,96,97]"
"!!"! = !!2 ! − !!" !!"# + ! !!2 ! − !!" !!"#$+ ! !!2 1 + !"# !" − !!" + ! !!"!!"!" − !!"!!"! + ! !!!!!!!"!"#$!"# + !""#$#%&'(!!"#$!"#$ "
Equation'1.2..Common.functional.form.of.a.force.field.[96].
More"detailed"representation"of"a"force"field"mathematical"equation,"with"kb,"kθ,"k!"="force"constants;"l=bond"
length;"θ="angle;"!=dihedral"angle;"n=periodicity;"A=repulsive"term"coefficient;"B=attractive"term"coefficient;"
r=distance"between"atom"i"and"atom"j;"q=atom"partial"charge)"
Force" fields" are" often" empirical" or" semi" empirical" in" order" to" fit" the" equations" to" the"
experimental"or"calculated"data."For"this"reason," in"the" last"few"years"several"different"force"
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fields" have" been" developed" and" they" differ" one" to" the" other" for" the" function" form" or" the"
parameters," or" both." Each" one" of" them" has" been" developed" in" order" to" give" a" reliable"
description"of"a"certain"type"of"molecular"system"(e.g."small"ligands,"proteins"or"nucleic"acids)"
and"this"means"that" to"date"a"unique" force" field" that" fits"every"kind"of"situation"has"not"yet"
been" developed." Consequently," it" is" impossible" to" establish" unequivocally"which" is" the" best"
force" field," because" the" “best”" is" clearly" dependent" on" what" properties" one" wishes" to"
calculate"and"what"kind"of"system"is"the"object"of"study.[98]"
"
" "
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STRUCTURESBASED'DRUG'DESIGN'
"
In" general," the" process" of" drug" design" aims" to" enhance" specific" drug\molecular" target"
interactions" in" order" to" improve" the" drug’s" activity" and/or" to" reduce" the" side" effects." The"
accessibility" to"structural" information"on"the"molecular" target"makes"this"process"easier"and"
therefore" preferable." Methodologies" that" exploit" available" target" structures" are" defined" as"
structureAbased&drug"design"methods."The"rapid"increase"in"the"number"of"determined"three\
dimensional" structures"of"potential"molecular" targets" (proteins,"nucleic"acids,"etc.)"has"been"
decisive"for"the"development"of"this"kind"of"molecular"modelling"approach.[99]""
The" structure\based" drug" design" process" can" be" an" iterative" procedure" in" which" at" each"
iteration" the" aim" is" to" improve" possible" drug\target" interactions." Initially," a" ligand"with" low"
activity"might"be"found"and"then"this"can"be"improved"through"structure"optimization.[100]"
The" first" stage" of" a" structure\based" approach" is" the" identification" of" the" optimal"molecular"
target"for"drug"design"and,"if"there"is"more"than"one"available"structure,"the"choice"of"the"best"
one" in" terms"of" structure"quality"and"biological" relevance."Structural" information"can"derive"
from" four" sources." The" first" and" most" common" one" is" X\ray" crystallography." The" main"
advantages"of"the"use"of"crystal"structures"are"that"ordered"solvent"molecules"can"be"visible"
and"that"the"quality"of"the"structure"itself"is"easily"determinable"through"the"examination"of"a"
few"parameters" (resolution,"R"value,"Rfree," temperature" factors,"values"of"ϕ" and"ψ"backbone"
angles)."The"second"source"of"structure"data"is"nuclear"magnetic"resonance"(NMR)."In"this"case"
there"are"no"similar"parameters"that"could"indicate"the"quality"of"the"structure"apart"from"the"
root" mean" square" deviation" value" of" the" coordinates." Even" if" structural" data" availability" is"
exponentially" increasing," there" is" still" a"huge"gap"between"known"structures"and"sequenced"
genome"portions."In"the"case"of"a"lack"of"experimental"structural"data"for"a"protein,"Molecular"
Modelling" can" be" a" third" source" of" structures." For" instance," homology" modelling" is" a"
computational"technique"that"enables"the"“building”"of"macromolecular"structures"exploiting"
the" existence" of" structural" data" of" similar" molecules." Proteins" can" be" considered" similar"
enough"for" the"reliability"of" this"approach" if" they"are"evolutionary"related"and"they"share"at"
least"30%"or"the"primary"sequence."Following"this"rule,"this"technique"could"be"used"to"model"
a" human" protein" when" the" same" protein," but" non\human," has" been" solved.[100\102]"
Alternatively," as" proteins" are" generally" at" an" energy\minimum" state,"de& novo"methods" that"
“fold”" primary" sequences" of" proteins" are" being" currently" developed." Unfortunately," due" to"
extensive" conformation" exploration," they" are" very" time" consuming" methods.[102]" Even" if"
models" produced" by" Molecular" Modelling" have" performed" well," it" is" preferable" to" use"
experimental" structural" data" if" possible.[100,101]" A" further" source" of" structural" data" is" cryo\
electron" microscopy" (cryo\EM)." This" source" is" not" commonly" used" because," even" if" always"
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improving," the"resolution"of" this" technique" is"not"at" the"same" level"of"X\ray"crystallography."
However,"these"data"can"be"used"to"aid"the"building"of"a"homology"model"of"the"protein.[103]"
Once" the" structure" has" been" chosen/produced," several" computer\aided" approaches" can" be"
used" for" structure\based" drug" design:" an" initial" compound" present" in" the" structure" can" be"
modified;"a"database"of"compounds"can"be"screened;"a"de&novo"generation"can"be"developed"
by"virtual"positioning"fragments"within"the"target"site"and"linking"them."All"of"these"are"based"
on"docking"and"scoring"methodologies.[100]"
"
DOCKING.AND.SCORING.
"
A"docking"process"allows"the"simulation"of"the"binding"mode"that"a"molecule"would"adopt"in"
its" interaction"with" its"molecular" target."The" ligand"conformation"and"orientation"within" the"
binding" pocket" is" called" pose" (exemplified" in" Figure" 1.16)" and" the" aim" of" this" kind" of"
methodology" is"to"have"a"prediction"of"binding"affinity"(that"often"translates" into"activity)"of"
the"docked"molecules."Docking"and" scoring"can"be"described" in"a"multi\step"procedure" that"
can" be" generalized" in" three" moments:" poses" generation," poses" scoring" and" final" pose"
selection.[93,101]"
"
!
Figure'1.15..Example.of.pose.of.a.molecule.in.the.RNA.binding.site.of.DENV.NS3.helicase..
The"docked"molecule"is"shown"as"a"space\filled"representation"and"the"protein’s"protein"surface"is"coloured"in"
green."
Ligand" poses" are" generated" by" search" algorithms." In" the" simplest" model," the" ligand" can"
translate" and" rotate" within" the" binding" site." However," in" reality" both" ligand" and" protein"
flexibility"are"important"factors,"greatly"increasing"the"degrees"of"freedom"involved"in"ligand\
molecular" target"binding.[93,100,101]"As" a" consequence," the" rigorous" search" for" all" the"possible"
binding"poses"and"their"evaluation"would"be"extremely"expensive"from"a"computational"point"
of" view." The" first" docking" programs" simplified" this" issue" by" computing" a" so\called" rigid"
Section"1:"INTRODUCTION" 1.2&MOLECULAR&MODELLING"!
38!
docking." This" approach"does" not" take" into" account" either" the" ligand"or" the" target"molecule"
flexibility," but" only" rotational" and" translational" degrees" of" freedom." With" the" advances" in"
computational"performance"and"program"improvements,"it"is"nowadays"possible"to"compute"
semi\flexible" and" flexible" docking," where" only" ligand’s" or" both" ligand’s" and" the" target"
molecule’s" flexibility"are"considered"respectively."This"has"produced"a"great"enhancement" in"
the" accuracy" of" results.[93,104]" Even" if" computational" capability" is" continuously" increasing," a"
rigorous" conformational" search" is" still" not" feasible." In" fact," only" a" small" amount" of" the"
conformational" space" is" sampled" by" docking" programs" and" the" sampling"method" can" differ"
according"to"the"searching"method."On"this"basis,"search"algorithms"can"be"divided"into"three"
groups."The"first"group,"called"systematic"methods,"achieves"the"construction"of"the"possible"
conformations"through"the"incremental"(e.g."every"30°)"rotation"of"torsional"angles."Random"
or"stochastic"methods"belong"to"the"second"group"of"search"algorithms."They"apply"random"
changes" to" the" conformation" of" the" ligands" and" then" they" evaluate" the" poses" with" a" pre\
defined"probability" function."The" third"group"of" searching"methods" is"by"simulation," such"as"
energy"minimisation"or"molecular"dynamics."By"these"methods,"the"attempt"is"to"find"the"pose"
at"the"energy"minima,"generally"considering"both"the"ligand"and"the"protein"as"flexible.[101,104]"
The"evaluation"of" the"generated"poses" is" accomplished"by" the"use"of" scoring" functions" that"
estimate"binding"free"energy"and"consequently"the"molecule’s"activity."As" in"the"case"of" the"
pose" searching" procedure," the" exhaustive" calculation" of" the" ligand\protein" interactions" is"
impractical." For" this" reason," some" approximations" have" been" developed" and" the" scoring"
functions"can"be"classified"in"force"field\,"empirical\"or"knowledge\based.[93,101,104]"As"the"name"
suggests," the" first" category" is" based" on" the" MM" force" fields" described" previously" and" on"
Equations"1.1"and"1.2."In"general"terms,"the"interaction"energy"is"calculated"through"the"sum"
of"the"receptor\ligand"interactions"and"the"internal"energy"of"the"ligand."In"the"case"of"flexible"
docking"software,"in"which"also"protein"flexibility"is"taken"into"account,"there"is"an"additional"
term"that"represents"the"internal"energy"of"the"protein."Empirical\based"methods"use"scoring"
functions" in"which"parameters"are"calculated" in"order"to"resemble"the"experimental"data"on"
binding"energies"or"affinities."Knowledge\based"scoring"functions"are"mathematical"equations"
that" are" built" in" order" to" reproduce" experimental" structures," with" the" assumption" that"
crystallographic"(or"NMR)"data"resembles"energetically"favoured"conformations.[101]""
Docking" and" scoring" experience" has" shown" that" different" molecular" systems" are" well"
evaluated" using" different" types" of" scoring" functions" and" that" each" scoring" function" carries"
some"imperfections,"as"they"are"approximate."If"the"ideal"scoring"method"is"not"known"for"a"
molecular"system,"a"common"procedure"is"to"repeat"the"scoring"with"more"than"one"method"
and"to"use"a"consensus"score"that"combines"the"obtained"results,"improving"the"probability"to"
identify" favourable" ligands.[95,101]" Despite" the" fact" that" a" consensus" score" increases" the"
procedure’s" performance," it" is" still" forecast" that" the" scoring" values" might" contain" some"
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deficiencies."Consequently,"the"user’s"contribution" in"selecting"the"final"poses"through"visual"
inspection"of"the"actual"ligand\protein"interactions"is"fundamental"for"the"selection"of"the"best"
molecules.[100,101,105]"
"
DE.NOVO.DRUG.DESIGN.
"
Unlike" in" virtual" screening" approaches" in" which" more" or" less" large" databases" of" known"
molecules"are"docked,"scored"and"rescored"in"the"desired"protein"site,"a"de&novo"drug"design"
approach"aims"to"build"new"chemical"entities"that"are"not"present"in"the"literature."This"can"be"
achieved"through"two"main"methodologies.[101,106]"
One"method"requires"the"binding"of"small"fragments"within"the"binding"site."These"molecules"
usually" follow"the"“rule"of" three”,"meaning"that" they"have"a"molecular"weight" less" than"300"
g/mol,"a" logP" less"than"3," less"than"3"hydrogen"bond"donors"and" less"than"3"hydrogen"bond"
acceptor"groups.[107]"Fragments"can"be"either"co\crystallised"with"the"protein"or"placed"in"the"
binding"site"with"the"docking"and"scoring"methodologies"explained"above."The"fragments"that"
bound"the"best"are"then"assembled"into"larger"molecules."These"new"molecules"can"then"be"
energy"minimised"and"their"best"pose"can"be"searched"with" the"same"procedure"of" the"one"
described"above.[101,106,108]"
The" second" method" is" principally" used" in" lead" optimization" procedures." The" methodology"
requires"a"“seed”"molecule"to"be"placed"in"the"binding"site."New"fragments"are"then"linked"to"
this"structure"in"specified"“growing"sites”"in"order"to"obtain"an"increase"of"the"binding"affinity."
Also"in"this"case,"the"new"molecules"obtained"can"then"be"energy"minimised"and"the"best"pose"
can"be"searched"with"the"same"procedure"of"the"one"described"above.[83,84]"
Despite"the"fact"that"with"these"techniques"there"is"the"possibility"to"explore"novel"chemical"
space," an"opportunity" that" is" not"normally" accomplished" through" common"virtual" screening"
approaches,"de&novo"drug"design"methods"are"not"widely"adopted"because"the"novel"designed"
molecules"often"are"very"complex"and"difficult"to"synthesise.[101,106,108]"Groups"are"trying"at"the"
present" time" to" overcome" this" major" problem," improving" the" available" programs," like"
LigBuilder"or"the"fragments"based"tools"in"the"Molecular"Operating"Environment"(MOE).[106,108]"
These"programs"are"now"able"to"rate"the"new"described"molecules"on"the"base"of"their"ease"
of"synthesis"and"to"use"this"information"to"improve"the"output."
"
"! '
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LIGANDSBASED'DRUG'DESIGN'
"
As" already"mentioned," if" possible," structure\based"drug"design" is" preferable." In" some" cases,"
such"as"membrane"bound"proteins,"the"three\dimensional"structure"of"the"target"is"difficult"to"
achieve"with"the"present"techniques"or"in"another"cases"the"structure"is"not"yet"available."If"it"
is" not" even" possible" to" build" a" homology"model," or" in" the" case" the" target"molecule" is" not"
known,"the"only"strategy"that"can"be"followed"is"to"apply"ligand\based"drug"design"methods."
The"common"feature"of"these"techniques"is"the"fact"that"the"drug"design"process"is"based"on"
drug\like"molecules," chemical" structures"and"on" their"activity"data."Three" techniques"can"be"
used:" pharmacophore" search," similarity" search" and" quantitative" structure\activity"
relationships" (QSAR)."Even" if" these"methods"are"classified"as" ligand\based"methods," it" is"not"
unusual"to"find"that"they"are"used"in"combination"with"structure\based"approaches.[93]"
"
PHARMACOPHORE.SEARCH.
"
A"pharmacophore"is"a"set"of"chemical"features"that"are"related"to"molecule"activity."Common"
features" usually" are:" hydrogen" bond" donor" (e.g." –OH)," hydrogen" bond" acceptor" (e.g."O,"N),"
hydrophobic" group" (e.g." –CH3)," aromatic" group," anion" (e.g." –OPO32\)" or" cation" (e.g." –
NH3+).[93,108]"
The"interaction"between"a"small"molecule"and"a"biological"target"does"not"only"depend"on"the"
presence"or"absence"of"particular"chemical"features" in"the"compound,"but"also"on"the"space"
disposition" of" these" groups." If" the" spatial" relationship" between" the" features" is" specified"
through" coordinates" and" distances" between" them," then" it" is" a" three\dimensional" (3D)"
pharmacophore.[93]" 3D" pharmacophores" are" commonly" used" also" in" structure\based" drug"
design"approaches"because"they"can"aid"molecule"conformation"selection"prior" to"a"docking"
procedure" in"order" to" select"only" those"molecules" that" can"potentially"establish" the"desired"
interactions.[101]" More" sophisticated" 3D" pharmacophores" can" also" include" the" projection" of"
features." In" this" case," the" interacting" group" of" the" biological" target" is" indicated" and" ligand"
features" that" are" able" to" give" that" interaction" and" that" are" at" the" correct" distance" are"
accepted.[108]"An"example"of"a"3D"pharmacophore"is"reported"in"Figure"1.17.""
A" pharmacophore" search" usually" consists" of" comparing" ligand’s" chemical" features" with" the"
features" indicated" in" the" pharmacophore." In" the" case" of" a" 3D" pharmacophore," it" is" a"
conformation\dependent"procedure,"so"the"search"should"be"conducted"on"all"the"significant"
and"acceptable"conformations"of"the"ligands.[93,101,108]""
"
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Figure'1.16..Example.of.3D.pharmacophore.for.DENV.protein.NS5.methyltransferase..
The"pharmacophore"features"are"shown"as"dotted"spheres."The"bound"ligand"is"represented"with"thicker"lines"and"
the"protein"residues"with"lines."
"
SIMILARITY.SEARCH.
"
If" a" lead" compound" is" available" it" is" possible" to" search"molecule" databases" in" order" to" find"
similar" molecule" that" could" display" drug" activity." Molecules" can" be" similar" across" different"
characteristics," but" in" order" to" make" a" comparison" and" calculate" a" similarity" index," it" is"
important" to" be" able" to" extrapolate" these" features" as" molecular" descriptors." Molecular"
descriptors"are"numbers"that"can"be"calculated"from"the"chemical"structure"of"a"molecule"and"
not" necessarily" experimentally" determined" also" if" they" could" have" an" experimental"
counterpart."According"to"the"information"required"for"the"calculation,"molecular"descriptors"
are"usually"categorised"as"one\dimension"(1D)"descriptors" if" they"require"only" the"molecular"
formula" (e.g." molecular" weight);" two\dimension" (2D)" descriptors" if" they" require" the" 2D"
chemical" structure" (e.g."partition" coefficient," count"of" chemical" features);" three\dimensional"
(3D)" descriptors" if" they" require" 3D" chemical" structure" (e.g." shape," molecular" volume," 3D"
pharmacophore"features).[93]"
The" calculation" of" the" similarity" index" from" these" descriptors" can" be" achieved" through"
different"methods,"but"most"of"them"give"a"numerical"output"that"ranges"from"0"to"1,"where"0"
signifies" absence" of" similarity" and" 1" suggests" the"maximum" grade" of" similarity." A" similarity"
index"of"1"does"not"necessarily"translate"to"molecular"identity."As"an"example,"2\chlorophenol"
and" 3\chlorophenol" (Figure" 1.18)" have" the" same"molecular" weight" (MW)" so" their" similarity"
index"regarding"this"descriptor"is"1,"but"they"are"not"the"same"molecule.[93]"
"
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2\chlorophenol"
MW="128.56"
"
3\chlorophenol"
MW="128.56"
""""""""""""""""""""A" """"""""""""""""""B"
Figure'1.17..Example.of.molecules.that.have.similarity.index.of.1.without.being.the.same.molecule..
The"two"described"molecules"have"the"same"molecular"weight"and"therefore"the"similarity"index"calculated"on"this"
descriptor"is"1."However"using"other"properties"they"are"not"equal."A).2Fchlorophenol..B).3Fchlorophenol..
"
QSAR.
"
Quantitative" structure\activity" relationships" (QSAR)" are"mathematical"models" that" correlate"
molecular" descriptors" to" activity." Their" aim" is" to" be" able" to" predict" how" the" molecular"
descriptor"could"be"modified"in"order"to"improve"the"molecules’"activity."In"order"to"compute"
these," it" is" necessary" to" have" a" set" of" molecules" with" known" activity" parameters" (e.g."
inhibitory"concentration"IC50)"and"molecular"structure."The"QSAR"model"correlates"the"activity"
data"to"properties"inherent"to"the"structure"of"the"molecules"of"the"set,"with"the"aim"to"give"
an" indication" as" to" which" are" the" important" features" for" new" molecules" with" enhanced"
activity.[93,108]" It" is" seen" immediately" that" the"choice"of" the"adequate"molecular"descriptor" is"
crucial" for" a" useful" QSAR" study" that" could" be" predictive." For" this" reason," more" than" one"
descriptor"is"commonly"taken"into"consideration"in"one"drug"design"process.[108]"
"
MOLECULAR'DYNAMICS'SIMULATION'
"
Together"with"energy"minimization,"molecular"dynamics"(MD)"is"a"type"of"simulation"that"can"
be"performed"with"computational"chemistry."It"is"considered"to"be"an"important"investigative"
technique"that"consists"in"the"analysis"of"the"temporal"behaviour"of"a"molecular"system"over"
time." This"means" that" it" is" possible" to" gain" information"about" the"motion"of" the"atoms"and"
about" the" stability" of" the" system" itself." MD" simulations" apply" classical" mechanics" and"
molecular" mechanics" functions" to" the" N" interacting" atoms" of" the" system" and" Newton’s"
equation"of"motion,"reported"in"Equation"1.3,"is"applied"to"each"one"of"them.[90,93]"According"
to" Newton’s" second" law" of" motion," if" a" force" F" is" applied" to" an" object" with" mass" m" an"
acceleration"a"that"is"proportional"to"the"original"force"will"be"produced."This"expression"can"
be"translated"into"another"form"in"which"the"force"is"in"relation"to"the"distance"(r)"and"to"the"
time" (t)" according" to" the" derivative" expression" indicated" in" Equation" 1.3." This" equation" is"
coupled"to"the"calculation"of"energies,"forces"and"potentials"on"the"atoms"that" is"performed"
through"the"force"field"functions"described"previously"in"the"FORCE&FIELDS"paragraph.[90,93]""
OH
Cl
OH
Cl
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" !! = !! ∗ !! = !! ∗ !!!!!!! "
Equation'1.3..Newton’s.equation.of.motion.[90].
F=force,"m=mass,"a=acceleration,"r=distance,"t=time"
In" some"aspects" a"MD" simulation" can"be" compared" to" a" silent" cinematographic"movie." In" a"
simplistic"view,"a"movie"consists"of"a"series"of"snapshots"taken"at"a"very"short"time"period"one"
after"another"and"shown"at"a"high"speed."In"the"same"way,"in"a"MD"simulation"the"whole"time"
period" (usually" from" tens" of" ps" to" ns" or" even"ms"with" powerful" computers)" is" divided" into"
small" time" steps" (usually" of" the" order" of" fs)" and" a" snapshot" (i.e." the" state" of" the"molecular"
system)" is" taken" at" each" time" step." Snapshots" include" the" coordinates" of" each" atom" that" is"
part"of"the"system,"but"also"other"information"like"each"atom’s"energy,"velocity,"force,"as"well"
as"system"temperature"and"pressure."The"change"in"the"position"and"parameters"of"the"atom"
are"calculated"from"one"step"to"the"other"by"solving,"simultaneously,"the"motion"equations."In"
this"way"the"atom’s"motion"is"approximated"to"the"sum"of"little"linear"movements"dependent"
to" the" initial" velocity"and" force"applied" to"each"atom"at"each" time" step."Usually" the"motion"
equations"are"solved"making"sure"that"the"total"temperature"and"pressure"of"the"system"are"
constant"during"the"whole"duration"of"the"simulation.[90,93]""
As"already"discussed,"the"fact"that"MM"is"used"rather"than"QM"introduces"into"the"simulation"
a" series" of" approximations." Therefore," standard" MD" simulations" cannot" be" used" for" the"
simulation" of" particular" properties" that" depend" on" electronic" distribution," like" chemical"
reactions," bond" or" angle" vibrations," and" electronically" excited" state." These" are" more"
accurately"described"by"QM"methods.[90]"
"
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1.3.INTRODUCTION.TO.THE.BIOLOGICAL.
ASSAYS..
"
The"potential"antiviral"compounds"identified"with"several"Molecular"Modelling"approaches"for"
DENV"NS3" helicase," NS5" RNA\dependent" RNA" polymerase" and"NS5"Methyltransferase"were"
tested"in"vitro"using"different"types"of"assays."For"a"better"understanding"of"the"results,"here"is"
reported"a"brief"introduction"to"the"tests"performed."Unless"otherwise"stated,"the"biochemical"
assays"were"performed"by"the"author.""
CYTOPATHIC'EFFECT'(CPE)'INHIBITION'ASSAY'
"
The"cytopathic"effect" (CPE)" inhibition"assay"was"performed"by"our"collaborators"at" the"Rega"
Institute"for"Medical"Research,"K."U."Leuven"(Belgium)"and,"differently"from"the"other"tests,"it"
is"a"cell"based"in&vitro"assay"that"aims"to"evaluate"the"general"antiviral"activity"of"compounds."
The"particular"cell"lines"used"are"susceptible"to"infection"when"exposed"to"specific"pathogens."
For"DENV" infection,"Vero" cells"were" found" to"be" suitable."DENV" infection"of" untreated" cells"
leads" to" cell" death." Therefore," the"ability"of" the" compounds" to" inhibit" viral" infection" can"be"
measured" through" cell" viability." Specific" reagents" are" able" to" produce" coloured" derivatives"
when" they" react" with" molecules" that" indicate" that" the" cell" is" alive" (for" instance" ATP)."
Alternatively,"substances"(e.g."methylene"blue)"that"stain"only"living"cells"can"be"used"for"the"
same"purpose."
The" assay" protocol" used" consists" of" exposing" infected" cells" to" different" compound"
concentrations" and" then" observing" cell" viability" through" quantification" of" the" obtained"
coloration" through" ultraviolet" light" (UV)" absorption." By" subsequently" plotting" compound"
concentration" against" cell" viability" it" is" possible" to" calculate" the" half" maximal" efficacious"
concentration"(EC50)" for"active"compounds."Figure"1.19"shows"a"schematic" representation"of"
the"protocol"and"of"the"analysis"of"the"results."8000"Vero"cells"per"well"were"exposed"to"the"
compounds"before"being"incubated"for"eight"days"with"DENV2."After"this,"following"fixing"and"
staining"with"methylene" blue" the" inhibition" of" CPE"was" evaluated" by"UV" absorption" against"
two"control"systems:"infected"cells"and"non\infected"cells."Similar"experiments"conducted"on"
uninfected"cells"were"used"to"monitor"compound"toxicity."
"
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Figure'1.18..Schematic.representation.of.the.CPE.assay..
In"each"well"the"infected"cells"are"incubated"with"the"compounds"at"different"concentrations"for"eight"days."Then"
they"are"fixed"and"stained"with"methylene"blue."In"this"example"the"test"well"plate,"the"cell"control"(non\infected"
cells)"and"a"viral"control"(untreated"infected"cells)"are"indicated."An"example"of"a"slightly"active"compound"is"
highlighted"in"green"and"an"example"of"a"cytotoxic"compound"is"highlighted"in"purple."Data"is"then"collected"and"
plotted"in"concentration\activity"charts"for"EC50"calculation..
"
THERMAL'SHIFT'ASSAY'(TSA)'
"
The"thermal"shift"assay"(TSA)"is"usually"performed"to"evaluate"the"ability"of"molecules"to"bind"
to"proteins." It" is"based"on" the"principle" that" the" complex"of"a"protein"with"a" ligand" is"more"
stable" than" the" protein" alone." Consequently,"when" a" protein" is" heated" and" it" is" induced" to"
unfold,"it"will"have"a"higher"melting"point"(Tm)"if"it"is"bound"to"a"ligand."The"method"used"for"
the"determination"of" the"melting"point" is"a" fluorescent"probe" (e.g." sypro"orange,"SO)" that" is"
quenched" in" solution," while" it" is" fluorescent" upon" binding" to" the" hydrophobic" regions" of"
proteins." As" a" protein" unfolds," it" exposes" more" hydrophobic" regions" and" therefore" the"
fluorescence" intensity" grows" proportionally" to" this" phenomenon," until" the" protein" is"
completely" melted." The" intensity" of" fluorescence" is" measured" and" plotted" against"
temperature"for"the"interpolation"of"the"melting"point,"as"shown"in"Figure"1.20."The"melting"
point"(Tm)"is"represented"by"the"temperature"in"which"50%"of"the"protein"is"unfolded"and"this"
value"can"be"calculated" from"the"curve." Ligands"can" induce"some"changes" in" the"stability"of"
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the"protein"upon"binding"(either"stabilising"or"destabilising"the"system)"and"this"is"reflected"in"
deviations" in" Tm." Therefore," the" binding" ability" of" compounds" can" be" assessed" through"
measurements"of"Tm"shifts,"with"respect"to"the"protein"alone."At"higher"temperatures,"other"
phenomena"take"place,"such"as"protein"aggregation"and/or"dye"dissociation,"and"lead"to"a"loss"
of"fluorescence."Thus,"only"the"range"of"temperatures"around"the"melting"point"is"considered"
in"data"analysis.[109]"
"
!
Figure'1.20..Fluorescence.profile.according.to.increase.in.temperature.in.a.thermal.shift.assay..
"
FLUORESCENCE'POLARISATION'(FP)'ASSAY'
"
A"fluorescence"polarisation"(FP)"assay"is"used"to"assess"the"formation"of"a"complex"between"a"
protein"and"a"ligand"that"contains"a"fluorophore"(also"called"probe)."The"assay"is"based"on"the"
fact"that"when"a"fluorophore"is"excited"with"linearly"polarised"light,"it"emits"light"with"a"degree"
of"polarisation,"which"is"inversely"proportional"to"its"Brownian"motion"in"solution."In"this"type"
of"motion,"the"velocity"of"a"particle"is"inversely"proportional"to"its"mass."Therefore,"when"the"
probe"is"alone"in"solution,"the"mass"of"the"system"is"low"and"also"the"fluorescence"polarisation"
results"to"be"low."However,"when"the"probe"is"bound"to"the"protein,"the"mass"of"the"system"is"
significantly"higher,"as"well"as"the"FP"value."Figure"1.21"shows"a"schematic"representation"of"
the"basic"principle"of"the"fluorescence"polarisation.""
"
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Figure'1.19..Schematic.representation.of.the.FP.assay..
The"monochromatic"light,"at"the"ideal"absorption"wavelength"for"the"probe,"is"produced"by"a"light"source"and"then"
it"is"polarised"through"a"polarisation"filter"(a)."The"polarised"light"interacts"with"the"molecules"in"solution."Here"two"
possible"scenarios"are"shown:"the"probe"in"solution,"that"is"able"to"move"more"than"the"probe"in"complex"with"the"
protein."The"fluorescence"produced"is"then"analysed"with"a"detector"after"the"passage"through"a"polarisation"filter"
that"selects"only"parallel"waves"with"respect"to"the"source"polarisation"(b),"and"one"that"selects"only"perpendicular"
waves"with"respect"to"the"source"polarisation"(c)...
Using" the" excitation" light" plane" as" a" reference," the" parallel" and" the" perpendicular" emission"
light"intensity"are"detected"and"the"FP"is"calculated"according"to"Equation"1.4.[110]"
" !" = !∥ − !!!∥ + !!!
Equation'1.4..Fluorescence.polarisation.[110].
I"is"the"parallel"emission"light"intensity"and"I"is"the"perpendicular"emission"light"intensity..
According"to"this"formula,"the"probe"concentration"and"the"fluorescence"absolute"intensity"do"
not" affect" FP" values," therefore" they" have" to" be" chosen" according" to" the" instrument"
sensitivity.[110]"However," this" implies" that" if"dissociation"constants"have" to"be"computed," the"
fluorescent" ligand" concentration" must" be" kept" constant" and" the" test" must" be" done" on"
different"protein"concentrations.""
The"aim"of"the"assay"was"to"assess"the"putative"competition"activity"of"the"compounds"with"
the"natural"substrate"for"the"active"site."Consequently,"the"natural" ligand"with"a"fluorophore"
probe"was"used"and"after"the"calculation"of"the"natural"ligand"binding"dissociation"constant,"a"
fixed" concentration" of" protein" and" probe"were" chosen" for" compound" screening" at"multiple"
concentrations." A" reduction" of" FP" is" correlated" with" the" probe" displacement" from" the"
protein’s" site" and" therefore" it" is" also" related" to" compound" inhibition"of" the"natural" ligand" \"
protein"complex"formation.""
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The"probes"used"in"this"study"were"two,"one"for"each"DENV"NS3"helicase"binding"site."For"the"
RNA"tunnel,"a"10"nucleotide"RNA"strand"corresponding"to"the"5’"end"of"the"DENV"genome"was"
used."The"small"nucleic"acid"filament"was"coupled"to"the"fluorophore"(6\carboxyfluorescein,"or"
6\FAM)" in" the"5’"position."No"problems" related" to"RNA" secondary" structure" formation"were"
anticipated,"as"the"length"of"the"RNA"strand"is"too"small"to"give"energetically"feasible"folding."
The" oligonucleotide" is" represented" in" Figure" 1.22." The" position" of" the" 6\FAM" probe" at" the"
5’end"of"the"oligonucleotide"was"considered"to"improve"the"test"performance"as"the"protein"
binds"the"oligonucleotide" in"this"region."Consequently,"the"difference"in"movement"between"
the"bound"and"the"unbound"probe"is"higher"and"therefore"the"variance"in"FP"values"as"well."
"
!
Figure'1.20..RNA.probe..
The"fluorophore"is"highlighted"in"orange"and"the"RNA"oligonucleotide"is"highlighted"in"green."The"two"groups"are"
connected"with"an"aliphatic"linker..
For"the"helicase"NTP"binding"site,"a"GTP"molecule"modified"with"a" fluorophore"(bodipy)"was"
used." As" DENV" helicase" has" a" NTPase" activity," the" assay" was" carefully" performed" in" the"
presence"of"EDTA"(ethylenediaminetetraacetic"acid),"a"chelating"agent"for" ions."The"aim"was"
to" remove" the" catalytic" ion" from" the" binding" site" (Mg2+" or" Mn2+)," avoiding" the" probe’s"
hydrolysis."The"structure"of"the"GTP"probe"is"reported"in"Figure"1.23."
"
!
Figure'1.21..GTP.probe..
The"fluorophore"is"highlighted"in"orange"and"the"GTP"is"highlighted"in"green."The"two"groups"are"connected"with"an"
aliphatic"linker."The"position"of"the"substitution"is"unspecified..
Section"1:"INTRODUCTION" 1.3&INTRODUCTION&TO&THE&BIOLOGICAL&ASSAYS"!
49!
The" main" interactions" between" DENV" helicase" and" the" NTP" occur" at" the" phosphate" level,"
therefore" it" is" important" that" the" fluorophore" is" linked" to" the"nucleotide"at" the" level"of" the"
base"or"of"the"sugar"moiety"(as"in"this"case)"and"not"to"the"third"phosphate"group"in"order"to"
assure" binding." The" probe" used" in" the" assay" contained" a" mixture" of" the" two" possible"
substitutions"in"the"sugar"hydroxyl"groups:"either"2’"or"3’.""
"
HELICASE'ATPASE'ACTIVITY'INHIBITION'ASSAY'
"
The"helicase"ATPase"activity"inhibition"assay"was"performed"with"the"objective"of"studying"the"
inhibition" of" the" NTPase" activity" of" DENV" helicase" exhibited" by" designed" compounds." The"
assay"principle"concerns"the"liberation"of"a"phosphate"group"for"each"starting"molecule"during"
ATP" hydrolysis." If" the" enzyme" is" capable" of" this" reaction," there" is" liberation" of" the" anionic"
group" that" can" be" detected" with" a" colorimetric" method," described" schematically" in" Figure"
1.24.""
"
!
Figure'1.22..Schematic.representation.of.the.ATPase.assay..
The"helicase"hydrolyses"ATP"to"ADP"and"phosphate."The"phosphate"is"complexed"by"ammonium"molybdate,"
forming"an"α\Keggin"structure."After"the"reduction"of"a"Mo"atom"by"ascorbic"acid,"the"complex"converts"to"a"β\
Keggin"structure,"which"is"blue"and"adsorbs"light"at"595nm."The"presence"of"an"inhibitor"impedes"the"formation"of"
phosphate"and"therefore"the"development"of"the"blue"colour..
The" ammonium" molybdate" coordinates" the" phosphate" group," creating" a" complex" 3D"
arrangement"called"an"α\Keggin"structure."The"reduction"of"a"Mo(VI)"atom"to"Mo(II),"with"the"
transfer"of"4"electrons"from"the"oxidation"of"ascorbic"acid"is"aided"by"the"acid"environment"of"
sodium" citrate" in" acetic" acid" and" triggers" a" rearrangement" of" the"α\Keggin" cage" to" another"
complex"3D"structure"called"β\Keggin" that"absorbs" light"at"595nm,"giving"a"blue"colour." Like"
the" formation" of" the" latter" structure," also" 595nm" light" absorption" is" proportional" to" the"
concentration" of" the" phosphate" ion" in" solution," resulting" in" a" reliable" method" for" the"
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assessment" of" the" ATPase" activity" of" the" protein" through" the" assessment" of" phosphate"
concentration.""
For"every"experiment,"a"calibration"curve"is"built"from"known"concentrations"of"a"phosphate"
salt," in" order" to" reduce" random" errors" correlated" with" slightly" different" reactant" volumes"
used." The" inhibition" of" the" ATPase" activity" is" assessed" by" comparing" the" concentration" of"
phosphate"ions"produced"by"the"helicase"in"presence"of"the"compound"and"the"one"produced"
by"the"enzyme"alone,"taking"into"account"the"spontaneous"ATP"hydrolysis"in"solution."
"
HELICASE'UNWINDING'ACTIVITY'INHIBITION'ASSAY''
"
!
Figure'1.23..Schematic.representation.of.the.helicase.unwinding.activity.assay...
See"the"text"for"further"explanation"of"the"steps..
The"helicase"unwinding"activity"inhibition"assay"was"performed"by"our"collaborators"at"AFMB"
in"Marseille"University"(France)"with"the"aim"of"studying"the"activity"of"designed"compounds"
and" the" correspondence" with" the" RNA" binding" activity" measured" with" fluorescence"
polarisation."The"assay"is"based"on"the"ATP\dependent"unwinding"reaction"performed"by"the"
helicase,"as"shown"in"Figure"1.25."A"double"stranded"RNA"(dsRNA)"is"prepared"by"annealing"a"
5’"32P"labelled"RNA"strand"with"a"longer"non\labelled"RNA"strand."The"reaction"is"then"started"
by"adding"ATP."If"the"helicase"is"active,"the"dsRNA"is"divided"into"two"ssRNA"filaments."As"the"
labelled"ssRNA"and"the"labelled"dsRNA"have"different"molecular"weights,"they"can"be"resolved"
in"polyacrylamide"gel"and"quantified"through"autoradiography."The"relative"concentration"of"
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these"two"species" indicates"the"unwinding"activity"of" the"helicase." If" the"enzyme"has"a"good"
activity,"ssRNA"will"be"in"greater"quantity,"while"the"action"of"an"inhibitor"will"impede"nucleic"
acid" unwinding," giving" higher" concentration" of" the" dsRNA" species." By" testing" different"
compound" concentrations" and" comparing" the" ssRNA" and" dsRNA" amounts" to" the" ones"
produced"by"the"enzyme"alone,"IC50"values"can"also"be"determined."
"
POLYMERASE'ACTIVITY'INHIBITION'ASSAY'USING'
RADIOACTIVE'PROBES'
"
The"polymerase"activity" inhibition"assay"was"performed"by" J.\C."Guillemot"group"at"AFMB" in"
Marseille"University"(France)"with"the"aim"of"assessing"the"ability"of"compounds"to"inhibit"the"
activity"of"the"polymerase"enzyme."The"polymerase"activity"was"observed"by"applying"the"test"
schematised"in"Figure"1.26.""
"
!
Figure'1.24..Schematic.representation.of.the.polymerase.activity.assay..
See"the"text"for"further"explanation"of"the"steps..
Briefly," given" a" RNA" template" and" the" necessary" nucleotides," the" synthesis" of" a"
complementary"RNA"strand"can"be"detected"with"a"radiometric"method."The"RNA"template"(a"
polyU"strand"in"the"scheme,"as"an"example)"is"usually"a"strand"formed"by"“cold”"nucleotides."
The"“bricks”"necessary"for"the"RNA"synthesis"are"given"with"a"percentage"of"radiolabelled"(in"
the"case"of"this"particular"experiment"with"tritium,"3H)"complementary"nucleotides"(in"green"in"
the"figure)"that"can"be"incorporated"in"the"double"strand"RNA"(dsRNA)"during"the"enzymatic"
activity."After"stopping"the"polymerase"reaction,"by"sequestering"the"catalytic"ions"with"EDTA,"
the"buffer" solution"contains" the"dsRNA"as"well" as" the"exceeding"nucleotides."Therefore," the"
dsRNA" is" fixed"on" filter" paper" that" allows" the" passage"of" the" nucleotides" alone." In" this"way"
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errors" due" to" the" presence" of" radiolabeled" nucleotides" that" were" not" incorporated" are"
eliminated."The"radioactivity" is"then"evaluated." In"the"presence"of"an" inhibitor,"the"synthesis"
of" dsRNA" is" reduced" (or" completely" blocked)" and" consequently," less" radiolabeled" dsRNA" is"
collected" in" the" filter" and" the" detected" radioactivity" is" lower." The" comparison" of" the"
radioactivity" values" obtained" for" protein\compound" complexes" at" various" concentrations"
compared"to"the"ones"obtained"from"the"protein"alone"can"therefore"be"used"for"testing"the"
inhibitory"activity"of"the"molecules"and"IC50"determination.""
"
POLYMERASE'ACTIVITY'INHIBITION'ASSAY'USING'
PICOGREEN'
"
A"second"assay"that"did"not"rely"on"radioactive"labelling"was"also"used"by"J.\C."Guillemot"group"
at" AFMB" in" Marseille" University" (France)" to" measure" inhibition" of" polymerase" using" a"
fluorescent" dye" PicoGreen®." Also" in" this" case" the" formation" of" dsRNA" is" monitored" as" an"
indication" of" the" enzyme" activity." The" fluorescent" dye" is" able" to" bind" to" both" dsDNA" and"
dsRNA" superstructures" that" form" spontaneously." The" molecule" structure" of" PicoGreen®" is"
reported"in"Figure"1.27.""
"
!
Figure'1.25..PicoGreen...
The"quinolinium"group"that"intercalates"between"base"pairs"is"highlighted"in"green;"while"the"benzo\thiazolinium"
moiety"that"interacts"with"the"negatively"charged"phosphates"is"highlighted"in"green."The"two"groups"are"coupled."
The"aliphatic"arms"are"able"to"span"along"4"base"pairs."
PicoGreen®"has"excitation"and"emission"wavelengths"of"485nm"and"530nm"respectively,"both"
when"it"is"free"in"solution"and"when"it"is"bound"to"the"nucleic"acid."Figure"1.26"also"shows"the"
binding"mode"of" the"molecule:" its"quinolinium"group" intercalates"between"base"pairs,"while"
the" benzo\thiazol" moiety" is" able" to" create" electrostatic" interactions" with" the" negatively"
charged"phosphates"of" the"RNA," stabilising" the"whole" aromatic" coupled" system" in" a"precise"
conformational"state."This"rigidification"of"the"molecule"upon"dsRNA"binding"produces"an"up"
to" 1000\fold" increase" of" fluorescence" intensity" of" PicoGreen®." In" the" assay," this" increase" is"
proportional"to"dsRNA"formation"itself"and"therefore"it"can"be"used"to"quantify"the"production"
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of" double" stranded" nucleic" acid.[111]" High" fluorescence" values" are" expected" for" the" protein"
control," while" a" decrease" of" fluorescence" is" expected" in" the" presence" of" an" inhibitor" that"
blocks" the" synthesis" of" RNA" and" therefore" the" formation" of" dsRNA." Testing" different"
compound" concentrations" in" comparison" to" the" results" of" protein" alone," IC50" values" of" the"
molecules"can"also"be"obtained."
"
METHYLTRANSFERASE'2’SO'AND'NS7'METHYLATION'
ACTIVITY'INHIBITION'ASSAY'
"
The"methyltransferase"activity" inhibition"assay"was"performed"by"K."Barral"group"at"AFMB"in"
Marseille"University" (France)." It" is" the" same" as" the" polymerase" activity" inhibition" assay" that"
uses"radiolabeled"probes."The"only"difference"is"that"the"radioactive"probe"used"is"S\adenosyl"
methionine"(SAM),"with"a"tritium"(3H)"atom"on"the"methyl"group"linked"to"the"sulphur"of"the"
molecule."This"group"is"transferred"to"the"cap"by"the"NS5"MTase"and"therefore"incorporated"in"
the"capped"RNA."Differently"capped"RNAs"can"allow"the"assessment"of" the" two"methylation"
processes"(7MeGpppA\RNA"for"2’\O"methylation"GpppA2’OMe\RNA"for"N\7"methylation)."Similarly"
to" the" polymerase" assay," also" in" this" case" the" radioactivity" values" are" proportional" to" the"
methylation" reaction" catalysed"by" the"protein" and" they" can"be"used" to" assess" the" ability" of"
small"molecules"to"inhibit"the"enzyme."
"
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1.4.AIMS.AND.OBJECTIVES.
"
The" four" serotypes" of" the" mosquito\borne" dengue" virus" (DENV)" are" a" health" burden"
responsible"for"around"50\100"million"new"cases"and"22,000"deaths"per"year."This"pathogen"is"
worryingly"spreading"out"of"the"endemic"regions,"putting"at"risk"2.5\3.5"billion"people."Despite"
the"efforts"of"the"past"20"years"only"symptomatic"therapy"is"available"to"date,"making"antiviral"
research"on"DENV"a"global"health"unmet"need."As"vaccine"development"has"turned"out"to"be"
more" challenging" than" expected," the" development" of" anti\DENV" drugs" is" important" for"
infection"management."
Following"this,"the"overarching"aim"of"this"PhD"thesis"was"to"identify"novel"targets"to"combat"
DENV"infection"and"subsequently"to"discover"potential"original"chemical"leads"exploiting"those"
targets."This"main"aim"was"subdivided"as"follows."
I. Identify"suitable"drug"targets."Anti\DENV"drugs"could"target"either"host"or"viral"proteins."
Even" if" more" sensible" to" serotype\specificity" and" to" emergence" of" resistance," viral"
targets"are"currently"better"understood"and"usually"different"from"host"factors,"allowing"
a" reduction" in"off\target"effects"probability."The"objective"was" therefore" to" find"novel"
potential"ways"to"target"viral"proteins"essential"in"DENV"replication"that"are"preferably"
not"present"in"humans."
II. To"generate"knowledge"in"order"to"understand"better"the"mechanisms"and"roles"of"the"
chosen" targets" in" DENV" replication." The" four" chosen" targets" have" been" extensively"
studied" during" the" last" few" years." However," knowledge" generated" about" their"
mechanisms"and"roles"is"still" incomplete"and"this"could"be"partially"responsible"for"the"
challenges"that"have"been"met"in"finding"potent"anti\DENV"therapeutic"agents."For"this"
reason,"basic" research"was" included"during" this"PhD" to" increase"understanding"of" the"
mode" of" action" of" a" promising" capsid" inhibitor" (ST\148)" and" of" the" means" of"
translocation"of"NS3hel"along"the"RNA."
III. Find"novel" chemical" leads" to"develop"effective"antiviral" agents"against"DENV" infection"
through" applying" classical"Medicinal" Chemistry" approaches," chemical" synthesis" and" in&
vitro"assays."In"particular,"by"carrying"out"different"in&silico"approaches"for"the"screening"
of"publicly"available"libraries"or"for"fragment\based"drug"discovery;"starting"either"from"
known"protein"inhibitors"or"from"modelling"the"interactions"of"the"known"structures"of"
the"four"chosen"targets"with"small"molecules."
"
"
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2.1.INTRODUCTION..
"
A'PROMISING'DRUG'TARGET'
"
Three" structural" proteins" are" encoded" in" the" viral" (+)ssRNA:" Envelope" (E)," the" membrane"
protein" precursor" (prM)" and" the" capsid" protein" (C)." All" of" these" proteins" are" required" for" a"
correct" and" functional" assembly" of" the" virion." As" described" in" the" main" INTRODUCTION"
section," 180" copies" of" the" first" two"proteins" are" inserted" in" a" host" cell" derived" bilayer"with"
which"they"constitute"the"viral"envelope."This"structure"incorporates"multiple"copies"of"C"that"
complex"with"one"strand"of"viral"RNA,"forming"the"nucleocapsid.[1\3]"The"exact"mechanism"of"
the"construction"of"the"nucleocapsid"is"still"not"fully"understood,"but"it"is"supposed"to"involve"
prM,"E"and"probably"some"host"factors."Conversely,"its"critical"importance"in"the"formation"of"
infective" DENV" particles" has" been" demonstrated." In" fact," the" absence" of" C" induces" the"
formation"of"subviral"particles"that"do"not"contain"the"viral"genome"and"consequently"are"not"
able"to"replicate"in"new"host"cells.[4\6]""
The"interference"with"the"formation"or"with"the"disassembly"of"the"nucleocapsid"should"result"
in"the" inability"of"DENV"virus"to"deliver" its"genome"to"the"host"cell," impeding"the"replication"
cycle." Despite" the" fact" that" C" is" the" least" conserved" among" the" Flavivirus" family" (with"
homology" between"15\90%)," its" critical" function"makes" C" an" attractive" target" for" anti\DENV"
antiviral" therapy" development." This" hypothesis" is" supported" by" the" evidence" that" the"
molecule"ST\148,"active"against"all"four"DENV"serotypes"both"in&vitro"and"in&vivo,"indeed"binds"
and"inhibits"the"capsid"protein"C.[7,8]"
"
STRUCTURE'
"
The" immature" capsid" protein" contains" a" hydrophobic" signal" C\terminal" portion" (anchC)" that"
anchors" the" protein" to" the" ER" modified" membrane." This" portion" is" cleaved" by" the" viral"
protease"NS3pro"in"complex"with"the"cofactor"NS2B"during"maturation.[9]"The"mature"form"of"
C"is"a"highly"α\helical"12kDa"protein"that"forms"symmetric"homodimers"in"solution"that"were"
also"observed"in"the"NMR"structure"that"was"obtained"for"residues"21\100"(PDB"ID:"1R6R).[7,8]"
Each"monomer"is"constituted"of"four"α\helices"(from"α1"to"α4)."The"first"three"α\helices"(α1\
α3)"form"a"3\helix"core,"while"the"fourth"(α4)"is"longer"and"extends"from"this"bundle."Panel"A"
of"Figure"2.1"shows"the"surface"of"C"dimer,"where"monomers"are"differentiated"by"colour."In"
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panel"B"of" the" same" figure" the" ribbon" structure"of" the"C"dimer" is" represented,"where"α1" is"
coloured" in" green," α2" in" red," α3" in" blue" and" α4" in" silver," with" different" shades" in" order" to"
highlight"the"monomers.""
"
" "
A" B"
Figure'2.1..DENV.capsid.protein..(PDB:.1R6R).
A).Surface.of.the.C.dimer."The"surface"corresponding"to"one"monomer"is"coloured"in"red,"while"the"one"of"the"
other"monomer"is"in"light"blue."B).C.dimer.shown.as.ribbon."In"both"monomers"the"α\helices"are"represented"with"
the"same"colour"but"lighter"in"one"monomer"and"darker"in"the"other"monomer,"in"order"to"distinguish"them."α1"is"
shown"in"light/dark"green,"α2"is"in"orange/red,"α3"is"in"light/dark"blue"and"α4"is"represented"in"light/dark"grey."
As"can"be"observed"in"the"figure,"the"majority"of"monomer"contacts"in"the"dimer"involve"α2\
α2’" and" α4\α4’" and" the" bigger" α4" helix" was" indeed" found" to" be" essential" for" dimerization."
Furthermore," dimer\dimer" contacts" are" mainly" hydrophobic," with" very" few" electrostatic"
interactions.[6,8]"
A"high"percentage"(25%)"of"the"protein"is"constituted"by"basic"residues"(15"Lys"and"9"Arg)."The"
peculiarity"of" this" structure" is" that" the" total" charge" is"distributed" in" an"asymmetric"manner,"
placing" the"highest"density"of"positive" charges" in" the" solvent"exposed"portion"of" the"α4\α4’"
region."On" the" opposite" side," in" the" cleft" formed" by" α1\α1’" and"α2\α2’," residues" are" highly"
apolar,"forming"a"concave"hydrophobic"region.[8]""
Nuclear" localisation"sequences"(NLS)," involving"random"coils" (before"α1,"between"α3"and"α4"
and"after"α4)"and"a" solvent"exposed"site"of"α4" (Arg85\Lys86)"have"also"been" identified."The"
involvement"of"these"regions"(in"particular"the"one"between"α3"and"α4"and"the"one"within"α4)"
in"capsid"localisation"within"the"host"cell"nucleus"has"been"confirmed"with"mutational"studies."
As" these" sequences" resemble"NLS" in" other" proteins" (e.g." NS5" RdRp)," it" has" been" suggested"
that"nuclear"translocation"is"mediated"by"host"proteins"of"the"importin"family,"but"neither"the"
reason" for" C" nuclear" localisation" nor" the" mechanism" with" which" it" occurs" have" been" fully"
understood"to"date.[10,11]""
"
"
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MECHANISM'OF'ACTION'
"
It"has"been"shown"that"the"capsid"protein"is"fundamental"for"DENV"replication"as"its"deletion"
produces"“empty”"sub\viral"particles"that"do"not"carry"the"viral"genome"and"therefore"are"not"
infectious.[6]"It"appears"that"the"active"form"of"C"is"the"homodimeric"one"observed"in"solution,"
but" the" exact" mechanism" of" C" recruitment" and" nucleocapsid" formation" is" not" yet" fully"
understood." However," it" has" been" suggested" that" the" different" charge" and" hydrophobicity"
distribution"on"the"C"homodimer"play"an"important"role"for"nucleic"acid"incorporation"in"the"
virion" structure."According" to" this" hypothesis" (Figure" 2.2)" the"highly" conserved"hydrophobic"
portion" of" C" interacts" with" the" inner" part" of" the" hydrophobic" membrane" of" the" envelope,"
whilst"the"positive"charged"residues"binds"the"viral"RNA,"allowing"the"new"virion"particles"to"
carry"the"viral"genome"and"therefore"to"be"infective."The"interactions"with"the"RNA"are"non\
specific,"resembling"the"histone/chromatin"interaction.[8,12,13]""
"
"
Figure'2.2..Model.of.capsid.interactions.with.the.envelope.membrane.and.viral.RNA...
In"this"model"of"DENV"virion"structure,"C"interacts"with"the"envelope"membrane"through"its"hydrophobic"cleft,"
coloured"in"green"in"the"figure."On"the"other"side,"the"highly"positively"charged"surface"under"the"α4\α4’"helices"
interacts"electrostatically"with"the"viral"RNA,"rich"in"negative"charges"as"indicated"by"the"magenta"“\“"symbols."The"
membrane"is"represented"by"the"light"and"dark"red"rectangle"and"the"RNA"is"shown"as"a"purple"line."
It"has"been"shown"that"DENV"infection"causes"lipid"droplet"(LD)"redistribution"within"the"host"
cell.[14]"Even" if" the"exact"mechanism" is"not" fully"understood," this" recruitment" is" fundamental"
for" viral" replication." It" has"been"observed" that"C" co\localises"with" these" LDs"within" the" cells"
during"infection.[14]"Further"experiments"have"demonstrated"that"C"is"able"to"bind"LDs"through"
the"same"highly"conserved"hydrophobic"region"on"the"α2\α2’"helices"of"the"dimer.[10,14]"On"the"
basis"of" the" fact" that"C\LD"association"occurs"early" in"DENV" infection," it"has"been"suggested"
that" LD" might" aid" nucleocapsid" formation" by" providing" a" support" for" C\RNA" complex"
construction."However,"as"it"cannot"be"excluded"that"C"binds"the"RNA"after"its"transfer"to"the"
ER"for"particle"morphogenesis,"the"exact"role"of"LD"and"the"C\LD"complex"remains"unclear.[14]"
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C"has"other"unclear"behaviours"that"have"yet"to"be"elucidated."Similarly" to"LD"association,"C"
has"shown"to"be"able"to"bind"plasma"low\density"and"very\low"density"lipoproteins"(LDLs"and"
VLDLs" respectively)" through" the" conserved" highly" hydrophobic" α2\α2’" helices" of" the" dimer."
However," the" importance" of" this" phenomenon" is" unclear" as" these" complexes" have" not" yet"
been" observed" in& vivo," probably" because" of" the" transient" nature" of" the" complex" itself.[15]"
Moreover,"as"already"mentioned,"the"capsid"translocates"to"the"nucleus"during"infection."The"
reason"and"the"exact"mechanism"of"this"delocalisation"are"unknown,"but"the"NLS"sequences"
identified"have"proven"to"be"essential"for"this"phenomenon.[10,11]""
"
POSSIBLE'MOLECULAR'TARGET'SITES'
'
C"does"not"interact"with"natural"small"molecule"ligands,"differently"from"other"viral"proteins,"
like" NS3hel" that" binds" NTP.[6]" Therefore," the" protein" does" not" present" putative" druggable"
binding"sites."However,"C"displays"regions"with"different"properties"that"allow"the"protein" in"
the" homodimeric" form" to" interact" with" different" partners.[6,8]" Even" if" C" has" many" unclear"
functions" in" the" DENV" replication" cycle" (see" above)," the" main" established" purpose" of" C"
remains" nucleocapsid" formation" for" the" inclusion" of" the" viral" genome" in" the" novel" virion"
particles."As"explained"in"the"model"schematised"in"Figure"2.2,"C"interacts"with"both"RNA"and"
the" envelope" membrane" and" C" homodimer" constitutes" the" minimum" functional" unit.[8,12,13]"
Different" studies," including" the"cryo\electron"microscopy" (cryo\EM)"structure"of"DENV"virion"
determination," have" shown" that" the" homodimers" interact" with" each" other" in" a" disordered"
manner," creating" bigger" complexes" to" form" the" nucleocapsid.[6,13,16,17]" Consequently," as" the"
interaction" between" homodimers" appears" to" be" important" for" the" stability" of" the"
nucleocapsid,"the"interference"with"this"protein\protein"interaction"is"a"promising"strategy"for"
drug"design.""
"
" "
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STS148'
"
"
Figure'2.3..STF148.molecular.structure...
Chemical"name:"3\amino\N\(5\phenyl\1,3,4\thiadiazol\2\yl)\6,7,8,9\tetrahydro\5H\cyclohepta[b]thieno[3,2\
e]pyridine\2\carboxamide.
ST\148,"in"Figure"2.3,"is"a"promising"anti\DENV"compound"that"was"identified"with"a"CPE\based"
HTS" campaign," screening" approximately" 200,000" compounds." It" is" active" in& vitro" against" all"
four"DENV"serotypes"(with"IC50"between"2.8"and"0.016"μM)"and"it"is"selective"for"Flaviviruses."
It" was" also" proven" not" to" be"mutagenic.[4]" Drug\resistant" viruses"were" isolated" in& vitro" and"
showed"a"single"point"mutation"(S34L)"on"the"C"protein,"suggesting"that"the"antiviral"activity"of"
the"compound"involves"this"viral"component."Furthermore,"the"mutation"does"not"appear"to"
interfere"with"neither" the" viral" fitness"nor"C"properties." Ser34" is" a" highly" conserved" residue"
among"DENV"serotypes"positioned"near" the"end"of"α1"helix," in"a" likewise" conserved" region,"
explaining"the"compound’s"efficacy"against"all"serotypes.[4]"Furthermore,"ST\148"binds"directly"
with" C," corroborating" the" importance" of" this" viral" protein" in" the" antiviral" activity" of" the"
molecule." In&vivo"studies"in"the"AG\129"model"have"highlighted"that"ST\148"is"well"tolerated,"
but" has" low" oral" bioavailability" compared" to" intraperitoneal" administration." More" and"
importantly,"the"compound"has"demonstrated"its"efficacy"after"administration"by"either"route"
through" decreasing" viral" titers" both" in" tissues" and" in" the" blood," as" well" as" the" levels" of"
inflammatory"cytokines.[4]""
Further" in&vitro"assessments"not"only"confirmed"existing"data,"but"also"brought"new"insights"
about"the"compounds’"activity."Through"time\of\addition"studies,"ST\148"was"shown"to"inhibit"
DENV" infection," but" neither" through" a" virucidal" effect" nor" RNA" synthesis" interference.[4,5]"
Instead" it" inhibits" the"production"of" infectious"virions"through"both"viral"entry"and"assembly"
steps" in" the" replication" cycle." Specifically," ST\148" interferes" with" the" assembly" and" the"
disassembly" of" the" nucleocapsid," through" the" stabilisation" of" C" self\interaction," in" a" dose"
dependent"manner."Nevertheless,"the"compound"does"not"appear"to"impede"the"interaction"
of" C" with" either" LDs" or" RNA," or" the" transport" of" the" target" protein" to" the" nucleus" of" the"
infected"cell,"confirming"that"these"phenomena"are"not"related"to"the"antiviral"activity"of"the"
molecule.[5]"
"
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AIMS'AND'OBJECTIVES'
"
ST\148"has"often"shown"to"be"a"promising"inhibitor"of"DENV"infection"through"interaction"with"
the"C"protein."However,"the"mechanism"of"this"interaction"is"not"understood."With"the"aim"of"
building"a"model"of"ST\148"antiviral"activity"for"future"development"and"improvement"on"this"
molecule,"its"mechanism"of"action"was"investigated"through"Molecular"Modelling"techniques."
Work"was"performed" in"collaboration"with"Heidelberg"University"and"SIGA"Technologies" Inc."
that"provided"the"biological"data"used"as"a"starting"point"for"the"in&silico"studies."
"
"""""" "
Section"2:"CAPSID"AS"A"DRUG"TARGET" 2.2&RESULTS&AND&DISCUSSION&"!
!70"
2.2.RESULTS.AND.DISCUSSION.
"
MOLECULAR'MODELLING'STUDIES'
"
The"biological"data"summarised"in"the"introduction"is"suggestive"of"the"mode"of"action"of"ST\
148"but" is"a"poor" indicator"of"how" it" functions"at" the"molecular" level."With" the"objective"of"
understanding" how" ST\148" could" stabilise" C" self\aggregation," several" molecular" modelling"
approaches," including" protein\protein" docking," molecular" dynamics" (MD)" simulations" and"
small" molecule" docking" were" used." As" the" functional" form" of" C" in" solution" is" through"
homodimers,"this"structure"was"considered"as"a"fundamental"unit"and"C"self\aggregation"was"
studied" through" the" simulation"of" the" formation"of" tetramers"both"with"wild" type" (WT)"and"
S34L"mutated"C"proteins."The"effect"of"ST\148"in"this"process"was"then"analysed."The"details"of"
all"the"procedures"are"explained"in"the"METHODS"chapter."
The"structural"starting"point"for"this"study"was"examining"the"5"most"different"models"out"of"
the"20"belonging"to"the"available"NMR"structure"of"DENV2"C"(PDB"ID:"1R6R[8])" together"with"
the"S34L"mutants"obtained"from"the"same"models."Tetramers"were"then"assembled"through"
rigid"protein\protein"docking"and" the"selection"of" the"complexes" to" study"was"based"on" the"
following:"biological"data"showed"no"reduction"in"nuclear"localisation"of"C"in"presence"of"the"
compound" and" that" NLS" sequences" have" been" shown" to" be" essential" for" this" process."
Therefore," it"was" first" assumed" that" the" interaction"between"C"homodimers"did"not" involve"
these"particular"amino"acids"as"otherwise"they"would"be"masked"and"no"nuclear" localisation"
would"occur.[5,11]"Secondly,"it"was"hypothesised"that"tetramer"formation"could"also"not"involve"
the" hydrophobic" regions" responsible" for" C\LD" complex" formation," as" no" effects" on" C\LD" co\
localisation"after" ST\148"exposure"were"observed.[5,8,10,12]" Thirdly," as" ST\148" resistant" viruses"
present"a"S34L"mutation,"it"was"inferred"that"C"dimer\dimer"interaction"could"involve"the"area"
where"this"residue"is"located"on"the"protein"surface"and"consequently,"models"of"the"tetramer"
in" which" this" occurred" were" prioritised.[4,5]" Finally," as" nucleocapsid" structure" has" been"
observed" to"be"disordered," the"symmetry"of" the" tetramer"was"not"considered"an" important"
element.[1,16,17]""
The"best"model"that"fitted"the"above"criteria"was"used"for"30"ns"MD"simulations"for"both"the"
WT"and" the"S34L"mutant" structure,"after" the" in& silico" insertion"of" the"mutation." In" line"with"
biological" data," the" two" molecular" systems" behaved" in" a" similar" way." In" both" cases," the"
tetramer"changed"during"the"first"2"ns"into"a"stable"conformation"that"was"maintained"for"the"
rest"of"the"simulation,"as"the"systems"had"reached"equilibrium."
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The"WT"and"S34L"tetramer"structures"obtained"after"the"energy"minimisation"step"of"the"MD"
protocol"were"used"for"ST\148"docking."A"30"Å"grid"placed"at"the"dimer\dimer"interface"of"the"
tetramer"complex"and"centred"on"either"S34"or"L34"was"used"for"each"molecular"system."The"
best" binding" pose" for" the" compound" in" the" two"molecular" systems" was" then" used" for"MD"
investigation,"as"previously"carried"out"for"the"apo"complexes."Both"for"WT\ST\148"and"S34L\
ST\148"complexes,"during"the"first"2"ns"of"the"simulation"a"similar"change"in"conformation"to"
the"apo"tetramers"was"observed."This"new"arrangement"was"then"maintained"for"the"rest"of"
the"total"30"ns"as"equilibrium"was"reached."As"an"example,"Figure"2.4"shows"the"equilibrated"
structures"for"the"WT"tetramers"in"absence"(on"the"left)"and"in"presence"(on"the"right)"of"the"
compound."
"
!
Figure'2.4..Equilibrated.structures.of.the.WT.tetramers.in.absence.and.presence.of.STF148...
The"MD"resulting"structures"for"the"WT"tetramers"are"shown."On"the"left"hand"side"of"the"arrow,"the"WT"tetramer"
is"not"in"complex"with"the"compound,"while"the"latter"is"present"in"the"complex"on"the"right."In"all"cases,"one"
homodimer"(indicated"with"HD1)"is"coloured"in"orange"and"red"while"the"other"one"(indicated"with"HD2)"is"
represented"in"cyan"and"blue."In"all"dimers,"different"shades"of"the"same"colour"are"used"to"highlight"monomers."
Ser34"at"the"interface"of"the"dimers"is"highlighted"with"a"space\filling"model"and"ST\148"is"shown"in"green."
"
!
Figure'2.5..Movements.of!α2.and.α3.for.STF148.accommodation.in.the.WT.structure..
The"observed"movement"of"α2"and"α3"helices"of"one"dimer"for"better"ST\148"binding"in"the"cleft"is"presented"here."
On"the"left"the"whole"tetramer"complex"is"shown,"while"the"figure"on"the"right"is"an"enlargement"of"the"binding"
cleft."The"red"ribbons"represent"the"tetramer"in"absence"of"the"ligand,"while"the"blue"ones"represent"the"stable"
complex"of"the"tetramer"with"the"compound."ST\148"is"shown"in"green"using"a"space\filling"model"and"the"
movements"of"the"α\helices"are"indicated"with"arrows."
In"the"WT"tetramer,"ST\148"binds"at"the"interface"of"the"two"dimers," in"a"cleft"formed"by"α1"
and"α3"helices"of"one"unit"and"α1"helix"of"the"other"one."This"pose"stabilises"after"20"ns"and"it"
is"retained"until" the"end"of"the"simulation." Interestingly,"the"α2"and"α3"helices"of"one"dimer"
shift" upon" pose" stabilisation" in" order" to" accommodate" better" the" ligand" in" the" cleft," as"
highlighted" in" Figure" 2.5." The" MD" simulation" of" the" S34L" mutant" in" complex" with" ST\148"
Section"2:"CAPSID"AS"A"DRUG"TARGET" 2.2&RESULTS&AND&DISCUSSION&"!
!72"
showed"a"different"behaviour." In" this" case," the" small"molecule"did"not" stabilise" in" the" same"
cleft"but"explored"one"dimer’s"solvent"exposed"surface"through"the"transient"interaction"with"
more"than"one"site."
With" the" aim" of" confirming" the" different" binding" of" the" compound" to" the" WT" and" S34L"
mutant," ST\148" was" docked" in" the" stable" WT" tetramer\ST\148" complex" structure." As"
previously"done,"the"20"Å"grid"was"centred"on"either"the"Ser"or"the"Leu34"at"the"interface"of"
the"two"dimers."The"docking"results"shown"in"panel"A"of"Figure"2.6"were"able"to"reproduce"the"
ST\148" binding"mode" observed" during" the"MD" simulation" of" the"WT" system." In" detail," the"
binding"site"is"primarily"composed"by"Val26,"Leu29,"Arg41"and"Arg68"of"one"dimer"and"Ser34"
of" the" other" one." The" binding" of" the" compound" arises" mainly" through" hydrophobic"
interactions"with"the"many"hydrophobic"residues"of"the"pocket"due"to"the"high"lipophilicity"of"
the"molecule."Ligand"binding"is"further"enhanced"by"the"π\π"stacking"between"Phe33"and"the"
ST\148"phenyl" ring"together"with"the" interaction"of" the"electron\dense"thieno[2,3\b]pyridine"
portion"of"the"small"molecule,"tethered"between"Ser34"and"Arg68,"and"the"positive"charge"of"
the"basic"residue."This"binding"mode"is"consistent"with"the"panserotypic"antiviral"activity"of"ST\
148"as" the"main" interacting" residues" (Phe33,"Arg68"and"Ser34)" are"highly" conserved"among"
DENV1\4"viruses"and"the"other"pocket"forming"amino"acids"are"either"conserved"or"maintain"
the"same"chemical\physical"properties.""
"
" "
A" B"
Figure'2.6..Pose.of.STF148.in.the.WT.and.S34L.tetramers...
A).WTFSTF148.complex..The"binding"pose"of"ST\148"in"the"WT"tetramer"is"presented"here."The"main"residues"
constituting"the"binding"pocket"are"highlighted"and"ST\148"is"represented"in"green."Both"ribbon"and"surface"of"the"
protein"are"shown,"one"dimer"is"coloured"in"blue,"whilst"the"other"one"is"in"red..B).S34LFST0148.complex..
Representation"is"the"same"as"in"panel"A,"but"after"the"in&silico"S34L"mutation"insertion."The"steric"clash"region"is"
circled"and"indicated."In"this"case"one"dimer"is"coloured"in"blue,"while"the"other"one"is"in"yellow."
Panel"B"of"Figure"2.6"shows"clearly"that"the"S34L"mutation"creates"a"steric"hindrance"that"does"
not"allow"the"binding"of"the"compound,"which"occurs"in"such"close"contact"with"Ser34"in"the"
WT"system."This"is"consistent"with"the"MD"simulations"that"showed"that"ST\148"is"not"able"to"
stabilise" in" the" binding" cleft" and" explores" one" dimer’s" surface." All" together," these" results"
support"that"the"S34L"resistant"mutation"does"not"allow"ST\148"to"bind"to"the"tetramer"in"the"
same"stable"mode"of"the"WT."
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Summarising," ST\148" stabilisation" through" dimer" bridging" is" supported" by" the" Molecular"
Modelling" results" and" a"model" of" the" compound’s"mode" of" action" can" be" proposed" on" the"
base"of"in&silico"and"biological"data."
"
MODEL'OF'STS148'MODE'OF'ACTION'
"
As" suggested" from" the"available"biological" data," it" appears" that" the"mechanism"of" action"of"
early"and"late"stage"inhibition"by"ST\148"is"given"by"stabilisation"of"higher\order"oligomeric"C"
structures."According"to"the"Molecular"Modelling"results,"this"is"accomplished"by"hydrophobic"
and"electrostatic"interactions"of"this"small"molecule"with"the"protein"in"a"binding"site"between"
the"capsid"dimers"and"thus"stabilises"the"tetramer"complex"itself."Accordingly,"ST\148"could"be"
classified" as" a" direct" protein\protein" interaction" (PPI)" stabiliser." Moreover," the" resistance"
inducing"S34L"mutation"can"also"be"explained"with" this"model"as"ST\148"has"been"shown"to"
bind" to" the"mutant," but" in" a" less" stable"manner," due" to" the" steric" hindrance" caused"by" the"
larger"Leu"side"chain"that"does"not"allow"compound"accommodation."
"
"
"
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2.3.CONCLUSIONS.
"
The"Molecular"Modelling"study"presented"in"this"section"was"designed"to"uncover"insights"in"
to" the"mechanism" of" action" of" ST\148," a" potent" panserotypic" DENV" inhibitor" that" interacts"
with"the"C"protein,"in"accordance"with"the"available"biochemical,"virological"and"imaging"data."
Several" computational" chemistry" techniques" were" employed" for" the" development" of" a"
methodology"that,"to"the"best"of"knowledge,"was"never"applied"to"this"molecular"target"and"
the"results"all"corroborated"the"experimental"data."Thus,"a"model"of"the"mechanism"of"action"
of" this" compound" has" been" developed" and" suggests" that" ST\148" acts" as" a" protein\protein"
interaction" stabiliser." Protein\protein" interactions" (PPIs)" are" involved" in" several" important"
cellular" processes" and" therefore" are" of" huge" interest" for" drug" development." However," the"
inhibition"or"the"stabilisation"of"PPIs"have"been"historically"challenging"drug"design"strategies,"
in"particular" for"small\molecules"development.[18\20]"The" interfaces"between"proteins" tend"to"
be" larger" and" shallower" than" pocket" binding" sites" and" require" a" good" understanding" about"
interactions" hotspots" that" contribute" the" most" in" binding." Fortunately," the" advances" in"
knowledge"and"in"scientific"tools"in"recent"years,"these"strategies"are"becoming"more"popular"
and" they" are" proving" in" a" number" of" cases" to" be" a" winning" strategy.[18\20]" In" this" study," a"
promising" anti\DENV" compound"was" shown" to" be" a" PPI" stabiliser," confirming" that" this" drug"
design"strategy"is"achievable"and"a"valid"tool"for"drug"discovery."The"further"development"of"
ST\148\like"molecules,"aided"by"the"information"obtained"with"this"collaborative"study,"could"
succeed" in" the" discovery" of" a" medicine" that" can" successfully" reach" the" market" for" DENV"
infection"therapy."
"
"
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2.4.METHODS.
"
The"computational"methods"for"this"study"are"presented"here."A"description"of"the"molecular"
modelling"programs"used"can"be"found"in"APPENDIX&2."
"
HARDWARE'DETAILS'
"
All"docking"simulations"were"performed"on"a"8"core"computer"with"Inter"Xeon"2.80"GHz"E5462"
CPUs,"while"MD"simulations"were"performed"on"a"32"core"computer"with"Inter"Xeon"2.20"GHz"
E5\4620"CPUs."
"
PROTEINSPROTEIN'DOCKING'
"
The" NMR" structure" of" C" (PDB" ID:" 1R6R[8])" was" downloaded" from" the" Protein" Data" Bank"
website.[21]"MOE"2010.10[22]"Protein"Consensus"tool"was"used"to"compare"the"20"dimer"models"
present"in"the"file"for"the"selection"of"the"5"most"different"structures"for"rigid"protein\protein"
docking."MOE" 2010.10[22]" Mutate" tool" was" used" for" the" construction" of" the" S34L"mutation"
structures" starting" from" those" of" the" wild" type" (WT)," as" both" of" them"were" used" for" each"
modelling" approach" undertaken." Prior" to" protein\protein" docking" simulation," each" protein"
structure" was" prepared" using" Schrödinger" Maestro" 9.5[23]" Protein" Preparation" Wizard."
Schrödinger" BioLuminate" 1.2[24]" Piper" was" then" used" for" protein\protein" docking." This"
simulation"was"performed"by"using"as"receptor"and"ligand"the"same"C"dimer."Complexes"were"
generated"by"standard"mode"rigid"docking,"probing"70,000"ligand"rotations."A"0.21"bonus"was"
given" to" the" tetramers" presenting" Ser34" in" the" dimer\dimer" interaction" surface." Finally," the"
best"model"was"chosen"through"visual"inspection."
"
MOLECULAR'DYNAMICS'SIMULATIONS'
"
GROMACS"4.5.3[25]"was"used"with"AMBER99" force" field" for" all" the"molecular"dynamics" (MD)"
simulations." Both"WT" and" the" S34L"mutant"were" used" for"MD" simulations." In" the"mutated"
molecular"system,"Ser34"was"substituted"by"Leu34"in&silico"with"MOE"2010.10[22]"Mutate"Tool,"
starting" from"WT." For"MD" simulation," a"minimum" 0.9" nm" distance" between" the"molecular"
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system" and" the" cubic" box" employed" and" periodic" boundary" conditions" (PBC)" were" applied."
Water"was"added"and"described"as"an"explicit" solvent"and" the"molecules"were" treated"with"
the"TIP3P"model."The"total"charges"of"the"systems"were"neutralised"by"adding"72"Cl\"ions."For"
the" ST\148\tetramer" complex" simulations," the" small" molecule" missing" parameters" were"
computed" using" AMBER12[26]" Antechamber" software," using" AM1\BCC" charge" method" and"
GAFF" force" field" for" atom" types." The" obtained" files" were" then" converted" with" acpype"
converted[27]" into" a" GROMACS\compatible" format." Two" consecutive" energy" minimisations"
were" initially"performed,"employing"the"steepest"descendent"(SD)"method"first"and"then"the"
conjugate" gradient" (CG)"method" after,"with" the" aim" of" a" faster" process" and"more" accurate"
result."A" force" tolerance"of" 100"kJ"mol\1" nm\1"was" set" for" SD,"while" a"10" kJ"mol\1" nm\1" force"
tolerance"was" applied"with" CG."However," in" both" cases" the"maximum"number" of" iterations"
was" set" to" 3,000" steps." Subsequently," a" position" restrain" force" of" 1,000" kJ" mol\1" nm\2" was"
applied" to" protein" (and" ligand)" atoms" for" water" molecules" relaxation." Aiming" a" smoother"
equilibration,"two"consecutive"50"ps"(50,000"steps,"step"size"of"1"fs)"position"restrained"MDs"
were" consequently" performed," saving" coordinates," velocity" and" energy" values" every" 500"
steps."NVT"conditions"(constant"number"of"atoms"N,"volume"V"and"temperature"T)"were"used"
for" the" first" position" restrained"MD" and" a" v\rescale" temperature" coupling" and" 0.1" ps" time"
constant"was"used"to"heat"the"system"to"300"K."NPT"conditions"(constant"number"of"atoms"N,"
pressure"P"and"temperature"T)"were"used"for"the"second"position"restrained"MD,"with"the"use"
of"both"temperature"(v\rescale,"temperature"300"K"and"time"constant"of"0.1"ps)"and"pressure"
(Berendsen"algorithm,"1"bar"pressure"and" time"constant"of"0.5"ps)"coupling."The"production"
simulations,"for"a"total"30"ns"(15,000,000"steps"with"2"fs"step"size)"simulation"time"each,"were"
run"in"the"already"described"NPT"conditions,"saving"coordinates,"velocities"and"energy"values"
every" 1,000" steps." In" all" simulation" stages," long\range" electrostatic" interactions" were"
calculated"with"the"Particle\Mesh\Ewald"(PME)"method"with"a"0.9"nm"short"range"cut\off"and"
short\range"non\bonded"interactions"were"computed"only"within"a"cut\off"of"1.4"nm."Results"
were"visually"inspected"with"VMD[28]"and"analysed"with"GROMACS"4.5.3[25]"tools"and"Grace[29]."
"
SMALL'MOLECULE'DOCKING'
"
The" small" molecule" docking" simulations" were" performed" with" Schrödinger" Maestro" 9.5[23]."
First,"the"protein"complexes"were"prepared"with"the"Protein"Preparation"Wizard"tool"and"ST\
148"was"prepared"with"LigPrep,"generating"all"possible"tautomers"and"Epik"ionisation"states"at"
pH"7.0"±"2.0."Secondly,"Glide"was"used"for"the"definition"of"the"grid"that"was"centred"on"the"
Ser34"(or"Leu34)"at" the" interface"of" the"two"dimers" in"the"tetramer"complex," for"all"docking"
simulations." The" grid" size" was" set" to" 30Å" for" the" first" docking" simulations" with" WT" and"
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mutated"systems;"while"it"was"set"to"20Å"for"the"second"case."The"inner"grid"box"size"was"set"
to" the"default"10Å" for"both"grids."The"same"software"was" then"used" for"docking"simulation,"
with" the" following" settings:" standard" precision" (SP)" mode," nitrogen" inversion" and" ring"
conformation" sampling," penalisation" of" non\planar" conformation" for" amides" and" no" energy"
minimisation" of" binding" poses." In" each" docking" simulation," 25" poses" were" generated" and"
refined"with"SP"mode"before"visual"inspection."
"
"
"
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3.1.INTRODUCTION.
"
A'PROMISING'DRUG'TARGET'
"
RNA"replication"is"an"essential"step"in"the"viral"replication"cycle."Using"a"positive"sense"single"
stranded" RNA" template," (+)ssRNA," the" replication" machinery" generates" a" minus\stranded"
RNA,"(\)RNA,"that"acts"as"a"template"for"the"synthesis"of"viral"(+)ssRNA."During"the"synthesis"of"
a" new" nucleic" acid"molecule," NS5" RNA\dependent" RNA" polymerase" (NS5" RdRp)" produces" a"
double"stranded"genome"(dsRNA)"that"has"necessarily"to"be"separated."The"novel"RNA"is"then"
modified"with"a" cap" structure"at" the"5’"end" that"protects" the"nucleic"acid" from"degradation"
and" allows" its" correct" transcription." Due" to" the" lack" of" appropriate" host" proteins," most" of"
these" steps" are" carried" out" by" viral\encoded" enzymes," mainly" belonging" to" NS3" and" NS5"
proteins.[1,2]" Three" enzymatic" properties" have" been" attributed" to" one" of" the" most"
characterised" viral" proteins," the" C\terminal" helicase" portion" of" the" NS3" multifunctional"
enzyme" (NS3hel):" nucleotide" triphosphatase" (NTPase)," helicase" and" 5’" RNA" triphosphatase"
(RNAse)." The" first" two" activities" work" in" concert," allowing" NS3hel" to" unwind" the" dsRNA"
produced" by" NS5" RdRp" in" a" NTP" dependent" manner." The" third" one," is" enhanced" by" the"
interaction"with"NS5"and"makes"NS3hel"responsible"for"the"first"of"the"four"capping"reactions"
further"explained"in"the"NS5&METHYLTRANSFERASE&AS&A&DRUG&TARGET"section.[3\5]""
All"of"this"clearly"indicates"that"NS3hel"is"highly"involved"in"essential"steps"of"RNA"replication."
Consequently," the" inhibition"of" this" viral" protein"would"block" the"process" in"more" than"one"
step.[3\6]" Thus," NS3hel" is" a" promising" drug" target" for" the" design" of" novel" potent" anti\DENV"
drugs," as" confirmed" by" the" fact" that" some" potential" enzyme" inhibitors" start" to" appear" in"
literature.[7\9]"
"
STRUCTURE'
"
The"overall"geometry"of"the"whole"NS3"enzyme"is"reported"in"Figure"3.1."The"N\terminal"170"
residues" (in" orange" in" the" figure)" have" a" serine" protease" function" (NS3pro)," while" the"
remaining" 70%" of" the" protein" is" the" NS3hel." NS3pro" is" responsible" for" the" cleavage" of" the"
polyprotein"at"the"junctions"between"C/prM,"NS2A/NS2B,"NS2B/NS3,"NS3/NS4A,"NS4A/NS4B"
and"NS4B/NS5."For" its"activity," the"presence"of"the"cofactor"NS2B"(in"yellow" in"Figure"3.1)" is"
necessary"as"it"stabilises"the"protease"in"the"active"form."The"interaction"between"these"two"
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proteins" occurs" between" the" central" hydrophilic" region" (residues" 49\95)" of" NS2B" and" its"
binding" site" in" the"NS3pro" structure." The"protease" active" site" is" flat," shallow"and"negatively"
charged," explaining" the" binding" preference" of" basic" residues" (Lys" and" Arg)." As" it" is" a" serine"
protease,"the"residues"that"catalyse"the"hydrolytic"brake"of"the"amidic"bond"are"a"His"(His51),"
an"Asp"(Asp75)"and"a"Ser"(Ser135).[4,6,10]""
"
!
Figure'3.1..Complete.NS3.enzyme.(PDB.2WZQ)..
The"protease"portion"is"coloured"in"orange,"while"the"helicase/NTPase"portion"is"shown"in"blue."Carbon"atoms"of"a"
small"portion"of"the"NS2B"cofactor"are"represented"in"yellow."
NS3hel" occupies" the" C\terminal" portion" of" NS3" and" it" is" constituted" by" 437" residues." It" is"
divided"into"3"equally"sized"domains,"as"reported"in"Figure"3.2."Domain"1"(residues"180\326),"
in" blue" in" the" figure," and" domain" 2" (residues" 327\481)," in" red," are" similar." They" are"
characterized"by"a"large"six"parallel"β\sheets"with"an"evident"twist"and"four"α\helices"around"
them"(as"visible"in"the"ribbon"structure"reported).[6,11,12]"The"main"difference"between"domains"
1"and"2" is" that" the"second"one"has"a" long"β\hairpin" that" is" in"contact"with"domain"3," in" the"
back"of"the"RNA"binding"site" in"the"region"where"the"nucleic"acid"enters"the"cleft."Domain"3"
(residues" 482\618)," in" green" in" the" figure," is" mainly" composed" of" α\helices," having" 4"
approximately"parallel"α\helices"and"other"three"short"α\helices."It"is"the"domain"that"differs"
the"most" to" the"helicases"of" other"members"of" the"Flaviviridae" family," as" for" example"HCV."
DENV"NS3hel" domain" 3" has" indeed" a" unique" fold" as" no" significantly" homologous" structures"
could"be" found" in" the"Protein"Data"Bank.[13]"Furthermore,"domain"3" is"not"always"present" in"
helicases."For"example,"human"helicases"do"not"have"a"third"domain.""
The"interfaces"of"the"domains"enclose"two"binding"sites."The"one"located"between"domain"1"
and" 2" can" accommodate" the" triphosphate" moiety" of" either" a" nucleotide" (NTP)" or" of" the"
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triphosphate" 5’" end" of" the" RNA" and" it" is"where" the" phosphatase" activity" (both"NTPase" and"
RNAse)" takes" place." A" second," larger," binding" site" is" between" the" three" domains" and" it" is"
responsible"for"the"binding"of"5"RNA"nucleotides"for"the"helicase"function.[6,11,12]""
"
" "
A" B"
Figure'3.2..Helicase.portion.of.NS3.(PDB:2JLV)..
A).Protein.surface."The"three"domain"surfaces"are"coloured"differently:"domain"1"is"blue,"domain"2"is"red"and"
domain"3"is"green."ATP,"in"pink,"is"in"the"NTP"binding"site,"between"domains"1"and"2."A"RNA"strand,"in"yellow,"is"in"
the"RNA"binding"site,"at"the"interface"of"the"three"domains."B).Protein.ribbon."In"this"figure"the"protein"is"
represented"as"ribbons."The"same"colour"scheme"of"A)"was"applied"here.""
On"the"basis"of"conserved"motifs,"RNA"and"DNA"helicases"are"divided" in" three"superfamilies"
(SF)."DENV"NS3hel"belongs"to"SF2"because"it"shares"with"these"enzymes"seven"motifs,"located"
in"domains"1"and"2."Motif"I"(Gly196\Thr200),"also"called"Walker"A"motif"or"“P\loop”,"and"motif"
II"(Asp284\His287),"also"called"Walker"B"motif"or"DEAH"box,"are"situated"in"domain"1"and"are"
involved"in"NTP"phosphate"and"a"divalent"ion"(either"Mg2+"or"Mn2+,"catalytically"necessary"for"
NTP" hydrolysis)" binding" respectively." In" domain" 2," two" arginines" (Arg460" and" Arg463)," also"
called"“Arg"fingers”,"that"belong"to"motif"VI"(Gln456\Arg463)"are"also"involved"in"NTP"binding"
and"hydrolysis."The"Walker"A"motif"is"the"most"conserved"motif"among"all"helicases."In"fact,"its"
GxGKT" sequence" is" conserved"among" the"whole"3" superfamilies."On" the"other"hand,"on" the"
basis" of" the"Walker" B" motif" residues," SF2" is" divided" into" 3" distinct" subfamilies:" DEAD" (e.g."
eIF4AIII," Vasa)," DEAH" (e.g." DENV" NS3hel)" and" DEXH" (e.g." HCV" NS3hel)" box" proteins." Other"
motifs" are" involved" in" the" binding" and" translocation" of" the" nucleic" acid:" motif" Ia" (Pro223\
Ala228)," Ib" (His262\Thr265)," IV" (Trp" 360\Ala367)" and" V" (Thr408\Ala416)." Finally," motif" III"
(Ile312\Pro324)"couples"the"two"enzymatic"activities"(NTPase"and"helicase).[6,14,15]""
The"N\"and"C\terminal"portions"of"NS3"have"very"different"functions"and"influence"each"others"
activity.[6,12]"Crystal"structures"of"the"full\length"NS3"protein"have"demonstrated"that"NS3pro"is"
placed"above"the"NTP"binding"site"of"NS3hel"and"that"the"two"portions"are"connected"through"
a" flexible" linker" (residues" 169\179)" that" confers" high" plasticity" to" the" structure.[12,16]" Two"
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crystal" structures" in" particular," showed" that" the" full\length" NS3" protein" can" adopt" two"
distinguishable"conformations"(I"and"II).[12]"“Conformation"II”"is"elongated,"and"NS3pro"seems"
to" be" rotated" by" approximately" 161°" with" respect" to" “conformation" I”," causing" the" loss" of"
some"contacts"between"the"helicase"and"the"protease."Experimental"data"has"shown"that"the"
two"conformations"have"different"helicase"activities,"with"conformation"I"being"less"efficient"in"
dsRNA"unwinding."One"hypothesis"is"that"the"lack"of"unwinding"efficacy"in"this"case"is"caused"
by" the"NTP" binding" inaccessibility," blocked" by"NS3pro." In" addition" to" this," the" fact" that" the"
protease" is" linked" to" the"membrane\inserted"protein"NS2B,"prompts" the"possibility" that" the"
rotation"of"the"protease"induces"a"different"orientation"of"the"whole"NS3"with"respect"to"the"
endoplasmic"reticulum"(ER)"membrane."A"model"of"this"mechanism"has"been"proposed"and"it"
is"schematised"in"Figure"3.3."According"to"the"model,"the"inhibition"of"the"helicase"activity"also"
derives" from" the" fact" that" conformation" I" (panel" A)" induces" the" RNA" binding" site" of" the"
helicase"to"face"the"membrane,"obstructing"the"binding"of"the"natural"substrate.[12]"
"
" "
"""A" ""B"
Figure'3.3..Model.of.the.two.conformations.of.NS3.in.respect.of.the.membrane...
A).Conformation.I."In"this"conformation"NS3"is"not"able"to"bind"either"ATP"or"RNA."The"NS3"structure"for"this"
conformation"was"taken"from"PDB"ID"2WZQ."NS3pro"(indicated"as"“Pro”)"surface"and"ribbon"are"coloured"in"orange"
and"for"NS3hel"(indicated"as"“Hel”)"are"in"blue."The"membrane"is"represented"in"pale"green"and"the"NS2B"cofactor"
is"coloured"in"red."The"RNA"molecule"is"represented"as"a"purple"circle,"while"ATP"is"represented"by"a"dark"green"
one."B).Conformation.II."In"this"conformation"NS3"is"able"to"bind"both"ATP"and"RNA."The"NS3"structure"for"this"
conformation"was"taken"from"PDB"ID"2WHX."The"same"colouring"scheme"as"A)"was"adopted"here.""
"
" "
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POSSIBLE'TARGET'SITES'
"
NS3" helicase" is" responsible" for" double" strand" RNA" unwinding," nucleoside" triphosphate"
hydrolysis" and"5’"RNA" triphosphatase"activity.[6]" In"order" to"accomplish" these" functions," this"
enzyme" presents" two" different" binding" pockets" that" could" be" used" for" rational" drug" design"
purposes:"one"for"NTP"and"one"for"single"strand"nucleic"acid"molecules.[19]""
In" the" NTP" binding" site," the" enzyme" is" able" to" bind" either" a" nucleotide" (NTP)" or" the"
triphosphate"5’"end"of" the"RNA." In"both" cases," the"enzyme"hydrolyses" the"γ\phosphate" in"a"
divalent"cation\dependent"manner"(either"with"Mn2+"or"Mg2+).[17,18]"The"interactions"between"
the"protein"and"the"ligand"are"mainly"at"the"level"of"the"phosphates"and"some"at"the"level"of"
the" ribose," but" no" particular" interactions" involving" the" base" of" the" nucleotide" have" been"
observed." This" explains" the" lack" of" specificity" in" regard" to" the" base,"which"means" that" it" is"
almost"completely"solvent\exposed."The"main"residues"directly"involved"in"ligand"binding"are:"
Thr200,"Lys201,"Arg418,"Asn329,"Asn416,"Arg463,"Gly198,"Lys199"and"Arg460"(reported"in"the"
schematic"ligand"interaction"view"of"Figure"3.4).[11,12,16,19]"
"
"
Figure'3.4..Schematic.representation.of.ATP.binding...
The"interaction"rendering"follows"the"legend"on"the"right."
When"the"enzyme"is"bound"to"RNA,"the"NTP"phosphates,"three"molecules"of"water"and"the"OH"
moiety" of" Thr200" mediate" the" octahedral" coordination" of" the" divalent" cation" (Mn2+" in" the"
figure)." In" this" conformation," the" water" molecule" that" takes" part" in" the" NTP" γ\phosphate"
hydrolysis"is"positioned"in"the"most"favourable"position"for"a"nucleophilic"attack."Furthermore,"
its" interaction"with"Glu285"and"Gln456" increases" its"nucleophilicity," facilitating" the" reaction."
When" RNA" is" not" bound" to" the" enzyme" in" the" cleft" at" the" interface" of" the" three" domains,"
Glu285"takes"the"place"of"one"water"molecule"in"the"divalent"cation"coordination,"leading"to"a"
Section"3:"NS3"HELICASE"AS"A"DRUG"TARGET" 3.1&INTRODUCTION"!
!86"
loss" in" NTPase" activity." Consequently," RNA" binding" increases" the" NTPase" efficiency" of" the"
enzyme.[11,12,16,19]"
The"nucleic"acid"binding"site" is"a"shallow"pocket"at"the"interface"of"the"three"domains."From"
crystallographic"data,"five"nucleotides"with"the"bases"stacked"one"to"the"other"can"take"place"
in" this" site." In"a" similar"manner" to" the"NTP"binding"site,"also" in" the"case"of" the"RNA"binding"
site," there" is" no" selectivity" to" the" different" nucleoside" types" as" very" few" interactions" are"
between" the" protein" and" the" bases," while" most" of" them" occur" at" the" level" of" the" ribose\
phosphate"backbone"(Figure"3.5).[19]"
"
!
Figure'3.5..Schematic.view.of.the.interactions.between.the.nucleic.acid.and.NS3.helicase...
The"five"co\crystallised"RNA"nucleotides"are"shown"and"protein"residues"are"indicated."Colouring"and"interactions"
are"shown"as"indicated"in"the"legend."
From" activity" assays," DENV" helicase" has" good" unwinding" activity" for" both" DNA" and" RNA."
However,"it"preferentially"binds"to"RNA,"explaining"a"slight"specificity"of"DENV"NS3hel"for"this"
nucleic"acid.[11,20]" It"has"been"hypothesised" that" this"might"be"due" to" some" interactions" that"
involve" the" OH" moieties" in" the" 2’" position" of" the" nucleotides." As" the" enzyme" has" to"
accommodate"the"negatively"charged"phosphate"groups,"it"is"not"surprising"that"in"this"pocket"
there"is"a"high"presence"of"basic"residues"(Arg"and"Lys)"that"at"physiological"pH"are"positively"
charged.[14,19]"
Studies"have"shown"that"the"mutation"of"some"residues"induces"the"inhibition"of"the"enzyme’s"
activity." Surprisingly," some" of" these" residues," like" Arg376," Lys377," Lys380," Asp334," Glu335,"
Glu336"and"Lys396"are"located"on"the"protein’s"surface"on"domain"2,"opening"the"possibility"
that"the"interaction"of"this"domain"with"other"proteins"or"even"with"the"second"chain"of"the"
unwinding"dsRNA"might"be"important."In"the"area"of"the"NTP"binding"site,"Gly198"and"Lys199"
mutation"to"Ala"inhibited"both"NTPase"and"helicase"activities,"while"four"arginines"(Arg460"and"
Arg463;"Arg457;"Arg458)"seem"to"be"important"for"the"NTPase"activity,"but"not"very"influential"
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on"helicase" function."Only"one" interesting"mutation"concerned" the"nucleic"acid"binding" site:"
Ile365Ala"that"inhibited"only"helicase"activity.[15,21]"
As"described"in"this"chapter,"the" lack"of"base\specificity" in"NTP"binding"and"the"shape"of"the"
RNA"binding"site"make"both"clefts"challenging"for"drug"design,"explaining"the"limited"advances"
in"the"discovery"of"NS3hel"inhibitors"despite"the"good"availability"of"structural"data.[22]""
"
MECHANISM'OF'ACTION'
"
As" for" other" SF2" helicases," like" HCV" NS3hel," RNA" translocation" occurs" in" a" 3’\5’" direction."
Crystal"structures"of"different"stages"of"the"supposed"mechanism"of"action"have"been"solved,"
but"they"did"not"give"valid"insights"into"particular"protein"changes"in"conformation"during"the"
NTP" binding\hydrolysis\release" cycle," maybe" due" to" particular" constraints" during"
crystallization.[19]"An"approximately"40ns"molecular"dynamics" (MD)" study" showed"a" scissors\
like"movement"of"the"enzyme"alone"that"was"not"shown"when"the"enzyme"was"only"bound"to"
ATP." This" suggests" a" mechanism" of" action" similar" to" HCV" NS3hel," in" which" a" ratchet\like"
movement" of" the" protein" domains" causes" the" translocation" of" the" enzyme" along" a" single"
stranded" RNA" (ssRNA)"molecule.[23\25]" However," key" aspects" of" the"mechanism" of" action" of"
DENV"NS3hel" remain" elusive.[19]" Further" knowledge" about" the" translocation"mechanism"and"
on" the" 3’\5’" directionality" in" particular"were"obtained"with"molecular" dynamics" and"binding"
energy" studies" computed" in" our" laboratories." The" new" insights" are" presented" in" the" NS3&
HELICASE&MECHANISM&OF&TRANSLOCATION&ALONG&RNA"section."
The"RNA"unwinding"mechanism"is"also"not"clear"to"date."There"are"two"possibilities:"a"passive"
or"an"active"unwinding."In"the"first"case"the"helicase"could"bind"to"single"stranded"RNA"taking"
advantage" of" the" spontaneous" opening" of" the" duplex" at" the" fork." The" translocation" of" the"
helicase"on"the"RNA"would"then"exert"the"unwinding"function."Even"though"this"mechanism"is"
serendipity\based,"it"should"have"high"efficiency"as"the"kinetics"of"local"base"opening"are"fast."
Efficiency"would,"however,"increase"in"the"case"of"an"active"mechanism"in"which"the"helicase"
would" operate" an" active" disruption" of" base" pairs" hydrogen" bonds." In" any" case," it" has" been"
proposed"that"the"β\hairpin"has"a"crucial"role"in"disrupting"the"stacking"interactions"between"
bases"and"stabilizing"the"unwound"state.[14,19]"
"
" "
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AIMS'AND'OBJECTIVES'
"
As"it"is"highly"involved"in"the"RNA"replication"cycle,"NS3hel"inhibition"would"lead"to"the"arrest"
of"DENV" infection.[5]"Given" its" three"enzymatic"activities,"NS3"could"be"targeted"with"several"
drug" design" strategies." For" instance," competitive" inhibitors" could" prevent" natural" substrate"
binding," or" allosteric" inhibitors" could" induce" structural" modifications" that" would" stop" the"
protein" activity" and" molecules" could" also" block" RNA" translocation." Furthermore," as" NS3"
interacts"with" other" proteins" in" the" replication" complex," the" disruption" of" these" complexes"
with"protein\protein"inhibitors"could"lead"to"an"antiviral"effect.[5,26]""
With" the" aim" of" discovering" novel," potent" inhibitors" of" DENV" NS3hel," three" Molecular"
Modelling" based" approaches" were" adopted." One" of" them," discussed" in" chapter" 3.2.1," was"
based" on" three" commercially" available" compounds" active" against" DENV" helicase.[7]" As" no"
structural"data"linked"to"these"results"was"available,"a"ligand\based"drug"design"approach"was"
applied"in"order"to"find"novel"potential"antiviral"compounds"on"the"basis"of"this"information."
Given" the" abundance" of" structural" data" on" NS3hel," the" other" two" studies" were" structure\
based"and"aimed"to"design"competitive"inhibitors"that"could"bind"the"RNA"(see"chapter"3.2.2)"
or"the"NTP"(see"chapter"3.2.3)"binding"sites"of"the"protein.""
"
"
"
"
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3.2.RESULTS.AND.DISCUSSION.
"
3.2.1'OUABAIN'SHAPESBASED'DRUG'DESIGN'
"
Despite" the" available" knowledge" on" DENV" NS3hel," the" lack" of" knowledge" on" the" enzyme’s"
mechanism"of"action"makes"drug"design"of"helicase"inhibitors"challenging.[4,5]"Nevertheless,"at"
the" 2011" International" Conference" on" Antiviral" Research" (24th" ICAR)" organised" by" the"
International"Society"for"Antiviral"Research"(ISAR),"three"compounds"were"reported"as"active"
against" this" viral" enzyme" for" the" first" time." These"molecules" (Ivermectin," Paromomycin" and"
Ouabain)"are"approved"drugs"for"diseases"not"related"to"viral"infection,"for"instance"congestive"
heart" failure" and" angina" pectoris." No" data" specifies" the" exact" site" of" interaction" of" these"
inhibitors"with" the"enzyme,"apart" from"a"molecular"modelling"study" that"suggested" that" the"
binding"site"could"be"the"entry"of"the"nucleic"acid"binding"site.[7]"
Consequently,"even"though"several"structures"of"NS3"helicase"have"been"solved"for"DENV," it"
was" decided" to" use" the" above" reported" promising" results" for" a" ligand\based" drug" design"
approach"for"the"design"of"novel"antiviral"drugs."Briefly,"the"drug"design"approach"applied"was"
based" on" the" selection" of" molecules" belonging" to" a" database" on" the" basis" of" their" shape"
similarity"with"one"of"the"three"active"compounds."The"selected"compounds"were"then"tested"
in&vitro"and"further"developed."
"
OUABAIN.AS.A.REFERENCE.MOLECULE.
"
The" optimal" condition" for" shape" screening" requires" the" presence" of" data" regarding" the"
template’s"active"conformation."At"the"time"of"the"study,"knowledge"regarding"the"interaction"
with"DENV"helicase"was"not"available"for"the"three"molecules"(Ivermectin,"Paromomycin"and"
Ouabain)." For" this" reason"and" since" the"active" conformation"does"not"always" correspond" to"
the"one"at"the"absolute"energy"minimum,"all"the"conformations"corresponding"to"local"energy"
minima" of" all" three" of" the" reference" molecules" were" explored" with" MOE" 2010.10,"
hypothesising"that"one"of"them"corresponds"to"the"active"conformation."The"screen"was"then"
performed" by" comparing" the" shape" of" molecules" belonging" to" the" database" with" shapes"
matching"the"query"conformations."Molecules"corresponding"to"the"highest"number"of"query"
shapes"are"more" likely" to"adopt" the"unknown" template"active" conformation." Therefore," the"
main" hypothesis" is" that" the" selection" of" those" molecules" would" lead" to" better" screening"
results."An"important"consequence"of"this"hypothesis"is"the"relevance"of"the"total"number"of"
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low"energy"conformations" that" the"query"molecule" can"adopt:" the" fewer" the"conformations"
the"higher"the"probability"that"screened"molecules"match"the"active"conformation."
Of"the"three"reference"molecules,"Ouabain"demonstrated"the"least"number"of"conformations"
and"was" chosen" as" the" reference"molecule." From" the" structures" reported" in" Table" 3.1," it" is"
possible"to"rationalise"this"with"the"fact"that"Ouabain"is"the"most"rigid"molecule,"characterised"
by"a"steroidal"core;"while"the"other"molecules"have"a"larger"number"of"freely"rotatable"bonds.""
"
Table'3.1..Chemical.structures.of.the.three.template.molecules..
Name. Structure.
Ivermectin.
"
Paromomycin.
"
Ouabain.
"
"
The" number" of" Ouabain" conformations" produced"was" 33." Since" this" number" is" too" high" to"
work" with" for" shape" comparisons," it" was" reduced" through" visual" inspection." Duplicate"
conformations"were"eliminated"and"similar" shapes"were"clustered."The" final"query" selection"
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was"of"the"three"most"different"Ouabain"templates,"called"Ouabain_1"(in"green),"Ouabain_10"
(in"blue)"and"Ouabain_22"(in"red)"as"reported"in"Figure"3.6.""
"
!
Figure'3.6..Shape.of.the.three.Ouabain.query.conformations..
The"surface"of"Ouabain_1"is"in"green,"Ouabain_10"is"in"blue"and"Ouabain_22"is"coloured"in"red."
"
SHAPE.SCREENING.
"
The" three" Ouabain" shape" queries" were" used" as" templates" for" the" screening" of" molecules"
belonging"to"the"SPECS"database,"a"collection"of"purchasable"drug\like"small"molecules,"whose"
structures" are" available" online.[27]" The" version" of" the" database" that" was" used" was" the" one"
updated"in"February"2012,"containing"approximately"209,950"drug\like"molecules.""
The" shape" screening"was" computed"with" the"OpenEye" ROCS" program" that" operates" a" rigid"
superposition"of"molecules" to" the"given"queries."As" the" shape" is" a" conformation\dependent"
descriptor,"in"order"to"compute"an"appropriate"shape"comparison"it"was"necessary"to"apply"a"
conformational" search" to" the" SPECS" database," obtaining" approximately" 7,130,000"
conformations.""
The" virtual" screening"was" conducted" comparing" each" small"molecule" conformation"with" all"
three" of" the" Ouabain" queries" and" scoring" the" match" with" the" Tanimoto" index." As" no"
knowledge" about" which" functional" groups" of" Ouabain" are" important" for" its" activity" was"
available"at"the"time"of"the"study,"only"shape"comparison"was"used"for"conformation"scoring.""
Conformations"were"ordered"according"to"the"score"and"only"the"best"results"were"analysed,"
searching"for"conformations"that"could"match"more"than"one"shape"query."The"screening"was"
repeated"five"times,"saving"1000,"2000,"3000,"4000"and"5000"best"hits"respectively."The"final"
screening" outputs" were" then" collected" and" compared." There" were" 45," 29," 17," 8" and" 3"
conformations"(corresponding"to"14,"11,"8,"4"and"3"different"molecules"respectively)"matching"
2" queries" when" 5000," 4000," 3000," 2000" and" 1000" hits" were" kept" respectively." No"
conformation" matched" all" three" queries." Interestingly," the" conformations" that" had" good"
overlap" with" two" queries" always" matched" query" Ouabain_1" and" either" Ouabain_10" or"
Ouabain_22." There" were" no"matches" that" involved" both" Ouabain_10" and" Ouabain_22," the"
most"different"shapes"amongst"the"three."
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According" to" the" study" hypothesis," a" higher" query" matching" corresponds" to" a" higher"
probability" in" matching" the" active" conformation" and" consequently" only" the" conformations"
that" matched" two" queries" in" each" screen" were" considered" for" further" investigation." Good"
Tanimoto" scores"belonged" to" the"elements"of" this" group"of" conformations" and" they" ranged"
from"a"maximum"of"0.7235"to"a"minimum"of"0.6925."For"each"entry," the"average"score"was"
computed" for" the" two" query" matches." The" chemical" diversity" of" the" molecules" was" also"
assessed"by"clustering" them" in"22"and"25"groups" for"structures"with"75%"and"85%"similarity"
respectively."These"two"parameters"and"the"visual"inspection"of"the"shape"superposition"were"
used" for" the"selection"of"11"compounds" (reported" in"APPENDIX&3)" that"were"purchased"and"
tested"in&vitro."
"
IN.VITRO.EVALUATION.OF.THE.SELECTED.COMPOUNDS.
"
All"the"purchased"molecules"were"tested"in&vitro"at"the"Rega"Institute"for"Medicinal"Research,"
K." U." Leuven" (Belgium)" by" our" collaborators." The" biological" assay" was" conducted" on" 8000"
DENV" infected" Vero" cells" per" well," with" the" aim" of" detecting" inhibition" of" virus\induced"
cytopathic"effect"(CPE)."The"cells"were"exposed"to"different"concentration"of"the"compounds"
(50,"16.7,"5.56,"1.85,"0.62,"0.21,"0.069"and"0.023"µg/ml)"and"then"incubated"with"DENV2."The"
result" appraisal" was" done" after" fixing" and" staining" the" cells." The" staining" procedure" was"
carried"out"with"methylene"blue"that"stains"only" live"cells."The" inhibition"of"CPE"was"visually"
evaluated" against" two" control" systems:" infected" cells" and" non\infected" cells." As"well" as" the"
eleven"purchased"compounds,"also"two"reference"molecules"were"tested" in" the"same"assay:"
Ribavirin,"that"shows"to"be"cytostatic"at"high"concentrations"and"dextran"sulphate"that"shows"
inhibitory"activity"at"high"concentrations."Unfortunately,"none"of"the"11"compounds"selected"
with" this" procedure" were" found" to" inhibit" DENV" cell" infection" at" any" of" the" tested"
concentrations."
Nevertheless,"five"of"the"11"selected"compounds"were"also"tested"on"DENV"NS3"helicase"with"
the" binding" and" enzymatic" assays" discussed" in" chapter" 3.4" of" this" section." All" these" assays"
were"performed"by" the" author" in"AFMB,"Marseille"University" (France)." In" the" first" case," the"
aim"was"to"assess"the"binding"ability"of"the"compounds"to"NS3"helicase"(TSA)"or"to"inhibit"the"
formation"of" the"protein\ligand"complex" (FP"assay,"using"either"a"GTP"or"a"RNA"probe)."The"
enzymatic"assay"evaluated" the" inhibitory"effect"of" the"compounds"on" the"ATPase"activity"of"
NS3hel."In"all"the"tests,"the"mother"solutions"were"prepared"by"solubilising"the"compounds"in"
100%" DMSO," for" a" final" concentration" of" 20mM." Compound" 1" (see" APPENDIX& 5)" showed"
solubility"problems"already"in"the"mother"solutions"and"only"a"concentration"of"10mM"could"
be"achieved."As"reported"in"chapter"3.4,"solubility"problems"occurred"in"the"TSA"and"ATPase"
assays"and"unfortunately"it"regarded"all"five"compounds"of"this"series.""
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Despite" solubility"problems,"encouraging" results" could"be"achieved" from" the"FP"assay,"using"
RNA\6FAM"as"fluorescent"probe:"four"of"the"five"selected"molecules"were"able"to" inhibit"the"
binding"of"RNA"to"NS3hel."Two"of"them"(compounds"2"and"3)"were"found"to"be"active"with"low"
µM"IC50"values,"while"the"other"two"(compounds"1"and"4)"demonstrated"a"weaker"inhibition"of"
RNA"binding."The"four"molecules,"their"structure"and"their"activity"data"(when"it"was"possible"
to" calculate" values)" are" reported" in" Table" 3.2." As" already" mentioned," none" of" these"
compounds"inhibited"DENV"infection"in"cells"as"they"were"either"cytotoxic"(e.g."compounds"2"
and"3)"or"they"did"not"have"antiviral"effects."However," the" inhibition"of"protein\RNA"binding"
could"be"an"appealing"mechanism"of"action"for"an"antiviral"drug"as"the"lack"of" interaction"of"
the" protein" with" the" natural" substrate" would" lead" to" a" loss" of" unwinding" activity." For" this"
reason,"compounds"2"and"3"were"selected"for"further"improvement"with"the"aim"of"improving"
activity"and"reducing"toxicity."
"
Table'3.2..Structure.of.compounds.that.inhibit.helicaseFRNA.binding..
Compound. NS3hel.IC50.(µM)a. CPE.(µM)b.
ID" Structure" DV3" DV4" CC50" EC50"
1.
"
37.90" 26.99" \" \"
2.
"
7.86" 8.58" 11.10" 12.00"
3.
"
15.77" ~7.12" 8.01" \"
4.
"
32.17" 40.96" \" \"
Abbreviations:.NS3hel="Non\structural"Protein"3"Helicase;"IC50="Half"Maximal"Inhibitory"Concentration;"DV3="Dengue"Virus"
Serotype"3;"DV4="Dengue"Virus"Serotype"4;"CPE="Cytopathic"Effect"Assay;"CC50="Half"Maximal"Cytostatic"Concentration;"EC50="
Half"Maximal"Efficacious"Concentration"
a="tests"performed"by"the"autor"at"AFMB,"Marseille"University"(France)"
b="tests"performed"by"the"Rega"Institute"for"Medicinal"Research,"K."U."Leuven"(Belgium)"
"
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PRELIMINARY.STRUCTUREFACTIVITY.RELATIONSHIP.DETERMINATION.
"
With" the" aim" of" confirming" compound" activity" and" of" gaining" preliminary" structure\activity"
relationships,"a"series"of"analogues"of"compounds"2"and"3"were"purchased"and"tested"in&vitro"
both"on"infected"cells"(CPE"assay)"and"on"the"protein"(FP"assay,"using"the"RNA\6FAM"probe)."
Our" collaborators" (Rega" Institute" of"Medical" Research," KU" Leuven" and"Marseille" University)"
performed" these" assays." The" CPE" assay" was" performed" as" described" before;" while" the"
evaluation" of" the" inhibition" of" RNA" binding" to" the" helicase" was" assessed" only" on" DENV4"
NS3hel," using" a" different" concentration" of" the" RNA" probe" (100nM," see" the" EXPERIMENTAL&
SECTION& for" further" details" about" the" conditions" of" the" biochemical" assays)." An" enzymatic"
assay"was"also"performed"on"compounds"2,"3" and"on" the" compound"3" analogues" that"gave"
positive"FP"results"(8)"in"order"to"establish"if"the"inhibition"of"protein\RNA"complex"formation"
corresponded"to"the"inhibition"of"the"helicase"activity"of"NS3hel."The"assay"was"designed"and"
performed"by"our"collaborators"in"Marseille"University,"and"monitored"the"unwinding"activity"
of"NS3hel."A"16"nucleotide"strand"of"32P"labelled"RNA"was"annealed"with"a"30"nucleotide"RNA"
strand."The"helicase"unwinding"reaction"was"then"performed"in"presence"of"ATP."The"quantity"
of"ssRNA"and"dsRNA"were"then"compared"after"a"run"on"non\denaturating"polyacrylamide"gel."
A"brief"description"of"this"assay"can"be"found"in"the"INTRODUCTION"section."Table"3.3"reports"
the" structures" of" the" analogue" compounds" and" their" activity" data" obtained" from" the" RNA"
binding"(FP)," the"enzymatic"and"the"CPE"assays."Compounds"2"and"3"were"retested"with"the"
biochemical"assays"and"the"new"data"are"reported"in"the"table."Due"to"solubility"issues,"IC50"of"
compounds" 5," 6" and" 7" could" not" be" determined" as" it" appeared" to" be" higher" that" their"
maximum"soluble"concentration"(250,"125"and"250µM"respectively)"in"the"assay"conditions.""
Unfortunately,"the"FP"results"in"Table"3.2"for"compounds"2"and"3"could"not"be"repeated."This"
was" probably" due" to" slightly" different" experimental" conditions" as" the" concentration" of" the"
RNA"probe"was"different"from"the"initial"test."However,"useful"activity"data"were"obtained"and"
preliminary"structure\activity"relationships"could"be"determined."An"important"observation"is"
the"coherence"of" the"RNA"binding" inhibition"and"of" the"enzymatic"activity" inhibition" results."
This"supports"the"hypothesis"that"compounds"that"inhibit"the"binding"of"RNA"to"NS3hel"cause"
a"loss"in"the"enzyme’s"function."
Consistently," as" well" as" compound" 2," all" its" analogues" with" the" indole" central" scaffold"
(compounds" 5," 6" and" 7)" were" inactive" in" both" biochemical" and" cell\based" in& vitro" systems."
Conversely," anti\DENV" activity" (either" from" biochemical" or" cell\based" assays)" could" be"
observed"for"the"other"three"molecules."These"results"suggest"that"a"phenyl"ring"in"the"central"
scaffold,"as"in"compounds"3,"8"and"9,"enhances"the"activity"of"the"compounds.""
"
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Table'3.3..Structure.and.activity.of.compounds.2.and.3.analogues..
Compound. FP.F.NS3hel.IC50.(µM)a.
Enzymatic.F.
NS3hel.IC50.
(µM)a.
CPE.(µM)b.
ID" Structure" DV4" DV4" CC50" EC50"
2.
"
>1000" >1000"
11.10" 12.00"
SI=1"
3.
"
37.99" 18.33" 8.01" \"
5.
"
>250" \"
51.11" 10.13"
SI=5"
6.
"
>125" \"
>22.54" 40.13"
SI=1"
7.
"
>250" \"
58.98" 10.51"
SI=6"
8.
"
245.6" 32.12"
>116" 2.85"
SI=41"
9.
"
>1000" \"
>142" 8.57"
SI=17"
Abbreviations:.FP="Fluorescence"Polarisation"Assay;"NS3hel="Non\structural"Protein"3"Helicase;"IC50="Half"Maximal"Inhibitory"
Concentration;"DV4="Dengue"Virus"Serotype"4;"Enzymatic="Enzymatic"assay;"CPE="Cytopathic"Effect"Assay;"CC50="Half"Maximal"
Cytostatic"Concentration;"EC50="Half"Maximal"Efficacious"Concentration;"SI="Selectivity"Index"
a="tests"performed"by"AFMB,"Marseille"University"(France)"
b="tests"performed"by"the"Rega"Institute"for"Medicinal"Research,"K."U."Leuven"(Belgium).
"
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Analysing"more"in"detail"compound"3"and"its"analogues"(compounds"8"and"9),"it"appears"that"
the" adamantane" group" could" be" involved" in" compound" 3" cytotoxicity" and" lack" of" antiviral"
effect" in" the"cell,"as" less"cytotoxicity"and"antiviral"activity"are"seen" in" the"analogues"without"
this"moiety."Unfortunately,"the"same"pattern"is"not"reproduced"in"the"biochemical"evaluation,"
where" the"most" active" compound" of" the" three" was" indeed" compound"3."While" in" the" CPE"
assay"a"comparable"but"slightly"better"activity"was"registered"for"compound"8"respect"to"9,"in"
the"biochemical"assay"while"8" retained"some"activity"and"compound"9"was"unable"to" inhibit"
either"RNA"binding"or"NS3hel"unwinding"activity."
Since"at"least"one"compound"(8)"was"able"to"inhibit"both"NS3hel"and"DENV"infection"in"cells,"it"
was"hypothesised"that"the"toxicity"related"to"compound"3"did"not"allow"a"proper"assessment"
of"its"antiviral"activity"in"infected"cells."Furthermore,"as"there"is"a"small"chemical"difference"(a"
Bromine" substituent" on" the" central" phenyl" ring)" between" compounds" 8" and" 9," such" a"
difference" on"NS3hel" inhibition"was" unexpected," but" suggested" that" there" could" be" cellular"
pathways,"not"investigated"in"this"study,"that"modify"the"inhibitors,"affecting"the"inhibition"of"
DENV"infection.""
"
CONCLUDING.REMARKS.
"
The" shape"screening"of" the"SPECS"database"allowed" the" selection"of"11"chemically"different"
commercially" available" compounds" that"were" purchased" and" tested" in& vitro" to" evaluate" the"
cell\based"interference"with"DENV"infection"as"well"as"the"inhibition"of"the"RNA"binding"to"the"
NS3hel" protein." Two" compounds" (2" and" 3)" showed" inhibition" of" RNA\NS3hel" complex"
formation" and" another" 5" analogues" of" these" two"molecules" were" purchased" and" tested." A"
further" evaluation" was" performed" for" these" molecules," as" also" their" enzymatic" inhibition"
activity" was" explored." Furthermore," the" original" two" compounds" were" retested" in" the"
biochemical" assays." Interestingly," only" compounds" 3" and" its" analogues" retained" activity" in"
either" cell\"or"biochemical\based"assays"or" in"both," suggesting" that"a"phenyl" ring" is" a"better"
central" aromatic" group" than" the" indole" moiety." However," it" is" more" difficult" to" define"
structure\activity"relationships"within"this"family"of"three"compounds"as"it"is"hypothesised"that"
there"might"be"other"cellular"mechanisms"that"have"not"been"explored"could"be" involved" in"
the" activity" of" these" compounds." Nevertheless," the" fact" that" compound" 8" inhibited" both"
NS3hel" and" viral" infection" in" Vero" cells," gives" an" important" support" to" one" of" the" founding"
hypothesis"of"this"thesis:"DENV"NS3hel"is"a"promising"drug"target"as"its"inhibition"stops"DENV"
infection."
To" the" best" of" knowledge" these" molecules" have" never" been" discovered" as" anti\DENV"
compounds"and"represent"an"interesting"novel"class"of"potential"antiviral"drugs."As"predicted,"
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the" inhibition" of" RNA" binding" was" also" very" well" correlated" with" the" inhibition" of" NS3hel"
unwinding" activity," suggesting" a" direct" or" indirect" interference" of" the" compounds" to" the"
protein\RNA" interaction." This" is" particularly" interesting" as" it" has" been" hypothesised" that"
Ouabain"could"interact"at"the"level"of"the"RNA"site.[7]"As"explained"more"in"details"in"APPENDIX&
2," shape" complementarity" between" two" molecules," as" well" as" their" surface" properties," is"
fundamental" for" the" strength" of" the" interaction" between" them.[28]" Consequently," as" the"
compounds"in"Table"3.2"were"selected"on"the"base"of"the"shape"similarity"with"Ouabain"and"as"
the" analogues" purchased" are" similar" to" the" parent" compounds," they" should" have" a" similar"
behaviour" in" the" interaction" with" NS3hel." The" activity" data" presented" here" confirm" that"
identified"compounds"have"a"similar"activity"behaviour"to"the"drug"design"starting"molecule,"
even"if"they"present"a"different"chemical"structure.""
To" the" best" of" knowledge" the" designed" shape\based" virtual" screening"method" used" for" the"
identification"of"compounds"2"and"3"followed"a"novel"workflow"of"in&silico"experiments"based"
on" the" assumption" that" one" of" the" selected" queries" represented" a" Ouabain\active"
conformation" and" that" active" shape\analogue" inhibitors" could" be" identified" in" those"
compounds" matching" the" highest" number" of" queries." Both" the" basic" assumption" and" the"
method"were"confirmed"by"the"activity"data"that"validated"the"designed"molecular"modelling"
approach"as"successful"in"identifying"novel"potential"antiviral"agents"with"a"chemical"scaffold"
that"has"never"been"proposed"for"DENV"NS3hel"inhibition"and"much"simpler"than"the"original"
natural"product"Ouabain.""
In" conclusion," this" study" has" determined" the" starting" point" for" future" drug" development"
projects" and" in" particular," the" more" detailed" investigation" of" the" effects" of" these" types" of"
compounds"in"the"cell"could"be"useful"for"directing"the"improvement"of"these"molecules."
"
"
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3.2.2'RNA'BINDING'SITE'COMPETITIVE'INHIBITORS'
DRUG'DESIGN'
"
PREVIOUS.WORK.
"
Previous"to"this"PhD"project,"a"drug"design"study"on"DENV"NS3hel"was"performed.[29]"The"aim"
was"to"identify"putative"panserotypic"antiviral"agents"that"could"bind"the"enzyme"in"the"RNA"
cleft" through"a"virtual"screening"approach."As"several"crystal"structures"of" the"helicase"were"
available," but" none" of" them" had" co\crystallised" inhibitors," two" structures" from" the" same"
crystallographic" series" were" chosen" for" the" purpose:" NS3hel" alone" (PDB" ID:" 2JLQ[19])" and"
NS3hel"in"complex"with"both"RNA"and"ATP"(PBD"ID:"2JLV[19])."Given"the"large"size"of"the"cleft,"
an" equivalent" sub\site" of" the" RNA" cleft" was" selected" for" both" molecular" systems." As"
mutational" studies" have" highlighted" the" importance" of" Ile365," the" chosen" site" was" in" the"
nucleic" acid" entry" site," between" domains" 2" and" 3.[15,21]" The" virtual" screening" technique"was"
applied"on"two"databases"of"approximately"200,000"drug\like"molecules"each"(SPECS"database"
updated"to"May"2011"and"SPECS\EX"database)"and"multiple"steps"were"used,"as"schematised"
in"Figure"3.7."Methods"and"parameters"can"be"found"in"reference"[29]."
"
!
Figure'3.7..Virtual.screening.workflow..
This"is"a"schematic"representation"of"the"workflow"followed"for"the"virtual"screening"study."The"main"steps"and"
programs"used"are"indicated"and"the"numbers"are"referred"to"the"number"of"molecules"at"every"step."The"plate"
represents"the"in"vitro"evaluation"of"the"compounds"with"CPE"assay."
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With" the" aim" of" reducing" the" input" number" of" compounds" for" the" docking" and" scoring"
procedures," the" conformations" corresponding" to" the" large" set"of" around"400,000"molecules"
was"first"searched"with"two"pharmacophores"built"for"each"one"of"the"two"protein"structures."
The" pharmacophore" for" 2JLV" (panel" A" of" Figure" 3.8)" was" obtained" first," through" the" PLIF"
statistical" analysis" of" the" first" two" RNA" nucleotides" interactions" with" the" protein" in" the" six"
available"helicase\RNA"complex"structures"(PDB"IDs:"2JLU,"2JLV,"2JLW,"2JLX,"2JLY"and"2JLZ).[19]"
This" pharmacophore" was" subsequently" transposed" to" the" 2JLQ" structure" where" excluding"
volumes" and" features" were" manually" moved" in" order" to" adapt" the" features" to" the" new"
residues"positions"(panel"B"of"Figure"3.8)."Both"pharmacophores"had"nine"features"centred"on"
the"RNA"molecule"for"the"essential"RNA\protein"interactions"reported"in"Table"3.4."Of"interest,"
almost" all" of" the" residues" involved" in" these" interactions" are" well" conserved" among" DENV"
serotypes."Only"Leu429" is" replaced"by"Met429" in"DENV"serotype"2,"conserving" the" residue’s"
hydrophobic"properties.""
"
" "
""""A" """""""""B"
Figure'3.8..Pharmacophores..
A).Pharmacophore.built.for.2JLV."2JLV"structure"and"the"pharmacophore"features"are"superposed"here."Some"
residues"are"indicated"and"shown"in"lines,"while"the"first"two"nucleotides"are"represented"with"thicker"lines."The"
features"are"represented"with"the"following"colour"scheme:"“hydrogen"bond"donor”"features"(F1,"F2)"are"in"purple;"
“hydrophobic”"centroid"(F3)"is"in"green;"“hydrogen"bond"acceptors”"(F4,"F6)"and"“anion"of"hydrogen"bond"
acceptor”"(F5)"features"are"in"cyan;"“hydrogen"bond"donor"or"acceptor”"feature"(F7)"is"in"dark"red;"“aromatic"or"
hydrophobic”"features"are"in"orange."B).Pharmacophore.built.for.2JLQ."2JLQ"structure"and"the"pharmacophore"
features"are"superposed"here"and"it"is"possible"to"observe"the"amino"acids"movements"and"feature"repositioning,"
with"respect"to"A)."Same"colour"scheme"of"A)"was"applied."
The"two"pharmacophore"filters"reduced"the"structures"to"a"total"of"9,459"molecules"that"were"
docked" in" the" selected" binding" site" using" Maestro" Glide" with" SP" mode." A" rescoring" was"
performed"with"FlexX"and"PLANTS"programs"and"a"consensus"score"function"allowed"further"
reduction"of"the"number"of"molecules"to"471"for"the"2JLQ"structure"and"504"for"2JLV.""
Obtained" poses"were" visually" inspected" and" clustered" according" to" their" chemical" structure"
and"to"the"binding"mode"within"the"targeted"site."In"pose"evaluation,"molecules"that"bound"to"
conserved" residues" among" the" four" DENV" serotypes" were" preferred" to" the" others." A" total"
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number" of" 50" compounds" were" selected" and," of" these," 37" were" purchased" and" one" was"
synthesised.[29]"
"
Table'3.4..Features.of.2JLV.and.2JLQ.pharmacophores..
Feature. Type.of.interaction. Groups.involved.
F1. Hydrogen"bond"donor" A1"2’OH"–"Pro363"carbonyl"O"
F2. Hydrogen"bond"donor" G2"base"NH2"–"Asp290"COO\"
F3. Hydrophobic"
A1"5’\C"–"Leu443,"Leu429,"Asp603.
F4. Hydrogen"bond"acceptor" A3"phosphate"O"–"Arg387"α\NH,"Thr408"OH"
F5. Anion"or"hydrogen"bond"acceptor"
G2"phosphate"O"–"Arg387"guanidine.
F6. Hydrogen"bond"acceptor"
G2"phosphate"O"–"Ile365"α\NH.
F7. Hydrogen"bond"donor"or"acceptor" Region"near"Asp409"
F8. Aromatic"or"hydrophobic"
A1"purine"–"Pro431"and"Leu443"
F9. Aromatic"or"hydrophobic"
"
CELLFBASED.DENV.INHIBITION.OF.THE.COMPOUNDS.
"
During"this"PhD"study,"the"available"38"molecules"were"tested"in&vitro"at"the"Rega"Institute"for"
Medicinal"Research,"K."U."Leuven"(Belgium)"with"the"same"assay"described"in"the"Ouabain\like"
shape" screening" study." The" assay" conditions" were" the" same," but" in" this" case" the"
concentrations"of"compounds"tested"were"100,"50,"25,"12.5,"6.25,"3.13,"1.56"and"0.78"µg/ml.""
One"of"the"38"tested"molecules"displayed"some"activity"against"DENV"infection:"compound"10,"
reported"in"Figure"3.9."
"
!
Figure'3.9..Compound.10..
This" molecule" demonstrated" 70%" inhibition" of" virus\induced" cytopathic" effect" (CPE)" at"
50μg/ml" and" 40%" inhibition" at" 25μg/ml" (50.25µM)," but" at" a" concentration" of" 100μg/ml"
N
S
OHO
S
N N
S
O
H
N
O
N
N
N+O–
O
Section"3:"NS3"HELICASE"AS"A"DRUG"TARGET" 3.2&RESULTS&AND&DISCUSSION"!
!101"
(200.99µM)"it"appeared"to"be"cytostatic"(data"not"shown)."From"the"titration"curves"in"Figure"
3.10"the"antiviral"and"antimetabolic"effects"of"the"compound,"were"evaluated"at"Leuven"and"
an"EC50"equal"to"201μM"and"a"CC50"higher"than"201μM"was"found."
"
!
Figure'3.10..ConcentrationFdependent.effect.of.compound.10.in.Vero.cells..
The"red"curve"shows"the"antiviral"activity"of"the"compound,"while"the"green"one"shows"the"cells"viability"at"the"
same"compound"concentration."EC50"and"CC50"values"are"reported"on"the"right."
The" previous" study" docking" results," reported" in" Figure" 3.11," suggested" that" compound" 10"
interacted"with"the"NS3hel"at"the"level"of"the"entry"of"the"nucleic"acid"binding"site,"preferably"
when"the"enzyme"assumes"the"conformation"that"allows"RNA"binding."As"shown"in"panel"A"of"
the"figure,"the"molecule"co\localises"with"the"RNA"backbone"and"it"interacts"with"the"protein"
similarly"to"the"natural"ligand.""
"
" "
A" B"
Figure'3.11..Docking.pose.and.interactions.of.compound.10.in.the.helicase.entry.site..
A).Docking.pose.of.compound.6."Here"the"compound"pose"is"superposed"to"2JLV"structure."The"protein"ribbons"are"
shown"in"white"and"the"mentioned"residues"are"indicated"and"have"green"carbon"atoms."The"RNA"strand"is"
represented"as"purple"lines"and"compound"10"is"coloured"by"element."B).Compound.10.ligand.interactions."The"
schematic"representation"of"compound"10"interactions"with"the"NS3hel"follows"the"legend"reported"in"the"bottom"
of"panel"B."
In"detail,"the"carboxylic"moiety"of"the"compound"hydrogen"bonds"with"the"Arg387"backbone"
amine"and"the"side"chain"guanidine"groups"and"with"the"Thr408"hydroxyl"moiety."Additionally,"
a"hydrophobic"contact" is"established"between"the"thiadiazole"ring"and"Thr224."The"molecule"
does" not" interact" directly" with" Ile365," but" is" positioned" in" its" near" vicinity." A" schematic"
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representation"of" the" interactions"of" the" compound"with" the"protein" is" reported"panel"B"of"
Figure"3.11."
As" already" discussed" in" the" INTRODUCTION" chapter," DENV" NS3" helicase" does" not" bind"
specifically"to"the"RNA"bases,"but"only"to"its"backbone."The"docking"simulation"suggested"that"
compound" 10" recreates" the" same" type" of" interactions," implying" that" the" molecule" could"
compete"with"the"RNA,"inhibiting"helicase’s"activity."
With"the"aim"of" improving"both"the"antiviral"activity"and"of"reducing"the"cytostaticity"of" the"
compound,"a"preliminary"structure\activity"study"was"performed."For"the"investigation"of"the"
relationship"between"the"cephalosporanic"core"and"activity"of"compounds,"four"commercially"
available" analogue" compounds" were" purchased" and" tested" for" cell\based" DENV" infection"
inhibition."The"scaffold"structure"and"the"substituents"of"the"compounds,"including"compound"
10,"are"reported"in"Table"3.5.""
"
Table'3.5..Compound.10.and.analogue.structures..
Scaffold:"
.......... .!
Compound. R1. R2.
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"
These" tabulated"molecules"were" tested" in" the" same" CPE" assay" previously" described." In" this"
case," the" tested" compound" concentrations"were" 50," 16.7," 5.56," 1.85," 0.62," 0.21," 0.069" and"
0.023"μg/ml."The"results"of"the"biological"test"for"the"4"analogue"compounds"are"reported"in"
Figure"3.12.""
!
Figure'3.12..In.vitro.results.for.compounds.11,.12,.13.and.14..
The"visual"inspection"of"the"inhibitory"effect"was"conducted"in"reference"to"two"controls:"infected"(VC)"and"non\
infected"(CC)"cells."The"concentrations"reported"above"are"in"μg/ml"and"the"compounds"are"indicated"on"the"left."
Of"the"compounds"tested"only"compound"13"did"not"demonstrate"inhibitory"activity"of"DENV"infection."
As" highlighted" by" the" green" circles" in" the" figure," three" of" the" four" molecules" retained"
inhibitory"activity"against"DENV"infections,"whilst"one"of"them,"compound"13,"did"not."Of"the"
three"active"molecules,"compound"11"shows"higher"activity"as"it"displays"partial"activity"at"the"
concentration" of" 16.7μg/ml" (34.76µM)" as" well" as" at" 50μg/ml" (104.06µM)." However," no"
complete" infection" inhibition" cold" be" achieved" for" any" compound" at" any" of" the" tested"
concentrations."
"
!
Figure'3.13..Results.of.the.cellFbased.assay.for.compound.11..
The"red"curve"shows"the"antiviral"activity"of"the"compound,"while"the"green"one"shows"cell"viability"at"the"same"
compound"concentration."EC50"and"CC50"values"are"reported"on"the"right..
Titration"curves"were"computed"in"Leuven"for"two"of"the"four"compound"10"analogues."Whilst"
compound" 14" demonstrated" toxicity" (CC50=40μM)," compound" 11" showed" a" similar" activity"
pattern"to"the"original"molecule"(EC50=208μM;"CC50>208μM)."Even"if"these"concentrations"are"
high,"the"chart"reported"in"Figure"3.13"shows"that"the"antiviral"activity"starts"at"a"slightly"lower"
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concentration," suggesting" that" improvements" on" the" activity" and" on" the" toxicity" of" this"
compound"series"can"be"made."
From"these"data,"preliminary"structure\activity"relationships"could"be"determined."Firstly,"the"
fact"that"three"compounds"retained"activity"in"cells"confirmed"that"the"cephalosporanic"core"is"
associated"with" an" antiviral" effect." Compound"13" was" the" only" compound"10" analogue" not"
substituted" in"R2"and"as" it"was"also"the"only"one"with"no"antiviral"activity," it"can"be" inferred"
that" the"presence"of"a"R2"group" in"necessary" for" inhibitory"activity."Unfortunately," the"same"
type" of" assessment" could" not" be" done" for" R1" as" no" purchasable" compounds" without" this"
substituent" could" be" found." Furthermore," of" the" new"molecule" series," the" compound" with"
higher" activity" (compound" 11)" is" also" the" one" with" a" tetrazole" R2" moiety" instead" of" a"
thiadiazole,"emphasising"the"importance"of"R2"and"suggesting"that"the"activity"is"linked"to"the"
chemical" nature" of" this" moiety." The" tested" modifications" at" R1" did" not" produce" a" similar"
change"in"DENV"infection"inhibition."
"
NS3HELFBASED.DENV.INHIBITION.OF.THE.COMPOUNDS.
"
Five"of"the"total"42"compounds"(38"from"the"virtual"screening"selection"plus"4"compound"10"
analogues)"were" tested"on"DENV"NS3hel" through"most"of" the"biochemical" assays"applied" in"
the"Ouabain"shape\like"virtual"screening"study:"TSA,"ATPase,"FP"with"GTP"bodipy"and"FP"with"
RNA\6FAM." These" assays" were" performed" by" the" author" at" AFMB," Marseille" University"
(France)."Since"the"selection"of"compounds"was"done"on"the"basis"of"chemical"diversity,"only"
one"molecule" of" the" cephalosporanic" compound" series"was" chosen." Being" one" of" the"most"
active" molecules" with" a" cephalosporanic" core," compound" 11" was" amongst" the" selected"
molecules."The"selected"compounds’"structure"and"solubility"are"reported" in"APPENDIX&5." In"
all"the"tests,"mother"solutions"were"prepared"by"solubilising"the"compounds"in"100%"DMSO,"
for" a" final" concentration" of" 20mM." Compound" 15" (see" APPENDIX& 5)" showed" solubility"
problems" already" in" the" mother" solutions" and" only" a" concentration" of" 10mM" could" be"
achieved." The" assays" were" performed" according" to" the" protocol" in" the" EXPERIMENTAL&
SECTION"chapter."
Three" of" the" five" compounds" precipitated" in" the" TSA" and" in" the" ATPase" assay" and"
consequently"could"not"be"assessed" for"NS3hel"binding"and" for" the" inhibition"of" the"ATPase"
activity" of" the" target" protein."Unfortunately" neither" of" the" other" two" compounds" bound" to"
NS3hel" in" the" thermal" shift"assay."One"compound"decreased" the"helicase"ATPase"activity"by"
31.6%"and"by"76.3%"in"two"screens"at"2mM"concentration."However,"these"results"were"not"
trusted"for"the"high"variability"of"the"inhibition"percentages"and"for"the"lack"of"reliability"of"the"
assay"itself"(see"chapter"3.4)."
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Unfortunately," no" compounds" inhibit" the" binding" of" either" GTP" bodipy" or" RNA\6FAM." As"
discussed"in"chapter"3.4,"some"molecules"gave"problems"with"the"FP"tests"as"they"showed"to"
interfere"with"the"assay"by"increasing"the"fluorescence"polarisation"values"in"a"concentration\
dependent"manner"also"in"absence"of"the"protein."As"the"results"were"not"clear,"it"was"chosen"
to"not"consider"the"assay"results"for"these"compounds."Of"the"total"15"tested"compounds,"all"
the"problematic"molecules"in"the"FP"assays"(two"and"four"with"the"GTP"bodipy"and"RNA\6FAM"
probes" respectively)" were" selected" with" this" structure\based" drug" design" study" for" the"
inhibition"of"NS3hel"through"RNA"cleft"binding."No"explanation"of"this"phenomenon"could"be"
found,"but"a"direct"interaction"with"the"probe"was"hypothesised."
Summarising," no" NS3hel" interaction" or" inhibition" could" be" determined" for" the" tested"
molecules." Compound"11" displayed"neither" solubility" problems"nor" interactions"with" the" FP"
assay" probes" and" consequently" it" could" be" assessed" with" the" biochemical" assays."
Unfortunately," none"of" the" tests"was" positive" for" this"molecule," suggesting" that" its" antiviral"
activity"does"not"involve"NS3hel."
"
CONCLUDING.REMARKS.
"
A"previous"drug"design"study"identified"38"molecules"for"the"inhibition"of"NS3hel"through"their"
interaction"with" the"RNA"binding" site," competing"with" the"natural" ligand."Cell\based" in& vitro&
assays" showed" that" one" of" the"molecules," compound"10," had" antiviral" activity"with" EC50" of"
201µM." Unfortunately," high" concentration" cytotoxic" effects" could" be" associated" to" the"
compound" as" well." From" the" assessment" in" the" same" assay" of" four" purchased" analogues,"
preliminary"structure\activity"relationships"could"be"gathered,"in"particular"on"the"role"of"the"
R2"substituent."Unfortunately,"even"if"activity"improvement"was"obtained"with"compound"11,"
the"EC50"values"were"still"very"high"and"the"selectivity"index"very"low.""
Five"of"the"total"42"compounds"(38"from"the"original"virtual"screening"and"the"4"compound"10"
analogues)" were" also" assessed" with" biochemical" assays," but" no" positive" results" could" be"
obtained."Compound"11"was"part"of"this"group"of"molecules,"but"no"direct"NS3hel"binding"or"
inhibition"of"the"protein"activity"or"formation"of"complexes"with"the"natural"substrates"could"
be"observed."Consequently," it"was"hypothesised" that" the" cell\base"activity"observed" for" this"
class"of"molecules"is"not"due"to"interaction"with"NS3hel,"but"to"other"mechanisms"that"could"
involve"either"viral"or"host"pathways."The"exact"mechanism"of"action"of"these"molecules"has"
not"been"determined"to"date."
Unfortunately,"the"lack"of"correspondence"between"cell\based"and"biochemical"assays"results"
did"not"validate"the"binding"mode" identified"for"compound"10"with"the"molecular"modelling"
study" that" was" designed" previously" to" this" PhD" project." The" method" itself" could" not" be"
validated"either."This"could"be"due"to"several"reasons"linked"to"either"one"of"the"steps"in"the"
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screening"workflow" (from" the" selection"of" the"RNA" sub\site" to" the"parameters" used" for" the"
docking" and" rescoring" procedures)." The" evaluation" of" each" factor" could" be" interesting" and"
could"improve"the"general"in&silico"approach"for"the"identification"of"novel"active"molecules."
In" conclusion," the" previous" Molecular" Modelling" study" and" the" small" structure\activity"
relationship" assessment" performed" in" this" PhD" study" identified" a" class" of"molecules"with" a"
cephalosporanic" scaffold" that" inhibit"DENV" infection" in" cells."Unfortunately," the"activity"was"
displayed"at"high"concentrations,"and"very"close"to"the"appearance"of"cytotoxicity,"and"it"could"
not"be" related"with"NS3hel" interaction"or" inhibition."Despite" the"possibility"of" improvement"
given" by" lower" antiviral" concentrations" with" respect" to" antimetabolic" ones," based" on" the"
unclear"mechanism"of"the"low"activity"of"this"class"of"compounds"and"their"difficult"chemistry,"
it"was"decided"not"to"further"develop"these"molecules"in"the"future."
"
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3.2.3'NTP'BINDING'SITE'COMPETITIVE'INHIBITORS'
DRUG'DESIGN'
"
DENV"NS3"helicase"has"proven"to"be"a"difficult"drug"design"target"and"this"might"be"related"to"
the" already" discussed" disadvantages" of" the" two" binding" sites"within" the" protein.[6,22]" Of" the"
two"pockets,"the"dimensions"of"the"helicase"NTP"binding"site"appear"to"be"suitable"for"small"
molecule"drug"design"and"it"would"not"require"the"selection"of"a"sub\site"within"it,"as"applied"
in"the"study"discussed"in"the"previous"chapter."NTP"binding"site"competitive"inhibitors"would,"
however,"be"potentially"more"toxic"as"they"mimic"NTPs"that"are"ubiquitous"and"bind"to"many"
human"proteins.[6,22]"
Nevertheless," the" work" reported" here" aimed" to" develop" a" method" that" could" allow" the"
discovery" of" novel" compounds" that" target" the" NTP" site" and" inhibit" selectively" the" NTPase"
activity"of"DENV"NS3hel,"without"interacting"with"host"helicases."This"was"chosen"as"a"target"
site"as"most"of"the"residues"that"form"it"are"highly"conserved"among"the"four"DENV"serotypes,"
aiding" the" possibility" of" designing" panserotypic" inhibitors." Furthermore," mutational" studies"
showed"that"some"of"these"residues"are"essential"for"the"ATPase"activity"of"DENV"NS3hel"and"
consequently," molecules" that" bind" to" them" could" be" good" competitive" inhibitors.[15,21]" As"
DENV"NS3hel" lacks"a"base"preference"upon"NTP"binding," the"design"of"nucleoside" inhibitors"
could" not" be" applied" for" the" scope" of" the" study." Alternatively," a" virtual" screening"workflow"
was" adapted" from" a" procedure" reported" in" the" literature.[30]" In" this" approach," docking" and"
scoring"procedures"were"performed"not"only"on"three"DENV"NS3"helicases,"but"also"to"three"
human"helicases."The"latter"were"used"as"anti\targets"and"the"compound"selection"was"based"
in" finding"molecules" that" showed" selective" binding" to" the" viral" enzyme"with" respect" to" the"
human"ones."
"
TARGETS.AND.ANTIFTARGETS.SELECTION.
"
In"order"to"find"compounds"that"would"selectively"bind"to"the"viral"helicase,"three"DENV"and"
three"human"helicase"structures"were"chosen"for"the"virtual"screening"approach"and"used"as"
target" and" anti\target" structures" respectively." In" both" cases," the" primary" criteria" for" the"
structure"selection"was"the"presence"of"the"ligand"(generally"ATP"or"an"analogue)"and"of"the"
catalytic" ion" (usually" Mn2+" or" Mg2+)" in" the" NTP" cleft." Afterwards," the" resolution" and" the"
biological" relevance"of" the"structure"were" taken" in" to"account."The"presence"of" the"divalent"
ion"in"the"structures"was"an"important"aspect"because"it"is"essential"for"substrate"binding"and"
for"the"hydrolysis"of"NTP"to"NDP"+"Pi.""
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Two"of"the"three"DENV"NS3hel"structures"(PDB"IDs:"2JLR"and"2JLV)[19]"were"co\crystallised"with"
an"ATP"non\hydrolysable"analogue"(ANPPNP);"while"in"the"third"one"(PDB"ID:2WHX)[12]"an"ADP"
molecule"is"bound"to"the"enzyme.""The"latter"structure"was"the"only"full"length"NS3"structure"
complexed"with"the"natural"ligand"in"the"NTP"site"available."As"it"would"have"been"interesting"
to" observe" if" interactions" with" the" protease" domain" could" be" used" for" selectivity"
improvement," it"was" selected"as"one"of" the" targets"despite" the" fact" that" the" ligand"was" the"
hydrolysed"form"of"ATP."
With"the"aim"of"designing"highly"selective"compounds"that"could"discriminate"between"highly"
similar"enzymes,"human"helicases"as"comparable"as"possible"to"DENV"NS3hel"were"selected."
For" this" exercise," the" 2JLV" FASTA" sequence" was" analysed" with" DELTA\BLAST" (Basic" Local"
Alignment"Search"Tool)"program,"searching"structures"within"the"Protein"Data"Bank"database."
Forty\eight"PDB"entries" that"were"similar" to" the"query"sequence"and"belonged"to" the"Homo"
Sapiens" genus" were" obtained." At" this" stage," also" protein" entirety" and" function" were"
considered," aiming" the" selection" of" three" different" types" of" anti\target" helicases" for" better"
sampling"of"the"possible"interactions"of"the"small"molecules."Differently"from"the"viral"crystal"
structures,"all"of"the"chosen"human"structures"had"an"ATP"analogue"(ANPPNP)"bound"to"the"
protein."
One"of"the"human"proteins"used"for"compound"selection"was"Upf1"(PDB:"2GJK),"which"is"a"SF1"
(superfamily" 1)" RNA\dependent" ATPase" involved" in" eukaryotic" nonsense\mediated" mRNA"
decay.[31]" The" second" human" enzyme" was" the" eukaryotic" initiation" factor" 4A\III" (eIF4AIII" or"
DDX48,"PDB:"2J0S),"a"DEAD\box"RNA"helicase"that," in"the"exon"junction"complex"(EJC),"binds"
mRNA"during" the" splicing"and"displaces" the" ribosome" from"mRNA,"acting"as"a" “memory”"of"
the" location" of" the" non\coding" region.[32]" The" third" anti\target" chosen"was" the" DEXD/H\box"
RNA" helicase" DDX19B" (PDB:" 3FHT)" that" aids" the" detachment" of" protein" from"mRNA" during"
mRNA"nuclear"export.[33]""
Before" starting" the" virtual" screening" procedure," all" six" structures" were" superposed,"
constraining"the"alignment"on"the"NTP"binding"site,"and"prepared"according"to"the"procedure"
described" in" the"METHODS" chapter." The" divalent" cation" present" in" all" the" structures" was"
maintained"for"all"the"docking"and"rescoring"simulations,"as"it"is"essential"for"NTP"binding"and"
catalysis."This"was"done"because"it"was"hypothesised"that"compounds"that"could"interact"with"
the"ion"could"also"bind"and"inhibit"better"to"the"enzyme."
"
. .
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IDENTIFICATION.OF.SELECTIVE.NS3HEL.INHIBITORS..
"
As"anticipated,"this"study"was"designed"with"the"aim"of"selecting"compounds"that"could"bind"
to"DENV"NS3hel"NTP"site,"but"not"to"the"corresponding"pocket"in"human"helicases."The"small"
molecule" database" for" this" study" was" SPECS," a" collection" of" purchasable" drug\like" small"
molecules," which" structures" are" available.[27]" At" the" time" of" the" study" it" contained"
approximately" 209,000" compounds." The" general" procedure" of" the" designed" molecular"
modelling"method"is"schematised"in"Figure"3.14.""
The"conformations"and"stereoisomers"of"the"molecules"belonging"to"the"SPECS"database"were"
first"searched"with"three"pharmacophores,"built"for"the"DENV"NS3"helicases"as"described"more"
in" detail" later" in" this" chapter."Of" the" positive" results," two" conformations" for" each"molecule"
were"kept" for"docking"evaluation."ATP"was"added"to"these"structures"because"a"comparison"
with"the"natural"ligand"scores"was"useful"later"in"the"workflow"for"compound"selection."A"total"
of"1,444"molecules"(2,580"conformations)"were"subsequently"further"evaluated."
The"new"database"of"molecules"was"then"processed"with"the"Maestro"LigPrep"program"that"
elaborated" all" possible" tautomer" and" ionisation" states" for" each" conformation," considering" a"
pH" of" 7" (±2)." The" chemical" evaluation" of" the" ligands" allowed" a"more" precise" scoring" in" the"
Maestro"Glide"docking"application"because"poses"are"scored"on"the"base"of"the"energy"(and"
likelihood)" related" to" the" chemical" structure" of" the" molecule" itself" as" well" as" on" the"
interactions" with" the" receptor." As" molecules" had" already" been" filtered" with" the"
pharmacophores," basic" information" about" the" preferred" chirality" and" E/Z" conformation" of"
molecules"were"known"and"stereoisomers"were"maintained"as"in"the"input"3D"structures."
The" prepared" ligands"were" then" docked" and" refined" in" each" target" structure"with"Maestro"
Glide" SP"mode" and" rescored"with" LeadIT" FlexX" and"PLANTS." Three"poses" for" each"molecule"
were"analysed"at"this"stage."The"scores"from"these"three"programs"were"then"evaluated"with"a"
consensus" scoring" function" (CS1," Equation" 3.1)" and" with" a" normalised" consensus" scoring"
function"(NCS1,"Equation"3.2),"as"reported"in"the"METHODS"chapter."These"functions"allowed"
the"ranking"of"the"molecules"according"to"a"unique"score"and"to"keep"those"that"performed"
within" the" best" 25%" results" in" all" the" programs" used."Only" 348," 351" and" 509"molecules" for"
2JLV," 2JLR" and" 2WHX" structures" respectively" were" consequently" kept" at" this" stage." These"
molecules"were"then"compared"and"2"conformations"of"the"molecules"that"were"kept" in"the"
docking" and" scoring" procedure" of" at" least" two" target" structures" were" saved" for" further"
evaluation." The" obtained" database" (412" molecules," 824" conformations)" represented" the"
compounds"belonging"to"the"SPECS"database"that"displayed"the"predicted"best"binding"at"this"
stage" to" the" explored" viral" target" and" it" was" used" for" the" final" selection" based" on" the"
specificity"of"the"molecules."This"was"performed"by"docking"and"scoring"the"conformations"in"
both" the" target" and" the" anti\target" structures" with" Maestro" Glide" XP" mode" and" rescoring"
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them" with" LeadIT" FlexX" and" PLANTS." Three" poses" were" generated" for" each" conformation"
entry."
The"best"pose" for"each"molecule"was" saved"and"all" the" scores"were" then"elaborated"with"a"
novel"consensus"scoring"function"(CS2,"Equation"3.3"reported"in"the"METHODS"chapter),"with"
the" aim" of" ranking" the" molecules" according" to" the" preferentiality" for" viral" helicases" over"
human" ones." With" this" function," a" unique" score" that" collects" Glide" XP," FlexX" and" PLANTS"
evaluations" in"one"normalised"value"was"computed"for"each"target"and"anti\target"structure"
used," obtaining" a" number" that" was" directly" proportional" to" the" binding" capacity" of" the"
molecule."The"final"score"was"then"calculated"by"subtracting"the"anti\target\related"scores"to"
the"target\related"ones."Consensus"scores"varied"from"a"minimum"of"\1.5011"to"a"maximum"of"
1.8671."From"a"qualitative"point"of"view,"positive"CS2"values"suggest"that"the"molecule"binds"
better" to" targets" than" to"anti\targets,"while"negative"ones" indicate" the"opposite" scenario."A"
score"around"0"should"mean"that"the"molecule"is"not"selective"between"the"two"protein"sets."
For" the" purpose" of" a" virtual" screening" approach," it"was" important" to" select" a" reference" for"
which"a"compound"could"be"considered"selective"or"not."This"was"achieved"comparing"the"CS2"
values"of"the"molecules"with"the"natural" ligand:"ATP."This"molecule" is"not"selective"between"
viral"and"human"enzymes"and"consequently"it"was"hypothesised"that"molecules"scoring"better"
than"ATP"bound"preferably"to"the"viral"helicases."As"expected,"CS2"value"for"ATP"was"around"0"
(0.0129)," confirming" that" the" designed"methodology" could" be" consistent"with" experimental"
data."The"molecules"that"scored"better"than"ATP"were"293."In"order"to"select"highly"selective"
molecules," the" 84" molecules" that" scored" 0.6" or" above" were" kept" for" the" last" stage" of" the"
procedure."
Chemical" structure" clustering" and" visual" inspection" of" the" poses" were" applied" for" the" final"
selection" of" 10" compounds." As" the" discovery" of" panserotypic" agents" would" be" preferred,"
molecules"that"bound"to"conserved"residues"among"the"four"DENV"serotypes"were"preferred"
to"the"others."As"intended"also"in"the"target"and"anti\target"structure"preparation"and"in"the"
pharmacophore"query"design,"all"the"selected"molecules"(reported"in"APPENDIX&4)"had"at"least"
one"carboxylic"group"for"metal"chelation."Unfortunately,"no"molecules"displayed"interactions"
with"the"DENV"NS3"protease"domain"in"structure"2WHX."
"
"
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Figure'3.14..Virtual.screening.workflow..
This"is"a"schematic"representation"of"the"general"procedure"followed"for"the"virtual"screening"study."The"main"
steps"are"indicated"and"the"numbers"refer"to"the"number"of"molecules"(conformations"in"brackets)"at"every"step."
Targets"(in"green)"and"anti\targets"(in"red)"are"reported"with"the"corresponding"PDB"ID."Molecular"modelling"
programs"and"functions"are"abbreviated"as"follows:"SP="Maestro"Glide"SP"mode;"FX="LeadIT"FlexX;"PL="PLANTS;"CS="
consensus"score;"NCS="normalised"consensus"score;"XP+R="Maestro"Glide"XP"mode"docking"and"rescoring"with"
LeadIT"FlexX"and"PLANTS."
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Pharmacophores'
"
The" DENV" helicase" pharmacophores" were" built" with" the" PLIF" tool" that" analysed" the"
interactions"between"the"protein"and"the"co\crystallised"ligand"in"the"NTP"binding"site"of"the"
three" target" structures." All" the" pharmacophores" were" then" manually" modified" in" order" to"
maintain"the"same"seven"features"across"the"three"structures."The"pharmacophore"for"2WHX"
was"the"most"extensively"modified"because"features"regarding"the"missing"γ\phosphate"had"to"
be" transferred" from" the" other" crystal" structures." Two" features" were" also" added" in" all" the"
queries"with"the"aim"of"involving"NS3hel"residues"at"the"NTP"base"level,"but"in"a"region"that"is"
distant" from" that" of" human" helicase" responsible" for" adenosine\specificity" in" these" proteins."
Glu233"and"Arg418"were"suitable"for"this"scope,"as"shown"in"Figure"3.15,"and"the"projection"of"
the" features" were" positioned" on" each" residue" side" chains’" functional" group" (features" were"
hydrogen" bond" donor" and" acceptor" respectively)." This" figure" shows" an" example" of" DENV\
human" helicases" superposition" (PDBs:" 2JLV" and" 3FHT)" where" base" interactions" of" human"
proteins"and"the"targeted"residues"in"the"pharmacophores"are"highlighted."
"
!
Figure'3.15..Target.and.AntiFtarget.superposition..
Here,"2JLV"(residues"carbon"atoms"in"yellow"and"AMPPNP"ones"in"orange)"is"superposed"to"3FHT(residues"carbon"
atoms"in"cyan"and"AMPPNP"ones"in"dark"green)."Intermolecular"interactions"are"shown"with"green"dashed"lines."
The"two"AMPPNP"molecules"are"well"overlapped"in"the"phosphate"region"and"both"coordinate"a"divalent"cation"
(cyan"sphere)."In"the"human"helicase"two"aromatic"residues"(in"this"case"Phe112"and"Phe433)"stack"with"the"ATP"
base"and"adenine"N7"and"NH2"groups"are"hydrogen"bonded"with"protein"residues"(in"this"case"Arg114"and"Gln119),"
achieving"base"specificity."
The"three"pharmacophores"are"shown"in"Figure"3.16;"while"Table"3.6"describes"their"features,"
the"type"of"interaction"involved"and"in"which"structural"pharmacophore"they"are"present."For"
pharmacophore"design,"all" the"selected"residues"or"at" least" their"properties" (for"Arg418"and"
Lys201)" were" conserved" among" the" four" DENV" serotypes," aiding" the" design" panserotypic"
inhibitors."Furthermore," four"of" the"amino"acids"were"also"shown"to"be"essential" for"NS3hel"
ATPase" activity" as" their" mutation" to" Ala" impaired" this" function." These" residues" were" the"
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“arginine"fingers”"(Arg460"and"Arg463)"and"the"Gly198"and"Lys199,"belonging"to"the"Walker"A"
motif.[15,21]""
In"the"pharmacophore"search,"compounds"that"matched"at"least"three"essential"features"were"
kept." Two" searches" were" computed" for" each" structure:" one" with" F3," F4" and" F6" essential"
features"and"one"with"F3,"F4"and"F7"features."The"results"were"then"combined"together"with"
the" aim" of" obtaining" molecules" that" could" mimic" the" α" and" the" β" phosphates" of" NTP" and"
interact"either"with"Glu233"or"Arg418."
"
" "
A" B"
"
C"
Figure'3.16..Pharmacophore.queries..
A)"Pharmacophore.for.2JLR.structure..The"2JLR"structure"and"its"pharmacophore"are"superposed."Important"
residues"are"indicated,"the"divalent"cation"is"shown"as"a"green"sphere"and"the"ligand"is"shown"with"thicker"lines."
The"features"are"represented"with"the"following"colour"scheme:"“hydrogen"bond"donor"and"acceptor”"feature"(F1)"
is"in"dark"red;"“hydrogen"bond"acceptor”"features"(F2,"F5,"F8)"are"in"cyan;"“anion"and"hydrogen"bond"acceptor"and"
metal"ligator”"features"(F3,"F4)"are"in"blue;"“hydrogen"bond"donor"projection”"(F6)"and"“hydrogen"bond"acceptor"
projection”"(F7)"features"are"in"yellow."B).Pharmacophore.for.2JLV.structure..The"2JLV"structure"and"its"
pharmacophore"are"superposed."The"same"colour"scheme"as"A)"was"applied."C).Pharmacophore.for.2WHX.
structure..The"2WHX"structure"and"its"pharmacophore"are"superposed."The"same"colour"scheme"as"A)"was"applied."
"
"
"
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Table'3.6..Pharmacophores.features..
Feature. Type.of.interaction. Groups.involved. Structures.
F1.
Hydrogen"bond"donor"and"
acceptor"
NTP"3’"and"2’"OH"and"Arg418,"
Asn329,"Arg463"
All"
F2. Hydrogen"bond"acceptor" N7"of"Adenine"and"Lys201" All"
F3.
Anion"and"Hydrogen"bond"
acceptor"and"metal"ligator"
NTP"γ\phosphate"and"Mn2+,"
Arg460,"Lys199"
All"
F4.
Anion"and"Hydrogen"bond"
acceptor"and"metal"ligator"
NTP"β"\phosphate"and"Mn2+,"
Thr200,"Arg463,"Gly198"and"
Lys199"
All"
F5. Hydrogen"bond"acceptor"
NTP"α\phosphate"O"and"Lys201"
α\NH"
All"
F6.
Hydrogen"bond"donor"
projection"
Glu233"
All"
F7.
Hydrogen"bond"acceptor"
projection"
Arg418"
All"
F8. Hydrogen"bond"acceptor" Other"NTP"α\phosphate"O"" Only"2WHX"
"
"
ACTIVITY.OF.THE.SELECTED.COMPOUNDS.
"
Five"of" the"10"molecules" identified" in& silico"were"purchased"molecules"and"tested" in&vitro"at"
the"Rega" Institute" for"Medicinal"Research,"K."U."Leuven" (Belgium)"by"our"collaborators,"with"
the" same"methodology" reported" for" the"Ouabain" shape" virtual" screening" study"discussed" in"
chapter"3.2.1."Unfortunately,"none"of"the"tested"compounds"were"found"to"inhibit"DENV"cell"
infection"at"any"of"the"tested"concentrations"(with"CC50"and"EC50"above"50"µg/ml)."""
Nevertheless," all" 5" of" them" were" tested" on" DENV" NS3" helicase" using" biochemical" assays,"
aiming"to"assess"the"binding"ability"of"the"compounds"to"NS3hel"(TSA),"to"inhibit"the"formation"
of"the"protein\ligand"complex"(FP"assay,"using"either"a"GTP"or"a"RNA"probe)"and"the"inhibitory"
effect"of" the"compounds"on"the"ATPase"activity"of"NS3hel."The"choice"of" the"molecules"was"
mainly" based" on" the" chemical" similarity" of" the" structures," intending" to" explore" as" much"
chemical"space"as"possible."In"all"the"tests,"the"mother"solutions"were"prepared"by"solubilising"
the" compounds" in" 100%" DMSO," for" a" final" concentration" of" 20mM." No" solubility" problems"
occurred"for"these"compounds"neither"in"mother"solution"preparation"nor"in"the"biochemical"
assays." Details" about" biochemical" assays" protocols" are" reported" in" the" EXPERIMENTAL&
SECTION"chapter."
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Unfortunately,"no"compounds"inhibited"helicase\ligand"complex"formation"in"either"of"the"two"
FP"assays."However,"one"of" them"(compound"16," in"APPENDIX&5)" showed"a"negative"shift" in"
the"melting"temperature"(Tm)"with"respect"to"the"protein"alone,"with"a"Tm"decrease"at"1mM"
concentration"of"3.31°C"and"1.94°C" for"DENV3"and"DENV4"NS3hel" respectively." In" the" same"
assays"AMPPNP,"a"known"helicase"binder,"presented"a"Tm"increase"of"4.27°C"and"3.75°C"for"
DENV3"and"DENV4"NS3hel"respectively."These"data"suggest"that"compound"16"might"interact"
with" NS3hel," but" destabilises" it." As" the" same"molecules" did" not" exhibit" positive" or" reliable"
results" in"the"other"biochemical"assays,"no"titration"curves"with"the"thermal"shift"assay"have"
been"performed"and"the"compound"was"not"further"developed."
Another"compound"(compound"17,"in"APPENDIX&5)"decreased"the"helicase"ATPase"activity"by"
62.7%"in"one"of"two"screens"at"2mM"concentration,"but"did"not"affect"the"enzymatic"activity"in"
the" other" one." However," these" results" were" not" trusted" because" of" high" variability" of" the"
inhibition"percentages"and"for"the"lack"of"reliability"of"the"assay"itself"(see"chapter"3.4)."As"no"
other"promising"data"were"obtained"for"compound"17,"it"was"not"taken"further."
"
CONCLUDING.REMARKS.
"
A"molecular"modelling"method"was"designed"for"the"discovery"of"DENV"NS3hel"inhibitors"that"
could" target" the"NTP"binding"site."The"main"objective"was" to" identify"compounds"that"could"
selectively"bind"to"the"viral"helicase"and"consequently" reduce"the"toxicity" risk"related"to"the"
use"of"this"pocket"as"a"target."Particular"attention"was"also"drawn"to"the"conservation"of"the"
targeted" residues" because" the" design" of" panserotypic" inhibitors" would" be" preferable." This"
virtual" screening" approach" allowed" the" gradual" selection" of" small" drug\like" molecules"
belonging"to"the"SPECS"database"from"around"209,000"to"10"final"compounds."Using"multiple"
docking"and" scoring"programs"and" steps,"exploiting" structures" for" three"DENV"helicases"and"
three" human" helicases," a" specifically" built" consensus" score" was" applied" for" compound"
selection." In" comparison" with" ATP," identified" molecules" in" comparison" to" ATP," exhibited" a"
higher"discrimination"towards"the"viral"protein"with"respect"to"the"human"one."To"the"best"of"
knowledge,"no"similar"approaches"have"been"applied"previously"that"target"the"DENV"NS3hel"
NTP"binding"site"for"the"discovery"of"novel,"potential"virus"inhibitors."
Unfortunately,"the"selected"compounds"did"not"show"significant"activity"in"the"in&vitro"assays"
performed."As"other"compounds"obtained"from"other"approaches"within"this"PhD"study"were"
more" promising," none" of" the" compounds" identified" and" discussed" above" were" further"
developed."
In"conclusion,"the"experimental"data"suggest"that"this"molecular"modelling"approach"was"not"
successful"in"identifying"anti\DENV"agents."However,"the"methodology"seems"to"mimic"reality"
in" the" lack" of" ATP" preferentiality" for" viral" helicase" proteins." For" this" reason," it" would" be"
Section"3:"NS3"HELICASE"AS"A"DRUG"TARGET" 3.2&RESULTS&AND&DISCUSSION"!
!116"
worthwhile" to" apply" again" the" methodology" using" different" experimental" conditions." For"
example," another" virtual" database" of" small"molecules" could" be" assessed" at" the"NS3hel"NTP"
binding"site"to"compare"to"SPECS."In"addition,"it"would"also"be"interesting"to"change"docking"
programs"and/or"their"settings"in"order"to"explore"the"general"virtual"screening"workflow.""
"
"
"
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3.3.CONCLUSION.
"
Given"its"important"role"in"the"viral"replication"cycle,"it"was"hypothesised"that"the"inhibition"of"
DENV"NS3hel"could"produce"an"antiviral"response."Thus,"with"the"aim"of"designing"novel"anti\
DENV"agents,"three"drug"design"approaches"were"performed."All"three"of"them"were"based"on"
the" virtual" screening" of" drug\like" small" molecule" databases" and" when" active" hit" molecules"
were"found,"preliminary"structure\activity"relationships"were"searched"with"the"assessment"of"
analogue"molecules."The"designed"molecular"modelling"methodologies"were"novel"and"never"
applied"on"DENV"NS3hel"before."One"of"them"was"a"ligand"shape\based"virtual"screening"that"
used"Ouabain"as"a"reference"molecule"for"the"search"of"novel"inhibitors,"whilst"the"other"two"
were"structure\based"and"aimed"to"discover"compounds"that"could"bind"the"RNA"and"the"NTP"
binding"site"of"the"protein,"giving"particular"attention"to"target"residues"that"were"conserved"
in"identity"or" in"properties"amongst"DENV"serotypes"for"the"design"of"potential"panserotypic"
inhibitors."Unfortunately,"structure\based"molecular"modelling"approaches"showed"that"DENV"
NS3hel"is"a"challenging"drug"target"and"that"even"if"it"is"one"of"the"better"characterised"DENV"
proteins,"further"knowledge"on"its"mechanism"of"dsRNA"unwinding"is"needed"for"drug"design"
improvement."Conversely,"the"ligand\based"approach"was"particularly"successful"in"identifying"
a" novel" class" of" NS3hel" inhibitors" that" could" be" further" developed" in" the" future" and" that"
supported"the"basic"hypothesis"of"the"in&silico"approach."Most"importantly,"a"4\benzylidene\1\
phenylpyrazolidine\3,5\dione" compound" with" antiviral" activity" applied" to" infected" cells"
inhibited" the" unwinding" activity" of" enzyme" through" the" disruption" of" the" protein\RNA"
complex."Thus,"DENV"NS3hel"was"validated"as"a"promising"anti\DENV"target"that"can"be"used"
for"either"ligand"or"structure\based"drug"design"approaches."
"
"
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3.4.BIOCHEMICAL.ASSAYS.ON.DENV.NS3.
HELICASE.
"
As" part" of" a" secondment" period" in" Marseille" University," four" different" biochemical" tests"
involving"NS3hel"were"performed"and"are"reported" in"Table"3.7"with"the"aim"of"assessing" in&
vitro"the"activity"of"compounds"designed"with"the"three"drug"design"approaches"described"in"
chapters" within" this" section." Fifteen" molecules" (reported" in" APPENDIX& 5)" were" tested," five"
from" each" virtual" screening" approach." The" choice" of" the" compounds" among" the" small"
molecules"found"was"mainly"based"on"chemical"diversity."Mother"solutions"were"prepared"for"
all" tested" compounds" by" dissolving" them" in" 100%" dimethylsulfoxide" (DMSO)." Two" different"
helicase"domains"of"the"NS3"protein"were"used"for"the"biochemical"assays:"DENV"3"and"DENV"
4"NS3"helicase" domains." Some" tests"were" performed"on"both" serotypes,"while" others"were"
performed" only" on" one" of" them," according" to" the" enzyme" and" time" availability." A" brief"
description" of" these" assays" can" be" found" in" the" INTRODUCTION& section," while" general"
procedures," results" and" test" calibrations" are" reported" here." Further" details" of" compound"
evaluation" are" discussed" in" the" RESULTS& AND& DISCUSSION" chapter" of" this" section," in" the"
corresponding"paragraph" for" each"drug"design" study."Other" in& vitro" tests" (cytopathic" effect,"
CPE," inhibition" and" NS3hel" unwinding" assay)" were" performed" by" our" collaborators" and"
consequently"are"not"discussed"in"this"chapter."
"
Table'3.7..Summary.of.assays.performed.for.DENV.helicase..
Name. What.it.measures. Enzyme(s).used.
Thermal"Shift"Assay"(TSA)" Protein"melting"temperature"(Tm)"shift"due"to"compound"binding."
DENV3"NS3hel"
DENV4"NS3hel"
ATPase"assay"
Compound"inhibition"of"ATP"hydrolysis,"
through"the"measurement"of"the"
phosphate"ions"produced"and"detected"
with"a"colorimetric"method."
DENV4"NS3hel"
Fluorescence"Polarisation"(FP)"
using"a"RNA"probe"(RNA_BS9.2012:"
RNA\6FAM)"
Fluorescence"polarisation,"different"for"
probe"bound"or"unbound"o"the"protein."It"
was"used"to"identify"compound"inhibition"
of"RNA"binding."
DENV3"NS3hel"
DENV4"NS3hel"
FP"using"GTP"bodipy"
Fluorescence"polarisation,"different"for"
probe"bound"or"unbound"o"the"protein."It"
was"used"to"identify"compound"inhibition"
of"NTP"binding."
DENV3"NS3hel"
DENV4"NS3hel"
Abbreviations:"TSA="Thermal"Shift"Assay;"Tm="Melting"Temperature;"DENV3="Dengue"Serotype"3;"NS3hel="Non\Structural"
Protein"3"Helicase;"DENV4="Dengue"Serotype"4;"ATPase="Adenosine"Triphosphatase;"ATP="Adenosine"Triphosphate;"FP="
Fluorescence"Polarisation;"RNA="Ribonucleic"Acid;"GTP="Guanosine"Triphosphate;"NTP="Nucleoside"Triphosphate"
"
" "
Section"3:"NS3"HELICASE"AS"A"DRUG"TARGET" 3.4&BIOCHEMICAL&ASSAYS&ON&DENV&NS3HEL"!
!119"
THERMAL.SHIFT.ASSAY.(TSA).
"
The"thermal"shift"assay"(TSA)"was"performed"on"both"DENV"helicase"serotypes"with"the"aim"of"
determining" the" binding" capacity" of" the" compounds." As" a" reference," the" known" ATPase"
inhibitor" Adenosine" 5’\(β,γ\imido)" triphosphate" (AMPPNP)," that" binds" to" the" enzyme," was"
used."Initially"the"assay"was"performed"using"Mg2+"in"the"buffer"because"the"presence"of"the"
catalytic" divalent" ion" is" important" also" for" NTP" analogues" (like" AMPPNP)" binding."
Unexpectedly," in" these" conditions" not" even" the" reference" molecule" was" showing" positive"
results."Therefore"Mg2+"was"substituted"with"Mn2+"and"in"the"new"conditions"it"was"possible"to"
observe"binding"between"the"helicase"and"AMPPNP"through"a"significant"shift" in"the"protein"
melting"point"(Tm).""
All" the" compounds," were" screened" at" a" concentration" of" 1mM" (or" 0.5mM" for" less" soluble"
compounds),"while"AMPPNP"was"screened"at"0.5mM."The"final"content"of"DMSO"was"equal"to"
5%,"and"the"Tm"were"confronted"with"the"Tm"of"the"protein"in"buffer"and"in"buffer"with"5%"
DMSO."Eight"of" the"total" fifteen"compounds"precipitated"during" the"assay"and"consequently"
their"binding"to"NS3hel"could"not"be"assessed."Unfortunately,"it"has"not"been"possible"to"test"
the"precipitated"compounds"at"lower"concentration."The"shift"in"the"melting"point"(ΔTm)"was"
calculated"subtracting"the"melting"temperature"of"the"protein"in"buffer"with"5%"DMSO"to"the"
one" of" the" assessed" molecular" system." Only" the" reference" molecule" (AMPPNP)" gave" a"
significant" increase" in"melting" temperature." In" all" the" other" cases" a" reduction" of" Tm" values"
could" be" observed" and" this"was"meaningful" only" in" the" case" of" one" compound"designed" to"
bind"the"NTP"binding"site"(see"chapter"3.2.3).""
"
ATPASE.ASSAY.
"
The"ATPase"assay"was"executed"in"order"to"assess"the"capability"of"all"the"fifteen"compounds"
to"inhibit"the"hydrolysis"of"ATP"performed"by"DENV"helicase."Only"DENV4"NS3hel"was"used"for"
this"assay."The"ATPase"enzymatic"activity"of"the"protein"is"assessed"through"the"evaluation"of"
the"concentration"of"phosphate" ion"after"a" time"period."The" reaction" time,"ATP"and"protein"
concentrations" were" chosen" following" assay" calibration." The" compounds" were" screened" at"
2mM"and"the"results"were"confronted"with"a"positive"(Protein"alone"in"buffer"and"10%"DMSO)"
and"a"negative" (Protein"with"AMPPNP,"known"ATPase" inhibitor)" control."All" compounds"and"
controls" were" screened" in" duplicates." Blanks" with" ATP" and" the" compound" (but" without"
protein)" were" analysed" as" well" for" background" noise" detection." A" titration" curve" of" known"
concentrations" of" potassium" phosphate" was" used" for" quantitative" determination." As"
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happened"in"the"previous"assay,"the"same"eight"compounds"precipitated"and"therefore"could"
not"be"assessed"with"this"test."
The"results"were"dubious"for"AMPPNP"as"it"was"not"possible"to"reproduce"the"same"inhibitory"
effect" in" the"duplication"of" the"assay,"as" shown" in"Figure"3.17."Unfortunately," the" causes"of"
this"could"not"be"established."Of"the"tested"compounds,"three"(two"selected"by"targeting"the"
NTP"binding"site"and"one"by"targeting"the"RNA"cleft)"showed"some"positive"results."However,"
since"these"molecules"also"absorb"at"the"wavelength"used"for"the"phosphate"detection,"there"
was" not" enough" confidence"on" the" reliability" of" this" assay." Consequently," it"was" decided" to"
assess"NS3hel\NTP"binding" inhibition"through"fluorescence"polarisation,"using"GTP"bodipy"as"
probe"and"the"original"assay"was"not"further"considered.""
"
!
Figure'3.17..ATPase.assay.results.for.AMPPNP...
The"phosphate"concentrations"values"are"reported"for"the"Positive"control"and"the"system"with"AMPPNP"in"
duplicate"(AMPPNP\1"and"AMPPNP\2)."The"phosphate"concentration"of"the"positive"control"is"also"shown"with"the"
red"line."
"
FLUORESCENCE.POLARISATION.(FP).ASSAY..
"
The" fluorescence"polarisation" (FP)" assay"was"used" for" the"analysis"of" compounds"binding" to"
the"two"helicase"binding"sites,"exploiting"two"fluorescent"probes."The"binding"was"assessed"on"
both"DENV"helicase"serotypes."For"the"NTP"binding"site"the"used"probe"was"GTP"bodipy,"while"
for" the" RNA" binding" site" a" RNA" oligonucleotide" linked" to" a" 6\carboxyfluorescein" (6\FAM)"
molecule"was"chosen."As"DENV"helicase"is"not"base"specific"in"either"binding"sites,"the"probe"
selection"was"based"on"the"best"assay"performance"that"could"be"obtained.""
" "
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FLUORESCENCE.POLARISATION.(FP).ASSAY.WITH.GTP.BODIPY.PROBE.
"
The"assay"calibration"aimed"to"find"the"ideal"concentrations"of"the"probe"and"of"the"protein"to"
use"in"order"to"maximise"the"test"sensibility."It"was"also"assessed"the"importance"of"the"use"of"
a"ion"chelating"agent"(EDTA)"that,"removing"the"catalytic"divalent"ion,"impeded"the"hydrolysis"
of" the" probe" from" GTP" bodipy" to" GDP" bodipy" that" would" decrease" the" probe" binding" and"
consequently"alter"the"fluorescence"polarisation"(FP)"values."The"dissociation"constant"(Kd)"of"
the" helicase" –" probe" complex" was" determined" during" the" calibration" by" testing" different"
protein" concentrations"with" the"minimum"probe"concentration"possible" (100nM)."As" the"Kd"
was"found"to"be"around"1µM"for"both"helicase"serotypes,"a"concentration"higher"than"the"Kd,"
but"not"in"the"plateaux"range"of"the"chart"was"chosen"for"compound"screening:"3"µM."Figure"
3.18" shows"an"example"of" calibration"curve" (DENV3"NS3hel)."Here" the"dissociation"constant"
and"the"chosen"protein"concentrations"are"indicated."
"
!
Figure'3.18..FPFGTP.calibration.curve.for.DENV3.NS3hel..
The"variation"of"the"fluorescence"polarisation"(FP)"is"plotted"against"the"protein"concentration."The"dissociation"
constant"of"1.10µM"is"indicated"with"Kd"and"the"chosen"working"protein"concentration"is"shown"as"well.".
All" compounds"were" tested" at" eight" concentrations"with" 2X" dilution," starting" from" 1mM"or"
from" the"maximum" possible" concentration" of" the" compound" (see"APPENDIX& 5)" in" order" to"
avoid"precipitation."Dilutions"were"done" in"DMSO" in"order" to"have" the"same"DMSO"content"
(5%)"in"all"the"wells."Similarly"to"the"ATPase"inhibition"assay,"AMPPNP"was"used"as"a"negative"
control." Blanks" with" all" compounds" concentrations" and" the" GTP" probe" in" buffer" were" also"
prepared"in"order"to"exclude"background"noise."The"six"compounds"that"gave"a"reduction"of"
the" fluorescence" polarisation" (which" means" a" reduction" in" GTP" bodipy" binding)" with"
concentration" increase" and" the" ones" that"were" found" positive"with" the" ATPase" assay"were"
selected"and"the"test"was"repeated"other"two"times"with"the"aim"of"improving"the"statistical"
relevance" of" the" results." Three" compounds" in" particular" (one" from" each" virtual" screening"
study)"gave"interesting"results."The"chemical"structure"of"these"compounds"(3,"15"and"17)"can"
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be" found" in" APPENDIX& 5." IC50" values" for" these" molecule" were" calculated" and" ranged"
approximately"between"8"and"130"µM."Interestingly,"of"these"three,"the"compound"designed"
to"bind"the"NTP"site"(17)"was"also"found"positive"in"the"ATPase"assay."
A"further"check"had"to"be"performed"for"two"compounds"designed"to"target"the"RNA"site"as"
the"blank" showed"an" increase" in"polarisation" correlated"with" compound"concentration."GTP"
bodipy" and" the" compounds" (at" the" same" concentrations)" were" tested" in" combination" and"
alone."Also"in"this"case"the"results"were"not"clear"and"it"was"not"possible"to"determine"if"the"
FP"increase"was"correlated"only"with"compound"fluorescence"and"interaction"with"the"protein,"
or" if" it" involved"also" interactions"with"the"probe."Unfortunately,"one"of"these"two"molecules"
was" also" amongst" the" three" compounds" with" positive" results." Furthermore," despite" GTP"
bodipy"binding"inhibition"could"be"observed"for"some"compounds,"in"any"tested"compound"no"
consistency"could"be"reproduced" in"the"triplicates"curves,"as"exemplified" in"Figure"3.19."This"
decreased" the"confidence" in" the"obtained" results," in"particular" in" the"statistical" relevance"of"
the" calculated" IC50" values." For" this" reason," they"are"not" reported"here."As" the"whole" results"
were" so" unclear" and" no" reason" that" could" explain" this" behaviour" could" be" found," it" was"
decided"to"not"consider"them"for"future"compound"developments."
"
!
Figure'3.19..Example.of.GTPFFP.assay.triplicate.curves...
This"example"reports"the"three"curves"of"FP"assay"on"DENV4"NS3hel"probe"for"a"compound"that"showed"to"inhibit"
GTP"bodipy"binding."The"polarisation"is"reported"for"the"logarithm"of"the"compound"concentration"(in"µM)."The"
three"repeats"(indicated"as"Test"1,"blue"curve"and"symbols;"Test"2,"green"curve"and"symbols;"Test"3,"red"curve"and"
symbols)"are"different."The"curve"in"black"(indicated"as"Blank)"refers"to"the"system"in"absence"of"the"protein."
"
FLUORESCENCE.POLARISATION.(FP).ASSAY.WITH.RNAF6FAM.PROBE.
"
Similarly"to"the"other"FP"assay,"also"for"this"test"an"assay"calibration"was"performed,"following"
the"same"protocol." In" this"case"EDTA"was"not"used"because"no"catalytic" ions"are" involved" in"
the" site" of" interest." The" probe" (RNA\6FAM)" concentration" used" was" of" 50nM" and" several"
concentrations"of"the"two"helicases"domains"were"assessed."The"dissociation"constants"of"the"
complex"were"found"to"be"very"similar:"17.64nM"for"DENV3"NS3hel"and"17.44nM"for"DENV4"
NS3hel." Also" in" this" case," a" protein" concentration" higher" than" this" value," but" not" in" the"
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plateaux"area"of"the"chart"was"chosen"for"compound"screening:"40nM."Figure"3.20"shows"an"
example"of"calibration"curve"(DENV4"NS3hel)."Here"the"dissociation"constant"and"the"chosen"
protein"concentrations"are"indicated."
All"compounds"were"tested"at"eight"concentrations"with"2X"dilution,"starting"from"1mM"or"the"
maximum" possible" concentration" of" compound" (see" APPENDIX& 5)" in" order" to" avoid"
precipitation."Small"molecule"dilutions"were"done"in"DMSO"in"order"to"have"the"same"DMSO"
content"(5%)"in"all"the"wells."AMPPNP"was"tested"as"well"as"a"negative"control."Blanks"with"all"
compounds" concentrations" and" the" RNA" probe" in" buffer" were" also" prepared" in" order" to"
exclude"background"noise."
"
!
Figure'3.20..FPFRNA.calibration.curve.for.DENV4.NS3hel...
The"variation"of"the"fluorescence"polarisation"(FP)"is"plotted"against"the"protein"concentration."The"dissociation"
constant"of"17.44nM"is"indicated"with"Kd"and"the"chosen"working"protein"concentration"is"shown"as"well."
The" first" screen" of" the" compounds" showed" that" almost" all" of" them" gave" a" reduction" in" FP"
values," which" corresponds" to" the" inhibition" of" the" RNA\helicase" complex" formation." As"
predictable,"AMPPNP" (the"negative" control)"did"not"give"a"positive" result," as" its"binding" site"
does"not" correspond" to" the"RNA"pocket." Excluding" the" two"molecules" that"did"not" show"FP"
reduction," compounds"were" retested" twice" in" order" to" increase" statistical" relevance" of" the"
results."Differently"to"what"experienced"for"the"NTP"binding"site,"the"obtained"triplicate"curves"
were"much"more" consistent," as" exemplified" in" Figure"3.21," and" results"were"assessed" to"be"
more"reliable."Only"one"set"of"experiments"(the"first"data"obtained"for"DENV3"NS3hel)"had"to"
be"removed,"as"the"middle"part"of"the"curve"was"not"well"described"and"led"to"large"bias"in"the"
calculation"of"the"IC50.""
Similar" to" the" other" FP" assay," a" further" check" had" to" be" performed" for" 4" of" the" total" 15"
compounds," as" the" blank" showed" an" increase" in" polarisation" correlated" with" compound"
concentration."Interestingly,"all"of"them"had"been"selected"with"the"virtual"screening"targeting"
the"RNA"binding" site"and" this"will" be" further"discussed" in" chapter"3.2.2."RNA\6FAM"and" the"
compounds" (at" the" same" concentrations" reported" above)" were" tested" in" combination" and"
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alone."Also"in"this"case"the"results"were"not"clear"and"it"was"chosen"to"not"consider"the"assay"
results"for"these"compounds."
IC50s"were"calculated"for"compounds"that"did"not"present"problems"with"the"assay"and"values"
ranged" approximately" between" 8" and" 41" µM" for" the" four"most" attractive" compounds" (see"
study" chapters" for" further"details)."Other" values"were" generally" above"200"µM." Intriguingly,"
the"higher"binding"activity"was"associated"with" compounds" selected" through"a" ligand\based"
approach" that" employed" a" shape" screening" using"Ouabain" as" a" template"molecule" and" this"
aspect"will"be"further"discussed"in"chapter"3.2.1.""
"
!
Figure'3.21..Example.of.GTPFRNA.assay.triplicate.curves...
This"example"reports"the"three"curves"of"FP"assay"on"DENV4"NS3hel"probe"for"a"compound"that"has"been"shown"to"
inhibit"RNA\6FAM"binding."The"polarisation"is"reported"for"the"logarithm"of"the"compound"concentration"(in"µM)."
The"three"repeats"(indicated"as"Test"1,"blue"curve"and"symbols;"Test"2,"green"curve"and"symbols;"Test"3,"red"curve"
and"symbols)"are"more"consistent"that"in"the"FP\GTP"assay."The"curve"in"black"(indicated"as"Blank)"refers"to"the"
system"in"absence"of"the"protein."
"
"
"
"
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3.5.COMPUTATIONAL.METHODS.
"
The"computational"methods" for"all" the"studies"discussed" in"chapters" from"3.2.1" to"3.2.3"are"
presented" here." A" description" of" the" molecular" modelling" programs" used" can" be" found" in"
APPENDIX&2."
"
HARDWARE'DETAILS'
"
All"of"the"calculations"were"performed"on"an"8"core"computer"with"Inter"Xeon"2.80"GHz"E5462"
CPUs.""
"
OUABAIN'SHAPESBASED'DRUG'DESIGN'
"
QUERY.SELECTION.AND.PREPARATION.
"
A" conformational" search" was" performed" with" MOE" 2010.10[34]" software" for" Ouabain,"
Ivermectin" and" Paromomycin." The" conformation" search" was" conducted" with" the" Import"
Conformation"tool"exploring"250"conformations"per"molecule,"with"the"following"parameters:"
stochastic" strain" limit"of"7," superposed"RMSD"test"of"0.15," refinement"conformation" limit"of"
300,"stochastic"search" failure" limit"of"30,"stochastic"search" limit"of"300,"energy"minimisation"
iteration"limit"of"200,"energy"minimisation"gradient"test"of"0.5."Subsequently,"hydrogen"atoms"
were"added"and"the"conformations"were"energy"minimized"using"MMFF94x"force"field,"with"a"
0.001" gradient," adjusting" hydrogens" and" lone" pairs" and" calculating" the" force" field" partial"
charges."
As" Ouabain" was" selected" as" a" query" molecule," the" number" of" its" conformations" was"
consequently" reduced" to" obtain" the" smallest" number" of" queries." The" conformations" were"
superposed"and" the"molecular" surface"was" calculated" for"each"one"of" them."Through"visual"
inspection"of"both" the" surfaces"and"atoms" superposition," the" conformations"were" clustered"
according" to" shape" similarity" and" the" three" most" different" conformations" were" chosen" as"
shape"screening"queries."
" "
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DATABASE.PREPARATION.
"
The" approximately" 209,950" screened" molecules" were" downloaded" from" SPECS" database"
(updated"to"February"2012).[27]"Prior"to"the"shape"screening,"a"conformational"search"on"these"
structures" was" performed," using" MOE" 2010.10[34]" Import" Conformation" tool." For" each"
molecule"100"conformations"were"explored,"with"the"following"parameters:"stochastic"strain"
limit" fixed" to" 7," superposed" RMSD" test" to" 0.15," refinement" conformation" limit" to" 300,"
stochastic" search" failure" limit" to" 30," stochastic" search" limit" to" 300," energy" minimisation"
iteration" limit" to" 200," energy" minimisation" gradient" test" to" 0.5." The" molecules" were" also"
filtered,"omitting"compounds"with:"transition"metals,"more"than"8"rings,"d\hybridized"atoms,"
molecular" weight" over" 600" Da," more" than" 12" donor/acceptor" groups," more" than" 4" chiral"
centres,"over"3"unconstrained"chiral"centres,"more"than"7"rotatable"bonds,"single"bond"chain"
length" over" 6" and" logP" under" \4" or" over" 8." Subsequently," hydrogens" were" added" and" the"
conformations" were" energy" minimized" with" MMFF94x" force" field," with" a" 0.001" gradient,"
adjusting" hydrogens" and" lone" pairs" and" calculating" the" force" field" partial" charges." The" final"
conformations"were"approximately"7,130,000.""
"
SHAPE.SCREENING.
"
The"five"shape"screenings"of"the"database"molecules"were"computed"with"the"OpenEye"ROCS"
3.1.2[35]" software," using" all" three" Ouabain" queries" and" considering" all" the" database"
conformations"as"separate"molecules."Only"shape"comparison"between"the"molecules"and"the"
queries"was"considered"for"conformation"scoring"and"the"ranking"followed"the"Tanimoto"index"
values."Three"maximum"hits"were"kept"for"each"conformation"and"only"the"best"1,000;"2,000;"
3,000;" 4,000" and" 5,000" hits," according" to" the" screening" protocol," were" transcribed" in" the"
output"files."
"
RESULTS.ANALYSIS.
"
The"results" for"each"screening"were"observed"and"compared."The"most"promising"molecules"
were" then" observed" in" the" MOE" 2010.10[34]" environment." The" molecular" surface" of" these"
molecules" was" calculated" with" the" MOE" Surfaces" and" Maps" tool" and" all" the" selected"
conformations" were" compared" to" the" queries" on" the" basis" of" the" volume" and" atom"
superposition."In"this"way,"the"best"molecules"were"chosen"and"purchased"from"SPECS.[27]"
After" in& vitro" evaluation" of" the" compounds," the" analogues" of" compound" 2" and" 3" were"
purchased"from"SPECS[27]"as"well."
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NTP'BINDING'SITE'COMPETITIVE'INHIBITORS'DRUG'
DESIGN'
"
PROTEINS.PREPARATION.
"
All"target"(PDB"IDs:"2JLV,"2JLR[19]"and"2WHX[12])"and"anti\target"(PDB"IDs:"2GJK[31],"2J0S[32]"and"
3FHT[33])"structures"were"downloaded"from"the"Protein"Data"Bank[13]"and"completed"with"MOE"
2010.10[34]" software." The"missing" side" chains"of" residues"were"added"and"energy"minimised"
with" AMBER99" force" field" and" 0.001" gradient." This" procedure"was" applied" to" the" following"
amino" acids:" Arg184" and" Arg480" in" 2JLR;" Lys33," Glu43," His60," Glu61," Arg62," Asn74," Glu92,"
Glu93," Lys107," Ile123," Lys143," Asp175," Lys213" in" 2WHX;" Glu21," Asp22," Arg105," Arg151,"
Lys195,"Lys314,"Glu314,"Leu410"and"Ile411"in"2J0S."In"all"of"them,"all"water"and"co\crystallised"
molecules"were"removed,"except"for"AMPPNP"(or"ADP)"and"the"divalent"cation."All"structures"
were"then"protonated"with"MOE"2010.10[34]"Protonate"3D"tool,"considering"a"temperature"of"
300K"and"a"pH"of"7."All"structures"were"aligned"with"MOE"2010.10[34],"constraining"alignments"
to"have"the"best"superposition"possible"of"the"NTP"binding"sites."
Additional" preparation" was" performed" for" the" docking" simulations" performed" with"
Schrödinger"Maestro"9.3[36]"Glide"program,"using"the"Protein"Preparation"tool.""
"
LIGAND.PREPARATION.
"
The" starting" ligand"database"was"originated" from" the" SPECS"database" (updated" to" February"
2012).[27]"Prior" to"pharmacophore"filtering," the" ligand"preparation" included"a"conformational"
search" using" MOE" 2010.10[34]" Import" Conformations" tool" with" the" following" settings:" 100"
conformations"explored"per"molecule,"stochastic"strain"limit"fixed"to"7,"superposed"RMSD"test"
to"0.15,"refinement"conformation"limit"to"300,"stochastic"search"failure"limit"to"30,"stochastic"
search" limit"to"300,"energy"minimisation" iteration" limit"to"200,"energy"minimisation"gradient"
test"to"0.5."Furthermore,"compounds"with"transition"metals,"more"than"8"rings,"d\hybridized"
atoms," molecular" weight" over" 600Da," more" than" 12" donor/acceptor" groups," more" than" 4"
chiral" centres," logP" under" \4" and" over" 8," over" 3" unconstrained" chiral" centres,"more" than" 7"
rotatable" bonds" and" single" bond" chain" length" over" 6," were" omitted." Ligands" were"
subsequently"also"protonated.""
The" ligand"databases"used" for"docking"and"scoring"simulations"were"prepared"with"Maestro"
9.3[36]"LigPrep"tool,"using"OPLS_2005"force"field."Tautomers"for"each"molecule"were"designed"
considering" all" possible" ionisation" states" at" pH" 7" ±" 2" with" Epik" and" maintaining" the" input"
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chiralities."A"filter"was"also"applied"to"remove"molecules"with"molecular"weights"higher"than"
600Da,"more"than"9"rings,"more"than"4"chiral"centres"and"more"than"12"hydrogen"bond"donor"
or"acceptor"groups."
"
PHARMACOPHORE.
"
For" each" target" protein" (PDBs" 2JLV," 2JLR" and"2WHX)" a" pharmacophore"was"built"with"MOE"
2010.10[34]" Protein" Ligand" Interaction" Fingerprints" (PLIF)" tool." The" annotation" points" were"
assigned"with" the"Unified"scheme,"extra"volumes"were"added" for"binding"site"size"definition"
and" the" features" were" modified" manually" through" visual" inspection." 2JLR" and" 2JLV"
pharmacophores"had"7"features"and"2WHX"had"8.""
The"prepared"ligand"conformations"were"searched"with"these"pharmacophores"and"the"best"2"
conformations" for"each"molecule" that"matched"at" least" three"essential" features"of" the" total"
were"saved."Two"pharmacophore"searches"were"performed:"one"with"F3,"F4"and"F6"essential"
features"and"the"other"one"with"F3,"F4"and"F7"ones"(see"chapter"3.2.3)."The"results"of"the"two"
searches"were"merged" and" a"maximum" two" conformations" for" each" unique"molecule"were"
saved"in"a"database."
"
DOCKING.
"
An" ATP" molecule" was" added" as" a" reference" to" the" pharmacophore\filtered" ligands" prior"
Maestro"9.3[36]"LigPrep"small"molecule"preparation"(see"above)."
All"docking"simulations"were"performed"with"Schrödinger"Maestro"9.3[36]"Glide"program."Prior"
docking," the" receptor" grids"were"built" selecting" the" co\crystallised"AMPPNP" (or"ADP)" as" the"
centre"and"a"9Å"grid" length." In"all" cases," the"catalytic" ion"present" in" the"structures" (Mn2+"or"
Mg2+)"was"retained."
All"the"docking"simulations"were"performed"in"a"semi\flexible"approach"with"the"sample"ring"
conformation" option" for" an" exhaustive" conformational" search" for" the" ligands." Ligands" with"
more" than" 300" atoms" or" more" than" 50" rotatable" bonds" were" excluded." The" non\bonded"
interactions"were" calculated"with" a" 0.8nm" van" der"Waals" radii" scaling" factor" and" a" 0.15nm"
partial"charge"cut\off."Only"a"maximum"of"3"conformations"were"kept"for"each"ligand"and"they"
were"not"energy"minimised"after"the"docking"because"a"refinement"procedure"was"applied"on"
the"docking"output."The"first"docking"calculations"were"applied"only"to"target"structures"and"
were" performed" with" standard" precision" (SP);" while" the" ones" implemented" on" both" target"
and\antitarget" receptors"were"executed"with"extra"precision" (XP)."The" resulting"poses"were,"
then,"visually"inspected"with"the"MOE"2010.10[34]"software."
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RESCORING.
"
The" docking" results" were" rescored" with" other" two" programs:" LeadIT" FlexX" 2.1.3[37]" and"
PLANTS.[38]"No"molecule"placement"was"performed"in"this"case"and"poses"were"scored"in"their"
input"conformation"and"position"within"the"binding"pocket."The"prepared"target"proteins"were"
used"with"both"softwares.""
The"receptor"binding"site"was"prepared"with"LeadIT"software,"and"the"centres"of"the"receptor"
sites"were"chosen"in"the"same"way"as"described"for"the"Maestro"Glide"docking."In"all"cases"the"
grid"sphere"had"a"radius"equal"to"20Å.""
For"PLANTS"rescoring"the"AMPPNP"or"ADP"molecules"had"to"be"removed"prior"to"simulation."
The" same" grid" centres" as" in" the" Glide" docking" procedure"were" used" and" in" all" systems" the"
binding" site" radius"was" set" to" 9Å." The" search" algorithm"used"20" ants" and"CHEMPLP" scoring"
function"was"used.[39]""
"
CONSENSUS.SCORE.1.(CS1).
"
All" scores" obtained"with" the" first" Glide" docking" and" FlexX" and" PLANTS" rescoring" procedure"
were" processed" with" a" scoring" function" (consensus" scoring" function" 1)" that" was" previously"
developed"in"our"laboratory."For"each"set"of"data,"the"value"corresponding"to"the"lowest"25%"
of" the" scores" (first" or" lower" quartile," Q1)" was" calculated." Then,"molecules" that" had" a" score"
lower"than"Q1"(representing"the"best"25%"of"poses)"were"rewarded"with"a"“+1”"score,"while"
the" ones" with" score" equal" or" higher" than" Q1" were" assessed" with" a" “0”" or" “\1”" score"
respectively."Then," the" total" consensus" score" (CS1)"was"obtained" from"the"sum"of" the"given"
scores"for"each"set"of"data."Equation"3.1"shows"the"mathematical"expression"of"the"consensus"
score"function."
" !"1! = !"#$(!!,!"#$% − !!"#$%,!) + !"#$(!!,!"#$% − !!"#$%,!) + !"#$(!!,!"#$%& − !!"#$%&,!)"
Equation'3.1..Consensus.scoring.function.1..
CS1="consensus"score"1;"i="pose;"Q1,name="first"quartile"of"the"“name”"set"of"data"(Glide,"FlexX"and"PLANTS"set"of"
scores);"xname,i="score"obtained"by"pose"“i”"with"the"“name”"software"(Glide,"FlexX"or"PLANTS)"
A"normalised"consensus"score"(NCS1)"was"also"calculated,"using"Equation"3.2:"
" !"#1! = !!"#$%,!!"#!"#$% + !!"#$%,!!"#!"#$% + !!"#$%&,!!"#!"#$%&"
Equation'3.2..Normalised.consensus.scoring.function.1..
NCS1="normalised"consensus"score"1;"i="pose;"Minname="lowest"value"of"the"“name”"set"of"data"(Glide,"FlexX"and"
PLANTS"set"of"scores);"xname,i="score"obtained"by"pose"“i”"with"the"“name”"software"(Glide,"FlexX"or"PLANTS)"
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Molecules" were" ranked" according" to" the" CS1" and" the" NCS1" in" descending" order" and" only"
molecules" that" had" CS1" equal" to" 3" (and" therefore" performed" in" the" best" 25%"with" all" the"
modelling"programs)"were"kept,"in"a"single"conformation"for"further"analysis."
The"saved"molecules"from"all"three"docking"and"rescoring"procedures"were"merged"and"two"
conformations" for" each" compound" that" had" CS1" =" 3" in" at" least" two" of" the" three" target"
molecular"systems"were"kept"for"further"proceedings."
"
CONSENSUS.SCORE.2.(CS2).
"
A"new"consensus"score"function"was"designed"on"purpose"for"this"study"with"the"objective"of"
finding"molecules"that"bind"viral"helicase"better"than"host"ones,"with"a"higher"discrimination"
than" the" natural" ligand" (ATP)." Therefore," for" each" molecule" a" normalised" consensus" score"
(NCS)"was"calculated" for"each"molecular" system,"using"Equation"3.2."Subsequently," the"anti\
target"NCSs"were"subtracted"from"the"target"NCSs,"obtaining"the"consensus"score"2"(CS2)."The"
mathematical"form"of"the"scoring"function"is"reported"in"Equation"3.3."
" !"2! = !!"#$%,!!"#!"#$% + !!"#$%,!!"#!"#$% + !!"#$%&,!!"#!"#$%& !"#$%!&− !!"#$%,!!"#!"#$% + !!"#$%,!!"#!"#$% + !!"#$%&,!!"#!"#$%& !"#$!!"#$%!&"
Equation'3.3..Consensus.scoring.function.2..
CS2="consensus"score"\"2;"i="pose;"Minname="lowest"value"of"the"“name”"set"of"data"(Glide,"FlexX"and"PLANTS"set"of"
scores);"xname,i="score"obtained"by"pose"“i”"with"the"“name”"software"(Glide,"FlexX"or"PLANTS)"
In" general," higher" NCS" is" associated" with" a" better" theoretical" binding" of" the" ligand" to" the"
protein." Consequently," a" positive" CS2"means" that" the" docking" procedure" suggests" that" the"
molecule"has"preference"to"bind"to"the"target"enzyme."
Molecules"with"CS2"equal"or"higher"than"0.6"were"selected"for"visual"inspection."
"
"
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3.6.EXPERIMENTAL.SECTION.
"
COMPOUND'PREPARATION'
"
Of"the"15"tested"compounds,"14"were"purchased"from"SPECS[27]"and"one"(18)"was"chemically"
synthesised"in"house"in"a"previous"study.[29]""
For"each"compound,"a"solution"of"20mM"in"DMSO"was"prepared,"starting"from"approximately"
5mg" of" compound." Two" compounds" (1" and" 15)" did" not" dissolve" at" this" concentration" and"
therefore" they"were"diluted" to"10mM" in"DMSO."These" solutions"were" then"used"as" starting"
material"for"the"biophysical"and"enzymatic"assays."
"
THERMAL'SHIFT'ASSAY'(TSA)'
"
The" thermal" shift"assay" (TSA)"was"performed"on" two"DENV"NS3hel" from"different" serotypes"
(EVA314," from" serotype" 3," 50.554" kDa" and" EVA186," from" serotype" 4," 50.912kDa)." Both"
proteins" were" previously" prepared" and" purified" in" AFMB,"Marseille" University" laboratories."
The"buffer"used" for" the"assay"was" constituted"of"Tris" (pH"7.5)"50mM,"NaCl"150mM,"TEMED"
200mM"and"MnCl2"2mM"in"water."SYPRO"ORANGE"(SO,"with"excitation"wavelengths"at"300nm"
and"470nm"and"emission"wavelength"at"570nm)"was"used"as"fluorescent"probe."
PCR"plates"with"96"wells"were"used"and"each"well"was"prepared"with"25µL"of" total" solution"
(20µL" of" protein," 1.25µL" of" compound" 20mM" solution" and" 3.5µL" of" SO" solution)." The" final"
concentration"of" the"proteins"were"0.81mg/mL"for"DENV3"and"0.72mg/mL"for"DENV4,"while"
the" final" concentration" of" the" compounds"was" of" 1mM" in" each"well," except" for" the" poorly"
soluble" compounds" (1" and"15)" that"were" at" 0.5mM." Three" controls"were" also" prepared" for"
each"protein:"one"with"0.5mM"of"AMPPNP"as" it" is" known" to"bind" the"enzyme,"one"with"5%"
DMSO"and"one"with"the"protein"alone."
Before"performing"the"assay,"the"wells"were"visually"inspected"in"order"to"detect"the"presence"
of" eventual" precipitated" compounds." The" assay"was" performed" in" a"modified" PCR"machine"
that"reads"the"fluorescence"as"a"function"of"temperature."It"was"set"for"360"cycles"of"12s"each"
with"a"temperature"increase"of"0.2°C,"starting"from"a"temperature"of"20°C.""
The" resulting" charts" of" fluorescence" on" temperature" were" analysed" with" ORIGIN." For" each"
protein,"a"temperature"window"was"chosen"in"order"to"include"the"reported"thermal"shift"and"
Section"3:"NS3"HELICASE"AS"A"DRUG"TARGET" 3.6&EXPERIMENTAL&SECTION"!
!132"
the"curves"were"fitted"with"a"Boltzmann"distribution."Melting"points"and"fitting"errors"were,"in"
this"way,"determined."
"
ATPASE'ASSAY''
"
The"ATPase"assay"was"performed"on"DENV4"NS3hel"(EVA186,"serotype"4,"50.912kDa)"that"was"
previously"prepared"and"purified"in"AFMB,"Marseille"University"the"laboratories."Solutions"(A,"
B," C" and" D)" for" the" phosphate" colouring" reaction" were" prepared" on" the" day" of" the" assay."
Solution" A" contained" 12%" ascorbic" acid" in" HCl" 1M;" solution" B" contained" 1%" ammonium"
molybdate"tetra"hydrate" in"water;"solution"D"contained"2%"sodium"citrate" in"2%"acetic"acid."
Solution"C"was"prepared"less"than"one"hour"before"detection"and"it"was"obtained"by"mixing"2"
parts"of"solution"A"with"one"part"of"solution"B."
For" each" assay," two" premix" solutions"were" prepared" in" reaction" buffer" (Tris" pH" 7.5" 50mM,"
MgCl2"2mM,"BSA"0.1mg/mL):"one"containing"ATP" (premix" I)" and"one"containing" the"enzyme"
with"or"without"inhibitor"(premix"II)."At"time"0,"premix"II"was"transferred"in"premix"I"and"the"
reaction"was"incubated"at"37°C."
At"desired"time"points,"20µL"of"mixture"were"sampled."In"the"sampling"volumes"the"reaction"
was"stopped"with"0.5µL"EDTA"50mM"in"a"96"well"plate"with"the"flat"bottom."A"volume"of"60µL"
of"solution"C"was"added"to"each"well"and"the"obtained"mixture"was"incubated"for"5"minutes"at"
room"temperature."Consequently,"60µL"of"solution"D"were"added"to"the"mixture"and"the"wells"
analysed"with"Magellan"spectrophotometer"at"a"wavelength"of"595nm."Eight"concentrations"
(obtained"with"2X"serial"dilutions"from"an"initial"concentration"of"10mM)"of"KH2PO4"with"EDTA"
were" also" always" analysed" with" this" colorimetric" assay" as" a" reference" for" the" correlation"
between"the"absorbance"and"the"phosphate"concentration."
"
ASSAY.CALIBRATION.
"
The"assay"was" first" performed"with" four"enzyme"concentrations" (0," 25," 50"and"100nM)"and"
two"DMSO"percentages"(0%"or"10%)"were"tested"for"each"one"of"them."In"all"the"cases,"an"ATP"
concentration"of"0.5mM"was"used."The"reaction"was"sampled"at"the"following"times:"0,"3,"6,"9,"
12"and"15"minutes"from"the"beginning."Phosphate"concentration"curves"were"calculated"with"
a"spread"sheet"and"the"optimal"protein"concentration"was"chosen."
Subsequently," the"assay"was"performed"with"two"ATP"concentrations"(0.5"and"0.25mM)"and"
two" DMSO" percentages" (0%" or" 10%)"were" tested" for" each" one" of" them." In" all" the" cases," a"
protein"concentration"of"25nM"was"used."The"reaction"was"sampled"at"the"following"times:"0,"
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3," 6," 9," 12" and" 15" minutes" from" the" beginning." Phosphate" concentration" curves" were"
calculated"with"a"spread"sheet"and"the"optimal"ATP"concentration"was"chosen."
"
COMPOUND.SCREENING.
"
After" calibration," it" was" chosen" to" use" 0.25mM" and" 25nM" ATP" and" enzyme" concentration"
respectively"for"the"assay."All"15"compounds"designed"for"NS3hel"inhibition"were"screened"in"
duplicates"at"2mM"concentration,"following"the"general"procedure"reported"above."The"poorly"
soluble" compounds" (1" and" 15)" were" tested" at" 1mM" concentration." In" this" way" the" system"
always"contained"10%"DMSO."For"each"compound"a"blank"containing"all"substances"except"the"
enzyme"was"prepared"for"background"effects"exclusion."A"known"helicase"inhibitor"(AMPPNP)"
was"also"tested"with"10%"DMSO"as"a"negative"control."The"protein"without"inhibitors"and"with"
10%"DMSO"was"used"as"positive"control.""
The" reaction" was" stopped" after" 8" minutes" and" phosphate" concentration" was" calculated" as"
described"above."At" the"beginning"and"at" the"end"of" the"assay," the" reaction" solutions"were"
visually"inspected"in"order"to"detect"the"presence"of"eventual"precipitated"compounds."
"
FLUORESCENCE'POLARISATION'(FP)'GENERAL'
PROCEDURE''
"
This" assay"was" carried"out"with" two"probes" in" order" to" assess" the" compounds’" competition"
with"RNA"or"NTP"binding."Helicases"from"two"viral"serotypes"were"used"in"appropriate"buffer"
for" the" assay:" DENV\3" (EVA314," from" serotype" 3," 50.554kDa)" and" DENV\4" (EVA186," from"
serotype" 4," 50.912kDa)." The" enzymes" were" previously" prepared" and" purified" in" AFMB,"
Marseille"University"laboratories."
The" assay"was" carried"out" at" room" temperature" in" a" PHERAstar"multidetector" plate" reader,"
using"the"“480"520"520”"optic"module."Greiner"black"plates"with"flat"bottom"wells"were"used.""
The"fluorescence"polarisation"values"for"each"well"were"saved"as"a"spread"sheet"and"analysed"
with"GraphPad"PRISM"6.0"software."
"
"
"! '
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FP'WITH'GTP'PROBE'
"
ASSAY.CALIBRATION.
"
For" NTP" binding" competition" analysis" ATP\bodipy" and" GTP\bodipy" probes" were" purchased."
They"are"NTPs" linked" through" the" ribose" to"a" fluorescent"moiety" (bodipy"FL,"with"excitation"
wavelength"of"488nm"and"emission"wavelength"of"512nm).""
Titration" curves"were" obtained" varying" the" enzyme" concentrations" (12" concentrations" from"
40µM" to" 78nM," with" 2X" dilution" factor" for" the" enzyme" and" 0nM)" and" with" a" constant"
concentration" of" the" NTP\bodipy" probe" of" 100nM." The" buffer" used" for" the" assay" was"
constituted"of"Tris"(pH"7.5)"25mM,"DTT"2mM"and"EDTA"0.5mM"in"water.""
Titration" curves"were" obtained" for" both" DENV"NS3hel" serotypes" and" both" NTP" probes." For"
assay"validation,"a"titration"curve"was"also"performed"with"DENV3"NS3hel"and"GTP\bodipy"in"
the" presence" of" AMPPNP" 1mM." Data" analysis" was" performed" and" the" NTP\bodipy" binding"
constant"(Kd)"was"calculated"in"all"the"tested"conditions.""
Greiner"96"half" area"wells" plates"were"used"and" for" each"well" a" total" volume"of" 100µL"was"
prepared."
"
COMPOUND.SCREENING.
"
Compound" screening"was" performed" on" both" helicase" serotypes" in" the" same" buffer" as" the"
assay"calibration,"in"Greiner"384"wells"and"for"each"well"a"total"volume"of"20µL"was"prepared."
Constant" protein" and" GTP\bodipy" concentrations" (of" 3µM" and" 100nM" respectively)" were"
used;"while"all"compounds"were"tested"at"eight"concentrations"with"2X"dilution,"starting"from"
1mM"or"from"the"maximum"concentration"possible."Compound"dilutions"were"carried"out" in"
DMSO"in"order"to"have"the"same"DMSO"content"(5%)"in"all"of"the"wells."AMPPNP"was"tested"
as"well"as"a"negative"control."Blanks"with"all"compound"concentrations"and"the"GTP"probe"in"
buffer"were" also" prepared" in" order" to" exclude" background" noise." The" test"was" repeated" in"
duplicate"for"selected"molecules.""
"
"
"
"
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FP'WITH'RNA'PROBE''
"
ASSAY.CALIBRATION.
"
For"RNA"binding"competition"analysis"the"RNA"oligonucleotide"(RNABS9.2012)"was"used"as"the"
fluorescent" probe." It" is" a" 10" nucleotides" RNA" oligomer" bound" to" the" fluorophore"
carboxyfluorescein"(6\FAM,"with"excitation"wavelength"of"495nm"and"emission"wavelength"of"
520nm)"at"the"5’end."
All"titration"curves"were"obtained"varying"the"enzyme’s"concentrations"(from"0"to"20µM)"and"
with"a"constant"concentration"of"the"RNA"probe,"at"50nM."The"buffer"used"for"the"assay"was"
constituted"of"Tris"(pH"7.5)"25mM,"DTT"2mM"and"MgCl2"2mM"in"water."For"assay"validation,"
titration"curves"were"also"performed"with"the"two"enzymes"and"RNA"probe"in"the"presence"of"
ATP" 2mM" or" AMPPNP" 2mM." In" more" detail," for" DENV3" NS3hel," twelve" concentrations" of"
protein" (from"10µM"to"0nM,"with"2X"dilution" factor" for" the"enzyme)"were" tested"with"RNA"
and"eight"of" them"(from"10µM"to"0nM,"with"4X"dilution" factor" for" the"enzyme)"were"tested"
also" with" the" addition" of" ATP" (2mM)." For" DENV4" NS3hel," fifteen" concentrations" of" protein"
(from" 20µM" to" 0nM,"with" 2X" dilution" factor" for" the" enzyme)"were" tested"with" RNA,"whilst"
eight"of"them"(from"10µM"to"0nM,"with"4X"dilution"factor"for"the"enzyme)"were"tested"with"
the"addition"of"ATP"(2mM)"or"AMPPNP"(2mM)."
The"possible" interference"of"DMSO" in" the"assay"was"also"assessed" for"both"proteins." In" this"
case,"the"wells"were"prepared"with"a"constant"concentration"of"protein"(10µM)"and"the"RNA"
probe"(50nM)"and"different"DMSO"concentrations:"0%,"1%,"2%,"3%,"4%,"5%"and"10%."
Data"analysis"was"performed"and"the"RNA"probe"dissociation"constant"(Kd)"was"calculated" in"
all"the"tested"conditions.""
The"assay" calibration"was"performed" in"Greiner"96"half" area"wells" and" for" each"well" a" total"
volume"of"100µL"was"prepared."
"
COMPOUND.SCREENING.
"
Compound" screening"was" performed" on" both" helicase" serotypes" in" the" same" buffer" of" the"
assay"calibration"in"Greiner"384"wells"and"for"each"well"a"total"volume"of"20µL"was"prepared."
Constant"protein"and"RNA"probe"concentrations"(of"40nM"and"50nM"respectively)"were"used;"
while"all"compounds"were"tested"at"eight"concentrations"with"2X"dilution,"starting"from"1mM"
or" from" the"maximum" concentration" possible." Compound" dilutions" were" done" in" DMSO" in"
order" to" have" the" same" DMSO" content" (5%)" in" all" the" wells." AMPPNP"was" included" in" the"
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experiment" as" a" negative" control." Blanks" with" all" compound" concentrations" and" the" RNA"
probe" in" buffer" were" also" prepared" in" order" to" exclude" background" noise." The" test" was"
repeated"in"duplicate"for"selected"molecules."
"
"
"
"
"
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4.1.INTRODUCTION.
"
NS3'HELICASE'MECHANISM'OF'TRANSLOCATION'
"
NS3hel" involvement" in"essential"steps"of"the"viral"RNA"processing," including"RNA"unwinding,"
NTP" binding" and" hydrolysis," RNA" translocation" and" RNA" triphosphatase" activity,"makes" this"
protein"an"attractive"antiviral"drug"target.[1\6]"Indeed,"the"knowledge"on"DENV"NS3"helicase"is"
increasing"and" some"potential" enzyme" inhibitors" that"putatively" target" the"RNA"binding" site"
have"started"to"appear"in"literature.[7\9]"Deeper"insights"about"this"protein"can"be"found"in"the"
NS3&HELICASE&AS&A&DRUG&TARGET"section"of"this"thesis."
The" unwinding" function" of" this" enzyme" occurs" in" a" NTP\dependent" manner," involving" the"
protein"translocation"along"the"nucleic"acid."The"direction"of"the"movement"along"the"nucleic"
acid"has"been"explored"for"several"DNA"and"RNA"helicases"and"a"3’\5’"directionality"was"found"
for" helicases," belonging" to" superfamily" 2" (SF2).[10,11]" The" molecular" mechanism" behind" the"
translocation"activity"of"the"enzyme"has"been"described"for"the"hepatitis"C"virus"(HCV)"NS3hel,"
which" belongs" to" SF2" as" well" as" for" the" DENV" helicase.[12,13]" Two" crystal" structure" series"
suggested" that" the"helicase" translocation" is"driven"by" the"chemical"energy"of"ATP"hydrolysis"
and"that"it"occurs"mainly"through"the"rotation"of"domain"2"(D2)"that"produces"a"“scissors\like”"
movement" that" prompts" a" “ratchet”" translocation" pattern." In" the" absence" of" the" natural"
ligand,"the"NTP"binding"site"is"open"and"5"nucleotides"can"be"accommodated"in"the"RNA"cleft."
Upon"NTP"binding,"D2"rotates"towards"domain"1"(D1),"closing"the"NTP"cleft"and"reducing"the"
RNA"pocket"size."In"this"stage,"changes"in"D1"interactions"with"the"nucleic"acid"strand"causes"
the"exit"of"the"3’"nucleotide"from"the"binding"pocket,"with"only"4"nucleotides"remaining"in"the"
cleft." NTP" hydrolysis" products" are" then" released" through" the" rotation" of" D2" away" from"D1."
During"NTP"cleft"opening,"D2"interactions"with"RNA"shift"and"allow"the"entrance"in"the"nucleic"
acid"pocket"of"a"novel"nucleotide"at"the"5’"end"of"the"RNA,"bringing"back"the"number"of"bound"
nucleotides" to" 5." Thus," according" to" this" model," the" hydrolysis" of" one" molecule" of" NTP"
corresponds" to" the" helicase" movement" of" one" nucleotide" along" the" viral" genome.[11\13]"
Unfortunately,"the"same"type"of"structural"investigation"could"not"give"exhaustive"insights"for"
DENV" NS3hel," probably" due" to" the" crystallographic" conditions.[14,15]" A" published" molecular"
dynamics"(MD)"study"suggested"that"there" is"an"analogy"between"dengue"virus"and"the"HCV"
helicases"as"a"similar"dynamism"could"be"observed"for"the"helicase"alone"or" in"complex"with"
ATP.[16]"As" these"molecular" systems"did"not" include" the"RNA" strand," the" simulations"did"not"
explain" the" DENV" NS3hel" translocation" mechanism" for" this" complex." Consequently," the"
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mechanism" of" translocation" of" DENV" NS3hel" along" the" RNA" remain" elusive" to" date," in"
particular"the"reasons"why"it"occurs"in"a"3’\5’"direction."
"
AIMS'AND'OBJECTIVES'
"
Being"highly"involved"in"the"RNA"replication"cycle,"NS3hel"inhibition"would"lead"to"the"arrest"
of" DENV" infection.[17]" Although" knowledge" on" NS3hel" is" increasing" and" inhibitors" start" to"
appear"in"the"literature,"the"development"of"compounds"that"apply"any"of"these"strategies"has"
been" challenging," as" the" real" mechanism" of" action" of" the" helicase" is" not" yet" fully"
understood.[17,7\9]"
As"this"important"knowledge"could"aid"structure\based"drug"design"efforts,"this"study"aimed"at"
obtaining" a"more" detailed" understanding" of" the" protein" activity," using"molecular"modelling"
techniques"that"is"believed"to"have"never"been"applied"before"to"DENV"NS3hel."As"a"dynamic"
process"was"investigated,"the"approaches"used"were"based"on"MD."In"addition"to"classical"MD"
(cMD)"simulations"of"systems"involving"DENV"NS3hel,"accelerated"MD"(aMD)"simulations"were"
applied" as" well" in" order" to" improve" the" exploration" of" the" system" energy" surface.[18\20]" As"
molecular"processes"that"involve"large"protein"molecules"usually"involve"collective"changes"in"
conformations,"the"use"of"powerful"statistical"methods"such"as"Principal"Component"Analysis"
(PCA)" was" applied" as" it" aids" the" exploration" of" collective" low\frequency" motions" of"
biomolecules.[21,22]"MD"trajectories"were"therefore"used"to"extract"linear"correlated"vibrational"
modes" of" group" of" atoms." The" in" silico" thermodynamic" study" of" the" protein\nucleic" acid"
recognition"has"been"of" considerable" interest" in" recent"years," as" these" types"of" interactions"
are" very" common.[23,24]" The" evaluation" of" free" energy," in" particular," allowed" not" only" to"
understand"processes"at"the"atomic"level"and"how"they"proceed,"but"also"to"probe"states"that"
are" not" experimentally" accessible.[25]" Several" studies" on" molecular" systems" reported" in" the"
literature" have" demonstrated" a" good" agreement" between" free" energy" calculations" and"
experimental"values,"giving"mechanistic"insights"of"chemical"and"biochemical"phenomena"and"
sometimes"being"successfully"predictive.[26,27]"As"the"aim"of"this"study"was"to"understand"the"
3’\5’" directionality" also" at" a"molecular" level," the"MD" trajectories"were"also"used" for"binding"
energy" estimation"with"MMGBSA[28\35]" (molecular"mechanics"Generalised"Born" surface" area)"
methodologies." A" description" of" this" technique" is" reported" in" APPENDIX& 2" in" the" AMBER&
chapter."
Classical"and"accelerated"MD"approaches"were"applied"to"two"crystal"structures"representing"
the" DENV" NS3hel\RNA" complex" in" presence" and" in" absence" of" a" bound" nucleoside"
triphosphate" (NTP)." The" trajectory" analysis," including" visual" inspection," PCA" and" MMGBSA"
calculations," allowed" the" identification"of" dynamic" features" of"DENV"NS3hel" that" could" give"
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interesting" hints" on" the" mechanism" and" rationale" behind" the" translocation" of" the" protein"
along"RNA"at" the"molecular" level," in"particular"of" the"3’\5’"directionality."Here," the"obtained"
results" are" presented" and" discussed," as" well" as" a" proposed" hypothesis" on" the" possible"
mechanism"of"DENV"helicase"movements"along"the"nucleic"acid."
"
"
"
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4.2.RESULTS.AND.DISCUSSION.
"
CLASSICAL'MOLECULAR'DYNAMICS'SIMULATIONS'
"
This"study"was"applied"to"the"two"crystal"structures"of"the"DENV"NS3hel\RNA"complex"in"the"
presence" and" in" the" absence" of" a" NTP" bound" to" the" protein." The" PDB" structures" for" these"
systems" belonged" to" the" same" crystallographic" series" and" their" IDs" were" 2JLV" and" 2JLU"
respectively.[15]" The" RNA" fragment" used" was" of" 5" nucleotides" with" the" same" sequence" (5’\
AGACU\3’)" for" both" molecular" systems." Following" system" preparation," three" 40ns" MD"
simulations" were" performed" for" each" molecular" system" with" the" GROMACS" program," as"
described" in" the"METHODS" chapter," with" the" aim" of" improving" the" conformational" space"
exploration"respect"to"a"single"120ns"simulation.""
All" the"MD" simulations" were"monitored" with" backbone" RMSD" and" total" energy" fluctuation"
evaluation." Figure" 4.1" shows" an" example" of" total" energy" (panel" A)" and" backbone" RMSD"
monitoring" (panel" B)," taken" from" one" of" the" MD" simulations." From" this" analysis" the" MD"
duration"appeared" to"be" appropriate" and" the"molecular" systems" showed" to"be"equilibrated"
from"early"stages"of"the"MD"simulations.[26]""
"
" "
"""""""A" """"""B"
Figure'4.1..Example.of.total.energy.and.backbone.RMSD.monitoring...
Examples"of"MD"simulations"RMSD"and"total"energy"analysis..A).Time.evolution.of.the.system.total.energy..This"
example"is"from"a"NS3hel\RNA"complex"without"ATP..B).RMSD.time.variations.of.the.protein.backbone."This"
example"is"from"a"NS3hel\RNA\ATP"complex..
Residue" RMSD" fluctuations" (RMSF)"were" also" computed" on"MD" trajectories." All" simulations"
had" a" similar" residue" RMSF" pattern" with" no" significant" differences" between" the" molecular"
systems"with"or"without"ATP,"as"shown"in"panel"A"of"Figure"4.2."This"is"consistent"with"the"fact"
that"no"significant"differences"between"the"B\factors"of"the"original"PDB"structures"(panel"B"of"
Figure"4.2)"can"be"detected"by"comparison."The"highest"RMSF"values"calculated"from"the"MD"
simulations" were" recorded" in" particular" for" residues" 168\172," belonging" to" the" helicase\
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protease"linker,"which,"due"to"the"absence"of"the"protease"portion"of"NS3,"was"very"flexible."
Additional" high" RMSF" values" were" mainly" recorded" for" other" solvent" exposed" residues."
Comparing"the"charts"in"panel"A"of"Figure"4.2"with"the"original"PDB"B\factors"in"panel"B"of"the"
same" figure," it" is"possible" to"see" that" the"high"RMSF"residues"correspond" to"protein" regions"
with" high" B\factors," indicating" that" RMSF" patterns" and" simulated" protein" vibration" are"
compatible"with"experimental"data."
"
"
A"
"
B"
Figure'4.2..Residue.RMSF.and.PDB.BFfactors.""
A).Residue.RMSF."The"RMSF"values"for"each"residue"calculated"from"all"the"MD"simulations"are"plotted"here."The"
trajectories"involving"the"NS3hel\RNA\ATP"and"the"NS3hel\RNA"complexes"are"indicated"with"their"names"in"the"
legend"and"the"MD"simulations"are"specified"with"numbers"from"1"to"3."B).PDB.BFfactors."The"atom"B\factors"of"the"
original"PDB"used"for"the"two"molecular"systems"(NS3hel\RNA\ATP"and"NS3hel\RNA"complexes)"are"presented"
here."Data"was"taken"from"PDB"ID"2JLV"and"2JLU"for"the"NS3hel\RNA\ATP"and"NS3hel\RNA"systems"respectively."
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LARGE.SCALE.CONFORMATIONAL.CHANGES..
"
The"MD" trajectories" were" observed" in" order" to" assess" the" influence" of" ATP" on" the" overall"
enzyme" movements," but" the" visual" inspection" of" the" trajectories" failed" to" highlight" major"
protein" movement" differences" between" the" two" molecular" systems" nor" the" “ratchet\like”"
behaviour"previously"reported"in"literature.[16]"
Low" frequency" collective" movements" of" large" molecules" are" often" associated" with" large"
molecule" function." However," they" are" difficult" to" detect" through" simple" visual" inspection."
Consequently," for" a" better" understanding" of" relative" domain" movements," Principal"
Component"Analysis"(PCA)"was"applied"to"all"the"trajectories.[21]"PCA"is"a"statistical"tool"that,"if"
applied" to" a" MD" trajectory," can" be" used" to" separate" the" modes" in" the" movement" of" the"
molecule"and"to" identify"the"major"collective"fluctuations"of"a"protein."This"method"is"based"
on"the"construction"of"a"covariance"matrix"of"Cartesian"coordinates,"which"diagonalisation"is"
used" to" obtain" eigenvectors" and" eigenvalues." The" first" are" the" vectorial" description" of" the"
fluctuation,"while"the"second"are"the"representation"of"the"contribution"of"the"eigenvector"to"
the"total"motion."Eigenvectors,"or"principal"components"(PC),"are"usually"sorted"according"to"
their" eigenvalues" and" it" was" observed" that" the" modes" that" contribute" most" to" the" total"
movement" are" also" representative" of" the" slowest" dynamical" transitions," usually" associated"
with"protein"function.[21,22]""
PCA"was"computed"on"all"RNA"atoms,"while"only"Cα"atoms"were"considered"for"the"protein,"in"
order" to" highlight" major" protein" movements" and" ignore" artificial" apparent" correlations"
between" slow" side\chain" fluctuations" and" backbone" motions." The" calculated" eigenvectors"
were"in"descending"order"of"contribution"and"for"all"the"simulations"the"first"10"modes"were"
found"to"represent"between"56.8%"and"71.7%"of"the"total"system"motion,"as"shown"in"Table"
4.1."Figure"4.3"shows"an"example"of"how"the"percentage"associated"to"these"10"eigenvectors"
decreases" (panel" A)" and" how" the" cumulative" percentage" grows" (panel" B)" according" to"
eigenvector"number."
"
Table'4.1..Percentage.of.total.motion.described.by.the.first.10.eigenvectors.for.all.MD.simulations..
First.10.eigenvectors.of.simulation. Percentage.of.total.motion.
N
S3
he
lF
RN
A.
co
m
pl
ex
. MD1. 58.7%"
MD2. 71.7%"
MD3. 67.7%"
N
S3
he
lF
RN
AF
AT
P.
co
m
pl
ex
. MD1. 68.5%"
MD2. 56.8%"
MD3. 63.7%"
The"molecular"system"is"reported"in"the"first"column"and"the"three"MD"
simulations"for"each"one"of"them"is"indicated"by"MD,"followed"by"a"number."
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" "
""""""""""A" """"""""B"
Figure'4.3..First.10.eigenvectors.contribution.of.motion.""
The"data"for"this"figure"is"from"the"third"simulation"of"the"NS3hel\RNA\ATP"molecular"complex."For"a"better"
understanding"of"the"charts,"the"percentage"related"to"some"eigenvectors"is"reported."A).Example.of.contribution.
percentage.variation..B).Example.of.cumulative.percentage.variation..
"
Eigenvectors"were"then"used"singularly"and"collectively"for"trajectory"filtering"and"porcupine"
plots" construction." In" all" of" the" simulations" fluctuations" were" not" involving" major" domains"
rearrangement," particularly" in" the" NS3hel\RNA\ATP" molecular" system." Furthermore," an"
important"contribution"was"given"by"the"more"flexible"RNA"3’"and"5’"ends,"particularly"evident"
in" those" simulations" that" showed" peculiar" 3’" or" 5’" patterns," described" in" the" SMALL&
CONFORMATIONAL& CHANGES" chapter." Protein"motions" with" high" contribution" were" always"
associated"to"a"fluctuation"of"RNA"binding"site"dimensions,"with"a"general"trend"of"domains"1"
(D1)"and"2"(D2)"to"get"closer"to"domain"3"(D3),"representing"between"17.6%"and"37.4%"of"the"
total" motion" according" to" the" simulation." Other" motions" regarding" independent" domain"
movements" particularly" for" D2"which" has" been" shown" to" be"more" flexible" than" the" others,"
consistent" with" the" translocation"mechanism" described" for" HCV" helicase.[12,13]" Never" in" the"
first" five" eigenvectors" and" very" few" of" the" first" modes" were" similar" to" the" “scissors\like”"
pattern" described" for" HCV" helicase" and" they" always" represented" vibrations" with" low"
contributions"to"the"whole"motion"(never"higher"than"2.8%)."These"modes"involved"the"more"
external" portions" of" the" domains" and" never"with" the" D1" and" D2" regions" that" interact"with"
RNA." Figure" 4.4" shows" an" example" of" a" porcupine" plot" in" which" the"main"movements" are"
associated"with" the" protease\helicase" linker" region" and" vibration" that" causes" the" change" in"
RNA"binding"site"size.""
"
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Figure'4.4..Example.of.porcupine.plot.""
The"porcupine"plot"of"the"second"eigenvector"(corresponding"to"8.6%"of"motion)"of"a"MD"simulation"of"the"NS3hel\
RNA"molecular"system."The"front"and"lateral"view"are"reported"on"the"left"and"on"the"right"respectively."The"
protein"is"shown"with"a"red"ribbon"and"the"RNA"is"represented"as"orange"cartoon."The"vectors"associated"to"this"
mode"are"shown"as"blue"needles."
The" variation" with" time" of" the" distance" between" key" residues" alpha\carbons" (Cα)" was" also"
computed"on"all"simulations."Table"4.2"reports"the"selected"amino"acid"pairs"and"the"relative"
domain"movements"that"they"were"selected"for,"while"Figure"4.5"shows"the"position"of"these"
residues" in" the" protein." In" both" cases," domain" 1" is" indicated" by" D1," domain" 2" by" D2" and"
domain"3"by"D3." The" searched"patterns" in" residue"pair" distances"were" the"ones" that"would"
confirm"a"domain"2"lateral"rotation"consistent"with"previously"published"observations.[16]""
"
Table'4.2..Residue.pairs.selected.for.relative.domain.movement.monitoring..
DOMAIN.RELATIVE.
MOVEMENT. RESIDUES.
D1.–.D2.
Thr224"–"Ile410"
Glu285"–"Met413"
Lys201"–"Asn416"
D1.–.D3.
Arg225"–"Asp541"
Pro245"–"Arg538"
Thr267"–"Arg538"
D2.–.D3.
Ile365"–"Asp603"
Lys366"–"Pro604"
Arg387"–"Arg599"
Arg387"–"Asp541"D1:!domain!1;!D2:!domain!2;!D3:!domain!3.!
"
90°"
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Figure'4.5..Position.within.NS3hel.of.the.residue.pairs.for.domain.movements.monitoring...
Domains"1,"2"and"3"are"indicated"by"D1,"D2"and"D3"respectively."The"selected"residues"are"indicated"and"differently"
coloured."Amino"acids"selected"for"the"D1\D2"relative"movements"are"in"blue,"the"ones"for"the"D1\D3"relative"
movements"are"in"red"and"the"ones"for"the"D2\D3"relative"movements"are"in"yellow."Asp541"is"coloured"in"orange"
because"it"was"selected"for"both"D1\D3"and"D2\D3"relative"fluctuations."
In"particular,"a"HCV\like"NTP"binding"site"closure"would"be"associated"with"an"increase"of"the"
distance" between" residues" of" D2" and" D3," simultaneous" to" a" decrease" in" distance" between"
residues"from"D1"and"D2."Opposite"patterns"would"be"expected"in"the"case"of"NTP"binding"site"
opening."Generally,"small"distance"variations"could"be"observed"for"all"residue"pairs,"indicating"
small" overall" changes" in" protein" conformation." Within" these" small" fluctuations," distance"
oscillations" between"0.25nm"and"0.70" could" be"observed" for" Ile365"–"Asp603" and" Lys366"–"
Pro604" pairs" (representative" of" the" D2\D3" relative" motion)" in" both" molecular" systems."
Although"these"distance"fluctuations"could"look"similar"to"what"has"been"previously"published,"
they"were" never" accompanied" by" opposite" direction" distance" variation" of" the"D1\D2" amino"
acids"pairs"(e.g."Lys201"–"Asn416),"excluding"the"presence"of"a"“scissors\like”"movement"of"D2"
in" these"MD"simulations." This"was" in" agreement"with" the"PCA" results" that" showed" that" this"
pattern"was"not"an"important"component"of"the"total"motion."Furthermore,"the"RNA"binding"
site" dimension" fluctuations" and" domain" independent" movements" observed" in" the" filtered"
trajectories,"could"be"associated"with"some"residue"pairs"fluctuations,"as"patterns"D1\D3"and"
D2\D3" distance" patterns" were" often" similar." An" example" of" these" distance" fluctuations" is"
reported" in" Figure" 4.6." Here," the" small" distance" fluctuation" patterns" between" the" Cα" of"
residues"belonging"to"Ile365\Asp603"(for"D2\D3"relative"movements)"and"Arg225\Asp541"(for"
D1\D3" relative" movements)" pairs" are" similar," while" the" ones" of" Lys201\Asn416" (for" D1\D2"
relative"movements)"are"not."This"could"be"correlated"with"the"fluctuation"of"RNA"binding"site"
size"variation"described"above."
"
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Figure'4.6..Residues.Cα.distance.patterns.""
The"distance"between"Cα"atoms"of"one"residue"pair"for"each"domain"relative"movement"is"reported"here."Ile365\
Asp603,"Arg225\Asp541"and"Lys201\Asn416"amino"acids"pairs"were"chosen"to"study"D2\D3,"D1\D3"and"D1\D2"
relative"movement"respectively.""
"
NS3HEL.COMPLEXES.WITHOUT.RNA.
"
One"hypothesis"that"could"explain"the"lack"of"“scissors\like”"movements"is"that"the"presence"
of"the"RNA"in"the"system"stabilises"and"constrains"the"protein"movements."In"order"to"verify"
this"theory,"new"MD"simulations"were"performed"following"the"same"procedure"of"the"already"
described" simulations." In" this" case" triplicate" MD" simulations" were" performed" for" two"
molecular"systems" in"which"the"helicase"was"not"bound"to"the"nucleic"acid"were"considered"
for"the"new"MD"simulations:"one"with"the"apo"form"of"the"protein"and"one"with"the"protein"in"
complex"an"ATP"molecule,"with"PDB"IDs"2JLQ"and"2JLR"respectively.""
Already" from" visual" inspection," it" appeared" that" the" protein" was"more" flexible" and" free" to"
explore"the"conformational"space,"in"particular"in"the"case"of"the"apo"protein,"indicating"that"
natural"substrate"binding"(either"RNA"or"ATP)"stabilises"the"molecular"system."Similarly"to"the"
previous"molecular" systems,"also" in" the"cases"of"NS3hel"alone"or" in"complex"with"RNA"clear"
“scissors\like”"patterns"could"not"be"directly"observed,"while"the"variation"of"the"RNA"binding"
site" size"was" significant." This"was" confirmed"by"PCA," as"movements" associated" to"RNA" cleft"
size"variations"were"often"described"by"the"first"eigenvector"(representing"between"18.8%"and"
31.9%"of"motion).""
The"pairwise" residue"Cα"distance" investigation" confirmed"a" general" domain"movement," less"
important" in" the" NS3hel\ATP" system" as" the" distances" fluctuated" generally" less" in" this" case."
However," the"D1\D2"and" the"D2\D3" fluctuations"were"neither"contemporary"nor" inverted" in"
direction."This"suggests"that"in"the"presence"of"the"ATP"molecule,"the"helicase"is"more"stable"
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in"the"conformation"that"is"more"convenient"for"molecule"binding,"while"in"the"absence"of"this"
molecule,"the"protein"explores"more"the"available"conformational"space.""
The" lack" of" consistency" of" the" distances" variations" and" of" the" observation" of" the" RNA" cleft"
opening"and"closing"movement,"did"not"confirm"that"the"helicase," in"the"absence"of" ligands,"
gives"a"“scissors\like”"conformational"change"that"resembles"the"one"observed"in"the"case"of"
the"HCV"helicase.[12,13]"Therefore,"it"was"concluded"that"the"lack"of"the"“scissors\like”"pattern"
in" the"MDs" of" the" helicase" complexes" with" RNA" were" not" related" to" a" dynamic" constraint"
caused"by"this"substrate."
"
BINDING.FREE.ENERGY.CALCULATIONS"
"
The" average" interaction" energies" and" their" components" were" calculated" for" each" MD,"
following" the" procedure" reported" in" the"METHODS" chapter." A"microscopic" system" explores"
many" states" at" a" given" temperature" and" these" are" reflected" in" thermodynamic" properties."
Consequently," free" energy" calculations" need" to" sample" as" extensively" as" possible" the"
configurations"at"that"temperature."One"of"the"most"common"approaches"to"do"this"is"based"
on"MD"simulations"from"which"snapshots"are"saved"and"used"for"system"probing.[36]"As"in"all"
MD" the" system" was" well" equilibrated" from" the" early" stages" of" the" simulation," 1906"
representative" snapshots" for" the" binding" free" energy" calculations" were" taken" from" each"
trajectory" and" each" one" of" them" was" used" for" free" binding" energy" estimation," merging"
molecular"mechanics"with"an" implicit" solvent"model" through"MMGBSA"methodology.[36,37]" In"
molecular"complexes"treated"with"implicit"solvents,"molecule"entropy"is"defined"through"the"
translational" and" rotational" freedom" (vibrational" entropy)" and" its" possible" low" energy"
configurations"(conformational"entropy)."It"has"been"shown"that"upon"ligand\protein"binding,"
the"overall" loss"of" ligand"entropy"and" the"consequent" increase"of" free"energy"of" the"system"
can" make" a" big" contribution," especially" in" high\affinity" complex" systems.[38]" Consequently,"
entropy" can" be" an" important" contribution" to" binding" energy." However," with" MMGBSA"
methods," the" largest" standard" deviations" and" errors" have" been" related" to" the" uncertainty"
calculation"of"this"energy"component.[22,39]"From"these"considerations"and"since" in"this"study"
the"aim"was"to"compare"the"behaviour"of"different"molecular"systems"but"involving"the"same"
complex"of" interest"counterparts," it"was"decided"to"estimate"the"free"energy"values" ignoring"
the"entropic"term"of"Equation"A2.13"in"APPENDIX&2."
For"all"the"MD"simulations,"the"obtained"binding"free"energy"profile"was"overall"constant"for"
the" duration" of" the" simulation," as" shown" in" the" examples" in" Figure" 4.7." Here" the" results"
obtained" for" two" simulations" of" the" NS3hel\RNA" and" NS3hel\RNA\ATP" complexes" are"
reported.""
"
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Figure'4.7..Time.variation.of.binding.free.energy.values...
One"example"of"time"variation"of"the"NS3hel\RNA"binding"free"energy"is"reported"here"for"each"molecular"system."
In"both"cases,"the"values"obtained"for"the"NS3hel\RNA"and"NS3hel\RNA\ATP"complexes"are"indicated"with"“NS3hel\
RNA”"(light"blue"line)"and"“NS3hel\RNA\ATP”"(light"red"line)"respectively."Averages"are"also"reported"as"“Average"
NS3hel\RNA”"(dark"blue"line)"and"“Average"NS3hel\RNA\ATP”"(dark"red"line)."In"these"examples,"the"averages"
values"were"\113.50"kcal/mol"and"\122.69"kcal/mol"for"NS3hel\RNA"and"NS3hel\RNA\ATP"systems"respectively."
"
Table'4.3..Binding.free.energy.components.of.the.DENV.NS3helFRNA.interaction.in.absence.of.ATP..
" MD.1. . MD.2. . MD.3. . Average.
Contribution. Value"(kcal/mol)" " Std" "
Value"
(kcal/mol)" " Std" "
Value"
(kcal/mol)" " Std" "
Value"
(kcal/mol)"
∆Eint" 0.68" " 0.22" " 0.68" " 0.22" " 0.68" " 0.22" " 0.68"
∆EvdW" \87.75" " 5.11" " \106.07" " 8.66" " \96.97" " 6.62" " \96.93"
∆ECoul" \776.06" " 42.90" " \769.20" " 40.86" " \766.28" " 36.31" " \770.51"
∆Egas" \863.12" " 43.48" " \874.59" " 39.41" " \862.56" " 37.48" " \866.76"
∆Gsol"" 749.62" " 40.01" " 735.45" " 38.13" " 731.71" " 32.35" " 738.93"
∆Gtot"" \113.50" " 6.78" " \139.14" " 9.41" " \130.85" " 8.30" " \127.83"
Values"for"all"three"MDs"are"reported,"as"well"as"the"overall"averages."The"three"simulations"are"indicated"with"
MD1,"MD2"and"MD3."Eint:"internal"energy;"EvdW:"van"der"Waals"energy;"ECoul:"Coulomb"energy;"∆Egas"="∆Eint"+"∆EvdW"
+"∆ECoul" ;"Gsolv:" solvation"energy"based"on"Generalised"Born"method;"∆Gtot:" total"binding" free"energy"calculated"
with"MMGBSA;"Std:"standard"deviation."
"
Table'4.4..Binding.free.energy.components.of.the.DENV.NS3helFRNA.interaction.in.presence.of.ATP..
" MD.1. . MD.2. . MD.3. . Average.
Contribution. Value"(kcal/mol)" " Std" "
Value"
(kcal/mol)" " Std" "
Value"
(kcal/mol)" " Std" "
Value"
(kcal/mol)"
∆Eint" 0.68" " 0.23" " 0.68" " 0.23" " 0.68" " 0.22" " 0.68"
∆EvdW" \102.21" " 6.40" " \98.19" " 5.16" " \95.44" " 5.62" " \98.61"
∆ECoul" \816.17" " 36.08" " \878.09" " 55.05" " \809.11" " 43.94" " \834.46"
∆Egas" \917.70" " 37.37" " \975.59" " 56.40" " \903.87" " 44.82" " \932.39"
∆Gsol"" 782.56" " 32.67" " 845.17" " 51.75" " 781.19" " 40.17" " 802.97"
∆Gtot"" \135.14" " 8.72" " \130.42" " 8.46" " \122.69" " 8.15" " \129.41"
Values"for"all"three"MDs"are"reported,"as"well"as"the"overall"averages."The"three"simulations"are"indicated"with"
MD1,"MD2"and"MD3."Eint:"internal"energy;"EvdW:"van"der"Waals"energy;"ECoul:"Coulomb"energy;"∆Egas"="∆Eint"+"∆EvdW"
+"∆ECoul" ;"Gsolv:" solvation"energy"based"on"Generalised"Born"method;"∆Gtot:" total"binding" free"energy"calculated"
with"MMGBSA;"Std:"standard"deviation."
"
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In" line"with"all" the"data"discussed"above," the" interaction"energy"profile"confirmed"that" in"all"
the"MDs" the"molecular" systems"were"well" equilibrated" and" stable." From" the" comparison"of"
the"results"obtained"for"the"two"molecular"systems,"the"presence"or"absence"of"ATP"does"not"
significantly" affect" the" interaction" energy" values," in" line" with" the" RMSD" and" total" energy"
profiles." This" is" confirmed" by" the" average" values" of" the" total" binding" energy" and" of" its"
components"over"whole"trajectories"(Tables"4.3"and"4.4)."
The" five" nucleotides" and" residues" in" proximity" of" the" RNA" strand"were" selected" for" a"more"
detailed"binding"free"energy"evaluation"with"the"MMGBSA"method."The"selected"amino"acids"
were" the" ones" within" the" ranges:" Ala222\Val227;" Tyr242\Ala246;" Met260\Leu269;" His287\
Cys292;" Val362\Ala367;" Gln384\Thr389;" Thr407\Ser411;" Cys428\Val432;" Ile442\Ala444;"
Asp484\Ala486;"Met537\Pro543;"Ala598\Leu607."The"interaction"energy"was"decomposed"per"
residues"and"the"contribution"of"each"one"of"the"computed"amino"acid"was"obtained"from"the"
same" representative" snapshots" used" for" the" total" binding" energy" calculations," following" the"
procedure"described"in"the"METHODS"chapter.""
Figure"4.8"shows"the"average"values"of"the"interaction"energy"contribution"for"all"the"analysed"
residues," as" well" as" RNA" nucleotides." The" residues" that" give" higher" contribution" to" RNA"
binding"are"Arg225"and"Arg387"in"particular"and"also"Thr224,"Thr244,"Ser364,"Ile365,"Ser386,"
Thr408," Ile410" and" Arg599." Other" residues" with" lower," but" still" significant," energy"
contributions"are:"Pro245,"Cys261,"Ala263,"Thr264,"Phe288,"Asp290,"Lys388,"Leu429,"Pro431"
and"Leu443"and"Arg538."Not"surprisingly,"most"of"these"residues"correspond"to"the"interacting"
residues"reported"in"the"crystallographic"data"(see"Figure"3.5"in"the"NS3&HELICASE&AS&A&DRUG&
TARGET" section)"and"they"belong"to"domains"1"and"2."This"complies"with"the"fact"that"most"
contacts"that"the"enzyme"has"with"the"RNA"are"at"the"level"of"the"sugar\phosphate"backbone"
of"the"nucleic"acid.[15]"In"line"with"the"RMSD,"total"energy"and"total"binding"free"energy"data,"
also" the" residue" free" energy" contribution" displays" no" relevant" differences" between" the"
complexes"in"presence"or"absence"of"ATP."The"only"main"dissimilarity" is"Arg538,"but"this"can"
be" connected" to" a" different" initial" position" of" the" side" chain" of" the" residue" rather" than" to"
peculiar"binding"mechanism"at"this"level."
Interestingly,"residues"involved"in"hydrogen"bonds"with"the"RNA"2’OH"groups"and"considered"
to" be" responsible" for" DENV" NS3" helicase" specificity" for" RNA" (Pro223," Thr264," Pro363" and"
Asp409),"had"a"small"contribution"to"the"total"interaction"energy"(see"Figure"4.8).[5,15]"Counting"
the" hydrogen" bonds" between" these" amino" acids" and" the" correspondent" hydroxyl" groups"
showed"that"these"interactions"were"not"stable"in"time,"explaining"the"minor"contribution"to"
the" total" interaction" energy" of" these" amino" acids." However," this" does" not" exclude" the"
importance"of"these"contacts"in"RNA"preferentiality,"as"the"rapid"formation"and"disruption"of"
these"interactions"was"observed"throughout"the"simulations"and"could"be"important"in"nucleic"
acid"recognition"and"translocation"along"the"binding"pocket."
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"
!
Figure'4.8..Per.residue.binding.free.energy.decomposition.""
The"average"per"residue"binding"free"energy"values"are"reported"here."Data"was"obtained"by"averaging"the"results"
of"the"triplicate"MD"results,"for"each"molecular"system."Results"for"NS3hel\RNA\ATP"and"NS3hel\RNA"complexes"
are"indicated"as"“AVERAGE"NS3hel\RNA\ATP”"and"“AVERAGE"NS3hel\RNA”"respectively."The"residues"discussed"in"
the"text"are"indicated"here."
"
SMALL.CONFORMATIONAL.CHANGES.
"
In"addition"to"the"average"values,"the"analysis"of"the"time"variation"of"the"per"residue"binding"
free" energy" values" gave" useful" insights" into" change" in" conformations" of" small" residues," in"
particular" near" the" RNA" extremities." The" two" oligonucleotide" ends" (A1" and"U5)" themselves"
appeared" to" have" a" more" variable" interaction" energy" pattern," explaining" why" they" have" a"
lower" binding" free" energy" contribution" respect" to"G2," A3" and" C4" (see" Figure" 4.8)." This"was"
consistent" with" the" high" flexibility" of" 3’" and" 5’" nucleic" acid" ends" observed" with" visual"
inspection" and" principal" component" analysis." Both" nucleotides" were" very" flexible" in" all"MD"
simulations,"but" in"some"of" them"particular"movement"patterns"could"be"observed"at" the"5’"
and"3’"end."However,"no"correlation"with"the"presence"of"ATP"was"found."
In" three"trajectories" (two"from"the"complex"with"ATP"and"one" from"the"one"without)" it"was"
possible"to"observe"a"clear"rotation"of"A1,"prompting"the"G2"phosphate"to"move"away"from"
DENV" NS3hel" domain" 2" and" the" increase" of" the" nucleic" acid" strand" curvature." Major"
transitions"in"the"protein"are"accomplished"by"the"α1’"helix"and"the"loop"before"it"(Motif"IV),"
the"loop"between"β2A’"sheet"and"α2’"and"the"α3’"helix"and"the"loop"before"it"(Motif"V)."While"
the" latter"two"portions"of"DENV"NS3"helicase"followed"the"RNA"trend,"Motif" IV," in"particular"
Ile365," seemed" to" move" in" the" opposite" direction." This" increase" in" space" between" the"
molecular"partners"triggers"the"break"of"the"hydrogen"bond"between"Ile365"backbone"and"G2"
phosphate"as"the"distance"between"the"gap"between"the"Ile365"α\nitrogen"and"G2"phosphate"
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oxygen"grew"from"2.79Å"to"5.67Å,"negatively"affecting"the"binding"free"energy"contribution"of"
the" residue" (panel" B" of" Figure" 4.9)." The" hydrogen" bond" break" was" accompanied" by" the"
rotation"of"the"Ile365"side"chain"into"a"hydrophobic"site"given"by"GLn384,"Thr389,"Val406"and"
Val362"(panel"A"of"Figure"4.9).""
"
"
"
"A" """""""B"
Figure'4.9..Movement.pattern.around.RNA.5'.end...
A).MD.visualisation."The"shift"of"G2"phosphate"and"Ile365"side"chain"are"represented"here"by"superposition"of"two"
frames"of"the"trajectory"of"a"MD"simulation."The"ribbons"and"the"carbon"atoms"of"the"frame"at"the"beginning"of"the"
trajectory"are"in"orange,"while"the"ones"of"the"frame"taken"from"around"the"middle"of"the"simulation"are"in"green."
The"shifts"are"indicated"by"black"arrows."The"hydrogen"bond"between"Ile365"and"G2"phosphate"present"at"the"
beginning"of"the"simulation"is"shown"as"a"black"line."Discussed"residues"are"indicated."B).Time.variation.of.perF
residue.binding.free.energy."Data"for"Ile365"and"Leu443"are"described"as"an"example."Here,"the"Ile365"free"energy"
contribution"increases"upon"hydrogen"bond"break"in"the"first"2ns,"while"β\hairpin"residues"(exemplified"by"Leu443)"
remain"constant."
The" RNA" shift" exposed" the" A1" ribose" and" in" particular" its" 5’" hydroxyl" moiety" to" the" RNA"
binding"site"entrance,"suggesting"that"this"could"favour"the"entrance"of"a"novel"nucleotide"in"
the" cleft" and" therefore" be" important" in" 3’\5’" translocation"of" the" helicase" along" the" nucleic"
acid." Importantly," in" A1" rotation," its" base" did" not" move" from" its" position," blocked" by"
hydrophobic"contacts"mainly"between"the"A1"base"and"residues"Leu429,"Pro431"and"Leu443."
These" interactions" appeared" to" be" conserved" during" all" MD" simulations," explaining" the"
unchanging"interaction"energy"contribution"pattern"of"these"residues."On"this"base,"it"could"be"
hypothesised" that" these" hydrophobic" residues" play" a" key" role" in" impeding" NS3hel" to"
translocate"towards"the"RNA"3’"end"by"maintaining"in"place"the"base"of"the"nucleotide"in"the"
5’"end"of"the"binding"site."
Similarly"to"the"other"terminus,"the"3’"end"of"the"nucleic"acid"strand"was"flexible"in"all"the"MD"
simulations."However,"in"four"trajectories"(two"from"the"complex"with"ATP"and"two"from"that"
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without)"the"U5"nucleotide"base"moved"out"of"the"binding"site"and"interacted"with"domain"1."
Unlike" the" conformation" variations" described" for" the" 5’" RNA" end," U5" did" not" change"
conformation"always"in"the"same"way"and"the"protein"residues"were"more"static,"suggesting"
that" the" free" energy" contribution" of" the" amino" acids" varied" as" a" consequence" of" U5"
movement." Two"examples"of"how"different" the"U5"displacement" from" the"RNA"binding" site"
was" are" presented" in" Figure" 4.10" (panels" A" and" B)." The" shift" of"U5" from" the" RNA" cleft"was"
reversible" in" two"of" the" four" simulations," confirming" that" the"newly"established" interactions"
between" the"nucleotide"and" the"protein"were"neither" stable"nor"mechanistically" relevant" to"
explain"the"NS3hel"translocation"along"the"nucleic"acid."Nevertheless,"the"fact"that"the"3’"end"
nucleotide,"differently"to"the"one"in"the"5’"end,"was"flexible"and"free"to"exit"the"RNA"cleft," is"
relevant"and"supports"the"hypothesis"that"the"β\hairpin"residues"(Leu429,"Pro431"and"Leu443)"
have"an"important"role"in"the"3’\5’"directionality"of"NS3hel"translocation"mechanism."
"
" "
A" B"
Figure'4.10..Movement.pattern.around.RNA.3'.end...
The"two"panels"illustrate"how"different"and"unstable"the"3’"nucleotide"displacement"from"the"RNA"binding"site"
could"be."Each"panel"shows"the"superposition"of"three"frames"taken"from"the"same"MD"trajectory."Different"panels"
correspond"to"different"MD"simulations."In"both"panels,"the"protein"surface"is"in"grey"and"some"residues"are"
indicated"with"lines."The"carbon"atoms"of"the"initial"RNA"conformation"are"in"orange."An"intermediate"
conformation"is"shown"in"magenta"and"a"third"conformation"is"shown"in"cyan."
" "
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ACCALERATED'MOLECULAR'DYNAMICS'SIMULATIONS'
"
Despite" the" novel" insights" on" residue" changes" in" conformations" that" prompt" the" 3’\5’"
directionality"of"the"helicase"along"the"RNA,"no"major"protein"conformational"changes"could"
be"identified"and"the"role"of"ATP"could"not"be"assessed.""
Big" molecules," such" as" proteins" and" nucleic" acid," explore" their" conformational" space" by"
passing"from"one"local"energy"minimum"to"another,"crossing"energy"barriers,"and"this"requires"
timescales"of"milliseconds"to"seconds"or"even"longer,"according"to"the"molecular"system.[18,19]"
As"MD"simulations"require"considerable"calculation,"classical"molecular"dynamics"are"usually"
performed" in" a" nanosecond" timescale." If" insufficient" energy" is" supplied," the" conformational"
space"beyond"high"barriers" cannot"be"easily"explored," “trapping”" the"molecular" system" in"a"
local"minimum"for"periods"of" time" that"can"be" longer" than" the"simulation" itself."This"means"
that" nanosecond" time" frame" classical"MD" allows" the" exploration" of" the" free" energy" surface"
around"the" local"minimum,"usually"close"to"the" initial"conformation,"but" fails" in"the"study"of"
long"timescale"large"molecule"conformation"transitions"that"require"a"broader"sampling"of"the"
free"energy" surface.[18]"On" this"base," it"has"been"hypothesised" that" the"performed"40ns"MD"
simulations" failed" to"produce" insights" in" broader" protein" changes" in" conformations"because"
not"enough" simulation" time"was"given" to" the" systems" for" an"appropriate"exploration"of" the"
free" energy" surface." As" the" available" computational" power" was" not" enough" to" perform"
millisecond" time" scale" cMD," an" alternative" MD" approach" was" used:" accelerated" molecular"
dynamics"(aMD)."
Accelerated" molecular" dynamics" is" a" method" that" enhances" sampling" compared" to" cMD,"
without" increasing"the"necessary"simulation"time." In"the" last"decade"this"approach"has"been"
applied" in" several" studies," thanks" to" its" relatively" simple" application" that" does" not" alter" the"
approximated"shape"of"the"free"energy"landscape"of"the"system,"making"it"ideal"for"the"study"
of" large" scale" global" motions.[18,19,40\44]" It" is" a" powerful" tool" that" has" shown" to" be" able" to"
produce" consistent" results" with" millisecond" time" scale" cMD" simulations" in" conformational"
space"exploration.[20]""
The"method"reduces"the"amount"of"computational"time"spent"in"a" local"energy"minimum"by"
the"molecular" system"by"applying"a"bias"potential"ΔV(r)" to" the" real"potential"V(r)"only"when"
the"system"is"below"a"chosen"threshold"energy"E."Only"in"this"case"the"simulation"is"performed"
on" the" modified" potential" V*," while" the" true" potential" is" applied" in" the" case" of" an" energy"
greater" than" E." The" mathematical" form" of" the" potential" alteration" is" reported" in" Equation"
4.1.[19,40]" In" this"way," the" energy" barriers" near" the" local"minima" are" reduced," facilitating" the"
passage"from"a"local"minima"to"the"other"and"reducing"the"time"spent"in"the"minima"wells"by"
Section"4:"NS3HEL"MECHANISM"OF"TRANSLOCATION"ALONG"RNA" 4.2&RESULTS&AND&DISCUSSION"!
!158"
the" molecular" system." Figure" 4.11" shows" a" schematic" representation" of" the" described"
potential"modification." !∗ ! = ! ! ! ,! ! + ∆! ! ,!!!!!(!) ≥ !! ! < !""
Equation'4.1.'Calculation.of.the.modified.potential.V*(r).[40]""
V*(r):"modified"potential;"V(r):"real"potential;"ΔV(r):"bias"or"boost"potential;"E:"threshold"energy"
"
!
Figure'4.11..Schematic.representation.of.the.potential.modification...
The"real"potential"V(r)"is"modified"by"the"application"of"the"boost"potential"ΔV(r)"when"the"system"is"at"an"energy"
below"the"chosen"threshold"E,"as"explained"in"the"text."
If" E"or"ΔV(r)" are" too"high," the"minima"wells"will" not"be" sampled" sufficiently" and" in" extreme"
cases"might"also"disappear."In"the"opposite"case,"if"they"are"too"small"the"modified"potential"
will"be"too"similar"to"the"real"one"and"sampling"will"not"be"effective."Consequently,"the"choice"
of"E"and"ΔV(r)"are" important" for"a"correct"potential" smoothening.[18]"ΔV(r)" is"calculated"with"
Equation" 4.2" and" depends" on" two" factors:" E" and" a" tuning" parameter" α." Thus," the" needed"
parameters"to"set"aMD"simulations"are"E"and"α.[18,40]"
" ∆! ! = ! ! − !(!) !! + ! − !(!) "
Equation'4.2.'Calculation.of.the.boost.potential.ΔV(r).[40]""
ΔV(r):"bias"or"boost"potential;"E:"threshold"energy;"V(r):"real"potential;"α:"tuning"parameter.
These" equations" are" applied" to" the" dihedral" potential" of" a" molecular" system" because" the"
major" component" that" determines" protein" conformation" is" given" by" torsional" rotations."
However,"it"has"been"shown"that"if"explicit"solvent"is"used"in"a"simulation,"a"better"sampling"is"
obtained"if"a"boosting"potential"energy"is"applied"also"to"solvent"molecules"as"well"in"order"to"
avoid"the"slowing"down"of" large"scale"protein"movements"caused"by"diffusion"of"the"solvent"
around"the"large"molecule.[18,19,40]"For"this"reason,"also"a"potential"energy"bias"was"applied"in"
this"study,"using"a"so"called"“dual\boost”"a"MD"approach."
With"the"aim"of"revealing"insights"in"DENV"NS3hel"mechanism"of"translocation"along"the"RNA,"
the"method"was"applied"to"the"same"molecular"systems"used"previously:"the"NS3hel\RNA"and"
the"NS3hel\RNA\ATP"complexes,"taken"from"the"same"PDB"IDs"(2JLU"and"2JLV"respectively).[15]"
From"previous"published"work,"it"was"seen"that"optimal"E"and"α"parameters"can"be"calculated"
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from"residue"and"atom"numbers"and" from" the"average"potential" and"dihedral"energies" that"
can"be"obtained"from"cMD"simulations.[18,19,40]"Thus,"two"40ns"cMDs"were"performed,"one"for"
each" molecular" system," following" the" procedure" reported" in" the" METHODS" chapter." The"
simulations"were" repeated"because"at" the" time"of" the" study" it"was"not"possible" to"perform"
aMD" with" GROMACS," the" software" used" for" the" cMD" simulations" presented" above."
Consequently," another" MD" program" (AMBER)" was" used" instead." The" average" dihedral" and"
potential"energies"obtained"from"the"40ns"cMD"simulations"were"used" in"Equations"4.3,"4.4,"
4.5"and"4.6"reported"in"the"METHODS"chapter"for"the"calculation"of"the"E"and"α"parameters"
for" the" two" boost" potentials." Table" 4.5" reports" the" average" dihedral" (DIHED)" and" potential"
(POT)"energies"obtained"from"the"cMD"simulations"and"the"calculated"E"and"α"parameters"for"
the"dihedral"(Edihed"and"αdihed)"and"the"potential"(Epot"and"αpot)"biases."Numbers"of"atoms"in"the"
system"and"of"protein"residues"are"also"stated."All"values"are"reported"for"the"NS3hel\RNA"and"
NS3hel\RNA\ATP"complexes."ATP,"where"present,"was"not"considered"in"the"residue"count"as"
the"changes"in"conformations"of" interest"regarded"the"protein"and"the"RNA"strand"only."The"
calculated"parameters"were"then"used"for" the"setup"of" two"200ns"aMD"simulations,"one"for"
each" molecular" system," with" the" AMBER" program." The" obtained" trajectories" were" then"
analysed"in"a"similar"way"to"that"done"for"the"cMD"simulations"computed"with"GROMACS."
"
Table'4.5..Parameters.for.aMD.simulations..
. NS3helFRNA. NS3helFRNAFATP. Measure"unit"
DIHED. 7992.46" 8024.84" kcal/mol"
Protein.residues.number. 456" 456" "
Edihed. 9816.46" 9,848.84" kcal/mol"
αdihed. 364.8" 364.8" kcal/mol"
POT. \186,592.95" \205,418.33" kcal/mol"
System.atoms.number. 77316" 76122" "
Epot. \174,222.39" \193,238.81" kcal/mol"
αpot. 12,370.56" 12,179.52" kcal/mol"
"
During" the"aMD"simulations"an"average"of"102.21"kcal/mol"and"101.93"kcal/mol" total"boost"
potential" was" applied" for" the" NS3hel\RNA" and" NS3hel\RNA\ATP" complexes" respectively." As"
shown" in" Figure" 4.12," the" applied" boost" varied" during" the" simulation" as" higher" ΔV(r)" was"
applied"in"correspondence"to"local"minima."This"variation"suggested"that"different"regions"of"
the"free"energy"surface"were"sampled,"complying"with"the"aim"of"the"method."In"the"charts"in"
the" figure" the" time" variation" of" ΔV(r)" is" shown" in" grey" and" the" 5" period" running" average" is"
shown"in"black"for"a"better"visualisation"of"the"boost"potential"trend"during"the"simulation."For"
the"NS3hel\RNA"complex" (panel"A"of" Figure"4.12)" the"applied"ΔV(r)" ranged"between"169.36"
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kcal/mol"and"47.16"kcal/mol;"while"for"the"NS3hel\RNA\ATP"complex"(panel"B"of"Figure"4.12)"it"
was"between"168.02"kcal/mol"and"53.66"kcal/mol.""
"
" !
"""A" """B"
Figure'4.12..Applied.boost.potential.trend.during.aMD...
In"both"panels"the"boost"potential"is"plotted"against"simulation"time."The"trend"is"shown"with"a"grey"line,"while"the"
5"point"moving"average"trend"is"represented"with"a"black"line."A).Data.for.the.NS3helFRNA.complex..B).Data.for.
the.NS3helFRNAFATP.system..
"
LARGE.SCALE.CONFORMATIONAL.CHANGES.
"
As"shown"in"Figure"4.13,"RMSD"fluctuations"were"different"for"the"two"molecular"systems"and"
reach"a"maximum"value"of"4.3Å"and"4.0Å"for"the"NS3hel\RNA"and"NS3hel\RNA\ATP"complexes"
respectively.""
"
!
Figure'4.13..Protein.backbone.RMSD.for.aMD.simulations.""
The"RMSD"values"of"the"protein"backbone"are"plotted"here"against"simulation"time."Data"for"the"NS3hel\RNA"and"
the"NS3hel\RNA\ATP"complexes"are"shown"in"grey"and"in"black"respectively."
Comparing"this"figure"with"panel"B"of"Figure"4.1"it"appears"that"RMSD"values"were"higher"than"
the" ones" recorded" for" the" cMD" simulations," confirming" a" greater" exploration" of"
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conformational"space"of"the"protein"with"the"aMD"approach."Furthermore,"higher"fluctuations"
of"the"values"are"also"consistent"with"a"higher"exploration"of"the"free"energy"landscape."
The"two"panels"of"Figure"4.14"show"the"RNA"RMSD"time\dependent"variations"after"fit"on"the"
nucleic" acid" strand" (panel" A)" or" on" the" protein" backbone" (panel" B)." A" much" higher" RNA"
displacement" was" observed" for" the" NS3hel\RNA" system" with" both" fitting" methods." In"
particular," in" this"molecular" system" a" shift" in" RNA" position" respect" to" the" protein" occurred"
approximately"between"90ns"and"150ns"and"higher"changes"in"RNA"conformations"appeared"
after" approximately" 60ns" for" the" rest" of" the" simulation." In" the" NS3hel\RNA\ATP" system,"
changes"in"RNA"conformation"are"more"relevant"approximately"in"the"last"20ns"of"simulation"
and"no"significant"shift"from"the"protein"can"be"observed."
"
" "
""A" ""B"
Figure'4.14..RNA.RMSD.""
The"RMSD"values"of"the"RNA"with"different"fitting"methods"are"plotted"here"against"simulation"time."In"both"
panels,"data"for"the"NS3hel\RNA"and"the"NS3hel\RNA\ATP"complexes"are"shown"in"grey"and"in"black"respectively."
A).RNA.RMSD.with.fit.on.RNA..B).RNA.RMSD.with.fit.on.the.protein.backbone..
Per\residue"RMSD"fluctuations"(RMSF)"calculated"for"the"two"molecular"systems"are"shown"in"
Figure" 4.15." In" both" cases," the" most" flexible" residues" of" the" protein" were" located" in" the"
protease\helicase"linker"sequence"and"mainly"solvent"exposed"regions"of"the"protein."Higher"
RMSF"values"were"also"generally"associated"with"D2"and"D3"(from"residue"318"to"residue"618),"
indicating"a"higher" flexibility"of" these" two"domains." Importantly," in"both" types"of" simulation"
high"RMSF"values"were"associated"with"a"sequence"belonging"to"D1"and" formed"by"the"β2A"
sheet" and" a" random" coil" (residues" 241\257)." Significantly" higher" values" for" the"NS3hel\RNA"
complex" respect" to" the"NS3hel\RNA\ATP"one"were" recorded" for" the"protease\helicase" linker"
region"(residues"168\180)"and"the"RNA"strand"(residues"619\623)."The"latter"is"consistent"with"
the" RMSD" observations" discussed" above." Like" for" the" cMD" simulations," also" for" aMD" the"
regions"with" high" RMSF" values" corresponded" to" residues"with" high" B\factors" in" the" original"
PDB" files" (2JLU" and" 2JLV" for" the"NS3hel\RNA" and"NS3hel\RNA\ATP" complexes" respectively),"
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confirming" that" the" conformational" changes"occurred" in" the" simulations"are" consistent"with"
the"experimental"data.""
"
!
Figure'4.15..Residue.RMSF.from.aMD.simulations."
The"RMSF"values"for"each"residue"calculated"from"all"the"MD"simulations"are"plotted"here."The"trajectories"
involving"the"NS3hel\RNA\ATP"and"the"NS3hel\RNA"complexes"are"indicated"with"these"names"in"the"legend"and"
they"are"shown"with"a"black"and"a"grey"line"respectively."
Plotting" the" variation"with" time"of" residue"RMSD"values" (Figure" 4.16)" indicated" that" even" if"
regions"with"high"RMSF"are"similar,"in"the"two"molecular"systems"the"RMSD"values"changed"in"
different"moments"in"the"simulation."Particularly"relevant"RMSD"variations"are"highlighted"in"
the"figure."As"already"mentioned,"the"linker"region"between"NS3pro"and"NS3hel"(residues"168\
180)"was"very" flexible," in"particular" in" the"NS3hel\RNA"system."The"most"relevant"difference"
between" the" two" simulations" is" the"D1" region"between" residues" 241\257," corresponding" to"
the"β2A"sheet"and"a"random"coil."Even"if"the"total"RMSF"values"are"similar"(see"Figure"4.15),"in"
the" aMD" without" ATP" this" sequence" changes" conformation" after" 20ns" and" maintains" high"
RMSD"values"for"the"rest"of"the"simulation,"while"in"the"other"aMD"RMSD"increases"only"after"
approximately"170ns."Not"surprisingly,"differences"between"the"two"simulations"also"involved"
the"ATP"binding"site"as"the"presence"of"the"natural"ligand"constrained"the"binding"residues"in"
their"conformation."In"particular"two"D2"sequences"appeared"to"have"higher"RMSD"values"in"
the"system"without"ATP:"residues"317\330"(belonging"to"motif"III,"responsible"for"NTPase"and"
helicase" activities" coupling)" and" residues" 462\470" (partially" belonging" to" motif" VI," also"
involved" in"NTP"binding)." Importantly," less"difference" could"be"observed" for" the"portions"of"
these" motifs" in" proximity" of" the" ATP" base." Consistently" with" DENV" NS3hel" lack" of" base"
selectivity" for" NTP" binding," during" the" NS3hel\RNA\ATP" simulation" the" ATP" base" was"
particularly"flexible"and"interacted"non\specifically"with"sequences"of"domains"1"and"2,"while"
the"phosphate"portion"of"the"ligand"was"binding"stably"in"the"cleft."This"explained"the"higher"
RMSD"values"for"the"portions"of"motifs"III"and"VI"close"to"the"ATP"base"in"the"simulation."Other"
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solvent\exposed" regions" with" high" RMSD" values" are" not" highlighted" because" they" are" not"
relevant"for"the"discussion"of"the"helicase"translocation"along"the"RNA."
"
!
Figure'4.16..PerFresidue.timeFdependent.RMSD.variations.""
The"RMSD"time\dependent"variations"are"indicated"for"each"residue"for"the"two"molecular"systems"(NS3hel\RNA"
and"NS3hel\RNA\ATP"complexes)."The"RMSD"values"are"indicated"with"a"colour"gradient"ranging"from"light"blue"
(low"RMSD)"to"dark"red"(high"RMSD)."Discussed"residue"regions"are"highlighted"with"green"boxes"and"indicated."
With" the" aim" of" assessing" global" protein" movements," also" for" the" aMD" simulations" the"
variation" upon" time" of" the" distance" between" key" residues" Cα" atoms" was" computed" on" all"
simulations."The"same"residue"pairs"(reported"in"Table"4.2"and"Figure"4.5)"were"used,"but"like"
in" the" case" of" the" cMD" simulation" no" relevant" patterns" that" could" explain" domains" relative"
movements"were"observed."
More"informative"was"the"principal"component"analysis"that"was"computed"for"the"two"aMD"
simulations,"using"all"heavy"atoms"belonging"to"the"RNA"strand"and"protein"Cα"atoms."Where"
present" ATP" was" not" selected" because" the" aim" for" PCA" was" to" identify" protein" and" RNA"
conformational"changes"that"could"give"an"insight"of"the"helicase"mechanism"of"translocation."
The" calculated" eigenvectors" were" in" descending" order" of" contribution" and" for" all" the"
simulations"the"first"10"modes"represented"68.66%"and"60.05%"of"the"total"system"motion"for"
the"NS3hel\RNA"and"NS3hel\RNA\ATP"complexes"respectively."Table"4.6"shows"the"percentage"
(%)" and" the" cumulative" percentage" (Cumulative" %)" of" motion" represented" by" the" first" 10"
eigenvectors"of"the"two"aMD"simulations."Values"are"also"plotted"in"Figure"4.17."
"
& '
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Table'4.6..Percentage.and.cumulative.percentage.of.motion.represented.by.the.first.10.eigenvectors.of.the.two.
aMD.simulations..
Eigenvector.
NS3helFRNA. NS3helFRNAFATP.
%" Cumulative"%" %" Cumulative"%"
1. 20.05" 20.05" 24.55" 24.55"
2. 16.50" 36.55" 7.39" 31.94"
3. 7.91" 44.46" 5.89" 37.83"
4. 6.12" 50.58" 5.79" 43.63"
5. 4.40" 54.99" 3.87" 47.49"
6. 3.13" 58.12" 3.38" 50.88"
7. 2.80" 60.92" 2.95" 53.82"
8. 2.20" 63.12" 2.24" 56.07"
9. 2.01" 65.13" 2.09" 58.15"
10. 1.85" 66.98" 1.89" 60.05"
"
" "
""""A" """"B"
Figure'4.17..First.10.eigenvectors.contribution.of.motion.""
Data"for"these"charts"was"taken"from"Table"4.6."In"both"panels"the"NS3hel\RNA"system"is"shown"in"grey"and"the"
NS3hel\RNA\ATP"one"is"in"black."A).Contribution.percentage.contribution.of.eigenvectors..B).Cumulative.
percentage.contribution.of.eigenvectors..
The" projection" on" the" trajectories" of" the" ten" eigenvectors" showed" that" in" both" molecular"
systems" the" most" interesting" time\dependent" variations" upon" time" of" the" eigenvalues"
belonged"to"the"first" five"PC"(Table"4.7)."As"they"also"represented"approximately"50%"of"the"
total"motion"in"both"simulations,"they"were"further"analysed."
The"investigation"of"the"atomic"RMSF"for"first"five"modes,"showed"a"general"increase"of"values"
with" eigenvector" number" increment." This" confirmed" that" largest" amplitude" principal"
components"describe"the"slower"dynamical"transitions."The"first"5"modes"of"the"NS3hel\RNA"
system" had" general" lower" RMSF" values" than" the" other" complex," indicating" faster" atomic"
vibration"in"the"NS3hel\RNA\ATP"simulation."
"
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Table'4.7..Time.variation.of.the.first.5.eigenvalues.for.the.NS3helFRNA.and.NS3helFRNAFATP.simulations..
NS3helFRNA. NS3helFRNAFATP.
! !
! !
! !
! !
! !
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In" Table" 4.8," two" examples" of" per\atom" RMSF" charts" for" each" simulation" are" reported,"
showing" how" values" varied" according" to" mode" number" and" between" the" two" molecular"
systems." Here" RMSF" values" are" reported" for" each" atom" selected" for" PCA." Atoms" 168\618"
correspond"to"protein"residues"168\618"because"only"Cα"atoms"were"selected"for"the"protein"
molecule." Some" protein" and" RNA" regions" were" associated" with" high" RMSF" values" in" both"
simulations." In" particular," these" regions" were" mainly" solvent" exposed" random" coils," the"
protease\helicase"linker"(residues"168\180),"the"D1"flexible"portion"discussed"above"(residues"
241\257),"the"two"ATP"binding"motifs"(residues"317\330"and"residues"462\470),"D2"α1’"and"α2’"
helices,"the"D2"loop"that"follows"α3’"helix"(residues"410\416)."Within"the"RNA,"vibration"could"
be" associated"mainly"with" the" two" strand" extremities," in" particular" to"U5." In" all" the"modes"
obtained"for"the"two"aMD"simulations,"the"movements"involved"mainly"D2"and"D3,"indicating"
that"these"domains"were"generally"more"flexible"than"D1."RNA"movements"involved"mainly"a"
general"backbone"bent"and"U5"flexibility"that"prompts"its"displacement"from"the"RNA"binding"
site.""
"
Table'4.8..Atom.RMSF.according.to.motion.mode..
NS3helFRNA. NS3helFRNAFATP.
! !
! !
"
Differently" from" the" cMD" simulations," a" “scissors\like”" pattern" could" be" observed" in" both"
simulations." The" “scissors\like”" pattern" was" mainly" due" to" D2" lateral" rotation" towards" D1,"
affecting"the"size"of"the"ATP"cleft"and"of"the"RNA"binding"site"entrance,"but"not"the"distance"
from"D3."Figure"4.18"shows"the"porcupine"plots"for"the"corresponding"principal"components"
that"describe"the"“scissors\like”"movement"for"the"NS3hel\RNA"(panel"A)"and"the"NS3hel\RNA\
ATP"(panel"B)"molecular"systems.""
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"
"
A"
"
B"
Figure'4.18..Porcupine.plot.of.“scissorsFlike”.movement.""
The"porcupine"plot"of"the"second"eigenvector"(corresponding"to"16.5%"of"motion)"of"the"NS3hel\RNA"molecular"
system"simulation"is"presented"here."The"front"and"lateral"view"are"reported"on"the"left"and"on"the"right"
respectively."The"protein"is"shown"with"a"red"ribbon"and"the"RNA"is"represented"in"green."The"vectors"associated"to"
this"mode"are"shown"as"blue"needles."For"image"clarity,"vectors"associated"with"RNA"movements"are"not"displayed."
A).NS3FRNA.complex..B).NS3helFRNAFATP.complex..
D2" rotation" involved" also" regions" in" contact" with" the" nucleic" acid" and" in" particular" the"
interaction"between"motif"IV"(on"the"α1’"helix,"residues"363\366)"and"G2"phosphate"moiety."In"
the"NS3hel\RNA"system,"this"pattern"is"described"already"in"PC2,"representing"16.50%"of"the"
total" motion." Conversely," in" the" other" molecular" system," it" was" only" described" by" PC4,"
representing" only" 5.79%" of" motion," making" this" vibration" mode" much" less" relevant." This"
90°"
90°"
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suggested"that"the"presence"of"the"natural"substrate"constrains"the"molecular"system"in"the"
closed"conformation,"while"when"the"protein"was"unbound"to"ATP"it"was"more"free"to"explore"
the"conformational"space."This"was"consistent"with"the"translocation"model"proposed"for"HCV"
NS3hel"in"which"the"binding"of"a"NTP"molecule"prompts"the"protein"to"pass"from"an"open"to"a"
closed" conformation." Furthermore," in" the" NS3hel\RNA\ATP" simulation" D2" rotation" was" not"
only"lateral,"but"the"oscillation"was"also"affecting"the"distance"from"D3"(as"shown"in"panel"B"of"
Figure"4.18),"making"the"movement"pattern"not"completely"consistent"with"the"HCV"“scissors\
like”"oscillation.""
NS3pro\NS3hel" linker"and"D1" residues"241\257"movements"were"present" in"all" eigenvectors"
and"represented"different"components"of" their" total"motion,"clearly"visible"also" in" trajectory"
visual" inspection." In" the" NS3hel\RNA" simulation," the" latter" protein" region" shifted" from" its"
initial" position" in" the" first" 40ns," almost" contemporarily" to" U5" displacement" from" the" RNA"
binding"site,"which"was"described"in"all"five"eigenvectors,"with"different"extent."Differently,"in"
the"NS3hel\RNA\ATP" simulation," the" displacement" of" this" protein" region" started" only" in" the"
last"part"of"the"simulation,"consistently"with"PC1"trend"(Table"4.7)."Of"interest,"also"in"this"case"
the"U5"displacement"from"the"RNA"binding"site"occurred"at"the"end"of"the"simulation,"in"the"
last" 15ns," suggesting" that" the" two" movements" could" be" connected." U5" fluctuations" were"
described"mainly"by"the"third"and"fifth"eigenvector"and"had"consequently"low"contribution"to"
the" total" motion" (5.89%" and" 3.85%" of" motion" respectively)." Conversely," the" RNA" 5’" end"
movement"was"described"also"by"the"first"mode.""
As"predictable,"flexibility"of"loops"involving"part"of"the"ATP"binding"site"and"including"parts"of"
mainly"motif" III" (residues"317\330)" and"motif"VI" (residues"462\470)"was"more" important" for"
the"NS3hel\RNA"complex"and"it"was"recorded"already"in"the"first"eigenvector"(PC1,"20.05%"of"
total"motion)." In"this"simulation"the"α3’"helix"and"the" loop"that"follows" it" (residues"410\416)"
showed" some" flexibility" already" in" PC1" and" was" a" more" important" component" in" principal"
modes"4"and"5"(6.12%"and"4.40%"of"total"motion"respectively)."Here,"these"residues"shift"away"
from"RNA"and"protrude"towards"the"ATP"binding"site,"affecting"its"size."This"protein"sequence"
is"part"of"D2"motif"V," responsible"of"RNA"binding," through" interactions"between"Thr408"and"
A3"phosphate"group"and"Asp409"and"G2"2’OH"moiety"(see"Figure"3.5"in"the"NS3&HELICASE&ANS&
A&DRUG&TARGET" section)." In" this"aMD"simulation,"an"additional" interaction"between" Ile"410"
and"A3"phosphate"was"observed."However,"the"displacement"of"residues"410\416"caused"the"
disruption"of"this"interaction,"as"well"as"a"weakening"of"that"of"Thr408."This"shift"was"observed"
also"in"the"visual"inspection"of"the"trajectory"and"occurred"mainly"between"103ns"and"125ns"
of"simulation,"compatibly"with"the"PC5"eigenvalue"time"pattern"around"100ns"(Table"4.7)." In"
the"NS3hel\RNA\ATP"molecular" system," the"ATP"binding"motifs" vibrations" (residues"317\330"
and"residues"462\470)"had"a"lower"component"in"the"total"motion."From"visual"inspection"of"
the"aMD"trajectory"the"amplitude"of"these"movements"was"also"smaller"and"the"presence"of"
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the"ligand"did"not"allow"changes" in"the"cleft"size." Importantly,"also"the"shift"of"residues"410\
416"was" impeded"by"the"presence"of"ATP."Thus,"not"only"the"fluctuation"was" less" important"
than" in" the" NS3hel\RNA"molecular" system" simulation" (only" 3.87%" of" total"motion)," but" the"
Ile410\A3"phosphate"hydrogen"bond"was"stabilised"by"the"presence"of"ATP.""
"
BINDING.FREE.ENERGY.CALCULATIONS"
"
The"average" interaction"energies"and" their" components"were"calculated" for"each"aMD" from"
2000" frames" saved" from" the" two" trajectories," following" the" same"procedure"applied" for" the"
cMD"simulations.""
As" reported" in" Table" 4.9," the" estimated" binding" free" energy" was" not" significantly" different"
between" the" two"molecular" systems," with" average" values" of" \107.72" kcal/mol" and" \114.10"
kcal/mol"for"the"NS3hel\RNA"and"the"NS3hel\RNA\ATP"systems"respectively.""
"
Table'4.9..Binding.free.energy.components.of.the.DENV.NS3helFRNA.interaction.for.aMD.simulations..
" NS3helFRNA. . NS3helFRNAFATP. .
Contribution. Value"(kcal/mol)" " Std" "
Value"
(kcal/mol)" " Std" "
∆Eint" \1.7"E\06" " 8.59"E\05" " 1.65E\06" " 8.72E\05" "
∆EvdW" \104.14" " 8.54" " \100.22" " 7.86" "
∆ECoul" \696.96" " 70.58" " \775.80" " 58.70" "
∆Egas" \801.12" " 70.61" " \876.01" " 60.58" "
∆Gsol"" 699.40" " 57.11" " 761.91" " 51.03" "
∆Gtot"" \101.72" " 21.28" " \114.10" " 17.80" "
Average"values"for"the"aMD"are"reported,"as"well"standard"deviations."The"molecular"
systems"are"indicated"with"NS3hel\RNA"and"NS3hel\RNA\ATP."Eint:"internal"energy;"EvdW:"
van"der"Waals"energy;"ECoul:"Coulomb"energy;"∆Egas"="∆Eint"+"∆EvdW"+"∆ECoul;"Gsolv:"
solvation"energy"is"based"on"the"Generalised"Born"method;"∆Gtot:"total"binding"free"
energy"calculated"with"MMGBSA;"Std:"standard"deviation."
"
These"averages"were"calculated"over"the"whole"trajectories"of"the"aMD"simulations."However,"
as"already"explained,"the"aim"of"the"accelerated"molecular"dynamics"method"is"to"avoid"that"
the"molecular" system" gets" trapped" in" energy"minima"wells" for" too" long" time" and" applies" a"
boost"potential"when"the"energy"of"the"system"is"below"a"certain"threshold." In"this"way,"the"
conformational"space"of"the"molecular"system"is"explored"better."This"was"confirmed"for"the"
helicase"complexes"by"the"results"presented"above."Consequently,"also"the"snapshots"used"for"
the"MMGBSA"calculations"belonging" to"different" conformations"and" the"averages"calculated"
on"the"whole"trajectories"are"not"indicative"of"the"free"energy"status"of"the"systems"and"the"
time"variation"of"the"values"were"much"more"informative."Figure"4.19"shows"the"binding"free"
energy"profile"for"the"two"molecular"systems.""
"
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"
Figure'4.19..Time.variation.of.binding.free.energy.values.for.aMD.simulations...
Time"variation"of"the"NS3hel\RNA"binding"free"energy"is"reported"here"for"each"molecular"system."The"values"
obtained"for"the"NS3hel\RNA"and"NS3hel\RNA\ATP"complexes"are"indicated"with"“NS3hel\RNA”"(light"blue"line)"and"
“NS3hel\RNA\ATP”"(light"red"line)"respectively."Averages"are"also"reported"as"“Average"NS3hel\RNA”"(dark"blue"
line)"and"“Average"NS3hel\RNA\ATP”"(dark"red"line)."The"average"values"were"\101.72"kcal/mol"and"\114.10"
kcal/mol"for"NS3hel\RNA"and"NS3hel\RNA\ATP"systems"respectively."
Values" ranged"between" \46.14" kcal/mol" to" \164.88" kcal/mol" and" \61.01" kcal/mol" to" \163.92"
kcal/mol" for"the"NS3hel\RNA"and"NS3hel\RNA\ATP"complexes"respectively,"showing"a"higher"
binding"energy"fluctuation"for"the"simulation"performed"without"ATP."The"variation"patterns"
for" the" two" aMD" simulations" do" not" resemble" any" of" the" first" five" PCA" eigenvector" time"
fluctuations" (in" Table" 4.7)," indicating" that" the" NS3hel\RNA" binding" energy" change" does" not"
depend" on" a" single" component" of" the" protein" total" motion." Furthermore," no" particular"
similarities" with" backbone" and" RNA" RMSD" variation" could" be" observed," suggesting" that"
binding"energy"changes"were"not"only"related"to"global"protein"or"RNA"motions.""
Aiming" to" obtain" a" better" insight" into" the" causes" of" binding" energy" variations," the" five"
nucleotides" and" residues" in" proximity" of" the" RNA" strand"were" selected" for" a"more" detailed"
binding"free"energy"evaluation"using"the"MMGBSA"method,"with"the"same"procedure"adopted"
for" the" cMD" simulations." As" for" the" total" average" binding" energy," also" in" this" case" average"
values"could"not"be"indicative"of"the"free"energy"status"of"the"system."However,"as"they"could"
give"an"idea"about"the"most"important"residues"upon"RNA"binding,"they"were"calculated"and"
are"shown"in"Figure"4.20."The"residues"that"gave"the"highest"contribution"to"RNA"binding"were"
Arg225" and" Arg387" in" particular," but" also" Thr224," Thr244," Ser364," Ser386," Lys388," Thr408,"
Ile410"and"Arg538."Other"residues"with"lower,"but"still"significant,"energy"contributions"were:"
Pro245," Cys261," Ala263," Thr264," Phe288," Thr289" Asp290," Ile365," Lys366," Leu429," Pro431,"
Leu443"and"Arg599."Not"surprisingly,"most"of"these"residues"corresponded"to"the"interacting"
residues"reported"in"the"crystallographic"data"(see"Figure"3.5"of"the"NS3&HELICASE&AS&A&DRUG&
TARGET"section)"and"they"belong"to"domains"1"and"2."This"complied"with"the"fact"that"most"
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contacts"that"the"enzyme"has"with"the"RNA"are"at"the"level"of"the"sugar\phosphate"backbone"
of"the"nucleic"acid.[16]""
"
!
Figure'4.20..Per.residue.binding.free.energy.decomposition.""
The"per"residue"binding"free"energy"average"values"are"reported"here."Data"was"obtained"by"averaging"the"results"
for"each"molecular"system."Results"for"NS3hel\RNA\ATP"and"NS3hel\RNA"complexes"are"indicated"as"“NS3hel\RNA\
ATP”"and"“NS3hel\RNA”"respectively."Residues"discussed"in"the"text"are"indicated"here."
Generally," the" same"per\residue"pattern" could"be"observed" for" the" two" simulations."Also" in"
aMD" simulations," residues" involved" in" hydrogen" bonds" with" the" RNA" 2’OH" groups" and"
considered"to"be"the"responsible"for"DENV"NS3"helicase"specificity"for"RNA"(Pro223,"Thr264,"
Pro363"and"Asp409),"had"a"small"or"even"positive"contribution"to"the"total"interaction"energy,"
even" if" the" expected" interactions" could" be" observed" in" the" trajectories" inspection.[5,15]"
However,"this"does"not"exclude"the"importance"of"these"contacts"in"RNA"preferentiality,"as"the"
rapid" formation" and" disruption" of" these" interactions" was" observed" throughout" the"
simulations,"explaining"the"average"value.""
A" few"key"and" relevant"differences"between" the"molecular" systems" involved"mainly"Thr244,"
Phe288," Thr289," Asp290," Lys366," Lys388" and" Ile410" protein" residues." A" big" dissimilarity" in"
binding" energy" averages" was" recorded" for" RNA" nucleotides" C4" and" U5" in" particular." In" the"
latter" case," binding" energy" decomposition" average" values" were" positive" in" both" aMD"
simulations," in" particular" in" the" one" with" ATP." As" it" will" be" further" discussed" in" the" next"
chapter," this" could"be" linked"with"an"unfavourable"binding" to" the"protein"when"U5" is" inside"
the"RNA"binding"site"that"justified"the"displacement"of"the"RNA"3’"end"form"the"cleft.""
The" per\residue"decomposition" variations" against" simulation" time"were" also" computed." The"
most"interesting"patterns"are"discussed"in"the"next"chapter"with"the"conformational"changes"
that"could"explain"them."
"
"
"
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SMALL.CONFORMATIONAL.CHANGES.IN.AMD.SIMULATIONS.
"
The" per\residue" decomposition" average" and" time" variations" of" the" binding" free" energy,"
together" with" the" visual" inspection" of" the" trajectories" highlighted" small" conformational"
changes"that"could"be"relevant"in"explaining"the"helicase"mechanism"of"translocation."
Similarly"to"that"observed" in"the"cMD"simulations," from"trajectory"visualisation"the"3’"and"5’"
end"of"the"RNA"strand"were"more"flexible"than"the"other"nucleotides."The"central"part"of"the"
nucleic"acid" (A3"and"C4" in"particular)"appeared" to"be"bound"to" the"protein" in"a"more"stable"
manner,"explaining"their"lower"per\residue"binding"free"energy"values."Consistently,"a"bent"in"
the"RNA" strand" could" also" be"observed" in" both" trajectories," but" it"was"more" evident" in" the"
simulation"without"ATP"and"occurred"only"at"the"end"of"the"simulation"in"the"other"complex."
At"the"5’"end"of"the"RNA"strand,"the"nucleotide"flexibility"involved"mainly"A1"and"G2."In"both"
aMD"simulations,"the"G2"phosphate"moved"away"from"D2,"causing"a"rotation"of"A1"nucleotide"
and" a" shift" in" G2" base." The" latter" was" particularly" evident" in" the" NS3hel\RNA" complex," in"
relation" with" the" more" evident" RNA" bent." In" this" simulation," when" the" G2" base" shifted," it"
interacted" with" Phe288," Thr289" and" Asp290," explaining" the" binding" free" energy" difference"
between"the"two"molecular"systems"for"these"residues."In"analogy"with"what"observed"in"the"
cMD" simulations," the" A1" rotation" generally" did" not" involve" a" displacement" of" this" part" of"
nucleotide" from" the" occupied" area" of" the" binding" site," but" caused" the" shift" of" the" ribose"
portion,"placing"the"5’"OH"group"in"a"more"exposed"region"of"the"RNA"binding"site"entrance."
Importantly,"this"change"in"conformation"would"facilitate"the"entrance"of"a"novel"nucleotide"in"
the"RNA"cleft,"as"would"happen"in"the"3’\5’"helicase"translocation"along"the"nucleic"acid."The"
A1" base" was" constrained" in" its" position" by" the" D2" β\hairpin" through" hydrophobic" contacts"
mainly"between"A1"base"and" residues" Leu429,"Pro431"and"Leu443."These" interactions"were"
conserved"in"both"aMD"simulations"and"the" interacting"energy"contribution"pattern"of"these"
residues" was" constant" during" the" simulation." This" supported" the" hypothesis" that" these"
hydrophobic"residues"play"a"key"role"in"impeding"NS3hel"to"translocate"towards"RNA"3’"end"by"
maintaining"in"place"the"base"of"the"nucleotide"in"the"5’"end"of"the"binding"site."Interestingly,"
during"a"small"time"frame"of"a"few"nanoseconds"in"both"simulations,"A1"base"shifted"forward,"
towards" the" binding" cleft" entrance." However," the" base"was" unable" to" exit" the" binding" site,"
blocked"by"the"β\hairpin,"giving"a"further"support"in"favour"of"the"hypothesis.""
As" well" as" Ile365" backbone" amino" group," which" showed" to" bind" G2" phosphate" also" in" the"
crystallographic"structures"(see"Figure"3.5"of"the"NS3&HELICASE&AS&A&DRUG&TARGET"section),"in"
the"aMD"also"Ser364"and"Lys366"side"chains"interacted"with"the"group"during"the"simulations."
The" G2" phosphate" displacement" was" accompanied" by" a" shift" of" the" α1’" helix," already"
discussed" in" the" PCA" results," that"moved" the" interacting" residues" in" the" opposite" direction,"
causing" a" disruption" on" the" phosphate\protein" hydrogen" bonds." For" example," the" distance"
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between"Ile365"backbone"nitrogen"and"the"interacting"phosphate"oxygen"oscillated"between"
2.70Å"and"9.62Å" in" the"NS3hel\RNA"simulation"and"between"2.63Å"and"11.06Å" in" the"other"
one"(Figure"4.21,"panel"A)."A"distortion"of"the"loop"before"the"α1’"helix,"composed"of"residues"
from"Pro363"to"Lys366,"could"also"be"observed."This"was"caused"by"the"rotation"of"Ile365"side"
chain"into"a"hydrophobic"region"of"D2"given"by"the"conserved"residues"Gln384,"Thr389,"Val406"
and" Val362." The" Ile365" change" in" conformation" had" also" been" observed" in" the" cMD"
simulations,"but" in"the"aMD"ones"it"did"not" impede"the"interaction"of"this"residue"with"RNA."
The"distortion"of"the"Pro363\Lys366"loop"was"important"as"Ser364"interactions"with"the"RNA"
occurred" only" when" the" Ile365" side" chain" was" interacting" with" the" hydrophobic" groove."
Furthermore,"this"also"exposed"the"Ile365"backbone"amino"group"more"to"the"solvent,"making"
it" hypothetically" available" for" the" interaction" with" the" phosphate" moiety" of" an" incoming"
nucleotide." An" example" of" G2" phosphate" shift" and" of" Pro363\Lys366" loop" distortion" with"
Ile365" interaction"with" the"hydrophobic"area" is" shown" in"panel"B"of"Figure"4.21,"where" two"
frames" of" the"NS3hel\RNA" simulation" are" superposed." As" it" occurs" at" the" same" time"of" the"
phosphate"shift,"in"this"example"the"conformational"change"disrupts"the"interactions"between"
Ile365"and"the"RNA"and"no"additional" interactions"are"present."However," it"can"be"observed"
here"that"the"loop"distortion"allows"Ser364"to"get"closer"to"G2"phosphate.""
The"positions"of"the"residues"and"of"the"phosphate"moiety"oscillated"between"the"bonded"and"
the"unbounded"conformations"during"both"aMD"simulations,"indicating"that"these"interactions"
are"not"stable."The"oscillation"of"the"G2"phosphate"position"is"probably"also"connected"to"the"
presence"of"Asp603"in"the"RNA"binding"site"entrance"(not"displayed"in"Figure"4.21)."When"the"
G2"phosphate"shifted"away"from"D2,"it"got"closer"to"the"negatively"charged"Asp603,"creating"
an" electrostatic" repulsion." This" repulsion" could" explain" the" positive" value" of" this" residue"
binding"free"energy"contribution"as"well"as"the"oscillating"pattern"in"the"phosphate"position."In"
the" NS3hel\RNA\ATP" complex," the" bound" conformations" were" more" important" than" in" the"
other" molecular" system," as" shown" by" the" distance" pattern" in" panel" A" of" Figure" 4.21."
Furthermore," the" bound\unbound" oscillations" were" less" frequent" and" slower," allowing" the"
observation" of" clear" bound\unbound" patterns" in" the" per\residue" binding" energy"
decomposition"of"the"involved"residues," in"particular"Ser2364"and"Ile365."The"interactions"of"
Lys366" side" chain" with" G2" phosphate" were" more" frequent" in" the" NS3hel\RNA" simulation,"
suggesting"that"the"residue"flexibility"plays"an"important"role"in"its"interactions"with"RNA."
"
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"""""A" ""B"
Figure'4.21..Movement.pattern.around.RNA.5'.end...
A).Time.variation.of.the.distance.between.Ile365.N.and.the.interacting.G2.phosphate.O.atoms."Data"for"NS3hel\
RNA"and"NS3hel\RNA\ATP"simulations"is"presented"in"blue"and"in"red"respectively."B).Example.of.G2.phosphate.
shift.and.Ile365.side.chain.change.in.conformation."The"shift"of"G2"phosphate"and"Ile365"side"chain"are"
represented"here"by"superposition"of"two"frames"of"the"trajectory"the"NS3hel\RNA"simulation."The"ribbons"and"the"
carbon"atoms"of"the"frame"at"the"beginning"of"the"trajectory"are"in"orange,"while"the"ones"of"the"frame"taken"from"
around"the"middle"of"the"simulation"are"in"green."The"shifts"are"indicated"by"arrows."The"hydrogen"bond"present"at"
the"beginning"of"the"simulation"is"represented"as"a"black"dotted"line."Discussed"residues"are"indicated.""
Similarly"to"the"G2"phosphate,"also"for"that"of"A3"more"interactions"were"observed"during"the"
aMD"simulations"than"in"the"crystal"structure"(see"Figure"3.5"of"the"NS3&HELICASE&AS&A&DRUG&
TARGET" section)." Consistently" with" the" good" binding" free" energy" contribution" averages" (in"
Figure"4.20),"as"well"as"Arg387,"also"Ser386,"Lys388"side"chains"and"the"backbone"amino"group"
of" Ile410" interacted"with" this"moiety" through"hydrogen"bonds"and"electrostatic" interactions"
(for" the" basic" residues)." During" aMD" visual" inspection," relevant" changes" in" Arg387"
conformations"could"be"observed,"as"shown"in"Figure"4.22,"where"snapshots"from"the"NS3hel\
RNA"trajectory"and"the"NS3hel\RNA\ATP"one"were"superposed"in"panels"A"and"B"respectively."
During"the"simulations,"the"residue’s"side"chain"turned,"breaking"the"interactions"with"A3"and"
G2"phosphates" and" forming"new"unstable"hydrogen"bonds"with"C4"and"U5"phosphates" and"
bases."The"side"chain"rotation"was"not"permanent"in"either"of"the"simulations,"but"it"was"more"
stable"in"the"simulation"of"the"NS3hel\RNA"system."The"observed"flexibility"of"Arg387"could"be"
relevant"for"helicase"translocation"mechanism"as" it"shows"the"ability"of"this"residue"to"move"
along"the"RNA,"facilitating"the"helicase"shift"along"the"nucleic"acid.""
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"""A" """B"
Figure'4.22..Arg387.change.in.conformation...
The"ribbons"and"the"carbon"atoms"of"the"frame"at"the"beginning"of"the"trajectory"are"in"orange,"while"the"ones"of"
the"frame"taken"later"on"in"the"simulation"are"in"green."The"shift"is"indicated"by"a"black"arrow."The"hydrogen"bonds"
formed"between"Arg387"and"the"RNA"phosphates"are"represented"as"black"dotted"lines."RNA"nucleotides"are"
indicated."A).Shift.in.NS3helFRNA.simulation..The"shift"of"Arg387"side"chain"is"represented"here"by"superposition"of"
two"frames"of"the"NS3hel\RNA"simulation..B).Shift.in.NS3helFRNAFATP.simulation..The"shift"of"Arg387"side"chain"is"
represented"here"by"superposition"of"two"frames"of"the"NS3hel\RNA\ATP..
As"already"discussed"in"the"PCA"results," in"NS3hel\RNA"the"shift"of"residues"410\416"is"more"
important" than" in" the" other" molecular" system" as" the" loop" is" allowed" to" occupy" the" ATP"
binding" site" by" the" absence" of" the" ligand." Some" fluctuations" in" the" loop" conformations"
occurred"also" in" the"presence"of"ATP,"but" they"were" smaller," as" shown" in"panel"A"of" Figure"
4.23.""
"
" "
"""A" """B"
Figure'4.23..Ile410.change.in.conformation...
A).Time.variation.of.the.distance.between.Ile410.N.and.the.interacting.A3.phosphate.O.atoms."Data"for"NS3hel\
RNA"and"NS3hel\RNA\ATP"simulations"is"presented"in"blue"and"in"red"respectively."B).Example.of.G2.phosphate.
shift.and.Ile365.side.chain.change.in.conformation..The"maximum"shifts"of"Ile410"and"Thr408"residues"and"of"RNA"
backbone"are"represented"here"by"superposition"of"two"frames"of"the"NS3hel\RNA"simulation..The"ribbons"and"the"
carbon"atoms"of"the"frame"at"the"beginning"of"the"trajectory"are"in"orange,"while"the"ones"of"the"frame"taken"at"
around"100ns"of"the"simulation"are"in"green."The"shifts"are"indicated"by"black"arrows."The"hydrogen"bonds"formed"
between"A3"phosphate"and"Ile410"and"Thr408"are"represented"as"black"dotted"lines."Discussed"residues"and"RNA"
nucleotides"are"indicated."
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Here," the" distance" between" Ile410" backbone" nitrogen" and" the" interacting" A3" phosphate"
oxygen"is"plotted"against"time,"with"values"ranging"between"2.68Å"and"11.08Å"in"the"NS3hel\
RNA" simulation" and" between" 2.68Å" and" 6.54Å" in" the" NS3hel\RNA\ATP" one." After"
approximately"80ns"of"the"NS3hel\RNA"simulation,"residues"410\416"shifted"away"from"RNA,"
which" increased" its"curvature"at" the"same"time."This"produced"a"permanent"break"of" Ile410"
interactions"with"the"phosphate"and"a"consequent"increase"of"free"energy"contribution"of"this"
residue"to"nucleic"acid"binding,"explaining"the"difference"in"Ile410"average"contribution"to"the"
total"binding"energy"between"the"two"molecular"systems."The"effect"on"Thr408"contribution"
was" less"pronounced"as" the"position"of" this" residue"changed" less," leading"to"a"weakening"of"
the"hydrogen"bonds"with"the"phosphate,"but"not"to"their"complete"disruption."The"described"
residues’"changes"in"conformation"are"shown"in"panel"B"of"Figure"4.23,"where"two"frames"of"
the"NS3hel\RNA"simulation"are"superposed."
Similarly"to"cMD"simulations,"the"3’"end"of"the"nucleic"acid"strand"was"very"flexible,"prompting"
a"permanent"U5"displacement"from"the"RNA"binding"site"in"all"the"aMD"simulations."The"fact"
that"the"3’"end"nucleotide,"differently"to"the"one"in"the"5’"end,"was"flexible"and"free"to"exit"the"
RNA"cleft," supports" the"hypothesis" that" the"β\hairpin" residues" (Leu429,"Pro431"and"Leu443)"
have"an"important"role"in"the"3’\5’"directionality"of"the"NS3hel"translocation"mechanism."From"
visual" inspection"of"both"aMD"trajectories," the"U5"base"displacement" from"the"RNA"binding"
site" was" almost" simultaneous" with" the" D1" residues" 241\257" large" scale" change" in"
conformation"described"previously."These"two"changes"in"conformations"were"not"stable"nor"
specific"as"they"changed"within"and"between"the"aMD"simulations."As"already"mentioned,"the"
U5" displacement" and" D1" residues" 241\257" change" in" conformation" started" after"
approximately" 40ns" and" 170ns" in" the" NS3hel\RNA" and" NS3hel\RNA\ATP" simulations"
respectively." Not" surprisingly," the" U5" displacement" from" the" RNA" cleft" caused" a" general"
change" in" the"nucleotide"conformation." In"particular," the"shift"of" the"U5"phosphate"position"
caused"an"increase"of"the"Thr244"binding"free"energy"value"in"relation"with"the"disruption"of"
the"residue’s"interaction"with"this"moiety."Nevertheless,"when"out"of"the"RNA"cleft,"U5"formed"
new"interactions"with"D1,"mainly,"and"D3,"which"enhanced"the"binding"energy"component"of"
this"nucleotide."These"interactions"involved"residues"like"Pro245,"Thr267"and"Arg538"and"were"
neither"stable"nor"specific,"but"prompted"a"better"contribution"of"this"nucleotide"to"the"total"
binding"free"energy."Even"residues"that" in"the"crystal"structure"are"far"from"the"RNA"binding"
site"like"Tyr242"or"Gln243,"interacted"with"U5"phosphate"during"the"nucleotide"displacement,"
aided"by"the"D1"241\257"region"change"in"conformation."Even"if"these"interactions"were"only"
transient" and" different" between" the" simulations," they" suggested" that" the" 241\257" region"
could" be" involved" in" the" 3’" end" displacement" from" the" RNA" cleft" though" its" transitory"
stabilisation."The"U5"displacement"occurred"much"later"in"the"simulation"for"the"NS3hel\RNA\
ATP" system" respect" to" the"NS3hel\RNA"one,"explaining" the"much"more"positive"value"of"U5"
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average" binding" energy" and" the" more" negative" Thr244" one." An" example" of" the" U5"
displacement"from"the"RNA"binding"site"is"presented"in"Figure"4.24.""
"
!
Figure'4.24..U5.and.protein.D1.241F257.sequence.flexibility.examples.in.aMD.simulations.""
To"exemplify"the"non\specific"flexibility"of"U5"nucleotide"and"of"D1"241\257"residues"three"frames"from"the"NS3hel\
RNA"trajectory"are"superposed"here."The"ribbon"and"the"atoms"from"the"three"snapshots"are"coloured"in"orange,"
green"and"blue."For"an"easier"visualisation"RNA"nucleotides"from"A1"to"C4"are"in"a"lighter"shade"of"the"
correspondent"colour"for"the"snapshot."U5"and"D1"241\257"sequence"are"indicated"with"black"arrows."
"
PROPOSED.MECHANISM.OF.TRANSLOCATION.ALONG.THE.RNA.
"
The" results" obtained" from" the" accelerated" molecular" dynamics" approach" applied" to" the"
helicase\RNA"complex" in" the"presence"and" in" the"absence"of"ATP," revealed" important"novel"
insights"in"the"DENV"NS3hel"mechanism"of"translocation."As"presented"earlier"in"the"chapter,"
HCV" NS3hel" crystal" structures" showed" that" the" enzyme" translocates" along" the" nucleic" acid"
with"a"ratchet\like"mechanism"that"involve"the"NTP"binding"site"opening"and"closing"through"
D2" lateral" rotation." In" the"absence"of" the"natural" ligand," the"NTP"binding" site" is"open"and"5"
nucleotides" can"be" accommodated" in" the"RNA" cleft."Upon"NTP"binding,"D2" rotates" towards"
domain"1"(D1),"closing"the"NTP"cleft"and"reducing"the"RNA"pocket"size."In"this"stage,"changes"
in"D1" interactions"with" the"nucleic"acid" strand"causes" the"exit"of" the"3’"nucleotide" from"the"
binding" pocket,"with" only" 4" nucleotides" remaining" in" the" cleft." NTP" hydrolysis" products" are"
then" released" through" the" rotation" of" D2" away" from" D1." During" NTP" cleft" opening," D2"
interactions" with" RNA" shift" and" allow" the" entrance" in" the" nucleic" acid" pocket" of" a" novel"
nucleotide"at"the"5’"end"of"the"RNA,"bringing"back"the"number"of"bound"nucleotides"to"5."At"
the"end"of"the"cycle,"HCV"NS3hel"has"thus"shifted"by"one"nucleotide"towards"the"5’"end"of"the"
viral"genome.[11\13]""
The" starting" system" structures" (PDB" IDs" 2JLU" and" 2JLV)" superposition" RMSD" is" only" 0.38Å,"
suggesting" that" the" starting" protein" conformations" were" the" same" for" the" two" molecular"
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systems,"in"line"with"the"fact"that"only"observation"of"the"crystal"structures"could"not"explain"
the" DENV" NS3hel" mechanism" of" translocation.[15]" Since" large" and" small" scale" changes" in"
conformations" were" generally" more" evident" in" the" molecular" system" without" ATP," it" was"
hypothesised"that"the"crystal"structures"corresponded"to"DENV"NS3hel"closed"conformation,"
with"the"natural"ligand"bound"to"the"NTP"pocket."In"HCV"NS3hel,"in"this"state"the"protein"only"
binds" four"nucleotides"and"not"5"as" shown"by"DENV"NS3hel" crystal" structures."According" to"
the"hypothesis" that" the"crystal" structures" represent" the"closed"conformation,"as" the"protein"
opens"and"a"novel"nucleotide"enters"the"RNA"site,"six"nucleotides"should"bind"to"the"helicase."
However," as" U5" displacement" from" the" RNA" binding" site" was" observed" in" both" aMD"
simulations" in" different" measure," no" support" for" six" binding" nucleotides" in" the" open"
conformation"was"obtained."Thus,"a"clear"hypothesis"on"the"number"of"nucleotides"bound"to"
the"DENV"protein"in"the"open"and"in"the"closed"conformations"is"difficult"to"formulate.""
RMSD"patterns"and"principal"component"analysis"of"the"aMD"simulations"were"consistent"with"
crystal" structures" B\factors," confirming" the" reliability" of" the" observed" changes" in"
conformations."The"large"scale"system"vibration"involved"mainly"domain"2,"suggesting"that"the"
key"role"of"the"flexibility"of"this"domain"in"the"protein"function."A"D2"rotation,"similar"to"what"
reported" for" HCV," could" be" described" with" PCA," in" particular" for" the" system" without" ATP,"
suggesting"that"also"DENV"NS3hel"could"translocate"with"a"ratchet\like"mechanism,"driven"by"
NTP"binding"that"favours"the"protein"closed"conformation."
According" to" the" ratchet\like" model," the" molecular" system" without" ATP" would" pass" to" the"
open" conformation" through" D2" rotation" and" changes" in" D2\RNA" interactions." Most" of" the"
changes" in" contacts"described" in" the"previous" chapter" involved" indeed"D2\RNA" interactions."
Additionally,"contacts"variations"were"more"important"in"the"NS3hel\RNA"complex,"supporting"
the" hypothesis" that" the" crystal" structures" represent" the" closed" conformation" and" that" the"
molecular" system" without" ATP" tends" to" pass" to" the" open" conformation." In" particular," a"
significantly"bigger"shift"of"Ile410"was"only"possible"when"the"NTP"binding"site"was"not"bound"
to" the" ligand." Furthermore," Ser364\Lys388" sequence" interactions" with" the" RNA" were" less"
stable" in" the" closed" conformation" complex" without" ATP." All" of" these" transient" losses" of"
contact" would" allow" the" shift" of" D2" over" the" RNA" during" enzyme" opening." Moreover," the"
higher" flexibility" of" Arg387" in" the" NS3hel\RNA" system" could" be" relevant" for" the" helicase"
translocation" mechanism" as" it" shows" the" ability" of" this" residue" to" move" along" the" RNA,"
facilitating"the"helicase"shift"along"the"nucleic"acid."
Some" small" scale" residue" changes" in" conformation" observed" in" the" aMD" simulations" and"
confirmed"in"the"free"energy"time"fluctuations,"also"gave"important"insights"about"DENV"NS3"
helicase"3’\5’"translocation"directionality."Both"RNA"ends"were"very"flexible"as"they"were"less"
involved" in" stacking" interactions" than" the" other" nucleotides." Not" constrained" by" strong"
interactions"with" the"protein," the"base"at" the"3’"end"was"able" to"exit" from" the"original" site,"
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breaking"the"π\π"stacking"with"the"neighbour"C4"and"allowing"more"space"in"the"RNA"cleft."On"
the" other" end," A1" base" showed" that" its" hydrophobic" contact" with" the" conserved" β\hairpin"
residues" Leu429," Pro431" and" Leu443" is" constant" and" stable" throughout" the" simulation" and"
sufficiently"strong"to"maintain"the"base"in"the"same"site,"impeding"the"helicase"to"translocate"
in" the" 5’\3’" direction" along" the" RNA." It"was" therefore" hypothesized" that" these" hydrophobic"
residues"are"crucial"for"DENV"NS3hel"translocation"directionality."
Some"indications"on"the"mechanism"of"insertion"of"a"new"nucleotide"at"the"5’"end"were"given"
by"the"motion"patterns"observed"in"the"RNA"and"in"the"protein"at"the"level"of"the"binding"site"
entry" region." The" fluctuations" in" interaction" between" the" region" around" Ile365" and" G2"
phosphate,"were" linked" to" the"opposite"movement"of" the"RNA"and" the"α1’"helix"and" to" the"
Ile365" side" chain" turn" towards" a" D2" hydrophobic" cleft" formed" by" the" conserved" residues"
GLn384,"Thr389,"Val406"and"Val362."The"distortion"of"the"Pro363\Lys366"loop"exposed"more"
the" Ile365" backbone" amino" group" to" the" solvent,"making" it" hypothetically" available" for" the"
interaction"with" the" phosphate"moiety" of" an" incoming" nucleotide." The" change" of" hydrogen"
bonds" for" Ile365" could" be" aided" by" the" observed" interaction" between" Ser364" and" G2"
phosphate"as"it"only"occurred"when"the"Ile365"side"chain"is"facing"the"hydrophobic"cleft."The"
observed" importance" of" Ile365" side" chain" hydrophobic" interactions" was" also" supported" by"
mutational"studies"that"showed"that"the"replacement"of"this"residue"with"an"alanine"impaired"
the" unwinding" activity" of" DENV" NS3hel" without" affecting" the" ATPase" activity.[45,46]" The"
movement"of"RNA"away"from"D2"caused"a"bend"in"the"RNA"that"placed"the"5’"OH"group"of"A1"
in" front" of" the"RNA"binding" site" entrance." This" conformation"would" facilitate" the" entry" of" a"
novel"nucleotide"in"the"RNA"cleft,"supporting"the"importance"of"the"described"small"changes"
in"conformation"in"the"helicase"3’\5’"translocation"along"the"RNA."
Summarising," it" is"here"proposed"that"DENV"NS3hel"translocation"along"the"RNA"depends"on"
both"large"and"small"scale"changes"in"conformation."According"to"this"hypothesis,"D2"rotation"
is" linked" to" NTP" binding" and" produces" a" ratchet\like" movement" that" resembles" HCV"
mechanism"of"translocation"aided"by"transient"changes"in"residue"contacts"with"RNA."The"3’\5’"
directionality" of" the" protein" movement" along" the" nucleic" acid" is" mainly" depending" on" the"
presence"of"hydrophobic" residues"on"domain"2"β\hairpin" that" impede" the"movement" in" the"
opposite"direction,"just"like"a"pawl"in"a"ratchet."Additionally,"the"instability"of"G2"contacts"with"
D2"and" the" interactions"of" Ile365" side" chain"with"a" conserved"hydrophobic" site" in"domain"2"
could"be"important"factors"in"the"mechanism"of"entry"of"a"novel"nucleotide"at"the"nucleic"acid"
5’"end"in"the"RNA"binding"site."
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4.3.CONCLUSION.
"
In" this" study" two" different" molecular" systems" were" analysed" with" molecular" dynamics"
simulations" with" the" aim" of" investigating" the" behaviour" of" DENV" NS3hel" during" its"
translocation" along" the" RNA" strand," still" elusive" to" date.[15]" Classical" and" accelerated" MD"
simulations"have"been"performed"for"the"NS3hel\RNA"complex"with"and"without"ATP"and"the"
trajectories" were" analysed" and" used" for" binding" free" energy" estimation" with" the"MMGBSA"
methods.""
The" aMD" method" was" more" successful" in" producing" relevant" results" for" the" scope" of" the"
study,"namely"to"understand"the"mechanism"of"NS3hel"translocation"along"the"RNA"strand."In"
these" simulations" the" complete" transition" from" a" closed" to" an" open" conformation" of" the"
protein"has"not"been"obtained,"probably"because"a"high"energy"barrier"must"be"overcome"and"
the"applied"boost"potential"to"achieve"this"was"not"sufficient."Thus,"it"might"be"informative"to"
repeat" the" in& silico&experiment"with" a" higher" boost" and" compare" the" results"with" the" ones"
discussed"here."Furthermore," it"would"also"be"revealing"to"extend"the"RNA"strand"by"adding"
nucleotides" at" both" RNA" ends" and" evaluate" the" differences" in" the" conformational" changes"
discussed"here.""
Nevertheless," the" results" obtained" with" this" study" represent" a" substantial" increase" in" the"
understanding"of"this"enzyme"mechanism"of"action"and"it"is"believed"that"for"the"first"time"a"
hypothesis" on" DENV" NS3hel" translocation" along" the" RNA" has" been" formulated." Results"
indicated" that"both" large"scale"domain"movements"and"small" residue"conformation"changes"
are" important" and" that" the" protein" translocates" along" the" viral" genome" in" a" NTP\driven"
“ratchet\like”"manner," similarly" to" HCV.[12,13]" Residues" that" are" particularly" important" in" the"
translocation"mechanism"and"directionality"were"identified"and"could"be"used"for"future"drug"
design" approaches." For" example," a" conserved" hydrophobic" region" of" D2" formed" by" Val362,"
Gln384,"Thr389"and"Val406"could"be"used"as"a" target" site" for"a" structure\based"drug"design"
approach,"since"it"unexpectedly"showed"to"be"important"and"could"be"used"for"the"design"of"
novel"inhibitors"of"DENV"NS3hel."
"
"
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4.4.METHODS.
"
The" computational" methods" for" all" this" study" are" presented" here." A" description" of" the"
molecular"modelling"programs"used"can"be"found"in"APPENDIX&2."
"
HARDWARE'DETAILS'
"
The"GROMACS"40ns"cMD"simulations"were"performed"on"a"32"core"computer"with"Inter"Xeon"
2.20"GHz" E5\4620" CPUs,"while" the"AMBER14"MD" simulations"were" carried" out"with" a" Tesla"
K20c"GPU"on"a"32"core"computer"with"Inter"Xeon"2.20"GHz"E5\4620"CPUs."Trajectory"analysis"
calculations"were"performed"on"an"8"core"computer"with"Inter"Xeon"2.80"GHz"E5462"CPUs."
"
SYSTEM'PREPARATION'
"
The" selected"DENV"NS3hel" structures" (PDB" IDs:" 2JLU" and" 2JLV" for"NS3hel\RNA" and"NS3hel\
RNA\ATP" systems" respectively)"were" downloaded" from" the" Protein"Data" Bank" site.[15,47]" The"
systems"were"prepared"removing"water"molecules,"non\catalytic" ions"and"glycerol"whenever"
these" elements" were" present," using" MOE" 2010.10.[48]" In" PDB" 2JLV" AMPPNP" molecule" co\
crystallised"with"the"enzyme"was"modified"to"ATP"with"MOE"Builder."The"same"tool"was"also"
used" for" the" deletion" of" incomplete" RNA" nucleotides" in" the" original" crystal" structures." The"
missing" side" chain" of" Lys388" in" 2JLU" structure" was" built" with" MOE" Mutate" tool" and" then"
energy"minimised"with" AMBER99" force" field" and" 0.001" gradient," using" the" same"modelling"
program.""
"
CLASSICAL'MOLECULAR'DYNAMICS'SIMULATION'
"
For" each" of" the" molecular" systems," the" first" set" of" classical" MD" (cMD)" simulations" were"
computed"with"the"GROMACS"4.5.3[49]"program,"using"a"modified"version"of"the"implemented"
AMBER99" force" field." The" modification" regarded" the" insertion" of" missing" ATP" topology"
parameters." Polyphosphate" parameters" to" be" used" with" AMBER" force" field" have" been"
calculated" at" the" University" of" Michigan" using" molecular" orbital" calculations" at" the" RHF/6\
31+G*" level.[50]" The" same" research" group" also" reported" that" the" application" of" these"
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parameters"to"ATP"were"suitable"and"gave"good"agreement"with"CHARMM."Consequently,"the"
polyphosphate" parameters" were" used" for" ATP" topology" building" for" the" MD" simulations"
reported" in" this" work," according" to" the" methodology" used" by" R." Bryce" group.[51]" In" all" the"
simulations" the" system" was" automatically" protonated" according" to" the" selected" force" field"
during" topology" generation." The" simulation"was" conducted" in" PBC" conditions," using" a" cubic"
box"with"0.9nm"minimum"distance"between"the"molecular"system"and"the"box."Explicit"water"
molecules"described"with"the"TIP3P"model"were"added"and"the"systems"were"neutralised"with"
the" addition" of"monovalent" ions:" 3" Na+" and" 5" Na+" in" the" NS3hel\RNA" and"NS3hel\RNA\ATP"
system"respectively."
Two" consecutive" energy" minimisations" were" initially" performed," employing" the" steepest"
descendent" (SD)"method" first" and" then" the" conjugate" gradient" (CG)"method" after,"with" the"
aim"of"a"faster"process"and"more"accurate"result."A"force"tolerance"of"100"kJ"mol\1"nm\1"was"
set" for" SD," while" a" 10" kJ" mol\1" nm\1" force" tolerance" was" applied" with" CG." In" both" energy"
minimisations" the" maximum" number" of" iterations" was" set" to" 3,000" steps." Subsequently," a"
position" restrain" force" of" 1,000" kJ" mol\1" nm\2" was" applied" to" protein" and" ligand" atoms" for"
water" molecules" relaxation." Aiming" for" a" smoother" equilibration," two" consecutive" 50" ps"
(50,000"steps,"step"size"of"1"fs)"position"restrained"MDs"were"performed,"saving"coordinates,"
velocity" and" energy" values" every" 500" steps." NVT" conditions" (constant" number" of" atoms" N,"
volume"V"and"temperature"T)"were"used"for"the"first"position"restrained"MD"and"a"v\rescale"
temperature" coupling"and"0.1"ps" time"constant"was"used" to"heat" the" system" to"300"K."NPT"
conditions" (constant"number"of" atoms"N,"pressure"P" and" temperature"T)"were"used" for" the"
second"position"restrained"MD,"with"the"use"of"both"temperature"(v\rescale,"temperature"300"
K"and" time"constant"of"0.1"ps)"and"pressure" (Berendsen"algorithm,"1"bar"pressure"and" time"
constant" of" 0.5" ps)" coupling." A" 40" ns" (20000000" steps" with" 2" fs" step" size)" production"
simulation"with" leap\frog" algorithm"was" run" in" triplicates" for" each"molecular" system" in" the"
same"NPT"conditions"described"above."Coordinates,"velocities"and"energy"values"were"saved"
every" 1500" steps." In" all" simulation" stages," long\range" electrostatic" interactions" were"
calculated"with"the"Particle\Mesh\Ewald"(PME)"method"with"a"0.9"nm"short"range"cut\off"and"
short\range"non\bonded"interactions"were"computed"only"within"a"cut\off"of"1.4"nm."
Trajectories"were"visually"inspected"with"VMD"1.9.1[52],"analysed"with"GROMACS"4.5.3[49]"tools"
and"Grace"5.1.22[53]"and"used"for"principal"component"analysis"(PCA)"and"binding"free"energy"
estimation."
" "
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ACCELERATED'MOLECULAR'DYNAMICS'SIMULATIONS'
"
For"the"application"of"the"accelerated"MD"(aMD)"method,"calculations"were"performed"with"
the"AMBER"14[54]"program,"using"the"AMBER12SB"force"field.""
The"molecular" systems"were" automatically" protonated" according" to" the" selected" force" field"
during" topology" generation." The" simulation"was" conducted" in" PBC" conditions," using" a" cubic"
box"with"1.0nm"minimum"distance"between"the"molecular"system"and"the"box."Explicit"water"
molecules"described"with"the"TIP4P\Ew"model"were"added"and"the"systems"were"neutralised"
with" the"addition"of"monovalent" ions:"3"Na+"and"5"Na+" in" the"NS3hel\RNA"and"NS3hel\RNA\
ATP"system"respectively."
Two"consecutive"energy"minimisations"were" initially"performed,"one" restraining"protein"and"
ligand" atoms"with" a" 10" kcal"mol\1" Å\1" force" and" one"with" no" restraints." Both" of" them"were"
performed"for"6000"steps,"employing"the"steepest"descendent"(SD)"method"in"the"first"3000"
steps" first" and" the" conjugate" gradient" (CG)"method" for" the" last" 3000" steps,"with" the"aim"of"
obtaining" a" faster" process" and" more" accurate" result." The" systems" were" subsequently"
equilibrated"in"three"steps."First,"a"1ns"(500,000"steps,"step"size"of"2"fs)"NVT"(constant"number"
of"atoms"N,"volume"V"and"temperature"T)"equilibration"was"computed,"restraining"the"main"
chain"atoms"with"a"force"of"10"kcal"mol\1"Å\1."Here,"temperature"was"linearly"raised"from"0"to"
300K,"using" Langevin"dynamics" and" collision" frequency"of" 2"ps\1." Secondly," a" 2ns" (1,000,000"
steps," step" size" of" 2" fs)" NPT" (constant" number" of" atoms"N," pressure" P" and" temperature" T)"
equilibration"was"computed,"restraining"the"main"chain"atoms"with"a"force"of"10"kcal"mol\1"Å\1."
Here,"temperature"was"maintained"at"300K,"using"Langevin"dynamics"and"collision"frequency"
of"2"ps\1"and"pressure"was"set"to"1atm"by"applying"the"Berendsen"algorithm"coupling"with"a"
relaxation"time"of"2"ps."Thirdly,"a"3ns"(1,500,000"steps,"step"size"of"2"fs)"NPT"(constant"number"
of" atoms"N," pressure" P" and" temperature" T)" equilibration"was" computed,"with" no" restraints"
and" the" same" temperature" and" pressure" coupling" of" the" second" equilibration." In" all"
equilibration" stages," long\range" electrostatic" interactions" were" calculated"with" the" Particle\
Mesh\Ewald"(PME)"method"with"a"1.0"nm"cut\off"and"a"SHAKE"bond"constraint"was"applied.""
Prior"to"the"aMD"simulation"a"40ns"(20,000,000"steps"with"2"fs"step"size)"cMD"with"the"leap\
frog" algorithm" was" computed" for" both" the" NS3hel\RNA" and" NS3hel\RNA\ATP" molecular"
systems"with"the"same"NPT"conditions"described"for"the"last"two"equilibration"stages.""
The"aMD"method"was"performed"on"the"equilibrated"systems"and"a"dual"boost"(for"dihedral"
and"potential"energies)"was"applied."The"threshold"energies"(Edihed"and"Epot,"see"Equation"4.2)"
and" tuning" parameters" (αdihed" and" αpot," see" Equation" 4.2)" were" computed" using" the" cMD"
results"in"the"following"Equations:"
"
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!!"!!" = 4!!"#$! "#!!!"#!! ∗ !"# /5"
Equation'4.3.'Dihedral.tuning.parameter.[40]..
αdihed:"tuning"parameter"for"dihedral"potential"boost;"RES:"number"of"residues"in"the"large"molecule..!!"!!" = !"#$! + 5 ∗ !!"!!" "
Equation'4.4.'Dihedral.threshold.energy.[40]..
Edihed:"threshold"energy"for"dihedral"potential"boost;"DIHED:"average"dihedral"energy"obtained"from"cMD"
simulations..!!"# = !0.16!!"#$! "#!!!"#$%!! ∗ !"#$% "
Equation'4.5.'Potential.energy.tuning.parameter.[40]..
αpot:"tuning"parameter"for"potential"energy"boost;"ATOMS:"number"of"atoms"in"the"molecular"system,"including"
water"molecules..!!"# = !"# + !!"#"
Equation'4.6.'Dihedral.threshold.energy.[40]..
Epot:"threshold"energy"for"potential"energy"boost;"POT:"average"potential"energy"obtained"from"cMD"simulations..
The"values"of"the"number"of"residues"of"the"large"molecules"(RES),"the"number"of"atoms"in"the"
systems"(ATOMS),"the"average"dihedral"energy"(DIHED)"and"the"average"potential"energy"
(POT)"used"for"a"MD"set"up"are"reported"in"Table"4.5."
A" 200ns" (100,000,000" steps" with" 2" fs" step" size)" aMD" with" the" leap\frog" algorithm" was"
consequently" computed" for" both" the" NS3hel\RNA" and" NS3hel\RNA\ATP" molecular" systems"
with"the"same"NPT"conditions"described"for"the"last"two"equilibration"stages."
In"all"AMBER"cMD"and"aMD"simulations,"long\range"electrostatic"interactions"were"calculated"
with" the" Particle\Mesh\Ewald" (PME)" method" with" a" 1.0" nm" cut\off" and" a" SHAKE" bond"
constraint"was"applied."
aMD"trajectories"were"visually"inspected"with"VMD"1.9.1[52],"analysed"with"AMBER"14[54]"tools"
and"Grace"5.1.22[53]"and"used"for"principal"component"analysis"(PCA)"and"binding"free"energy"
estimation."
"
PRINCIPAL'COMPONENT'ANALYSIS'
"
Principal" component" analysis" (PCA)"was" computed" on" trajectories" obtained"with" GROMACS"
cMD"or" AMBER" aMD." In" both" cases," the" overall" translational" and" rotational"motions" of" the"
system"were"eliminated"by"centring"the"system"and"by"a" least"square"fit" to"the"backbone"of"
the" protein." The" covariance" matrix" Cij" of" the" analysed" atomic" coordinates" was" generated"
according"to"Equation"4.7."Here," i"and"j"are"two"atoms"and"represent"all"the"possible"ij"atom"
pairs"of"Cartesian"coordinates"(x)."The"<>"brackets" indicate"average"values."Cij" is"a"symmetric"
3N"x"3N"matrix,"where"N"is"the"number"of"atoms"considered."The"matrix"can"be"diagonalised"
with"an"orthonormal"transformation"matrix"R,"whose"columns"correspond"to"the"eigenvectors"
or" principal" or" essential" modes." Eigenvectors" represent" the" vectorial" description" of" each"
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component"of" the"motion,"while"eigenvalues" (the"diagonalisation" results)" correspond" to" the"
contribution"of"that"particular"mode"to"the"total"motion"of"the"system."
" !!" = !! − !! ∗ !! − !! "
Equation'4.7.'Covariance.matrix.[55]..
Cij:"covariance"matrix"of"all"possible"ij"atom"pairs;"i,j="atoms;"<>:"average"values..
For" the" cMD" simulations" performed" with" GROMACS" 4.5.3[49]," PCA" was" performed" with" the"
same"program"on"Cα"atoms"of" the"protein"and"all"atoms"of"RNA." In"order" to" investigate" the"
main"system"fluctuations,"the"first"10"principal"models"were"analysed"for"each"cMD"simulation"
and" for" each" of" these" eigenvectors," the" filtered" trajectory" was" visually" inspected" and" a"
porcupine"plot"was"built."
For" the" aMD" simulations" performed"with" AMBER" 14,[54]" PCA"was" performed"with" the" same"
program"on"Cα"atoms"of"the"protein"and"RNA"heavy,"when"present"in"the"simulation."In"order"
to" investigate" the"main" system" fluctuations," the" first" 10"principal"models"were" analysed" for"
each" aMD" simulation." The" first" 5" eigenvectors"were" further" investigated" through" trajectory"
projection,"atom"RMSF"calculation,"visual" inspection"of" the" filtered" trajectory"and"porcupine"
plot"design."
"
BINDING'FREE'ENERGY'CALCULATIONS'
"
The" trajectories" of" cMD"and"aMD" simulations"were"used" for" the" calculations"of" the"binding"
free"energy"of"RNA"to"DENV"NS3"helicase."The"system"coordinates,"excluding"water"molecules"
and"non\catalytic"ions,"were"saved"with"VMD"1.9.1.[52]"A"total"of"1906"and"2000"frames"were"
saved" for" each" cMD" and" each" aMD" trajectory" respectively." The" binding" free" energy" (see"
Equations"A2.12"and"A2.13"of"APPENDIX&2)"of"the"nucleic"acid"to"the"helicase"was"calculated"
with" the" MMPBSA" program" of" the" AMBER" suite" through" a" Generalized" Born" Surface" Area"
(MMGBSA)"approach"computed"with"the"inbuilt"MMPBSA"program."AMBER"12[56]"and"AMBER"
14[54]"versions"of"the"program"were"used"for"the"cMD"and"aMD"simulations"respectively."For"
polar"solvation"contribution"calculations"a"salt"concentration"of"0.100M"was"chosen"and"the"
dielectric"constants" for"the"solvent"and"for"the"solute"were"set"to"80"and"1"respectively."For"
nonpolar" solvation" contributions" the" surface" tension" and" the" offset" constant" were" set" to"
0.0072"kcal"mol\1"Å\2"and"\1.008"kcal"mol\1"and"the"SASA"was"computed"using"a"water"probe"
with"1.4"Å"radius."
Binding" and" free" energies" were" calculated" for" each" trajectory" frame" saved" and" plotted" in"
spread" sheet" charts,"where"averages" and" standard"deviations"were" calculated." The"entropic"
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term"of" the" free"energies"was"not" calculated," as" the"objective"of" this"work"was" to" compare"
binding"energies"rather"than"calculating"their"absolute"values."
For"a"deeper"analysis"of"the"interactions"between"RNA"and"the"DENV"NS3"helicase"residues"of"
interest," further" MMGBSA" calculations" with" binding" free" energy" decomposition" to" each"
residue"were"computed"with"the"same"variables"values"described"above.""
"
"
"
"
Section"4:"NS3HEL"MECHNISM"OF"TRANSLOCATION"ALONG"RNA" 4.5&BIBLIOGRAPHY"!
!187"
4.5.BIBLIOGRAPHY.!
[1]:"A."J."Stevens,"M."E."Gahan,"S."Mahalingam,"P."A."Keller,"The"Medicinal"Chemistry"of"Dengue"Fever,"J.&
Med.&Chem."52"(2009),"p."7911\7926,"DOI:"10.1021/jm900652e"
"
[2]:"J."Lescar,"D."Luo,"T."Xu,"A."Sampath,"S."P."Lim,"B."Canard,"S."G."Vasudevan,"Towards"the"design"of"
antiviral"inhibitors"against"flaviviruses:"The"case"for"the"multifunctional"NS3"protein"from"Dengue"virus"
as"a"target,"Antiviral&Research"80"(2008),"p.94\101,"DOI:"10.1016/j.antiviral.2008.07.001""
"
[3]:"C."G."Noble,"Y\L"Chen,"H."Dong,"F."Gu,"S."P."Lim,"W."Schul,"Q\Y"Wang,"P\Y"Shi,"Strategies"for"
development"of"dengue"virus"inhibitors,"Antiviral&Research"85"(2010),"p."450\462,"DOI:"
10.1016/j.antiviral.2009.12.011"
"
[4]:"D."Benarroch,"B."Selisko,"G."A."Locatelli,"G."Maga,"J.\L."Romette,"B."Canard,"The"RNA"helicase,"
nucleotide"5’\triphosphatase,"and"RNA"5’\triphospatase"activities"of"Dengue"virus"protein"NS3"are"Mg2+\
dependent"and"require"a"functional"Walker"B"motif"in"the"helicase"catalytic"core,"Virology"328"(2004),"p."
208\218,"DOI:"10.1016/j.virol.2004.07.004"
"
[5]:"C.\C."Wang,"Z.\S."Huang,"P.\L."Chiang,"C.\T."Chen,"H.\N."Wu,"Analysis"of"the"nucleoside"
triphosphatase,"RNA"triphosphatase,"and"unwinding"activities"of"the"helicase"domain"of"dengue"virus"
NS3"protein,"FEBS&Letters"583"(2009),"p."691\696,"DOI:"10.1016/j.febslet.2009.01008"
"
[6]:"S."P."Lim,"Q.\Y."Wang,"C."G."Noble,"Y.\L."Chen,"H."Dong,"B."Zou,"F."Yokokawa,"S."Nilar,"P."Smith,"D."
Beer,"J."Lescar,"P.\Y."Shi,"Ten"years"of"dengue"drug"discovery:"Progress"and"prospects,"Antiviral&Research"
100"(2013),"p."500\519,"DOI:"10.1016/j.antiviral.2013.09.013"
"
[7]:"E."Mastrangelo,"M."Pezzullo,"M."Bolognesi,"S."Keptein,"J."Neyts,"B."Pastorino,"X."de"Lambellerie,"M."
Milani,"Targeting"the"Flavivirus"Helicase,"Abstracts/Antiviral&Research&90"(2011),"p."A21\A78,"DOI:"
10.1016/j.antiviral.2011.03.155"
"
[8]:"E."Mastrangelo,"M."Pezzullo,"T."De"Burghgraeve,"S."Kaptein,"B."Pastorino,"K."Dallmeier,"X."de"
Lamballerie,"J."Neyts,"A."M."Hanson,"D."N."Frick,"M."Bolognesi,"M."Milani,"Ivermectin"is"a"potent"inhibitor"
of"flavivirus"replication"specifically"targeting"NS3"helicase"activity:"new"rospects"for"an"old"drug,"Journal&
of&Antimicrobial&Chemotherapy"67"(2012),"p."1884\1894,"DOI:"10.1093/jac/dks147"
"
[9]:"C."M."Byrd,"D."W."Grosenbach,"A."Bernhanu,"D."Dai,"K."F."Jones,"K."B."Cardwell,"C."Schneider,"G."Yang,"
S."Tyavanagimatt,"C."Harver,"K."A."Wineinger,"J."Page,"E."Stavale,"M."A."Stone,"K."P."Fuller,"C."Lovejoy,"J."
M."Leeds,"D."E."Hruby,"R."Jordan,"Novel"Benzoxazole"Inhibitor"of"Dengue"Virus"Replication"That"Targets"
the"NS3"Helicase,"Antimicrobial&Agents&and&Chemotherapy"57"(2003),&p."1902\1912,"DOI:"
10.1128/AAC.02251\12"
"
[10]:"A."M."Pyle,"Translocation"and"Unwinding"Mechanism"of"RNA"and"DNA"Helicases."Annual&Review&of&
Biophysics"37"(2008),"p."317\338,"DOI:"10.1146/annurev.biophys.37.032807.125908"
"
[11]:"K."Büttner,"S."Nehring,"K.\P."Hopfner,"Structural"basis"for"DNA"duplex"separation"by"a"superfamily\2"
helicase,"Nature&Structural&and&Molecular&Biology"14"(2007),"p."647\652,"DOI:"10.1038/nsmb1246"
"
[12]:"M."Gu,"C."M."Rice,"Three"conformational"snapshots"of"the"hepatitis"C"virus"NS3"helicase"reveal"a"
ratchet"translocation"mechanism,"PNAS"107"(2010),"p."521\528,"DOI:"10.1073/PNAS.0913380107"
"
[13]:"T."C."Appleby,"R."Anderson,"O."Fedorova,"A."M."Pyle,"R."Wang,"X."Liu,"K."M."Brendza,"J."R."Somoza,"
Visualizing"ATP\Dependent"RNA"Translocation"by"the"NS3"Helicase"from"HCV,"Journal&of&Molecular&
Biology"405"(2010),"p."1139\1153,"DOI:"10.1016/j.jmb.2010.11.034"
"
Section"4:"NS3HEL"MECHNISM"OF"TRANSLOCATION"ALONG"RNA" 4.5&BIBLIOGRAPHY"!
!188"
[14]:"T."Xu,"A."Sampath,"A."Chao,"D."Wen,"M."Nanao,"P."Chene,"S."G."Vasudevan,"J."Lescar,"Structure"of"
the"Dengue"Virus"Helicase/Nucleoside"Triphosphatase"Catalytic"Domain"at"a"Resolution"of"2.4Å,"Journal&
of&Virology"79"(2005),"p."10278\10288,"DOI:"10.1128/JVI.79.16.10278\10288.2005"
"
[15]:"D."Luo,"T."Xu,"R."P."Watson,"D."Scherer\Becker,"A."Sampath,"W."Jahnke,"S."Sum"Yeong,"C."Hoe"Wang,"
S."Pheng"Lim,"A."Strongin,"S."G."Vasudevan,"J."Lescar,"Insights"into"RNA"unwinding"and"ATP"hydrolysis"by"
the"flavivirus"NS3"protein,"The&EMBO&Journal"27"(2008),"p."3209\3219,"DOI:"10.1038/emboj.2008.232"
"
[16]:"E."Mastrangelo,"M."Bolognesi,"M."Milani,"Flaviviral"helicase:"Insights"into"the"mechanism"of"action"
of"a"motor"protein,"Biochemical&and&Biophysical&Research&Communications"417"(2012),"p."84\87,"DOI:"
10.1016/j.bbrc.2011.11.060"
"
[17]:"A."Sampath,"R."Padmanabhan,"Molecular"targets"for"flavivirus"drug"discovery,"Antiviral&Research&
81"(2009),"p."6\15,"DOI:"10.1016/j.antiviral.2008.08.004"
"
[18]:"D."Hamelberg,"J."Mongan,"J."A."McCammon,"Accelerated"molecular"dynamics:"A"promising"and"
efficient"simulation"method"for"biomolecules,"Journal&of&Chemical&Physics"120"(2004),"p."11919\11929,"
DOI:"10.1063/1.1755656"
"
[19]:"D."Hamelberg,"C."A."F."de"Oliveira,"J."A."McCammon,"Sampling"of"slow"diffusive"conformational"
transitions"with"accelerated"molecular"dynamics,"Journal&of&Chemical&Physics"127"(2007),"p."155102,"
DOI:"10.1063/1.2789432"
"
[20]:"L."C."T."Pierce,"R."Salomon\Ferrer,"C."A."F."de"Oliveira,"J."A."McCammon,"R."C."Walker,"Routine"
Access"to"Millisecond"Time"Scale"Events"with"Accelerated"Molecular"Dynamics,"Journal&of&Chemical&
Theory&and&Computation"8"(2012),"p."2997\3002,"DOI:"10.1021/ct300284"
"
[21]:"S."Hayward,"B."L."de"Groot,"Normal"Modes"and"Essential"Dynamics"\"Methods"in"Molecular"Biology,"
vol."443"(2008),"p."89\106,"Humana&Press,&Totowa,&NJ.&
"
[22]:"B."Hess,"Convergence"of"sampling"in"protein"simulations,"Physical&Review&E"65"(2002),"p."031910,"
DOI:"10.1103/PhysRevE.65.031910"
"
[23]:"S."Roy,"S."Sen,"Exploring"the"potential"of"complex"formation"between"a"mutant"DNA"and"the"wild"
type"protein"counterpart:"a"MM"and"MD"simulation"approach,"Journal&of&Molecular&Graphics&and&
Modelling"25"(2006),"p."158\168,"DOI:"10.1016/j.jmgm.2005.11.004"
"
[24]:"G."Paillard,"R."Lavery,"Analyzing"Protein\DNA"Recognition"Mechanism,"Structure"12"(2004),"p."113\
122,"DOI:"10.1016/j.str.2003.11.022"
"
[25]:"C."D."Christ,"A."E."Mark,"W."F."van"Gunsteren,"Basic"ingredients"of"free"energy"calculations:"a"
review,"Journal&of&Computational&Chemistry"31"(2010),"p."1569\1582,"DOI:"10.1002/jcc.21450"
"
[26]:"P."Kollman,"Free"energy"calculations:"applications"to"chemical"and"biochemical"phenomena,"
Chemical&Reviews"93"(1993),"p."2395\2417,"DOI:"10.1021/cr00023a004"
"
[27]:"B."Kuhn,"P."A."Kollman,"Binding"of"a"diverse"set"of"ligands"to"avidin"and"streptavidin:"an"accurate"
quantitative"prediction"of"their"relative"affinities"by"a"combination"of"molecular"mechanics"and"
quantum"solvent"models,"Journal&of&Medicinal&Chemistry"43"(2000),"p."3786\3791,"DOI:"DOI:"
10.1021/jm000241h"
"
[28]:"R."N."Shinde,"M."E."Sobhia,"Binding"and"discerning"interactions"of"PTP1B"allosteric"inhibitors:"Novel"
insights"from"molecular"dynamics"simulations,"Journal&of&Molecular&Graphics&and&Modelling"45"(2013),"
p."98\110,"DOI:"10.1016/j.jmgm.2013.08.001"
"
[29]:"S.\F."Chen,"S."Cao,"S."Han,"J.\Z."Chen,"Insight"into"the"structural"mechanism"for"PKBα"allosteric"
inhibition"by"molecular"dynamics"simulations"and"free"energy"calculations,"Journal&of&Molecular&
Section"4:"NS3HEL"MECHNISM"OF"TRANSLOCATION"ALONG"RNA" 4.5&BIBLIOGRAPHY"!
!189"
Graphics&and&Modelling"48"(2014),"p."36\46,"DOI:"10.1016/j.jmgm.2013.12.002"
"
[30]:"W."Xue,"H."Liu,"X."Yao,"Molecular"Mechanism"of"HIV\1"Integrase\vDNA"Interactions"and"Strand"
Transfer"Inhibitor"Action:"A"Molecular"Modeling"Perspective,"Journal&of&Computational&Chemistry"33,"p."
527\536"(2012),"DOI:"10.1002/jcc.22887"
"
[31]:"C."Gao,"J."M."Herold,"D."Kireev,"Assessment"of"free"energy"predictors"for"ligand"binding"to"a"
methyllysine"histone"code"reader,"Journal&of&Computational&Chmistry"33"(2012),"p."659\665,"DOI:"
10.1002/jcc.22888"
"
[32]:"D."P."Oehme,"R."T."C."Brownlee,"D."J."D."Wilson,"Effect"of"atomic"charge,"solvation,"entropy,"and"
ligand"protonation"state"on"MM\PB(GB)SA"binding"energies"of"HIV"protease,"Journal&of&Computational&
Chemistry"33"(2012),"p."2566\2580,"DOI:"10.1002/jcc.23095"
"
[33]:"X."X."Yao,"C."G."Ji,"D."Q."Xie,"J."Z."H."Zhang,"Molecular"dynamics"study"of"DNA"binding"by"INT\DBD"
under"a"polarized"force"field,"Journal&of&Computational&Chemistry"34"(2013),"p."1136\1142,"DOI:"
10.1002/jcc.23244"
"
[34]:"V."Tsui,"D."A."Case,"Theory"and"applications"of"the"Generalised"Born"solvation"model"in"
macromolecular"simulations,"Biopolymers"56"(2001),"p."275\291,"DOI:"10.1002/1097\
0282(2000)56:4<275::AID\BIP10024>3.0.CO;2\E"
"
[35]:"H."Gohle,"C."Kiel,"D."A."Case,"Insights"into"protein–protein"binding"by"binding"free"energy"
calculation"and"free"energy"decomposition"for"the"Ras–Raf"and"Ras–RalGDS"complexes,"Journal&of&
Molecular&Biology"330"(2003),"p."891\913,"DOI:"10.1016/S0022\2836(03)00610\7"
"
[36]:"N."Foloppe,"R."Hubbard,"Towards"Predictive"Ligand"Design"With"Free\Energy"Based"Computational"
Methods?,"Current&Medicinal&Chemistry"13"(2006),"p:"3583\3608.,"DOI:"
10.2174/092986706779026165#sthash.d1egOHBo.dpuf"
"
[37]:"A."D."MacKerell"Jr.,"L."Nilsson,"Molecular"dynamics"simulations"of"nucleic"acid\protein"complexes,"
Current&Opinion&in&Structural&Biology"18"(2008),"p."194\199,"DOI:"10.1016/j.sbi.2007.12.012"
"
[38]:"C.A."Chang,"W."Chen,"M."K."Gilson,"Ligand"configurational"entropy"and"protein"binding,"PNAS"104"
(2007),"p."1534\1539,"DOI:"10.1073/pnas.0610494104"
"
[39]:"C."S."Page,"P."A."Bates,"Can"MM\PBSA"calculations"predict"the"specificities"of"protein"kinase"
inhibitors?"Journal&of&Computational&Chemistry"27"(2006),"p."1990\2007,"DOI:"10.1002/jcc.20534"
"
[40]:"J."Wereszczynski,"J."A."McCammon,"Computational"Drug"Discovery"and"Design"\"Accelerated"
Molecular"Dynamics"in"Computational"Drug"Design,"Baron&Riccardo&Ed.&Springer&Science&+&Business&
Media"(2012),"p."515\524,"DOI:"10.1007/978\1\61779\465\0_30"
"
[41]:"B."J."Grant,"A."A."Gorfe,"J."A."McCammon,"Ras"Conformational"Switching:"Simulating"Nucleotide\
Dependent"Conformational"Transitions"with"Accelerated"Molecular"Dynamics,"PLoS&Computational&
Biology"5"(2009),"p."e1000325,"DOI:"10.1371/journal.pcbi.1000325"
"
[42]:"P."R."L."Markwick,"J."A."McCammon,"Studying"functional"dynamics"in"bio\molecules"using"
accelerated"molecular"dynamics,"Physical&Chemistry&Chemical&Physics"13"(2011),"p."20053\20065,"DOI:"
10.1039/c1cp22100k"
"
[43]:"B."Fuglestad,"P."M."Gasper,"J."A."McCammon,"P."R."L."Markwick,"E."A."Komives,"Correlated"Motions"
and"Residual"Frustration"in"Thrombin,"Journal&of&Physical&Chemistry"117"(2013),"p."12857\12863,"DOI:"
10.1021/jp402107u"
"
[44]:"C."A."F."de"Oliveira,"B."J."Grant,"M."Zhou,"J."A."McCammon,"Large\Scale"Conformational"Changes"of"
Trypanosoma"cruzi"Proline"Racemase"Predicted"by"Accelerated"Molecular"Dynamics"Simulation,"PLoS&
Section"4:"NS3HEL"MECHNISM"OF"TRANSLOCATION"ALONG"RNA" 4.5&BIBLIOGRAPHY"!
!190"
Computational&Biology"7"(2011),"p."e1002178,"DOI:"10.1371/journal.pcbi.1002178"
"
[45]:"A."E."Matusan,"M."J."Pryor,"A."D."Davidson,"P."J."Wright,"Mutagenesis"of"the"Dengue"Virus"Type"2"
NS3"Protein"within"and"outside"Helicase"Motifs:"Effects"on"Enzymatic"Activity"and"Virus"Replication,"
Journal&of&Virology"75"(2001),"p."9633\9643,"DOI:"10.1128/JVI.75.20.9633\9643.2001"
"
[46]:"A."Sampath,"T."Xu,"A."Chao,"D."Luo,"J."lescar,"S."G."Vasudevan,"Structure\Based"Mutational"Analysis"
of"the"NS3"Helicase"from"Dengue"Virus,"Journal&of&Virology"80"(2006),"p.6686\6690,"DOI:"
10.1128/JVI.02215\05"
"
[47]:"Protein"Data"Bank,"www.pdb.org"(Accessed,"October"2014)"
"
[48]:"Chemical"Computing"Group"Inc.,"Molecular"Operating"Environment"(MOE)"2010.10,"1010"
Sherbooke"St."West,"Suite"#910,"Montreal,"QC,"Canada,"H3A"2R7,"(2010)"
"
[49]:"D."van"der"Spoel,"E."Lindahl,"B."Hess,"G."Groenhof,"A."E."Mark,"H."J."Berendsen,"GROMACS:"Fast,"
flexible"and"free,"Journal&of&Computational&Chemistry"26"(2005),"p."1701\1718,"DOI:"10.1002/jcc.20291"
"
[50]:"K."L."Meagher,"L."T."Redman,"H."A."Carlson,"Development"of"Polyphosphate"Parameters"for"Use"
with"the"AMBER"Force"Field,"J.&Comput.&Chem."24"(2003),"p."1016\1025,"DOI:"10.1002/jcc.10262"
"
[51]:"The"University"of"Manchester,"Brice"Group:"Computational"Biophysics"and"Drug"Design,"AMBER"
parameter"database,"http://www.pharmacy.manchester.ac.uk/bryce/amber"(Accessed"April"2014)"
"
[52]:"W."Humphrey,"A."Dalke,"K."Schulten,"VMD"–"Visual"Molecular"Dynamics,"Journal&of&Molecular&
graphics"14"(1996),"p."33\38,"DOI:"10.1016/0263\7855(96)00018\5"
"
[53]:"Stambulchik,"Evgeny"(1998\2000),"Grace,"retrieved"2009\06\20"
"
[54]:"D.A."Case,"V."Babin,"J.T."Berryman,"R.M."Betz,"Q."Cai,"D.S."Cerutti,"T.E."Cheatham,"III,"T.A."Darden,"
R.E."Duke,"H."Gohlke,"A.W."Goetz,"S."Gusarov,"N."Homeyer,"P."Janowski,"J."Kaus,"I."Kolossváry,"A."
Kovalenko,"T.S."Lee,"S."LeGrand,"T."Luchko,"R."Luo,"B."Madej,"K.M."Merz,"F."Paesani,"D.R."Roe,"A."
Roitberg,"C."Sagui,"R."Salomon\Ferrer,"G."Seabra,"C.L."Simmerling,"W."Smith,"J."Swails,"R.C."Walker,"J."
Wang,"R.M."Wolf,"X."Wu"and"P.A."Kollman,"AMBER"14,"University"of"California,"San"Francisco"(2014)."
"
[55]:"D."van"der"Spoel,"E."Lindahl,"B."Hess,"A."R."van"Buuren,"E."Apol,"P."J."Meulenhoff,"D."P."Tieleman,"A."
L."T."M."Sijbers,"K."A."Feenstra,"R."van"Drunen"and"H."J."C."Berendsen,"Gromacs"User"Manual"version"4.5,"
(2010),"www.gromacs.org"
"
[56]:"D."A."Case,"T."A."Darden,"T."E."Cheatham,"III,"C."L."Simmerling,"J."Wang,"R."E."Duke,"R."Luo,"R."C."
Walker,"W."Zhang,"K."M."Merz,"B."Roberts,"S."Hayik,"A."Roitberg,"G."Seabra,"J."Swails,"A."W."Götz,"I."
Kolossváry,"K."F."Wong,"F."Paesani,"J."Vanicek,"R."M."Wolf,"J."Liu,"X."Wu,"S."R."Brozell,"T."Steinbrecher,"H."
Gohlke,"Q."Cai,"X."Ye,"J."Wang,"M.\J."Hsieh,"G."Cui,"D."R."Roe,"D."H."Mathwes,"M."G."Seetin,"R."Salomon\
Ferrer,"C."Sagui,"V."Babin,"T."Luchko,"S."Gustarov,"A."Kovalenko,"P."A."Kollman,"AMBER"12,"University"of"
California,"San"Francisco"(2012)"
"
!!
"
"
Section.5:.NS5.METHYLTRANSFERASE.AS.A.DRUG.TARGET.
"
"
"
"
"
"
"
"
"
"
Section 5:  
NS5 METHYLTRANSFERASE AS A 
DRUG TARGET 
"
Section"5:"NS5"METHYLTRANSFERASE"AS"A"DRUG"TARGET" 5.1&INTRODUCTION"!
192!
5.1.INTRODUCTION..
"
A'PROMISING'DRUG'TARGET'
"
Viral" RNA" plays" a" fundamental" role" in" the" replication" cycle" because" it" is" necessary" for" the"
synthesis"of"the"viral"proteins"and"of"a"new"genome"for"the"nascent"virions.[1,2]"In"order"to"be"
able"to"be"recognised"by"host"cell"ribosomes,"the"RNA"must"present"a"chemical"modification"at"
the"5’"end"called"cap."The"same"structure"is"also"fundamental"for"increasing"the"RNA"stability"
itself" as" it" impedes" the" action" of" several" cellular" 5’" exonucleases" that" are" responsible" for"
nucleic"acid"degradation."The"cap"structure"is"given"by"a"guanosine"nucleoside"that"is"linked"to"
the" 5’" end" RNA" nucleoside" (usually" adenosine)" through" a" 5’\5’" triphosphate" bridge." This"
structure"can"then"be"methylated,"giving"different"types"of"caps,"depending"on"the"number"of"
methylations"as"shown"in"Figure"5.1."A"cap"0"is"methylated"in"the"guanine"N\7"position;"a"cap"1"
is"methylated"in"the"guanine"N\7"position"and"in"the"5’"end"RNA"nucleoside"2’"hydroxyl"group;"
while"cap"2"is"methylated"as"a"cap"1"with"an"additional"methyl"group"on"the"2’"hydroxyl"group"
of"the"second"nucleotide"of"the"5’"end"of"the"RNA.[3]"
"
!
Figure.5.1..General.cap.structure...
The"general"structure"of"a"RNA"cap"is"reported"here."The"guanosine"is"linked"to"the"5’"end"nucleoside"through"a"5’\
5’"triphosphate"bridge."Different"methylation"states"give"different"cap"types."Cap"0"(green"arrows)"is"methylated"
once,"cap"1"(orange"arrows)"is"methylated"twice"and"cap"2"(light"blue"arrows)"is"methylated"three"times."Added"
methyl"groups"are"highlighted"with"circles"and"the"5’"and"3’"end"of"the"RNA"are"indicated."
DENV" ribonucleic" acid" is" modified" with" a" cap" 1" structure" that" is" usually" indicated" in" the"
following" way:" 7MeGpppA2’OMe\RNA.[4,5]" It" has" been" shown" that" the" methylation" in" the" N\7"
position"is"fundamental"for"an"efficient"RNA"translation,"making"it"an"essential"feature"for"viral"
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replication." Conversely," the" lack"of" the"2’\O"methylation"does"not" stop" viral" replication," but"
the" viruses" formed" are" highly" attenuated" because" this" methylation" is" critical" for" avoiding"
cellular" recognition" that" the" viral" RNA" as" non\self," that" would" lead" to" immune" system"
activation.[6]"
Also"eukaryotic"mRNA" is" capped"co\transcriptionally" in" the"cell"nucleus,"but"as"dengue"virus"
replication"occurs" in"the"cell"cytoplasm,"there"are"no"possibilities" for" the"virus"to"exploit" the"
host"capping"proteins"and"therefore"it"has"evolved"its"own"capping"machinery.[3,4]" In"general,"
capping"occurs"in"four"stages."Prior"to"capping,"the"nascent"RNA"strand"has"a"triphosphate"A"at"
the" 5’" end" (pppA\RNA)." This" nucleoside" is" first" processed" by" the" NS3" RNA" triphosphatase"
(RNAse)" that" cleaves" the" γ\phosphate," resulting" in" an" A" diphosphate" 5’" end" (ppA\RNA)."
Secondly,"a"not"yet" identified"guanylyltransferase,"transfers"a"GMP"moiety"from"GTP"to"ppA\
RNA," forming" the" non\methylated" form" of" the" cap:" GpppA\RNA." At" this" point," NS5"
methyltransferase"(MTase)" is"responsible"for"the"third"and"fourth"steps"as" it"methylates"first"
the"N\7"of"G"and"then"position"2’\O"of"A.[3,4,7]"
From"that"which"is"stated"above,"it"can"be"inferred"that"the"cap"is"essential"for"viral"RNA"and"
therefore"it"is"essential"for"the"viral"replication"cycle."NS5"MTase"is"responsible"for"two"of"the"
four" steps"of" cap" formation"and" it"has"been"shown" that" it’s"activity" is"essential" for"effective"
viral" replication.[8,9]" Consequently,"NS5"MTase" is" a" promising" target" for" drugs" that"would"be"
potentially"potent"and"selective"anti\DENV"agents.[4,10\12]"
"
STRUCTURE'
"
NS5"methyltransferase"is"the"N\terminal"portion"of"the"104"kDa"multifunctional"non"structural"
protein"NS5."NS5"is"not"only"the"largest"dengue"virus"protein,"but"also"the"most"conserved"one"
within"the"Flavivirus"genus"and"among"DENV"serotypes"with"64%"amino"acid"homology.[12\14]"
Within"NS5,"three"principal"functional"domains"have"been"identified."At"the"N\terminal"(amino"
acids"1\263),"NS5"has"a"S\adenosyl\L\methionine"(SAM)"dependent"methyltransferase"(MTase)"
function"that"allows"the"completion"of"the"RNA"capping."The"region"between"residues"320"and"
368" is" responsible" for" the"binding"of" another" viral" encoded"protein:"NS3." In" fact," these" two"
enzymes"appear"to"regulate"each"other’s"function"as"it"has"been"reported"that"NS5"enhances"
the"NTPase"and"5’"RNA"triphosphatase"activity"of"NS3."The"C\terminal"region"of"NS5"is"a"RNA\
dependent"RNA"polymerase"(RdRp)."The"function"of"the"RdRp"is"to"synthesize"a"double"strand"
RNA"from"a"RNA"template."This"allows"the"synthesis"of"a"negative"stranded"RNA"molecule"that"
serves"as"a"template"for"the"transcription"of"the"viral"genome.[4,14]""
Unfortunately,"the"structure"of"the"full\length"protein"has"not"yet"been"solved"and"therefore"
the" exact" interaction" between" the" RdRp" and" the" MTase" is" not" known." However," SAXS"
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experiments"have" shown" that" the" two"NS5"domains" can"adopt" several" relative"orientations,"
due" to" the" flexibility" of" the" linker" that" connects" them" (His263" to" Pro271).[15]" One" of" these"
orientations"was"proposed"for"West"Nile"virus"(WNV)"using"an"in&silico"model.[16]"By"means"of"a"
protein\protein" docking" algorithm" and" mutational" studies," it" has" been" proposed" that" the"
Lys46," Arg47" and"Glu49" loop" of" the"MTase" interacts"with" Leu512" of" the" RdRp" (numeration"
refers" to" DENV3)." As" NS5" is" highly" conserved" in" the" Flavivirus" genus," this" model" could" be"
transferred" also" to" DENV.[17]" A" second" orientation" has" been" proposed" on" the" basis" of" two"
recent"crystal"structures:"the"full"length"Japanese"Encephalitis"Virus"(JEV)"NS5"protein"and"the"
DENV"NS5"RdRp"with"a"small"linker"portion"(residues"268\271)."The"conformation"of"the"linker"
atoms" of" the" latter" are" consistent" with" the" JEV" NS5" structure" and" suggest" that" the"MTase"
domain"is"in"contact"with"the"base"of"the"RdRp"fingertips,"on"the"opposite"side"with"respect"to"
the"other"model.[15]"
"
" "
A" B"
Figure'5.2..DENV.NS5.methyltransferase..(PDB:.2P3L).
A).Overall.globular.structure.of.NS5.MTase."The"proteins"subdomains"are"coloured"differently:"the"N\terminal"
(residues"1\54)"domain"in"red,"the"core"domain"in"yellow"(residues"55\222)"and"the"C\terminal"domain"(residues"
223\267)"in"blue."SAM"and"a"cap"analogue"are"shown"in"grey"using"a"space\filling"model."B).Secondary.structure.of.
NS5.MTase."The"same"colour"representation"as"A)"has"been"used,"but"ribbons"are"shown"instead"of"the"surface"and"
the"small"molecules"are"represented"in"grey."
The"MTase" is"a"monomeric"protein" that" takes"a"globular" form"with"dimensions"of"55"x"45"x"
40Å." It" can"be"divided" into" three"sub\domains."The"enzyme’s"catalytic"domain" is" in" the"core"
sub\domain"(in"yellow"in"Figure"5.2),"which"is"constituted"by"residues"55\222."The"secondary"
structure"of"this"region"shows"7"β\sheets"fringed"by"4"α\helices"and"it"resembles"the"catalytic"
domain" of" other" SAM\dependent" methyltransferases," making" NS5\MTase" a" challenging"
molecular" target." The" only" differences" between" NS5" MTase" and" the" consensus"
methyltransferase" scaffold" are" the" complete" or" partial" absence" of" two"α\helices." At" the" N\
terminal"of" the"enzyme" (residues"1\54)" there" is" the"N\terminal" sub\domain" (in" red" in"Figure"
5.2)"that"contains"a"helix\turn\helix"motif"followed"by"a"β\sheet"and"an"α\helix."Between"these"
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two" sub\domains" there" are" two" α\helices" and" two" β\sheets" that" constitute" the" third" sub\
domain,"at"the"C\terminal"portion"of"NS5"MTase"(residues"223\267;"in"blue"in"Figure"5.2).[4,13,18]"
"
POSSIBLE'MOLECULAR'TARGET'SITES'
!
Figure'5.3..NS5.MTase.bound.to.a.short.cap.analogue.and.to.a.SAH.molecule..(PDB:.2P3L).
In"this"structure"a"cap"analogue,"on"the"left,"is"bound"in"the"GTP"binding"site"and"a"SAH"molecule,"on"the"right,"is"
bound"to"the"SAM"binding"site."Between"these"areas"there"is"a"large"positively"charged"surface"that"might"aid"the"
binding"of"the"RNA"molecule."Protein"surface"is"in"blue"and"small"molecules"are"shown"with"a"space\filling"model."
Available"crystallographic"structures"show"that"NS5"MTase"has"three"main"binding"sites.[5,7,9,18\
21]"One"of"them"allows"the"interaction"with"a"molecule"of"SAM"(on"the"right"in"Figure"5.3)."This"
cofactor"is"essential"for"the"methylation"reaction,"as"it"is"the"source"for"the"methyl"group,"but"
it" has" been" recently" demonstrated" that" it" is" not" essential" for" protein" folding.[21]" A" second"
binding"site"is"named"the"“GTP"binding"site”"because"the"first"solved"crystallographic"structure"
of"this"enzyme"in"the"presence"of"GTP"showed"that"this"molecule"binds"in"this"region"(on"the"
left" in" Figure" 5.3)." Between" these" two" areas" there" is" a" large" shallow" surface" rich" in" basic"
residues" (Lys"and"Arg)" that"at"physiological"pH"are"positively" charged."There" is"no" structural"
evidence,"but"it"is"thought"that"such"a"large"area"of"positive"charge"could"assist"the"binding"of"
the"negatively"charged"phosphates"of"the"RNA"molecule.[4,18]"
Most" of" the" NS5" MTase" crystal" structures" solved" to" date," have" a" molecule" of" S\adenosyl\
homocysteine"(SAH),"the"demethylated"form"of"SAM,"bound"to"the"protein"and"it"is"assumed"
that"SAM"binds"in"the"same"place"during"the"methylation"reaction."The"most"recent"published"
structures" either" lack" the" methylation" cofactor" or" have" a" SAM" molecule" bound" to" the"
described"cleft,"confirming"that"SAM"indeed"binds"in"the"same"mode"of"SAH.[9,21]"The"ribose"of"
the"SAM"molecule" interacts"with" the"protein" through"water\mediated"hydrogen"bonds"with"
Gly106,"Glu111"and"Thr104"and" the" rest"of" the"molecule"binds" to"Ser56,"Thr219,"Glu86"and"
Trp87.[4,18,20]"The" adenine"moiety" of" the"methylation" cofactor" is" positioned" in" a" hydrophobic"
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pocket" constituted" by" residues" Thr104," Lys105," Val132" and" Ile147" and" the"most" important"
hydrogen" bonds" interactions" occur" between" the" base" and" Asp131," Lys105" and" Val132"
residues."Above" this" region," there" is"a"unique" to" flaviviruses"MTases"additional"hydrophobic"
pocket"(Phe133,"Ile147,"Gly148,"Glu149,"Arg160,"Arg163,"Val164)"that"has"been"exploited"for"
the"design"of"SAM\analogue"inhibitors"(“SAH"analogues”"reported"in"the"FUTURE&POTENTIAL&
TREATMENTS" chapter"of" the"main" INTRODUCTION" section)" that"present"hydrophobic"groups"
that"can" interact" in"this"area.[20]"The" ligand" interaction"schemes"for"these"two"molecules"are"
reported"in"Figure"5.4.""
"
" "
""""A" """"""""B"
""""""""""Legend:""
"
"
Figure'5.4..SAM.and.SAH.analogue.ligand.interaction.scheme..(from.PDBs.3P97.and.3P8Z.respectively)"
A).Interactions.between.DENV.MTase.and.SAM..B).Interactions.between.DENV.MTase.and.a.SAH.analogue..In"
both"cases,"rendering"follows"the"legend"reported"beneath"the"two"panels..
There" is" a" highly" conserved" K\D\K\E" tetrad" among" different" methyltransferases" and" it" is"
present"also"in"the"NS5"MTase"with"residues"Lys61,"Asp146,"Lys182"and"Glu218."Even"if"they"
are"distant"in"the"primary"structure,"they"are"located"in"near"positions"in"the"3D"conformation"
and"they"are"thought"to"be"the"active"site"of"the"methylation"reaction."The"exact"mechanism"is"
not"yet"completely"known,"but"mutational"studies"have"shown"that"while"the"2’\O"methylation"
requires"all" four"residues,"the"N7"methylation"only"requires"Asp146,"suggesting"that"the"two"
methylations"might"be"slightly"different.[4,8,18,20]""
The"GTP"binding" site" is" at" approximately"12.3"Å" from" the"SAM"binding" site" and" therefore" it"
cannot" be" the" site"where" the" nucleotide" is" positioned"during" the"methylation."However," all"
crystallographic"structures"with"cap"analogues"show"that" these"molecules"bind" in" this"highly"
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conserved"region."Studies"have"also"outlined"that"the"mutation"of"residues"in"this"area"(Phe25,"
Lys29," Ser150," Asn18," Ser216)" inhibits" the" enzyme’s" function," in" particular" the" 2’\O"
methylation.[4,7,18]" Biological" assays" have" demonstrated" that" the" enzyme" binds" only" capped"
RNA"molecules" that"have"AG"as" the"two"RNA"bases"at" the"5’"end." In" fact,"5’\AG"sequence" is"
strictly"conserved"in"the"Flavivirus"genus.[4,5]"The"requirement"for"DENV"MTase\RNA"binding"of"
a"cap"with"these"characteristics"is"supported"by"the"specificity"of"Guanine"binding"given"by"the"
fundamental"hydrogen"bond"between"the"aromatic"NH2"of"G"and"the"carbonyl"oxygen"atoms"
of"Leu17"and"Leu20."Furthermore,"the"base"interacts"with"Phe25"through"a"π\π"stacking,"but"
no" interactions"occur"at" the"N\7" level," leaving" space" for"a"methyl"moiety" in" this"position,"as"
shown" in" some"crystal" structures" (e.g."PDB:"2P3O)."The" ribose"creates"hydrogen"bonds"with"
Asn18"and" Lys14,"while" the"phosphates" interactions"were"defined"with" less"precision" in" the"
structures" and" involve" residues" like" with" Ser214," Lys14," Arg215" and" Ser150.[4,7]" The" main"
MTase\RNA"interactions"described"here"are"schematised"in"Figure"5.5."
"
"
"
"
""""""""""""Legend:"
"
"
"
"
"
"
Figure'5.5..Schematic.representation.of.the.GTP.F.MTase.interactions..
In"order"to"show"the"interactions,"the"complex"of"the"MTase"with"a"methylated"cap"analogue"(PDB"2P41)"was"used."
The"interaction"rendering"follows"the"legend"on"the"right..
Structures"with"different"small"cap"analogues"have"been"solved."One"particular"series,"showed"
that"the"guanine"has"always"the"same"binding"mode,"while"a"second"base"can"assume"three"
different" conformations.[5]" This" information," together"with" the" fact" that" the" residues" in" this"
region"are"important"for"2’\O"but"not"for"N7"methylation,"suggest"that"this"could"be"the"region"
for" the" binding" of" the" cap" during" the" methylation" at" the" A" ribose." Two" of" the" three"
conformations"place"the"second"base"above"the"guanine,"stacking"with"it"(for"instance"shown"
in"Figure"5.3)."The"third"conformation"is"thought"to"be"flexible"and"elongated"towards"the"SAH"
molecule,"but"the"density"map"was"not"sufficient"to"prove"this."These"structures"do"not"give"a"
! ! !
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valid" insight" into" the" methylation" process," but" imply" the" hypothesis" that" the" missing"
guanylyltransferase" in" the" capping" procedure" could" be" the" NS5" MTase" itself," but" further"
studies"are"needed"to"support"this.[5]"
Like"the"SAM"cleft,"also"the"GTP"binding"site"could"be"used"for"drug"design."In"particular,"one"
study"has"demonstrated"that"a"Ribavirin,"G"analogue,"is"able"to"interact"with"the"protein"in"a"
similar"manner"and"to"have"some"inhibitor"activity.[19]"Even"if"this"compound"has"no"efficacy"in"
treating"DENV\infected"patients," this"could"be"a"starting"point" for" the"development"of"novel"
antiviral"agents.[4,19]"
A"shallow,"highly"positively"charged"area"sits"between"the"described"binding"sites."There"is"no"
structural" proof," but" it’s" position" and" high" prevalence" of" conserved" basic" residues," suggest"
that"it"could"host"the"non\specific"interactions"with"the"RNA"phosphates."The"structure"of"the"
enzyme"with"a"longer"RNA"molecule"(8"nucleosides)"has"been"solved.[17]"Unfortunately"it"was"
not" able" to" give" useful" evidence" as" it" shows" a" complex" of" two" RNA" molecules" with" four"
enzyme"molecules"that"is"not"stable"in"solution."The"determination"of"the"exact"binding"mode"
would"be"useful" for"a"better"understanding"of" the"enzyme’s"mechanism"of"action"and"could"
aid"the"drug"design"of"inhibitors"that"exploit"this"site.[4,17]"
"
MECHANISM'OF'ACTION'
"
The"exact"mechanism"of"action"of"the"enzyme"is"not"fully"understood"to"date,"but"two"models"
have"been"proposed.[4,13]"
The" first"model" is" also" called" “Single\MTase"model”" as" it" requires" only" one"NS5" protein" for"
each"RNA"strand."According"to"this"model,"after"the"first"SAM\dependent"methylation"at"the"
N7"position"of"the"cap"guanosine,"the"MTase"slides"along"the"RNA"chain,"positioning"the"cap"
guanosine"in"the"GTP"binding"site."This"places"the"A"in"the"active"site"for"the"2’\O"methylation,"
after"the"replacement"of"the"SAH"molecule"with"a"SAM"molecule.[4,13]""
The" second" model," called" “Double\MTase" model”," requires" the" presence" of" two"
methyltransferase" for" each" RNA" molecule." According" to" this" model," after" the" N\7" SAM\
dependent"methylation,"the"complex"dissociates"and"the"RNA"binds"to"a"second"NS5"MTase,"
positioning"the"cap"guanine"in"the"GTP"binding"site"and"the"adenine"in"the"optimal"position"for"
the"2’\O"methylation.[4,13]"""""""
"
" "
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A'FRAGMENTSBASED'DRUG'DESIGN'STUDY'
"
The" previous" chapters" outlined" the" importance" of" DENV"MTase" and" why" it" is" a" good" drug"
target."Unfortunately,"drug"design"studies"reported"in"the"literature"based"on"virtual"screening"
campaigns" or" on" the" modification" of" natural" substrates" have" not" produced" promising"
inhibitors"to"date.[11,20,22,23]"An"alternative"drug"design"strategy"could"be"to"apply"a"fragment\
based"drug"discovery" (FBDD)"methodology." This" drug"discovery" tool" has"now"been"used" for"
over" 15" years" and" the" Food" and" Drug" Administration" (FDA)" approval" of" the" first" drug"
discovered" with" this" methodology" was" Vemurafenib" in" 2011." This," together" with" many"
successful" examples," has" increased" FBDD" popularity" within" big" and" small" pharmaceutical"
companies" as" well" as" in" Academia.[24\27]" The" basis" of" FBDD" is" the" use" of" small" molecules"
(fragments)"with"a"molecular"weight" (MW)" lower" that"300"Da"as"a" screening" tool" instead"of"
the"bigger"compounds"(with"MW"around"500Da)"used"in"HTS"campaigns.[24,25,27]"The"idea"that"
starting"from"smaller"molecules"leads"to"higher"success"rate"is"corroborated"by"the"analysis"of"
drugs"on"the"market"and"the"starting"point"(or"“prototype”)"from"which"they"were"developed."
Commonly," less" complex" molecules" as" “prototype”" are" much" more" common" than" more"
complex"ones."The"general"procedure"for"a"FBDD"approach"consists"in"the"design"of"a"library"
of" fragments" that" is" then" screened" in& vitro." The" positive" resulting" fragments" are" then"
elaborated"though"in&silico"design"and"Medicinal"Chemistry"evaluations."The"design"of"a"good"
library"is"therefore"essential"for"the"outcome"of"the"study."Fragments"generally"follow"the"rule"
of"three"(MW"lower"than"300Da,"up"to"three"hydrogen"bond"acceptors,"up"to"three"hydrogen"
bond"donors" and" a"maximum"calculated" logP"of" 3)," avoiding"unwanted" scaffolds" (e.g." toxic,"
unstable"or" reactive)." The"advantage"of" the" screen"of" fragments"over"drug\like"molecules" is"
the"fact"that"as"the"number"of"atoms"involved"is" lower,"the"possible"chemical"space" is"much"
smaller"(around"107"possible"molecules"against"1060"minimum)"and"therefore"it" is"possible"to"
explore" a" larger" portion"of" the" space"with" reasonable\size" libraries."However," being" smaller"
molecules," fragments" have" also" lower" affinity" for" the" target" (around" 0.1\10" mM)."
Consequently," in" screening," fragments" are" evaluated" with" several" biochemical" techniques"
searching"generally"for"consensus."A"pivotal"feature"and"limitation"of"FBDD"is"the"requirement"
of" the" determination" of" the" structure" (either" through" X\ray" crystallography" or" NMR)" of" the"
protein\fragment"complexes"for"the"elaboration"of"the"hit"fragments.[24,25,27]"
In"collaboration"with"Marseille"University,"a"FBDD"study"is"being"carried"out"for"the"discovery"
of"novel"inhibitors"against"DENV"NS5"MTase."As"several"structures"of"the"MTase"are"available,"
it"seemed"a"suitable"target"for"a"FBDD"and"it"was"indeed"possible"to"crystallise"the"protein"and"
to"soak"fragments"for"co\crystallisation."An"initial"pool"of"500"fragments"with"molecular"weight"
under" 300Da" was" screened" against" the" MTase" with" a" thermal" shift" assay" (TSA)." The" 30"
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compounds" that" were" shown" to" bind" to" the" protein" by" giving" an" increase" in" melting"
temperature" of" at" least" 0.5°C" were" then" selected" for" X\ray" crystallography" and" high"
concentration"screening" for" inhibition"of"MTase"enzymatic"activity."The"“bottle"neck”"of" this"
procedure"was"the"X\ray"crystallography"as"only"seven"molecules"were"solved"in"complex"with"
DENV3"NS5"MTase"after"crystal"soaking."These"compounds"were"then"assessed"for"inhibition"
of"MTase"activity"at"several"concentrations"for"IC50"determination.[9]"This"is"the"starting"point"
for"fragment"elaboration,"as"described"later"in"this"chapter."Figure"5.6"shows"an"image"of"the"
protein" co\crystallised"with" the" fragments"and" the" IC50" values" for" the" seven"molecules"were"
calculated"and"are"reported"in"APPENDIX&6."
"
!
Figure'5.6..Image.of.the.crystal.structure.of.the.NS5.MTase.in.complex.with.seven.fragments.and.SAM...
The"protein"is"represented"with"a"blue"surface,"SAM"is"coloured"in"orange"and"the"fragments"are"represented"with"
the"ball"and"stick"model."In"order"to"show"all"fragments,"two"views"with"90°"rotation"are"displayed."
"
AIMS'AND'OBJECTIVES'
"
As"documented"in"the"introduction,"DENV"NS5"MTase"is"a"promising"drug"target"and"FBDD"is"a"
successful" approach" for" the"development"of"novel"drugs."With" the"aim"of"discovering"novel"
potent" inhibitors" of" NS5" MTase" that" could" be" developed" as" anti\DENV" drugs," a" study" in"
collaboration" with" Marseille" University" has" been" carried" out." Starting" from" the" available"
structural" data" of" NS5" MTase" in" complex" with" fragments," Molecular" Modelling" techniques"
have" been" applied" on" three" of" the" seven" fragments" for" an" iterative" process" of" fragment"
elaboration"via"molecule"“growing”"and"“linking”."A" fourth" fragment"was"also"explored"with"
the"aim"of"understanding" its"mode"of"action,"as" its"binding"pose"did"not"appear"to" justify" its"
inhibitory"activity.""
"
""""" "
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5.2.RESULTS.AND.DISCUSSION.
"
5.2.1'FRAGMENT'GROWING'DRUG'DESIGN'
"
!
Figure'5.7..Fragment.2A4..
Here,"fragment"2A4"is"shown"in"complex"with"NS5"MTase."The"position"in"respect"of"the"whole"protein"of"fragment"
2A4"is"reported"on"the"left"and"a"closer"view"of"the"two"identical"2A4"fragments"bound"to"the"MTase"is"reported"on"
the"right."The"protein"complex"on"the"left"is"the"same"as"reported"in"Figure"5.6."The"protein"is"shown"with"a"blue"
surface"and"2A4"is"represented"with"the"ball"and"stick"model"on"the"left"and"with"lines"in"the"magnified"view"on"the"
right."
The"first"de&novo"drug"design"approach"was"applied"to"fragment"2A4"(thieno[2,3\b]pyrazin\7\
amine)."The"structure"of"NS5"MTase" in"complex"with"SAM"and"2A4"has" recently"been"made"
available"in"the"Protein"Data"Bank"with"PDB"ID"4DTK.[9]"As"shown"in"Figure"5.7,"two"fragment"
molecules"were"solved"in"the"crystal"structure"and"they"both"were"located"in"the"GTP"binding"
cleft."These"molecules"show"a"π\π"stacking"interaction"between"them,"but"only"the"lower"one"
is"bound"to"the"enzyme"through"a"second"π\π"stacking"with"Phe25,"resembling"the"same"type"
of"interaction"of"the"GTP."
Superposing"the"protein\fragment"structure"with"one"available"in"the"literature"that"contains"
guanidine"(PDB"ID"2P1D[18]),"a"good"overlap"of"the"lower"2A4"fragment"with"the"GMP"molecule"
could"be"observed,"as"shown" in"Figure"5.8."Additional" to"the"π\π" stacking"with"Phe25," the"G"
base"interacts"with"the"enzyme"also"through"hydrogen"bonds"between"the"amine"group"in"the"
2" position" and" the" carbonyl" oxygen" atoms" of" Leu17" and" Leu20." As" already"mentioned," this"
interaction" is" the" reason" for" the" specificity" of" the" viral" RNA" cap" binding" that" has" a" very"
conserved" 7MeGpppA2’OMe" structure.[4,7]" Fragment" 2A4" does" not" present" a" similar" group," but"
interestingly," in" the" protein\fragment" structure" a" highly" ordinate" molecule" of" water" is"
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approximately" co\localised" with" the" G" amino" group" and" interacts" with" Leu17" and" Leu20,"
confirming"the"importance"of"these"hydrogen"bonds."
"
!
Figure'5.8..Overlap.of.2A4.fragment.with.GMP.molecule.from.a.published.crystal.structure.(2P1D)..
2A4"fragment’s"carbon"atoms"are"coloured"in"cyan,"while"the"GMP"ones"are"in"orange."Some"protein"residues"are"
displayed"as"lines"and"a"molecule"of"water"(red"sphere)"from"the"fragments’"crystal"structure"is"also"reported."
The" inhibition" assay" for" the" fragments" showed" that" 2A4" is" not" one" of" the"most" active" as" it"
displays"IC50"values"higher"that"10mM"for"both"the"2’\O"and"the"N\7"methylations."However,"
as"one"of"the"two"2A4"fragments"resembles"the"GTP"binding"mode"and"as"GTP"analogues"(e.g."
Ribavirin)"can"inhibit"NS5"MTase,"it"was"hypothesised"that"2A4"could"be"used"for"the"design"of"
a" novel" competitive" inhibitor" of" the" NS5"MTase" cap" binding." Consequently," the" lower" 2A4"
fragment"was" chosen" for" a" “growing”"de& novo" drug" design" strategy"with" the" aim"of" adding"
functional" groups" that" could" enhance" molecule" binding" and" activity." The" addition" of" three"
groups" (from" now" on" called" R1," R2" and" R3)" on" the" possible" sites" reported" in" Figure" 5.9"was"
attempted"through"iterations"for"progressive"molecule"improvements"with"the"aid"of"de&novo"
molecular"modelling"tools,"of"a"pharmacophore"and"of"docking"simulations."
"
!
Figure'5.9..Fragment.2A4.growing.sites...
2A4"structure"is"shown"here"with"atom"numbering."The"three"growing"groups"are"indicated"with"R1,"R2"and"R3."
.
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GENERAL.PROCEDURE.
"
!
Figure'5.10..Schematic.representation.of.the.de'novo.drug.design.study.applied.to.2A4.fragment...
The"main"steps"of"the"general"procedure"are"reported"here"and"commented"in"the"text."
The" general"workflow"of" the"molecular"modelling" study" is" reported" in" Figure" 5.10." The" first"
modification" of" 2A4" was" based" on" the" observations" of" the" crystal" structures" and" regarded"
group" R1." The" resulting" molecule" was" then" used" as" an" input" for" three" de& novo" design"
computational" tools" (MOE" MedChem" Transformations," MOE" Combinatorial" Builder" and"
LigBuilder)" for" growing" procedures" on" groups" R2" and" R3." The" results" were" then" visually"
inspected" and" used" for" the" design" of" a" database" of" 2A4" derivatives" that" were" docked" and"
scored" (with"Maestro" Glide)" in" the"MTase" structure." The" binding" poses" were" then" visually"
inspected"and"used"for"the"construction"of"a"novel"database"of"2A4"derivatives."The"docking\
inspection\database" design" process" was" repeated" in" an" iterative" manner" for" molecule"
improvement." Due" to" the" large" number" of" obtained" poses," the" first" docking" results" were"
filtered" using" a" pharmacophore" for" a" faster" identification" of" good" binding" poses." All" of" the"
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procedure" reported" here" was" performed" prior" to" the" chemical" synthesis" and" evaluation" of"
designed"compounds."
"
PHARMACOPHORE.
"
The" three" computational" tools" used" for" molecule" growing" were:" MOE" MedChem"
Transformations," MOE" Combinatorial" Builder" and" LigBuilder." All" three" of" them" use" a"
pharmacophore"query"in"order"to"add"to"the"molecule"functional"groups"that"can"improve"its"
binding"to"the"protein.""
For"the"two"MOE\based"tools,"the"pharmacophore"query"(shown"in"Figure"5.11)"was"built"as"
described"in"the"METHODS"chapter"of"this"section.""
"
!
Figure'5.11..Pharmacophore.used.for.2A4.growing.approaches..
Some"MTase"residues"are"indicated"and"shown"as"lines."A"GMP"molecule"(from"2P1D)"is"reported"with"orange"
carbon"atoms"and"the"pharmacophore"features"are"represented"by"the"dotted"spheres."F1"and"F2,"in"orange,"
indicate"aromatic"groups;"F3,"in"purple,"indicates"a"hydrogen"bond"donor"group;"F4,"in"pink,"indicates"a"hydrogen"
bond"donor"or"acceptor"group;"F5,"in"pink,"indicates"a"hydrogen"bond"acceptor"group;"F6"and"F7,"in"yellow,"indicate"
the"projection"of"a"hydrogen"bond"acceptor"group;"F8,"in"yellow,"indicates"the"projection"of"a"hydrogen"bond"donor"
group."
Features"were"built"on"the"basis"of"the"conserved"GTP"interactions"with"NS5"MTase"displayed"
in"the"published"crystallographic"data."In"particular,"the"π\π"stacking"between"the"G"base"and"
Phe25" was" represented" by" “aromatic" group”" features" (F1" and" F2," in" orange)," while" the"
hydrogen" bonds"with" Leu17" and" Leu20"were" considered" through" a" “hydrogen" bond" donor”"
feature" (F3," in" purple)" placed" on" the" highly" ordered"water"molecule" crystallised" in" the" 2A4"
structure."Furthermore,"the"interactions"between"the"GTP"2’"hydroxyl"group"with"both"Asn18"
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main" chain" carbonyl" oxygen" and" Lys14" side" chain" amine" moiety" were" considered" with" a"
“hydrogen"bond"donor"or" acceptor”" feature" (F4," in"pink)."Additional" interesting" interactions"
for"pharmacophore"building"were"the"ones"involving"Arg22,"Lys29,"Lys14"and"Glu157"(features"
F5" to" F8)." As" no" indication" was" available" for" the" preferred" position" in" these" cases," the"
projection"(in"yellow)"of"the"feature"was"used"in"most"of"them."Of"the"total"8"pharmacophore"
features," only" the" three" most" important" ones" in" GTP" binding" (F1," F2" and" F3)" were" also"
considered"essential"in"the"MOE\based"growing"procedures.""
All"the"residues"considered"in"the"design"of"the"pharmacophore"(Phe25,"Leu17,"Leu20,"Asn18,"
Lys14,"Arg22,"Lys29"and"Glu157)"are"conserved"among"all"DENV"serotypes"and"three"of"these"
residues" (Phe25," Lys29"and"Asn18)"are"essential" for" the"methylation"processes," in"particular"
for" the" 2’\O" methylation," as" demonstrated" by" mutational" studies.[4,7,18]" This" opened" the"
opportunity"of"designing"potent"panserotypic"DENV"inhibitors."
Differently"from"MOE,"LigBuilder,"the"third"computational"tool"used"for"2A4"growing,"builds"a"
pharmacophore" on" the" basis" of" the" receptor\fragment" complex" that" is" given" as" input."
Interestingly," the"most" important" features" of" the" pharmacophore" built" by" LigBuilder" and" of"
the"one"built" for"MOE"were" in" common," as" shown"by" the" superposition" in" Figure"5.12."Not"
surprisingly,"these"features"were"the"ones"derived"from"GTP"binding"mode."
"
!
Figure'5.12..Superposition.of.the.pharmacophores.built.with.LigBuilder.and.MOE..
The"LigBuilder"pharmacophore"is"represented"by"the"grids,"while"the"MOE"one"is"represented"by"the"solid"spheres."
It"is"possible"to"observe"that"the"hydrogen"bond"donor"features"of"LigBuilder"(blue"grids)"correspond"to"the"same"
features"in"MOE"(F3,"F4)."In"the"same"way"also"the"hydrophobic"LigBuilder"feature"(grey"grid)"corresponds"to"the"
aromatic"MOE"features"(F1"and"F2)"and"the"hydrogen"bond"acceptor"LigBuilder"feature"(red"grid)"corresponds"to"
the"same"MOE"features"(F5"and"F6)."
"
" "
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R1.MODIFICATION.
"
Based"on"the"observations"from"the"protein\2A4"and"GTP\protein"complexes"superposition,"R1"
was" the" first" growing" position" of" 2A4" that" was" evaluated." The" aim" was" to" reproduce" the"
hydrogen" bonds" with" the" carbonyl" oxygens" of" Leu17" and" Leu20," essential" for" G" specific"
recognition."For"this"group,"the"MOE"MedChem"Transformations"tool"was"used."Two"possible"
groups"were"evaluated:"a"hydroxyl"and"an"amino"group."They"were"both"placed" in"the"same"
position" of" the" ordered" water" molecule," but" as" only" the" amine" could" interact" with" both"
residues,"this"group"was"selected"and"compound"19"was"developed"further."Figure"5.13"shows"
compound"19"structure"and"binding"pose."
"
A" """"B"
! "
"
Figure'5.13..Compound.19..
A).Chemical.structure.of"compound.19..B).Compound.19.binding.pose."The"new"amine"group"of"compound"19"
shows"a"good"overlap"with"the"water"molecule"and"it"interacts"with"both"Leu17"and"Leu20."Here,"a"few"protein"
residues"are"indicated"and"shown"as"lines,"while"the"original"2A4"fragment"and"compound"19"have"purple"and"blue"
carbon"atoms"respectively.".
Later"in"the"molecule"improvement"process,"it"was"observed"that"the"original"amino"group,"in"
position" 7," did" not" display" interactions" with" the" protein" as" this" area" is" designated" to"
accommodate" the"N\7"methyl" group" of" the" capped" RNA" for" 2’\O"methylation." Therefore," a"
small"docking"study"was"computed"on"three"compounds"with"the"amino"group" in"position"6"
(compound" 20)," in" position" 7" (compound" 21)" or" in" both" positions" (compound" 22)."
Informatively," while" the" molecules" with" NH2" in" position" 6" had" very" similar" binding" poses,"
compound"21"flipped,"but"they"all"maintained"the"hydrogen"bond"interactions"with"Leu17"and"
Leu20." This" further" confirmed" the" importance" of" these" residues" in" ligand" binding" and"
suggested"that"of"the"two"amino"groups,"only"the"one"in"position"6"was"fundamental"and"that"
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the" one" in" position" 7" could" be" removed." The"molecules" designed" for" further" improvement"
were"indeed"based"on"the"scaffold"reported"in"Figure"5.14."
"
" "
""A" """B"
"
! "
""C" """""""""""""""""""D"
Figure'5.14..Compounds.20,.21.and.22.and.new.molecular.scaffold..
A).Compound.20.binding.pose."Protein"residues"are"indicated"and"designed"with"lines,"while"ligands"are"shown"
with"thicker"lines."2A4"carbon"atoms"are"coloured"in"grey,"while"compound"20"ones"are"in"cyan."B).Compound.21.
binding.pose."The"same"rendering"as"in"A)"was"applied."C).Compound.22.binding.pose..The"same"rendering"as"in"A)"
was"applied."D).New.molecular.scaffold.for.molecule.improvement..Only"the"NH2"in"position"6"was"retained."
Atomic"numbering"is"reported"in"the"structure."
"
R2.AND.R3.“GROWTH”.
"
With"the"aim"of"growing"the"fragment"with"R2"and"R3"groups,"three"computational"tools"were"
used:" two" MOE\based" applications" (MedChem" Transformations" and" Combinatorial" Builder)"
and" LigBuilder" software." As" the" binding" pocket" is" shallow," LigBuilder" software" built" huge"
molecules" with" side" chains" exiting" the" cleft" as" a" result." As" this" fell" outside" the" exploration"
objective,"dummy"atoms"had"to"be"added"to"“close”"the"binding"site"and"improve"the"results"
for"this"computational"approach."
The"results" from"the"three"applications"were"visually" inspected"and"used"for" the"design"of"a"
database" of" molecules" given" by" the" combination" of" R2" and" R3" groups." The" total" of" 109"
molecules" (from" the" combination" of" 4" R2" groups" and" 27" R3" chains)" were" then" docked"with"
Maestro" Glide." As" already"mentioned" in" the" general" procedure" description," given" the" large"
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number"of"poses"obtained,"the"same"pharmacophore"built"for"the"MOE\based"tools"was"used"
to"detect" the"best"binding"molecules." For" this" reason,"only"molecules" that"matched" in" their"
absolute"position"at"least"four"of"the"eight"designed"features"(with"F1"and"F2"essential)"were"
kept." The" resulting" 15" best" molecules" showed" that" R2" interactions" with" the" protein" rarely"
involved"Lys29,"but"always"Arg22"through"either"carbonyl"or"carboxyl"groups."Only"two"types"
of"R3"were"interesting"as"they"interacted"with"Lys14"in"almost"all"the"combinations"with"R2."Of"
the" two," the" best" interacting" R3" side" chain" appeared" to" contain" a" phenol" group" that" also"
interacted"with"Ser213,"as"shown"by"compound"23"in"Figure"5.15."
"
"
Figure'5.15..Compound.23.binding.pose..
Example"of"result"from"the"first"docking"procedure."In"compound"23"R2"interacts"with"Arg22"through"the"terminal"
carbonyl"moiety,"while"R3"presents"the"phenol"portion"that"binds"to"Lys14"and"Ser213."The"protein"residues"are"
indicated"and"represented"as"lines,"while"small"molecules"are"shown"with"thicker"lines."The"original"2A4"fragment"
carbon"atoms"are"coloured"in"grey,"while"the"compound"ones"are"in"orange."
"
R2.AND.R3.OPTIMISATION.
"
The" results" from" the" growing" and" docking" procedure" and" R1" optimisation" were" used" for"
further"development"through"the" iterative"procedure"discussed"above."Several"combinations"
of"R2" and"R3" groups"were"assessed"as"well" as" the"possibility" to"move" their" position"and" the"
most"relevant"outcomes"are"discussed"here."
The"movement"of"R3"from"position"3"to"position"4"(with"the"substitution"of"the"N"atom"in"4"to"
C)" was" examined" with" the" aim" of" improving" the" interactions" with" Lys14" and" Ser213" and"
removing" the" vinyl" portion" of" the" linker" that" bridges" the" phenol" moiety" and" the"molecule"
scaffold"(as"in"compound"23)."The"position"of"the"phenol"hydroxyl"group"was"also"investigated,"
as"shown"in"Figure"5.16."At"the"same"time,"R2"improvement"was"attempted"with"the"design"of"
a" series" of" α\," β\" and" γ\ketoacids"with" different" linker" lengths," aiming" for" the" simultaneous"
interaction"with"Arg22"and"Lys"29.""
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Generally," in" absence" of" α\," β\" and" γ\ketoacids" in" R2," almost" all" the" new" R3" moieties" in" 4"
displaced" the" bicyclic" scaffold," resulting" in" the" loss" of" the" Phe25" stacking" and" often" of" the"
Leu17" hydrogen" bond." The" ketoacid" moiety" in" R2" allowed" the" establishment" of" a" second"
hydrogen" bond" between" the" molecules" and" Arg22," but" no" new" interactions" that" involved"
Lys29"could"be"observed."Only"two"compounds"gave"partial"desired"MTase"binding."
"
""""""“Original”:"""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""“New”:"
"
"
"
"
"
A"
"
"
B" C"
Figure'5.16..First.R2.and.R3.optimisation.attempt..
A).Structure.of.the.modification.of.the.R3.scaffold."The"changes"in"position"and"structure"of"R3"are"represented"
here"and"atom"numbering"is"reported."B).Compound.20.and.compound.24.overlapping.binding.poses."A"
comparison"between"the"original"R3"moieties"is"presented"through"the"overlap"of"the"binding"poses"of"compound"
20"and"24."Protein"residues"are"indicated"and"represented"with"lines,"while"small"molecules"are"shown"with"thicker"
lines."Carbon"atoms"of"Compound"20,"those"of"compound"24"and"of"2A4"are"coloured"in"cyan,"orange"and"grey"
respectively."C).Compound.25.binding.pose..The"same"rendering"as"in"B)"was"applied"and"compound"25"has"orange"
carbon"atoms."
Compound"24"(in"Figure"5.16)"was"able"to"bind"to"Lys14"and"Ser213,"but"a"molecule"shift"gave"
a" less" favourable"position" for" the" interactions" involving" the"amine" in"position"6"as"well" as" a"
weaker" stacking"with"Phe25." Compound"25" (in" Figure"5.16)" interacted"with"both"Arg22" and"
Lys29," but" unfortunately" with" the" loss" of" the" hydrogen" bond" with" Lys14." From" these" first"
optimisation" attempts" it" could" be" inferred" that" the" new" R3" moiety" did" not" improve" the"
molecule"with"these"R2"groups"that"did"not"represent"a"huge"step"in"molecule"optimisation."
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As"the"pocket"is"solvent"exposed,"the"flexibility"of"a"α\,"β\"and"γ\ketoacid"R2"group"could"give"
low" stability" to" the" complex" and" therefore" further" modifications" were" designed." The"
hydrophobicity" of" the" substituent" was" increased" in" order" to" reduce" the" solvent\dependent"
ligand" displacement" and" to" substitute" the" electrostatic" interaction" involving" Arg22" with" a"
cation\π"one."Docking" simulations" showed" that" in"order" to"place" a"benzyl" group" correctly" it"
was"necessary"to"move"R2"from"position"2"to"1."A"hydroxyl"group"in"the"meta\"or"para\"position"
was" also" inserted" for" the" interaction" with" Asp26." These" two" OH" positions" appeared" to" be"
equivalent"from"docking"simulations."
"
! "
"
""""""""""A"
! "
"""""""""B" """""""C"
Figure'5.17..Compound.26.and.compound.27..
A).Structure.of.compound.26..B).Structure.of.compound.27..C).Overlapping.poses.of.compounds.26.and.27."
Protein"residues"are"indicated"and"their"carbon"atoms"are"in"grey,"while"those"of"compound"26"are"in"orange,"and"
those"of"compound"27"are"in"green"and"of"fragment"2A4"are"in"cyan."
Interestingly," for" this" type" of" R2" moiety," a" better" binding" was" obtained" with" a" R3" group" in"
position" 4," in" particular" with" meta\hydroxyl" benzyl" substituents." Figure" 5.17" shows" two"
examples"of"the"designed"molecules"with"a"benzyl"R2"group"with"the"OH"group"(compound"26,"
in"orange)"or"without"(compound"27,"in"green)."
Even" if" a" cation\π" interaction" with" Arg22" was" achieved" and" hydrogen" bonds" with" Leu17,"
Leu20," Lys14" and" Ser213"were" generally"maintained," all" the" compounds"with" the" R2" benzyl"
group" displayed" a" decrease" in" π\π" stacking" with" Phe25." Therefore," the" phenyl" ring" was"
reduced" in" size" to" a" five\membered" one" (pyrrole," furan" and" thiazole)." Of" these," the" best"
substitution"resulted"to"be"the"pyrrole"ring"that"could"establish"a"hydrogen"bond"with"Asp26."
Compound"28"in"Figure"5.18"is"an"example"of"this"series."
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"
! "
"
A" B"
Figure'5.18..Compound.28..
A).Chemical.structure.of.compound.28..B).Binding.pose.of.compound.28."Protein"residues"are"indicated"and"their"
carbon"atoms"are"in"grey,"while"those"of"compound"28"are"in"orange"and"of"fragment"2A4"in"cyan..
A" further" iteration"was" undertaken"with"modifications" aimed" to" replace" the" sulphur" in" the"
benzenthiophene"core."The"thiophene"ring"was"substituted"with"a"pyrrole,"a"furan"or"an"indole"
moiety" in" compound"27."Unfortunately," the" binding" poses" did" not" give" insights" on" the" best"
ring"to"be"used"as"all"the"molecules"superposed"very"well"(data"not"shown)."
For" synthetic" purposes," the"methylene" bridges"were" substituted"with" ether"moieties" in" the"
most"interesting"compounds"(e.g."compounds"24,"26,"27"and"28)."The"obtained"binding"poses"
were"compared"with"those"of"the"original"compounds,"but"no"significant"differences"could"be"
observed," suggesting" that" this" substitution" could" be" applied" for" the" synthesis" of" novel"
compounds."
"
BIOLOGICAL.EVALUATION.OF.SYNTHESISED.COMPOUNDS.
"
The"chemical" synthesis"of" this"chosen"scaffold"appeared" to"be"challenging."Consequently,"of"
the" most" promising" molecules" described" above" only" one" final" compound" and" two"
intermediates"(see"Table"5.1)"were"synthesised"and"tested"for"MTase"inhibitory"activity"by"our"
collaborators"at"AFMB,"Marseille"University."Unfortunately,"neither"of"them"showed"inhibition"
activity" below" the" maximum" tested" concentration" (5mM)." Moreover," soaking" experiments"
with"these"compounds"was"not"successful"and"no"co\crystallised"structures"could"be"obtained"
by"our"collaborators."
"
1
2
3
4S
5
6
7
H2N
OH
NH
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Table'5.1..Synthesised.compounds.with.activity.data..
Scaffold:""""
""""""" "!
Compound. R1" R2.
NF7.methylation.
IC50.(mM).
2’FO.methylation.
IC50.(mM).
29.
" "
>5" >5"
30.
" "
>5" >5"
31. NH2 
"
>5" >5"
"
CONCLUDING.REMARKS.
"
Starting" from" the"GTP" site"binding" fragment"2A4"molecule" growing"procedures" and"docking"
simulations"produced"some"molecules"that"could"bind"to"the"NS5"MTase"GTP"binding"site"and"
inhibit"the"NS5"methyltransferase"enzyme"via"the"competition"with"the"natural"ligand."In"the"
attempt" of" directing" the" drug" design" towards" serotype\nonspecific" compounds," conserved"
amino"acids"were"selected"as"target"residues."Different"growing"locations"were"explored"and"
the"position"of"the"amine"present"in"the"2A4"fragment"was"evaluated."In"summary,"the"amine"
is"preferably"located"in"position"6,"complying"with"the"mechanism"of"MTase"G"preferentiality"
nucleotides"binding."The"other"side"chains"are"preferentially"situated"in"positions"2"(R2)"for"the"
interaction" with" Arg22" and" eventually" Lys29," and" 3" (R3)" for" the" interaction" with" Lys14" and"
Ser213." However," when" substituting" R2" with" an" aromatic" group" the" preferred" positions"
become" 1" and" 4." This" new" scaffold" (e.g." compounds" 26" and" 27)" gave" the"most" interesting"
binding"results"and"was"considered"to"be"a"good"starting"point" for" further"optimisation."The"
reduction" of" the" phenyl" group" in" R2" to" a" smaller" five\membered" ring" aided" a" better"
accommodation"of"the"molecules"in"the"binding"site"and"the"most"promising"molecule"of"this"
series"appeared"to"be"28."The"sulphur"in"the"benzenthiophene"core"was"also"investigated"and"
substituted,"but"no" improvements" could"be"observed" from"the"Molecular"Modelling" results."
Lastly,"for"synthetic"purposes"the"methylene\ether"substitution"of"the"1"and"4"side"chains"was"
assessed" to" be" equivalent" from" an" in& silico" binding" point" of" view." The" synthesis," biological"
N
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evaluation"and"soaking"experiments"were"performed"in"Marseille"University."The"synthesis"of"
this" scaffold" was" found" to" be" challenging" and" only" three" molecules" were" obtained," but"
unfortunately" none" of" them" showed" activity" against" DENV" 3" NS5" MTase" and" the" soaking"
experiments"failed"to"produce"crystal"structures"of"these"molecules"in"complex"with"the"same"
protein."
The"negative"experimental"results"might"suggest"that"the"Molecular"Modelling"approach"used"
in"this"study"failed"to"optimise"the"2A4"fragment"and"to"obtain"a"novel"potent"anti\DENV"drug."
However," it" is" important" to" underline" that" only" one" final" compound" analysed" (31)"
corresponded" to" a" compound" 24" analogue." Other"molecules" different" from" this" compound"
(e.g."26,"27"and"28)"showed"a"better"binding"than"24"but"have"not"been"assessed"to"date,"nor"
have" their" ether" analogues." Furthermore," the" other" two" tested" molecules" were" synthetic"
intermediates"and"consequently"they"were"not"expected"to"have"a"good"inhibitory"activity."In"
order" to"have" a" good"evaluation"of" the"Molecular"Modelling" and" to" validate" 2A4" as" a" good"
starting" fragment" for" drug" design," it" would" be" necessary" to" increase" the" amount" of"
experimental"data."Nevertheless,"due"the"synthetic"difficulties"and"to"better"results"obtained"
from" the"optimisation"of"other" fragments" (see"next" chapter)," this"might"not"be"done" in" the"
near"future."
"
" "
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5.2.2'FRAGMENT'LINKING'DRUG'DESIGN'
"
!
Figure'5.19..Fragments.2E11.and.2C3..
Here,"the"fragment"2E11"and"2C3"are"shown."The"localisation"of"the"two"molecules"within"the"protein\fragments"
complex"is"reported"on"the"left"and"a"closer"view"of"2E11"and"2C3"bound"to"the"MTase"is"reported"on"the"right."The"
protein"complex"on"the"left"is"the"same"reported"in"Figure"5.6."The"protein"is"shown"with"a"blue"surface"and"the"
fragments"are"represented"with"the"ball"and"stick"model"on"the"left"and"with"lines"on"the"right."2E11"carbon"atoms"
are"coloured"in"orange"and"for"2C3"they"are"in"yellow."
A" second" de& novo" drug" design" procedure" was" applied" to" two" fragments:" 2E11" (4\chloro\5\
methylbenzene\1,2\diamine)" and" 2C3" (2\amino\4\methylbenzoate)." The" selected" structures"
(2E11"in"orange"and"2C3"in"yellow"in"Figure"5.19)"bind"to"a"MTase"surface"region"that"is"well"
conserved" among" DENV" serotypes." 2E11" and" 2C3" were" chosen" because" a" linking" strategy"
could"be"applied"to"them,"as"they"appeared"to"be"at"an"appropriate"distance."Moreover,"they"
showed"a"better"inhibitory"activity"than"2A4,"in"particular"on"the"2’\O"methylation."IC50"values"
for" 2E11" were" 4.2mM" and" greater" than" 10mM" for" 2’\O" and" N\7" methylation" respectively;"
while"the"ones"for"2C3"were"4.4mM"and"6.5mM"respectively.""
The"original"crystal"structure"reported"two"binding"modes"for"2E11:"one"as"reported"in"Figure"
5.19" and" one" on" the" other" side" of" the" protein." As" only" one" is" located" at" an" appropriate"
distance"from"2C3"fragment,"only"the"first"binding"mode"was"considered"for"this"drug"design"
study." Furthermore," the" selected" 2E11" fragment" is" well" superposed"with" another" fragment"
(3C2)"which,"having"poorer"inhibitory"activity"(IC50"higher"than"10mM"for"both"methylations),"
was"therefore"ignored."
The"general"approach"adopted"in"this"study"was"based"on"the"connection"of"the"two"selected"
fragments"through"the"addition"of"a"linker"chain."Four"linker"strategies"were"adopted"and"the"
best" results"were"used" for"a"docking"procedure" that"allowed" the" selection"of" the"molecules"
that"best"improved"the"binding"of"the"initial"fragments.""
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Experimental" data" of" some" of" the" designed" molecules" were" then" used" for" preliminary"
structure\activity" relationship" (SAR)" determination" and" for" further" molecule" growing" and"
optimisation,"using"docking"and"molecular"dynamics"(MD)"simulations."
"
FRAGMENT.LINKING.
"
Four'linking'strategies'
"
Table'5.2..Original.fragments.and.linking.strategies..
Name. 2E11. 2C3. Linking.mode.
Original.
fragments. ! " ! " \"
LinkF1. ! " ! " ! "
LinkF2. ! " ! " ! "
LinkF3. ! " ! " ! "
LinkF4. ! " ! " "
"
" "
Cl
NH2
NH2
O-O
H2N
Cl
H
NH2
O-O
H
Cl
NH2
O-O
Linker
Cl
NH2
NH2
H
H
H2N
Cl
NH2
NH2
H2N
Linker
Cl
H
NH2
O-O
H2N
H
Cl
NH2
Linker
O-O
H2N
Cl
NH2
NH2
H
H
H2N
Cl
NH2
NH2
H2N
Linker
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The"two"fragments"were"used"as"starting"points" for" four" linking"strategies"that"reflected"the"
possible"combinations"of"those"connection"sites"of"each"structure"that"showed"suitability"for"a"
linking"procedure."A"total"of"four"growing"sites"for"2C3"and"two"growing"sites"for"2E11"were"
chosen,"as"schematised"in"Table"5.2,"where"the"red"hydrogen"atoms"represent"the"connection"
sites"for"each"structure"and"the"sketch"shows"the"pertinent"linking"mode."Other"combinations"
from"the"ones" shown"here"did"not"give"positive" results"and"will"not"be"discussed."Fragment"
linking" was" performed" with" the" MOE" Link" Multiple" Fragments" tool," as" explained" in" the"
METHODS"section.""
The" visual" inspection" of" the" results" showed" that" all" the" most" promising" structures" were"
belonging" to" the" first" linking"mode" (from"now"on"called"“Link\1”)"and" it"was"concluded" that"
only" in" Link\1" the" connectors"were"at" the"optimal"distance" for" the" linking"of" the" fragments."
The" computational" results" for" “Link\1”" often" connected" the" two" fragments" with" complex"
structures," but" they" could" be" clustered" and" manually" simplified." Interestingly," all" of" these"
patterns"connected"the"two"fragments"through"three"atoms"in"the"main"linker"chain."
Novel"molecules"with" linkers"derived"from"these"patterns"or"from"their"modification,"as"well"
as" from" other" three" atom" chain" possibilities," were" subsequently" designed" and" evaluated"
through"docking"simulations"using"the"MOE"Dock"tool."
"
Pharmacophore'
"
!
Figure'5.20..3D.pharmacophore.for.2E11.and.2C3.fragments..
Here,"the"3D"pharmacophore"is"superposed"to"the"original"fragments."2E11."Carbon"atoms"are"shown"in"orange,"
those"for"2C3"are"in"yellow"and"a"few"protein"residues"are"shown"as"lines."The"pharmacophore"features"are"
represented"as"dotted"spheres."Features"F1"and"F3"(in"orange)"indicate"the"presence"of"an"aromatic"ring,"while"F2"
(in"purple)"indicates"the"presence"of"a"hydrogen"bond"donor"group"and"F4"(in"green)"shows"a"hydrogen"bond"
acceptor."
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With"the"purpose"of"assuring"that"the"new"molecules"were"placed"with"the"same"position"and"
orientation"of"2E11"and"2C3,"a"3D"pharmacophore"was"used" for"molecule"placement" in" the"
MOE"docking" simulations."A" pharmacophore\constrained"placement"was" chosen"because" as"
the"fragments"are"bound"to"the"protein’s"surface"and"not"in"an"area"that"could"be"defined"as"a"
pocket,"unconstrained"docking"procedures"conducted"with"several"programs"were"not"able"to"
place"compounds"correctly.""
The"designed"features"indicated"four"main"groups"that"could"be"identified"both"in"the"original"
fragments"and"in"all"the"novel"molecules:"two"aromatic"rings"(F1"and"F3,"in"orange),"the"amine"
moiety" recognised" as" a" hydrogen" bond" donor" group" (F2," in" purple)" and" the" carboxylic" acid"
indicated"as"a"hydrogen"bond"acceptor"group"(F4,"in"green)."All"four"features"were"considered"
essential" for" a" correct" placement" of" the" docked" structures." Figure" 5.20" shows" the"
pharmacophore"features"superposed"to"the"2E11"and"2C3"fragments."
"
Optimisation'iterations'
"
Structures"giving"the"best"“Link\1”"results,"together"with"molecules"containing"different"short"
linkers,"were"used"to"design"a"database"of"25"molecules"that"were"then"docked"into"the"2E11"
and"2C3"fragments"binding"sites.""
The"best"results"obtained"had"a"three"atom"linker"with"an"sp2"carbon"in"the"middle,"linked"to"
an"out"of"chain"heteroatom"(O,"N"or"S)"through"a"double"bond."An"sp3"carbon" in"the"middle"
position"did"not"perform"as"well"and"a"carbon\carbon"double"bond"was"not"as"effective"as"the"
carbon\heteroatom."Furthermore,"the"three"most"promising"docking"results"(reported"in"Table"
5.3),"displayed"the"presence"of"two"nitrogen"atoms:"one"in"each"of"the"other"two"positions"of"
the"linker.""
"
Table'5.3..Three.best.binding.molecules..
Scaffold. Compound. X.
.
32. O"
33. NH"
34. S"
"
The" presence" of" these" two" NH" groups" at" the" 1" and" 3" position" of" the" linker" improved" the"
binding"by"adding"a"two"hydrogen"bonds"with"Glu112."This"was"also"due"to"an"overall"slight"
movement" in" the" new"designed"molecules" of" the" ring" from" 2E11" that" placed" the" hydrogen"
bond" donor" group" at" the" right" distance" for" the" interaction" with" Glu112." An" example" of" a"
binding"pose"(for"compound"32)"is"reported"in"Figure"5.21."
Cl
NH2
N
H
X
N
H
O-O
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"
!
Figure'5.21..Compound.32.binding.pose..
The"original"fragments"(2E11"on"the"left"and"2C3"on"the"right)"are"reported"with"green"carbon"atoms"while"
compound"32"carbons"are"in"orange."A"few"protein"residues"are"indicated"and"represented"by"lines."It"is"possible"to"
see"that"while"the"two"original"fragments"establish"only"one"hydrogen"bond"with"the"protein"(between"2C3"NH"and"
Glu112),"the"new"designed"molecule"demonstrates"three"hydrogen"bond"interactions"with"Glu112."
"
! " ! "
""""""""""""""""""A" """""""""""""""""""B"
" "
"""""C" """"""D"
Figure'5.22..Compounds.35.and.36..
A).Structure.of.compound.35..B).Structure.of.compound.36..C).Compound.35.binding.pose."Some"protein"
residues"are"indicated"and"shown"as"lines."Carbon"atoms"belonging"to"the"original"fragment"are"coloured"in"green"
while"those"of"the"new"compound"are"coloured"in"orange."D).Compound.36.binding.pose."The"same"rendering"of"
C)"is"used"here."Both"binding"poses"are"discussed"in"the"text."
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Two"other"molecules"(compound"35"and"compound"36,"in"Figure"5.22)"did"not"give"an"overlap"
with" the" original" fragments" as" good" as" 32," 33" and" 34," but" they" showed" some" of" the"
interactions"reported"above."In"both"cases,"the"linker"has"only"one"of"the"two"NH"groups"and"
therefore"only"two"of"three"hydrogen"bonds"with"Glu112."However,"as"32,"33"and"34"are"very"
rigid"molecules," the" conformation" adopted" in"MTase" binding" could" not" be" favoured" due" to"
conformational" strains." Conversely," the" compound" 35" linker" has" both" a" rigid" portion" (the"
amide)"and"a"flexible"part"(the"CH2)"that"allows"the"two"aromatic"rings"to"maintain"the"correct"
orientation.""
"
EXPERIMENTAL.DATA.OF.DESIGNED.COMPOUNDS.
"
Table'5.4..MTase.inhibition.data.for.synthesised.compounds..
Scaffold:"
"""" "!
Compound. X. R1. R2.
2’FO.
methylation.
IC50.(mM).
NF7.
methylation.
IC50.(mM).
37. NH" 2\NO2" 2\COOEt" >5" >5"
38. NH" 2\NO2" 2\COOH;"5\Me" >2.5" >5"
39. NH" 2\NH2" 2\COOH;"5\Me" >5" >5"
40. NH" 2\NO2" 2\COOH" >5" >5"
41. NH" 2\NH2" 2\COOEt" >2.5" >2.5"
42. NH" 2\NO2;"4\CF3" 2\COOH;"5\Me" 1" 1.2"
43. NH" 2\NO2;"4\Cl" 2\COOH;"5\Me" 2.5" 5"
44. NH" 2\NH2;"4\CF3" 2\COOH;"5\Me" 2.5" >2.5"
45. NH" 2\NH2;"4\Cl" 2\COOH;"5\Me" 2" 2.5"
46. NH" 2\NHCOOt\Bu;"5\Cl" 2\COOEt" >5" >5"
47. CH2" 2\NO2" 2\COOEt" >5" >5"
48. CH2" 2\NO2;"5\Cl" 2\COOEt" 1.2" 2.5"
49. CH2" 2\NH2;"5\Cl" 2\COOEt" >5" >5"
50. CH2" 2\NH2;"5\Cl" 2\COOH" >5" >5"
51. CH2" 2\NH2;"5\Cl" 2\COOMe" 2.5" 2.5"
52. CH2" 2\NH2" 2\COOH" >2.5" >2.5"
"
4
3
1
6
5
2 X NH
O
1
2
3
4
5
6
R1 R2
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A"collection"of"16"molecules,"representing"either"final"compounds"or"synthetic"intermediates"
were" synthesised"and"evaluated"by"our" collaborators" in"Marseille"University." Structures"and"
activity"data"for"these"compounds"are"reported"in"Table"5.4.""
Of"the"16"compounds,"six"showed"an"improved"inhibition"activity"against"either"MTase"2’\O"or"
N\7" methylation" or" both" and" preliminary" structure\activity" relationships" (SAR)" could" be"
derived."They"are"discussed"according"to"the"scaffold"presented"in"Table"5.4."In"the"case"of"the"
urea" linker" (compounds" from"37" to"46),"all"active"molecules" (from"42" to"45)"display"either"a"
chloro\" or" a" trifluoromethyl\" R1" substituent" on" the" left" ring," in" position" 4," while" inactive"
molecule"do"not,"making"an"electron\withdrawing"halogen"group"on"this"ring" is"essential" for"
activity."Only"one" inactive" compound" (46)" has" a" chlorine" substituent"on" the" left" ring,"but" in"
position"5" instead"of"4."However," this" single"molecule" is"not"enough" to" state" that" the"para\"
position"with"respect"to"the"linker"is"the"preferred"one"for"activity."A"carboxylic"group"is"also"
present"in"all"active"molecules,"making"it"another"fundamental"feature"for"MTase"inhibition."It"
is"not"clear"whether"an"amino"substituent"on"the"left"ring"is"preferable"to"a"nitro"group."Similar"
SARs"occur"in"the"amide"linker"series"(compounds"from"47"to"52)."However,"in"this"series,"the"
position" of" the" electron\withdrawing" halogen" group" is" moved" to" position" 5" and" the" ester"
seems"to"be"preferred"to"the"carboxylic"acid"in"the"right"ring."
Soaking"experiments"were"also"performed"in"Marseille"University"and"two"active"compounds"
(44"and"45)"were"co\crystallised"with"DENV"NS5"MTase."As"shown"in"panel"A"of"Figure"5.23,"a"
new"binding" site"with" respect" to" the"original" fragments"and" closer" to" the"SAM"binding" cleft"
was" found." As" an" example" of" the" new" contacts" occurring" between" these" ligands" and" the"
protein,"panel"B"of"Figure"5.23"reports"a"schematic"view"of"compound"44"interactions.""
"
"
"
"
"
A" B"
Figure'5.23..Compounds.44.and.45.new.binding.site...
A)"Binding.mode."Here"is"reported"the"overlap"of"the"binding"of"the"co\crystallised"compounds"44.and"45,"of"the"
2E11"and"2C3"fragments"and"of"the"docked"compound"32."The"protein"surface"is"coloured"in"grey"and"SAM"is"
shown"in"purple"with"the"space\filling"model."Compound"44"carbon"atoms"are"shown"in"dark"red,"those"for"
compound"45"are"in"green,"whilst"those"for"2E11"and"2C3"are"in"yellow"and"for"compound"32"are"in"cyan."B).Ligand.
interactions.scheme.for.compound.44."The"rendering"of"the"interactions"follows"the"reported"legend."
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Correlations" between" structural" and" activity" data" could" only" be" found" by" analysing" the"
symmetric"unit"of"the"complex,"suggesting"that"the"mode"of"action"of"this"series"of"molecules"
could"be"the"stabilisation"of"an"inactive"protein"homodimer."The"necessary"halogen"containing"
substituent" (either"Cl"or"CF3)" interacts" in"a"hydrophobic"pocket"of" the"symmetric"monomer,"
involving" Leu237," Met233," Leu238," Val234," Arg206." Similar" interactions" engage" the" methyl"
substituent" of" the" other" ring" and" residues" Met70," Ile220" and" Val205" of" the" symmetric"
monomer." A" third" hydrophobic" contact" involves" the" Pro108" of" the" original" monomer."
Hydrogen" bonds" are" established" between" the" carboxylate" and" Arg84" and" between" the"
aromatic"amine"and"His110"and"Glu112."The"carbonyl"oxygen"of"the"urea"linker"is"very"close"to"
the" Gly109" backbone" amine," but" distance" and" angle" are" not" ideal" for" hydrogen" bond"
formation." Not" all" of" the" residues" in" the" symmetric" monomer" are" identical" among" DENV"
serotypes," whereas" the" hydrophobicity" of" the" amino" acids" is." Conversely," all" interacting"
residues"in"the"original"monomer"are"well"conserved."
"
MOLECULE.GROWING..
"
Molecule'optimisation'
"
The"symmetric"dimer"was"reconstructed"and"used"for"compound"optimisation."A"comparison"
of"this"structure"with"the"ones"available"in"the"Protein"DataBank[28]"showed"a"different"Glu111"
side"chain"conformation"in"most"of"them,"correlated"to"the"presence"of"a"sulphate"ion"in"the"
position"indicated"in"Figure"5.24.""
"
!
Figure'5.24..Sulphate.ion.localisation.and.Glu111.new.conformation...
Here"is"reported"the"modified"reconstructed"symmetric"unit"of"the"protein\compound"44"complex"overlapped"with"
the"sulphate"ion"from"available"crystal"structures."The"monomer"surface"and"ribbon"are"coloured"in"blue,"while"the"
symmetric"monomer"ribbon"is"in"pink."A"few"protein"residues"are"reported"and"shown"as"lines,"apart"from"Glu111"
that"is"shown"with"thicker"lines."SAM"carbon"atoms"are"in"orange"and"those"for"compound"44"are"in"white."
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In"this"conformation"the"acidic"residue"is"able"to"interact"with"the"basic"Arg84."The"consensus"
of"the"presence"and"of"the"position"of"the"sulphate"in"many"crystal"structures"and"the"fact"that"
in"absence"of"this"ion"Glu111"locates"its"carboxylate"group"in"the"same"area,"suggested"that"a"
similar"feature"could"be"included"in"the"small"molecule"for"binding"improvement."In"order"to"
do" so," the" Glu111" side" chain" conformation" was" modified" and" energy" minimised" in" the"
reconstructed"dimer."The"new"Glu111"conformation"is"shown"in"Figure"5.24."
As"before,"databases"of"new"molecules"were"designed"and"docked"in"an"iterative"manner."The"
docking"and"scoring"procedures"were"performed"with"Maestro"Glide,"using"a"10"Å"grid"centred"
on"compound"44"as"reported"in"the"METHODS"chapter.""
From"visual"inspection"of"the"results,"interactions"of"compound"44"were"retained"in"molecules"
that"overlapped"well"with" compound"44," they"also"had"better"docking" scores." For" an"easier"
explanation" of" the" docking" results," Figure" 5.25" highlights" the" designed" modifications" to"
compound"44."
"
!
Figure'5.25..Compound.44.modifications...
Coloured"circles"highlight"the"modified"regions"of"the"structure"of"compound"44."See"text"for"further"explanation."
The"carboxylic"acid"(blue"circle)"was"removed"to"avoid"electrostatic"repulsion"with"Glu111"and"
it" was" substituted" with" OH" (that" could" give" hydrogen" bonds)" or" removed" completely." In"
general,"the"hydroxyl"group"was"not"fundamental,"but"improved"the"position"of"the"aromatic"
ring."With" the" aim" of" mimicking" the" sulphate" group," the"molecule" was" extended" from" the"
methyl"substituent"(yellow"circle)"and"an"anionic"moiety"was"inserted."Best"docking"molecules"
had"a"linker"that"connected"the"scaffold"to"a"new"ring"with"a"carboxylate"moiety"in"the"para\"
position."The"correct"curvature"in"the"shape"of"the"molecule"was"achieved"only"with"sulphonic"
esters" or" sulphonamides." As" shown" in" Figure" 5.26" (with" the" two" best" docking" results)," this"
construction"allows"the"placement"of"the"carboxylate"in"the"same"area"of"the"sulphate"ion"and"
its"interaction"with"the"backbone"amino"group"of"Glu111."The"position"of"this"side"chain"in"the"
phenyl" ring" indicated" in" grey" in" the" scheme"was" also" explored." Docking" simulation" showed"
that"both"the"original"substitution"and"the"new"position" indicated"by"the"yellow"arrow"were"
able"to"give"good"binding"poses."In"order"to"increase"molecule"flexibility,"the"left"NH"group"of"
the" urea" moiety" (green" circle)" was" substituted" with" a" methylene," obtaining" an" amide."
However," the" increase" in" flexibility" did" not" produce" binding" improvements." The" aromatic"
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amine"(red"circle)"was"substituted"with"a"nitro"group"for"a"better"understanding"of"the"role"of"
this" group" and" docking" simulations" suggested" that" this" substitution" is" not" favourable" as" it"
removes" two" hydrogen" bonds." The" ring" in" grey" and" the" third" ring" were" substituted" with" a"
furan"or"a"pyrazole"ring"and"this"replacement"was"sometimes"successful"in"producing"a"good"
pose." Taken" together," these" results" suggested" that" the" iterative" docking" procedure" was"
successful" in" improving" the" binding" mode" in" the" in& silico" model." The" six" best" compounds,"
including" these" two" (compounds" 53" and" 54)," and" their" binding" poses" can" be" found" in"
APPENDIX&7."
"
" "
A" B"
" "
C" D"
Figure'5.26..Compounds.53.and.54...
A).Structure.of.compound.53..B).Structure.of.compound.54..C).Compound.53.binding.pose..The"compound’s"
binding"pose"is"overlapped"to"compound"44"and"the"sulphate"ion."Also"SAM"is"present."Only"one"protein"monomer"
(blue"surface"and"ribbon)"is"displayed"for"simplicity."Some"protein"residues"are"also"displayed"as"lines"and"the"
sulphate"ion"is"represented"with"the"ball"and"stick"model."SAM"carbon"atoms"are"coloured"in"orange,"while"those"
for"compound"44"are"in"white"and"the"carbons"of"the"docked"molecule"are"in"purple."D).Compound.54.binding.
pose..The"compound’s"binding"pose"is"overlapped"to"compound"44"and"the"sulphate"ion."Also"SAM"is"present."The"
same"rendering"as"C)"was"applied."
"
Molecular'dynamics'simulations'
"
With" the" aim"of" understanding" the" role" and" the" impact" of" the" change"of"Glu111" side" chain"
conformation" in"the"docking"simulations,"5"ns"molecular"dynamics"(MD)"simulations"for" four"
molecular" systems"were" carried" out" with" GROMACS." The" four"molecular" systems" were" the"
symmetric"unit"with"no"ligands"and"in"complex"with"either"compound"44,"53"or"54.""
Interestingly," even" if" all" the" starting" structures" had" the" Glu111" in" the" crystal" structure"
conformation,"in"all"MD"simulations"Glu111"turned"and"interacted"with"Arg84,"confirming"that"
the"modification" done" for" the" docking" simulations" is" reasonable" in" physiological" conditions."
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More" stable"binding" could"be"observed" for" compounds"53" and"54" than" for"44."As" shown" in"
Figure" 5.27," for" compound" 44" MD," the" shift" of" the" Glu111" side" chain" placed" the" residue"
negative" charge" near" the" small" molecule’s" carboxylate" group," producing" an" electrostatic"
repulsion"and"a"distortion"in"the"urea"moiety"and"a"greater"solvent"exposure"of"the"ligand.""
"
!
Figure'5.27..Compound.44.decreased.binding.observed.with.MD...
The"Glu111"movement"and"the"consequent"decrease"in"compound"44"binding"are"represented"here."Two"
snapshots"from"the"MD"simulation"(at"0"and"2ns)"were"superposed"to"show"different"conformations"of"Glu111"and"
compound"44."Shifts"are"highlighted"with"arrows."The"original"MTase"monomer"ribbon"and"carbon"atoms"are"
coloured"in"blue,"while"the"ones"of"the"symmetric"monomer"are"in"pink"and"SAM"carbon"atoms"are"in"orange."In"all"
cases,"light"and"dark"shades"for"0ns"and"2ns"snapshots"respectively"are"used."Compound"44"carbon"atoms"are"
shown"in"green"and"in"dark"red"for"the"0ns"and"2ns"snapshots"respectively."
Conversely," the"Glu111" flipped"conformation"of" the" side"chain"was"particularly" stable" in" the"
other" two" molecules" simulations." Consequently," the" MD" results" gave" a" mechanistic"
explanation"as"to"why"compound"44"could"have"a"decreased"binding"compared"to"compounds"
53"and"54," supporting"the"docking"results" that"suggested"that" the"new"series"of"compounds"
could"potentially"have"an"improved"MTase"inhibitory."
"
Experimental'data'for'the'last'series'of'compounds'
"
From" the" last" suggested" series" of" compounds," five" molecules" without" the" OH" substituent"
(compounds"57,"60,"63,"66"and"69)"and"their"intermediates"were"synthesised,"assessed"in&vitro"
and" used" for" soaking" experiments" in"Marseille" University." Table" 5.5" shows" the" synthesised"
compounds" and" their" MTase" inhibitory" activity." Compound" 69" was" synthesised" but" its"
inhibitory"activity"results"are"not"available"to"date.""
As" shown" in" the" table," the" compounds" of" this" series" are"more" active" inhibitors" of" the" 2’\O"
methylation" than" N\7" methylation." This" pattern" was" found" also" with" the" most" active"
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compounds" (60" and"63)" giving" IC50" values"of" around"100µM"and"above"700µM"and" for"2’\O"
and"N\7"methylation"respectively."
"
Table'5.5..MTase.inhibition.data.for.synthesised.compounds..
Scaffold:"
"""""""" "!
ComF
pound. X.
SO2NH.
position. R1. R2.
2’FO.
methylation.
IC50.(µM).
NF7.
methylation.
IC50.(µM).
55. NH" 3" 4\COOMe" 2\NO2;"4\Cl" >500" >500"
56. NH" 3" 4\COOMe" 2\NH2;"4\Cl" 715" >500"
57. NH" 3" 4\COOH" 2\NH2;"4\Cl" 452" >500"
58. NH" 3" 4\COOMe" 2\NO2;"4\CF3" >500" >500"
59. NH" 3" 4\COOMe" 2\NH2;"4\CF3" 398" >500"
60. NH" 3" 4\COOH" 2\NH2;"4\CF3" 91" 1,200"
61. NH" 4" 4\COOMe" 2\NO2;"4\CF3" 676" >500"
62. NH" 4" 4\COOMe" 2\NH2;"4\CF3" 237" >500"
63. NH" 4" 4\COOH" 2\NH2;"4\CF3" 110" 742"
64. CH2" 4" 4\COOMe" 2\NO2;"4\CF3" 559" >500"
65. CH2" 4" 4\COOMe" 2\NH2;"4\CF3" 476" >500"
66. CH2" 4" 4\COOH" 2\NH2;"4\CF3" 332" >500"
67. CH2" 4" 4\COOMe" 2\NO2;"4\Cl" 473" >500"
68. CH2" 4" 4\COOMe" 2\NH2;"4\Cl" 430" >500"
69. CH2" 4" 4\COOH" 2\NH2;"4\Cl" In"progress" In"progress"
"
Importantly,"the"activity"data"agreed"with"the" in&silico"results"presented"above."As"suggested"
by"docking"results," the"substitution"of" the"urea" linker"with"a"more" flexible"methylene\amide"
decreases" activity." Furthermore," the" final" molecules" were" always" more" active" than" the"
synthetic" intermediates," confirming" that" the" carboxylic" acid" and" the" aromatic" amine" are"
important"for"molecule"binding."The"CF3"substituent"appeared"to"increase"activity"with"respect"
to" the" Cl" substituent," while" no" particular" activity" pattern" regarding" the" sulphanilamide"
position"could"be"observed.""
A" soaking" experiment" produced" a" structure" for" the"MTase" in" complex" with" compound" 57."
Comparison"of"this"structure"with"the"protein\compound"44"complex"showed"that"most"of"the"
protein" residues" have" retained" their" conformation." Conversely," the" Glu111" side" chain" was"
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crystallised" in"two"conformations"with"0.5"occupancy."One"of"them"is"exactly"the"same"as" in"
the"compound"44"complex."The"other"one"is"similar"to"the"conformation"that"was"built"for"the"
docking" simulations," confirming" that" this" modification" was" reasonable" in" physiological"
conditions."Furthermore,"as"a"consequence"of"the"latter"Glu111"conformation,"the"Arg84"side"
chain"is"shifted"as"well,"as"shown"in"Figure"5.28."
The" co\crystallised" inhibitors" (compounds" 44" and" 57" in" dark" red" and" in" blue" in" Figure" 5.28"
respectively)"overlap"well" in" the"same"binding"site."Due"to"a"small"shift"of" the"molecule," the"
interactions" between" His110" carbonyl" oxygen" and" urea" and" aromatic" amine" groups" are" no"
longer"recognised"by"the"modelling"program."However,"the"other"interactions"with"the"MTase"
monomer"are"maintained"and"they" involve"hydrophobic"contacts"with"Pro108"and"hydrogen"
bonds"with"Gly109"NH" (and" the" urea" carbonyl" oxygen)" and"Glu112" COO\" (and" the" aromatic"
amine)."The"latter"hydrogen"bond"explains"the"improved"activity"conferred"by"an"amino"group"
with" respect" to" the"nitro"moiety" in" the" same"position."By" reconstructing" the"unit" cell" it"was"
also" possible" to" confirm" that" the" halogen" group" (either" CF3" of" Cl)" sits" nicely" in" a" lipophilic"
pocket,"formed"mainly"by"Leu237,"Val234"and"Met233"of"the"symmetric"image"of"the"MTase.""
"
" "
""A" ""B"
Figure'5.28..Structure.of.MTase.in.complex.with.compounds.44.and.57...
A).Front.view..Here"the"superposition"of"the"crystallographic"structures"of"the"complexes"with"compounds"44"and"
57"are"presented."Compound"44.and"57.carbon"atoms"are"shown"in"dark"red"and"in"blue"respectively."Protein"
ribbons"and"residues"carbon"atoms"follow"a"similar"colour"code:"those"of"the"compound"44"complex"are"orange"
and"those"of"the"compound"57"are"in"light"blue."SAM"carbon"atoms"follow"the"same"colour"code."The"interacting"
residues"are"indicated"and"hydrogen"bonds"are"shown"with"red"dotted"lines."Both"side"chains"conformations"for"
Glu111"are"shown."B).Side.view."As"panel"A."Additionally,"also"Arg84"side"chain"conformations"are"shown."
"
Unfortunately,"the"new"compound"side"chain"in"57" is"solvent"exposed"and"does"not"bind"the"
MTase" close" to" the" SAM" site" differently" from" the" drug" design" aim" and" docking" results," as"
shown"in"panel"B"of"Figure"5.28"and"in"Figure"5.29."This"could"be"partly"due"to"the"interaction"
of" one" of" the" sulphonamide" oxygens" with" Arg68" of" the" symmetric" image." The" only" other"
contact" of" this" part" of" the"molecule" is" a" hydrophobic" interaction"with" the" symmetric" image"
Section"5:"NS5"METHYLTRANSFERASE"AS"A"DRUG"TARGET" 5.2&RESULTS&AND&DISCUSSION"!
227!
Met70."Consequently,"no"explanation"of"the"improved"activity"of"the"carboxylate"substituent"
over"the"ester"could"be"gathered"from"the"structural"results."A"hypothesis"on"why"the"added"
portion" of" the" molecule" presents" this" binding" conformation" could" be" that" a" clash" or" close"
contact" with" SAM" that" does" not" allow" the" compound" to" bind" to" the" protein" as" predicted."
However,"the"docking"simulations"were"performed"in"presence"of"the"natural"cofactor"and"this"
did"not"affect"molecules"poses."This"is"shown"in"Figure"5.29,"where"the"same"view"of"panel"B"
of"Figure"5.28"is"superposed"with"the"docking"pose"of"compound"53"(in"green"in"the"figure),"as"
an"example."Here," the"compound"53"portion"extends" towards" the"SAM"binding"site"and" the"
carboxylate" moiety" is" correctly" positioned" according" to" drug" design" aims" (see" previous"
chapter)"and"clashes"with"the"natural"cofactor"can"be"observed."
"
!
Figure'5.29..Comparison.of.compounds.44.and.57.crystal.structures.with.compound.53.docking.pose...
The"superposition"of"the"crystallographic"structures"of"the"complexes"with"compounds"44"and"57"and"of"the"
docking"pose"of"compound"53.is"presented"here."The"same"colour"code"as"Figure"5.28,"panel"B"was"applied."
Compound"53"carbon"atoms"are"reported"in"green."
""
CONCLUDING.REMARKS.
"
With"the"aim"of"discovering"potent"anti\DENV"drugs,"2E11"and"2C3"fragments"were"linked"in"
the"initial"drug"design"procedure"seeking"interactions"with"conserved"residues"among"the"four"
DENV"serotypes."An"iterative"process"of"designing"and"docking"allowed"molecule"optimisation."
Of" these," three" (compounds"32,"33" and"34)" demonstrated" a" good" overlap"with" the" original"
fragments" and" an" improvement" of" the" binding" properties" to" the" protein," and" another" two"
(compounds" 35" and" 36)" were" shown" to" be" interesting" as" they" could" reduce" the" rigidity" of"
compounds" 32," 33" and" 34," but" conserving" most" of" the" interactions" with" the"
methyltransferase.""
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A"set"of"16"compounds"(including"both"final"designed"molecules"and"synthetic"intermediates)"
were" synthesised" and" biologically" evaluated" in" Marseille" University." Two" of" the" active"
molecules" were" also" successfully" co\crystallised" with" DENV3" NS5"MTase." The" experimental"
data" provided" preliminary" structure\activity" relationships" and" to" construct" a" hypothesis" for"
which"the"mode"of"action"of"these"molecules"could"be"MTase"inactivation"through"homodimer"
stabilisation." One" of" the" co\crystallised" molecules" was" then" used" for" further" compound"
optimisation."
The"crystal"symmetric"dimer"was"reconstructed,"the"Glu111"side"chain"was"moved"according"
to"available" structural"data"and" the"model"was" then"used" for"docking" simulations."With" the"
aim" of" reproducing" the" interactions" of" a" sulphate" ion" present" in" several" available" crystal"
structures"of"DENV"MTase,"the"co\crystallised"compound"(44)"was"grown."Docking"and"design"
iterations"produced"six"molecules"(e.g."compounds"53"and"54)"that"could"potentially"improve"
binding"and"consequently"activity."
The" change" in" the" Glu111" side" chain" conformation" was" confirmed" to" be" physiologically"
relevant" through"molecular" dynamics" simulations." This" change" also" supported" the" fact" that"
compounds" like" 53" and" 54," which" bind" more" stably" NS5" MTase" in" the" new" Glu111"
conformation" respect" to"44," should" represent"an" improvement"with" respect" to" the"previous"
molecule"series."Moreover,"the"latest"experimental"data"showed"that"an"increase"of"over"100\
fold" activity" has" been" achieved" for" inhibiting" 2’\O" methylation" and" of" over" 14\fold" for"
inhibiting"N\7"methylation"compared"to"the"starting"fragments"2E11"and"2C3,"confirming"that"
the"linking"of"two"fragments"has"been"a"successful"approach"for"the"development"DENV"NS5"
MTase"inhibitors"through"the"designed"fragment\based"drug"design"study"discussed"here."
Unfortunately," the" latest"crystallographic"data"did"not"confirm"completely" the"binding"mode"
of"the"last"series"of"designed"molecules,"as"they"do"not"extend"towards"the"SAM"binding"site."
However," the"synthesis"and"evaluation"of"other"already"designed"molecules"different" in" this"
portion"of"the"structure"(e.g."compound"54,"which"has"a"smaller"aromatic"ring)"could"give"an"
improved" knowledge" of" the"mechanism" of" action" of" these" compounds" and" improve" future"
fragment\based"drug"design"iterations.""
Taken"together,"the"results"suggest"that"the"general"de&novo"drug"design"approach"applied"to"
2E11"and"2C3"fragments"was"successful"in"finding"inhibitors"of"DENV3"NS5"MTase"with"novel"
chemical"structures"and"further"development"of"these"molecules"will"lead"to"the"discovery"of"
compounds"that"could"one"day"be"used"in"DENV\infections"treatment."
"
" "
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5.2.3'FRAGMENT'2G3'MODE'OF'ACTION'
"
!
Figure'5.30.'Fragment.2G3...
Here,"fragment"2G3"is"shown"in"complex"with"NS5"MTase."The"position"in"respect"of"the"whole"protein"of"fragment"
2G3"is"reported"on"the"left"and"a"closer"view"of"the"2G3"fragment"bound"to"the"MTase"is"reported"on"the"right."The"
protein"complex"on"the"left"is"the"same"as"reported"in"Figure"5.6."The"protein"is"shown"with"a"blue"surface"and"2G3"
is"represented"with"the"ball"and"stick"model"on"the"left"and"with"lines"on"the"right..
The" most" active" fragment" that" was" co\crystallised" with" DENV3" MTase" was" 2G3" (2\(2,5\
dimethyl\1H\pyrrol\1\yl)benzoic"acid),"displaying"IC50"values"of"0.3"mM"and"2.0"mM"against"2’\
O" and" N\7" methylation" respectively." However," the" crystal" structure" did" not" aid" the"
understanding"of" the" fragments’" activity" as"2G3" is"placed"on" the" surface,"with"a"big" solvent"
exposed"fragment"portion,"as"shown"in"Figure"5.30.""
It"was"theorised"that"2G3"binds"to"another"site"of"the"MTase"for"its"inhibition"activity."As"the"
structure"was"obtained"by"soaking"the"already"formed"crystal"of"the"MTase\SAM"complex"in"a"
concentrated"solution"of"2G3," it"was"also"hypothesised"that" in"these"conditions"2G3"was"not"
able" to" displace" the" SAM" molecule" from" its" site" and" consequently" to" bind" correctly."
Furthermore,"SAM"binding"site"residues"are"well"conserved"among"DENV"serotypes,"so"if"2G3"
really" bound" to" this" cleft" it" could" be" an" interesting" starting" point" for" the" design" of" a" novel"
potent"serotype\nonspecific"DENV"inhibitor."
In" order" to" validate" this" hypothesis," a" binding" mode" for" 2G3" in" the" SAM" binding" site" was"
studied"through"docking"and"MD"simulations"and"is"discussed"here.""
"
2G3.BINDING.MODE.
"
Fragment"2G3"was"docked"in"the"SAM"binding"site"using"Maestro"Glide"software"and"a"9Å"grid"
centred"on"the"natural"substrate."In"the"best"binding"pose"obtained,"2G3"superposed"well"with"
SAM,"as"shown"in"Figure"5.31."In"particular,"overlap"between"the"pyrrole"and"phenyl"rings"with"
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the" SAM" base" and" ribose" respectively" could" be" observed." As" simplified" by" the" ligand"
interaction"scheme"in"panel"B"of"this" figure," in"this"binding"pose"the"two"rings"of"2G3"give"a"
hydrophobic" interaction"with" Ile147,"while" the" carboxylate"moiety"exhibits" electrostatic" and"
hydrogen" bond" interactions"with" the" Lys105" backbone" amino" group" and"His110" side" chain,"
retaining"some"of"the"SAM"interactions"with"DENV"MTase."
"
"
"
"""A" "B"
Figure'5.31..2G3.binding.mode...
A).2G3.binding.pose.overlapped.to.SAM.molecule..The"binding"pose"of"2G3"is"overlapped"to"the"SAM"molecule"for"
comparison."Some"protein"residues"are"indicated"and"represented"with"grey"carbon"atoms"and"part"of"the"protein"
surface"is"in"yellow."2G3"carbon"atoms"are"in"orange,"while"those"for"SAM"are"in"green."B).Ligand.interaction.
scheme.of.2G3.pose..The"main"interactions"of"the"fragment"with"the"protein"are"reported"with"the"rendering"
indicated"by"the"legend"on"the"bottom"of"the"panel."
"
2G3.BINDING.MODE.VALIDATION.
"
For" a" validation" of" the" 2G3" binding"mode" and" to" further" investigate" the" interaction" of" the"
ligand" carboxylate" with" His110," three" 3ns"MD" simulations" of" the" complex" were" performed"
with"GROMACS:"one"for"each"possible"protonation"state"of"the"amino"acid."The"neutral"His110"
with" the"hydrogen"on" the"ε" nitrogen"position" (HIE110)"was" the"preferred"protonation" state"
according"to"the"force"field"used"for"the"MD"simulations."Only"in"this"case"2G3"maintained"the"
docking" binding" pose," retaining" the" observed" interactions." Conversely," HIE110" changed"
conformation"for"hydrogen"bond"optimisation,"causing"a"shift"of"the"protein"loop."In"the"other"
two" cases" (with" positive" charged" His110," called" HIP110," and" with" the" neutral" His110"
protonated" on" the" δ" nitrogen," called" HID110)," the" amino" acid" retained" the" original"
conformation,"while"2G3"rotated,"loosing"the"SAM\ring"co\localisation"of"the"docking"pose"and"
reducing"the"hydrophobic" interaction"with" Ile147."All" the"new"fragment"conformations"were"
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stable"for"the"length"of"the"simulation."Figure"5.32"shows"the"conformations"adopted"by"2G3"
and"the"protein"main"changes"observed"in"the"three"MD"simulations"and"described"above."
"
!
Figure5.32..2G3.different.conformations.adopted.in.the.3.MD.simulations...
The"three"2G3"conformations"described"in"the"text"are"superposed"here"for"comparison."The"molecular"system"
with"HIE110"is"coloured"in"blue,"the"one"with"HID110"is"in"green"and"the"one"with"HIP110"is"in"orange."In"all"three,"
2G3"is"coloured"with"a"darker"shade"and"His110\carboxylate"hydrogen"bonds"are"shown"as"red"dashed"lines.""
Summarising," these" results" confirmed" that" the" ligand" can" assume"a" stable" pose" in" the" SAM"
binding"site"and"the"carboxylate\His110"interaction"is"one"of"the"most"important"in"fragment"
binding."However," a" stronger" validation"of" the"docking\derived"binding"mode"of" 2G3"would"
come"from"a"good"correlation"between"MTase" inhibitory"activity"and"docking"results"of"2G3"
analogues." For" this" reason," a" database" of" 2G3" analogues" was" designed" and" docked" with"
Maestro"Glide,"as"done" for" the"2G3" fragment."The"most" interesting"molecules" from"docking"
results"and"their"activity"prediction"are"reported"in"Table"5.6.""
2G3"analogues"from"70"to"76"retained"2G3"interactions"and"most"of"them"(70,"72,"73"and"74)"
showed" binding" improvement." In" detail," the" addition" of" hydroxyl" groups" to" the" pyrrole"
substituents" (as" in" compounds" 70," 72," 73" and" 74)" enhanced" binding" by" the" addition" of"
hydrogen"bonds"with"the"Thr104"hydroxyl"moiety"and"Gly148"backbone"amino"group,"while"a"
methylamino"substituent"of"the"phenyl"ring"in"meta\"position"with"respect"to"the"carboxylate"
group"(as"in"compounds"70"and"74)"could"interact"with"the"Gly81"carbonyl"oxygen."Panel"A"of"
Figure" 5.33" shows" compound" 70" binding" pose" as" an" example" of" these" interactions."
Furthermore,"a"hydroxyl"substituent" in"the"phenyl"ring" in"the"ortho\"position"with"respect"to"
the" carboxylate" group" (compound" 71)" overlaps" with" the" 2’OH" group" of" SAM" and" could"
therefore"be"interesting."However,"no"additional"interactions"could"be"detected"in"this"case,"as"
shown"in"panel"B"of"Figure"5.33,"and"consequently"the"activity"profile"of"this"residue"cannot"be"
predicted"in&silico."
Conversely," a" loss" of" activity"would" be" expected" for" compounds"75. and"76." These" two"2G3"
analogues" were" designed" to" confirm" the" importance" of" the" carboxylate\His110" interaction"
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observed" both" in" docking" and" MD" simulations" and" to" investigate" the" role" of" the" negative"
charge"in"small"molecule"binding."The"methyl"ester"was"chosen"over"more"bulky"substituents"
for"compound"75"in"order"to"minimise"the"steric"effect"in"molecule"binding."
"
Table'5.6..Structure.and.activity.prediction.for.improved.2G3.analogues..
Scaffold:"
"
!
Compound. R1. R2. R3. R4. R5. Activity.
prediction.
70. OH" OH" COOH" H" CH2NH2" Improvement"
71. H" H" COOH" OH" H" Not"predictable"
72. H" OH" COOH" H" H" Improvement"
73. OH" OH" COOH" H" H" Improvement"
74. H" OH" COOH" H" CH2NH2" Improvement"
75. H" H" COOCH3" H" H" Decrease"
76. H" H" CH3" H" H" Decrease"
"
"
"
A" B"
Figure'5.33..Binding.poses.of.compounds.70.and.71..
A).Compound.70..Compound"70"pose"is"superposed"with"the"2G3"fragment."Some"protein"amino"acids"are"
reported"as"lines"and"interacting"residues"are"highlighted"with"thicker"lines."Compound"70"carbon"atoms"are"in"
cyan"and"those"for"2G3"are"in"orange."B).Compound.71..Compound"71"pose"is"superposed"with"the"2G3"fragment"
and"SAM."2G3"and"some"protein"amino"acids"are"reported"as"lines"and"interacting"residues"are"highlighted"with"
thicker"lines."Compound"71"carbon"atoms"are"in"cyan,"those"for"2G3"are"in"orange"and"for"SAM"are"in"green."
" "
N
R3
R2R1
R4
R5
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CONCLUDING.REMARKS.
"
As" structural" data" from"Marseille" University" failed" to" explain"why" 2G3"was" the"most" active"
fragment" against"DENV"MTase" activity," a"Molecular"Modelling" study"was"performed"on" this"
fragment" for" the" investigation"of" its" inhibitory"mode"of"action." It"was"hypothesised" that" the"
fragment"binds" to" the"SAM"cleft"and"a"binding"mode"was"proposed"and"evaluated"with"MD"
simulations." In" order" to" validate" this" premise," 2G3" analogues"were"docked" in" the" same" site"
and" their"biological"activity"was"predicted."These"compounds"will"be"synthesised"and" tested"
for"their"MTase"inhibition"activity"in"Marseille"University."A"consensus"between"experimental"
and"docking"results"would"support"the"hypothesis"of"2G3"binding"to"the"SAM"cleft."This"would"
aid"a"successful"optimisation"of"the"fragment"and"as"the"protein"site"is"highly"conserved,"and"
could"lead"to"the"design"of"a"novel,"potent"and"panserotypic"drug"against"DENV."
Differently" to"all"other" structures"available" in" the" literature,"a"DENV"MTase"crystal" structure"
has"been" recently" solved" in" the"absence"of"SAM."The"published"protocol" consists"of"protein"
production,"unfolding"and"refolding,"after"SAM"(or"SAH)"removal.[21]"It"would"be"illuminating"to"
apply" the" same" protocol" as" described" in" this" reference" and" to" use" the" crystals"without" the"
natural"ligand"for"soaking"experiments"of"the"2G3"fragment"and"its"derivatives."This"could"be"a"
reliable"approach"for"the"validation"of"the"proposed"binding"mode"of"2G3."
"
"
"
"
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5.3.CONCLUSIONS.
"
The" presence" of" a" cap" structure" at" the" 5’" end" of" the" viral" genome" is" required" for" DENV"
replication" within" host" cells.[3\5]" As" this" is" a" cytosolic" process," for" cap" maturation" the" virus"
cannot"exploit"the"host"methyltransferases,"which"are"located"in"the"nucleus."This"makes"the"
viral"MTase"an"essential"enzyme"for"viral"replication"and"therefore"a"promising"drug"target.[3\5]"
In"collaboration"with"Marseille"University,"a"fragment"based"drug"discovery"(FBDD)"study"was"
started," aiming" to" discover" a" novel," potent" anti\DENV" drug." On" the" basis" of" structural" and"
biochemical"experimental"data"obtained" in"this" institution,"Molecular"Modelling"was"used"to"
aid" the" development" of" four" of" the" seven" active" fragments" that" successfully" inhibited" the"
enzyme"and"produced"soaked"crystals"of"DENV3"MTase."On"one"of"the"active"fragment"(2A4)"
growing" de& novo" drug" design" strategies" were" applied" for" the" improvement" of" the" small"
molecule"binding."With"the"same"purpose," two"other" fragments" (2E11"and"2C3)"were" linked"
and"then"grown"with"de&novo"drug"design"approaches."Finally,"a"binding"mode"different"from"
that" observed" in" the" crystal" structure" was" suggested" and" evaluated" for" the" most" active"
compound,"as"the"experimental"data"available"could"not"explain"such"MTase"inhibition."Even"if"
DENV"MTase"is"one"of"the"most"conserved"DENV"protein"(with"60\70%"homology"among"the"
four" serotypes)," particular" attention" has" been" given" to" how" well" conserved" interacting"
residues" were," in" order" to" direct" the" design" exercise" towards" serotype\nonspecific" agents."
Unfortunately," as" both" crystal" structures" and" biochemical" assays" were" based" on" DENV"
serotype"3,"it"cannot"be"assessed"to"date"if"this"additional"objective"was"accomplished."
FBDD"is"a"multidisciplinary"approach"that"has"proven"to"successfully"discover"drug"candidates"
(with"one"drug"approval)"starting"from"fragments"with"millimolar"activity"concentrations"and"
for"which"structural"data"can"be"obtained."To"the"best"of"knowledge,"this"iterative"process"of"
small"molecule"optimisation"and"evaluation"and" the"developed" in& silico"methodologies"have"
never"been"applied"before"to"this"molecular"target."Even"if"in"the"case"of"this"project"very"few"
iterations"have"been"performed"to"date,"activity"improvement"(of"even"over"100\fold"for"2’\O"
methylation)" has" already" been" achieved" for" one" of" the" three" studies" presented" here,"
indicating"that"the"designed"drug"design"method"is"moving"in"the"right"direction,"confirming"to"
be"a"suitable"approach"also"for"the"development"of"MTase"inhibitors."Future"drug"design"and"
evaluation" iterations" will" prompt" further" improvement" of" the" molecules" designed" and"
discussed"in"this"chapter,"leading"to"potential"novel,"potent"drugs"against"DENV"infection."
"
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5.4.METHODS.
"
The"computational"methods" for"all" the"studies"discussed" in"chapters" from"5.2.1" to"5.2.3"are"
presented" here." A" description" of" the" molecular" modelling" programs" used" can" be" found" in"
APPENDIX&2."
"
HARDWARE'DETAILS'
"
All"calculations"were"performed"on"a"8"core"computer"with"Inter"Xeon"2.80"GHz"E5462"CPUs."
"
PROTEIN'PREPARATION'
"
In"all"the"applications,"the"protein"structure"obtained"from"Marseille"University"was"prepared"
by" removing"water"molecules"and"adding"missing"hydrogen"atoms,"optimised"with" the"MOE"
2010.10[29]" Protonate" 3D" tool," considering" a" temperature" of" 300K," a" pH" of" 7" and" a" salt"
concentration"of"0.1M."Ligand"molecules"were"retained"or"deleted"according"to"necessity."
"
DESIGN'OF'SMALL'MOLECULE'DATABASES''
"
All"small"molecule"databases"were"prepared"with"MOE"2010.10.[29]"Compounds"were"designed"
with" the"Builder" tool,"energy"minimised"with"MMFF94x" force" field"and"steepest"descendent"
method," using" 500" iterations" and" gradient" of" 0.001" and" preserving" existing" chiralities."
Hydrogens" and" lone" pairs" were" adjusted" and" partial" charges" were" calculated." One"
conformation"was"saved"for"each"molecule."
"
PHARMACOPHORE'QUERIES'
"
All"pharmacophores"were"built"with"MOE"2010.10[29]"Query"Editor,"using"the"Unified"scheme."
Features"characteristics"and"size"were"chosen"according"to"occurrence."Essential"features"and"
partial"matches"were"set"according"to"necessity."
"
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MOE'MEDCHEM'TRANSFORMATIONS'
"
MOE"2011.10[30]"MedChem"Transformations"was"used"for"fragment"2A4"growth."The"starting"
fragment"was"set"as"ligand"and"the"atoms"that"had"to"be"subjected"to"the"medicinal"chemistry"
transformations"were"selected"according" to" the"purpose"of" the"calculation"and" the" receptor"
was" set" as" “Receptor" atoms”." The" first" drug" design" attempt" (R1" group"modification" for" 2A4"
fragment)" used" a" MOE" implemented" transformation" database"
($MOE/sample/mol/GrowthRXN.mdb)," while" all" the" other" design" attempts" used" a" database"
that" contained" the" transformations" implemented" by" the" software"
($MOE/sample/mol/GrowthRXN.mdb" and" $MOE/lib/medchem_rxn.mdb)" and" other" defined"
transformations" that" were" added." The" new" transformations" were" prepared" singularly" with"
ChemDraw"Ultra"12.0"and" imported" in"a"mdb"database" through"a" svl" command" reported" in"
the"MOE"online"manual:[31]"
"
The"number"of" iterations"was"decided"on"the"basis"of" the"results"obtained"and" it"was"never"
higher"than"5."Only"molecules"with"molecular"weight"under"500"Da,"SlogP"between"\4"and"8,"
total"polar"surface"area"(TPSA)"between"40"and"140"and"that"matched"at"least"3"(for"R1"group"
modification"for"2A4"fragment)"or"4"of"the"8"features"of"a"3D"pharmacophore"were"retained"
from" the" iterations." Three" features" of" the" pharmacophore" query"were" set" as" essential." The"
generated"structures"were"refined"through"a"500"iterations"procedure"with"gradient"of"0.001"
and"a"pharmacophore"restraint"force"constant."
The" resulting" molecules" were," then," visually" inspected" and" pharmacophore" searched,"
increasing" the" number" of" matching" features," usually" from" 4" to" 5." The" most" promising"
molecules"or"fraction"of"molecules"were"annotated"for"further"investigation."
"
MOE'COMBINATORIAL'BUILDER'
"
MOE" 2011.10[30]" Combinatorial" Builder" was" used" for" fragment" 2A4" growth." The" starting"
fragment"was"set"as"ligand"and"the"atoms"that"had"to"be"subjected"to"molecule"growing"were"
selected"according" to" the"purpose"of" the" calculation"and" the" receptor"was" set" as" “Receptor"
atoms”." For"molecule" growing" the" default" substituent’s" library,"with" 69" R\groups,"was" used"
($MOE/lib/buildfrag.mdb)." Only" molecules" with" molecular" weight" less" that" 500" Da," SlogP"
between"\4"and"8,"TPSA"between"40"and"140"and"that"matched"at"least"4"of"the"8"features"of"a"
run [‘$MOE/lib/svl/run/medchemtrns.svl’, [database, directory, 
opt], ‘_MedChemTrns_MakeMDB’] 
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3D"pharmacophore"were"retained"from"the"iterations."Three"features"of"the"pharmacophore"
query"were" set" as" essential." The" generated" structures"were" refined" through" a" 500" iteration"
procedure"with"gradient"of"0.001"and"a"pharmacophore"restraint"force"constant.""
The" resulting" molecules" were," then," visually" inspected" and" pharmacophore" searched,"
increasing" the" number" of"matching" features" from"4" to" 5." The"most" promising"molecules" or"
fraction"of"molecules"were"annotated"for"further"investigation."
"
LIGBUILDER''
"
The" following" LigBuilder" 1.2[32]" tools" were" used" for" molecule" growing:" POCKET," GROW,"
PROCESS.""
NS5"MTase"structure,"a"modified"2A4"fragment"(compound"19)"and"dummy"atoms"were"used"
for"binding"site"determination"with"POCKET."For"pharmacophore"determination"construction"
the"maximum"number"of" features"was"set" to"8"and"the"minimal" feature"distance"was"set" to"
3.5Å."The"GROW"process"was"performed"with"20"generations"and"a"maximum"population"of"
3000" molecules" for" the" genetic" algorithm." The" bioavailability" rules" were" set" as" default:"
molecular"weight"between"300Da"and"600"Da;" logP"between"3.00"and"6.00;"hydrogen"bond"
donor" groups" between" 2" and" 6;" hydrogen" bond" acceptor" groups" between" 2" and" 6." Only"
molecules"with"a"similarity"index"smaller"than"0.90"were"selected"for"the"mating"pool."Default"
chemistry"rules"and"forbidden"and"toxic"exclusions"were"used."
The"results"obtained"with"the"LigBuilder"program"were"then"visually"inspected"and"evaluated"
in"MOE[29]"environment.""
"
MOE'LINK'MULTIPLE'FRAGMENTS'
"
MOE"2011.10[30]"Link"Multiple"Fragments"was"used"for"2E11"and"2C3"fragments"linking."Three"
linking"sites"were"chosen"in"the"2E11"fragment"and"three"in"the"2C3"fragment,"adopting"a"total"
of"four"linking"strategies"employing"two"sites"at"the"time."All"the"linking"modes"were"based"on"
modified"structures"of"the"2E11"and"2C3"fragments."The"atoms"of"the"NS5"MTase"were"set"as"
“Receptor" atoms”." Linkers"were" taken" from" the"default" linker" library" ($MOE/lib/linker.mdb)"
that"contained"22,603" linker"conformations."Only"molecules"with"molecular"weight" less" that"
500"Da,"SlogP"between"\4"and"8"and"TPSA"between"40"and"140"were"retained."The"generated"
structures" were" refined" through" a" 500" iteration" procedure" with" gradient" of" 0.001." The"
resulting" molecules" were," then," visually" inspected" and" the" most" promising" ones" were"
annotated"for"further"investigation."
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MOE'DOCKING'
"
The" database" of" 2E11\2C3" derivatives" designed" on" the" base" of" the" MOE[30]" Link" Multiple"
Fragments" tool" was" docked" with" MOE" 2011.10[30]" Docking" tool." After" protein" and" small"
molecule"database"preparation," the"binding" site"was" identified"using" the"original" fragments."
Ligand" placement" was" restrained" with" the" use" of" a" four" (essential)" features" 3D"
pharmacophore." The" pose" generation" was" conducted" in" semi\flexible" conditions," with" a"
conformational" search" on" the" ligands." The" first" rescoring" was" calculated" with" the" default"
London" dG" scoring" function," while" the" second" one" used" was" the" GBVI/WSA" dG" scoring"
function."Before"the"second"rescoring"an"energy"minimisation"was"computed"with"AMBER99"
force"field,"considering"only"those"amino"acids"at"a"maximum"6Å"distance"from"the"ligands"and"
maintaining"the"protein"residues"as"fixed."This"refinement"was"computed"with"500"iterations"
and"a"0.01"gradient"and"it"was"constrained"by"the"use"of"the"same"pharmacophore"as"in"the"
placement" step." Duplicates" were" not" removed" after" the" refinement" and" a"maximum" of" 30"
poses"were"kept"after"the"first"refinement,"while"a"maximum"of"10"were"kept" in"the"second"
one."The"output"was"then"visually"inspected.""
"
MAESTRO'GLIDE'DOCKING'
"
Maestro"9.3"Glide"software[33]"was"used" for" the"docking"of" small"molecule"databases"of"2A4"
derivatives,"compound"44"derivatives"and"of"2G3"analogues."In"all"the"cases,"prior"to"docking"
simulation"the"protein"was"processed"with"Maestro"Protein"Preparation"tool"using"OPLS\2005"
force"field"and"ligand"databases"were"prepared"as"previously"described."The"docking"site"was"
identified"with"Maestro"Receptor"Grid"tool,"setting"the"centre"and"the"grid"size"according"to"
necessity."All"the"docking"simulations"were"performed"with"XP"precision,"using"a"semi\flexible"
approach"with"the"sample"ring"conformation"option"for"exhaustive"conformational"search"of"
ligands." Ligands" with" more" than" 300" atoms" or" more" than" 50" rotatable" bonds" were"
automatically"excluded."The"non\bonded" interactions"were" calculated"with"a"0.8nm"van"der"
Waals" radii" scaling" factor" and" a" 0.15nm" partial" charge" cut\off." Only" a" maximum" of" 10"
conformations" were" kept" for" each" ligand" and" they" were" not" energy" minimised" after" the"
docking"because"a"refinement"procedure"was"applied"on"the"docking"output."
For" the"2A4"derivatives," the"structure"of" the"MTase" in"complex"with" the" fragment"was"used"
and"the"grid"was"defined,"using"the"2A4"fragment"in"the"crystal"structure"as"the"centre"and"a"
length"of"10Å.""
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For" the" compound" 44" derivatives," a" modified" structure" of" the"MTase" in" complex" with" this"
molecule"was"used."The"symmetric"unit"of"the"crystal"was"reconstructed"with"MOE"2010.10[29]"
with"the"Superpose"tool."The"pdb"structure"of"the"reconstructed"symmetric"unit"of"the"MTase\
2C3"fragment"complex"was"available"and"was"used"as"a" template"as" it"superposed"very"well"
with"both"the"compound"44"original"monomer"and"its"symmetric"image."A"copy"of"the"original"
monomer"from"the"compound"44"complex"was"superposed"with"the"symmetric"image"of"the"
2C3"complex."The"two"protein"chains"representing"the"symmetric"unit"and"compound"44"were"
saved." The" side" chain" conformation" of" the" Glu111" near" the" SAM" binding" site" was" then"
modified"with"MOE"2010.10[29]"Rotamer"Explorer"and"protonated"with"the"Protonate"3D"toll,"
considering"a"temperature"of"300K,"a"pH"of"7"and"a"salt"concentration"of"0.1M."The"modified"
Glu111" and" the" nearby" Arg84" were" then" energy" minimised" with" AMBER99" force" field" and"
steepest" descendent"method," using" 500" iterations" and" a" gradient" of" 0.001." Hydrogens" and"
lone"pairs"were"adjusted"and"partial"charges"were"calculated."For"small"molecule"docking,"the"
grid"was"defined"using"compound"44"as"the"centre"and"a"length"of"10Å."
For" the"2G3"analogues," the" structure"of" the"MTase" in" complex"with" the" fragment"was"used"
and"the"grid"was"defined,"using"the"SAM"molecule"in"the"crystal"structure"as"the"centre"and"a"
length"of"9Å.""
"
MOLECULAR'DYNAMICS'SIMULATIONS'
"
GROMACS"4.5.3[34]"was"used"with"AMBER99" force" field" for" all" the"molecular"dynamics" (MD)"
simulations." A"minimum"0.9" nm"distance" between" the"molecular" system" and" the" cubic" box"
employed" and" periodic" boundary" conditions" (PBC)" were" applied." Water" was" added" and"
described" as" an" explicit" solvent" and" the"molecules"were" treated"with" the" TIP3P"model." The"
total" charges" of" the" systems" were" neutralised." Small" molecule" missing" topologies" were"
computed"with"AMBER"12[35]"Antechamber"software,"using"the"AM1\BCC"charge"method"and"
GAFF"force" field" for"atom"types."The"obtained"files"were"then"converted"with"acpype[36]" in"a"
GROMACS\compatible" format." Two" consecutive" energy" minimisations" were" initially"
performed," employing" the" steepest" descendent" (SD)"method" first" and" then" followed"by" the"
conjugate"gradient"(CG)"method,"with"the"aim"of"a"faster"process"and"a"more"accurate"result."
A"force"tolerance"of"100"kJ"mol\1"nm\1"was"set"for"SD,"while"a"10"kJ"mol\1"nm\1"force"tolerance"
was"applied"with"CG."In"both"cases"the"maximum"number"of"iterations"was"set"to"3,000"steps."
Subsequently," a" position" restrain" force" of" 1,000" kJ" mol\1" nm\2" was" applied" to" protein" (and"
ligand)" atoms" for" water" molecules" relaxation." Aiming" to" a" smoother" equilibration," two"
consecutive"50"ps"(50,000"steps,"step"size"of"1"fs)"position"restrained"MDs"were"consequently"
performed," saving" coordinates," velocity" and" energy" values" every" 500" steps." NVT" conditions"
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(constant"number"of"atoms"N,"volume"V"and"temperature"T)"were"used"for"the"first"position"
restrained"MD" and" a" v\rescale" temperature" coupling" and" 0.1" ps" time" constant"was" used" to"
heat" the" system" to" 300" K." NPT" conditions" (constant" number" of" atoms" N," pressure" P" and"
temperature" T)" were" used" for" the" second" position" restrained" MD," with" the" use" of" both"
temperature" (v\rescale," temperature" 300" K" and" time" constant" of" 0.1" ps)" and" pressure"
(Berendsen"algorithm,"1"bar"pressure"and" time"constant"of"0.5"ps)"coupling."The"production"
simulations"were"run"in"NPT"conditions"and"settings"(number"of"steps,"step"size,"frequency"of"
data" saving)" were" different" in" the" two" studies" (2E11\2C3" derivatives" optimisation" and" 2G3"
binding" pose" validation)." In" all" simulation" stages," long\range" electrostatic" interactions"were"
calculated"with"the"Particle\Mesh\Ewald"(PME)"method"with"a"0.9"nm"short"range"cut\off"and"
short\range"non\bonded"interactions"were"computed"only"within"a"cut\off"of"1.4"nm."Results"
were"visually"inspected"with"VMD[37]"and"analysed"with"GROMACS"4.5.3[34]"tools"and"Grace.[38]"
Four"MD"simulations"were"performed"for" the"2E11\2C3"derivatives"optimisation"study." In"all"
four"cases" the"protein"used"was" the" reconstructed"symmetric"unit" (with" the"original"Glu111"
conformation)"of"the"MTase\compound"44"complex"obtained"with"MOE"2010.10[29]"Superpose"
tool" (see"MAESTRO&GLIDE& DOCKING" chapter" of" this"METHODS& section)." The" four"molecular"
systems"were"the"protein"without"ligands"and"in"complex"with"either"compound"44,"53"or"54."
The"production"simulation"was"5ns"long"(2500000"steps"with"step"size"of"2fs)"and"coordinates,"
velocities"and"energy"values"were"saved"every"1,000"steps."
Three"MD"simulations"were"performed"for"2G3"binding"mode"validation."In"all"three"of"them"
the" molecular" system" was" the" MTase\2G3" complex" obtained" from" crystallographic" data."
His110" protonation"was"manually" set" and" different" in" the" three" simulations" (HIE110" in" the"
first,"HID110"in"the"second"and"HIP110"in"the"third)."The"production"simulation"was"3ns"long"
(1500000"steps"with"step"size"of"2fs)"and"coordinates,"velocities"and"energy"values"were"saved"
every"1,500"steps."
"
"
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6.1.INTRODUCTION.
"
A'PROMISING'DRUG'TARGET'
"
The"replication"of"the"viral"genome"is"an"essential"step"of"the"DENV"replication"cycle."The"lack"
of"viral"RNA"synthesis"would"indeed"produce"viral"particles"devoid"of"the"nucleic"acid."Even"if"
these"pseudovirions"would"be"able"to"enter"new"cells,"the"synthesis"of"novel"virions"would"not"
be"possible"due"to"the"absence"of"viral"genetic" information."As"a"consequence,"the" infection"
could"not"proceed."DENV"genome"replication"occurs"in"particular"membrane"structures"in"the"
host"cell"cytoplasm"and"it"consists"of"RNA"synthesis"from"a"RNA"template."Human"cells"do"not"
have"polymerases" that"are"able" to"use"RNA"as"a" template"and" this"explains" the" reason"why"
(+)ssRNA" viruses," like" DENV," have" evolved" to" encode" for" a" polymerase" protein.[1,2]" DENV"
polymerase"is"the"NS5"RNA\dependent"RNA"polymerase"(NS5"RdRp)."It"is"the"most"conserved"
viral" protein" in" DENV" and" as" it" is" one" of" the" key" enzymes" in" RNA" replication," its" inhibition"
would"arrest"the"DENV"replication"cycle"within"the"host"cell."This,"in"addition"to"the"fact"that"
human"cells"do"not"have"this"enzyme,"the" importance"of"RNA"replication" itself"and"the"drug"
design"experience" from"other"viruses"make"NS5"RdRp"one"of" the"most"attractive" targets" for"
DENV"infection"inhibition.[3\5]"
"
STRUCTURE'
.
DENV" polymerase" is" the" C\terminal" portion" (residues" 273\900)" of" the" NS5" protein." General"
considerations" on" the" full" length" protein" are" reported" in" the" introduction" to" the" NS5&
METHYLTRANSFERASE&AS&A&DRUG&TARGET"section."
The" RdRp" domain" assumes" the" typical" right\handed" shape," as" shown" in" Figure" 6.1." It" has"
overall"dimensions"of"65"x"60"x"40"Å"and"it"displays"a"total"of"27"α\helices"and"7"β\strands."It"
comprises"a"palm" (residues"497\542"and"601\705," in" green)," fingers" (residues"273\315,"416\
496" and" 543\600," in" red)" and" a" thumb" (residues" 706\900," in" blue)" sub\domains." Differently"
from"other"polymerases,"the"fingers"and"the"thumb"are"connected"through"the"protrusion"of"
one" fingertip.[5,6]" Furthermore," it" presents" two"nuclear" localization" sequences" (NLS," residues"
316\368,"in"yellow)"that"are"recognised"by"cellular"factors"that"transport"the"polymerase"into"
the" cell" nucleus." These" sequences" of" approximately" 20" amino" acids" each" are" strictly"
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conserved," suggesting" that" the" nuclear" localisation" of" RdRp" could" play" an" essential" role" in"
DENV"replication,"but"the"reason"for"this"is"still"unknown.[6]""
DENV"RdRp"is"a"primer\independent"polymerase"(or"de&novo"polymerase),"which"means"that"it"
is"able"to"initiate"RNA"synthesis"without"the"aid"of"a"co\factor"usually"defined"as"a"primer."The"
initiation" platform" is" therefore" given" by" a" loop" that" projects" towards" the" palm" sub\domain"
from" the" thumb," called" the" priming" loop" or" the" P\loop" (residues" 782\809," in" purple" in" the"
figure).[5,6]""
"
!
Figure'6.1..RdRp.structure..
The"domains"are"indicated"with"different"colours:"the"palm"is"in"green,"the"fingers"are"in"red,"the"thumb"is"in"blue,"
the"nuclear"localisation"sequences"are"in"yellow"and"the"priming"loop"in"is"purple."Two"arrows"show"the"entrance"to"
the"two"tunnels"described"in"the"text..
The"right\hand"shape"allows"the"definition"of"two"perpendicular"tunnels"that"intersect"in"the"
polymerase"active"site,"where"the"RNA"synthesis"reaction"occurs."The"active"site"is"in"the"palm"
sub\domain"and"comprehends"the"catalytic"triad"(Gly662,"Asp663"and"Asp664)"and"two"Mg2+"
catalytic" ions." The" first" tunnel" allows" the" template" ssRNA" entry." It" is" located" between" the"
fingers"and"the"thumb"(as"shown"in"Figure"6.1)"and"reaches"the"palm"sub\domain."Differently,"
the"second"tunnel"spans"the"whole"protein."From"the"side"shown"in"the"figure,"the"incoming"
NTP" enters" and" reaches" the" active" site,"where" it" is" incorporated" in" the" nascent" RNA" strand"
that"forms"a"dsRNA"with"the"template."The"dsRNA,"then,"exits"through"the"same"tunnel,"but"
on"the"other"side"of"the"protein.[5,6]"Five"crystal"structures"of"DENV"RdRp"are"available"in"the"
apo"form"or"in"a"complex"with"an"inhibitor"and"in"all"of"them,"the"exit"of"the"second"tunnel"is"
too"small"to"allow"the"exit"a"dsRNA"molecule."This"is"due"to"the"fact"that"in"all"the"structures,"
the" protein" is" in" the" pre\initiation" state," or" closed" conformation.[6\8]" During" the" elongation"
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process"NS5"RdRp"changes"conformation"and"the"clash"with"the"P\loop"is"removed,"enlarging"
the" exit" cleft." However," no" structural" knowledge" about" this" process" has" been" acquired" to"
date.[5,6]""
.
POSSIBLE'MOLECULAR'TARGET'SITES'
.
Polymerases" are" validated" drug" targets" in" antiviral" research" and" two"main" approaches" are"
possible"for"this"enzyme:"the"nucleoside"and"the"non\nucleoside"one.[3\5,9]""
Nucleoside"inhibitors"(NI)"are,"from"the"name,"nucleoside"analogues"that"aim"to"interact"with"
the"polymerase"at"its"active"site,"on"the"palm"domain,"following"host"kinase"conversion"into"its"
triphosphate" form" (see" the" main" INTRODUCTION" section" of" this" thesis)." The" polymerase"
catalyses" the" reaction" of" insertion" of" the" compound" into" the" nascent" RNA" strand." The"
compound" then" inhibits" RNA" synthesis" either" through" a" “chain" termination”"mechanism" (it"
does" not" allow" the" addition" of" further" nucleosides)," or" it" introduces" errors" in" the" genetic"
information."An"example"of"NI"compounds"is"NITD203,"whose"development"was"halted"at"the"
preclinical"stage"for"toxicity"problems.[3,4,9]""
Non\nucleoside" inhibitors" (NNI)" are" drug\like" small"molecules" that" do" not" interact"with" the"
polymerase"active"sites."Their"mechanism"of"action"is"usually"allosteric,"which"means"that"they"
produce"conformational"changes"in"the"protein,"inhibiting"its"activity."This"strategy"is"less"likely"
to"produce"high"toxicity,"but"is"more"prone"to"drug"resistance"because"it"involves"areas"of"the"
enzyme" that" were" less" subject" to" evolutionary" pressure.[3,5,9]" In" DENV" polymerase" four"
allosteric"sites"can"be"defined,"as"shown"in"Figure"6.2,"where"two"orientations"of"NS5"RdRp"are"
presented" and" the" entry" site" of" NTPs" is" indicated" as" well." From" the" analysis" of" the" crystal"
structure," two" cavities" (cavity" A" and" B," in" light" blue" and" in" light" purple" in" the" figure"
respectively)"were" found" in" the" thumb" sub\domain."Unfortunately," neither" of" them"has" the"
ideal"characteristics"for"drug"design:"cavity"A"does"not"display"residues"that"could"be"identified"
as"essential"using"mutagenesis"studies;"while"cavity"B" is"too"small"to"accommodate"drug\like"
molecules.[3,5]"Another"allosteric"site"(site"C,"in"green"in"the"figure)"was"used"for"the"evaluation"
of" a" class"of" compounds" (e.g."NITD\1"and"NITD\107)" that"bound" to" the"enzyme" in"a"pocket,"
near"Thr413,"where"the"RNA"template"is"supposed"to"interact"with"the"protein."However,"low"
cell\based"activity"is"slowing"the"development"of"these"compounds.[7,10,11]"Another"target"site"
(site"D," in" red" in" the" figure)"was" selected" in"one"of" the" studies"presented"here" and" is"more"
deeply" discussed" further" in" the" report." This" site" is" located" on" the" priming" loop" and" the"
compounds" binding"with" Trp795" and" Arg737"were" aimed" at" blocking" the" enzyme" in" a" non\
active"conformation.""
"
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Figure'6.2..Allosteric.sites.of.NS5.RdRp.""
The"polymerase"domain"of"NS5"is"represented"here"in"two"orientations"given"by"a"180°"rotation,"as"indicated"by"the"
blue"arrow."For"an"easier"understanding"of"the"protein"orientation,"the"NTP"entry"tunnel"is"indicated"by"the"“NTP”"
orange"arrow."Protein"surface"not"belonging"to"allosteric"sites"is"coloured"in"grey."Cavity"A"is"shown"in"light"blue,"
cavity"B"is"in"light"purple,"site"C"is"in"green"and"site"D"is"in"red."
"
MECHANISM'OF'ACTION'
"
The"polymerases"catalyses"RNA"replication"in"two"stages."The"first"one"is"de&novo"initiation"of"
synthesis."In"this"process,"the"enzyme"uses"the"P\loop,"probably"Trp795,"to"place"the"incoming"
NTP" (“n”)" in" the" correct" position" for" hydrogen" bonding" with" the" 3’" end" nucleotide" of" the"
template."Then,"when"the"second"NTP"(“n+1”)"enters"the"cleft"it"stacks"with"the"first"NTP"and"
interacts"with" the" second" 3’" end" nucleotide" of" the" template." The" correct" positioning" of" the"
molecular" system" is" aided" by" the" presence" of" residues" (Arg737," Arg729" and" Ser710)" that"
interact"with"the"NTP"phosphates."Once"this"configuration"is"formed,"the"catalytic"aspartates"
and" the" catalytic" Mg2+" catalyse" the" nucleophilic" attack" of" the" “n”" 3’OH" to" the" “n+1”" α\
phosphate"for"the"formation"of"a"new"phosphate"link"between"the"two"nucleotides,"with"the"
elimination"of"a"pyrophosphate"molecule.[3,5,6]"No"protein"structures"of"NS5"RdRp"in"complex"
with"the"template"are"available"and"therefore"there"is"no"accurate"knowledge"of"the"initiation"
process"of"the"RNA"synthesis."However,"it"was"possible"to"construct"models"of"this"mechanism"
using"other"structural"data,"like"the"bacteriophage"Φ6"RdRp"in"complex"with"the"template"and"
two" NTPs." These" models" allowed" the" formulation" of" the" initiation" hypothesis" presented"
above.[3,6]"
Following" the" initiation"process," there" is" an"elongation" step" that" increases" the"nascent"RNA"
length,"on"the"bases"of"the"template"sequence."As"already"mentioned," in"order"to"pass"from"
the"initiation"to"the"elongation"step,"the"protein"must"change"conformation,"allowing"a"bigger"
cleft" for" the"exit"of" the" resulting"dsRNA."Also" in" this" case," there" is"no"structural" information"
that" could" explain" the" exact"molecular" changes" that" occur." However," the" high" temperature"
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factors" of" the" finger" sub\domain" in" DENV" crystal" structures" suggest" that"movement" of" this"
portion"could"be"involved"in"the"conformational"change.[6]"
"
AIMS'AND'OBJECTIVES'
"
Essential" for" RNA" replication" and" a" validated" target," DENV" NS5" RdRp" is" probably" the"most"
attractive" molecular" object" for" antiviral" drug" design." Two" strategies" have" been" historically"
applied" to" the" design" of" inhibitors" of" this" enzyme:" nucleoside" (NI)" and" non\nucleoside"
inhibitors" (NNI)." Pro" and" cons" can" be" characterised" for" both" class" of" drugs" and" have" been"
discussed" in"this"thesis."Given"the" lower"toxicity"rate"and"the"higher"suitability"for"molecular"
modelling" drug" design" of" NNI," this"was" the" preferred" strategy" in" this" PhD."With" the" aim" of"
designing"novel,"potent"DENV"inhibitors,"two"virtual"screening"campaigns"were"carried"out"on"
two"putative"allosteric"sites."In"the"first"case,"the"protein"region"close"to"the"priming"loop"(site"
D)"was" chosen" for" the"design"of" compounds" that" could" inhibit"RNA"synthesis" initiation."This"
study" is" discussed" in" chapter" 6.2.1." In" the" second" study," on" the" basis" of" the" structural"
knowledge"of"known"compounds,"a"second"allosteric"binding"site"(site"C)"was"chosen"and"the"
results"are"discussed"in"chapter"6.2.2."
"
"
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6.2.RESULTS.AND.DISCUSSION.
"
6.2.1'ALLOSTERIC'INHIBITORS'BINDING'SITE'D'
"
RdRp"is"a"well"known"target"that"has"been"used"for"drug"design"studies"for"dengue"and"other"
viruses."For"instance,"both"nucleosides"and"allosteric"inhibitors"were"designed"against"HCV,"a"
pathogen"that"has"been"taken"as"a"model"of"drug"discovery"in"other"Flaviviridae"viruses.[9]"As"
the"aim"of"this"work"was"to"design"novel"NNIs"against"DENV,"it"was"appealing"to"capitalise"on"
the" knowledge" gained" from" HCV" NNIs." However," overlapping" the" two" RdRp" structures" the"
sites" of" HCV" for" the" NNIs" do" not" correspond" to" similar" pockets" in" the" DENV" structure" and"
consequently"HCV"inhibitors"cannot"be"used"as"a"starting"point"for"DENV.[5,9]"
In" this" study," the"choice"of" the"allosteric"binding"site"was"based"on" the"knowledge" that"one"
particular" residue" (Trp795," on" the" priming" loop," P\loop)" is" thought" to" be" essential" for" RNA"
synthesis" initiation.[5,6]" Consequently," it" was" hypothesised" that" compounds" binding" in" the"
region"near"this"residue"could"inhibit"this"essential"step"of"viral"replication."A"structure\based"
virtual" screening"was" therefore"designed" for" the" selection"of" putative"RdRp"NNIs"using" as" a"
start" the" SPECS[12]" database" (updated" to" February" 2012)" comprising" around" 209,945"
molecules."
"
PROTEIN.MODELS.
"
At"the"time"of"the"study,"only"one"series"of"two"crystal"structures"(PDB"IDs:"2J7W"and"2J7U)"
were"available"in"the"protein"Data"Bank.[6,13]"They"both"presented"the"structure"of"DENV3"NS5"
RdRp"domain,"but"in"one"of"the"structures"(PDB"ID"2J7W)"the"protein"was"co\crystallised"with"
a"3’dGTP"molecule," a"non\specific"RNA"polymerase" inhibitor." The" small"molecule"phosphate"
portion"was" resolved," differently" from" its" sugar" and" the" base"moieties." On" the" basis" of" the"
position"of" this"portion"of" the" inhibitor"within" the"crystal" structure," it"was"suggested" that" in"
the"initiation"of"RNA"synthesis"the"conserved"residue"Trp795"mimics"a"primer"for"the"stacking"
of"the"first"nucleotide"of"the"nascent"RNA"strand.[6]"This"residue"was"consequently"chosen"as"a"
target" residue" for" the" drug" design" study" discussed" here," with" the" hypothesis" that" RNA"
synthesis" initiation" could" be" blocked" through" the" disruption" of" the" first" nucleotide\Trp795"
stacking." By" superposition" of" the" two" structures" belonging" to" this" crystallographic" series," is"
appeared" that" one" of" the" residues" responsible" for" nucleotide" binding" (Arg737)" has" two"
different" conformations" depending" on" the" interaction" with" the" inhibitor," as" presented" in"
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Figure" 6.3." Thus," it"was" hypothesised" that" inhibition" of"DENV"NS5"RdRp" could" be" enhanced"
through"blocking"the"conserved"residue"Arg737"in"the"3’dGTP"unbound"conformation."On"the"
base" of" these" assumptions" the" enzyme" conformation" of" the" 2J7U" crystal" structure" and" the"
protein" region" highlighted" in" Figure" 6.3" and" presented" as" site" D" in" the" introduction" to"NS5"
RdRp"was"chosen"as"a"target"site"for"the"discovery"of"novel"RdRp"NNIs."
"
!
Figure'6.3..NS5.RdRp.site.for.allosteric.inhibitor.design...
On"the"left"is"shown"the"whole"protein"with"NLS"regions"in"yellow,"palm"domain"in"green,"thumb"domain"in"blue,"
fingers"domain"in"red"and"the"priming"loop"in"purple."On"the"right"is"represented"the"overlap"of"the"2J7U"and"2J7W"
structures"in"proximity"of"the"priming"loop."Here"the"interactions"of"the"triphosphate"moiety"of"3’dGTP"molecule"
(from"2J7W)"are"displayed"with"blue"dotted"lines."The"2J7W"residues"are"coloured"in"cyan"and"the"2J7U"residues"
are"coloured"in"orange."The"only"residue"with"a"different"conformation"is"Arg737..
In" both" structures" of" the" crystallographic" series" available" at" the" time" of" the" study," three"
protein" fragments" (residues" Val310\Ala316;" Ala406\Asp419;" Tyr451\Ala472)" are" missing.[6]"
One" of" them" in" particular," identified" as" “loop" 3”" (L3," Ala406\Asp419)" is" located" in" direct"
proximity"of"the"selected"target"binding"site."Consequently,"a"model"of"the"complete"protein"
had"to"be"built" through"a"homology"modelling"approach"prior"to"the"application"of" the"drug"
design" exercise." As" sufficient" homology" with" complete" polymerase" structures" could" not" be"
found," the" more" complete" RdRp" structure" from" WNV" (PDB" ID:" 2HFZ[14])" was" chosen" as" a"
template" because" of" the" high" residue" homology" (70%)" between" the" two" proteins." A" higher"
residue"identity"generally"corresponds"to"a"higher"probability"of"obtaining"a"reliable"model"of"
the"protein"of"interest."Statistical"analyses"showed"that"for"big"proteins"like"RdRp,"a"minimum"
of" 20\30%" of" residue" identity" should" be" aimed" for" in" order" to" have" confidence" in" the"
constructed"model.[15,16]" Therefore," 70%" homology"was" considered" a" good" value." Aiming" to"
maintain" the" crystallised" part" of" the" protein" in" the" original" conformation," only" the"missing"
parts"of"DENV"RdRp"were"modelled,"according" to" the"procedure"described" in" the"METHODS"
section."The"amino"acids"at" the"boundaries"of" the"missing" fragments"were"modelled"as"well"
with"the"aim"of"obtaining"the"most"reasonable"structure"possible."The"obtained"model"(model"
A)"superposed"very"well"with"the"original"structure,"with"a"RMSD"value"of"0.60Å."Even"if"not"
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conserved" in" all" four" DENV" serotypes," the" potential" importance" of" Thr413" in" allosteric"
inhibitor" binding" has" been" reported" in" the" literature.[7,10,11]" The" loop" containing" this" residue"
was"modeled" in"two"different"conformations."A"second"model" (model"B)"was"therefore"built"
for" DENV" RdRp," with" Thr413" conformation" being" the" only" difference" between" the" two"
homology"models."Also"model"B"superposed"very"well"with"the"original"structure,"with"a"RMSD"
value"of"0.60Å."Figure"6.4"shows"the"difference"in"Thr413"conformation"in"the"two"models."
The"quality"of"the"models"was"assessed"through"Ramachandran"plot"evaluation"that"showed"
that"more"residues"were"outliners"compared"to"the"original"structure."The"outliners"belonged"
to"protein"sites"far"from"the"selected"target"site"and"most"of"them"were"however"very"close"to"
the" allowed" region" of" the" psi\phi" plot." The" quality" of" the" two" models" was" consequently"
considered"suitable"for"the"purpose"of"this"study."
"
!
Figure'6.4..Superposition.of.models.A.and.B..
Protein"backbone"is"represented"in"grey"and"Trp795"is"reported"for"better"understanding"of"Thr413"position."
Thr413"carbon"atoms"from"model"A"are"in"cyan,"while"those"from"model"B"are"in"orange."
Two"crystal" structure" series"of"DENV3"NS5"RdRp"were"published" in"2013.[7,8]" In"one"of" them"
(PDB"IDs:"4HHJ"and"3VWS),"a"new"crystallisation"technique"was"applied."Of"the"two"structures"
(PDB" ID:" 3VWS)" one" had" an" allosteric" inhibitor" co\crystallised" and" resolved" and" the" protein"
adopted" a" different" conformation" with" respect" to" all" the" other" structures.[7]" In" the" other"
publication," additional" residues" belonging" to" the"MTase\RdRp" linker"was" shown" to" stabilise"
the"protein."Some"of"the"linker"residues"were"resolved"in"the"crystal"structure"(PDB"ID"4C11).[8]"
In"the"two"new"crystal"structures"of"the"NS5"RdRp"with"no"ligands"(PDB"IDS:"4HHJ"and"4C11),"
the"Val310\Ala316"missing"loop"of"2J7U"could"be"defined,"whilst"the"other"two"loops"were"still"
missing."Superposing"the"homology"models"on"them,"RMSD"values"of"0.73Å"and"0.86Å"were"
obtained" for" 4HHJ" and" 4C11" respectively," showing" a" good" overlap." Furthermore," the"
superposition"of"the"loop"Tyr308\Gly322"that"was"modelled"in"the"present"study"and"that"was"
resolved"in"the"new"structures"returned"RMSD"values"of"1.10Å"and"1.13Å"for"4HHJ"and"4C11"
respectively." These" low" RMSD" values" supported" the" reliability" of" the"model" and" confirmed"
that" this" region"has"a"random"coil" secondary"structure." In" the"new"structures"more"residues"
were"resolved"also"in"proximity"of"the"other"two"missing"sequences"of"2J7U,"but"they"were"not"
informative"enough"on"the"quality"of"models"A"and"B."
Section"6:"NS5"POLYMERASE"AS"A"DRUG"TARGET" 6.2&RESULTS&AND&DISCUSSSION"!
!253"
IDENTIFICATION.OF.ALLOSTERIC.INHIBITORS.THROUGH.VIRTUAL.
SCREENING.
"
A" virtual" screening" strategy" was" designed" for" the" selection" of" compounds" from" the" small"
molecule"drug\like"database"SPECS"containing"around"209,000"molecules."Differently" to" that"
done" in" previous" studies" the" 2D" ligand" structures" were" directly" prepared" with" Maestro"
LigBuilder" tool" that"generated"all" the"possible" ionisation"states"at"pH"7" (±2),"all" the"possible"
tautomers"and"all"combinations"of"possible"stereoisomers"for"each"molecule"and"scored"each"
one"of"them."Approximately"498,000"structures"were"generated."As"this"was"considered"to"be"
already"a"high"number"of"structures"to"dock"in"the"selected"site,"it"was"decided"not"to"further"
explore" the"molecules’" conformations." The" prepared" ligands"were" then" used" for" the" virtual"
screening" approach" schematised" in" Figure" 6.5." The" same" approach" was" used" for" both"
homology"models"(model"A"and"B)"separately."
Briefly," the" compounds" were" initially" docked" and" scored" with" Maestro" Glide" in" the" two"
models’"grid"centred"on"Trp795"with"high"throughput"virtual"screening"(HTVS)"precision"mode."
The" docking" was" implemented" in" a" semi\flexible" way" in" order" to" explore" the" molecules’"
conformational" space." Compared" to" other" precision"models," HTVS" has" a" lower" accuracy" of"
score" values," but" it" was" considered" sufficient" for" a" starting" point" to" reduce" the" number" of"
compounds."A"quick"visual"inspection"of"the"results"showed"that"not"all"the"compounds"were"
binding" the" enzyme" near" Trp795." Consequently," the" output" databases" were" filtered"with" a"
one\feature" pharmacophore" in"MOE"environment" that" selected"only" those" compounds" that"
bound" to" the"protein" in" the"desired" area."Only" the"best" 5,000"unique"molecules" that"had"a"
negative"docking"score"were"then"saved"for"further"analysis."
These" structures" were" then" docked" a" second" time" in" the" models" using" a" semi\flexible"
approach"with"Maestro"Glide"SP"mode"and"rescored"with"LeadIT"FlexX"and"PLANTS."For"each"
one"of" the"5" compound"conformations" saved," the" scores"obtained"with" the" three" softwares"
were"collected"with"a"consensus"score"and"a"normalised"consensus"score"function"(Equations"
6.1" and" 6.2" in" the"METHODS" chapter)." In" this"way," the" two" best" scoring" conformations" for"
each"compound"that" resided"within" the"best"25%"of" the"molecules" in"all" the"used"programs"
were"saved.""
"
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Figure'6.5..Schematic.representation.of.the.virtual.screening.methodology..
The"main"steps"are"indicated"and"the"numbers"are"referred"to"the"number"of"molecules"(conformations"in"
brackets)"at"every"step."Homology"models"are"reported"with"the"letters"A"for"model"A"and"B"for"model"B."Molecular"
modelling"programs"and"scoring"functions"are"abbreviated"as"follows:"HTVS="Maestro"Glide"HTVS"mode;"SP="
Maestro"Glide"SP"mode;"FX="LeadIT"FlexX;"PL="PLANTS;"CS="consensus"score;"NCS="normalised"consensus"score;"
XP="Maestro"Glide"XP"mode."
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The"resulting"conformations"were" then"docked"a" third" time" in"a"semi\flexible"manner" in" the"
two"homology"models"using"Maestro"Glide"with"XP"mode."The"final"results"were"collected"and"
a" comparison"between" the" two"models"was"made"as"well" as" the"visual" inspection"of"all" the"
poses."The"visual"inspection"of"the"compounds"highlighted"that"there"were"different"preferred"
binding"modes,"as"displayed" in"Figure"6.6."Some"molecules," like" the"one" in"yellow,"bound" in"
the" cleft" going" across" Trp795," from" a" smaller" pocket" near" Arg737" (“P1”)" to" another" small"
pocket"on"the"other"side"(“P2”)."Interactions"primarily"involved"a"π\π"stacking"interaction"with"
Trp795" and" often" direct" interactions" with" Arg737," as" intended" in" the" virtual" screening"
approach"design."Other"poses"showed"that"molecules,"like"the"one"in"cyan,"extended"from"P1"
to"another"small"pocket"(“P3”)"situated"below"Arg737," in"the"same"region"where"the"3’dGTP"
was" located" in" the" 2J7W" structure." In" this" case," molecules" did" not" interact" directly" with"
Trp795," but" their" position" could" impede" the"movement" from" the" “inactive”" to" the" “active”"
conformation"of"Arg737,"leading"to"a"loss"of"nucleotide"capability"of"the"polymerase.""
Smaller"molecules"with"respect"to"the"ones"described"above"(like"the"molecule"in"red"and"the"
one"in"dark"green"in"the"figure),"bound"the"protein"mainly"in"P1."This"group"of"molecules"gave"
a"π\π"stacking"with"Trp795"and"most"of"the"structures"interacted"directly"with"Arg737.""
"
!
Figure'6.6..Preferred.compounds.binding.modes..
Here,"examples"of"molecules"binding"the"RdRp"site"are"reported"as"compounds"coloured"in"red,"yellow,"cyan"and"
dark"green."The"reference"protein"residues"(Thr413,"Arg737"and"Trp795)"are"in"light"green"and"the"priming"loop"
backbone"is"shown"as"a"purple"ribbon."The"protein"surface"is"reported"in"grey."P1="pocket"1;"P2="pocket"2;"P3="
pocket"3."See"text"for"pockets"descriptions."
Molecules"were" ranked" according" to" the" final" docking" scores," classified" on" the" basis" of" the"
pose" (as" described" above)" and" their" chemical" structures" were" clustered" with" the" aim" of"
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selecting" compounds" as" different" as" possible." In" pose" evaluation," molecules" that" bound" to"
conserved"residues"among"the"four"DENV"serotypes"were"preferred"to"the"others"in"order"to"
direct"drug"design" towards"panserotypic" inhibitors"of"DENV" infection."As" the"only"difference"
between"the"models"was"the"Thr413"side"chain"conformation"and"since"this"residue"was"not"
involved" in" all" the" binding" modes" (Figure" 6.6)," several" compounds" matched" both" models"
selection."These"molecules"were"generally"preferred.""
Thus,"29"molecules"were"chosen"and"purchased"from"SPECS.[12]"Their"chemical"structures"are"
reported"in"APPENDIX&8."
"
IN.VITRO.ACTIVITY.OF.THE.SELECTED.COMPOUNDS.
"
All" 29" purchased" compounds" were" tested" by" our" collaborators" in" the" Rega" Institute" for"
Medical"Research,"K."U." Leuven" (Belgium)"with" the"cell\based" in&vitro" assay"described" in" the"
NS3&HELICASE&AS&A&DRUG&TARGET"section."Two"further"compounds"(77"and"78"in"APPENDIX&9)"
were" synthesised" by" a" student" in" our" laboratory" as" part" of" a" structure\activity" study" of"
compound"79"(see"APPENDIX&8)"and"tested"in&vitro.[17]"
The" results" showed" that" one" compound" (compound"80," in" panel" A" of" Figure" 6.7)" is" able" to"
inhibit"DENV2"infection"with"an"EC50"of"2.63μM"and"a"CC50"greater"than"236μM."The"assay"was"
repeated" twice"more" for" results" validation" and" the" EC50" values" were" confirmed" to" be" very"
similar" (2.71µM"and" 3.80µM)." In" the" same" assays,"whilst" the" colorimetric" assay" displayed" a"
CC50" value" greater" than" 117.95µM," a" visual" inspection" of" the" cells" returned" CC50" values" of"
25.94µM" and" 52.84µM." Thus," a" therapeutic" window" was" found" although" needing"
improvement."
"
"
"
""A" """"""B"
Figure'6.7..Compound.80..
A).Chemical.structure.of.compound.80..B).CPE.inhibition.assay.results."Here,"cell"viability"is"reported"in"green"and"
the"antiviral"effect"is"in"red..
This"compound,"another"10"of"the"29"selected"and"compounds"77"and"78"were"also"tested"on"
DENV" NS5" protein" with" binding" and" enzymatic" assays" in" the" AFMB," Marseille" University"
laboratories"by"the"author"(binding"assay)"or"by"our"collaborators"(enzymatic"assay).""
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Unfortunately," compound" 80" neither" bound" to" the" enzyme" (with" ΔTm" of" \1.13°C" in" the"
thermal"shift"assay)"nor" inhibited"the"RNA"polymerisation" in" the"enzymatic"assay"performed"
with"3H\dATP."However,"a"better" inhibition"value"was"observed"in"the"polymerase"enzymatic"
assay"using"the"fluorescent"PicoGreen"probe."The"description"of"this"assay"can"be"found"in"the"
INTRODUCTION"section"of"this"thesis"and"the"IC50"obtained"was"31,7µM"(±8).""
As"already"mentioned,"one"compound"(81,"shown"in"Figure"6.8)"was"able"to"bind"to"NS5"full\
length"protein"in"the"TSA."It"gave"a"significant"increase"of"Tm"of"2.93°C,"whilst"SAM,"a"known"
binder"of"the"MTase"portion"of"NS5,"produced"a"Tm"shift"(ΔTm)"of"4.26°C."
"
! !
Figure'6.8..Chemical.structure.of.compound.81..
In" order" to" confirm" that" the" stabilisation" of" the" protein" and" the" consequent" increase" in"
melting"point"were"correlated"with"compound"binding,"titration"curves"for"both"compound"81"
and"SAM"were"performed."The"obtained"melting"temperature"shifts"are"reported"in"Table"6.1"
and"plotted"in"Figure"6.9."The"thermal"shift"assay"does"not"give"exact"dissociation"constant"(Kd)"
values"and"this"calculation"was"not"performed"for"either"molecules."However,"titration"results"
demonstrated" a" concentration\dependence" in" the" Tm" shift," supporting" that" both" SAM" and"
compound"81"could"bind"to"DENV"full"length"NS5"protein."
"
Table'6.1..Values.of.the.titration.curves.for.compounds.81.and.SAM..
Concentration.
(µM).
ΔTm.(°C).
Compound.81. SAM.
1000" 2.43318" 3.73165"
500" 1.97781" 3.91737"
250" 2.44157" 2.60798"
125" 2.28147" 2.38992"
62.5" 1.78645" 0.99795"
31.25" 1.81042" 0.46129"
15.625" 1.30409" 0.33007"
0" 0" 0"
"
Despite" the" above" results," compound" 81. did" not" exhibit" inhibitory" activity" of" the"
polymerisation"reaction."This"might"be"explained"in"two"ways:"either"the"compound"bound"to"
the"enzyme"without"interfering"with"its"activity"or" it"did"not"bind"to"the"RdRp"domain"of"the"
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NS5"full"length"protein,"thus,"not"producing"the"desired"effect."Furthermore,"in"the"cell\based"
in& vitro" assay," the" molecule" did" not" display" any" antiviral" activity" and" proved" to" be" very"
cytotoxic" with" a" CC50" less" than" 1.11µM." Given" these" results," it" was" decided" not" to" further"
develop"this"molecule,"in"favour"of"others"potentially"more"promising."
"
!
Figure'6.9..Titration.curves.for.compound.81.and.SAM..
The"Tm"shift"is"reported"for"compound"81"(black"diamonds)"and"SAM"(grey"squares)"at"the"tested"concentrations..
A"third"compound"that"gave"positive"results"was"compound"82,"shown"in"Figure"6.10."This"was"
the" only" molecule" that" gave" a" meaningful" concentration\dependent" inhibition" of" the" RdRp"
activity" in" the"biochemical"assay." IC50"values"were"determined"for" this"molecule"and"also" for"
compounds"80"and"81"because"they"were"found"positive"in"other"assays."In"order"to"increase"
the"assay"sensibility,"a"mini\genome"RNA"template"(constituted"of"the"5’"and"3’"UTRs"of"DENV"
genome)"was"used"instead"of"the"polyU"strand."
"
!
Figure'6.10..Chemical.structure.of.compound.82..
As" reported" in" Table" 6.2," IC50" determination" confirmed" that" the" only" compound" that"
significantly"inhibited"the"polymerase"activity"was"compound"82,"with"an"IC50"of"47.1µM"(±3.3"
St." Dev.)." Repeating" the" assay" using" PicoGreen" instead" of" the" tritium" labelled" dATP" and" a"
polyU"RNA"strand,"the"obtained"IC50"value"was"35.1µM"(±1.6"St."Dev.)."
Unfortunately,"the"TSA"did"not"show"protein"binding"for"compound"82"(with"ΔTm"of"\1.99°C)"
and" no" antiviral" activity" could" be" detected," while" cytotoxicity" was" observed" at" high"
concentrations" (CC50" of" 138µM)" for" compound"82." The" TSA" should" be" repeated" in" order" to"
0"
0.5"
1"
1.5"
2"
2.5"
3"
3.5"
4"
4.5"
0" 200" 400" 600" 800" 1000" 1200"
ΔT
m
.(°
C)
.
Concentralon.(µM).
Tm.shixs.
Compound"81"
SAM"
S S NH
O
O
O
HN
O
HN ONHO
O O
Section"6:"NS5"POLYMERASE"AS"A"DRUG"TARGET" 6.2&RESULTS&AND&DISCUSSSION"!
!259"
assess" if" this" result" is"due" to"an"actual" lack"of" interaction"or" if" the"assay"was"not"suitable" to"
detect" the" compound"binding"because"of" its" hydrophobicity." The" lack"of" activity" in" the" cell\
based"assay" could"be"explained"by"many" factors," like" lack"of" good"permeation" in" the" cell"of"
early"metabolism"of"the"compound."
"
Table'6.2..Polymerase.assay.IC50.results..
Compounds. IC50.(µM.±St..Dev.).
80. 124,7"±22,5"
82. 47,1"±3,3"
81. 148,2"±34,3"
"
Summarising,"two"promising"compounds"(80"and"82)"were"identified"with"the"designed"virtual"
screening"approach"and"consequently"two"classes"of"compounds,"one"for"each"molecule,"were"
further" developed" with" the" assessment" of" analogue"molecules" that" were" either" purchased"
from"SPECS"or" synthesised" and" tested" in& vitro." For" the" analogue" compounds," the"CPE" assay"
(performed"by"our"collaborators"in"the"Rega"Institute"for"Medical"Research,"K."U."Leuven)"was"
used" to" evaluate" their" activity" in" infected" cells" and" the" polymerase" activity" inhibition" with"
PicoGreen"fluorescent"probe"assay"was"performed"by"J.\C."Guillemot"group"in"AFMB,"Marseille"
University"to"assess"their"activity"on"the"target"protein.""
"
COMPOUND.80.ANALOGUES.
"
Compound"80"was"selected"from"the"SPECS"database"through"the"virtual"screening"approach"
discussed" previously." The" virtual" screening" approach" applied" to" both" models" returned" this"
molecule"as"a"positive"hit."Visual"inspection"of"the"binding"in"the"two"models"showed"that"the"
pose"was"the"same"and"it"is"presented"in"Figure"6.11."However,"only"the"binding"to"model"B"is"
presented" for" a" better" image" clarity." Using" the" reference" areas" of" Figure" 6.6," the"molecule"
spanned" from" the" P1" to" the" P2" regions" and" the" central" phenyl" ring" was" placed" on" top" of"
Trp795,"giving"a"π\π" stacking"with" this" residue."Other"hydrophobic" interactions" involved" the"
chlorine"substituted"phenyl"ring"that"was"placed"near"the"lipophilic"portions"of"the"Glu415"and"
Gln742" side" chains." All" the" amino" groups" were" involved" with" hydrogen" bonds" and" the"
counterparts"were" the" backbone" carbonyl" oxygens" of" Glu414" and" Thr413." The" third" phenyl"
ring"was"perpendicular"to"Arg792,"suggesting"that"it"might"interact"with"this"residue"through"a"
positive" charge\π" interaction." All" but" one" (Thr413)" of" the" mentioned" residues" are" well"
conserved" in" identity" or" in" properties" in" the" four" DENV" serotypes," complying" with" the"
possibility"of"designing"panserotypic"inhibitors"of"DENV."Thr413"is"a"Gln"in"DENV4"and"a"Val"in"
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DENV1." However," this" was" not" considered" an" issue" as" the" ligand" binding" involves" the"
backbone"of"this"residue."
"
!
Figure'6.11..Binding.pose.for.compound.80...
The"docking"pose"for"compound"80"in"model"B"is"presented"here."The"protein"surface"is"transparent"and"coloured"
in"white,"while"the"protein"ribbon"is"shown"in"light"blue."The"discussed"residues"are"indicated"and"showed"with"light"
blue"carbon"atoms."The"ligand"carbon"atoms"are"coloured"in"orange."Hydrogen"bonds"are"indicated"by"black"dotted"
lines..
As"described"above,"compound"80" showed"a" low"micromolar"activity" (EC50"between"2.61µM"
and" 3.80µM)" in" the" inhibition" of" DENV" infection" in" the" CPE" assay." Unfortunately," the"
polymerase" activity" inhibition" assay"was" not" clear" and" returned" different" values" in" two" IC50"
determinations." In" the" first" screen" performed"with" only" three" different" concentrations," this"
compound"did"not" show"a"promising"polymerase" inhibition"and" the" IC50"determination"with"
the"mini\genome"RNA"strand"and"tritium"labelled"ATP"nucleotide"returned"an"IC50"of"124,7µM."
Conversely," the"repetition"of" the" IC50"determination"with"the"assay"performed"using"a"polyU"
template"and"the"PicoGreen"fluorescent"probe"gave"a"better" inhibitory"response"with"IC50"of"
31.7µM." Consequently," at" this" stage" it" was" difficult" to" confirm" that" the" cell\based" activity"
derived"from"the"inhibition"of"DENV"NS5"RdRp"through"compound"binding"as"suggested"by"the"
molecular"modelling"results."
With"the"aim"of"confirming"the"activity"and"to"gain"further"insights"on"preliminary"structure\
activity" relationships" of" compound" 80," thirteen" analogue" molecules" were" purchased" from"
SPECS"and"tested" in&vitro"with"CPE"and"with"the"polymerase"activity" inhibition"assay,"using"a"
polyU"template"and"PicoGreen"fluorescent"probe."The"selection"of"these"compounds"was"also"
based"on"the"binding"mode"suggested"by"the"molecular"modelling"results"and"shown"in"Figure"
6.11,"as"a"further"objective"was"also"to"validate"this"model."Table"6.3"contains"the"structures"
and"the"assay"results"for"compound"80"and"the"purchased"analogues."Here,"the"indicated"CC50"
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and" EC50" values" were" obtained" from" the" CPE" assay" and" the" selectivity" index" (SI)" is" also"
reported."The"IC50"values"were"acquired"with"the"enzyme"inhibition"test."As"highlighted"in"the"
table," the" central" core" of" the" molecule" was" maintained" and" the" analogues" differed" from"
compound" 80" according" to" the" substituents" R1," R2" and" R3." Briefly," compound" 83" was"
purchased" to" assess" the" importance"of" the"phenyl"moiety." Compounds" from"84" to"91"were"
selected" for" the"evaluation"of" the" amide" group"and" compounds"88" to"91" in" particular"were"
selected" for" the" possibility" of" substituting" the" original" group" with" a" sulphonamide" moiety."
Compounds"92" to"95"were" selected" to"explore" the"possibility"of"expanding" the"hydrophobic"
portion"of"the"molecule"with"the"addition"of"another"phenyl"ring."
Table'6.3..Structures.and.results.for.compound.80.and.analogue.molecules..
Scaffold:"
"!
. R1. R2. R3.
CC50.
(µM)a.
EC50.
(µM)a.
IC50.
(µM.
±St..
Dev.)b.
80.
"
H"
"
236" 2.7"
31.7"
±8"
SI"="87"
83.
"
H"
"
>152.7" >152.7"
>400"
SI"="1"
84. H"
" "
10.1" 12.33" 25.4"
±6.3"SI"="1"
85.
"
H"
"
>130.4" >130.4"
283.1"
±33.5"
SI"="1"
86.
"
H"
"
>125.8" >125.8"
144.1"
±17"
SI"="1"
87. H"
" "
>136.1" 61.5"
127.4"
±36.5"
SI">"2"
88. H"
" "
>113.8" 54.5"
18.2"
±1.8"
SI">"2"
89. H"
" "
>106.5" >106.5"
4.1"
±0.6"
SI"="1"
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90. H"
" "
>102.1" 4.87"
3.7"
±0.5"
SI">"21"
91. H"
" "
>103.4" 43.2"
11.8"
±1.9"SI">"2"
92.
"
H"
"
0.68" 7.27"
3.6"
±0.6"
SI"="0.09"
93.
"
Cl 
"
>100.4" 7.64"
5.03"
±0.7"
SI">"13"
94. H"
 
"
>107.4" >107.4"
5.5"
±0.9"
SI"="1"
95. H"
 
"
>98.3" 33.0"
14.6"
±0.6"
SI">"3"
a="tests"performed"by"the"Rega"Institute"for"Medicinal"Research,"K."U."Leuven"(Belgium)"
b="tests"performed"by"AFMB,"Marseille"University"(France).!
Unfortunately," none" of" the" tested" analogues" improved" cell\based" DENV" infection" inhibition"
nor"increased"the"selectivity"index"of"87"for"compound"80."Conversely,"some"enhancements"in"
the"inhibition"of"the"polymerase"activity"were"achieved"for"some"molecules."Some"molecules"
were"active"in"both"assays,"suggesting"that"this"series"of"molecules"might"exert"their"antiviral"
function"through"the" inhibition"of"the"polymerase,"thus"supporting"NS5"RdRp"as"a"promising"
drug" target" for"anti\DENV"drug"design."However," the" lack"of"correspondence"between"some"
cell\based" and" biochemical" results," suggests" that" other" not" yet" identified" cellular" pathways"
might" be" involved" in" the" cell\based" activity" of" these" compounds." In" addition," lack" of"
penetration" or" intracellular" sequestration" could" also" be" implicated," but" has" not" been"
investigated" to" date." Nevertheless," preliminary" structure\activity" relationships" could" be"
hypothesised"on" the"basis"of" the"data"presented" in"Table"6.3"and"are" schematised" in"Figure"
6.12."
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Importantly," the" lack" of" both" cell" infection" and" enzyme" inhibition" shown" by" compound" 83"
suggests"that"the"presence"of"an"aromatic"group"at"the"end"of"the"R1"or"R2"is"essential"for"the"
activity"of"this"class"of"compounds."This"is"in"line"with"the"docking"results"that"demonstrated"
the" placement" of" the" chlorine" phenyl" ring" in" a" hydrophobic" area" of" the" binding" site." This"
essential"feature"is"represented"with"an"orange"circle"in"Figure"6.12.""
The" removal" of" the" amide" group" from" R1" or" R2" in" compound" 84" did" not" improve" enzyme"
inhibition"and"increased"the"toxicity"of"the"molecule,"as"the"infection"inhibition"was"associated"
with" cytotoxicity." Similarly," the" inversion" of" the" amide" in" R1" or" in" R2" (compounds"85" to"87)"
reduced"activity"in"both"cell\"and"enzyme\based"assays."Collectively,"these"results"suggest"that"
the"amide"is"an"important"moiety"for"compound"activity"and"that"it"must"be"placed"in"R1"with"
the"nitrogen"linked"to"the"central"core."This"complies"with"the"proposed"binding"pose"showed"
in" Figure"6.11,"where" the"amide"NH"group" interacts"with"Glu414" through"a"hydrogen"bond."
This" is"represented" in"Figure"6.12"with"a"blue"circle."Compounds"89" to"91"and"compound"95"
however" suggested" that" the"amide" could"be" substituted"with"a" sulphonamide" in"R2,"despite"
the"nitrogen"being"not" linked" to" the"central" core" (as" represented" in"Figure"6.12"by" the"blue"
circle)."All"of" these" improved"the" inhibition"of"RdRp"seen"with"compound"80" suggesting"that"
this"could"be"a"promising"substitution."Unfortunately,"this"increased"inhibition"was"at"variance"
with"the"binding"pose"of"compound"80,"as"the"substitution"would"impede"the"interaction"with"
Glu414"carbonyl"oxygen."The"difference"in"conformation"of"a"sulphonamide"with"respect"to"an"
amide"could"yet"produce"a"different"binding"mode"for"these"compounds."Unfortunately,"all"of"
the"compounds"with" the"sulphonamide"group"had"a"worse"selectivity" index" than"compound"
80"displaying"adverse"effects"at"high"concentrations"and"some"of"them"were"not"active"against"
the"infection."
Particularly" outstanding"was" compound"90" that"when" compared" to" the" reference"molecule"
showed"a"comparable"EC50"value"(4.87µM"against"2.7µM)"and"an"improved"IC50"value"(3.7µM"
against" 31.7µM)." Structurally" different" from" the" other" sulphonamide"molecules," it" contains"
two"condensed"rings"in"R3,"suggesting"that"both"infection"and"enzymatic"inhibitions"could"be"
improved" by" increasing" the" size" of" the" hydrophobic" group" in" the" region" represented" by" a"
green"circle"in"Figure"6.12."This"was"supported"by"the"group"of"molecules"(from"92"to"95)"with"
two" phenyl" rings" in" this" region." All" of" them" improved" the" inhibition" of" RdRp" in" respect" to"
compound"80," suggesting" that" this" could" be" a" promising" substitution." This" is" in" accordance"
with"the"proposed"binding"pose"showed"in"Figure"6.11,"where"the"aromatic"ring"of"compound"
80"interacts"with"Arg792"in"an"area"of"the"binding"site"that"is"large"enough"to"accommodate"a"
larger"hydrophobic"or"aromatic"moiety."Molecules"belonging"to"this"cluster"have"very"different"
groups" for" the" regions" highlighted" in" orange" and" in" blue" in" the" scheme" of" Figure" 6.12," but"
displayed" comparable" polymerase" inhibition," making" the" determination" of" SARs" more"
challenging." Conversely," the" CPE" assay" demonstrated" a" worse" selectivity" index" of" these"
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compounds" with" respect" to" compound" 80" as" they" displayed" adverse" effects" at" high"
concentrations" and" some"of" them"were" not" active" against" the" infection."Unpredictably," the"
cyclisation"of"the"amide"moiety"in"compound"93"produced"a"molecule"that"was"active"against"
DENV" infection" with" low"micromolar" EC50," suggesting" a" third" possibility," that" of" the" region"
highlighted"in"blue"in"the"scheme"of"Figure"6.12."This"could"be"further"explored"in"the"future.""
Molecule"95"was"selected"for"evaluation"as"it"contained"both"the"sulphonamide"and"the"two"
phenyl"rings"moiety"with"the"aim"of"combining"the"two"enhancement"effects."Unexpectedly,"a"
mild" improvement" of" enzymatic" inhibition" and" a"worse" cell\based" activity"were"obtained." It"
was"therefore"hypothesised"that"the"different"conformation"of"a"sulphonamide"with"respect"
to" an" amide" group" could" lead" to" a" different" molecular" conformation" that" allows" the"
accommodation"of"two"condensed"phenyl"rings,"but"not"of"two"separate"ones"in"the"binding"
site."Given"the"high"number"of"variables"in"cell\based"activity"assessment,"it"was"more"difficult"
to"suggest"a"reason"for"the"worse"EC50"value"of"this"compound."
Summarising," the" assessment" of" analogues" of" compound" 80" suggests" that" this" series" could"
stop"DENV\infection" through"NS5" RdRp" inhibition," validating"NS5" RdRp" as" a" promising" drug"
target" for" antiviral" development" as" its" inhibition" affects" cell" infection." However," other"
unidentified" cellular" pathways" might" be" involved" in" the" mechanism" of" action" of" these"
molecules" as" cell\based" and" biochemical" activity" did" not" always" match." Nevertheless,"
following" the" SARs" that"were" often" supported" by" the" binding" pose" of" compound" 80," these"
compounds"could"be"used"for"further"optimisation"as"they"have"shown"to"be"promising"anti\
DENV"agents."As"schematised"in"Figure"6.12,"an"aromatic"group"in"the"area"delineated"with"an"
orange" circle" and" an" amide" or" sulphonamide" moiety" in" the" blue" area" are" essential" for"
molecule"activity,"which"is"enhanced"with"large"aromatic"substituents"in"R3"(green"area"in"the"
scheme)."
"
"
Figure'6.12..Schematic.representation.of.the.SAR.for.compound.80.series.""
The"structure\activity"relationships"(SARs)"discussed"in"the"text"are"summarised"here."The"central"core"of"the"
molecule"is"presented"in"the"middle"and"in"the"circles"are"described"suggested"groups"that"are"required"or"that"
improve"activity."
" "
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COMPOUND.82.ANALOGUES.
"
Compound"82"was"selected"from"the"SPECS"database"through"the"virtual"screening"approach"
discussed"previously." In"the"final"selection" it"was"shown"to"bind" in"model"B"according"to"the"
pose"presented"in"Figure"6.13.""
"
!
Figure'6.13..Binding.pose.for.compound.82...
The"docking"pose"for"compound"82"in"model"B"is"presented"here."The"protein"surface"is"transparent"and"coloured"
in"red,"while"the"protein"ribbon"is"shown"in"light"blue."The"discussed"residues"are"indicated"and"shown"with"light"
blue"carbon"atoms."The"ligand"carbon"atoms"are"coloured"in"orange."Hydrogen"bonds"are"indicated"by"black"dotted"
lines..
Using"the"area"references"of"Figure"6.6,"the"molecule"spanned"from"the"P1"to"the"P2"sites"and"
the" central" fluorene" portion" was" placed" on" top" of" Trp795," giving" a" π\π" stacking" with" this"
residue," similarly" to" compound"80."One"of" the" two" furan" rings"was"placed" in"a"hydrophobic"
area" of" the" binding" cleft," described" by" the" lipophilic" portion" of" the" side" chains" of" residues"
Glu415,"Asn416"and"Gln742."This"placed"the"oxygen"atom"of"the"carbonyl"group"linked"to"the"
furan"itself" in"an"appropriate"position"of"a"hydrogen"bond"with"Trp795"side"chain"indole"NH."
Similarly"to"compound"82,"the"other"furan"ring"was"perpendicular"to"Arg792,"suggesting"that"it"
might" interact" with" this" residue" through" a" positive" charge\π" interaction." This" allowed" the"
interaction"of"the"oxygen"atom"of"the"carbonyl"group"linked"to"this"furan"ring"with"the"Thr413"
side" chain" hydroxyl" group" through" a" hydrogen" bond." Only" one" of" the" four" amino" groups"
formed" hydrogen" bonds" with" the" protein" and" this" interaction" involved" Thr413" backbone"
carbonyl" oxygen." All" but" one" (Thr413)" of" the" mentioned" residues" are" well" conserved" or"
maintained" their" properties" in" the" four" DENV" serotypes," complying" with" the" possibility" of"
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designing"panserotypic" inhibitors"of"DENV." In"position"Thr413"is"a"Gln" in"DENV4"and"a"Val" in"
DENV1."Unfortunately"one"of"the"modelled"interactions"of"compound"82"with"DENV"NS5"RdRp"
involves" the" side" chain" of" this" amino" acid." However," as" the" importance" of" this" single"
interaction" is" not" known," the" possibility" of" a" panserotypic" activity" of" compound" 82" is" not"
excluded.""
Compound" 82" showed" a" low"micromolar" activity" (IC50" of" 47.1µM" and" 35.1µM" according" to"
assay"settings)"in"the"inhibition"of"DENV"RdRp"activity"in"the"biochemical"assays"with"both"RNA"
template"and"probe"settings"used."Unfortunately,"the"CPE"assay"did"not"show"an"anti\infection"
activity"of"this"compound,"probably"due"to"its"cytotoxicity"(CC50"of"138µM)."
With" the" aim" of" confirming" the" NS5" RdRp" activity" inhibition," improve" the" cell" infection"
inhibition" and" to" gain" further" insights" on" preliminary" structure\activity" relationships" of"
compound"82," eleven" analogue"molecules"were" purchased" from" SPECS" and" four" (101,"102,"
103" and" 109)" were" synthesised." All" of" them" were" tested" in& vitro" with" CPE" and" with" the"
polymerase"activity"inhibition"assay,"using"a"polyU"template"and"PicoGreen"fluorescent"probe."
The" selection" of" these" compounds" was" also" based" the" binding" mode" suggested" by" the"
molecular"modelling"results"and"showed"in"Figure"6.13,"as"a"second"objective"was"to"validate"
this"model."Table"6.4"contains" the"structures"and"the"assay" results" for"compound"82"and" its"
analogues."Here,"the"indicated"CC50"and"EC50"values"were"obtained"from"the"CPE"assay"and"the"
selectivity" index" (SI)" is" reported" as" well." The" IC50" values" were" acquired" with" the" enzyme"
inhibition"test."As"highlighted"in"the"table,"all"the"compounds"were"symmetrical"and"most"of"
them" had" the" central" fluorene" scaffold" A." Amongst" these,"96" was" the" only" compound" that"
retained" the"sulphonylhydrazide"group,"which"was"substituted"by"a" sulphonamide"moiety" in"
the"other"molecules."In"particular,"100"to"108"were"selected"because"as"well"as"having"one"NH"
less"in"the"sulphonylhydrazide"group,"they"also"did"not"have"the"carbonyl"moiety"in"the"chain."
The"position"of"the"two"nitrogens"in"the"side"chains"was"assessed"through"compounds"97"and"
98,"while"the"importance"of"the"final"aromatic"ring"was"investigated"with"99,"and"106.to"108."
The"length"of"the"side"chains"of"the"central"scaffold"was"also"investigated"with"compounds"104"
to"107."In"order"to"confirm"the"results"and"to"investigate"the"role"of"chirality"in"the"activity"of"
compound" 100," the" three" compounds" 101" to" 103" were" synthesised." The" central" fluorene"
group"was"also"explored"with"compounds"109"and"110."
" "
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Table'6.4..Compound.80.and.analogue.molecules..
Scaffold"A:" Scaffold"B:" Scaffold"C:"
" "
"!
. Scaffold. R. CC50.(µM)
a. EC50.(µM)
a. IC50.(µM)
b.
82. A"
"
138" >200"
35.1"±1.6"
SI"="0"
96. A"
"
>88.6" >88.6"
89.4"±29.4"
SI"="1"
97. A"
"
>84.6" >84.6"
40.3"±5.6"
SI"="1"
98. A"
"
>81.1" >81.1"
Insoluble"
SI"="1"
99. A"
"
>113.5" >113.5"
357.2"±40"
SI"="1"
100. A"
"
5.61" 1.31"
2.8"±0.3"
SI"="4"
101c. A"
"
>93.9" 0.87"
19.0"±2.4"
SI">"107"
102c. A"
"
>93.9" 0.45"
16.1"±2.1"
SI">"211"
103c. A"
"
>93.9" 1.78"
11.2"±1"
SI">"53"
104. A"
"
>20.6" 48.2"
3.96"±0.9"
SI"="0.427"
SS
R R
O O O O
SS
R R
O
O O
O SS
R R
O O O O
O
H
N N
H
O
O
H
N N
H
O
N
H
N
N
H
O
N
N N
H
N OH
O
H
N
H
N
H
N
H
N
H
N O
Section"6:"NS5"POLYMERASE"AS"A"DRUG"TARGET" 6.2&RESULTS&AND&DISCUSSSION"!
!268"
105. A"
"
>104.9" 6.61"
13.5"±2.6"
SI">"16"
106. A"
"
>102.3" >102.3"
13.3"±0.8"
SI"="1"
107. A"
"
>108.6" >108.6"
64.6"±7.5"
SI"="1"
108. A"
"
>107.6" >107.6"
10.5"±1.2"
SI"="1"
109c. B 
"
>94.2" >94.2"
64.7"±6.8"
SI"="1"
110. C 
"
>100.3" 42.0"3.01"
49.48"±3.4"
SI">"2"
SI">"33"
a="tests"performed"by"the"Rega"Institute"for"Medicinal"Research,"K."U."Leuven"(Belgium)"
b="tests"performed"by"AFMB,"Marseille"University"(France)"
c="synthesised"compound.!
As" can" be" observed" in" the" table," improvement" of" both" NS5" RdRp" and" cellular" infection"
inhibition"could"be"achieved" for" some"of" compound"82" analogues," compared" to" the"original"
molecule."Some"molecules"were"active"in"both"assays,"suggesting"that"this"series"of"molecules"
might"exert" their"antiviral" function" through"the" inhibition"of" the"polymerase," thus"validating"
the" NS5" RdRp" as" a" promising" drug" target" for" anti\DENV" drug" design." Unfortunately," the"
compounds" that" were" active" in" the" CPE" assay" also" displayed" adverse" effects" at" higher"
concentrations," implying" that" this" class"of" compounds" still"needs" improvement."Even" if"data"
were" more" consistent" with" respect" to" compound" 80" series," the" lack" of" correspondence"
between"some"cell\based"and"biochemical"results,"might"imply"that"cellular"pathways"not"yet"
explored"could"be"involved"in"the"cell\based"activity"of"these"compounds."In"addition,"lack"of"
penetration" or" intracellular" sequestration" could" also" be" implicated," but" has" not" been"
investigated" to" date." Nevertheless," preliminary" structure\activity" relationships" could" be"
hypothesised"on" the"base"of" the"data"presented" in"Table"6.4"and"are" schematised" in" Figure"
6.15."
The"substitution"of" the" furan" ring"with"a"pyridine" (in"96)"did"not" improve" the"activity"of" the"
compound"in"cells"and"increased"the"IC50"value."Similarly,"the"rearrangement"of"R"components"
(in"97)"resulted"in"an"activity"profile"very"similar"to"the"original"molecule."The"importance"of"a"
hydrophobic"group"at"the"end"of"the"R"chain"was"confirmed"by"99"that"was"inactive"in"the"CPE"
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assay" and" inhibited" the" polymerase" function" only" at" high" micromolar" concentration."
Furthermore," the" structural" similar" compounds" 100" to" 108" compounds," all" displaying" an"
aromatic" of" hydrophobic" final"moiety" in" the" R" chain," showed" generally" good" activity" in" the"
biochemical" assay." The" antiviral" activity" of" compounds"100" and"104" in" cells"was" associated"
with"cytotoxicity,"while"it"was"lost"in"the"molecules"with"an"aliphatic"ring"or"chain"at"the"end"of"
R" (from"106" to"108)." It"was" consequently" hypothesised" that" the" presence"of" a" hydrophobic"
group"was"fundamental"for"RdRp"inhibition"(as"schematised"in"Figure"6.15"with"green"circles)"
and"an"aromatic"moiety"is"preferable"for"the"inhibition"of"infection"in"cells."This"is"in"line"with"
the"docking"pose"for"compound"82"suggested"by"the"molecular"modelling,"in"which"one"furan"
ring" is" placed" in" a" hydrophobic" area" of" the" binding" site" and" the" other" one" interacts" with"
Arg792.""
The" IC50" values" for" compounds" from" 106" to" 108" were" generally" lower" than" the" reference"
molecule," implying" that" substituents" without" the" carbonyl" group" and" with" a" sulphonamide"
substituting" the" sulphonylhydrazide" enhance" the"molecule" activity." This"was" an" unexpected"
result" as" in" the" in& silico"model" for" the" binding" of" compound" 82" placed" one" carbonyl" group"
interacting"with"the"Thr413"side"chain"OH,"whilst"the"other"one"hydrogen"bonded"with"Trp795"
(Figure"6.13).""
Unfortunately," no" insights" on" the" chain" length" could" be" obtained." The" only"molecules" that"
displayed"a"worse"RdRp"inhibition"(when"assessed),"as"well"as"lack"of"activity"in"cells,"were"the"
only"ones"with"no"NH"groups"(98"and"107)."This"implied"that"the"presence"of"at"least"one"NH"
moiety" is" important" for" activity," in" line" with" the" interaction" with" the" backbone" carbonyl"
oxygen" of" Thr413" observed" in" the" pose" in" Figure" 6.13." These" hypotheses" are" collectively"
represented"in"Figure"6.15"with"blue"circles."
Compounds"101"to"103"were"synthesised"de"novo"with"the"aim"of"finding"a"possible"synthetic"
route" for" the" fluorene\based"compounds," to"confirm"the"activity"of"100"and" to"evaluate" the"
importance" of" the" stereochemistry" of" this" compound." Compound"101"was" synthesised" as" a"
mixture" of" three" possible" stereoisomers" combinations" (R,R;" S,S" and" R,S)," whilst" the"
enantiomerically" pure" 102" and" 103" are" the" (R,R)" and" the" (S,S)" isomers" of" the" molecule"
respectively."The"three"compounds"displayed"very"similar"activity,"implying"that"the"chirality"is"
not"a"fundamental"factor"with"these"groups"linked"to"the"asymmetrically"substituted"carbon."
Interestingly,"all"three"products"showed"an"improved"cytotoxicity"profile"and"despite"adverse"
effects"still"observed"at"higher"concentration,"the"selectivity"index"had"values"between"53"and"
211." In" order" to" explain" this" difference" with" 100," it" was" hypothesised" that" the" purchased"
sample"was"less"pure"and"thus"had"greater"cytotoxicity."This"structure"was"however"confirmed"
to"be"the"most"active"one"of"the"whole"series"in"the"inhibition"of"DENV"infection"in"cells"EC50"
values"that"reached"sub\micromolar"concentrations,"in"particular"for"the"(R,R)"isomer.""
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The"central"fluorene"scaffold"was"also"explored"with"modifications"indicated"with"“scaffold"B”"
and"“scaffold"C”"in"Table"6.4."The"first"one"was"investigated"with"109,"which"was"synthesised,"
as"it"was"not"commercially"available."The"difference"from"the"original"fluorene"structure"is"the"
removal"of"the"methylene"linker"between"the"two"aromatic"rings."As"it"was"observed"that"the"
fluorene"scaffold"is"very"similar"to"anti\tumour"telomerase"inhibitors,"it"was"hypothesised"that"
the"cytotoxicity"of"these"compounds"could"have"been"related"to"this"off\target"mechanism."An"
important"characteristic"for"the"mode"of"action"of"the"anti\cancer"compounds"is"the"planarity"
of"the"central"core"of"the"molecule."It"is"necessary"for"G\quadruplex"(DNA"structure,"typical"of"
telomere"sequences)"intercalation"and"consequent"stabilisation,"which"inhibits"the"telomerase"
activity.[18]" For" this" reason" it" was" chosen" to" remove" the" methylene" moiety," producing" a"
scaffold" that" retains"aromatic"properties,"but" looses"planarity."This"molecule"was" inactive" in"
infected" cells" and" showed" a" lower" RdRp" inhibition" compared" to" 82," complying" with" the"
molecular" modelling" model" described" in" Figure" 6.13." According" to" this" binding" mode," the"
biphenyl"scaffold"of"109"would"be"placed"on"Trp795,"giving"a"π\π"stacking"with" this" residue."
However," as" this" scaffold" is" less" planar" than" a" fluorene," the" π\π" stacking" could" be" less"
important,"explaining"the"difference"in"results"observed"in"the"in&vitro"assays."It"was"therefore"
hypothesised" that" the" planarity" of" the" scaffold" is" important" for" the" activity" of" these"
compounds"and"consequently"that"the"methylene"group"in"the"fluorene"is"essential.""
"
Compound"82.
"
Compound"109.
"
"""A" """B"
Figure'6.14..CPE.assay.results.for.compounds.82.and.109...
A).Results.for.compound.82."Data"is"presented"as"a"percentage,"with"100%"representing"cell"controls."At"different"
compound"concentrations"(shown"in"µM),"the"residual"metabolic"activity"of"the"cells"is"reported"in"green,"while"the"
antiviral"activity"of"the"compound"is"shown"in"red."B).Results.for.compound.109."Data"is"presented"as"a"
percentage,"with"100%"representing"cell"controls."At"different"compound"concentrations"(shown"in"µg/ml),"the"
residual"metabolic"activity"of"the"cells"is"reported"with"a"green"line,"while"the"antiviral"activity"of"the"compound"
with"a"red"one."The"green"dashed"line"shown"the"residual"metabolic"activity"of"cells"evaluated"with"microscopic"
evaluation."
Comparing"the"assay"charts"(Figure"6.14),"the"decrease"of"metabolic"activity"in"the"presence"of"
109" occurred" at" slightly" higher" concentrations" (around" 18.84µM" instead" of" around" 6µM)."
However,"as"this"compound"was"not"tested"at"a"concentration"higher"than"94.2µM"it"was"not"
possible"to"assess"if"the"modification"was"successful"in"improving"the"cytotoxicity"profile"of"82."
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The"second"central"scaffold"was"investigated"with"110,"which"was"purchased."Also"in"this"case"
the"fluorene"was"modified"at"the"level"of"the"connecting"methylene,"but"this"time"the"CH2"was"
substituted"with"a"carbonyl"group,"resulting"in"a"fluorenone"core."Since"a"non\canonical"dose\
response"curve"was"obtained"in"the"CPE"assay"for"this"compound,"with"two"EC50"values,"these"
results" cannot" be" compared"with"other"molecules."However," evaluating" the"RdRp" inhibition"
data"of"110"with"104,"both"having"the"same"R"substituent,"more"than"a"ten\fold"reduction"in"
activity"was"observed."This"was"consistent"with"the"binding"mode"model"discussed"with"Figure"
6.13,"as" the"carbonyl"moiety"of" the" fluorenone"would"clash"with" the"protein"Thr413\Glu415"
loop." The" central" scaffold"would" consequently" be" shifted," weakening" the" π\π" stacking"with"
Trp795."Collectively,"these"results"suggest"that"the"methylene"group"is"essential"for"compound"
activity,"as"schematised"by"the"red"circle"in"Figure"6.15."
Summarising,"the"assessment"of"the"class"of"compounds"related"to"82"validated"NS5"RdRp"as"a"
promising" drug" target" for" antiviral" development" as" its" inhibition" also" affects" cell" infection."
Even"if"cell\based"and"biochemical"activity"did"not"always"match,"more"consistency"was"found"
with" respect" to" the" 80" series," suggesting" that" compound" 82" analogues" offer" a" better"
development"series"to"find"anti\DENV"agents."Further"optimisation"might"be"initiated"from"the"
observed"SARs" that"were"often"supported"by"compound"82"binding"pose"obtained" from"the"
virtual" screening" approach." As" schematised" in" Figure" 6.15," a" methylene" group" in" the" area"
shown"with"a"red"circle"is"indispensable"for"molecule"activity."Also"a"hydrophobic"group"in"the"
area"shown"with"a"green"circle"is"essential"for"activity"and"an"aromatic"moiety"is"preferable,"in"
particular" for" infection" inhibition" in" cells." Additionally," a" sulphonamide" replacing" the"
sulphonylhydrazide"group"and"the"removal"of"the"carbonyl"moiety"(blue"circle"in"the"scheme)"
enhance"both"cell"infection"and"RdRp"inhibition."
"
!
Figure'6.15..Schematic.representation.of.the.SAR.for.compound.82.series...
The"structure\activity"relationships"(SARs)"discussed"in"the"text"are"presented"here."The"fluorene"scaffold"of"the"
molecule"is"presented"in"the"middle"and"the"areas"with"suggested"groups"that"are"required"or"that"improve"activity"
are"described"in"the"circles..
" "
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CHEMICAL.SYNTHESIS.OF.COMPOUND.109.
"
!
Figure'6.16..Structure.of.compound.109..
N'4,N''4'\di(furan\2\carbonyl)\[1,1'\biphenyl]\4,4'\disulphonohydrazide" (109," Figure" 6.16)" was"
chosen"with"the"aim"of"exploring"the"importance"of"the"fluorene"scaffold"with"relationship"to"
activity"and"toxicity."As"it"was"not"possible"to"purchase"this"molecule,"it"was"prepared"with"a"
one"step"synthesis,"according"to"the"procedure"in"Scheme"6.1."In"this"reaction"two"molecules"
of" 2\furoic" hydrazide" (111)" react" with" one" of" biphenyl\4,4’\disulphonylchloride" (112)" in"
pyridine" (Py)" at" room" temperature" (r.t.)" through"a" coupling" reaction"mechanism" to"give" the"
symmetric"compound"109.[19,20]"
"
!
!
Scheme'6.1..Synthesis.of.compound.109..
Pyridine"was" chosen" to" facilitate" the" coupling" reaction" not" only" because" is" a" stronger" base"
than"the"hydrazide"compound"111,"but"also"because"it"could"be"the"solvent"for"the"reaction,"
as"compound"112"was"poorly"soluble"in"most"of"the"common"solvents."Another"reason"is"the"
fact" that"pyridine"has"shown"to"be"able" to"enhance"acylation"reactions"of"benzenesulphonyl"
chloride"derivatives"with"a"nucleophilic"catalysis.[21,22]""
The" reaction"was"monitored" by" TLC" until" 112" consumption." After" the" removal" of" Py" under"
vacuum," the" product" was" washed" with" water" in" order" to" remove" the" miscible" Py" and" the"
water" soluble" compound" 111." NMR" analysis" showed" that" the" obtained" product" needed"
purification," but" the"poor" solubility" of"109" in" the"most" common"organic" solvents"made" this"
difficult."As" it"did"not"dissolve" in" the"eluents," column"chromatography"could"not"be"applied."
Crystallisation"with"several"solvents"and"solvent"combinations"were"attempted,"revealing"1,4\
dioxane/water"mixture" as" the" successful" one."Unfortunately," the" elimination" of" 1,4\dioxane"
required"several"washes"with"ethanol"and"diethylether,"reducing"the"yield"considerably."NMR"
and"elemental"analysis"confirmed"that"the"obtained"compound"was"109."
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CHEMICAL.SYNTHESIS.OF.9HFFLUORENEF2,7FDISULPHONAMIDE.
COMPOUNDS.(101,.102.AND.103).
"
!
Figure'6.17..Compound.100..
In&vitro"assays"showed"that"9H\fluorene\2,7\disulphonamide"is"a"favourable"scaffold"for"both"
DENV"NS5" RdRp" and" cell\based" infection" inhibition."With" the" aim"of" improving" this" class" of"
molecules,"a"synthetic"pathway"was"developed"and"is"discussed"here."Furthermore,"one"of"the"
most"promising"compounds" (100)"displayed"two"chiral"centres,"but"no" information"about" its"
stereochemistry"was"available."Thus,"the"synthesis"of"this"compound"was"performed"with"the"
aim" of" confirming" its" activity" and" to" explore" the" importance" of" the" chirality" in" compound"
activity.""
"
!
Scheme'6.2..General.procedure.for.the.synthesis.of.compounds.100,.101.and.102...
(a:" i)" Acetic" Acid," 120°C," 4h;" ii)" NaOH;" b:" i)" 120°C," 2h;" ii)" CHCl3," reflux" 60°C," 1" h;" c:" N,N\diisopropylethylamine,"
dichloromethane,"r.t."1.5h)"
The"synthesis"required"three"steps,"as"described"in"Scheme"6.2,"and"each"one"of"them"will"be"
discussed"separately."Initially,"the"coupling"in"the"third"step"in"this"procedure"was"performed"
with" a" racemic" mixture" of" the" amine" compound" in" order" to" evaluate" the" possibility" of"
obtaining"and"separating" the" three"possible"stereoisomers" (R,R;"S,S;"and"R,S)."However,"also"
the"enantiomerically"pure" (R)"and" (S)"amines"were" reacted"with" the" same"sulphonylchloride"
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group"containing"precursor"for"the"synthesis"of"the"compounds"with"known"chirality"102"and"
103.""
"
Step'1:'synthesis'of'sodium'9HSfluoreneS2,7Sdisulphonate'(113)'
'
Sodium"9H\fluorene\2,7\disulphonate"(113)"was"synthesised"through"a"double"sulphonation"of"
fluorene" (114)," according" to" the" procedure" reported" in" Scheme" 6.3." In" this" reaction," two"
molecules"of"chlorosulphonic"acid"(115)"react"with"the"fluorene"molecule"(114)"in"glacial"acetic"
acid"at"120°C"for"4"hours"to"give"the"symmetric"compound"115"with"an"electrophilic"aromatic"
substitution"mechanism.[23]"
"
!
!
Scheme'6.3..Synthesis.of.compound.113..Reaction"conditions:"i)"CH3COOH,"120°C,"4h;"ii)"NaOH.
From" this" reaction" scheme," it" appears" that" 2" moles" of" chlorosulphonic" acid" are"
stoichiometrically"needed"for"product"formation."However,"a"higher"quantity"(almost"double)"
was" needed" for" the" synthesis" of" 113." The" reason" behind" this" aspect" could" be" the" high"
reactivity" of" this" molecule" with" water," producing" sulphuric" (H2SO4)" and" hydrochloric" (HCl)"
acids,"which"requires"anhydrous"conditions."Despite"the"attention"given"to"this"aspect"during"
the"synthesis,"probably"some"water"was"present"in"the"reaction"mixture,"partially"deactivating"
this"reagent"and"explaining"the"need"of"an"excess"quantity"of"HSO3Cl.""
The" reaction"was"monitored"with" TLC" and"when" it"was" concluded," the"mixture"was" treated"
with" sodium"hydroxide" (NaOH)" in"brine." In" this"way," the"excess"of" chlorosulphonic"acid"was"
deactivated"and"the"sodium"salt"of"the"disulphonic"acid"(113)"was"isolated"as"a"solid"due"to"its"
poor"solubility"in"water."The"residue"was"then"washed"with"brine"and"water."The"obtainment"
of"113"was"confirmed"by"NMR"analysis."
"
Step'2:'synthesis'of'9HSfluoreneS2,7Sdisulphonyl'dichloride'(116)'
"
9H\fluorene\2,7\disulphonyl" dichloride" (116)" was" synthesised" through" the" chlorination"
reaction"reported"in"Scheme"6.4."In"this"reaction,"sodium"9H\fluorene\2,7\disulphonate"(113)"
reacts" with" phosphorus" pentachloride" (PCl5)" without" solvent" at" 120°C" first" and" then" in"
chloroform"(CHCl3)"at"60°C"to"give"9H\fluorene\2,7\disulphonyl"dichloride"(116).[24]""
"
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Scheme'6.4..Synthesis.of.compound.116..Reaction"conditions:"i)"120°C,"2h;"ii)"CHCl3,"reflux"60°C,"1"h.
As" PCl5" reacts" violently" with" water," giving" phosphoric" acid" (H3PO4)" and" HCl" after" complete"
hydrolysis," all" the" steps" of" the" chlorination" were" performed" under" strictly" anhydrous"
conditions..The"reaction"was"initially"performed"in"absence"of"solvent."In"order"to"assure"the"
best"contact"between"the"reagents,"the"powders"were"pulverised"in"mortar"and"the"smallest"
flask"available"was"used."A"temperature"of"120°C"was"used"at"this"stage"as"it"is"lower"than"the"
melting" point" of" PCl5" (166°C" with" decomposition)," but" higher" than" the" boiling" point" of" the"
product"POCl3" (106°C)," allowing" the" removal"of" the" side"product," shifting" the"equilibrium"of"
the"reaction"towards"the"formation"of"116."With"the"consumption"of"PCl5"and"the"elimination"
of"POCl3,"the"stirring"of"the"suspension"became"more"difficult"and"consequently"the"reaction"
was" continued"with" the" use" of" a" solvent." At" reaction" completed," the" reaction" solution"was"
washed"with"water"in"order"to"remove"the"excess"of"PCl5"and"the"remaining"POCl3.".
The"product"was"purified"with"precipitation"with"an"appropriate"anti\solvent"from"a"solution"
of"CHCl3."Several"attempts"were"performed,"finding"petroleum"ether"as"the"best"precipitating"
solvent."The"obtainment"of"116"was"confirmed"by"NMR"analysis."
"
Step'3:'synthesis'of'final'compounds'(101S103)'
"
The"last"step"for"the"synthesis"of"compounds"101\103"was"performed"according"the"coupling"
reaction" reported" in" Scheme" 6.5." In" this" reaction" two" molecules" of" the" appropriate" α\
methylbenzylamine" (117)" react" with" one" of" 9H\fluorene\2,7\disulphonyl" dichloride" (116)" in"
dichloromethane" (DCM)" in" presence" of" N,N\diisopropylethylamine" (DIPEA)" at" room"
temperature" to"give" the" symmetric" compounds"101\103.[25]" For" the" synthesis"of"N2,N7\bis(1\
phenylethyl)\9H\fluorene\2,7\disulphonamide" (101)" (±)α\methylbenzylamine" was" used,"
aiming" the" synthesis" of" the" mixture" of" all" possible" isomer" combinations;" while" for" N2,N7\
bis((R)\1\phenylethyl)\9H\fluorene\2,7\disulphonamide"(102)"and"N2,N7\bis((S)\1\phenylethyl)\
9H\fluorene\2,7\disulphonamide" (103)" (R)\(\)\α\methylbenzylamine" and" (S)\(+)\α\
methylbenzylamine"were"used"respectively."Differently"from"the"coupling"reaction"performed"
for"the"synthesis"of"109,"a"stronger"base"had"to"be"used" in"this"case"because"Py" is"not"basic"
enough"to"facilitate"the"coupling"reaction."
"
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Scheme'6.5..Synthesis.of.compounds.101F103..
The"reaction"was"monitored"with"TLC"and"when"completed"the"solvent"was"removed"and"the"
solid" treated" with" HCl" 1N," obtaining" the" final" product" as" a" water" insoluble" solid" and" the"
residual" basic" compounds" in" solution." Column" chromatography"was" used" to" purify" the" final"
product," obtaining" compounds"101,"102" or"103" according" to" the" amine" used," as" confirmed"
from" NMR" and" elemental" analysis." Unfortunately," in" the" mass" spectroscopy" analysis" of" all"
three" the" compounds," the" molecular" signal" given" by" the" addition" of" a" H+" (M\H+)" was" not"
observed,"while"the"one"given"by"the"addition"of"Na+"(M\Na+)"was"present.""
The"M\Na+" signal" in" the"mass" spectra"and" the"elemental"analysis"were"equal"or" very" similar"
between"the"three"compounds,"confirming"that"they"differ"only"by"stereochemistry."The"(R,R)"
and" the" (S,S)" isomers" (as" in"102" and"103" respectively)"are"enantiomers,"as" they"are"one" the"
mirror"image"of"the"other."For"this"reason,"it"is"not"surprising"that"they"present"equivalent"1H\
NMR"and"13C\NMR"spectra"and"a"mixture"of"the"two"would"not"be"distinguishable"with"NMR."
The" third" supposed" component" of" the"101"mixture," the" (R,S)" isomer." It" contains" a" plane" of"
symmetry"and"thus"is"a"meso"compound"and"consequently"it" is"achiral,"despite"the"presence"
of"two"chiral"centres.""
"
" "
A" B"
"
C"
Figure'6.18..Three.possible.stereoisomers.of.compound.100...
A).(R,R).enantiomer.(as.in.102)..B).(S,S).enantiomer.(as.in.103)..C).(R,S).isomer.or.meso.compound..
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The" three" stereoisomers"are" shown" in" Figure"6.18." Experimental"data" showed" that"also"101"
had"equivalent"1H\NMR"and"13C\NMR"spectra,"implying"that"also"the"meso"isomer"(R,S)"could"
have"the"same"spectra"as"the"other"species."The"high"range"in"the"melting"temperature"of"101"
supports" that" this" product" is" a" mixture" of" compounds," but" unfortunately" the" other"
experiments"did"not"help"in"the"determination"of"the"nature"and"of"the"relative"quantity"of"the"
single"components.""
"
CONCLUDING.REMARKS.
"
A" virtual" screening" approach" has" been" applied" for" the" design" of" non\nucleoside" DENV"
polymerase"inhibitors"(NNI)."Two"very"similar"homology"models"of"the"protein"were"built"and"
used"for"compound"selection"and"the"binding"site"(called"“site"D”"in"this"thesis)"was"chosen"on"
the"basis"of"a"model" for"which"Trp795"plays"an"essential" role" in" the"RNA"synthesis" initiation"
step."A"filtered"selection"of"small"drug\like"molecules"belonging"to"the"SPECS"database"chose"
to"29" final" compounds" from"around"209,000"using" a" virtual" screening"methodology" that," to"
the"best"of"knowledge,"has"never"been"applied"to"this"molecular"target.""
This"molecular"modelling"approach"was"successful" in"identifying"two"compounds"(80"and"82)"
with"different"chemical" scaffolds" to"other"DENV"RdRp"NNIs" reported" in" the" literature."These"
two" showed" promise" in" their" evaluation" in& vitro"with" cell\" and" polymerase\based" assays." In"
both"cases,"analogue"molecules"were"purchased"or"synthesised"and"assessed"for"activity.""
Several" compounds" of" the" two" series"were" found" to" be" active" also" at" very" low"micromolar"
concentrations,"making" them"potential" leads" for"anti\DENV"agents,"despite"cytotoxicity"seen"
at"higher"concentrations"that"means"that"further"improvement"is"needed."Indeed,"the"possible"
methods" of" synthesis" used" for" compound" 100" could" be" a" starting" point" for" the" design" and"
assessment"of"other"82"analogues.""
Importantly,"the"fact"that"some"molecules"in"both"series"were"active"in"both"assays,"the"NS5"
RdRp" was" validated" as" a" promising" drug" target" for" anti\DENV" drug" design," as" its" inhibition"
affects" cell" infection." This" also" suggested" that" these" series" of" molecules" might" exert" their"
antiviral" function"through"the" inhibition"of"the"polymerase."However,"the" inhibition"of"DENV"
infection"in"cells"and"of"the"activity"of"DENV"RdRp"did"not"always"correlate"well,"in"particular"in"
the" series" of" 80" analogues," whilst" greater" consistency" was" seen" with" the" 82" analogues."
Consequently,"it"was"hypothesised"that"other"not"yet"explored"molecule"or"cell\based"factors"
might"be"involved"in"the"cellular"activity"of"these"compounds."However,"cell\based"results"also"
need" to" be" repeated" to" obtain" stronger" statistical" strength" of" the" results." Nonetheless,"
preliminary"structure\activity"relationships"could"be"hypothesised"for"both"series."In"the"case"
of"compound"82"analogues,"this"was"aided"also"by"the"four"molecules"that"were"successfully"
synthesised"and"tested,"as" they"not"only"confirmed"the"activity"of"one"compound"(100),"but"
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they" also" provided" important" knowledge" in" constructing" structure\activity" relationships."
Furthermore,"the"SARs"were"often"supported"by"the"binding"modes"of"compounds"80"and"82,"
suggesting"that"these"could"indeed"bind"site"D"of"the"RdRp."The"docking"binding"modes"were"
not"always"consistent"with"the"inhibition"data,"but"it"is"reasonable"to"hypothesise"that,"being"
allosteric" inhibitors," the" compounds" could" induce" small" conformational" changes" that" cannot"
be" predicted"with" semi\flexible" docking" simulations"where" the" protein" is" considered" a" rigid"
body."With"the"aim"of"validating"the"model"for"which"these"series"of"compounds"inhibit"DENV"
polymerase" by" binding" it" in" site" D," collaborators" in"Marseille" University" attempted" the" co\
crystallisation"of"compounds"80"and"82,"but"unfortunately"the"soaking"experiments"failed.""
Even" if"the"reference"protein"structure"belonged"to"DENV"serotype"3,"particular"attention"to"
the" conservation" of" the" interacting" protein" residues" was" given" in" the" molecular" modelling"
approach"to"compound"selection."Unfortunately," the" in&vitro"assays"have"not"been"repeated"
on"more" than"one" serotype" to"date."Both"CPE"and" the"polymerase"activity" inhibition"assays"
were" performed" with" DENV" serotype" 2" virus" and" NS5" RdRp" respectively." Thus," the" cross"
serotype"activity"of"these"compounds"has"not"yet"been"determined.""
In"conclusion,"the"molecular"modelling"approach"designed"in"this"study"successfully"identified"
two"novel"promising"anti\DENV"agents"that"were"further"developed"with"a"classical"Medicinal"
Chemistry"approach"and"the"establishment"of"a"route"for"the"synthesis"of"compound"82\like"
molecules." Improvements" of" these" two" series" of" compounds" are" still" needed" but" could" be"
achieved"using" the"built"SAR"models"and" the"synthetic" route"discussed"above," turning" these"
leads"into"potentially"good"candidates"for"the"treatment"of"DENV"infection."
"
" "
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6.2.2'ALLOSTERIC'INHIBITORS'BINDING'SITE'C'
"
Essential"for"RNA"replication"and"a"validated"target"also"for"other"viruses,"DENV"NS5"RdRp"is"
probably"the"most"attractive"molecular"target"for"antiviral"drug"design."One"of"the"most"active"
developers"of"both"nucleoside" (NI)" and"non\nucleoside" inhibitors" (NNI)" in" the" last" years"has"
been" the"Novartis" Institute" for"Tropical"Diseases" (NITD)." Through"high" throughput" screening"
(HTS)" of" compounds" with" an" enzymatic" assay," NITD" has" identified" a" N\sulphonylanthranilic"
acid" scaffold" with" RdRp" inhibitory" activity" that" was" developed" with" a" series" of" analogue"
molecules.[10,11]"As"the"mechanism"of"interaction"of"these"molecules"with"RdRp"was"not"clear,"
a" new" crystal" structure" of" NS5" RdRp" domain" was" published" in" complex" with" an" inhibitor"
belonging"to"this"NITD"series.[7]"However," in"this"complex,"the"ligand"(NITD\107)" is" located"in"
RdRp"site"C,"in"a"binding"mode"that"does"not"allow"immediate"correlation"between"the"activity"
values"of"the"compound"series"and"the"structural"information."
With"this"premise,"the"putative"binding"site"of"the"NITD"series"has"been"studied"with"the"aim"
of" identifying" structural" information" that" could" correlate"with" the" activity" data" published" in"
the"literature."The"final"objective"would"be"to"use"the"information"obtained"as"the"basis"for"a"
virtual"screening"approach"to"identify"novel"DENV"RdRp"NNIs."
"
PROTEIN.MODEL.
"
Two" crystal" structures" of" the" DENV3" RdRp" domain" have" been" published" after" the" virtual"
screening"study"described"in"chapter"6.2.1."These"structures"are"at"high"resolution"and"show"
more" resolved" residues" with" respect" to" the" previously" published" ones," but" they" are" still"
incomplete.[6,7]" In" particular," comparing" the" structure" of" the" enzyme" in" complex" with" the"
inhibitor"NITD\107"(PDB"ID:"3VWS[7])"with"the"apo"protein"(PDB"ID"2J7U[6]),"it"appears"that"the"
sequence"between"Ala406"and"Asp419"is"solved"in"the"more"recent"structure,"whilst"the"other"
two"not" present" portions" (Val310\Ala316" and"Tyr451\Ala472)" are" still"missing." Furthermore,"
several" conformational" changes" in" the" protein" upon" compound"binding" seem" to" trigger" the"
stabilisation"of" loop"3"(L3)"and"helix"α5"that"appear"highly"disordered"in"the"apo"form"of"the"
protein.""
3WVS"was"chosen"as"a"target"RdRp"structure"because"being"the"structure"co\crystallised"with"
NITD\107," it" complied" with" the" aim" of" this" study." However," as" already" mentioned," it" is"
incomplete"and"despite"the"fact"that"the"missing"loops"were"far"from"NITD\107"binding"site,"a"
model"of"the"protein"was"built"using"3VWS"as"a"template"and"homology"modelling."As"done"in"
the" previous" study," only" the" missing" fragments" (Glu309\Ser317" and" Cys449\Ala472)" were"
modelled"according"to"the"procedure"described"in"the"METHODS"chapter"and"the"rest"of"the"
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protein"was"maintained"as" in"the"crystal"structure."The"amino"acids"at"the"boundaries"of"the"
missing" fragments" were" modelled" as" well" with" the" aim" of" obtaining" the" most" reasonable"
structure"possible."As"no"other"RdRp"structures"with"similar"conformation"to"3VWS"could"be"
found,"the"missing"fragments"were"modelled"on"3VWS,"using"only"the"force"field"(AMBER99)"
parameters." The" obtained" model" superposed" very" well" with" the" original" structure," with" a"
RMSD" value" of" 0.08Å." The" quality" of" the" model" was" assessed" through" Ramachandran" plot"
evaluation" that" showed" only" one" extra" outliner" compared" to" the" original" structure." The"
outliners"belonged"to"a"protein"region"far"from"the"selected"target"site"and"were"however"very"
close" to" the" allowed" region" of" the" psi\phi" plot." The" model" was" consequently" considered"
suitable"to"be"used"for"the"determination"of"the"putative"binding"site"of"the"known"inhibitors"
and"for"the"subsequent"virtual"screening"approach."
"
NITD.SERIES.OF.COMPOUNDS.
"
The" published" NITD" series" of" N\sulphonylanthranilic" acid" derivatives" exhibited" polymerase"
activity" in" the" low" micromolar" range," but" no" potent" activity" in" cell\based" assay.[3,10]"
Compounds" NITD\1" and" NITD\107" are" shown" in" Figure" 6.19" and" the" other" compounds’"
structures"and"polymerase"IC50"values"are"reported"in"Table"6.5."
"
! " ! "
NITDF1"(IC50=7.2μM)" NITDF107"(IC50=113μM)"
Figure'6.19..Structure.and.IC50.values.for.NITDF1.and.NITDF107..
The" inhibitor" in" complex"with" the" RdRp" protein" in" the" newly" published" crystal" structure" of"
DENV" RdRp" is" NITD\107" (Figure" 6.19)." This" compound" is" commercially" available" and" it"
exhibited"an"IC50"of"113μM"in"DENV4"enzymatic"assay"and"EC50"of"100μM"in"the"DENV2"cell\
based"assay."It"is"therefore"weakly"active"against"DENV"RdRp,"but"it"has"been"shown"not"to"be"
cytotoxic" and" to" be" specific" for" the" enzyme." It" bound" full" length" NS5" with" a" dissociation"
constant" (Kd)" of" 173μM" and" for" the" RdRp" domain" with" a" Kd" of" 225μM.[7]" This" molecule" is"
structurally"similar"to"the"other"NITD"molecules,"but"amongst"the"whole"set"of"compounds"it"is"
the"one"that"differs"the"most"from"the"others"(Table"6.5)."
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Table'6.5..NITD.series.of.compounds.[10].
Scaffold:"
""""" "!
NITDF. R1. R2. R3. IC50.(μM).
2. 2\COOH" H" Benzyl" 0.7"
6. H" H" Benzyl" >20"
7. 2\COOMe" H" Benzyl" >20"
8. 2\COONH2" H" Benzyl" >20"
9. 3\COOH" H" Benzyl"" >20"
10. 4\COOH" H" Benzyl"" >20"
11. 2\COOH" 6\Cl" Benzyl"" 18.02"
12. 2\COOH" 5\Cl" Benzyl"" 0.77"
13. 2\COOH" 4\Cl" Benzyl"" 2.56"
14. 2\COOH" 3\Cl" Benzyl"" >20"
15. 2\COOH" 5\F" Benzyl"" 0.37"
16. 2\COOH" 5\methoxy" Benzyl"" 9.99"
17. 2\COOH" 4,5\dimethoxy" Benzyl". >20"
22. 2\COOH" H" H" >20"
23. 2\COOH" H" Me" >20"
24. 2\COOH" H" Isobutyl"" >20"
25. 2\COOH" H" Isopentyl"" 6.77"
26. 2\COOH" H" Ethilmorpholine" >20"
27. 2\COOH" H" Methyl\2\naphthalene" 0.37"
28. 2\COOH" 5\F" Methyl\2\naphthalene" 0.26"
"
In" the" crystallised" complex," two"molecules" of"NITD\107" are" interacting" between" each" other"
and"with"the"protein,"as"displayed"in"Figure"6.20."As"shown,"the"binding"site"is"located"on"the"
opposite"side"of"Trp795"with" respect" to"Arg737."Thus," it"does"not"coincide"with" the"nascent"
RNA"binding"groove,"but"rather"with"the"site"for"the"RNA"template"binding."The"phenyl"group"
of" one" NITD\107"molecule" forms" a" stacking" interaction" with" the" benzofuran"moiety" of" the"
other"one"and" the"main" contacts"with" the"protein" involve" the" stabilised" loop" L3" residues" in"
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particular.[7]"Unfortunately,"the"displayed"contacts"between"the"two"ligand"molecules"and"the"
protein"are"not"such"to"explain"the"activity"patterns"reported"in"Table"6.5."For"instance,"more"
active"molecules"have"a"highly"hydrophobic" large"moiety" in" the"R3"position;"whilst"NITD\107"
only" has" a" chlorine" atom." Observing" the" conformation" of" NITD\107" molecules" in" the" cleft,"
there"is"no"space"for"a"larger"group"in"this"position"and"the"activity"cannot"be"enhanced"with"
this"type"of"substitution"according"to"this"binding"model.""
"
"
"
""""""""A" """""""""B"
Figure'6.20..NITDF107.complex.with.the.protein.(PDB:.3VWS).."
A).Binding.pose.of.NITDF107..Here,"the"carbon"atoms"of"the"two"NITD\107"molecules"are"in"orange"and"the"
interacting"RdRp"residues"are"highlighted"and"indicated."Hydrogen"bond"interactions"are"shown"with"blue"dotted"
lines."B).Ligand.interaction.scheme.for.the.two.NITDF107.molecules."In"this"schematic"representation"of"the"
binding"mode"the"two"molecules"are"showed"in"red"and"in"green."The"interactions"are"shown"with"dotted"lines"
which"colour"recalls"the"corresponding"NITD\107"molecule."
In"order"to"have"a"better"understanding"of"the"real"binding"mode"of"this"series"of"molecules,"
docking" studies" were" performed." Attempts" were" conducted" with" three" docking" programs"
(Maestro"Glide,"PLANTS"and"LeadIT"FlexX)"for"all"the"NITD"series"of"compounds,"using"different"
docking" settings" as" well" as" exploring" different" protonation" states" for" the" ligands." Only" one"
docking" simulation," performed"with" LeadIT" FlexX" program," gave" relevant" results" that" could"
match" the"activity"data"published" in" the" literature."Most" intriguing" is" the" fact" that"NITD\107"
bound" to" the" enzyme" superposes"well" with" one" of" the" crystallised" ligands" in" 3VWS" (Figure"
6.21),"while"most"of"the"molecules"were"placed"in"another"area"of"site"C."The"main"difference"
between"the"crystallised"conformation"and"the"docking"pose"of"NITD\107"was"the"position"of"
the"phenyl"group."However,"this"does"not"appear"to"be"involved"in"important"interactions"with"
the"protein."This"gave"confidence"on"the"docking"simulation"reliability.""
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!
Figure'6.21..Superposition.of.NITDF107.crystallised.conformation.and.docking.pose..
The"carbon"atoms"of"the"crystallised"conformation"of"NITD\107"are"shown"in"orange"and"those"of"the"docking"pose"
are"in"green."Interacting"residues"are"highlighted"and"indicated."Hydrogen"bonds"are"shown"with"blue"dotted"lines..
The"best"scoring"molecules"were"also"the"most"active"compounds"of"the"series"(NITD\28"and"
NITD\27)."All"molecules"with"IC50"values"lower"than"20μM"displayed"a"similar"binding"mode"to"
that"given"by"NITD\28"and"shown"Figure"6.22"and"the"interactions"formed"with"the"RdRp"were"
consistent"with"the"activity"data."Compounds"with"an"IC50"higher"than"20μM"(considered"“less"
active”)"not"always"resembled"the"same"binding"as"the"“active”"ones."
"
!
Figure'6.22..NITDF28.binding.pose..
NITD\28"atoms"are"coloured"in"orange,"those"of"the"residues"composing"the"hydrophobic"area"of"the"site"are"in"
green"and"the"important"residues"are"indicated."Hydrogen"bonds"are"shown"as"blue"dotted"lines..
In" the" binding" mode" presented" in" Figure" 6.22," the" hydrophobic" R3" group" is" placed" in" a"
hydrophobic"pocket" (green" residues" in" the" figure)" given"by"Val411,"Phe412,"Val402," Lys401,"
Phe398" and" Phe485." Larger" hydrophobic" groups" are" able" to" better" occupy" this" pocket,"
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contributing" to" an" improved" binding" and" this" could" explain" why" compounds" with" larger"
hydrophobic" groups" in"R3"display"higher" inhibition"of" the"enzyme." Furthermore," compounds"
with" IC50" values" lower" than" 1μM," generally" displayed" an" additional" hydrophobic" interaction"
between" the" pyrazole" ring" and" Val603," while" compounds" with" higher" activity" placed" the"
aromatic"ring"away"from"this"residue,"near"Val411.""
Several" R1" and" R2" substituents" were" used" in" the" compound" series" and" the" activity" data"
indicated"that"the"presence"of"a"carboxylic"moiety" in"position"2"of"the"ring"was"fundamental"
for" the" activity" and" that" groups" that" are" able" to" increase" it’s" acidity" were" correlated" with"
higher"polymerase"inhibition.[10]"According"to"the"docking"model,"the"importance"derived"from"
the"fact"that"the"carboxylic"acid"is"involved"in"two"hydrogen"bonds"(with"the"Trp477"indole"NH"
and"with" the"Asn452"backbone"NH)"and"with"an"electrostatic" interaction"with" the"positively"
charged"Arg481."The"position"of" substituents" (e.g."halogens)" that"enhance" the"acidity"of" the"
COOH"moiety" in" this" ring" is" related" to" the"electron\withdrawing"effect" and" therefore"ortho\"
and" para\" positions" in" respect" to" the" carboxylate" group" would" be" preferred." However,"
molecules"with"a"halogen"in"the"ortho\"position"did"not"give"good"inhibition"activity."This"could"
be" explained" by" the" binding" mode" model" presented" here," in" which" a" substituent" in" this"
position"produces"a"steric"clash"with"the"protein.""
Almost"all"of"the"residues"discussed"in"this"binding"mode"are"well"conserved"in"identity"or" in"
physical" properties" amongst" the" four"DENV" serotypes," suggesting" that" inhibitors" that" target"
this" pocket" could" be" serotype\unspecific," in" accordance" with" the" aims" of" this" study." Only"
Thr413"is"not"conserved,"as"it"is"a"Val"in"DENV1"and"a"Gln"in"DENV4."However,"as"displayed"in"
Figure"6.22,"the"compounds" interact"with"the"backbone"amine"group"of"this"residue,"making"
the"conservation"of"this"amino"acid"less"important"for"panserotypic"drug"design.""
"
IDENTIFICATION.OF.ALLOSTERIC.INHIBITORS.THROUGH.VIRTUAL.
SCREENING"
"
The" protein" homology"model" and" the" binding"mode" hypothesis" obtained" from" the" docking"
simulation"of"the"known"N\"sulphonylanthranilic"acid"derivatives"were"used"for"the"design"of"a"
virtual"screening"approach"that"could"aid"the"identification"of"novel"antiviral"agents"within"the"
drug\like"small"molecules"SPECS[12]"database"(updated"to"February"2012)."The"complex"of"the"
most"active"molecule"(NITD\28)"with"the"protein"was"used"as"a"starting"point"for"this"study."A"
scheme"with" the"general" virtual" screening"workflow" is" reported" in"Figure"6.23,"while"details"
about"the"single"procedures"are"reported"in"the"METHODS"chapter."
"
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Figure'6.23..Schematic.representation.of.the.virtual.screening.workflow..
The"main"steps"are"indicated"and"the"numbers"are"referred"to"the"number"of"molecules"at"every"step."The"
homology"model"of"the"polymerase"is"reported"with"RdRp."Molecular"modelling"programs"and"functions"are"
abbreviated"as"follows:"FX="LeadIT"FlexX;"PL="PLANTS;"MOE="MOE;"CS="consensus"score;"NCS="normalised"
consensus"score..
As"explained"in"APPENDIX&2,"the"interactions"between"a"protein"and"a"ligand"occur"at"the"level"
of" their" surfaces" and" therefore" the" shape" complementarity" between" the" two"molecules," as"
well" as" their" surface"properties," is" fundamental" for" the" strength"of" the" interaction"between"
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them.[26]"For"this"reason"and"as"the"pose"of"the"NITD\28"was"considered"to"be"related"to"the"
compound" activity," its" shape"was" used" as" a" first" filter" of" the"more" than" 209,000"molecules"
belonging"to"the"database."On"the"basis"of"the"NITD\28"docking"conformation"a"shape"query"
was" built" with" OpenEye" ROCS" program." As" the" main" interactions" that" are" linked" to" the"
inhibitory" response" are" known," “color”" features" were" defined" in" the" query" as" well" as" the"
molecule"shape."A"total"of"seven"“color”"features"were"used:"two"ring" features"(in"green)"on"
the"naphthalene"portion;"one"anion"feature"(in"pink)"on"the"carboxylate"moiety;"one"hydrogen"
bond"donor"feature"(in"blue)"on"the"sulphonamide"NH"group;"three"hydrogen"bond"features"
(in" red),"one"on"a"sulphonamide"oxygen"and"one" for"each"carboxylate"oxygen"atoms."Figure"
6.24" shows" the"query"built" from"NITD\28" shape"and"pharmacophoric" sites" and"used" for" the"
first"filter"in"the"virtual"screening.""
"
!
Figure'6.24..Shape.query..
The"molecule"shape"(grey"shade)"and"the"“color”"features"are"reported"here"for"compound"NITD\28."The"green"
solid"spheres"represent"the"two"ring"features,"the"red"ones"the"three"hydrogen"bond"acceptor"ones,"the"blue"
sphere"the"hydrogen"bond"donor"and"the"pink"solid"sphere"the"anion"feature..
OpenEye"ROCS"is"a"program"that"runs"a"rigid"superposition"of"molecules"to"the"given"queries."
As"the"shape"is"a"conformation\dependent"descriptor,"a"conformational"search"was"applied"to"
the"SPECS"database"for"an"appropriate"shape"comparison."Hydrogen"atoms"were"also"added"
to" the" structures," as" described" in" the" METHODS" chapter." Approximately" 7,130,000"
conformations" were" obtained" and" screened" against" the" described" shape" query," saving" the"
5,000"best"scoring"hits.""
After" this" filtering," redundant" molecules" were" removed" and" the" NITD\28" compound" was"
added" with" the" aim" of" identifying" compounds" that" could" bind" the" polymerase" better" than"
NITD\28"and" therefore"be"more"active"against" the"enzyme."A" total"of"2,201"structures"were"
docked" in" the" RdRp" homology" model." The" docking" was" implemented" with" LeadIT" FlexX"
program,"using" the"NITD\28"molecule" for" the"selection"of" the"receptor"site."The"5"poses"per"
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ligand" produced" by" LeadIT" FlexX" were" then" rescored" using" PLANTS" and" MOE" programs."
Similarly" to" that" done" in" previous" virtual" screening" studies" of" this" PhD," the" scores" obtained"
from" the" three" programs" were" used" for" the" calculation" of" a" consensus" and" normalised"
consensus" score," with" the" functions" reported" in" the"METHODS" section." Of" all" the" docked"
molecules,"only"342"scored"in"the"best"25%"of"the"results"in"all"three"programs"and"only"six"of"
them"scored"better"than"NITD\28.""
All" the" poses" were" then" visually" inspected" for" final" selection," considering" docking" scores,"
chemical"clustering"and"the"displayed"interactions"with"the"polymerase."In"line"with"the"aims"
of" the"study,"particular"attention"was"given"to"the"six"molecules"that"scored"better"than"the"
NITD"series"most"active"molecule"(NITD\28)."
Three"molecules"(compounds"118,"119"and"120"in"APPENDIX&9)"were"selected"and"purchased"
from"SPECS.[12]"
"
BIOLOGICAL.EVALUATION.OF.THE.SELECTED.COMPOUNDS.
"
All"the"purchased"compounds"were"tested"in&vitro"with"the"CPE,"the"TSA"and"the"polymerase"
activity" inhibition" (with" radiolabelled" probes)" assays." Unfortunately," none" of" the" selected"
molecule"gave"positive"results"to"the"performed"tests."
"
CONCLUDING.REMARKS.
"
With" the" aim" of" discovering" novel" RdRp" NNIs," 3VWS" structure" was" completed" with" a"
homology"model" of" the" protein" and" it"was" used" as" a"molecular" target." Docking" simulations"
were"performed"on"this"structure"with"published"N\sulphonylanthranilic"acid"derivatives"and"
their"activity"data"was"used"for"the"identification"of"a"promising"allosteric"site"(site"C)"for"RdRp"
inhibition." As" most" of" the" residues" of" this" pocket" are" conserved" amongst" the" four" DENV"
serotypes,"compounds"that"bind"to"this"site"could"potentially"inhibit"the"polymerase"of"all"four"
DENV"serotypes."On"the"basis"of"these"results,"a"virtual"screening"approach"was"designed"to"
select"putative"novel"RdRp"inhibitors"from"the"SPECS[12]"database."The"methodology"combined"
shape" screening" with" docking" and" rescoring" techniques" and" allowed" the" selection" of"
compounds," using" NITD\28" as" a" reference." The" final" three" selected" compounds" were"
purchased" and" tested" with" cell\" and" polymerase\based" assays," but" unfortunately" none" of"
them"were"active"in"the"performed"assays."
The"activity"data"suggested"that"the"designed"virtual"screening"approach"was"not"successful"in"
identifying" anti\DENV" agents." Several" explanations" could" be" hypothesised" for" this." For"
instance,"probably"the"original"database"did"not"contain"molecular"types"that"could"match"the"
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binding"features"discovered"with"the"structure\activity"study."The"fact"that"very"few"molecules"
scored" better" than" NITD\28" could" suggest" that" this" is" possible." It" would" be" interesting" to"
employ" again" the"methodology" in" order" to" better" assess" its" prediction" power," in" particular"
with"different"starting"databases"to"assess"the"validity"of"this"hypothesis."
Despite"the"inability"to"find"new"DENV"inhibitors,"the"docking"simulations"on"the"published"N\
sulphonylanthranilic" acid" derivatives" and" the" building" of" structure\activity" relationships"
suggest"that"the"discussed"binding"mode"could" indeed"be"the"active"one."This"represents"an"
important" novel" piece" of" information" that" supports" the" polymerase" site" C" as" a" promising"
molecular"target"for"the"design"of"novel"anti\DENV"antiviral"agents."As"it" is"well"conserved"in"
identity"of"properties"amongst"the"four"serotypes,"it"could"be"further"explored"in"future"drug"
design"studies"for"the"development"of"serotype\unspecific"inhibitors"of"DENV"virus."
"
"
"
"
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6.3.CONCLUSION.
"
RNA\dependent" RNA" polymerase" (RdRp)" is" an" essential" enzyme" for" DENV" replication" as" it"
compensates" for" the" lack"of"RNA"polymerases" in"host"cells,"allowing"the"transcription"of" the"
viral"genome."Therefore,"it"is"an"attractive"drug"target"and"it"has"been"used"for"the"design"of"
antiviral"agents"against"DENV"and"other"RNA"viruses."
In"this"study"the"objective"was"to"select"potential"RdRp"inhibitors"from"a"small"molecule"drug\
like" database" (SPECS)" through" two" virtual" screening" approaches." The" first" was" aimed" at"
targeting" a" polymerase" area" (site" D)" that" involved" the" mechanistically" relevant" residues"
Trp795"and"Arg737."Twenty\nine"molecules"were"purchased"and"their"antiviral"behaviour"was"
assessed"in&vitro"and"10"of"them"were"also"tested"on"DENV"RdRp"with"binding"and"enzymatic"
assays." The" second" virtual" screening" approach"was" based" on" the" knowledge" acquired" from"
polymerase"inhibitors"reported"in"the"literature"with"the"objective"of"finding"compounds"that"
could"bind"the"enzyme"in"site"C."Three"molecules"were"purchased"and"tested"in&vitro"with"both"
cell\"and"polymerase\based"assays"for"anti\DENV"activity."Given"the"advantage"of"targeting"all"
four"DENV"serotype"at"the"same"time,"particular"attention"to"the"conservation"of"the"binding"
site" residues" was" given" in" both" molecular" modelling" approaches" of" compounds" selection."
Unfortunately,"the"in&vitro"assays"have"not"been"repeated"on"more"than"one"serotype"to"date"
as" both" CPE" and" the" polymerase" activity" inhibition" assays" were" performed" with" DENV"
serotype" 2" virus" and" NS5" RdRp" respectively." This" has" not" yet" allowed" the" testing" of" the"
hypothesis"of"panserotypic"inhibition"activity."Further"studies"should"be"performed"using"the"
other"three"DENV"sereotypes."
The"first"virtual"screening"approach"was"successful"in"identifying"two"compounds"(80"and"82)"
with" a" novel" chemical" scaffold" for" DENV" NNIs" and" with" promising" in& vitro" activity," with"
different" profiles." Compounds" 80" and" 82" analogues" were" consequently" purchased" or"
synthesised"and"assessed"for"activity."Several"compounds"of"the"two"series"were"found"to"be"
active"also"at"very"low"micromolar"concentrations,"making"them"promising"anti\DENV"agents,"
despite" their" cytotoxicity" adverse" effects" that" imply" they" still" need" improvement." Activity"
profiles" were" not" always" justified" by" the" in& silico" model" of" compounds" 80" and" 82" protein"
binding." However," it" cannot" be" excluded" that" the" model" does" not" consider" small" protein"
conformational"changes,"typical"of"allosteric"inhibitors"that"could"better"explain"the"biological"
results." Four" 82" analogues" were" successfully" synthesised" and" tested." The" activity" of" one"
compound"(100)"was"confirmed"and" important"knowledge"on"structure\activity"relationships"
could"be"achieved."Furthermore,"the"method"of"synthesis"that"was"developed"could"be"used"
for" the" design" and" assessment" of" additional," novel" 82" analogues" for" the" needed"
improvements."
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Unfortunately,"the"second"virtual"screening"approach"failed"in"the"identification"of"promising"
novel"antiviral"agents."However," this"study"allowed"the" identification"of"the"putative"binding"
pocket" for" the" published" N\sulphonylanthranilic" acid" derivatives" RdRp" allosteric" inhibitors,"
returning"an" important"novel"piece"of" information" that" supports" the"polymerase" site"C"as" a"
promising"molecular"target"for"the"design"of"novel"anti\DENV"antiviral"agents.""
Collectively," these" studies" support" that" RdRp" is" a" promising" drug" design" target" for" the"
development" of" anti\DENV" inhibitors." Furthermore," the"molecular"modelling" suggested" that"
both"the"novel" identified"allosteric"sites" (site"C"and"D)"are"suitable"molecular" targets" for" the"
design"of"RdRp"NNIs.""
"
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6.4.BIOCHEMICAL.ASSAYS.ON.DENV.NS5.
POLYMERASE.
"
As"part"of"a"secondment"period"in"Marseille"University,"the"biochemical"assays"involving"NS5"
RdRp"reported" in"Table"6.6"were"performed"with"the"aim"of"assessing" in&vitro" the"activity"of"
compounds"designed"with"the"three"drug"design"approaches"described"in"chapters"within"this"
section." Unfortunately," as" the" polymerase" activity" assay" required" the" use" of" radiolabelled"
material" for" which" an" appropriate" training" is" required," a" Marseille" University" researcher"
carried"out"some"of"the"steps"in"the"performance"of"this"assay."Fifteen"molecules"(reported"in"
APPENDIX& 9)" were" tested," 12" from" the" virtual" screening" performed" on" site" D" (discussed" in"
chapter"6.2.1)"and"3"from"the"one"performed"on"site"C"(discussed"in"chapter"6.2.2)."The"choice"
of"the"compounds"among"the"entire"selected"small"molecules"was"mainly"based"on"chemical"
diversity." All" tested" compounds" were" dissolved" in" 100%" dimethylsulphoxide" (DMSO)." As"
indicated" in"Table"6.6," two"different"proteins"were"used" in"the"two"assays:"DENV"3"NS5"full\
length"protein"and"DENV"2"RdRp"domain."An"introduction"to"these"assays"can"be"found"in"the"
INTRODUCTION&section,"whilst"general"procedures,"results"and"test"calibrations"are"reported"
here."Further"details"of"compound"evaluation"are"discussed"in"the"RESULTS&AND&DISCUSSION"
chapter"of"this"section,"in"the"corresponding"paragraph"for"each"drug"design"study."Another"in&
vitro" test"(cytopathic"effect,"CPE," inhibition)"was"performed"by"our"collaborators"at"the"Rega"
Institute"for"Medical"Research"(KU"Leuven)"and"consequently"is"not"discussed"in"this"chapter.""
"
Table'6.6..Summary.of.performed.assays.for.DENV.helicase..
Name. What.it.measures. Enzyme(s).used.
Thermal"Shift"Assay"(TSA)" Protein"melting"temperature"(Tm)"shift"due"to"compound"binding."
DENV3"full"length"
NS5"
Polymerase"activity"assay" Compound"inhibition"of"RNA"polymerisation,"exploiting"3H\NTPs." DENV2"NS5"RdRp"
Abbreviations:"TSA="Thermal"Shift"Assay;"Tm="Melting"Temperature;"DENV3="Dengue"Serotype"3;"NS5="Non\Structural"
Protein"5;"RNA="Ribonucleic"Acid;"3HFNTP="Tritium"Labelled"Nucleoside"Triphosphate;.DENV2="Dengue"Serotype"2;"RdRp="RNA\
Dependent"RNA"Polymerase""
"
" "
Section"6:"NS5"POLYMERASE"AS"A"DRUG"TARGET" 6.4&BIOCHEMICAL&ASSAYS&ON&DENV&NS5&RDRP"!
!292"
THERMAL.SHIFT.ASSAY.(TSA).
"
The"thermal"shift"assay"(TSA)"was"performed"on"DENV3"full"length"NS5"protein"with"the"aim"of"
determining" the"binding"capacity"of"all" fifteen"compounds."Differently" to" the"helicase," there"
are"no"known"compounds"that"bind"to"the"RdRp"domain"of"NS5"and"that"are"suitable"for"the"
assay." However," SAM" is" known" to" bind" to" the"MTase" portion" of" NS5" and" to" give" relevant"
melting"point" shifts" in" the"TSA."For" this" reason" the" full" length"NS5"protein"was"used" for" the"
assay"and"SAM"was"chosen"as"a"reference"molecule.""
All" the" compounds"were" screened" at" a" concentration" of" 1mM" (or" 0.5mM" for" a" less" soluble"
compound),"while"SAM"was"screened"at"0.5mM."The"final"content"of"DMSO"was"equal"to"5%,"
and" the"Tm"were" compared" to" the"Tm"of" the"protein" in"buffer" and" in"buffer" containing"5%"
DMSO."In"the"assay"conditions"one"compound"precipitated"and"gave"a"non\canonical"melting"
curve."Unfortunately," it" has" not" been" possible" to" test" the" precipitated" compounds" at" lower"
concentration."Also"other"compounds"did"not"give"canonical"curves"and"could"not"be"analysed"
with"this"assay."Nine"remaining"molecules"gave"canonical"curves"that"could"be"analysed."Tm"
shifts"(ΔTm)"were"calculated"by"subtracting"the"melting"temperature"of"the"protein"in"buffer"
with"5%"DMSO"to"the"one"of"the"assessed"molecular"system.""
One"of"the"tested"compounds"(81)"gave"a"significant"increase"of"Tm"(2.93°C)"as"well"as"SAM,"
the"reference"molecule,"that"gave"a"melting"point"increase"of"4.26°C."All"the"other"compounds"
gave" a" negative" shift" in" melting" point," often" not" significant." In" order" to" confirm" that" the"
stabilisation"of"the"protein"and"the"consequent"increase"in"melting"point"were"correlated"with"
compound" binding," titration" curves" for" this" compound" and" SAM" were" performed." Eight"
concentrations" with" 2X" dilutions" were" tested," from" 1mM," including" the" blank." For" each"
concentration,"the"Tm"shift"was"calculated"in"the"same"way"as"for"the"compound"screening.""
The"above"compound" that"bound" to" the" full" length"NS5"protein"had"been"selected"with" the"
virtual"screening"study"performed"on"site"D"of"NS5"RdRp"and"was"further"discussed"in"chapter"
6.2.1."
"
POLYMERASE.ACTIVITY.INHIBITION.ASSAY.
"
The"activity"of"the"polymerase"to"synthesise"a"novel"strand"of"RNA"in"the"presence"of"a"RNA"
template"and"of"suitable"nucleotides"was"analysed"in"order"to"assess"the"fifteen"compounds’"
inhibition" activity" of" this" process." The" protein" used" for" this" assay" was" the" RdRp" domain" of"
DENV"2"NS5"protein."An"initial"screen"in"triplicate"at"three"concentrations"(10µM,"20µM"and"
100µM)"was"performed" for"all" 15"molecules"and" the" results"were"analysed"considering" four"
controls."The"output"results"were"given" in"percentage"of" inhibition."The"positive"control"was"
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the" protein" in" the" assay" buffer" and" it" represented" the" 100%" activity" of" the" protein." The"
background"noise"was" also" evaluated"with" another" control" given"by" only" the"RNA" template"
and" nucleotides," in" the" absence" of" the" protein." Two" negative" controls"were" used" for" assay"
validation." In" one" case" 3’dATP" was" used," as" it" is" an" ATP" analogue" that," lacking" the" 3’" OH,"
interrupts" RNA" synthesis." An" ATP" analogue" was" chosen" because" the" RNA" template" in" the"
compound"screening"was"a"polyU"oligonucleotide." In"the"second"negative"control,"EDTA"was"
added" to" the"protein"buffer." Its" role"was" to" sequester" the" catalytic" ions" of" the" enzyme"and"
consequently"impede"the"polymerisation"reaction."
From" the" initial" screening" only" one" compound" (82)" showed" a" meaningful" concentration\
dependent"inhibition"of"the"RdRp"activity."The"same"assay"was"repeated"for"this"and"another"
two"compounds"(80"and"81),"testing"more"concentrations"for" IC50"determination." In"order"to"
increase"the"assay"sensitivity,"a"mini\genome"RNA"template"(constituted"of"the"5’"and"3’"UTRs"
of"the"DENV"genome)"was"used"instead"of"the"polyU"strand."
The" compound" that" was" shown" to" inhibit" the" NS5" RdRp" together" with" the" two" molecules"
picked"for"IC50"determination"were"chosen"with"the"virtual"screening"study"performed"on"site"
D"of"NS5"RdRp"and"was"further"discussed"in"chapter"6.2.1."
"
"
"
"
"
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6.5.COMPUTATIONAL.METHODS.
"
The" computational" methods" for" all" the" studies" discussed" in" chapters" 6.2.1" and" 6.2.2" are"
presented" here." A" description" of" the" molecular" modelling" programs" used" can" be" found" in"
APPENDIX&2."
"
HARDWARE'DETAILS'
"
All" the" calculations"were"performed"on" a" 8" core" computer"with" Inter" Xeon"2.80"GHz" E5462"
CPUs.""
"
HOMOLOGY'MODELLING'
"
For" both" studies" the" missing" fragments" of" the" DENV" RdRp" structure" were" modelled" with"
homology" modelling." All" needed" template" crystal" structures" and" FASTA" sequences" were"
downloaded"from"the"Protein"Data"Bank"and"GenBank"sites"respectively.[13,27]"Protein"crystal"
structures"were"then"prepared"by"removing"water"molecules"and"unwanted"ligands"and"ions."
The"homology"model"was"computed"with"the"Homology"Model"tool"of"MOE"2010.10"suite.[28]"
The"complete"FASTA"sequence"of"the"protein"was"modelled"on"the"template"crystal"structure."
The"protein"was"protonated"during"the"homology"modelling"procedure"that"was"performed"at"
a"simulated"temperature"of"300K."All"models’"pdb"files"were"modified"in"order"to"maintain"the"
correct" residues" numbering" system." Ramachandran" plots" were" computed" for" model"
evaluation"with"MOE"2010.10.[28]""
For" the" study" applied" to" site" D," the" FASTA" sequence" (Accession:" 2J7U_A)"was"modelled" on"
DENV"NS5" RdRp" (PDB" ID:" 2J7U[6])" template" for" the"whole" protein" and" on"WNV" polymerase"
(PDB"ID:"2HFZ[14])"for"the"three"missing"loops"(Tyr308\Asn321;"Lys401\Ala421;"Cys446\Trp474)."
The" final" model" was" refined" with" 0.5" RMS" gradient" and" AMBER99" force" field." From" the"
obtained"homology"model"(model"A)"a"second"one"(model"B)"was"built"by"changing"the"Thr413"
side" chain" conformation"with"MOE" 2010.10[28]" Rotamer" Explorer" tool." The"modified" Thr413"
was" then" energy" minimised" with" MOE" 2010.10,[28]" using" AMBER99" force" field" and" 0.001"
gradient."
For" the" study" applied" to" site" C," the" FASTA" sequence" (Accession:" 2J7U_A)"was"modelled" on"
DENV" NS5" RdRp" (PDB" ID:" 3VWS[7])" template" for" the" reconstruction" of" missing" fragments."
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Neither"the"intermediates"models,"nor"the"final"one"were"refined."The"model"was"saved"with"
the"protein"in"complex"with"one"of"the"co\crystallised"ligands"(VWS\1003\A)"present"in"3VWS"
crystal"structure"for"an"easier"site"centre"definition"in"the"docking"simulations."
"
SITE'D'VIRTUAL'SCREENING'INPUT'PREPARATION'
"
In"the"case"of"the"molecular"modelling"study"performed"on"RdRp"site"D,"the"homology"models"
were" pre\processed"with" Schrödinger"Maestro" 9.3[29]" Protein" Preparation" tool" and" used" for"
grid"generation,"adopting"the"same"criteria"for"both"model"A"and"B."Trp795"was"chosen"for"the"
grid"centre"and"the"length"was"set"to"9Å.""
The"ligand"database"collected"the"molecules"from"the"SPECS[12]"database"(updated"to"February"
2012)." The" 2D" molecule" structures" were" prepared" with" Maestro" 9.3[29]" LigPrep" tool," using"
OPLS_2005" force" field."For"each"molecule," tautomers"were"designed"considering"all"possible"
ionisation"states"at"pH"7"±"2"with"Epik"and"maintaining"the" input"chiralities."A"filter"was"also"
applied" to" remove"molecules"with"molecular"weight" higher" than" 600Da,"more" than" 9" rings,"
more"than"4"chiral"centres"and"more"than"12"hydrogen"bond"donor"or"acceptor"groups."
"
MAESTRO'GLIDE'DOCKING'SIMULATIONS''
"
In" the" case" of" the" molecular" modelling" study" performed" on" RdRp" site" D," three" different"
docking" simulations" using" Schrödinger"Maestro" 9.3[29]" Glide" applications"were" performed" in"
three"different"moments"of"the"virtual"screening"approach"that"was"applied"in"the"same"way"
to" both" homology" models." All" of" the" docking" simulations" were" performed" using" the" same"
protein" grids" and" in" a" semi\flexible" way" with" the" sample" ring" conformation" option" for" an"
exhaustive"conformational"search"for"the"ligands."Ligands"with"more"than"300"atoms"or"more"
than" 50" rotatable" bonds" were" automatically" excluded." The" non\bonded" interactions" were"
calculated"with"a"0.8nm"van"der"Waals"radii"scaling"factor"and"a"0.15nm"partial"charge"cut\off."
Different"precision"modes" and"different"numbers"of" conformations"were" saved" in" the" three"
docking"simulations."
The" initial" high" throughput" virtual" screenings"were" computed" in" the" HTVS"mode," using" the"
prepared" SPECS" database" (see" above)." Only" a" maximum" of" 2" conformations" were" kept" for"
each" ligand" and" they" were" energy" minimised" during" the" docking" simulation." The" resulting"
poses"were" filtered"with" a" single" featured" pharmacophore" built"with" the"United" scheme" in"
MOE" 2010.10[28]" and" ranked" according" to" the" docking" score."No" rotation" or" translation"was"
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allowed" for" the" pharmacophore" search." One" conformation" for" each" molecule" that" had" a"
negative"docking"score"was"saved"for"further"analysis."
The"second"docking"simulation"was"performed"on"these"filtered"molecules"with"SP"precision"
mode." Only" a" maximum" of" 5" conformations" were" kept" for" each" ligand" and" they" were" not"
energy" minimised" as" a" refinement" procedure" was" applied" on" the" docking" output." These"
conformations"were"then"rescored"as"reported"later"in"the"METHODS"chapter."
After"rescoring,"molecules"were"docked"for"the"third"time"with"Maestro"9.3[29]"Glide"with"XP"
precision"mode."Only"a"maximum"of"3"conformations"were"kept"for"each"ligand"and"they"were"
not" energy" minimised" as" a" refinement" procedure" was" applied" on" the" docking" output."
Molecules"were"then"visually"inspected"with"MOE"2010.10[28]"with"particular"attention"to"the"
molecules"that"were"present"in"the"results"obtained"for"both"homology"models."
"
FLEXX'AND'PLANTS'RESCORING'
"
In" the" case" of" the"molecular"modelling" study" performed" on" RdRp" site" D," the" results" of" the"
docking" performed" with"Maestro" 9.3[29]" Glide" with" SP" precision" results" were" rescored" with"
other" two" programs:" LeadIT" FlexX" 2.1.3[30]" and" PLANTS.[31]" In" both" cases" no" molecule"
placement"was" performed" and" poses"were" scored" in" their" input" conformation" and" position"
within"the"binding"pocket."
Both"models"were"used" in" the" same"way" for" the" receptor"binding" site"preparation"with" the"
LeadIT"software."Trp795"was"chosen"as"the"centre"of"the"receptor"site"and"the"grid"sphere"had"
a"radius"equal"to"16Å.""
The"RdRp"models"were"also"used"as"input"files"for"PLANTS"rescoring."The"same"grid"centres"as"
in" the" Glide" docking" procedure"were" used" and" the" binding" site" radius"was" set" to" 12Å." The"
search"algorithm"used"20"ants"and"CHEMPLP"scoring"function"was"used.[32]""
"
CONSENSUS'SCORE''
"
In"both"virtual"screening"approaches,"part"of"the"procedure"required"the"docking"of"molecules"
with"one"molecular"modelling"software"and"the"rescoring"of" the"obtained"results"with"other"
two"programs."Then," the"scores"were"processed"with"a"scoring" function."Different"programs"
were"used"in"the"two"studies,"but"the"same"previously"developed"consensus"scoring"function"
was"used.""
For"each"set"of"data,"the"value"corresponding"to"the"lowest"25%"of"the"scores"(first"or" lower"
quartile,"Q1)"was"calculated."Then,"molecules"that"had"a"score"lower"than"Q1"(representing"the"
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best" 25%" of" poses)" were" rewarded" with" a" “+1”" score," while" the" ones" with" score" equal" or"
higher"than"Q1"were"assessed"with"a"“0”"or"“\1”"score"respectively."Then,"the"total"consensus"
score"(CS)"was"obtained"from"the"sum"of"the"given"scores"for"each"set"of"data."Equation"6.1"
shows"the"mathematical"expression"of"the"consensus"score"function."Here"the"three"molecular"
modelling" programs" are" indicated" with" the" letters" A," B" and" C." In" the" case" of" the" virtual"
screening"approach"performed"on"RdRp"site"D,"the"three"programs"were"Maestro"9.3[29]"in"SP"
mode," LeadIT" FlexX" 2.1.3[30]" and" PLANTS.[31]" In" the" case" of" the" virtual" screening" approach"
designed" for" RdRp" site" C," the" three" programs" were" LeadIT" FlexX" 2.1.3[30]," MOE" 2010.10[28]"
PLANTS.[31]"
" !"! = !"#$(!!,! − !!,!) + !"#$(!!,! − !!,!) + !"#$(!!,! − !!,!)"
Equation'6.1..Consensus.scoring.function..
CS="consensus"score;"i="pose;"Q1,name="first"quartile"of"the"set"of"data"corresponding"to"that"letter"(see"text);"xname,i="
score"obtained"by"pose"“i”"with"the"software"corresponding"to"that"letter"(see"text)""
A"normalised"consensus"score"(NCS)"was"also"calculated,"using"Equation"6.2."The"same"letter\
code"was"applied"as"in"Equation"6.1."
" !"#! = !!,!!"#! + !!,!!"#! + !!,!!"#! "
Equation'6.2..Normalised.consensus.scoring.function..
NCS="normalised"consensus"score;"i="pose;"Minname="lowest"value"of"the"set"of"data"corresponding"to"that"letter"
(see"text);"xname,i="score"obtained"by"pose"“i”"with"the"corresponding"to"that"letter"(see"text)"
In"both"studies"Molecules"were"ranked"according"to"the"CS"and"the"NCS"in"descending"order"
and"only"molecules"that"had"CS"equal"to"3"(and"therefore"performed"in"the"best"25%"with"all"
the"modelling"programs)"were"kept,"in"single"conformation"for"further"analysis."
The"saved"molecules"from"all"three"docking"and"rescoring"procedures"were"merged"and"two"
conformations" for" each" compound" that" had" CS1" =" 3" in" at" least" two" of" the" three" target"
molecular"systems"were"kept"for"further"proceedings."
" "
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NSSULPHONYLANTHRANILIC'ACID'DERIVATIVES'SAR'
STUDY''
"
The"molecules"belonging"to"the"N\sulphonylanthranilic"acid"derivatives"series"published"in"the"
literature[10,11]"were"designed"with"MOE"2010.10[28]"Builder"tool"and"minimised"with"MMFF94X"
force"field"and"0.001"gradient.""
The"model" built" on" the" 3VWS" template"was" used" for" the" receptor" binding" site" preparation"
with" the" LeadIT" 2.1.3" software." The" ligand" saved" in" the" protein" model" (VWS\1003\A)" was"
chosen"as"the"centre"of"the"receptor"site"and"the"grid"sphere"had"a"radius"equal"to"9Å."
The"designed"database"of"molecules"was"used"for"the"docking"procedure"operated"with"LeadIT"
2.1.3" FlexX[30]," where" original" protonation" states" were" maintained" and" 100" poses" for" each"
molecule"were"saved."
The" results"were" then" visually" inspected" both" in" LeadIT" and" in"MOE" environments" and" the"
structure"of"the"RdRp"enzyme"in"complex"with"the"most"active"compound"(NITD\28)"was"used"
for"the"virtual"screening"procedure."
The"10"conformations"saved"for"each"of"the"NITD"series"molecules"were"then"correlated"with"
their"reported"IC50"values.[10]""
"
SITE'C'VIRTUAL'SCREENING'INPUT'PREPARATION'
"
In" both" studies," the" virtual" screening" approaches" were" performed" using" the" molecules"
belonging"to"the"SPECS[12]"database"(updated"to"February"2012)."In"the"case"of"the"molecular"
modelling"study"performed"on"RdRp"site"C,"the"ligand"preparation"included"a"conformational"
search" using" MOE" 2010.10[28]" Import" Conformations" tool" with" the" following" settings:" 100"
conformations"explored"per"molecule,"stochastic"strain"limit"fixed"to"7,"superposed"RMSD"test"
to"0.15,"refinement"conformation"limit"to"300,"stochastic"search"failure"limit"to"30,"stochastic"
search" limit"to"300,"energy"minimisation" iteration" limit"to"200,"energy"minimisation"gradient"
test" to" 0.5." Compounds" with" transition" metals," more" than" 8" rings," d\hybridized" atoms,"
molecular" weight" over" 600Da," more" than" 12" donor/acceptor" groups," more" than" 4" chiral"
centres,"logP"under"\4"and"over"8,"over"3"unconstrained"chiral"centres,"more"than"7"rotatable"
bonds" and" single" bond" chain" length" over" 6," were" omitted." Ligands" were" subsequently" also"
protonated."
"
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SITE'C'VIRTUAL'SCREENING'SHAPE'FILTER'
"
In"the"case"of"the"molecular"modelling"study"performed"on"RdRp"site"C,"the"first"filter" in"the"
virtual" screening" approach" was" a" shape" screening" performed" with" OpenEye" 3.1.2" ROCS.[33]"
From"the"N\sulphonylanthranilic"acid"derivatives"SAR"study,"the"binding"conformation"of"the"
most" active" molecule" (NITD\28)" was" used" as" a" query." Seven" “color”" features" were" also"
assigned" in" the" query" generation." All" the" conformations" of" the"molecules" belonging" to" the"
prepared"SPECS"database"(see"above)"were"treated"as"separate"molecules."
Molecules" were" aligned" and" scored" according" to" the" shape" overlap" and" to" the" chemistry"
features"match"with"the"assigned"“color”"pharmacophore."Implicit"Mills"Dean"force"field"was"
used"for"chemistry"evaluation"of"the"compound"database."Only"the"best"5,000"hits"were"then"
saved"in"the"output"file.""
The" only" one" conformation" for" each" molecule" was" then" kept" for" docking" and" rescoring"
procedures."
"
LEADIT'FLEXX'DOCKING'SIMULATIONS'
"
In"the"case"of"the"molecular"modelling"study"performed"on"RdRp"site"C,"the"homology"model"
prepared"on"3VWS"template"in"complex"with"NITD\28"was"used"for"the"docking"and"rescoring"
processes"described"here." The" receptor" site"was"prepared"with" LeadIT"2.1.3" software,"using"
the"ligand"as"the"centre"and"a"grid"sphere"with"radius"equal"to"6.5Å."
NITD\28" structure"was" added" to" the" shape" filtering" results" and" all" of" these"molecules"were"
docked"with" LeadIT"2.1.3"FlexX[30]," using" the"original"protonation" states." Five"poses" for"each"
molecule"were"saved."
"
MOE'AND'PLANTS'RESCORING'
"
In" the" case" of" the"molecular"modelling" study" performed" on" RdRp" site" C," the" results" of" the"
docking" performed"with" LeadIT" FlexX" 2.1.3[30]" were" rescored"with" the" other" two" programs:"
MOE" 2010.10[28]" and" PLANTS.[31]" In" both" cases" no" molecule" placement" was" performed" and"
poses"were"scored"in"their"input"conformation"and"position"within"the"binding"pocket."
The"first"rescoring"was"performed"with"MOE"2010.10[28]"Docking"tool."In"the"homology"model,"
the"ligand"(NITD\28)"was"selected"for"the"binding"site"determination"and"the"protein"was"set"
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as" the" receptor." Neither" placement" nor" refinements" were" performed" and" molecules" were"
rescored"with"London"dG"scoring"function."All"conformations"were"retained.""
The"model"was"also"used"as"input"files"for"PLANTS[31]"rescoring."The"same"grid"centre"as"in"the"
LeadIT" FlexX" docking" procedure" was" used" and" the" binding" site" radius" was" set" to" 16Å." The"
search"algorithm"used"20"ants"and"CHEMPLP"scoring"function"was"used.[32]"
"
"
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6.6.EXPERIMENTAL.SECTION.
"
6.6.1'BIOCHEMICAL'ASSAYS'
"
COMPOUND.PREPARATION.
"
Of"the"15"tested"compounds,"13"were"purchased"from"SPECS[12]"and"two"(compounds"77"and"
78)"were"synthesised"by"a"student"in"our"laboratory"as"part"of"a"structure\activity"study"of"one"
of"the"compounds"selected"for"the"RdRp"allosteric"site"D.[17]"
For" each" compound," a" mother" solution" of" 20mM" in" DMSO" was" prepared," starting" from"
approximately"5mg"of"compound."One"compound"(121)"did"not"dissolve"at"this"concentration"
and" therefore" it"was"diluted" to"10mM" in"DMSO."These"solutions"were" then"used"as" starting"
material"for"the"biochemical"assays."
"
THERMAL.SHIFT.ASSAY.(TSA).
"
The"TSA"assay"was"performed"on"one"DENV"full"length"NS5"protein"from"serotype"3"(EVA316,"
103.359kDa)."The"enzyme"was"previously"prepared"and"purified"in"the"laboratory."The"buffer"
used"for"the"assay"was"constituted"of"Tris"(pH"7.5)"50mM,"NaCl"150mM,"TEMED"200mM"and"
MgCl2"1mM"in"water."SYPRO"ORANGE"(SO,"with"excitation"wavelengths"at"300nm"and"470nm"
and"emission"wavelength"at"570nm)"was"used"as"fluorescent"probe."
PCR"plates"with"96"wells"were"used"and"each"well"was"prepared"with"25µL"of" total" solution"
(20µL" of" protein," 1.25µL" of" compound" 20mM" solution" and" 3.5µL" of" SO" solution)." The" final"
concentration"of"the"protein"was"0.40mg/ml,"while"the"final"concentration"of"the"compounds"
was"of"1mM"in"each"well,"except"for"the"poorly"soluble"compound"(121)"that"was"at"0.5mM."
Three"controls"were"also"prepared"for"each"protein:"one"with"0.5mM"of"SAM"as"it"is"known"to"
bind"the"enzyme,"one"with"5%"DMSO"and"one"with"the"protein"alone."
Before"performing"the"assay,"the"wells"were"visually"inspected"in"order"to"detect"the"presence"
of" eventual" precipitated" compounds." The" assay"was" performed" in" a"modified" PCR"machine"
that" reads" the" fluorescence" in" function"of" the" temperature." It"was" set" for"360" cycles"of"12s"
each"with"a"temperature"increase"of"0.2°C,"starting"from"a"temperature"of"20°C.""
The" resulting" charts" of" fluorescence" on" temperature" were" analysed" with" ORIGIN." For" each"
protein,"a"temperature"window"was"chosen"in"order"to"include"the"reported"thermal"shift"and"
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the"curves"were"fitted"with"a"Boltzmann"distribution."Melting"points"and"fitting"errors"were,"in"
this"way,"determined."
The" titration" curves" for" compound" 81" were" performed" with" the" same" protocol" as" the"
screening,"but"with"different"concentrations"of"the"molecule"(1mM,"500µM,"250µM,"125µM,"
62µM,"31µM,"16µM"and"0µM)."As"positive"control," the"same"approach"was"applied" to"SAM"
with"concentrations"of"500µM,"250µM,"125µM,"62µM,"31µM,"16µM"and"8µM."
"
POLYMERASE.ACTIVITY.INHIBITION.ASSAY.
"
The" inhibition" activity" of" the" 15" selected" compounds" was" assessed" by" measuring" the"
incorporation"of"radiolabeled"nucleotides"on"behalf"of"the"polymerase"enzyme"in"presence"of"
a" RNA" template." For" this" assay," an" active" form" of" DENV" serotype" 2" RdRp" domain" of" NS5"
protein" was" used." The" protein" was" previously" prepared" and" purified" in" AFMB," Marseille"
University" laboratories." The" reaction" buffer" was" constituted" of" Hepes" pH" 8.0" 50mM," KCl"
10mM," MgCl2" 1mM," MnCl2" 2mM" and" DTT" 10mM" in" water." Therefore," the" protein" mix"
contained"the"polymerase"domain"and"the"RNA"template"in"the"reaction"buffer."
The"compound"solutions"were"organized"in"96\wells"plates"and"concentrations"were"diluted"in"
different" way" with" water" according" to" the" final" desired" compounds" concentration," but"
maintaining"a"constant"quantity" (5%)"of"DMSO"for"all" the" tests."The"compounds"distribution"
was"performed"by"Biomek"NX"(Beckman)"pipetting"robot.""
Protein"mix"was" then" put" in" contact"with" the" prepared" compound" concentrations." Controls"
were"also"used" for"assay"validation." The"positive" control"was" composed"by" the"protein"mix,"
while" the"background"control" comprehended" the"RNA" template,"but"not" the"protein," in" the"
reaction"buffer." In"addition"to"these,"two"negative"controls"were"set"up,"both"containing"the"
protein"mix,"as"well"as"EDTA"(100mM)" in"one"case"and"the" inhibitor"3’dATP" (100mM)" in" the"
other"one."The"distribution"of"the"controls"and"of"the"protein"mix"in"the"plates"was"performed"
with"the"Biomek"3000"workstation.""
The" polymerase" reaction" was" started" by" the" addition" of" tritium\labeled" nucleotides,"
distributed" in" the" plates"with" Biomek" 3000." Then," the" plates"were" closed" and" incubated" at"
30°C"for"10"minutes."
The"reaction"was"stopped"with"the"addition"of"EDTA"100mM,"distributed"by"Biomek"3000."The"
products" were" transferred" to" a" membrane" filter" with" a" Packard" Filtermate" Harvester." The"
filters" were" washed" with" ammonium" formate" (pH" 8.0)," EtOH" and" dried." The" bound"
radioactivity" on" the" membranes" was" determined" with" liquid" scintillation" counting" and"
inhibition"percentage"was"calculated"for"each"compound."
As"the"assay"requires"the"use"of"tritium\labelled"products,"the"procedure"here"described"was"
applied"by"a"trained"scientist"in"Marseille"University."
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In"the"initial"screening,"the"compounds"were"tested"at"three"final"concentrations"(10,"20"and"
100µM)" according" to" the" procedure" reported" above," with" a" RdRp" final" concentration" of"
100nM."The"RNA" template"used"was"a"polyU"sequence"of"around"200"nucleotides"at"a" final"
concentration"of"100nM."ATP"(200µM,"2%"[3H]\ATP)"was"used"for"polymerization"monitoring."
The"assay"was"performed"in"triplicates."
Selected"compounds"were"tested"again"at"different"concentrations,"starting"from"100µM,"for"
IC50" determination" according" to" the" procedure" described" above." Also" in" this" case" the" assay"
was" repeated" in" triplicates," but" the" RNA" template" was" not" a" polyU" sequence," but" with" a"
minigenome,"constituted"of"the"two"UTR"regions"of"DENV"genome."
"
"
"
" "
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6.6.2'CHEMICAL'SYNTHESIS'
"
General.information.
"
All" chemicals," reagents" and" solvents" were" purchased" from" Aldrich" or" purified" by" standard"
techniques."
"
Thin'Layer'Chromatography'(TLC)'
"
Silica" gel" aluminium" backed" plates" (Merck" Kieselgel" 60F254," 0.2" thickness)" were" used." They"
were" developed" by" the" ascending" method." After" solvent" evaporation," compounds" were"
visualised"by"irradiation"with"ultraviolet"(UV)"light"at"254nm"and"366nm."
"
Column'Chromatography''
"
Glass"columns"were"slurry"packed"in"the"appropriate"eluent"under"gravity,"with"gel"silica"(40\
60µm)" from"Merck." Samples" were" applied" as" a" concentrated" solution" in" the" same" eluent."
Fractions"containing"the"product"were"identified"by"TLC,"combined"and"the"solvent"removed"in&
vacuo.""
"
Melting'point'
"
Melting"points"were"determined"using"Griffin"Melting"Point"Apparatus."
"
NMR'Spectroscopy'
"
1H"and"13C"NMR"spectra"were"recorded"on"a"Bruker"ADVANCE"500"spectrometer"(500MHz"and"
125MHz" respectively)" at" 25°C." Spectra" were" auto" calibrated" to" the" residual" signal" of" the"
deuterated" solvent" used." Chemical" shifts" (δ)" are" given" in" parts" per" million" (ppm)" and" the"
coupling"constants"(J)"are"given"in"Hertz"(Hz)."
Abbreviations:"s"(singlet),"d"(doublet),"t"(triplet),"q"(quartet),"m"(multiplet)."
"
Mass'Spectrometry'
"
Low" resolution" mass" spectra" were" recorded" on" a" Bruker" Daltonics" microTOF\LC" Mass"
Spectrometer." Atmospheric" pressure" electrospray" ionisation"method" (ESI)" in" positive" mode"
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and"Time\of\Flight"mass"analyser"with"Exact"Mass"measurements"capability"were"used."Mass\
charge"ration"(m/z)"is"given"in"Da."
Abbreviations:"M\H+"(molecular"ion"signal"given"by"the"addition"of"a"H+"ion),"M\Na+"(molecular"
ion"signal"given"by"the"addition"of"a"Na+"ion)."
"
Elemental'analysis'
"
The" elemental" analysis" was" performed" by"MEDAC" Ltd," Analytical" and" chemical" consultancy"
services."The"values"are"reported"in"percentage."
"
" "
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Synthesis.of.N'4,N''4'Fdi(furanF2Fcarbonyl)F[1,1'Fbiphenyl]F4,4'F
disulphonohydrazide.(109)..
"
Scheme:"
"
"
"
Reaction"conditions:"Pyridine,"0°C"to"r.t.,"4\5"h"
"
The" 2\Furoic" hydrazine" (111," 1.58g," 12.530mmol)" was" dissolved" in" pyridine" (30ml)" and" the"
solution"was" cooled" to"0°C."A" solution"of" the"biphenyl\4,4’\disulphonyl" chloride" (112," 2.00g,"
5.690mmol)"in"pyridine"(50ml)"was"added"to"the"first"solution"and"the"reaction"was"stirred"at"
room" temperature" for" 4\5" hours," monitoring" it" with" TLC" (EtOAc)." The" solvent" was" then"
removed"under"vacuum"and"the"residue"was"washed"with"water."The"solid"was"crystallised"in"
dioxane/water"and"washed"with"ethanol"and"diethylether,"obtaining"a"690mg" (1.300mol)"of"
compound" 109" (N'4,N''4'\di(furan\2\carbonyl)\[1,1'\biphenyl]\4,4'\disulphonohydrazide)" as" a"
white"solid.""
"
Yield:"23%.
"
Chemical"formula:"C22H18N4O8S2"
Molecular"Weight:"530.53"
Monoisotopic"mass:"530.06"
"
"
Aspect:"White"powder"
"
m.p.:"228\230°C"
"
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1H.NMR.(500MHz,"DMSO),"δ:"10.63"(s,"2H),"10.18"(s,"2H),"7.95\7.93"(m,"8H),"7.87\7.86"(Bs,2H),"
7.20"(d,"J=3.4,"2H),"6.62"(dd,"J1=3.4,"J2=1.5,"2H)"
"
13C. NMR. (125MHz," DMSO)," δ:" 156.90" (CH," aromatic)," 146.06" (CH," aromatic)," 145.34" (C,"
aromatic)," 142.41" (C," aromatic)," 139.20" (C," aromatic)," 128.35" (CH," aromatic)," 127.42" (CH,"
aromatic),"115.03"(CH,"aromatic),"111.83"(CH,"aromatic)"
"
ESIFMS.(MeOH)"m/z:"Insoluble"
"
Calculated.elemental.analysis.(%):"C,"49.81;"H,"3.42;"N,"10.56;"S,"12.09"
Experimental.elemental.analysis.(%):"C,"48.91;"H,"3.57;"N,"10.10;"S,"11.44"
"
"
" "
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Synthesis.of.sodium.9HFfluoreneF2,7Fdisulphonate.(113)"
"
Scheme:"
"
"
"
Reaction"conditions:"i)"CH3COOH,"reflux"120°C,"4"h;"ii)"NaOH"
"
Fluorene" (114," 10.0g," 60mmol)" was" added" to" glacial" acetic" acid" (CH3COOH," 60ml)" and" the"
system" was" cooled" to" 0°C." After" drop" wise" addition" of" chlorosulphonic" acid" (115," 8ml,"
120mmol)," the" reaction" mixture" was" refluxed" at" 120°C" under" controlled" atmosphere" and"
monitored"with" TLC" (CHCl3,"MeOH,"CH3COOH)."Other" 4ml"of" chlorosulphonic" acid" (60mmol)"
were" added" after" 2" and" 3" hours" and" the" reaction" reached" completion" after" 4" hours." The"
reaction"mixture"was"poured"into"240ml"of"a"solution"of"sodium"hydroxide"(10g)"in"brine."The"
precipitate"was"filtered,"washed"three"times"with"50ml"of"brine"and"twice"with"distilled"water"
and"it"was"dried"over"night"at"40°C"under"vacuum,"obtaining"20.87g"(56.3mmol)"of"compound"
113"(sodium"9H\fluorene\2,7\disulphonate)"as"a"beige"powder.""
"
Yield:"94%.
"
Chemical"formula:"C13H8Na2O6S2"
Molecular"Weight:"370.31"
Monoisotopic"mass:"369.96"
"
"
Aspect:"beige"powder"
"
1H.NMR.(500MHz,"D2O),"δ:"7.73"(s,"2H),"7.63"(d,"J=8.0,"2H),"7.51"(d,"J\8.0,"2H),"3.43"(s,"2H)"
"
13C.NMR. (125MHz,"D2O),"δ:"144.71"(C,"aromatic),"142.59"(C,"aromatic),"141.41"(C,"aromatic),"
124.35"(CH,"aromatic),"122.08"(CH,"aromatic),"120.78"(CH,"aromatic),"36.43"(CH2)"
"
" "
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Synthesis.of.9HFfluoreneF2,7Fdisulphonyl.dichloride.(116).
Scheme:"
"
! "
"
Reaction"conditions:"i)"120°C,"2h;"ii)"CHCl3,"reflux"60°C,"1"h"
"
Sodium"9H\fluorene\2,7\disulphonate" (113,"1.00g,"2.70mmol)"and"phosphorus"pentachloride"
(122,"1.35g,"6.47mmol)"were"separately"pulverised"in"a"mortar."The"two"powders"were"mixed"
in" a" 10mm" round" bottom" flask" and" stirred" at" 120°C" for" 2" hours." After" cooling" to" room"
temperature,"chloroform"(60ml)"was"added"to"the"formed"pink"paste"and"the"reaction"mixture"
was"refluxed"for"1"hour."The"reaction"mixture"was"washed"three"times"with"50ml"of"distilled"
water." After" separation" of" the" organic" phase," the" solvent"was" removed"under" vacuum." The"
solid" was" then" solubilised" in" a" minimum" quantity" of" chloroform" and" precipitated" with" the"
addition" of" a" minimum" quantity" of" an" antisolvent" (petroleum" ether)." The" precipitate" was"
filtered"and"washed"with"the"antisolvent,"obtaining"480mg"(1.32mmol)"of"compound"116"(9H\
fluorene\2,7\disulphonyl"dichloride)"as"a"pale"yellow"solid."The"reaction"was"repeated"with"the"
same" conditions," using" 1.5g" (4.05mmol)" and" 2.02g" (9.71)" of" 113" and" 122" respectively" and"
obtaining"645mg"(1.78)"of"116."
"
Yield:"50%"and"45%.
"
Chemical"formula:"C13H8Cl2O4S2"
Molecular"Weight:"363.24"
Monoisotopic"mass:"361.92"
"
"
Aspect:"pale"yellow"powder"
"
1H.NMR.(500MHz,"CDCl3),"δ:"8.24"(s,"2H),"8.11"(d,"J=8.2,"2H),"8.04"(d,"J=8.2,"2H),"4.15"(s,"2H)"
"
13C.NMR. (125MHz,"CDCl3),"δ:"145.63"(C,"aromatic),"145.41"(C,"aromatic),"144.3"(C,"aromatic),"
126.8"(CH,"aromatic),"124.17"(CH,"aromatic),"122.26"(CH,"aromatic),"37.32"(CH2)"
" "
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General.procedure.for.the.synthesis.of.compounds.with.a.9HFfluoreneF
2,7Fdisulphonylamide.scaffold.(101\103).
"
Scheme:"
"
"
"
Reaction"conditions:"DIPEA,"DCM,"r.t.,"1.5h"
"
9H\fluorene\2,7\disulphonyl" dichloride" (116," 200mg," 0.55mmol)" was" dissolved" in"
dichloromethane" (DCM," 17ml)" and" the" solution"was" cooled" to" \50°C." Then," the" appropriate"
amine"(117,"0.2ml,"1.55mmol)"and"N,N\diisopropylethilamine"(DIPEA,"0.2ml,"1.15mmol)"were"
added"to"the"solution"in"this"order."The"reaction"mixture"was"stirred"at"room"temperature"and"
monitored"with"TLC"(DCM/EA)"for"1.5"hours."The"solvent"was"then"evaporated"under"vacuum"
and"the"residue"was" treated"with"hydrochloric"acid"1N."The"solid"was" filtrated,"washed"with"
distilled"water"and"dried"over"night"at"40°C"under"vacuum."The"powder"was"then"purified"by"
column"chromatography"(silica"gel,"DCM/EtOAc),"obtaining"the"final"product."
"
"
" "
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Synthesis'of'N2,N7Sbis(1Sphenylethyl)S9HSfluoreneS2,7Sdisulphonamide'(101)'
"
Chemical"formula:"C29H28N2O4S2"
Molecular"Weight:"532.67"
Monoisotopic"mass:"532.15"
"
"
Yield:"66%"(194mg,"0.36mmol).
"
Aspect:"pale"yellow"powder"
"
m.p.:"178\190°C"
"
1H.NMR. (500MHz,"CDCl3),"δ:"7.84\7.79"(m,"6H),"7.17\7.10"(m,"10H),"4.94"(d,"J=6.9,"2H),"4.62\
4.57"(m,"2H),"3.79"(s,"2H),"1.50"(d,"J=6.9,"6H)"
"
13C.NMR.(125MHz,"CDCl3),"δ:"144.28"(C,"aromatic),"143.74"(C,"aromatic),"141.79"(C,"aromatic),"
140.10" (C," aromatic)," 128.48" (CH," aromatic)," 127.50" (CH," aromatic)," 126.36" (CH," aromatic),"
126.16" (CH," aromatic)," 124.12" (CH," aromatic)," 120.86" (CH," aromatic)," 53.88" (CH," aliphatic),"
36.75"(CH2,"aliphatic),"23.70"(CH3,"aliphatic)"
"
ESIFMS.(MeOH)"m/z:"555.1"(M\Na+)"
"
Calculated.elemental.analysis.(%):"C,"65.39;"H,"5.30;"N,"5.26;"S,"12.04"
Experimental.elemental.analysis.(%):"C,"65.29;"H,"5.38;"N,"5.35;"S,"11.84"
"
"
" "
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Synthesis'of'N2,N7Sbis((R)S1Sphenylethyl)S9HSfluoreneS2,7Sdisulphonamide'(102)'
"
Chemical"formula:"C29H28N2O4S2"
Molecular"Weight:"532.67"
Monoisotopic"mass:"532.15"
"
"
Yield:"56%"(165mg,"0.31mmol).
"
Aspect:"pale"yellow"powder"
"
m.p.:"177\180°C"
"
1H.NMR. (500MHz,"CDCl3),"δ:"7.84\7.79"(m,"6H),"7.17\7.09"(m,"10H),"5.10"(d,"J=7.0,"2H),"4.62\
4.56"(m,"2H),"3.77"(s,"2H),"1.49"(d,"J=7.0,"6H)"
"
13C.NMR.(125MHz,"CDCl3),"δ:"144.28"(C,"aromatic),"143.74"(C,"aromatic),"141.82"(C,"aromatic),"
140.11" (C," aromatic)," 128.47" (CH," aromatic)," 127.48" (CH," aromatic)," 126.35" (CH," aromatic),"
126.16" (CH," aromatic)," 124.12" (CH," aromatic)," 120.86" (CH," aromatic)," 53.89" (CH," aliphatic),"
36.75"(CH2,"aliphatic),"23.70"(CH3,"aliphatic)"
"
ESIFMS.(MeOH)"m/z:"555.1"(M\Na+)"
"
Calculated.elemental.analysis.(%):"C,"65.39;"H,"5.30;"N,"5.26;"S,"12.04"
Experimental.elemental.analysis.(%):"C,"65.33;"H,"5.24;"N,"5.21;"S,"11.91"
"
"
" "
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Synthesis'of'N2,N7Sbis((S)S1Sphenylethyl)S9HSfluoreneS2,7Sdisulphonamide'(103)'
"
Chemical"formula:"C29H28N2O4S2"
Molecular"Weight:"532.67"
Monoisotopic"mass:"532.15"
"
"
Yield:"73%"(215mg,"0.40mmol).
"
Aspect:"pale"yellow"powder"
"
m.p.:"173\176°C"
"
1H.NMR. (500MHz,"CDCl3),"δ:"7.84\7.79"(m,"6H),"7.16\7.08"(m,"10H),"5.06"(d,"J=7.0,"2H),"4.62\
4.57"(m,"2H),"3.78"(s,"2H),"1.49"(d,"J=7.0,"6H)"
"
13C.NMR.(125MHz,"CDCl3),"δ:"144.28"(C,"aromatic),"143.74"(C,"aromatic),"141.82"(C,"aromatic),"
140.11" (C," aromatic)," 128.46" (CH," aromatic)," 127.47" (CH," aromatic)," 126.35" (CH," aromatic),"
126.17" (CH," aromatic)," 124.12" (CH," aromatic)," 120.86" (CH," aromatic)," 53.89" (CH," aliphatic),"
36.75"(CH2,"aliphatic),"23.70"(CH3,"aliphatic)"
"
ESIFMS.(MeOH)"m/z:"555.1"(M\Na+)"
"
Calculated.elemental.analysis.(%):"C,"65.39;"H,"5.30;"N,"5.26;"S,"12.04"
Experimental.elemental.analysis.(%):"C,"65.46;"H,"5.33;"N,"5.37;"S,"11.88"
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Drug" discovery" on" DENV" has" been" shown" to" be" challenging" in" the" last" decades," and" the"
development"of"novel"therapeutic"agents"is"still"an"unmet"need"to"date."In"order"to"meet"this"
need,"this"PhD"study"had"the"overarching"aim"to"design"novel"molecules"as"potential"antiviral"
agents"against"DENV."This"main"aim"was" subdivided" in" three"parts:" to" identify" suitable"drug"
targets,"to"generate"knowledge"on"these"targets"and"to"design"novel"antiviral"agents"against"
DENV"infection."
With" the" aim" of" identifying" suitable" drug" targets," four" promising" strategies" to" target" viral"
proteins" were" identified." The" proteins" were:" the" capsid" structural" protein" (C)," the"
NTPase/helicase"portion"of"NS3"(NS3hel),"the"methyltransferase"domain"of"NS5"(NS5"MTase)"
and"the"RNA\dependent"RNA"polymerase"part"of"NS5"(NS5"RdRp)."All"of"them"are"essential"for"
DENV"replication"and"are"not"present"in"humans,"aiding"the"design"of"potential"selective"anti\
DENV"agents."
With" the" aim" of" improving" the" understanding" of" the" molecular" targets," this" work" has"
successfully" uncovered" important" and" novel" knowledge" about" DENV," through" two" basic"
research"studies.""
As" discussed" in" section" 2," molecular" modelling" and" docking" simulations" have" shown" a"
promising"anti\DENV"compound"(ST\148)"active"against" the"virus"both" in&vitro"and" in&vivo" to"
inhibit"the"capsid"protein"(C)"through"the"stabilisation"of"higher\order"oligomeric"C"structures,"
confirming" that" protein\protein" interaction" stabilisation" is" an" achievable" and" valid" tool" for"
antiviral"drug"discovery.[1]"The"understanding"of"the"mechanism"of"action"of"this"compound"is"
an" important" discovery" that" should" allow" the" development" of" ST\148\like" molecules" that"
might" succeed" in" the" discovery" of" a"medicine" able" to" reach" the"market" for" DENV" infection"
therapy."
In" another" study" presented" in" section" 4," a" novel" approach" that" included" classical" and"
accelerated" MD" simulations," principal" component" analysis" and" binding" free" energy"
calculations" has" produced" relevant" results" for" understanding" the" mechanism" of" NS3hel"
translocation"along"the"RNA"strand"that"other"studies"were"unable"to"reveal.[2]"Thus," for"the"
first" time" it" has" been" possible" to" formulate" a" hypothesis" according" to" which" the" 3’\5’"
translocation" of" NS3hel" involves" both" large" scale" domain" movements" and" small" residue"
conformation" changes" and" occurs" in" a" NTP\driven" “ratchet\like”" manner," similarly" to" HCV."
Residues" particularly" important" in" the" translocation" mechanism" and" directionality" were"
identified"and"could"be"used"for"future"drug"design"approaches."
With"the"aim"of"discovering"novel"antiviral"agents,"drug"discovery"approaches"have"also"been"
applied"using"the"interaction"of"different"disciplines."Several"molecular"modelling"techniques,"
classical" Medicinal" Chemistry" approaches," chemical" synthesis" and" in& vitro" assays" were"
combined"and"have"been"applied" to" the" four" viral\encoded"proteins" identified" as" promising"
drug"targets."Even"if"challenges"were"encountered"in"all"the"fields,"problems"were"found"with"
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the" in&vitro"assays"that"did"not"always"allow"an"understanding"of"the"activity"of"the"designed"
compounds," in"particular" for"NS3hel" and"NS5"RdRp" inhibitors" (discussed" in" sections"3"and"6"
respectively)."For"instance,"some"assays"were"not"returning"consistent"results"when"repeated"
with" the" same" or" slightly" different" conditions." For" example," the" fluorescence" polarisation"
assay"with"GTP"bodipy"did"not"return"consistent"results"and"changing"the"polymerase"activity"
inhibition" assay" from" using" 3H\labelled" nucleotides" to" the" fluorescent" probe" PicoGreen"
changed" the" IC50" values" for" compound"80." In" general," in" the" structure\activity" relationships"
definition" the" cell" activity" assays" was" less" informative" than" in" the" biochemical" assays,"
suggesting" that" the" latter" should" be" considered" the" primary" activity" assays." Many" factors"
might" explain" this," including" difficulty" to" cross" the" cell" membrane," intracellular" molecule"
sequestration," interaction" etc." Consequently," the" reliability" of" in& vitro" assays" has" been"
confirmed"to"be"an"issue"that"has"slowed"down"anti\DENV"drug"discovery"and"that"has"yet"to"
be"resolved."However,"the"cellular"cytotoxicity"seen,"especially"at"high"concentrations"did"raise"
issues"with"some"chemical"scaffolds"and"aided"in"selecting"molecules"to"study"further."
Furthermore,"the"assays"have"not"generally"been"repeated"in"more"than"one"DENV"serotype"
and" consequently" the" attention" given" in" drug"design" to" the"potential" serotype" specificity" of"
the"compounds"could"not"be"assessed."
Despite" these" issues," the" molecular" modelling\based" drug" discovery" studies" returned"
molecules"with" IC50s" in"the" low"µM"range,"making"them"good" leads"for"further"development"
and"compatible"with"published"DENV"inhibitors.[3,4]"
Based"on"co\crystallised"fragments"that"inhibited"DENV"NS5"MTase,"two"fragment\based"drug"
discovery" (FBDD)" approaches"were"applied" to" this" enzyme"and"were"discussed" in" section"5."
Even"if"very"few"iterations"of"compound"design"and"evaluation"have"been"performed,"activity"
improvement"(sometimes"over"100\fold"for"2’\O"methylation)"was"achieved"for"one"scaffold,"
indicating" that" the" designed" drug" design" method" is" moving" in" the" right" direction" and"
confirming"FBDD"as"a"suitable"multidisciplinary"approach"for"the"development"of"NS5"MTase"
inhibitors."Future"improvements"of"the"designed"molecules"should"lead"to"the"development"of"
promising"drugs"against"DENV"infection."The"activity"pattern"was"also"explored"with"molecular"
modelling"for"one"of"the"co\crystallised"fragments"and"it"was"hypothesised"that"it"could"act"as"
a"S\adenosyl"methionine"(SAM)"competitive"inhibitor.""
In" sections" 3" and" 6" several" virtual" screening" campaigns" based" on" different" general"
methodologies" were" applied" to" NS3hel" and" NS5" RdRp" with" the" aim" of" selecting" putative"
inhibitors" from" a" database" of" drug\like" small" molecules" (generally" SPECS)" were" discussed."
Identified" hit" molecules" were" further" progressed" through" the" assessment" of" analogue"
compounds" that"were" purchased" or" synthesised" and" for" some" series" preliminary" structure\
activity"relationships"were"suggested.""
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One"of" the"virtual" screening" campaigns"was"a" ligand\based" shape" screening," as"discussed" in"
section" 3." This" was" grounded" on" the" hypothesis" that" shape" complementarity" between" two"
molecules," as" well" as" their" surface" properties," is" fundamental" for" the" strength" of" the"
interaction"between"them."Ouabain,"a"natural"product"that"was"found"to"inhibit"NS3hel,"was"
used"as"a"reference"and"compounds"with"a"similar"shape"were"searched."Thus,"a"novel"series"
of" NS3hel" inhibitors" have" been" identified," validating" NS3hel\RNA" complex" disruption" as" an"
anti\DENV"drug"development"strategy"and"supporting"the"study’s"basic"hypothesis."
All" the" other" virtual" screening" campaigns" were" structure\based." Unfortunately," the" two"
designed"to" target" the"NTP"and"the"RNA"binding"site"confirmed"that"NS3hel" is"a"challenging"
drug" target" and" did" not" return" promising" inhibitors" (section" 3)." However," as" discussed" in"
section"6,"one"of"the"two"designed"approaches"that"aimed"the"inhibition"of"NS5"RdRp"through"
an" allosteric" inhibition" approach" was" successful" in" identifying" two" novel" chemical" scaffolds"
with"different"in&vitro"activity"profiles"that"probably"bind"to"the"polymerase"site"D."Thus,"DENV"
NS5" RdRp" was" validated" as" an" antiviral" target" and" the" design" of" non\nucleoside" inhibitors"
(NNIs)" was" confirmed" as" a" valid" drug" development" strategy." Four" compounds" were" also"
synthesised," confirming" the" activity" of" 100" and" identifying" a" synthesis" pathway" for" 9H\
fluorene\2,7\disulphonamide\based"compounds."Even"if"cell\"and"enzyme\based"assay"results"
were" not" always" consistent," preliminary" structure\activity" relationships" (SARs)" could" be"
established." Aiming" to" improve" these" compounds’" activity," and" cytotoxicity," these" scaffolds"
could"be"further"developed" in"the"future," through"constructed"SARs"and"suggested"chemical"
synthetic" approach." Although" no" promising" inhibitors" were" identified"with" the" other" RdRp\
based" virtual" screening" approach" presented" in" section" 6," this" study" identified" the" putative"
binding" pocket" for" the" published" N\sulphonylanthranilic" acid" derivative" RdRp" allosteric"
inhibitors," returning" an" important" novel" piece" of" information" that" corroborates" polymerase"
site"C"as"a"potential"molecular"target"for"the"design"of"novel"anti\DENV"antiviral"agents.""
In" summary," this" PhD" study" has" made" a" positive" step" forward" in" anti\DENV" research:" an"
increase" in" the"basic"understanding"on"DENV," in"particular" about" the"viral" enzymes"and" the"
approaches"that"can"be"adopted"for"the"development"of"anti\DENV"drugs"was"achieved,"novel"
promising" DENV" inhibitor" scaffolds" have" been" discovered" and" developed" and" the" chemical"
synthesis"of"one"of"them"was"suggested."
" "
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APPENDIX.1:.VACCINES.AND.DRUGS.IN.
DEVELOPMENT.
"
The" vaccines" and" drugs" in" development" for"DENV" are" reported" in" three" tables:" one" for" the"
vaccines" in"clinical"trials,"one"for"the"drugs"developed"to" inhibit"viral"targets"and"one"for"the"
drugs"designed" to" target"host"proteins."References"about" the" reported"molecules"are"at" the"
end"of"the"appendix."
"
Table'A1.1..Status.of.DENV.vaccine.development.onFgoing.in.clinical.trials..
Vaccine.
type. Developers. Description. Doses. Status.
LI
VE
.A
TT
EN
U
AT
ED
.V
IR
U
S.
VA
CC
IN
ES
.
(L
AV
).
WRAIR"and"GSK"
DENV"attenuated"by"
several"passages"in"dog"
kidney"cells;"
Tetravalent"formulation"
2"
Phase.II.completed[1]"
Proven"to"be"safe"and"
immunogenic"but"protective"
efficacy"needs"to"be"
evaluated"
(delayed)"
NIH,"NIAID,"LID,"
Biological"E."
(Panacea),"Biotec"
(Butantan),"
Vabiotech"
Reverse"genetics"
application:"deletion"of"30"
nucleotides"in"the"3’"
untranslated"region"(UTR)"
of"the"genome"of"all"four"
DENV"serotypes"
(TVA003)"
2" Phase.II[2].
LI
VE
.C
H
IM
ER
IC
.V
IR
U
S.
VA
CC
IN
ES
.
CDC,"Takeda"
Structural"genes"from"
DENV1,"3"and"4"are"
inserted"in"a"DENV2"
attenuated"genome"
(replacement"of"the"3’"
loop"structure)."
(DENVax)"
2" Phase.II[3].
Sanofi"Pasteur"
The"licensed"YFV"17D"
vaccine"is"used"as"a"
backbone"for"the"
expression"of"all"four"
DENV"prM"and"E"proteins."
(CYDATDV)"
3"
Phase.III[4]"
but"Phase"IIb"showed"only"
30%"effectiveness"and"
efficacy"only"on"DENV1,"3"
and"4."
PU
RI
FI
ED
.
IN
AC
TI
VA
TE
D
.
VI
RU
SE
S.
(P
IV
).
GSK,"WRAIR,"
FIOCRUZ"
Whole"inactivated"DENV1,"
2,"3"and"4"with"a"GSK"
adjuvant"
(DPIVA001)"
2" Phase.I[5].
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D
N
A.
VA
CC
IN
E.
NMRC"(USA)"
All"serotypes"DENV"prM"
and"E"genes"inserted"in"a"
non\replicating"adenovirus"
vector;"
With/without"adjuvant"
(TVDV)"
3" Phase.I[6].
RE
CO
M
BI
N
AN
T.
SU
BU
N
IT
S.
Hawaii"Biotech,"
Merck"
Recombinant"truncated"
(80%"of"protein)"DENV1,"2,"
3"and"4"E"proteins"with"
native\like"conformation,"
cultured"in"Drosophyla"
cells;"
With/without"adjuvant"
(V180)"
3" Phase.I[7].
Abbreviations:"WRAIR,"Walter"Reed"Army"Research"Institute;"GSK,"GlaxoSmithKline;"NIH,"National"Institute"of"Health;"
NIAID,"National"Institute"of"Allergy"and"Infectious"Diseases;"LID,"Laboratory"of"Infectious"Diseases;"CDC,"Center"for"Disease"
Control;"FIOCRUZ,"Oswaldo"Cruz"Foundation;.NMRC,"Naval"Medical"Research"Center"
"
" "
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Table'A1.2..Potential.inhibitors.of.viral.targets..
Name. Drug.Discovery.Method. Target. In.vitro.activity.
In.vivo.
activity. Progress.
NITD448[8].
(s.m.).
In&silico"virtual"
screening"and"in&
vitro"validation"
E.
(βOG"
pocket)"
Inhibits"membrane"
fusion"and"viral"
entry"
ND" Interrupted"
(poor"
selectivity"
and"Pk)"
“Thiophene"
quinazoline”[9].
(s.m.)"
In&silico"virtual"
screening"and"in&
vitro"validation"
E.
(βOG"
pocket)"
Interacts"with"E"
protein"and"blocks"
entry"after"
internalisation"in"
endosomes."
Active"also"against"
YFV,"WNV,"JEV."
ND""
(precipitation"
in"mouse"
model"GI"
tract)"
Interrupted"
(no"in&vivo"
validation)"
P02[10]"
(s.m.).
In&silico"virtual"
screening"and"in&
vitro"validation"
E.
(βOG"
pocket)"
Interacts"with"E"
(competition"with"
βOG"assessed)"and"
inhibits"DENV"and"
YFV."
ND" No"follow"
up"studies"
reported"
A5[11]"
(s.m.).
In&silico"virtual"
screening"and"in&
vitro"validation"
E.
(βOG"
pocket)"
Inhibits"E\mediated"
fusion"and"is"active"
against"DENV,"YFV"
and"WNV."Not"
cytotoxic."
ND" No"follow"
up"studies"
reported"
1662G07[12]"
(s.m.).
HTS,"using"FP"
based"on"
competition"
with"a"binding"
peptide"
E.
(βOG"
pocket)"
Inhibits"DENV2"
fusion"and"interacts"
with"both"pre\"and"
post\fusion"E"
ND" Interrupted"
(No"
sufficiently"
broad"
spectrum)"
DN59[13,14].
(p.).
Synthetic"
peptides"
(portions"of"E)"
tested"with"
plaque"
formation"
inhibition"assay"
E.
(sequence:"
conserved"
stem"
region)"
Broad"spectrum"
flavivirus"inhibitor"
(DENV,"WNV,"JEV,"
TBEV),"inducing"the"
production"of"
empty"virions."It"
binds"to"lipid"
bilayers"and"
trimeric"E"proteins"
ND" Further"
studies"
needed""
(peptide\
related"issues"
for"drug"
discovery)"
1OAN1[14,15]"
(p.).
Peptides"with"in&
silico"optimised"
sequences"
E.
(sequence:"
mimic"of"β\
sheet"
connecting"
domains"I"
and"II)"
Binds"to"DENV2"
soluble"E"and"
inhibits"DENV2"
binding"to"target"
cells"
ND" Further"
studies"
needed""
(but"it"has"
peptide\
related"issues"
for"drug"
discovery)"
Antibiotic"SA\
17[16,17]"
(s.m.).
CPE"on"DENV2"
infected"cells"of"
doxorubicin"
analogues"
E.
(βOG"
pocket,"
according"to"
docking"
simulation)"
Broad"spectrum"
inhibition:"DENV"(1,"
2"and"3),"YFV."It"
binds"directly"to"
viral"particle,"
blocking"the"entry"
in"host"cells."
"
"
"
ND" On\going"
preclinical"
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Antibiotic"LCTA\
949[18]"
CPE"on"DENV2"
infected"cells"of"
teicoplanin"
aglycon"
derivatives"
Entry.
(unknown"
target)"
Broad"spectrum"
entry"inhibition:"
DENV,"YFV,"WNV,"
JEV,"TBEV"
ND" No"follow"
up"studies"
reported"
3\O\sulphated"
glucuronide"
derivatives[19].
(s.m.)"
Design"and"
synthesis"of"
compounds,"
based"on"
carbohydrate"
structures"of"
active"glycans"
E.
(probably"
absorption"
binding"site)"
Inhibits"cell"
infection"and"virion"
binding"to"host"
cells."
ND" No"follow"
up"studies"
reported"
ST\148[20,21]"
(s.m.).
HTS"of"
compounds"on"
DENV\infected"
cells"
C.
(C\C"
proteins"
interface)"
Inhibits"cell"
infection,"reducing"
both"virion"
assembly"and"
disassembly."It"
binds"to"C"and"
enhances"C\self"
aggregation."
Efficacious"in"
AG\129"
mouse"
model."
On\going"
preclinical"
Retro"tripeptide[22]"
(p.).
Substrate"
mimetics"(with"
aromatic"N\
termini)"
screening"
NS3F2B.
protease.
(competiti\
ve"inhibitor)"
Active"on"DENV"
and"WNV"
proteases."
ND" No"follow"
up"studies"
reported"
Cyclic"peptide[23]"
(p.).
Screening"of"
natural"peptides"
and"optimisation"
by"cyclisation"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
protease,"probably"
binding"to"the"
active"site"
(docking)."
Permeates"cells,"
but"no"EC50"
reported."
ND" No"follow"
up"studies"
reported"
Tetrapeptide[24]"
(p.).
Screening"of"
aldehyde"
tetrapeptides"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
protease,"probably"
binding"to"the"
active"site"
(docking)."
ND" No"follow"
up"studies"
reported"
α\ketoamides[25]"
(s.m.).
HTS"and"SAR"
study"
NS3F2B.
protease.
Active"on"DENV"
and"WNV"
proteases"and"on"
DENV"infected"
cells."
ND" No"follow"
up"studies"
reported"
Phthalazine"
derivatives[26]"
(s.m.).
HTS"on"protease"
and"SAR"study"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
protease,"but"not"
active"on"cells"
(permeability"
issues)."
ND" No"follow"
up"studies"
reported"
166347[27]"
(s.m.).
HTS"on"protease"
and"SAR"study"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
and"WNV"
proteases,"but"not"
active"on"cells"
(permeability"
issues)."
"
"
ND" No"follow"
up"studies"
reported"
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Anthracene"
based[28,29]"
(s.m.).
Virtual"screening"
of"small"
molecules"and"
SAR"studies"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
protease"and"in"
infected"cells."
ND" No"follow"
up"studies"
reported"
Aminobenzamide"
scaffold[30]"
(s.m.).
Rational"design"
of"
aminobenzami\
de"derived"
compounds."
NS3F2B.
protease.
Active"on"DENV"
and"WNV"
proteases,"but"not"
active"on"cells."
ND" No"follow"
up"studies"
reported"
Quinoline"
derivatives[31]"
(s.m.).
Virtual"screening"
and"scaffold"
hopping."
NS3F2B.
protease.
Active"on"DENV"
protease"and"in"
DENV"replicon"
assay"
ND" No"follow"
up"studies"
reported"
1,3,4\oxadiazole"
derivatives[32]"
(s.m.)"
Screening"of"a"
focused"library"
of"synthesised"
compounds."
NS3F2B.
protease.
Active"on"DENV"
and"WNV"
proteases."
Unknown"activity"
on"cells."
ND" No"follow"
up"studies"
reported"
8\
hydroxyquinoline"
derivatives[33]"
(s.m.)"
SAR"study"on"
previously"
identified"WNV"
protease"
inhibitors"
NS3F2B.
protease.
(competiti\
ve"inhibitor).
Active"on"DENV"
and"WNV"
proteases."
Unknown"activity"
on"cells."
ND" No"follow"
up"studies"
reported"
BP2109[34]"
(s.m.)"
HTS"on"infected"
cells"
NS3F2B.
protease.
Active"on"DENV"
infected"cells"and"
causes"mutations"in"
NS3"protease"in"
resistant"viruses."
ND" No"follow"
up"studies"
reported"
Ivermectin[35,36,37]"
(s.m.).
Docking"and"
enzymatic"assay"
NS3hel.
(RNA"
binding"site"
competitive"
inhibitor)"
Broad"spectrum"
(DENV,"WNV,"YFV)"
inhibition"of"dsRNA"
unwinding"and"
active"on"DENV"
NS3\2B"protease."
More"active"for"
WNV"and"YFV"in"
cells."
ND" No"follow"
up"studies"
reported"
Ouabain,"
Avermectin[37]"
(s.m.).
Docking"and"
enzymatic"assay"
NS3hel.
(RNA"
binding"site"
competitive"
inhibitor).
Broad"spectrum"
(DENV,"WNV,"YFV,"
TBEV)"inhibition"of"
unwinding."
ND" No"follow"
up"studies"
reported"
ST\610[38]"
(s.m.).
HTS"on"infected"
cells"
NS3hel.
(RNA"
binding"site).
Inhibits"cell"
infection"in"all"
DENV"serotypes"
and"a"mutation"on"
NS3hel"RNA"
binding"pocket"
(A263T)"causes"
resistance."It"
inhibits"unwinding"
activity."
"
"
"
"
Efficacious"in"
AG\129"
mouse"
model."
No"follow"
up"studies"
reported"
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NITD\618[39]"
(s.m.).
HTS"on"DENV2"
replicon"
NS4B.
"
Selective"DENV"(1\
4)"inhibitor."
Resistant"viruses"
present"A119T"and"
P104L"mutations."
The"latter"is"
important"for"
NS4B\NS3hel"
interactions."
Poor"Pk"for"
testing"
No"follow"
up"studies"
reported"
Lycorine[40]"
(s.m.).
HTS"on"WNV"and"
DENV1"replicons"
and"SAR"study"
NS4B. Selective"inhibitor"
of"DENV"and"WNV"
RNA"replication."
Resistant"virus"
mutations"(V9M)"
suggest"it"interacts"
with"NS4B."
ND" No"follow"
up"studies"
reported"
SDM25M[41]"
(s.m.).
HTS"on"DENV2"
replicon"
NS4B. Inhibitor"of"DENV."
Resistant"viruses"
develop"a"mutation"
(F164L)"on"NS4B."
Also"the"reported"
P104L"mutation"on"
NS4B"confers"
resistance."
ND" No"follow"
up"studies"
reported"
SAH"analogue[42]"
(s.m.).
Structure\based"
drug"design"and"
SAR"
NS5.
MTase.
(SAM"
binding"
pocket)"
It"is"a"competitive"
inhibitor,"selective"
for"DENV"NS5"
MTase"over"human"
MTases."Cell"
permeability"
problems."
ND" No"follow"
up"studies"
reported"
Aadamantan"
ureidopropanoic"
acid"derivative[43]"
(s.m.).
HTVS" NS5.
MTase.
(2’O"MTase,"
putative"
SAM"
binding"
pocket)"
It"inhibits"2’O"
methylation."
Docking"predicted"
competition"with"
SAM."
ND" No"follow"
up"studies"
reported"
ATA[44]"
(s.m.).
VS" NS5.
MTase.
(putative"
RNA"binding"
site)"
It"inhibits"both"N7"
and"2’O"
methylation"of"
DENV"and"WNV."
ND" No"follow"
up"studies"
reported"
Ribavarin[45]"
(s.m.).
Binding"and"
crystal"structure"
NS5.
MTase.
(GTP"site)"
Inhibits"NS5"MTase." Not"
efficacious"on"
humans"
Interrupted"
Sinefungin[45]"
(s.m.)"
Binding" NS5.
MTase.
(SAM"site).
Inhibits"DENV"NS5"
MTas"but"it"
interacts"also"with"
host"factors"
"
"
"
"
"
"
ND" Interrupted"
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NITD008[46]"
(s.m.).
Design"of"
adenosine\based"
nucleoside"
analogues"
NS5.
RdRp.
(NI).
Broad"spectrum"
inhibitor"of"several"
flaviviridae"
(DENV1\4,"WNV,"
YFV,"PV,"HCV)."
Triphosphate"
inhibits"NS5"RdRp"
through"chain"
termination."
Efficacious"in"
AG\129"
mouse"
model."
Interrupted"
(2"weeks"
toxicology"
problems)"
NITD203[47]"
(s.m.).
Design"of"
adenosine\based"
nucleoside"
analogues"
(prodrug"of"
NITD449)"
NS5.
RdRp.
(NI).
Broad"spectrum"
inhibitor"of"several"
flaviviridae"
(DENV1\4,"WNV,"
YFV,"HCV)."It"
inhibits"RNA"
synthesis"in"DENV"
replicon."
Efficacious"in"
AG\129"
mouse"
model."
Prodrug"was"
necessary"for"
Pk"
improvement
."
Halted""
(2"weeks"
toxicology"
problems)"
Balapiravir[48,49]"
(s.m.).
Cytidine"analog"
prodrug"
developed"for"
HCV"
NS5.
RdRp.
(NI).
Active"in"DENV"
replicon"assay."
Phase"II"
clinical"trials"
did"not"show"
neither"
clinical"nor"
virological"
improvement
."
Probably"due"
to"decreased"
phosphorila\
tion."
Interrupted"
N\
Sulfonylanthranilic"
Acid"
Derivatives[50,51,52]"
(s.m.).
HTS"with"RdRp"
enzymatic"assay"
NS5.
RdRp.
(NNI).
Inhibits"DENV"NS5"
RdRp"and"binds"in"
the"RNA"tunnel."
Poor"activity"in"
CPE."
ND" No"follow"
up"studies"
reported"
Abbreviations:.s.m.="small"molecule;"E="envelope"protein;"βOG="β\N\octyl\glucoside;"ND="not"determined;"Pk="
pharmacokinetics;"GI="gastrointestinal;"YFV="Yellow"Fever"Virus;"WNV="West"Nile"Virus;"JEV="Japanese"Encephalitis"Virus;"DENV="
Dengue"Virus;"HTS="High"Throughput"Screening;"FP="Fluorescence"Polarisation"assay;"p.="peptide;"TBEV="Tick\Borne"Encephalitis"
Virus;"CPE="CytoPathic"Effect"inhibition"assay;"C="capsid;"SAR="Structure"Activity"Relationships;"NS3hel="NS3"helicase/NTPase;"
NS5.MTase="NS5"methyltransferase;"MTase="methyltransferase;"HTVS="High"Throughput"Virtual"Screening;"VS="Virtual"
Screening;"GTP="Guanosine"triphosphate;"NS5.RdRp="NS5"RNA\dependent"RNA"polymerase;"NI="Nucleoside"Inhibitor;"PV="
Powassan"Virus;..
"
" "
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Table'A1.3..Potential.host.target.inhibitors..
Name.
Drug.
Discovery.
Method.
Target. In.vitro.activity. In.vivo.activity. Progress.
Benzomorphane"
derivatives[53].
(s.m.).
CPE\based"
HTS"and"SAR"
evaluation"
TranslaF
tion.
(unknown"
target)"
Inhibits"RNA"
translation"through"
interaction"with"host"
factors."Broad"
flavivirus"spectrum"
(DENV,"YFV,"WNV)"
Efficacious"on"
AG\129"mice"
Interrupted"
(adverse"
effects"at"
higher"doses)"
AP30451[54].
(s.m.)"
Replicon\
based"HTS"
Early.
translaF
tion.
(unknown"
target)"
Inhibits"RNA"
translation"through"
interaction"with"host"
factors."Broad"
flavivirus"spectrum"
(DENV,"YFV,"WNV,"
Kunjin"virus)"
ND""
"
On\going"
SAR"studies"
Isoxazole\pyrazole"
derivatives[55]"
(s.m.).
CPE\based"
HTS"
DHODH. Inhibits"DENV"in"
infected"cells"through"
host"DHODH"
inhibition"and"
consequent"U"
depletion."Broad"
spectrum:"flavivirus"
(YFV,"WNV,"DENV),"
hepacivirus"(HCV),"
alphavirus"(WEEV)"
rhabdovirus"(VSV),"
retroviruses"(HIV)"
Not"efficacious"
on"AG\129"
mouse"model"
(due"to"U"
uptake"from"
diet)"
Interrupted"
(lack"of"
efficacy"in"
vivo)"
ETAR[56]"
(s.m.).
Ribavirin"
analogues"
screening"
IMPDH. Inhibits"DENV"in"
infected"cells"through"
host"IMPDH"inhibition"
and"consequent"GMP"
depletion."Broad"
spectrum:"DENV1\4,"
LGTV,"MODV"
ND" No"follow"
up"studies"
reported"
AZD0530"and"
Dasatinib[57]"
(s.m.)"
Replicon\
based"HTS"
Fyn.
kinase.
(ATP"
binding"
site)"
Inhibit"RNA"replication"
through"inhibition"of"
Fyn"kinase."Resistant"
viruses"present"the"
T108I"mutation"on"
NS4B."
ND" No"follow"
up"studies"
reported"
Celgosivir[57,58,59,60]"
(s.m.).
Prodrug"of"a"
natural"
product"with"
known"ER"
glucosidase"
inhibition"
activity."
αF
glucosiF
dase.I.
and.II.
Effective"against"
DENV1\4."Impedes"
NS1"correct"folding"
through"α\
glucosidases"(I"and"II)"
inhibition"at"nM"
concentration."
Efficacious"on"
AG\129"mouse"
model."
Phase"Ib"
clinical"trial:"
safe"
compound;"
non\significant"
reduction"of"
viral"load"and"
fever."
"
"
On\going"
(Next"clinical"
trial"will"be"
improved"
with"dose"
frequency"or"
multi\therapy"
adjustments)"
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U18666A[61]"
(s.m.).
Known"
compound"
that"inhibits"
intracellular"
trafficking"of"
cholesterol."
. Blocks"DENV"entry"
and"intracellular"
trafficking"(in"
cholesterol\loaded"
late"endosomes)"and"
inhibits"de"novo"
sterols"synthesis,"
producing"antiviral"
effect."
ND" No"
following"
studies"
reported"
Abbreviations:.s.m.=.small"molecule;"CPE="CytoPathic"Effect"inhibition"assay;"HTS="High"Throughput"Screening;"SAR="Structure"
Activity"Relationships;"DENV="Dengue"Virus;"YFV="Yellow"Fever"Virus;"WNV="West"Nile"Virus;"ND="not"determined;"DHODH="
Dihydroorotate"Dehydrogenase;"HCV="Hepatitis"C"Virus,"WEEV="Western"Equine"Encephalitis"Virus,"VSV="Vesicle"Stomatitis"Virus;"
HIV=Human"Immunodeficiency"Virus;"IMPDH="Inosine"Monophaosphate"Dehydrogenase;"LGTV="Langat"Virus;"MODV="Modoc"
Virus;.
"
"
"
" "
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APPENDIX.2:.INTRODUCTION.TO.USED.
MOLECULAR.MODELLING.PROGRAMS..
"
SCHRÖDINGER.MAESTRO.GLIDE".
"
Maestro" is" the" unified" graphical" interface" for" all" the" products" of" Schrödinger," a" provider" of"
chemical"simulation"software"for"use"in"pharmaceutical,"biotechnology"and"materials"science"
research." This" program" gives" the" possibility" to" perform" different" types" of" computational"
chemistry"analysis"and"Glide"(Grid\based"Ligand"Docking"with"Energetics)"is"the"algorithm"used"
for"docking"calculations.[1]""
The"docking"calculation"operated"with"Glide"can"be"run"in"rigid"or"semi\flexible"modes."In"the"
first"case,"ligands’"input"conformations"are"placed"as"they"are"in"the"receptor"pocket"and"only"
rotation"and"translation"degrees"of"freedom"are"used"for"pose"generation;"while"if"the"semi\
flexible"approach" is" chosen," the"generation"of"poses"produces" several" ligand"conformations."
The" conformational" search" is" conducted" by" dividing" each" ligand" into" a" core" and" rotamer"
groups"and"the"number"of"final"conformations"depended"on"the"number"of"rotatable"bonds,"
conformationally" labile" 5\" and" 6\" membered" rings," and" asymmetric" pyramidal" trigonal"
nitrogen"centres.[1]"
Both" in" rigid"and"semi\flexible"docking"modes," the"protein"binding"site"must"be" input" to" the"
program" for" the" evaluation" of" the" interactions."Glide" represents" the" target" site"with" a" grid,"
which"points"contain"informations"about"the"shape"and"the"properties"of"the"cleft."The"grid"is"
positioned"by"using" a" box" centred" in" the"binding" site"by" the"user." The"box"must" contain" all"
ligand" atoms" for" correct" docking," therefore" the" size" is" calibrated" during" the" receptor" grid"
calibration."A"smaller"box" is"also"created"by" the"program"during"grid"preparation."This" inner"
box"has"the"same"centre"of"the"outer"one"and"it"describes"the"space"region"in"which"the"small"
molecule’s"centre"(the"midpoint"between"the"two"furthest"atoms"of"the"core"region)"is"initially"
positioned"during"the"placement.[1]"
In"all"docking"modes,"the"produced"poses"pass"through"a"series"of"hierarchical" filters"for"the"
evaluation" of" the" interactions" with" the" protein." In" this" filtering" process," the" first" pose"
assessment"is"computed"through"the"Schrödinger’s"discretized"version"of"an"empirical"scoring"
function"in"which"favourable"hydrophobic,"hydrogen\bonding,"and"metal\ligation"interactions"
are" rewarded," and" steric" clashes" are" penalized." The" ligand" conformations" can" then" be"
minimized"and"at"the"end"of"the"process,"the"refined"poses"are"re\scored"with"a"Schrödinger’s"
registered"GlideScore"scoring"function,"reported"in"Equation"A2.1.[1]"
"
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!"#$%& = 0.065 ∗ !"# + 0.130 ∗ !"#$ + !"#$ + !"#$% +!"#$% + !"#$% + !"#$ + !"#$"
Equation'A2.1..GlideScore.scoring.function.[1].
vdW="van"der"Waals"energy;"Coul="Coulomb"energy;"Lipo="lipophilic"term;"Hbond="hydrogen\bonding"term;"Metal="
Metal\binding"term;"BuryP="penalty"for"buried"polar"groups;"RotB="penalty"for"freezing"rotatable"bonds;"Site="polar"
interactions"in"the"active"site"
With"Maestro" Glide" software" it" is" possible" to" choose" between" three" precision"modes:" high"
throughput" virtual" screening" (HTVS)," standard" precision" (SP)" and" extra" precision" (XP)." The"
precision" mode" determines" the" number" of" energy" components" that" are" considered" in" the"
pose"scoring"and"consequently"the"scoring"function"complexity"and"the"calculation"time."HTVS"
allows"the"fastest"docking"simulations"of"the"three."It"does"not"produce"very"accurate"results,"
but" it" allows" the" screening" of" a" very" large" number" of" molecules" rapidly." SP"mode" is" more"
accurate"and"it"is"appropriate"for"screening"ligands"of"unknown"quality"in"large"numbers"with"
a"reasonable"calculation"time."The"XP"scoring"function"includes"additional"terms"over"SP"and"a"
more"complete"treatment"of"some"of"the"SP"terms"for"the"offset"of"observed"underestimation"
in" the" SP" version." In" detail," explicit"water"molecules" are" used" as" a"measure" of"whether" the"
complex" is" physically" realistic;" penalties" are" assigned" to" structures" where" statistical" results"
suggest"that"one"or"more"groups"are"inadequately"solvated;"rewards"are"given"for"occupancy"
of"well\defined"hydrophobic"pockets"by"hydrophobic"ligand"groups.[1]""
"
SCHRÖDINGER.BIOLUMINATE".
"
BioLuminate"is"a"Schrödinger"product"that" is"able"to" interface"with"Maestro." It"was"designed"
for"protein"modelling"and"has"a"wide"range"of"tools"that"allow"protein"analysis"(e.g."structure"
quality"assessment),"protein"engineering"(e.g."homology"modelling"or"protein\protein"docking)"
and"antibody"modelling"(e.g."antigen\antibody"complex"prediction).[2]"
The"prediction"of"protein\protein"interactions"can"be"achieved"with"the"implemented"protein\
protein"docking"procedure"that"uses"the"PIPER"program.[3]"With"this"program"it"is"possible"to"
dock"two"arbitrary"proteins"or"one"protein"with"itself"for"dimer"or"trimer"simulation."The"main"
difference"between"the"two"cases"is"that"in"the"latter"one"symmetry"is"taken"into"account"in"
the"docking"procedure."Furthermore,"a"special"docking"can"be"performed"for"antigen\antibody"
complexes," as" the" software" is" able" to" recognise" the" features" of" the" binding" site" of" the"
antibodies,"giving"more"accurate"results." In"all" the"kind"of"simulation,"a"protein" is" treated"as"
“receptor”" and" the" other" one" as" the" “ligand”." In" the" case" of" antigen\antibody" complex" the"
antibody" is" always" the" receptor," while" in" the" other" cases" it" makes" no" difference." Protein\
protein"docking"is"performed"rigidly,"sampling"the"interactions"between"the"protein"partners"
through" translation" and" rotation" of" the" “ligand”" in" respect" of" the" “receptor”." The" resulting"
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poses"are"not"energy"minimised,"but"scored"according"to"the"scoring"function"in"Equation"A2.2"
that"estimates"the"binding"energy.[2,3]"
" ! = !!""# + !!!"# !!!"# + !!!"!# + !!!"#$ "
Equation'A2.2..PIPER.scoring.function.[3].
S="score;"()shape="shape"contribution;"Eattr="energy"related"to"attractive"interactions;"Erep="energy"related"to"
repulsive"interactions;"Eelec="electrostatic"contribution;"Epair="pairwise"desolvation"contribution;"a,b"and"c="weight"
coefficients"for"terms"
Poses"are"evaluated"according"to"the"shape"complementarity,"to"the"electrostatic"contribution"
(Eelec)"and"to" the"desolvation"contribution" (Epair)."The"shape"complementarity" is"evaluated"by"
considering"both"attractive"(Eattr)"and"repulsive"(Erep)" interactions."As"the"docking"used"a"rigid"
body" model" that" does" not" consider" the" small" protein" changes" in" conformations" upon"
interaction," a" weighting" factor" (a)" is" used" to" allow" some" atomic" overlaps." Electrostatic"
contributions"are"calculated"with"a"simplified"Generalised"Born"equation"and"the"desolvation"
component"is"given"by"a"function"that"considers"“receptor”"and"“ligand”"atoms"interactions"in"
a"pairwise"manner."Weighting"factors"(a,"b"and"c)"were"calibrated"using"test"cases.[3]""
The"top"1000"scoring"poses"are"clustered"and"the"centre"of"the"cluster"is"returned"as"result"by"
the" program.[2]" The" procedure" can" be" biased" by" introducing" constraints" that" increase" or"
decrease"the"attractive"or"the"repulsive"factors"on"specific"residues."This"can"be"useful"to"drive"
the"docking"for"consistency"with"known"experimental"data.[2]"
"
SCHRÖDINGER.MAESTRO.PREPARATION.TOOLS.
"
Prior" either" small" molecule" or" protein\protein" docking," it" is" advisable" to" prepare" the"
molecules." For" docking" simulations" performed" with" Schrödinger" programs," this" can" be"
achieved" with" two" programs" within" the" Mestro" interface:" Protein" Preparation" Wizard" (for"
protein"preparation)"and"LigPrep"(for"small"molecule"preparation).[4,5]"
Protein" structures," in" particular" X\ray" data,"might" contain:" unwanted" co\crystallised" ligands,"
more" than" one" protein" chain," water" molecules," cofactors," ions," buffer" elements" and" even"
errors" (for" instance"missing" atoms" and" partial" or"missing" residues)." For" this" reason," before"
calculations," a" protein" should" be" prepared" and" this" process" is" automated" by" the" Protein"
Preparation" Wizard." It" allows" to" delete" unwanted" molecules" (e.g." water" or" unwanted"
cofactors)," fix" incomplete"protein"residues," fill"missing" loops," find"atoms"that"overlap,"create"
disulphide" bonds," fix" metal" coordination," check" bond" orders" and" atom" types," fix" the"
orientation" of" amino" acids’" functional" groups," protonate" and" charge" the" structure" and" to"
chose"between"alternate"states"if"present.[4]"
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Small"molecule"preparation"consists"mainly"in"the"optimisation"and"evaluation"of"the"chemical"
structures" and" can" be" performed" with" the" LigPrep" program." It" consists" in" the" addition" of"
hydrogens" according" to" atomic" valences," generation" of" possible" ionisation" states" in" a" pH"
range,"generation"of"possible"tautomers,"exploration"chirality"(if"desired),"generation"of" low\
energy" ring" conformation," and" geometry" optimisation." For" each" small" molecule" that" is"
prepared," several" structures" are" generated" with" different" properties," following" the" above"
mentioned"steps."These"structures"are"then"evaluated"according"to"their"chemical"properties"
and"the"assigned"score"can"be"used"in"Glide"docking"simulations"for"a"more"precise"pose"score"
that" considers" not" only" the" interactions" between" the" protein" and" the" ligand," but" also" the"
ligand’s" properties" in" that" chemical" state." For" this" reason" ligand" preparation" generally"
improves"modelling"results.[5]"
"
LEADIT.FLEXX".
"
FlexX" is" a" computer" program" licensed" by" BioSolveIT" that" performs" docking" and" scoring"
procedures." As" in" most" of" docking" programs," the" protein" is" considered" to" be" rigid," so" the"
protein"must"be"given"in"a"conformation"similar"to"the"bound"state.[6]"
Prior" docking" or" rescoring" simulations," protein" structure" preparation" and" adjustments" (e.g."
atom" protonation," unwanted" chains" and" cofactors" removal," choice" between" residues’"
alternate" states)" is" advisable," but" usually" performed" with" other" molecular" modelling"
programs."As"for"Scrhödinger\based"docking"simulations,"also"in"this"case"the"protein"binding"
site"must"be" indicated" for"poses"evaluations." The"docking" site" is" a" spherical" region"of" space"
that"must"contain"all"the"atoms"of"the"docked"ligands."It"is"defined"by"the"user"by"selecting"a"
centre" and" a" sphere" radius.[6]" Ligand’s" structure" preparation" (in" particular" correct" hydrogen"
atoms" additions" and" energy" minimisation)" is" also" advisable," but" is" usually" performed" with"
other"molecular"modelling"programs."
FlexX"is"a"fragment\based"docking"program,"in"the"sense"that"during"placement"the"ligands"are"
split"and"a"base"fragment"is"selected."This"molecule"portion"is"then"positioned"in"the"receptor"
site,"finding"the"placements"that"give"most"interactions"with"the"protein."The"base"fragment"is"
then" gradually" grown" up" to" the" original" compound" using" a" torsion" angle" database."
Consequently," the"new" fragment"placement" is"optimised"and" the"best" solutions"are"chosen."
This" is" an" iterative" process" that" ends" when" the" ligand" is" completely" reconstructed" and" its"
conformational"space"has"been"explored.[6,7]"
Poses"are"scored"with"an"empirical"scoring"function."This"means"that"the"contributions"to"the"
binding" energy" (∆Gbind)" were" calibrated" through" the" analysis" of" a" set" of" protein\ligand"
complexes."The"main"binding"energy"contributions"are"given"by"solvent"effects"(∆Gsolv),"specific"
protein\ligand" interactions" (∆Gint)," the" energy" needed" for" freezing" internal" rotatable" bonds"
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(∆Grot)," conformational" energy" (∆Gconf)," the" energy" involved" in" vibrational" modes" changes"
(∆Gvib)" and" the" loss" in" rotational" and" translational" free" energy" (∆Gt/r)," as" shown" in" Equation"
A2.3.[6]"
" ∆!!"#$ = ∆!!"#$ + ∆!!"# + ∆!!"# + ∆!!"#$ + ∆!!"# + ∆!!/! "
Equation'A2.3..FlexX.scoring.function.[6].
∆Gsolv="solvent"effects"energy;"∆Gint="specific"protein\ligand"interactions"energy;"∆Grot="energy"involved"in"freezing"
internal"rotatable"bonds;"∆Gconf="energy"involved"in"conformational"changes;"∆Gvib="energy"involved"in"vibrational"
modes"changes;"∆Gt/r="loss"in"transational"and"rotational"free"energy"
"
PLANTS".
"
PLANTS" (Protein\Ligand" ANT" System)" is" a" docking" algorithm.[8]" It" is" based" on" a" class" of"
stochastic" algorithms" called" Ant" Colony" Optimization" (ACO)," inspired" by" the" indirect"
communication" (in" the" form" of" pheromone)" among" real" ants" finding" the" shortest" path"
between" their" nest" and" a" food" source." The" artificial" ants" in" PLANTS" are" randomized"
procedures" that"generate"a"complete"candidate"solution"using"a"constructive"mechanism." In"
this" docking" system," both" the" ligand" and" the" protein" are" treated" as" flexible," taking" into"
account" the" ligand’s" translational," rotational" and" torsional" degrees" of" freedom" and" the"
protein’s"torsional"degrees"of"freedom."At"the"end"of"the"process"the"generated"solutions"are"
post\processed"and"sorted"according"to"increasing"scoring"function"values.[8,9]"
There" are" two" available" scoring" functions" in" PLANTS:" the" PLP" scoring" function" (fPLP)" and"
CHEMPLP"scoring" function" (fCHEMPLP)." fPLP" is" considers"distance\based"potentials"only"and"
has"the"form"reported"in"Equation"A2.4.[9]"
" !"#" = !!"! + !!"#$!!"# + !!"#$!!!"# + 0.3 ∙ !!"#$%!!"#$ − 20.0"
Equation'A2.4..PLANTS.scoring.function.[9].
fplp="steric"intercations"between"the"protein"and"the"ligand;"ftors\lig="torsional"potential"of"the"ligand;"fclash\lig="clash"
term"for"the"ligand;"fscore\prot="intramolecular"protein"interactions"
fCHEMPLP" introduces" angle\dependent" terms" for" hydrogen\bonding" and"metal" binding," and"
intralingand"interactions"are"taken"in"account,"as"shown"in"Equation"A2.5.[9]"
" !"#$%&'& = !!"! + !!!!"!!! + !!"#$!!"# + !!"#$!!!"# + 0.3 ∙ !!"#$%!!"#! − 20.0"
Equation'A2.5..PLANTS.scoring.function.[9].
fplp="steric"intercations"between"the"protein"and"the"ligand;"fchem\hb="hydrogen"bonds"and"metal"contacts"between"
the"protein"and"the"ligand;"ftors\lig="torsional"potential"of"the"ligand;"fclash\lig="clash"term"for"the"ligand;"fscore\prot="
intramolecular"protein"interactions"
In"both"scoring"functions"a"penalty"term"is"added"if"the"ligand’s"reference"point"is"outside"the"
predefined"binding"site"of"the"protein.[8,9]"
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As" described" in" the" other" docking" programs," prior" the" simulation," protein" structure"
preparation"and"adjustments"(e.g."atom"protonation,"unwanted"chains"and"cofactors"removal,"
choice" between" residues’" alternate" states)" is" advisable," but" usually" performed" with" other"
molecular"modelling"programs."Also" in" the"case"of"PLANTS," the"protein"binding"site"must"be"
indicated" for" poses" evaluations." The" docking" site" is" a" spherical" region" of" space" that" must"
contain"all"the"atoms"of"the"docked"ligands."It"is"defined"by"the"user"by"selecting"a"centre"and"
a" sphere" radius.[8]" Ligand’s" structure" preparation" (in" particular" correct" hydrogen" atoms"
additions" and" energy" minimisation)" is" also" advisable," but" is" usually" performed" with" other"
molecular"modelling"programs."
"
MOE"DOCKING.
"
Molecular"Operating" Environment" (MOE)" is" an" integrated" software" package" that" allows" the"
application"of"a"wide"range"of"molecular"modelling"techniques"to"molecular"systems."Docking"
and"scoring"are"some"of"the"possible"tools"that"can"be"used"with"MOE.[10]"
As" described" in" the" other" docking" programs," prior" the" simulation," protein" structure"
preparation"and"adjustments"(e.g."atom"protonation,"unwanted"chains"and"cofactors"removal,"
choice"between"residues’"alternate"states)"is"advisable"and"can"be"performed"with"this"suite."
For" instance," hydrogens" can" be" added" and" energy" minimised" in" a" pH" and" temperature\
dependent"manner"using"the"Protonate3D"tool,"while"incomplete"residues"can"be"constructed"
with"the"Mutate"tool."During"the"simulation," the"protein"region" in"which"the"small"molecule"
must" be" placed" is" indicated" by" the" user" through" box" size" and" centre." Ligand’s" structure"
preparation"(in"particular"correct"hydrogen"atoms"additions"and"energy"minimisation)" is"also"
advisable,"and"can"be"performed"using"the"Database"tools.[10]"
The"MOE"docking"and"scoring"application"works"through"six"steps"that"can"be"switched"on"or"
off"according" to" the"purpose"of" the"study."The" first" stage" in" the"docking"algorithm" is" the"3D"
conformational"search"of"the"ligands."It"is"a"systematic"search"that"employs"a"set"of"preferred"
of" torsion" angles" to" routable" bonds" and" saves" a" maximum" of" 5,000" conformers" for" each"
ligand."As"this"conformational"search"does"not"change"bond"lengths"and"angles"and"it"does"not"
explore" ring" conformations." Therefore," it" is" important" that" the" starting" conformations" are"
reasonable.[10]""
The"second"step"(placement)"a"set"of"poses"are"generated"and"scored"for"each" ligand." If" the"
binding"mode"of"reference" ligands" is"known,"then" it" is"possible"to"use"this" information:"a"3D"
pharmacophore"can"be"built"and"used"for"constraining"the"generation"of"the"pose"on"the"base"
of"the"given"features.[10]"
The" third" stage" of" the" docking" algorithm" is" the" first" rescoring" that" evaluates" the" generated"
poses" on" the" base" of" the" ligand\protein" contacts." The" default" London" dG" scoring" function"
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estimates"the"binding"free"energy"(ΔG)"of"the"poses"on"the"base"of"the"gain/loss"of"the"ligand"
rotational"and"translational"entropy"(s);"the"energy"correlated"to"the"ligand’s"loss"of"flexibility"
(Eflex);" the"energy" associated"with"hydrogen"bonds" (Eh\bond);" the"energy"of"metal" interactions"
(Emetal);" the" desolvation" energy" for" each" atom" (Edes).[10]" The" functional" form" of" the" scoring"
function"is"reported"in"Equation"A2.6:"
" ∆! = ! + !!"#$ + !!!!"#$ + !!"#$% + !!"#"
Equation'A2.6..London.dG.scoring.function..(modified.from[10]).
ΔG=binding"free"energy,"s=gain/loss"in"ligand"rotational"and"translational"entropy,"Eflex=energy"correlated"to"the"
ligand’s"loss"in"flexibility,"Eh\bond=hydrogen"bond"energy,"Emetal=metal"interactions"energy,"Edes=desolvation"energy"
Another" scoring" function" is"GBVI/WSA"dG." It" is" an" empirical" scoring" function" that" estimates"
the"binding"free"energy"(ΔG)"through"Equation"A2.7:""
" ∆! ≈ ! + ! !! ∆!!"#$ + ∆!!"# + ∆!!"# + !∆!"!"#$!!"# "
Equation'A2.7..GBVI/WSA.dG.scoring.function.[10].
ΔG=binding"free"energy,"c=gain/loss"of"ligand"rotational"and"translational"entropy,"α=AMBER"force"field\dependent"
constant,"β=MMFF94x"force"field\dependent"constant,"ΔEcoul=electrostatic"interactions,"ΔEsol=solvation"
electrostatic"term,"ΔEvdw=van"der"Waals"interactions,"ΔSAweighted=weighted"surface"area"
The"binding" free"energy"estimation" is" calculated" through" the"calculation"of" several" ligand"or"
binding"parameters"and"force"field\dependent"constants"(α"with"AMBER"and"β"with"MMFF94x"
force" fields)" that" were" calibrated" during" the" force" field" optimisation" on" 99" protein\ligand"
complexes."More" in" detail," the" calculated"main" components" to" the" binding" energy" are:" the"
gain" or" loss" of" the" ligand’s" rotational" and" translational" entropy" (c);" the" electrostatic"
component" (ΔEcoul)"calculated"through"Coulomb’s"equations;" the"solvation"electrostatic" term"
(ΔEsol)" computed" through" the" Generalised" Born" equation," the" van" der" Waals" contribution"
(ΔEvdw);"the"penalization"for"the"solvent"exposed"surface"area"of"the"ligand"(ΔSAweighted).[10]"
The" fourth" step" of" the" docking" procedure" is" the" molecular" mechanics" force" field" or" grid"
refinement"that"has"the"aim"of"optimising"the"protein\ligand"interactions.[10]"
The" fifth" stage" of" the" docking" algorithm" is" the" pharmacophore" constraint" that" induces" the"
poses" refinement" to" comply" the" formation" of" the" known" interactions" according" the" given"
features." It" also"works"as" a" filter"of" the"poses," eliminating" the"poses" that"do"not" satisfy" the"
given"pharmacophore.[10]"
The"sixth"stage"of"the"algorithm"is"the"second"rescoring"of"the"poses"with"one"of"the"scoring"
methods." Possible" rescoring" functions" are" the" same" as" in" the" first" and" the" default" one" is"
GBVI/WSA"dG"scoring"function.[10]"
"
"
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MOE"FRAGMENTFBASED.DRUG.DESIGN.TOOLS.
"
Also"de&novo"drug"design"can"be"carried"out"with"MOE"tools,"with"the"modification"of"existing"
structures"for"the"achievement"of"more"active"molecules.""
MedChem"Trasformations"is"one"of"these"tools"and"it"allows"alterations"of"existing"ligands"or"
fragments"in"order"to"build"novel"molecules"in"a"rational"manner."The"general"methodology"of"
the"program"consists"of"a"series"of"iterations"in"which"the"selected"regions"of"the"molecule"are"
transformed." For" each" cycle," the" resulting" new" molecules" are" then" filtered" (according" to"
molecular" properties," QSAR" models," fingerprints" or" pharmacophores)," synthetically" scored,"
energy"minimised"and"evaluated"according"scoring"functions.[10]"
The" transformations"can"be"of" two" types:" those" that"can"preserve"or" those" that"can"change"
properties." From" medicinal" chemistry" studies" available" in" literature," the" most" common"
transformations"have"been" collected" in"MOE"databases." They"are"written"as" transformation"
rules"that"appear"like"chemical"reactions:"on"the"left"of"an"arrow"there"is"the"initial"chemical"
substructure,"while"on"the"right"of"it"there"is"the"new"substructure.[10]"An"example"is"reported"
in"Figure"A2.1.""
" !
Figure'A2.1..Example.of.transformation..
In"this"example"hydrogen"is"transformed"in"a"chloride"atom."On"the"left"of"the"arrow"there"is"the"original"structure"
and"on"the"right"there"is"the"new"one."
After"two"short"energy"minimisations"(one"without"the"receptor"and"one"with"the"receptor),"
the" new" coordinates" are" checked" and" structures" presenting" bond" lengths" or" angles" with"
values"outside"the"normal"range"are"ruled"out.[10]"
As"mentioned" above," the" newly" designed"molecules" are"marked"with" a" synthetic" feasibility"
score" that" ranges" from" 0" (not" feasible" synthesis" of" the" molecule)" to" 1" (molecule" fully"
synthesizable)."This"is"a"recent"development"of"the"software,"aiming"the"improvement"of"the"
major" problem" of" de& novo" drug" design" approaches:" the" generation" of" non\synthesisable"
molecules." The" score" is" calculated" through" three" steps." At" the" beginning," a" retrosynthetic"
bond" disconnection" approach" is" adopted" until" no"more" bonds" can" be" disconnected." All" the"
resulting"fragments"are"then"compared"to"the"molecules"present"in"a"software\implemented"
database" that" contains"possible" starting"materials." The"heavy" atoms"of" these" fragments" are"
then" “marked”." The" fraction" of" the" “marked”" heavy" atoms" over" the" total" number" of" heavy"
atoms"of"the"molecule"constitutes"the"synthetic"feasibility"score.[10]"
At"the"end"of"the"transformation"cycle,"if"the"structure"of"the"receptor"is"present,"a"refinement"
is" usually" applied." This" allows" the" energy" minimisation" of" the" new" molecules" within" the"
H Cl
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binding" pocket," using" the" chosen" force" field" functions." If" the" receptor" is" not" present," a"
tethered"minimisation"can"be"applied"to"the"molecule"in"order"to"relax"the"structure.[10]"
Another"MOE"tool"that"allows"modification"of"a"ligand"is"the"Combinatorial"Builder"tool."This"
program"generates"all"the"possible"products"that"can"be"built"keeping"a"common"scaffold"and"
applying" a" set" of" R\groups" described" in" a" database." In" the" same"manner" as" the"MedChem"
Transformations,"the"generated"molecules"are"filtered"with"molecular"descriptors"and"possibly"
with"user\defined"QSAR"models,"fingerprints"or"pharmacophores."Then,"they"are"synthetically"
scored"and"refined.[10]""
For"the"generation"of"the"new"molecules,"the"user"must"select"the"attachment"points"and"the"
software"inserts"the"R\groups"in"these"locations."The"new"molecules"are"first"filtered"in"order"
to"eliminate"undesirable"chemical"groups"(e.g."peroxides)."Then,"all"of"the"possible"rotamers"of"
the" R\groups" are" generated" through" an" application" that" samples" torsion" angles" related" to"
rotatable" bonds." If" the" receptor" is" present," the" conformations" that" give" clashes"with" it" are"
automatically" removed." In" the" end," the" duplicate" and" the" high\energy" structures" are"
removed.[10]"
As" well" as" the" “growing”" approach" applied" through" the" tools" described" above," it" is" also"
possible"to"link"close"fragments"to"form"a"ligand"that"potentially"binds"the"protein"better"with"
the"Link"Multiple"Fragment"tool."The"program"connects"two"or"more"independent"fragments"
via"inserting"linkers"between"user\defined"sites"in"the"starting"fragments.[10]"
The" construction" of" the" new"molecules" is" operated" exploiting" built\in" databases" of" several"
conformations" of" possible" linkers." The" user\defined" hydrogen" atoms" are" substituted" by" the"
heavy"atoms"of"the"linkers"and"the"new"joined"structures"are"subsequently"protonated"before"
their"evaluation"in"terms"of"bond"order,"correct"geometries"and"clash"energies.[10]"
In" a" similar" manner" to" the" other" MOE" de& novo" drug" design" tools," the" new" structures" are"
filtered" through" molecular" properties" and" user\defined" QSAR" models," fingerprints" and"
pharmacophores;"as"well"as"being"synthetically" scored." In" the"presence"of" the" receptor," it" is"
also" possible" to" refine" and" score" the" structures" through" a" force" field" refinement" with"
pharmacophore"restraints,"as"for"the"other"tools.[10]"
"
LIGBUILDER..
"
LigBuilder"is"a"structure\based"drug"design"software"that"computes"two"de&novo"approaches:"
molecule" growing" and" molecule" linking.[11]" The" main" program’s" goal" is" the" construction" of"
novel" chemical" ligands" within" the" constraints" of" the" target"molecule" and" consequently" the"
structure" of" the" receptor" is" necessary" for" the" application" of" this"methodology." In" the"main"
software"procedure,"before"the"construction"of"novel"chemical"entities,"the"binding"pocket"is"
analysed"and"a"pharmacophore"is"built."The"new"ligand"molecules"are"then"evolved"through"a"
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genetic"algorithm"and"scored"according" to" their" chemical" viability"and"binding"affinity."After"
this,"the"molecules"are"also"evaluated"for"their"drug\likeness,"chemical"stability"and"potential"
toxicity.[11]""
The" receptor"analysis" is"operated"by" the"LigBuilder"POCKET" tool." It" requires" the"presence"of"
the" protein’s" structure" alone" and" the" structure" of" a" docked" reference" ligand" for" binding"
pocked"localisation."The"program"recognises"the" ligand"and"builds"a"grid"box"that"covers"the"
small"molecule"and"the"protein" in" that" region."Through"a"hydrogen"probe," it" then"calculates"
the"accessibility"of"the"pocket."Key"interaction"sites"are"identified"with"different"probes"in"the"
vacant" places," allowing" to" build" a" pharmacophore" with" the" following" possible" features:"
hydrogen"bond"donor,"hydrogen"bond"acceptor"and"hydrophobic"regions.[11]""
The" outputs" from" POCKET" are" then" used" for" the" “building\up" method”." Molecules" are"
constructed" in" a" fragment\based" manner," meaning" that" an" initial" starting" structure" is"
necessary"for"the"construction"of"novel"chemical"entities."The"construction"of"these"molecules"
is" obtained" through" three" main" operations:" growing," linking" and" mutation." In" the" growing&
operation," the" growing" sites\selected" hydrogen" atoms" are" substituted" with" new" fragments"
that" are" contained" in" a" building" block" library," maintaining" the" hydrogen\heavy" atom" bond"
orientation."As"the"new"constructed"bond"is"rotatable,"a"rotamer"exploration"is"computed"in"
order" to" evaluate" the" conformation" at" the" energy" minimum" within" the" protein’s" binding"
pocket."If"more"than"one"energy"minimum"are"recognised,"the"different"conformations"at"the"
minima" are" kept" and" considered" as" different"molecules." The" linking& operation" adopts" three"
types" of" algorithms" according" to" the" distance" of" the" atoms" to" link." If" two" structures" collide"
through"a"pair"of"hydrogen"atoms,"a"CH2"group" is"used"to"substitute"the"two"hydrogens"and"
link"the"molecules."If"the"collision"happens"between"two"heavy"atoms,"the"program"will"create"
a"new"bond"between"them,"but" if"the"two"heavy"atoms"overlap,"one"of"them"is"deleted"and"
the" other" one" is" used" to" connect" the" two" structures." The"mutate& operation" allows" C," N," O"
atoms"with"the"same"hybridization"to"mutate"to"each"other."All"the"heavy"atoms"are"evaluated"
in" respect"of" the"pharmacophore"that"was"built"with"POCKET"and" if" it"does"not" fit" the"given"
feature"it"will"be"mutated"to"a"more"appropriate"heavy"atom."At"the"end"of"these"operations"
all" the" new" hydrogen" atoms" are" labelled" as" growing" sites," unless" they" are" too" close" to" the"
receptor.[11]""
The"evolution"of"the"new"molecules"is"computed"through"a"genetic"algorithm"approach"that"is"
a"search"that"mimics"the"natural"process"of"evolution."In"LigBuilder,"the"initial"ligand"structure"
(or"seed"structure)"is"used"to"generate"a"first"population"of"new"molecules"obtained"through"
the"growing,"linking,"mutate"operations."Each"molecule"of"this"population"is"then"scored"with"
a" fitness" value."With" a" fitness" value\weighted" random" selection" of" the"molecules" a"mating"
pool" of" parent" molecules" that" are" structurally" different" is" built." Importantly," during" the"
selection," the"best" ranked"molecules"are"directly"copied"from"the"old"population" in"order" to"
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ensure" the"enhancement"of" the" trend" in" the" fitness"value."The"mating"pool" is" then"used" for"
new"growing," linking"and"mutate"operations," for" the" construction"of" the"next" generation"of"
population"of"molecules."The"whole"process"continues"in"an"iterative"manner."Each"iteration"is"
called"generation"and"the"number"of"generations"is"decided"by"the"user"prior"the"beginning"of"
the"methodology."When"the"number"of"generations"has"been"reached"and"the"last"population"
has"been"formed,"the"molecules"are"ranked"according"to"the"fitness"value.[11]""
The"fitness"value"calculation"is"operated"through"the"consideration"of"two"factors:"the"binding"
affinity" and" the" bioavailability." The" SCORE" algorithm" employs" a" linear" empirical" scoring"
function"that"estimates"binding"free"energy,"computing"the"binding&affinity.[11]"It"was"built"on"
the"bases"of"the"study"of"170"protein\ligand"complexes"and"it"can"be"described"with"Equation"
A2.8."
" ∆!!"#$ = ∆!!"# + ∆!!!!"#$ + ∆!!!"#$%!!"#$ + ∆!!"#"! + ∆!!"
Equation'A2.8.'LigBuilder.SCORE.scoring.function.[11].
ΔGbind=binding"free"energy,"ΔGvdw=van"der"Waals"interaction,"ΔGH\bond=hydrogen"bonding"energy,"
ΔGhydrophobic=hydrophobic"interaction,"ΔGrotor=entropy"loss"for"rotatable"bonds"freezing,"ΔG0=empirical"constant"
The" binding" free" energy" is" calculated" through" the" sum" of" various" energy" components"
associated" to" molecule" binding:" van" der" Waals" interactions" (ΔGvdw)," hydrogen" bond"
interactions"(ΔGH\bond),"hydrophobic"interactions"(ΔGhydrophobic)"and"the"loss"of"entropy"linked"to"
the" rotatable" bonds" freezing" (ΔGrotor)." The" bio\availability" component" of" the" fitness" value"
consists" in" the" application" of" Lipinski’s" rules" for" the" design" of" drug\like" molecules" to" be"
delivered" orally." The" score" is" based" on" the" violation" of" these" rules:" violation" of" these" rules"
produces"a"proportional"decrease"in"the"bio\availability"score.[11]""
On"top"of"the"fitness"value,"molecules"are"also"evaluated"through"chemical"rules"and"toxicity"
parameters."The"chemical&rules"are"applied" in"order"to"rule"out"molecules"that"might"not"be"
chemically" stable." This" is" achieved" through" the" identification" of" unacceptable" (e.g."
heteroatoms"bound" to"each"other"or" too"many"heteroatoms"bound" to" the" same"carbon)"or"
forbidden" structures." Similarly," the" toxicity" of" the" molecules" is" predicted" through" the"
individuation"of"particular"chemical"structures"(e.g."epoxide"groups)"that"have"been"associated"
with"drug"toxicity.[11]""
"
OPENEYE.ROCS.
"
The" interactions" between" a" protein" and" a" ligand" occur" at" the" level" of" their" surfaces" and"
therefore" the" shape" complementarity" between" the" two"molecules," as" well" as" their" surface"
properties,"is"fundamental"for"the"strength"of"the"interaction"between"them.[12]"The"shape"of"a"
molecule"can"be"defined"in"different"ways,"but"in"a"very"broad"sense"it"can"be"indicated"as"the"
Section"8:"APPENDIXES" APPENDIX&2"!
!348"
part"of"space"that"is"delimited"by"the"object’s"surface"and"occupied"by"the"object"itself.[13]"On"
the" base" of" the" principle" that" “if" two" molecules" have" a" similar" shape," perhaps" they" have"
similar"properties”," shape" similarity" searches"have"been"widely"used" in"molecular"modelling"
approaches,"in"particular"for"ligand\based"drug"design"approaches.[13,14]""
OpenEye"ROCS"is"a"software"that"allows"to"compare"molecules"and"determine"their"similarity"
with" a" shape\based" superimposition" method.[15]" In" order" to" have" the" same" shape," two"
molecules"must"have"the"same"volume"and"this"is"why"in"this"method"the"volume"calculation"
is"fundamental."Nevertheless,"the"volume"is"a"scalar"field"as"it"can"be"expressed"with"a"number"
and" therefore" the"molecule’s" conformation" is"not" specified"with" this"descriptor."Hence," two"
molecules" that" have" the" same" volume" do" not" necessarily" have" the" same" shape." For" this"
reason," even" if" volume" and" shape" are" closely" related," the" only" volume" calculation" is" not"
sufficient" for" an" appropriate" shape" screening.[15]" On" the" base" of" this," ROCS’s" fundamental"
equation"for"shape"comparison"can"be"written"as"follows:"
" !!,! = !! + !! − 2!!,!"
Equation'A2.9.'ROCS.fundamental.equation.for.shape.comparison.[15].
S=shape"similarity,"I=self\volume"overlaps,"O=overlap"between"the"2"functions,"f,g=molecules"
The"shape"similarity"(Sf,g)"between"two"molecules"f"and"g"is"calculated"through"the"molecules’"
volumes" (self\volume" overlaps," If" and" Ig)" that" are" independent" of" orientation" and" the"
orientation\dependent" overlap" between" the" two" functions" (Of,g)." If" the" two"molecules" have"
the"same"shape,"If"and"Ig"will"be"equal"and"correspondent"to"double"of"the"value"of"overlap"Of,g"
and" therefore"Sf,g"will" be"equal" to"0."Otherwise," if" the"overlap" is"not" complete," Sf,g"will" be"a"
positive"number.[15]"
For"a"better"shape"comparison,"ROCS"applies"an"orientation"search"on"the"molecules"in"order"
to" find" the" best" overlap" that" outputs" the" lower" Sf,g" value" and" then" it" evaluates" the" shape"
similarity"according"to"the"chosen"scoring"method."The"most"common"scoring"method"used"in"
shape"comparison"is"the"Tanimoto"index"that"is"calculated"through"Equation"A2.10."
" !!,! = !!,!!! + !! − !!,!"
Equation'A2.10.'Tanimoto.index.equation.[15].
Tf,g=Tanimoto"index,"I=self\volume"overlaps,"O=overlap"between"the"2"functions,"f,g=molecules"
If"two"molecules"have"the"same"shape,"the"overlap"of"the"volumes"(Of,g)"will"be"equal"to"the"
volume"of"one"molecule"(I)"and"the"two"volumes"(If"and"Ig)"will"be"equal."This"means"that"the"
Taimoto"index"(Tf,g)"will"be"equal"to"1."Otherwise"the"score"will"be"inferior"to"1.[15]"
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Not"only"molecular"volume"and"orientation"are" important" in"shape"comparison,"but"also"the"
molecule’s" conformation" is" fundamental." ROCS" does" not" compute" conformational" searches,"
therefore"conformations"need"to"be"prepared"prior"the"simulation.[15]""
As" previously" stated," shape" is" not" the" only" 3D" feature" that" is" essential" for" protein\ligand"
recognition"and"binding."Physical\chemical"properties"and"their"distribution"of"the"molecule’s"
surface"have"also"a"key"role.[12,14]"One"way"of"representing"the"space"distribution"of"chemical"
features" is" the" pharmacophore.[16,14]" ROCS" allows," optionally," to" consider" these" features" as"
well"as"the"molecules’"shapes"for"the"similarity"screening"through"the"use"of"“color"features”."
In" this"way," the"position"of"hydrogen"bond"donors,"hydrogen"bond"acceptors,"anion,"cation,"
ring"or"hydrophobic"groups"can"be"used"for"a"more"accurate"molecule"superimposition"and/or"
scoring." ROCS" assesses" chemical" similarity" between" the" query" and" the" screened"molecules"
with" one" of" the" two" color" force" fields" at" disposition" (Implicit" Mills" Dean" and" Explicit" Mills"
Dean)." Both" of" them" have" the" same" color" atom" types" described" above," the" same" list" of"
chemical"functional"groups"and"a"weight"term"that"describes"the"strength"of"the"interaction."
The"main"difference"between"the"two"force"fields"is"the"way"that"ionisable"groups"are"treated."
Explicit"Mills"Dean"force" field"does"not"have"a"pKa"model"and"consequently"uses" the"atoms’"
protonation" states" given" in" input." On" the" other" hand," Implicit" Mills" Dean" force" field" has" a"
simple"pKa"model"that"allows"it"to"define"the"ionisation"state"(considering"pH"7)"of"the"atoms,"
irrespective"of"the"input"structures."The"choice"between"the"two"force"fields" is"consequently"
based"on"the"preparation"of"the"molecules.[15]"
"
GROMACS..
"
GROMACS" (GROningen"Machine" for"Chemical" Simulations)" is" a" freeware" software," originally"
developed"in"the"University"of"Groningen"(Netherlands),"that"gives"the"possibility"to"perform"
energy" minimization," molecular" dynamics" (MD)" and" peculiar" MD" procedures.[17,18]" The" MD"
simulation"itself"is"only"part"of"the"entire"procedure,"which"is"composed"by"the"following"main"
steps:"generation"of"a"topology"file,"generation"and"solvation"of"the"box,"neutralization"of"the"
system,"energy"minimisation,"equilibration"and"proper"MD"simulation."
"
Topology'file'generation'
GROMACS"software"needs"a"topology"input"file"to"run"the"simulation."A"topology"file"contains"
a"list"of"the"constant"attributes"of"each"atom"of"the"system."Furthermore,"it"contains"also"the"
instructions"on"how" these"parameters" should"be"applied" in" the"energy" functions."This" file" is"
necessary"for"all"the"steps"of"the"simulation"and"every"time"GROMACS"uses"the"topology"file"it"
updates" it"with" the" changes"made" to" the" system" (e.g." addition" of"water"molecules)." As" the"
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information" format" varies" from" one" force" field" to" another," it" is" at" this" point" that" the" user\
chosen" force" field" and" the" preferred" water" model" have" to" be" specified." A" water" model" is"
defined" as" the" geometry," together" with" other" parameters" such" as" the" atomic" charges" and"
Lennard\Jones"parameters,"of"the"water"molecules"that"will"constitute"the"environment"of"the"
system.[17]""
"
Generation'and'solvation'of'the'box'
In"a"MD"study," the"system" is"confined" in"a"physical"space"called"“box”"that"can"have"shapes"
with"different"complexity"(triclinic,"cubic,"octahedron"or"dodecahedron)."Confining"the"system"
in" a" finite" volume" could" create" some" artefacts" at" the" boundaries" of" this" space." In" order" to"
minimize" these" edge" effects," GROMACS" uses" periodic& boundary& conditions" (PBC)" combined"
with" the"minimum& image& convention& (for" which" only" the" nearest" image" of" each" particle" is"
considered"for"short"range"non\bonded"interaction"terms).[17]"With"PBC,"the"space\filling"box"
that"contains"the"system"is"surrounded"by"translated"copies"of"itself,"as"shown"in"Figure"A2.2.""
"
!
Figure'A2.2..Illustration.of.the.periodic.boundary.condition.concept...
One"box"and"three"images"box"are"represented."The"molecular"system"in"the"box"is"represented"by"a"protein"(red"
ribbon)"and"small"molecules"(colours"space\filling"model"representation)."The"movement"of"two"small"molecules"
out"of"the"box"is"simulated"with"arrows"that"show"how"the"periodic"boundary"conditions"allow"having"always"the"
same"number"of"molecules"in"the"simulation"box."
With"periodic"boundary"conditions,"if"a"particle"leaves"the"box"during"the"simulation,"another"
image"particle"will" replace" it," entering" from" the"other" side"of" the"box." In" this"way," the" total"
number"of"particles"inside"the"box"remains"constant.[17,19]"Some"times,"PBC"are"not"desired"in"a"
molecular" system" (e.g." in" the" study" of" molecular" adsorption" onto" a" surface)," but" with"
molecular"systems"in"solution"it"is"usually"advisable"to"use"PBC.[19]"If"PBC"conditions"are"used,"
it"is"important"to"make"sure,"though,"that"the"molecular"system"cannot"interact"with"itself"in"
the"neighbour"box."For"this"reason,"non\bonded"interactions"cut\offs"are"usually"set"to"be"at"
least"double"the"minimum"distance"between"the"molecular"system"and"the"box.[17]"
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Once"generated," the"box" is" then" filled"with"randomly"positioned"water"molecules"generated"
according"to"the"chosen"water"model"(exemplified"in"Figure"A2.3)."
"
!
Figure'A2.3..Image.of.the.system.box.filled.with.water.molecules..
The"box"edges"are"in"blue"and"the"water"molecules"are"represented"by"red"dots."The"molecular"system"(a"protein)"
is"represented"in"lines."
"
Neutralization'of'the'system'
Due"to" the"use"of"PBC," if" the"system"has"a"net"charge,"even" if" this" is"very"small," this"will"be"
multiplied" by" the" infinite" number" of" boxes" created," generating" an" infinitive" net" charge." In"
order" to" avoid" this" issue," the" system" is" neutralised" by" replacing" random" solvent"molecules"
with"monoatomic"ions"in"random"positions.[17]""
"
Energy'minimisation'(EM)'
In"a"MD"simulation"the"initial"state"of"the"simulation"is"important"because"it"can"determine"the"
success" or" the" failure" of" the" simulation" itself." For" example" a" system" with" high\energy"
interactions" can" give" simulation" instability." For" this" reason," it" is" important" that" the" system"
structure" is" prepared" (e.g." by" adding" hydrogen" atoms," completing" incomplete" residues," or"
deleting"unwanted"factors)"prior"to"the"simulation,"as"explained"also"in"the"docking"programs"
chapters." Additionally," it" is" wise" to" operate" an" energy" minimization" (EM)" prior" the" system"
equilibration" and" the"MD" production" steps," in" order" to" improve" the"mentioned" simulation"
instability"issues.[19]""
In" GROMACS," EM" can" be" operated" with" several" integrators," according" to" the" system" size,"
calculation" time" and"desired" precision." The"most" used" integrators" are:" steepest" descendent"
and" conjugated"gradient." Steepest"descendent" integrator" calculates" the" force"on"each"atom"
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and" for" the" following" time" steps" it" moves" the" atoms" according" the" direction" of" the" force"
gradient." At" the" beginning" of" the" minimisation" it" quickly" reaches" a" conformation" near" the"
energy" minima," but" then" it" is" very" slow" in" reaching" the" minima" itself." On" the" other" side,"
conjugate"gradient"method," through"the"use"of"a"vector"orthogonal" to" the" force"gradient," is"
slower" in" the" early" stages" of" energy" minimisation," but" more" efficient" near" the" energy"
minimum"compared"to"steepest"descendent"algorithm.[17]"
"
System'equilibration'
The"system" is" in"a"water"environment,"but"water"molecules"are"added" in" random"positions."
Therefore," they" do" not" “solvate”" correctly" with" the" molecular" system." Furthermore," the"
system"at" this" stage" is"not"described"by" important"physical"parameters,"as" temperature"and"
pressure." Therefore," before" the" proper" MD" simulation" is" undertaken" it" is" useful" to" run" a"
position" restrained" molecular" dynamics" (PR\MD)." With" PR\MD" the" atom" positions" of" the"
macromolecule"are"restrained"(kept"still,"or"“frozen”),"while"the"solvent"molecules"are"left"free"
to" move" and" to" “soak”" into" the" macromolecule." Given" that" the" relaxation" time" (the" time"
needed"for"a"perturbed"system"to"return"to"equilibrium)"of"water"is"more"or"less"10ps,"the"PR\
MD"has"to"be"longer"than"this"time,"at"least"an"order"of"magnitude"bigger."Moreover,"during"
the"equilibration"period," the" system" is" coupled" to" a"preferred" temperature" and/or"pressure"
and/or"volume"of"the"box."Most"commonly,"the"system"is"treated"in"NVT"(constant"number"of"
atoms"N,"volume"V"and" temperature"T)"or" in"NPT" (constant"number"of"atoms"N,"pressure"P"
and" temperature"T)" conditions." The"difference"between" the" two" is" that" in" the" first" case" the"
volume" of" the" box" is" kept" constant," while" in" the" second" case" the" pressure" is" maintained"
constant.[17,19]""
The"control"of"the"temperature"can"be"achieved"with"several"methods."For"instance,"velocity"
rescaling" temperature" coupling" corrects" temperature" deviations" acting" on" the" velocity" of"
random"atoms,"but"ensuring" that" the"kinetic"energy" is" equally"distributed"between"“solute”"
and"solvent."To"force"a"constant"temperature"is"necessary"because"the"truncation"on"the"force"
calculation" or" integration" errors" that" can" occur" during" a"MD" simulation" can" produce" small"
drifts"in"this"descriptor"that"are"not"related"to"the"physical"behaviour"of"the"system."Similarly,"
also"the"pressure"of"the"system"can"be"controlled"through"several"methods."For"instance,"the"
Berendsen"pressure"coupling"corrects"pressure"drifts"by"acting"on"the"box"volume.[17]"
"
Molecular'dynamics'simulation'
This"is"the"proper"production"step."Longer"MD"simulations"should"resemble"better"molecular"
mechanisms,"but"this" implies"also"longer"computational"time."Consequently," it" is"common"to"
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select" the" total" simulation" time" on" the" base" of" a" compromise" between" accuracy" and"
computational"time."
"
Trajectory'analysis'
MD"trajectories"can"be"analysed"with"GROMACS"with"several"tools."Most"of"the"time,"the"main"
informations" that"are"achieved" from"a"molecular"dynamics" simulation"are" the"monitoring"of"
the"system"total,"potential,"kinetic"energies,"the"system’s"temperature"and"pressure"in"order"
to" verify" that" these" elements" are" constant" during" the" simulation," as" well" as" the" visual"
inspection"of"the"trajectory.[17]""
The"equilibrium"status"of"the"system"can"be" investigated"through"the"calculation"of"the"root"
mean"square"deviation"(RMSD)"of"the"atoms"for"each"time"step."The"RMSD"is"a"statistical"tool"
that" measures" the" average" distance" between" the" atoms" in" a" molecule" with" respect" to" a"
reference"structure."The"calculation"of"RMSD"values"is"performed"applying"Equation"A2.11."
"
!"#$! !!, !! = !! !! !! − !! !! !!!!! ! "
Equation'A2.11.'RMSD.calculation.[17].
mi!="mass"of"atom"i,"ri=position(of(atom(I(at(time(t,(M=mass(of(the(N(atoms,(t1=time,'t2=reference'time'(usually'0)"
On" the" base" of" RMSD" values," structures" clustering" can" be" performed" and" the" ensemble" of"
conformations"that"the"molecular"system"adopts"during"the"simulation"can"be"assessed."
It" is"also"possible" to" inspect" the" time"variation"of" the"distance"of"atoms"and" to"monitor" the"
formation/brake"of"hydrogen"bonds."In"the"latter"case,"the"program"recognises"the"presence"
of"groups"that"can"interact"with"this"non\covalent"bond"and"if"distance"(less"than"0.35nm)"and"
angle"(angle"with"the"vertex"on"the"hydrogen"between"0°"and"30°)"features"are"respected"then"
the"hydrogen"bond"is"recognised.""
"
AMBER..
"
Assisted"Model"Building"with"Energy"Refinment"(AMBER)"is"a"suite"of"programs"that"allows"to"
perform" MD" simulations" and" to" make" calculations" on" the" obtained" trajectories.[20,21]" MD"
simulations" are" performed" by" a" tool" named" sander" and" similarly" to" GROMACS," precise"
preparation" steps" before" the" production" simulation" itself" must" be" performed" because" a"
proper" system" preparation" is" crucial" for" the" outcome" of" the" production" simulation" itself."
These" steps" are" the" preparation" of" the" molecular" system" with" topology" determination,"
simulation" box" preparation" and" (generally)" solvation," system" neutralisation," energy"
minimisation" and" equilibration." Furthermore," as" already" explained," the" choice" of" force" field"
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and" water" model" are" also" important" and" depend" on" the" molecular" system" that" has" been"
studied."Like"GROMACS,"energy"minimisations"can"be"computed"with"different"methods"(e.g."
steepest" descendent" or" conjugate" gradient)" and" MD" simulations" follow" the" Leap" Frog"
algorithm"described"in"the"main"INTRODUCTION"section"of"this"thesis."
As"well"as"for"common"analysis,"with"AMBER"MD"trajectories"can"be"used"for"the"application"
of" the" Molecular" Mechanics" Poisson\Boltzman" (and" Generalized" Born)" Surface" Area"
(MMPB(GB)SA)"approach."It"is"computed"by"MMPBSA"program"within"this"suite"and"allows"the"
calculation" of" binding" free" energy" (ΔGbind)" of" molecular" complexes.[22]" The" calculation" is"
performed"on"snapshots"taken"from"MD"trajectories"because" in"the"average"of"the"obtained"
values"give"a"more"accurate"estimation"of"the"interaction"energy."
MMPBSA"estimates"the"ΔGbind"values"according"Equation"A2.12."
" ∆!!"#$ = !!"#$%&' − !!"#"$%&! − !!"#$%& "
Equation'A2.12.'General.equation.for.the.estimation.of.the.binding.free.energy.[22,23].
ΔGbind=binding"free"energy,"Gcomplex=free"energy"of"the"complex,"Greceptor=free"energy"of"the"receptor,"Gligand=free"
energy"of"the"ligand"
This"calculation"requires"the"free"energies"of"the"complex,"of"the"ligand"and"of"the"receptors"
that"are"averaged"upon"the"set"intervals"of"time"in"the"MD"simulation."The"three"free"energy"
components" are" computed" on" the" base" of" the" molecular" mechanics" energy" (EMM)," the"
solvation"energy"(Esol)"and"the"solute"entropy"(S),"as"reported"in"Equation"A2.13.[20,22,23]""
" ! = !!! + !!"# − !""
Equation'A2.13..Free.energy.calculation.[20,22,23].
G=free"energy,"EMM="molecular"mechanics"energy,"Esol=solvation"energy,"T=temperature,"S=solute"entropy"
The"molecular"mechanics" energy" (EMM)" is" force" field" based" and" it" follows" the" general" force"
field"function"reported"in"Equations"1.1"and"1.2"(see"main"INTRODUCTION"section).[20,21,23]"This"
is"the"molecular"mechanics"component"of"the"MMPB(GB)SA"approach."
The" solvation" energy" is" estimated" through" its" decomposition" in" polar" and" nonpolar"
contributions."The"first"one"applies"the"implicit"solvent"approach," in"which"the"solvent" is"not"
considered" as" a" group" of"molecules," but" as" a" continuous"medium." In" this" case," the" solvent"
interactions" are" measured" exploiting" its" dielectric" constant." The" polar" contribution" is"
computed" through" two" different" equations:" Poisson\Boltzman" (PB)" or" Generalized" Born"
(GB).[20,21,23]" The" PB" equation" is" a" second\order" differential" equation" that" correlates" the"
distribution"of"the"charge"throughout"the"system"(charge"density)"and"the"dielectric"constant"
to"the"electrostatic"potential"that"is"used"for"the"calculation"of"the"polar"solvent"contribution."
With" this"method" the" solute" is" considered" to" be" a" body"with" constant" low" dielectric" value,"
while" the"solvent"has"a"high"dielectric." In" the"GB"model," the"solute" is"considered"as"a"set"of"
Section"8:"APPENDIXES" APPENDIX&2"!
!355"
spheres"with"charges"and"different"dielectric"constant"to"the"continuum"solvent"and"it"recalls"
Coulomb’s"equations.[19]"This"is"the"PB"or"GB"part"of"the"MMPB(GB)SA"approach."
The"nonpolar"solvation"contribution"is"computed"through"the"solvent"accessible"surface"area"
(SASA)" method" that" probes" the" solute’s" surface" with" a" water" molecule" according" to" the"
following"equation:"" !!"#,!" = !! ∙ !"!" + !"
Equation'A2.14..Nonpolar.solvent.contribution.[19,22,24].
Esol,np=non\polar"solvation"energy"contribution,"γ="surface"tension"coefficient,"o=offset"constant"
Here,"the"non\polar"solvation"energy"is"correlated"to"SASA"using"a"surface"tension"coefficient"
(γ)"and.an"offset"constant"(o).[19,21,24]"
"
"
"
" "
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APPENDIX.3:.SHAPEFBASED.VIRTUAL.
SCREENING.SELECTED.MOLECULES.
"
Compound. Molecule.structure. Name.
1.
"
4\(4\(2,4\dichlorobenzyl)piperazin\1\
yl)\1\phenyl\1H\pyrazolo[3,4\
d]pyrimidine"
2.
"
4\((1\(3,4\dichlorobenzyl)\1H\indol\3\
yl)methylene)\1\phenylpyrazolidine\
3,5\dione"
3.
"
2\bromo\4\((3,5\dioxo\1\
phenylpyrazolidin\4\ylidene)methyl)\
6\methoxyphenyl"adamantane\1\
carboxylate"
4.
"
naphthalene\2,7\diyl"bis(azepane\1\
carboxylate)"
123.
"
1\(5\methoxy\2\methylphenyl)\3\(4\
(3\methoxyphenyl)piperazin\1\
yl)pyrrolidine\2,5\dione"
124.
"
7\(2\cyclohexyl\2\oxoethyl)\3\
(naphthalen\2\yloxy)\4H\chromen\4\
one"
125.
"
"
3\benzyl\7\((4\methyl\5\phenyl\4H\
1,2,4\triazol\3\yl)thio)\3H\
[1,2,3]triazolo[4,5\d]pyrimidine"
126.
"
1\benzyl\4\((4\
cyclohexylphenyl)sulfonyl)piperazine"
Cl
Cl
N
N
NN
N
N
N
N
H
N
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O
Cl
Cl
N
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N
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O N
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O N N
O
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NN
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N N
N
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O
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127.
"
4\(3\(2\(2,4\dichlorophenyl)\8,9\
dimethyl\7H\pyrrolo[3,2\
e][1,2,4]triazolo[1,5\c]pyrimidin\7\
yl)propyl)morpholine"
128.
"
2\(benzo[d][1,3]dioxol\5\
ylmethylene)\3\oxo\2,3\
dihydrobenzofuran\6\yl"2\
fluorobenzoate"
129.
"
2\(4,9\dimethyl\7\oxo\3\phenyl\7H\
furo[2,3\f]chromen\8\yl)\N\(1,1\
dioxidotetrahydrothiophen\3\yl)\N\
methylacetamide"
"
NO N
N
N
N
N
Cl
Cl
O
O
F
O
O O
O
O
N
S
O
O
O
O
O
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APPENDIX.4:.NS3HEL.NTP.SITE.VIRTUAL.
SCREENING.SELECTED.MOLECULES.
"
Compound. Molecule.structure. Name.
16.
"
2\(4\((2\(p\
tolylcarbamoyl)hydrazono)methyl)p
henoxy)acetic"acid"
17.
"
4\((4\chloro\2\((4,6\dioxo\2\
thioxotetrahydropyrimidin\5(2H)\
ylidene)methyl)phenoxy)methyl)ben
zoic"acid"
130.
"
2\(4\(1,8\dioxo\1,2,3,4,5,6,7,8,9,10\
decahydroacridin\9\yl)\2\
methoxyphenoxy)acetic"acid"
131.
"
2\((2\((3\methoxy\5\(1H\tetrazol\1\
yl)phenyl)amino)\2\
oxoethyl)thio)acetic"acid"
132.
"
3\(benzo[d][1,3]dioxol\5\
ylcarbamoyl)cyclopentanecarboxylic"
acid"
133.
"
3\((5\(4\methoxybenzylidene)\2,4\
dioxothiazolidin\3\yl)methyl)benzoic"
acid"
134.
"
4\((4\oxo\5\(4\
propoxyphenyl)thieno[2,3\
d]pyrimidin\3(4H)\yl)methyl)benzoic"
acid"
N
H
N
H
O
N
O
O
OH
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HN
N
H
O
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O
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O
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135.
"
5\(5\((2\
(allylcarbamothioyl)hydrazono)meth
yl)furan\2\yl)isophthalic"acid"
136.
"
3\(5\((2,4\dioxo\1,5\
dioxaspiro[5.5]undecan\3\
ylidene)methyl)furan\2\yl)benzoic"
acid"
137.
"
3\((1\carbamothioyl\3\methyl\5\
oxopyrazolidin\4\yl)diazenyl)benzoic"
acid"
"
O
HO
O
HO
O N
H
N
H
N
S
O
OH
O
O
O
O
O
O
OHNN
N
HN
O
H2N
S
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APPENDIX.5:.NS3HEL.POTENTIAL.INHIBITORS.
TESTED.DURING.THE.SECONDMENT.PERIOD.
"
The" following" table" reports" the" compound" number," its" structure," the" virtual" screening"
approach" used" for" its" identification" and" the" maximum" concentration" at" which" it" could" be"
solubilised"in"water,"starting"from"a"20mM"(10mM"for"compounds"1"and"15)"solution"in"100%"
DMSO."
"
Compound" Structure. Design.approach" Soluble.at"
1.
"
4\(4\(2,4\dichlorobenzyl)piperazin\1\yl)\1\phenyl\1H\
pyrazolo[3,4\d]pyrimidine"
LigandFbased.
virtual.screening.
(chapter&3.2.2).
100μM"
2"
"
4\((1\(3,4\dichlorobenzyl)\1H\indol\3\yl)methylene)\1\
phenylpyrazolidine\3,5\dione"
100μM"
3"
"
2\bromo\4\((3,5\dioxo\1\phenylpyrazolidin\4\
ylidene)methyl)\6\methoxyphenyl"adamantane\1\
carboxylate"
500μM"
4"
"
naphthalene\2,7\diyl"bis(azepane\1\carboxylate)"
100μM"
123.
"
1\(5\methoxy\2\methylphenyl)\3\(4\(3\
methoxyphenyl)piperazin\1\yl)pyrrolidine\2,5\dione"
500μM"
Cl
Cl
N
N
NN
N
N
N
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O
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11"
"
3\(((1\methyl\1H\tetrazol\5\yl)thio)methyl)\7\(1\
methyl\4\nitro\1H\pyrazole\3\carboxamido)\8\oxo\5\
thia\1\azabicyclo[4.2.0]oct\2\ene\2\carboxylic"acid"
StructureFbased.
virtual.screening.
on..
RNA.binding.site"
(chapter&3.2.3)&
2mM"
15"
"
ethyl"4\(5\(2,5\dichlorophenyl)furan\2\yl)\6\methyl\2\
oxo\1,2,3,4\tetrahydropyrimidine\5\carboxylate"
500μM"
18.
"
1\(4\oxo\6\((p\tolylthio)methyl)\1,4\dihydropyrimidin\
2\yl)\3\phenylguanidine"
250μM"
138.
"
2\methoxyethyl"4\(3\(4\chlorophenyl)\1\phenyl\1H\
pyrazol\4\yl)\6\methyl\2\oxo\1,2,3,4\
tetrahydropyrimidine\5\carboxylate"
250μM"
139.
"
3\benzyl\4\((2\(piperazin\1\yl)ethyl)amino)\2H\
chromen\2\one"
2mM"
N
S
H
N
O
NN
O
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H
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16"
"
2\(4\((2\(p\
tolylcarbamoyl)hydrazono)methyl)phenoxy)acetic"acid"
StructureFbased.
virtual.screening.
on.
NTP.binding.site"
(chapter&3.2.4)&
2mM"
17"
"
4\((4\chloro\2\((4,6\dioxo\2\thioxotetrahydropyrimidin\
5(2H)\ylidene)methyl)phenoxy)methyl)benzoic"acid"
2mM"
130.
"
2\(4\(1,8\dioxo\1,2,3,4,5,6,7,8,9,10\decahydroacridin\9\
yl)\2\methoxyphenoxy)acetic"acid"
2mM"
131.
"
2\((2\((3\methoxy\5\(1H\tetrazol\1\yl)phenyl)amino)\2\
oxoethyl)thio)acetic"acid"
2mM"
132.
"
3\(benzo[d][1,3]dioxol\5\
ylcarbamoyl)cyclopentanecarboxylic"acid"
2mM"
"
N
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APPENDIX.6:.FRAGMENTS.SOLVED.IN.
COMPLEX.WITH.NS5.METHYLTRANSFERASE.
"
Fragment. Structure. IC50.2’OFmethylation.
IC50.
NF7.methylation. Name.
2A2.
"
>10"mM" 7"mM" Pyridine\4\carboxylic"acid"
2A4.
"
>10"mM" >10"mM" 7\aminothieno[2,3\b]pyrazine"
2C3.
"
4.4"mM" 6.5"mM" 2\amino\4\methylbenzoic"acid"
2E11.
"
4.2"mM" >10"mM"
4\chloro\5\
methylbenzene\1,2\
diamine"
2G3.
"
0.3"mM" 2"mM"
2\(2,5\
dimethylpirrol\1\
yl)benzoic"acid"
3A9.
"
4"mM" 4"mM"
2,3\dihydro\1\
benzofuran\5\
carboxylic"acid"
3C2.
"
>10"mM" >10"mM"
4\
(trifluoromethyl)ben
zene\1,2\diamine"
"
N
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O
N
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H2N
O
OH
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F
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APPENDIX.7:.COMPOUNDS.DESIGNED.FROM.
COMPOUND.44.MODIFICATIONS..
"
Compound. Structure. Binding.pose.
53.
!! " "
54.
"
"
140.
! " "
141.
"
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142.
"
"
143.
"
"
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H
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APPENDIX.8:.SELECTED.MOLECULES.FROM.
RDRP.SITE.D.VIRTUAL.SCREENING.STUDY.
"
Compound. Molecule.structure. Name.
79.
"
N\(3,5\dimethylphenyl)\3\ethoxy\4\
fluorobenzenesulfonamide"
80.
"
2\chloro\N\(3\(3\(2\
phenylacetyl)thioureido)phenyl)benz
amide"
81.
"
4\bromo\2\((2\(4\morpholino\6\((4\
(trifluoromethyl)phenyl)amino)\1,3,5\
triazin\2\yl)hydrazono)methyl)phenol"
82.
"
N'2,N'7\di(furan\2\carbonyl)\9H\
fluorene\2,7\disulfonohydrazide"
121.
"
quinolin\8\yl"1\methyl\2\oxo\1,2\
dihydrobenzo[cd]indole\6\sulfonate"
144.
"
N1,N5\bis(2\
carbamoylphenyl)glutaramide"
145.
"
2\((5\(3\fluorophenyl)\4\phenyl\4H\
1,2,4\triazol\3\yl)thio)\N\(1\
phenylethyl)acetamide"
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146.
"
2\((4\fluorophenyl)(5\hydroxy\3\
phenyl\1H\pyrazol\4\
yl)methyl)malononitrile"
147.
"
4\(2\chlorophenyl)\2\cyclopropyl\5\
(1\(p\tolyl)\1H\tetrazol\5\
yl)pyrimidine"
148.
"
6\(4\nitrobenzyl)benzo[b]pyrido[3,2\
f][1,4]oxazepin\5(6H)\one"
149.
"
2\(4\chloro\2\methylphenoxy)\N\(4\
(pyrrolidine\1\
carbonyl)phenyl)acetamide"
150.
"
2\(4\methoxyphenoxy)\N\(4\((4\
methylpiperazin\1\
yl)sulfonyl)phenyl)acetamide"
151.
"
3\(furan\2\yl)\2\phenyl\5\(p\
tolyl)dihydro\2H\pyrrolo[3,4\
d]isoxazole\4,6(5H,6aH)\dione"
152.
"
5\((4\bromo\1H\pyrazol\1\yl)methyl)\
N\(2\chloro\5\
(trifluoromethyl)phenyl)furan\2\
carboxamide"
153.
"
N\(3\acetylphenyl)\4\
((tetrahydrofuran\2\
yl)methoxy)benzamide"
N
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N N
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N N
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N N
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154.
"
4\(((3\(2\(tert\butylamino)\2\
oxoethoxy)benzyl)amino)methyl)ben
zoic"acid"
155.
"
1\([1,1'\biphenyl]\4\yloxy)\3\(3,5\
dimethyl\1H\1,2,4\triazol\1\
yl)propan\2\ol"
156.
"
5\((4\(2,4\
dichlorophenoxy)phenyl)amino)\5\
oxopentanoic"acid"
157.
"
2\((3\hydroxyphenyl)amino)\2\
oxoethyl"4\(5\((2\methoxy\2\
oxoethyl)thio)\1H\tetrazol\1\
yl)benzoate"
158.
"
2\((4\chlorophenoxy)methyl)\5\((4\
fluorobenzyl)amino)oxazole\4\
carbonitrile"
159.
"
3\(4\chloro\3\methylphenoxy)\5\(2\
(4\nitro\1H\pyrazol\1\
yl)acetamido)benzoic"acid"
160.
"
N\(4\((1H\imidazol\1\
yl)methyl)phenyl)\3\
(benzo[d][1,3]dioxol\5\
yl)propanamide"
161.
"
5\amino\3\methyl\1\(6\(p\
tolyloxy)pyrimidin\4\yl)\1H\pyrazole\
4\carbonitrile"
162.
"
2\(3,4\dimethoxyphenyl)\N\(4\
ethylphenyl)acetamide"
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163.
"
N\(2\carbamoylphenyl)\5\((3\
chlorophenoxy)methyl)furan\2\
carboxamide"
164.
"
2\(4\methoxyphenyl)\N\(4\((3\
methyl\1,2,4\oxadiazol\5\
yl)methoxy)benzyl)ethanamine"
165.
"
5\((1\methyl\1H\indol\3\
yl)methylene)\3\(3\
methylbenzyl)imidazolidine\2,4\dione"
166.
"
3\(4\chlorophenyl)\1\((4\
chlorophenyl)sulfonyl)\1H\1,2,4\
triazol\5\amine"
167.
"
3\benzyl\2\(pyridin\2\yl)\2,3\
dihydroquinazolin\4(1H)\one"
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INHIBITORS.TESTED.DURING.THE.
SECONDMENT.PERIOD.
"
The" following" table" reports" the" compound" number," its" structure," the" virtual" screening"
approach" used" for" its" identification" and" the" maximum" concentration" at" which" it" could" be"
solubilised" in" water," starting" from" a" 20mM" (10mM" for" compound" 121)" solution" in" 100%"
DMSO."
"
Compound" Structure. Design.approach"
77.
"
N\(3,5\dimethylphenyl)\4\methoxybenzenesulfonamide"
Allosteric"site"D"
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3\(N\(3,5\dimethylphenyl)sulfamoyl)benzoic"acid"
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2\chloro\N\(3\(3\(2\
phenylacetyl)thioureido)phenyl)benzamide"
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82.
"
N'2,N'7\di(furan\2\carbonyl)\9H\fluorene\2,7\
disulfonohydrazide"
121.
"
quinolin\8\yl"1\methyl\2\oxo\1,2\
dihydrobenzo[cd]indole\6\sulfonate"
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"
N1,N5\bis(2\carbamoylphenyl)glutaramide"
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"
2\((5\(3\fluorophenyl)\4\phenyl\4H\1,2,4\triazol\3\
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"
2\((4\fluorophenyl)(5\hydroxy\3\phenyl\1H\pyrazol\4\
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"
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148.
"
6\(4\nitrobenzyl)benzo[b]pyrido[3,2\f][1,4]oxazepin\
5(6H)\one"
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2\(4\chloro\2\methylphenoxy)\N\(4\(pyrrolidine\1\
carbonyl)phenyl)acetamide"
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"
4\((4\([1,1'\biphenyl]\2\yloxy)phenyl)amino)\4\
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4\(((1\phenyl\1H\tetrazol\5\yl)thio)methyl)\N\(thiazol\
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Characterization of the Mode of Action of a Potent Dengue Virus
Capsid Inhibitor
Pietro Scaturro,a Iuni Margaret Laura Trist,b David Paul,a Anil Kumar,a* Eliana G. Acosta,a Chelsea M. Byrd,c* Robert Jordan,c*
Andrea Brancale,b Ralf Bartenschlagera,d
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germanya; School of Pharmacy and Pharmaceutical Sciences, Cardiff University,
Cardiff, United Kingdomb; SIGA Technologies, Inc., Corvallis, Oregon, USAc; German Center for Infection Research, Heidelberg, Germanyd
ABSTRACT
Dengue viruses (DV) represent a significant global health burden, with up to 400 million infections every year and around
500,000 infected individuals developing life-threatening disease. In spite of attempts to develop vaccine candidates and antiviral
drugs, there is a lack of approved therapeutics for the treatment of DV infection. We have previously reported the identification
of ST-148, a small-molecule inhibitor exhibiting broad and potent antiviral activity against DV in vitro and in vivo (C. M. Byrd
et al., Antimicrob. Agents Chemother. 57:15–25, 2013, doi:10.1128/AAC.01429-12). In the present study, we investigated the
mode of action of this promising compound by using a combination of biochemical, virological, and imaging-based techniques.
We confirmed that ST-148 targets the capsid protein and obtained evidence of bimodal antiviral activity affecting both assembly/
release and entry of infectious DV particles. Importantly, by using a robust bioluminescence resonance energy transfer-based
assay, we observed an ST-148-dependent increase of capsid self-interaction. These results were corroborated by molecular mod-
eling studies that also revealed a plausible model for compound binding to capsid protein and inhibition by a distinct resistance
mutation. These results suggest that ST-148-enhanced capsid protein self-interaction perturbs assembly and disassembly of DV
nucleocapsids, probably by inducing structural rigidity. Thus, as previously reported for other enveloped viruses, stabilization
of capsid protein structure is an attractive therapeutic concept that also is applicable to flaviviruses.
IMPORTANCE
Dengue viruses are arthropod-borne viruses representing a significant global health burden. They infect up to 400 million people
and are endemic to subtropical and tropical areas of the world. Currently, there are neither vaccines nor approved therapeutics
for the prophylaxis or treatment of DV infections, respectively. This study reports the characterization of the mode of action of
ST-148, a small-molecule capsid inhibitor with potent antiviral activity against all DV serotypes. Our results demonstrate that
ST-148 stabilizes capsid protein self-interaction, thereby likely perturbing assembly and disassembly of viral nucleocapsids by
inducing structural rigidity. This, in turn, might interfere with the release of viral RNA from incoming nucleocapsids (uncoat-
ing) as well as assembly of progeny virus particles. As previously reported for other enveloped viruses, we propose the capsid as a
novel tractable target for flavivirus inhibitors.
Dengue virus (DV) belongs to the genus Flavivirus, a largegroup of emerging pathogens capable of causing severe hu-
man diseases. Among these, DV represents the most prevalent
mosquito-borne human-pathogenic virus worldwide, comprising
4 serotypes that are transmittedmainly by infectedAedesmosqui-
toes during a bloodmeal. DV infections can lead to awide range of
clinical manifestations, ranging from asymptomatic infections to
life-threatening dengue hemorrhagic fever and shock syndrome.
A recent study estimated around 390 million DV infections each
year, resulting in approximately 100 million symptomatic cases
and around 25,000 deaths (1). Despite intense efforts and growing
public interest, no licensed antiviral drug against DV infection is
available, and the most advanced DV vaccine candidate did not
meet expectations in a recent large clinical trial (2).
DVhas a single-strandedRNA genome of positive polarity that
codes for a polyprotein, which is co- and posttranslationally pro-
cessed into three structural proteins (capsid, prM, and envelope)
and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) (3). The virus enters mammalian cells via recep-
tor-mediated endocytosis. In the endosomal compartment, the
low pH induces a conformational change in the envelope (E) pro-
tein, triggering membrane fusion and nucleocapsid release into
the cytoplasm (4, 5). Disassembly of the nucleocapsid occurs by a
poorly understoodmechanism leading to the release of viral RNA
into the cytoplasm of infected cells. Upon synthesis of viral pro-
teins, massive intracellular membrane remodeling events occur,
which is a conserved feature among plus-strand RNA viruses (6,
7). These rearrangements include membrane invaginations into
the endoplasmic reticulum (ER), which are the assumed sites of
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flavivirus genome replication, and can be observed in both mam-
malian and arthropod cells (8, 9). Nucleocapsid formation is
thought to occur in close proximity to replication sites (9). The
envelope is acquired by budding through the ER membrane into
which the envelope proteins E and prM have been inserted. As-
sembled virions, stored within ER stacks in highly ordered arrays,
are released from the cell via the conventional secretory pathway,
where cleavage of the prM protein by furin, a protease residing in
the trans-Golgi network (TGN), occurs. This cleavage is required
to render DV particles infectious.
The mature capsid protein (C) is a highly basic protein of 12
kDa that forms homodimers in solution (10, 11). The three-di-
mensional structure of DV C protein was solved by nuclear mag-
netic resonance (NMR) (12), indicating that the monomer con-
sists of four alpha helices (!1 to!4). The longest helix,!4, extends
away from the core of the protein. It has a high density of basic
amino acid residues on the solvent-accessible surface that were
proposed to interact with the viral RNA. On the opposite side of
the molecule, the surface, formed primarily by !2-!2= and !1-
!1=, is largely uncharged and proposed to interact with mem-
branes (12). Although the C protein is the least conserved among
flavivirus proteins, both its charge distribution and structural
properties are well conserved.
We have recently reported the identification of a small-mole-
cule inhibitor, ST-148, inhibiting replication of all DV serotypes
with high potency (13). Intraperitoneal and intravenous admin-
istrations of ST-148 in the AG129 mouse model revealed good
bioavailability of the compound, which significantly reduced
plasma viremia and viral load in spleen and liver of DV-infected
mice. Selection of ST-148-resistant viruses led to the identification
of a single S34L amino acid change in C protein which was shown
to confer resistance to ST-148. Additionally, in vitro binding stud-
ies of ST-148 to purified C protein suggested that the compound
bound equally well to wild-type (WT) and S34L-containing C
proteins. Although these studies identified C protein as the pri-
mary target of ST-148, its mode of action remained unknown. In
the present study, we addressed this aspect by using a combination
of biochemical, virological, and imaging-based methods. We ob-
tained evidence that ST-148 enhanced C protein self-interaction,
providing an explanation for the observed impairment of DV as-
sembly/release as well as entry competence of virus particles.
MATERIALS AND METHODS
Antibodies and sera.Mouse monoclonal antibodies recognizing human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (sc-47724/0411)
and human lamin A/C (sc-7292/636) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody against
human ATP5B (3D5; no. ab14730) was purchased from Abcam, and
mouse monoclonal antibody against human vimentin (VI-10) was ob-
tained fromGeneTex Inc. (Irvine, CA).Mouse anti-Envelopemonoclonal
antibody (3H5-1) was purchased from the ATCC. Mouse anti-capsid
monoclonal antibody derived from hybridoma cells (6F3.1) was a kind
gift of John G. Aaskov (Queensland University of Technology, Australia),
and rabbit polyclonal serum anti-capsid was a kind gift of Andrea Gam-
arnik (Fundación Instituto Leloir, Argentina). J2mousemonoclonal anti-
double-stranded RNA (dsRNA) antibody was purchased from English
and Scientific Consulting (Szirak, Hungary). The secondary anti-mouse
and anti-rabbit horseradish peroxidase-conjugated antibodies were pur-
chased from Sigma-Aldrich (St. Louis, MO).
BRET. For donor saturation assays (DSA), 293T cells were transfected
in 24-well plates with 20 ng/well of the DNA construct coding for the
bioluminescence resonance energy transfer (BRET) donor (Rluc-capsid)
and increasing amounts (20 to 1,000 ng/well) of the DNA construct cod-
ing for the BRET acceptor (yellow fluorescent protein [YFP] capsid). The
total amount of transfected DNAwas completed to 1,020 ng with pcDNA
3.1(") empty vector. Forty-eight hours after transfection, cells were
washed with phosphate-buffered saline (PBS) and harvested in 290 #l
PBS. For each sample, three aliquots of 90#l were distributed to wells of a
96-well microplate (black, flat bottomed; Nalgene Nunc, New York, NY).
Total YFP expressionwasmeasured by using aMithras LB940 plate reader
(Berthold Technologies, Bad Wildbad, Germany), with excitation and
emission filters set at 485 and 535 nm, respectively. The luciferase sub-
strate coelenterazineH (PJK, Kleinblittersdorf, Germany) thenwas added
to a final concentration of 5 #M, and luminescence and fluorescence
emissions were measured consecutively using a Mithras LB940 plate
reader. For BRET measurements, filters were set to 485 nm for luciferase
emission and 535 nm for YFP emission. Donor saturation curves were ob-
tained by plotting the BRET values on the y axis and the ratio between the
fluorescence of the acceptor (netYFP $ YFP % YFP0, where YFP0 is the
fluorescence value in cells expressing the BRET donor alone) and the lu-
minescence of the donor on the x axis. For ST-148 dose-response curves,
a 1:50 ratio of donor to acceptor (in the BRETmax range) was used, and
various concentrations of ST-148 (10, 5, 2.5, 1.25, 0.625, 0.312, 0.156,
0.078, 0.039, 0.019, 0.0097, and 0.0048 #M), or the highest equivalent
amount of dimethylsulfoxide (DMSO) solute, were added to each well 30
min before transfection. BRET ratios were calculated as described by An-
gers et al. (14).
Cell culture.Huh7,VeroE6, BHK-21, andHEK-293T cells weremain-
tained in Dulbecco’s modified Eagle medium (DMEM; Invitrogen,
Karlsruhe, Germany) supplemented with 2 mM L-glutamine, nonessen-
tial amino acids, 100 U of penicillin/ml, 100 #g of streptomycin/ml, and
10% fetal calf serum. Cells were passaged in regular intervals by
trypsinization and replating of appropriate dilutions.
Immunoblot analysis. Samples were denatured in 2& protein sample
buffer (200 mM Tris [pH 8.8], 5 mM EDTA, 0.1% bromophenol blue,
10% sucrose, 3% SDS, 1 mM dithiothreitol [DTT]) and incubated for 5
min at 95°C. Proteins were separated by SDS-PAGE and transferred onto
polyvinylidene difluoride membranes by using a mini-SDS-PAGE wet-
blotting apparatus (Bio-Rad, Munich, Germany). Membranes were
blocked with 5% nonfat dry milk in PBS-0.5% Tween 20 (PBST) and
incubated with primary antibodies (capsid, 1:50; GAPDH, 1:1,000; lamin
A/C 1:1,000; vimentin, 1:1,000; ATP5B, 1:1,000) by overnight incubation
at 4°C. After 3 washes with PBST, membranes were incubated with sec-
ondary horseradish peroxidase-conjugated antibodies, developed with
the Western lightning plus-ECL reagent (PerkinElmer, Waltham, MA),
and bands were imaged using an Intas ChemoCam Imager 3.2 (Intas,
Göttingen, Germany).
Immunofluorescence analysis. Huh7 cells were seeded onto glass
coverslips in 24-well plates at a density of 6 & 104 cells per well and
infected the next day with DV or DVS34L at a multiplicity of infection
(MOI) of 1. Four h postinfection (p.i.), ST-148 was added at a final con-
centration of 10 #M. For quantification of lipid droplets (LDs) and
costaining of capsid with dsRNA, 48 h after infection cells were fixed with
4% paraformaldehyde (PFA) (ApplichemGmbH, Darmstadt, Germany),
4% sucrose and processed exactly as previously described by using a rabbit
anti-capsid antibody (1:1,000), amouse anti-dsRNA (1:500), andBodipy-
488 (1:500), which stains neutral lipids (15). Secondary staining was car-
ried out using anti-mouse Alexa 546- and anti-rabbit Alexa-633-conju-
gated antibodies. All images were processed using the ImageJ software
package (National Institutes of Health, Bethesda, MD). The background
level, calculated from mock-infected cells, was subtracted (%25 pixel),
and the 566- and 488-nm channels were smoothed with the mean func-
tion set at 1.0. For visualization and quantification of nuclear and cytoso-
lic capsid, cells were fixed with 4% paraformaldehyde (PFA) for 10min at
room temperature and permeabilizedwith 0.5% (vol/vol) TritonX-100 in
PBS. Primary stainingwas carried out by 45-min incubationwith amouse
Mode of Action of Dengue Virus Capsid Inhibitor
October 2014 Volume 88 Number 19 jvi.asm.org 11541
 on Septem
ber 18, 2014 by Cardiff Univ
http://jvi.asm
.org/
Downloaded from
 
anti-capsid antibody diluted in PBS containing 3% goat serum. After ex-
tensive washes with PBS, secondary staining was carried out by a 45-min
incubation with an Alexa 568-conjugated secondary antibody diluted
1:1,000 in PBS containing 3% goat serum. Nuclear DNAwas stained with
4=,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Karlsruhe,
Germany). For staining of LDs, Bodipy-488 was added (1:500 dilution) to
each coverslip for 10min at room temperature. Samplesweremounted on
glass slideswith FluoromountG (SouthernBiotechnologyAssociates, Bir-
mingham, AL), and images were acquired using a Leica CTR MIC fluo-
rescence microscope or a Nikon Eclipse Ti spinning-disc confocal laser
microscope. Immunofluorescence signals were quantified using ImageJ,
and images were assembled with the Adobe Photoshop software package.
For quantification of LD size and number, cells were stained as described
above and imaged using a 63! objective, and the size and number of
Bodipy-488-stained LDs was calculated by using ImageJ. For each condi-
tion, at least 10,000 LDs in more than 500 cells and 8 to 10 fields of view
were examined.
Infectivity assay. For the determination of virus titers, Huh7 target
cells were seeded into 96-well plates (104 cells/well) the day before infec-
tion. Cells were inoculatedwith serial dilutions of virus-containing super-
natants that had been filtered through a 0.45-"m-pore-size filter. Infected
cells were detected by immune staining of the E protein using the mouse
anti-E antibody (3H5-1; diluted 1:500) and secondary horseradish perox-
idase-conjugated antibody (1:200). Virus titers (the 50% tissue culture
infective dose [TCID50]/ml) were calculated as previously reported (16).
Determinationof antiviral activity of ST-148.Huh7 cellswere seeded
into 12-well plates at a density of 1 ! 105 cells per well and incubated
overnight. Cells then were infected with DV, DVS34L, DVR2A, or
DVR2AS34L at an MOI of 0.1 in the presence of a range of compound
concentrations. Seven compound concentrations (25, 8, 2.5, 0.8, 0.25,
0.025, and 0.008 "M) were used to determine the 50% effective concen-
tration (EC50). After 1 h, inocula were removed and fresh medium con-
taining various concentrations of ST-148 was added to each well. After a
48-h incubation period, supernatants were harvested and filtered through
a 0.45-"m-pore-size filter, and 10-fold dilutions were used to determine
virus titer by plaque assay as described previously (13). EC50s were calcu-
lated by fitting the data to a four-parameter logisticmodel (variable-slope,
nonlinear regression model) to generate a dose-response curve by using
the GraphPad Prism 5.0 software package (GraphPad Software, San Di-
ego, CA). From this curve, the concentration of compound that reduced
virus-induced cytopathic effect (CPE) by 50% was calculated.
In vitro transcription andRNA transfection. In vitro transcripts were
generated as previously described (17). For RNA transfection, Huh7 or
293T single-cell suspensions were prepared by trypsinization, washed
with PBS, and resuspended at a concentration of 1! 107 cells (Huh7) or
1.5! 107 cells (293T) per ml in Cytomix, supplemented with 2 mMATP
and 5 mM glutathione. Ten "g of subgenomic or genomic in vitro tran-
script thenwasmixedwith 400"l of the cell suspension and transfected by
electroporation using a Gene Pulser system (Bio-Rad) and a cuvette with
a gap width of 0.4 cm (Bio-Rad) at 975 "F and 270 V. Cells were imme-
diately diluted into 20 ml of DMEM complete and seeded in the appro-
priate format (1 ml/well in 24-well plates, 2 ml/well in 12-well plates, and
15 ml/dish in 15-cm-diameter dishes).
Lentivirus production. The pWPI-BLR capsid constructs, encoding
either the capsid WT or containing the S34L mutation, and the pWPI-
Puro-prM-E constructs were cotransfected into 293T cells with plasmids
encoding Gag-Pol of HIV and the G protein of vesicular stomatitis virus
(ratio, 3:3:1) as previously reported (16). After 48 and 72 h, supernatants
were harvested, clarified through 0.45-"m-pore-size filters, pooled, and
stored in aliquots at#20°C until use.
Molecular modeling. For protein-protein docking, the NMR struc-
tures of DV capsid dimers (PDB entry 1R6R) (12) were used. The 20
dimer models were compared using the MOE Protein Consensus tool
(version 2010.10; Chemical Computing Group Inc., Montreal, QC, Can-
ada), and the 5 most different structures were selected for rigid protein-
protein docking. Each dimer model was used both with theWT sequence
and with the S34L mutation, inserted with the MOE Mutate tool. All
structures were prepared using the SchrödingerMaestro protein prepara-
tion wizard (version 9.5; Schrödinger, LLC, New York, NY). For each
model, protein-protein docking was performed with Schrödinger Bio-
Luminate Piper (version 1.2; Schrödinger, LLC, New York, NY) using the
same dimer structure for both receptor and ligand entries. The standard
mode was applied, probing 70,000 ligand rotations and giving a 0.21 bo-
nus to the complexes that involved Ser34 in the interactions. The best
tetramer model was selected by visual inspection.
All of themolecular dynamics (MD) simulations were computed with
GROMACS (version 4.5.3) (18) and the AMBER99 force field. All simu-
lations were performed on both WT and S34L mutant structures; the
mutationwas inserted starting from theWT structure. Periodic boundary
conditions were applied, using a cubic box with 0.9-nm minimum dis-
tance between themolecular system and the box. Explicit watermolecules
described with the TIP3P model were added, and systems were neutral-
ized with the addition of 72 Cl# ions. Missing ST-2148 topology param-
eters were computed with Antechamber, which is part of the Amber soft-
ware package (versionAMBER12;University of California, San Francisco,
CA). Atom partial charges were obtained with the AM1-BCC charge
method, while atom types and force field missing parameters were as-
signed with the GAFF force field. The coordinate and topology files then
were converted into GROMACS-compatible format with the acpype con-
verter (Department of Biochemistry, University of Cambridge, United
Kingdom).
Prior to the production simulation, two energy minimizations were
performed: first with the steepest descendant and second with conjugate
gradient methods. Both energy minimizations were implemented for
3,000 steps (with a step size of 1 fs), with a force tolerance of 100 kJ mol#1
nm#1 for the steepest descent and of 10 kJmol#1 nm#1 for the conjugated
gradient. Successively, the protein atomswere constrainedwith a position
restraint of 1,000 kJ mol#1 nm#2, and water molecules were relaxed with
two 50-ps (50,000 steps, step size of 1 fs) position-restraint MDs. Coordi-
nates, velocities, and energy values were saved every 500 steps in both
stages. The first position-restraint MDwas conducted under NVT condi-
tions (constant number of atoms, N, volume, V, and temperature, T),
allowing the system to be heated to 300 K with v-rescale temperature
coupling and 0.1-ps time constant. The second stage then was performed
under NPT conditions (with constant number of atoms, N, pressure, P,
and temperature, T). Both temperature (with v-rescale, temperature of
300 K and time constant of 0.1 ps) and pressure coupling (with Berendsen
algorithm, 1 bar pressure and time constant of 0.5 ps) were applied in this
case. A 30-ns (15,000,000 steps with 2-fs step size) production simulation
was run for each molecular system under the NPT conditions described
above. Coordinates, velocities, and energy values were saved every 1,000
steps. In all procedures, a 0.9-nm short-range cutoff was applied for long-
range electrostatic interactions that were calculatedwith the particlemesh
Ewald (PME) method, while short-range nonbonded interactions were
calculated within a cutoff of 1.4 nm.
For ST-148 docking, each small-molecule docking simulation was
performed using Schrödinger Maestro (version 9.5; Schrödinger, LLC,
New York, NY). Prior to docking, the protein and ST-148 were prepared
with the protein preparation wizard tool and LigPrep, respectively, gen-
erating all possible tautomers and ionization states at pH 7.0 $ 2.0. For
each docking, the grid was generated with Glide, defining appropriate
center and box sizes. Docking was performed with Glide standard preci-
sion (SP) mode, sampling nitrogen inversions and ring conformations
and penalizing nonplanar conformations for amides. The 25 poses gener-
ated then were refined with the SP mode.
Plasmid constructs. Plasmids carrying the subgenomic replicon
(pFK-sgDVsR2A) and the full-length genomes, pFK-DVs and pFK-
DVs.R2A (carrying a Renilla luciferase reporter gene), are based on the
DV-2 16681 strain and have been described recently (17) (Fig. 1A). The
S34L amino acid substitution conferring resistance to ST-148 was intro-
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duced into the capsid coding region by site-directed mutagenesis using
PCR with the external primers capsid_AgeI_frw (5=-AACAAACCGGTA
GAGCCGAGGGCAG-3=) and capsid_NaeI_rev (5=-TAATGATCATGC
CGGCAGATCTGCG-3=) and the internal primers capsid_S34L_frw (5=-
CAAAGAGATTCCTACTTGGAATGCT-3=) and capsid_S34L_rev (5=-A
GCATTCCAAGTAGGAATCTCTTTG-3=; mutated codons are under-
lined) and inserted into pFK_DVs and pFK_DVsR2A via AgeI/NaeI re-
striction sites. Numbers given refer to amino acid positions in the capsid
open reading frame. For BRET experiments, Gateway technology was
employed. TheWT or S34L capsid coding regions as well as the DVNS4A
coding region (which served as a negative control) were amplified by PCR
using full-length genomes as the templates and the external primers
s_mC_LM_N (5=-TAGGTACCGGATGAATAACCAACGGAAAAAGG-
3=), as_mC_LM_N (5=-TAGATATCCTATCTGCGTCTCCTATTCAAG
ATG-3=), s_NS4A_LM_N (5=-TAGGTACCGGTCTCTGACCCTGAAC
CTAATCACAG-3=), and as_NS4A_LM_N (5=-TAGATATCCTATCTCT
GTTTTTCAGGTTCTGG-3=) to generate intermediate entry clones.
Amplicons were inserted into the entry vector backbone (pENTR4 vector;
Invitrogen, Karlsruhe, Germany) via KpnI/EcoRV restriction sites. Gate-
way destination clones encoding humanized Renilla luciferase and YFP
were generated using standard cloning PCR-based procedures, creating
pT-Rex-DEST30-nt-RL and pT-RexTM-DEST30-nt-YFP plasmids. Fi-
nally, expression clones were generated by LR reaction according to the
manufacturer’s instructions, with slightmodifications. Briefly, 150 ng en-
try clone, 150 ng destination vector, 1!l LR clonase enzymemix, adjusted
to a total volume of 10 !l with 10 mM Tris-HCl (pH 8.0), was incubated
at 25°C for 2 h or overnight. The reaction was stopped by the addition of
1!l Proteinase K (2!g/!l) and incubation at 37°C for 10min. Finally, the
complete reaction mixture was transformed into competent Escherichia
coliDH5" cells. Isolated plasmids were sequence verified, and expression
was confirmed by Western blot analyses of transfected cells and by fluo-
rescencemicroscopy (data not shown). For the production of lentiviruses
expressing the structural proteins, the capsid and prM-Envelope coding
sequences were amplified by PCR using full-length genomes as the tem-
plate and the following primers containing the given unique restriction
sites, an AUG initiation codon, and a stop codon at the 3= end: capsid_
SbfI_frw (5=-ATGTATGTCCTGCAGGGCCACCATGAATAACCAACG
GAAAAAGGCGAAAAAC-3=), capsid_MluI_rev (5=-CTAACATTTAC
GCGTCTATCTGCGTCTCCTATTCAAGATGTTCA-3=), prM-E_SbfI_
frw (5=-TATGTCCTGCAGGGCCACCATGAGAGCCGAGGGCA-GGG
GAAGTCTTCTAACATGCGGGGACGTGGAGGAAAATCCCGGGCC
CTCTGCCGGCATGATCATT-3=), and Env_MluI_rev (5=-CTAACA
TTTACGCGTCTAGGCCTGCA-CCATGACTCCCAAATACAGT
GT-3=). A Thosea asigna virus (TaV) 2A coding sequence, mediating self-
cleavage, was inserted upstream of the capsid anchor sequence to ensure
cleavage at the capsid-anchor junction. The capsid coding region was
inserted into a pWPI-BLR vector carrying the blasticidin resistance gene,
and the prM-E cassette was inserted into a pWPI-Puro vector encoding a
puromycin resistance gene as previously described (16). All constructs
were verified by nucleotide sequence analysis.
qRT-PCR analysis. Total cellular RNA from#5$ 105 virus-infected
cells and 1/10 of the corresponding supernatants was isolated by using the
NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany) as recom-
mended by the manufacturer. The cDNA was prepared using a high-
capacity cDNA reverse transcription kit (Applied Biosystems, Life Tech-
nologies). Quantitative real-time PCR (qRT-PCR) was carried out using
an ABI Prism 7000 sequence detector system (Applied Biosystems, Foster
City, CA). For each primer set, reactions were conducted in triplicate by
FIG 1 Schematic representation of constructs used in this study and antiviral potency of ST-148. (A) Schematic representation of genomic and subgenomic
constructs. The DV2 full-length genome is shown at the top (DV). The 5= and 3= N terminal regions are depicted with their putative secondary structures.
Polyprotein cleavage products are separated by vertical lines and labeled as specified in the introduction. DVR2A is derived from the DV2 full-length genome by
insertion of a Renilla luciferase coding sequence preceded by the capsid cyclization sequence (CAE) and followed by a Tosea asigna virus 2A cleavage site. The
middle panel depicts the constructs used for production of trans-complemented DV particles (DVTCP). sgDVR2A is a subgenomic reporter replicon that is
packaged into virus-like particles by the capsid and prM/envelope proteins transiently expressed in trans via two different lentiviruses (pWPI capsid-BLR and
pWPI prME-Puro, respectively). All constructs are derived from the DVs2 16681 isolate (17). The right panel depicts the constructs used for BRET experiments.
YFP and Renilla luciferase proteins were N-terminally fused to either capsid or NS4A of DV2 (strain 16681). (B) Structure of ST-148. (C) Antiviral potency of
ST-148. Huh7 cells were infected at a DV or DVR2A reporter virus MOI of 0.1, with the virus containing or not containing the resistance mutation S34L, for 60
min at 37°C in the presence of various concentrations of the compound. After removal of the inoculum and several washings with PBS, cells were incubated with
freshmediumcontaining various concentrations of ST-148 orDMSO.After 48 h, virus amounts released into the supernatantwere determined byPFUassaywith
VeroE6 cells. Data represent averages and error ranges from two independent experiments.
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using theGreenDye RT-PCRmastermix (PJKGmbH,Hilden, Germany)
according to the manufacturer’s instructions, with the following primers
binding to a regionwithin theDVNS5 coding sequence (primer polarities
are indicated): sDV2-9687 (5=-GCCCTTCTGTTCACACCATT-3=; for-
ward) and asDV2-9855 (5=-CCACATTTGGGCGTAAGACT-3=; reverse).
The total volume of the reaction mixture was 15 !l, and reactions were
performed in two stages: stage 1, 15 min at 95°C; stage 2, 40 cycles of 15 s
at 95°C and 60 s at 60°C. Quantities of DV RNA were calculated by using
serial dilutions of known amounts of DV in vitro transcripts that were
processed in parallel as previously described (19).
Sequence alignments. Sequence alignments were performed with the
following flaviviruses (UniprotKB/Swiss-Prot accession numbers are giv-
en): DV-1 (Brazil/97-11/1997), P27909; DV-2 (Thailand/16681-PDK53),
P29991;DV-3 (Martinique/1243/1999),Q6YMS3;DV-4 (Thailand/0348/
1991), Q2YHF0;West Nile virus, P06935; yellow fever virus (Ivory Coast/
1999), Q6J3P1; Japanese encephalitis virus (SA-14), P27395; Kunjin virus
(MRM61C), P14335; and St. Louis encephalitis virus (MS1-7), P09732.
Statistical analyses. Statistical analyses were performed by applying
the two-tailed, unpaired Student’s t test. In some cases, indicated in Re-
sults, data were analyzedwith one-way analysis of variance (ANOVA) and
Dunnett’s post hoc test formultiple comparisons to nontreated controls or
ANOVA and Tukey’s post hoc test to compare every group to each other,
as indicated in the figure legends.Microsoft Excel andGraphPadPrism (v.
5.0) were used for statistical analyses.
Subcellular fractionation. For subcellular fractionation of cytosolic,
membrane, nuclear, and postnuclear fractions, the Qproteome cell com-
partment kit, purchased from Qiagen (Hilden, Germany), was used as
recommended by the manufacturer. In brief, 106 Huh7 cells were seeded
into 10-cm-diameter dishes the day before infection. Cells were infected
with either DVWT or DVS34L at an MOI of 1 for 4 h at 37°C and washed
three times with PBS, and then complete medium containing 10 !M
ST-148 or DMSO was added to the cells. After 48 h, cells were washed 3
times with ice-cold PBS, trypsinized, and collected by 5 min of low-speed
centrifugation (700 " g). Collected fractions were acetone precipitated
overnight at#20°C and resuspended in equal volumes of 2" SDS loading
buffer. One-tenth of the total cell suspension was saved as the input, and
equal amounts of each fraction were subjected to SDS–12% PAGE as
described above. Fraction purity was evaluated by determining amounts
of cytosolic (GAPDH), membrane (ATP5B), nuclear (lamin A/C), and
postnuclear/cytoskeletal (vimentin) markers.
Production of trans-complemented DV particles. To produce trans-
complemented DV particle (DVTCP) stocks, 293T cells were electropo-
rated with 10 !g of subgenomic DVR2A (sgDVR2A) replicon RNA,
seeded into 15-cm-diameter dishes, and incubated at 37°C. The next day,
cells were inoculated with lentiviral particles encoding capsid and prM-E
for 8 h. Cells were washed carefully 3 times with PBS, fresh medium was
added, and cells were cultured at 33°C for 4 to 6 days. Supernatants were
pooled and filtered through a 0.45-!m-pore-size filter, and 15 mM
HEPES (pH 7.2 to 7.5) was added to the medium. DVTCP stocks were
stored in aliquots at#80°C until use.
Transient replication assay and DVTCP-based virus entry assay.
Huh7 cells transfected with full-length DVR2A RNA were seeded into
12-well plates. Replication was determined by measuring luciferase activ-
ity in cell lysates 4, 24, 48, and 72 h after transfection. For harvest, cells
were washed once with PBS and lysed by adding 200 !l lysis buffer as
previously described (19). Cells were frozen immediately at #70°C, and
after thawing, lysates were resuspended by gentle pipetting. For each well,
20!l lysate, mixed with 400!l assay buffer (25mM glycylglycine, 15mM
MgSO4, 4 mM EGTA, 1 mM DTT, 2 mM ATP, 15 mM K2PO4 [pH 7.8],
1.42 !M coelenterazine H), was measured for 10 s in a luminometer
(Lumat LB9507; Berthold, Freiburg, Germany). Each well was measured
in duplicate. To determine the amount of infectious virus particles re-
leased into culture supernatants 72 h after electroporation, naive Huh7
cells were inoculated with these supernatants, and 48 h later luciferase
activity was determined. Kinetics of virus replication were calculated by
normalizing the relative light units (RLU) measured at a given time point
to the respective 4-h value. Four-hour values, reflecting transfection effi-
ciency, were comparable among samples and biological replicates, and no
statistically significant differences were observed. For DVTCP experi-
ments, Huh7 cells were inoculated with particles composed ofWT capsid
protein or containing the S34L resistance mutation for 90min at 37°C. At
different times before, during, or after inoculation, 10!MST-148 or 0.1%
DMSO was added to the medium. Replication was measured 48 h after
inoculation.
Virucidal assay. Preparations of DV and DVS34L particles (corre-
sponding to 3.8 " 106 TCID50/ml) were incubated for 1 h at 37°C in
DMEM containing 10 !M ST-148 or 0.1% DMSO. Viruses were serially
diluted, and the remaining infectivity was measured by TCID50 assay.
Analysis of infected cells by transmission electron microscopy.
Huh7 cells (6" 104) were seeded onto glass coverslips, and around 16 h
later, cells were infected with either DV or DVS34L at an MOI of 3. After 4
h, cells were washed three times with prewarmed PBS, and DMEM con-
taining 10 !M ST-148 or 0.05% DMSO was added. After a 48-h incuba-
tion period, cells were fixed and prepared for transmission electron mi-
croscopy as described previously (20).
RESULTS
ST-148 is a potent inhibitor of DV. ST-148 (Fig. 1B) was identi-
fied by a high-throughput screen as a potent inhibitor of DV,
exhibiting antiviral activity against all four serotypes and reducing
viremia in vivo (13). In the first set of experiments, we confirmed
the antiviral potency of ST-148 by using synthetic DV-2-based
clones derived from the isolate 16681 (Fig. 1A) (17), which was
used throughout the study. To determine the inhibitory potency
of the compound, Huh7 cells were infected with DV or the
DVR2A luciferase reporter virus, encoding either the WT or the
previously identified ST-148 resistancemutation in capsid protein
(S34L). Released infectivity was assessed by a PFU titration assay
using culture supernatants harvested 48 h after infection. As pre-
viously observed for the DV-2 NGC strain (13), ST-148 also in-
hibited 16681-derivedDVwith EC50s in the low-nanomolar range
(52 and 37 nM, respectively) (Fig. 1C and Table 1). These values
were around 220- to 300-fold higher in the case of theDVS34L- and
DVR2AS34L-resistant mutants, respectively, corroborating our
previous findings and validating the antiviral potency of ST-148
independent of the DV strain used.
ST-148 does not affect viral RNA replication but inhibits DV
spread. Previous time-of-addition studies have shown that ST-
148 is effective when added up to 12 h postinfection, suggesting a
postentry mechanism of action (13). However, the virus yield in-
hibition assays used allowed several cycles of viral replication;
therefore, possible effects onDV entry, viral RNA replication, and
assembly or release of virus particles could not be distinguished. In
order to dissect the possible impact of ST-148 on different steps of
the viral replication cycle, we first assessed viral RNA replication
TABLE 1 Antiviral activity of ST-148 against DV 16681-based viruses
Virus EC50
a (!M)
DV2 0.052$ 0.016
DVR2A 0.037$ 0.028
DVS34L 11.79$ 2.34
DVR2AS34L 11.14$ 3.27
a Cells were infected with given viruses at an MOI of 0.1 and treated with ST-148.
Culture medium was collected 48 h postinfection, and virus titers were determined by
plaque assay (Huh7 cells; CC50% 100 !M as determined in reference 13). Data
represent averages and error ranges from two independent experiments.
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and virus spread by using a DVR2A luciferase reporter virus and
addition of ST-148 4 h postinfection, i.e., after virus entry had
taken place. Virus replication in infected cells was determined 24,
48, and 72 h after infection by luciferase assay (Fig. 2A). Effects on
virus production were quantified by using culture supernatants of
infected and drug-treated cells harvested 72 h after inoculation,
infection of naive Huh7 cells, andmeasuring luciferase activity 48
h later (Fig. 2B). While viral RNA replication was not affected by
ST-148, luciferase counts detectable in the reinfection assay were
decreased 60 to 80%, arguing that the compound reduced virus
production (Fig. 2A and B, respectively).
To corroborate that the antiviral effect of ST-148 observed was
due to virus production and independent from virus entry under
these conditions and to investigate the phenotype of the ST-148-
resistant mutant, we next determined the replication competence
of either virus in Huh7 cells that had been transfected with the
correspondingDV genomes, deliberately bypassing the entry step.
Under these conditions, both viruses replicated comparably re-
gardless of ST-148 treatment (Fig. 2C). However, a significant
!80% reduction of amounts of infectious virus was observed ex-
clusively for the WT virus (Fig. 2D), confirming a selective inhi-
bition of the late steps of the DV replication cycle by ST-148.
ST-148 inhibits the production of infectiousDVparticles. In
order to determine whether the reduction of virus production
resulted from an impairment in virus particle release or a reduc-
tion of their specific infectivity, we next performed infectivity and
viral RNA titration experiments. Huh7 cells were infected with 1
MOI of DV, and various concentrations of ST-148 were added 4 h
after infection. Amounts of released viral RNA and infectious DV
particles in the supernatant were determined 48 h later by qRT-
PCR and TCID50 assay, respectively (Fig. 3A and B). These exper-
iments revealed a dose-dependent reduction of virus titers as de-
duced from the up to 10-fold smaller amounts of infectivity and
viral RNA observed at the highest inhibitor concentration.
We next investigated whether the observed reduction of virus
titer resulted from an impairment of virus spread or from a direct
block in virus particle production by using a single-cycle infection
experiment. Huh7 cells were infected with DV or DVS34L at an
MOI of 1 and incubated for 48 h to allow for nearly complete
infection of the cell monolayer (Fig. 3C). Released viruses then
were removed by extensive washing, and medium containing
DMSO, ST-148, or brefeldin A, which served as a positive control,
was added to the cells. Cells were incubated for just 12 h, which is
the estimated length of a single complete DV replication cycle (21
and B. Schmid, unpublished observations). Therefore, reinfecting
or superinfecting virus produced within this time period would
not significantly contribute to extracellular virus titer. Viral RNA
contained within infected cells or released into the culture super-
natant was quantified by RT-qPCR. In addition, infectivity titers
were determined by limiting-dilution assay. Under these condi-
tions, a highly significant reduction of !90% of infectivity was
observed for the drug-treated WT virus, while the S34L mutant
was unaffected by ST-148 treatment (Fig. 3D). Concomitantly,
ST-148 profoundly reduced secretion of viral RNA by !70% in
the case of DV WT, while no statistically significant reduction
could be observed for the DVS34L-resistant variant (Fig. 3E). As
FIG 2 ST-148 does not affect viral RNA replication but reduces production of infectious DV particles. (A) No effect of ST-148 on replication kinetics of the
DVR2A reporter virus.Huh7 cells were infectedwithDVR2A at anMOI of 0.1 or 1 for 4 h at 37°C,washedwith PBS, and incubatedwith freshmediumcontaining
5 "MST-148 or DMSO. At the indicated time points after infection, luciferase activity was measured in the lysates as described in Materials andMethods. Note
that error bars are poorly visible due to the size of the graph. (B)Reduction of virus production by ST-148. Supernatants of infected cells treatedwith 5"MST-148
were harvested 72 h postinfection and used to infect naive Huh7 cells. After 48 h, cells were harvested and luciferase activity was determined. (C) Comparison of
replication kinetics of DVR2A and DVR2AS34L in the presence or absence of ST-148. Huh7 cells were electroporated with 10 "g of capped in vitro transcripts of
WTDVR2A orDVR2AS34L (S34L), and 4 h later, 5"MST-148 orDMSOwas added to themedium. At time points specified at the bottom, luciferase activity was
determined. (D) Inhibition of virus production by DVR2A- and DVR2AS34L-transfected cells upon ST-148 treatment. Supernatants of transfected and ST-148-
treated cells were harvested 72 h postinfection and used to infect naive Huh7 cells. After 48 h, cells were harvested and luciferase activity was determined. Data
shown in each panel represent averages and standard deviations from three independent experiments (***, P# 0.001; *, P# 0.05).
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expected, in both cases BFA treatment drastically reduced titers of
both viral RNA and infectivity (Fig. 3D and E; black columns),
consistent with an earlier report (22). In conclusion, these results
suggest that ST-148 reduces DV particle production. The con-
comitant reduction of extracellular infectivity and viral RNA
amounts implies that ST-148 has no significant effect on specific
infectivity of DV particles.
ST-148 additionally inhibits DV entry. Since viral RNA rep-
lication in the presence of ST-148 was unaltered and the observed
inhibitory effect of the drug on assembly/release of DV particles
was rather modest compared to the high inhibitory potency ob-
served by virus yield inhibition assay, we hypothesized that ST-
148 has an additional effect on virus entry. To verify this hypoth-
esis, we developed a trans-complementation system, which allows
production of infectious virus-like particles containing a sub-
genomic replicon that are unable to spread in cell culture (23, 24,
25, 26, 27). These particles, whichwe call DV trans-complemented
particles (DVTCP), in analogy to our earlier report on HCVTCP
(16), were obtained by transfecting subgenomic replicons into
helper cells that provide the structural proteins in trans (Fig. 4A).
Since packaged subgenomic repliconRNAs lack the region encod-
ing the structural proteins, DVTCP only support a single round of
infection.Moreover, DVTCP encode theRenilla luciferase reporter
gene; therefore, single-round infection can bemeasured as a func-
tion of luciferase activity.
Takingadvantageof luciferase-encodingDVTCPcomposedofWT
or S34L capsids, we performed time-of-addition studies by treating
cells before, during, or at different times after infection with ST-148
andmeasured luciferase activity 48 h later. As shown in Fig. 4B,max-
imal antiviral activitywas achievedwhen cellswere treatedprior to or
during infection, reducing viral replication up to 70% (P! 0.001).
Significant antiviral effect was still obtained up to 120min postinfec-
tion (i.e., 30minafter removalof virus inoculum),whereas treatment
at later time points had no effect (Fig. 4B).
To exclude a general nonspecific virucidal effect of ST-148
on DV particles, we incubated high-titer virus stocks of DV or
DVS34L with 10 "M ST-148 for 1 h at 37°C and determined the
infectivity titer after extensive dilution by TCID50 assay (Fig.
4C). Under these conditions, no significant reduction of viral
infectivity could be observed. Taken together, these data sug-
FIG 3 Inhibition of the release of infectious DV particles by ST-148 as revealed by single-cycle experiments. (A) Production of infectious extracellular DV upon
ST-148 treatment. (B)Quantification of released viral RNA.Huh7 cells were infectedwithDVR2A at anMOI of 1 for 4 h at 37°C, washedwith PBS, and incubated
with fresh medium (nontreated [NT]) or medium containing DMSO or the given concentrations of ST-148. After 48 h, clarified supernatants were used for
TCID50 assay to quantify infectivity titers or two-step qRT-PCR for quantification of viral RNA amounts released into the supernatant. Data were analyzed using
one-way ANOVA andDunnett’s post hoc test (**, P! 0.01; ***, P! 0.001). (C)Determination of infection efficiency. Cells were infected withDV orDVS34L and
48 h later were fixed and analyzed by immunofluorescence using a DV E-specific antibody. Nuclear DNA was stained with DAPI. Numbers in the lower right of
the panels refer to the percentage of infected cells (means from at least 1,500 cells# standard deviations). (D and E) Effect of ST-148 on single-roundDVparticle
release. Huh7 cells were infectedwithDVorDVS34L for 48 h, washed extensively with PBS, and incubated for 12 hwithmedium containing 0.1%DMSO, 1"g/ml
brefeldin A (BFA), or 10 "M ST-148. Released infectivity and viral RNA were quantified by TCID50 assay and qRT-PCR, respectively. Results represent means
and standard deviations from at least 3 independent experiments. (ns, nonsignificant; *, P! 0.05; ***, P! 0.001).
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gested that ST-148 specifically blocks DV entry, which is not
due to a virucidal effect.
ST-148 does not affect colocalization of capsid with lipid
droplets anddsRNAbut increases clusteringof virusparticles in
the ER. In DV-infected cells, C protein resides both in the cyto-
plasm and nucleus (28, 29, 30). Cytosolic capsid protein was
shown to localize around LDs (15) and in close association with
vesicle packets, which are sites of RNA replication (30, 31, 32),
while nuclear capsid protein accumulates in nucleoli and was re-
ported to interact with nuclear proteins (33, 34, 35). In order to
investigate whether ST-148 would affect the recruitment of capsid
to LDs and its colocalization with dsRNA, we performed colocal-
ization studies usingDV-infected cells treatedwith ST-148. Treat-
ment was started 4 h postinfection until cells were fixed by using
paraformaldehyde and a low concentration of Triton X-100 as
reported earlier (15). As shown in Fig. 5A, we could not observe a
difference between inhibitor- and DMSO-treated cells, and colo-
calization of capsid around LDs or with dsRNA appeared unal-
tered. To rule out possible effects of ST-148 on LDmorphology or
abundance, we quantified their average sizes and numbers per cell
(Fig. 5B and C). While LD size was comparable between DMSO-
and ST-148-treated cells, the overall amount of LDs per cell ap-
peared slightly reduced upon drug treatment; however, this dif-
ference was not statistically significant. In agreement with previ-
ous reports (15), we observed an increase in the overall amount of
LDs/cell in DV infected cells (Fig. 5C). These results indicate that
ST-148 does not alter recruitment of capsid around LDs or its
colocalization with dsRNA.
With the aim of gaining insights into the mode of action of
ST-148, we next investigated the effect of the compound on the
ultrastructural morphology of DV-infected cells treated with ST-
148 by using transmission electron microscopy (Fig. 5D). Both
DV- and DVS34L-infected cells contained the characteristic mem-
brane invaginations, which have been proposed to represent viral
replication factories (vRFs) (9), and virions forming regular arrays
within the ER. Treatment ofDV-infected cells with ST-148 did not
affect themorphology of vRFs, consistent with a lack of inhibition
of viral RNA replication, whereas the overall amount of virions
was drastically reduced. Interestingly, in the case of the WT virus,
the fewer virions that could be found intracellularly in ST-148-
treated cells appeared to form larger arrays than control cells (Fig.
5E). This phenotype was specific and not found with ST-148-
treated cells that had been infected with the DVS34L-resistant mu-
tant (Fig. 5E).
FIG 4 ST-148 additionally inhibits DV particle entry. (A) Schematic representation of the system used to produce trans-complemented DV particles (DVTCP).
293T cells were electroporated with 10 !g of capped in vitro transcripts of the subgenomic replicon sgDVR2A (segment 1). The next day, cells were transiently
transduced with lentiviruses expressing the structural proteins capsid (wild type or containing the ST-148 resistance mutation S34L) and prM-E (segment 2).
Replicating viral RNA is packaged in trans (segment 3), giving rise to DVTCP stocks that are released into the culture supernatant and harvested 4 to 6 days after
transduction (segment 4). (B) Effect of ST-148 on entry of DVTCP. Huh7 cells were infected with DVTCP (WT or the S34L mutant) for 90 min at 37°C. The
inoculum was removed and fresh medium was added. At time points specified at the bottom of the graph, medium was replaced by medium containing 10 !M
ST-148 or 0.1% DMSO. In one case ("120 min), cells were pretreated with ST-148 for 2 h prior to infection. Cells were harvested 48 h postinfection, and
luciferase activities in the lysates weremeasured. (C)No virucidal effect of ST-148. Stocks ofDVWTorDVS34L were incubated at 37°C for 1 hwith 10!MST-148
or 0.1% DMSO and used to determine infectivity titers by limiting-dilution assay (TCID50). Data represent averages and standard deviations from three
independent experiments (ns, nonsignificant; *, P# 0.05; **, P# 0.001).
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ST-148 alters intracellular distribution of capsid protein.
Several lines of evidence point toward a functional role for flavi-
virus capsidwithin the nucleus of infected cells. For instance,West
Nile virus capsid protein has been proposed to dynamically shuttle
between the cytoplasm and the nucleus, and the temporal regula-
tion of this process was suggested to prevent premature encapsi-
dation of viral RNA at early stages of infection (33, 36). For Japa-
nese encephalitis virus, it was shown that disrupting nuclear
localization affected virus replication and pathogenesis in mice
(37). In the case of DV, several studies reported the presence of C
protein in the nucleoli of infected cells (28, 33, 34, 38). Moreover,
DVCprotein has been shown to interact with a number of nuclear
proteins, including hnRNP-K and histones (39, 40, 41); however,
the relevance of nuclear localization of DV C protein with respect
to viral replication is unclear (28). In light of these reports, we
investigated the influence of ST-148 on the nuclear accumulation
of C protein by using an immunofluorescence protocol that in-
cludes the permeabilization of the nucleus. Consistent with earlier
reports (15), under these conditions we detected capsid both in
the cytosol andwithin the nucleoli of infected cells (Fig. 6A andB).
In the case of DV WT-infected cells, ST-148 treatment increased
capsid accumulation within the nucleoli compared to that of
DMSO-treated control cells. In contrast, although the S34L-con-
taining capsid protein exhibited enhanced nuclear localization,
this subcellular distributionwas not affected by ST-148 treatment.
To further investigate the intracellular distribution of C pro-
tein upon ST-148 treatment, we generated subcellular fractions of
DV- or DVS34L-infected cells by using a method that allows sepa-
ration of cytosolic, membrane, nuclear, and insoluble postnuclear
proteins (Fig. 6C). This approach revealed that ST-148 treatment
reduced the abundance of cytosolic WT C protein, concomitant
with an increase of this protein in the postnuclear, insoluble frac-
tion (Fig. 6C). In contrast, subcellular distribution of the S34L
capsid protein was not affected by the treatment of infected cells
with the compound (Fig. 6C). In conclusion, these results show
that ST-148 reduces the abundance of cytosolic capsid concomi-
tant with an accumulation of the protein in nuclear, detergent-
resistant aggregates, which might contribute to the observed re-
duction of virus particle production.
ST-148 increases capsid self-interaction. DV capsid forms
dimers (10) and, eventually, oligomers during nucleocapsid as-
sembly. It is plausible to assume that the stability of capsid oligom-
FIG 5 Effect of ST-148 on subcellular localization of viral RNA and protein and accumulation of DV particles in ER stacks. (A) Colocalization of capsid with
dsRNA and LDs in ST-148 treated cells. Huh7 cells were infected with DVWT at anMOI of 1, and 4 h later, DMSO or 10!MST-148 was added to the medium.
After 48 h, cells were fixed with 4%PFA in 4% sucrose. To visualize cytosolic LD-associated capsid protein, cells were permeabilized with 0.1%Triton X-100 and
incubated with a rabbit polyclonal anti-capsid antibody, mouse anti-dsRNA antibody, and Bodipy-488 (to detect LDs). Scale bars represent 10 !m. (B and C)
Impact of ST-148 on LD size and number, respectively. The mean area and number of LDs per cell has been calculated by using the Fiji plug-in of ImageJ. Each
data set represents averages and standard deviations from at least 500 cells per condition (a.u., arbitrary units; *, P" 0.05). (D) Accumulation of DV particles in
ER stacks upon ST-148 treatment. Huh7 cells were infected with DVWT or the DVS34L mutant (S34L) at anMOI of 3. Four hours after infection, the inoculum
was removed and cells were incubated for 44 h in the presence of 10 !M ST-148 or DMSO. Cells were fixed, processed, and analyzed by transmission electron
microscopy as described in Materials and Methods. The areas boxed in the left panels are shown at higher magnification on the right. Scale bars in each panel
represent 200 nm. (E) Quantification of intracellular DV particle distribution. The number of virions present in ER stacks was quantified and assigned to 3
categories according to the number of virions per stack. Each column represents the mean of at least 1,000 virions from at least 15 infected cells per condition.
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ers is important for assembly of infectious virus particles and for
uncoating during virus entry. Since ST-148 appeared to affect
both the efficiency of virus production and entry properties of DV
particles, we assumed that this compound affects capsid self-in-
teraction. To address this assumption, we used a BRET-based as-
say, which allows investigating the protein of interest within its
physiologically relevant subcellular compartment in live cells (42).
BRET is detected when energy emitted by the Renilla luciferase
(Rluc) of a donor fusion protein is transferred to an acceptor YFP
fusion partner following catalytic degradation of the cell-perme-
able Rluc substrate coelenterazine H (Fig. 7A) (14). In the first set
of experiments, we performedDSA by using capsid proteins fused
N terminally with either YFP or Rluc (Fig. 1A). As shown in Fig.
7A, a nonlinear increase in BRET intensity and a rapid saturation
of the BRET signal was detected when a fixed amount of the Rluc-
capsid construct was coexpressed with increasing quantities of the
YFP-capsid construct. This pattern clearly indicated specific cap-
sid self-interaction. In contrast, increasing concentrations of a
FIG 6 ST-148 induces accumulation of capsid protein in nuclear insoluble aggregates. (A) Intracellular distribution of capsid protein upon ST-148 treatment.
Huh7 cells were infected with DV or DVS34L at an MOI of 1, and 4 h later, DMSO or 10 !M ST-148 was added to the medium. After 48 h, cells were fixed with
4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and immune stained for capsid with a mouse monoclonal antibody. Scale bars represent 20 !m.
(B) Image-based quantification of intracellular distribution of capsid protein. The extent of nuclear localization of capsid was determined by quantifying
capsid-specific signals detected in the nucleus (N) and the cytoplasm (C), respectively, and calculating the ratio of mean fluorescence (F) in these two
compartments [F(N/C)]. Results represent themeans" standard errors of themeans (n! 50). Data were analyzed using one-way ANOVAwith Tukey’s post hoc
test (***, P# 0.001; ns, nonsignificant). (C) Subcellular fractionation of DV proteins. Huh7 cells were infected with DV or DVS34L at anMOI of 1, and 4 h later,
cells were treated with DMSO or 10 !M ST-148. Intracellular distribution of capsid in soluble cytosolic (Cyt), membrane-associated (Membr), nuclear (Nuc),
and postnuclear insoluble (Post-Nuc) fractions was evaluated by Western blotting. GAPDH, ATP5B, lamin A/C, and vimentin served as specificity controls for
the various fractions. Numbers below each lane refer to the relative amounts of C proteins as determined by densitometry. After subtraction of the background,
capsid-specific signals in each fraction were normalized to the corresponding input and expressed as a fold of total signal in the four fractions. Numbers on the
left refer to the positions of molecular weight standards (in thousands). One result from two independent experiments is shown.
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YFP-NS4A construct (used as a negative control) coexpressed
with the Rluc-capsid construct resulted in only a weak and linear
increase of BRET, which is a characteristic pattern for noninter-
acting proteins (43, 44).
Besides providing information on the specificity of a given in-
teraction determined by BRET, additional parameters, such as
BRETmax, i.e., the BRET signal at which the saturation curve
reaches a plateau, and BRET50, i.e., the concentration of acceptor
giving 50% of BRETmax, can be extrapolated from DSA experi-
ments. While BRETmax is a function of the distance and orienta-
tion between the donor and acceptorwithin their oligomeric com-
plex, BRET50 reflects the relative affinity between the fusion
proteins. As deduced from the BRET50 values, the S34L mutation
did not alter capsid self-interaction, and no significant difference
between the oligomerization profiles of WT and S34L capsid pro-
teins could be observed (BRET50 of WT, 4.99! 1.071; BRET50 of
the S34L mutant, 4.01! 0.67) (Fig. 7A).
We next evaluated the effect of increasing concentrations of
ST-148 onWT and S34L capsid self-interaction under conditions
of BRETmax, i.e., "50-fold excess of YFP-capsid plasmid relative
to the Rluc-capsid plasmid (Fig. 7B). Under these conditions, we
observed a dose-dependent increase of the BRET ratio, first de-
tectable at 156 nMST-148 and reaching a plateau at 1.25#M.This
increase in BRET signal was found only with the WT capsid pro-
tein, whereas the oligomerization status of the S34L capsid ap-
peared unaffected for all tested concentrations, demonstrating the
specificity of the ST-148-mediated enhancement of capsid self-
interaction. These results support the notion that ST-148 directly
affects capsid protein. The correlation between antiviral efficacy
and enhancement of capsid self-interaction argues that increased
capsid oligomerization is responsible for the antiviral activity of
ST-148.
In silico modeling corroborates ST-148-mediated stabiliza-
tionof interdimer capsid interactions.To further understand the
mode of action of ST-148 at the molecular level, we performed
molecular modeling studies of WT and S34L capsid protein by
using protein-protein docking, MD simulations, and small-mol-
ecule docking. These studies were based on the NMR structures
reported byMa et al. (PDB accession no. 1R6R) (12). Since capsid
protein was reported to form stable dimers in solution (10, 12),
they were considered fundamental units; therefore, the formation
of tetramers was simulated. Since we observed the nuclear accu-
mulation of capsid in the presence of ST-148, only tetramers that
did not involve nuclear localization sequences (NLS) (28) at the
interaction surfaces were considered, assuming that otherwise
these NLS were hidden. Likewise, complexes that did not involve
LD-binding domains (12, 45, 46)were preferred, because no effect
on capsid-LD colocalization by ST-148 was detected. Priority was
given to complexes in which the protein-protein interaction sur-
face involved Ser34, as this amino acid residue was altered in the
case of the ST-148-resistant DV mutant (Fig. 8A). The symmetry
of the tetramer was not considered an important element, as cryo-
electron microscopy data revealed that the DV nucleocapsid is
disordered (47, 48, 49).
Two 30-ns MD simulations were performed on the best te-
tramer complex: one on the WT and one on the same structure
containing the S34Lmutation. In accordance with the BRET data,
the two structures behaved similarly, indicating no differences
between the WT and the mutant proteins in the absence of the
inhibitor. In both cases, the tetramer quaternary structure
changed during the first 2 ns (see Videos S1 and S2 in the supple-
mental material) and was stable for the rest of the simulation,
suggesting that the system reaches equilibrium.
By using the energy-minimized tetramer structures of both the
WT and S34L capsid, we next docked ST-148 using a 30-Å grid
centered on the two Ser34 (or Leu34 in case of the mutant) resi-
dues at the dimer-dimer interface and examined the obtained ST-
148 pose for WT and the S34L mutant over a 30-ns MD simula-
tion. Comparable to theMD simulations in the absence of ligands,
a similar change in the quaternary structures of bothWTand S34L
capsid could be observed during the first 2 ns (see Videos S3 and
S4 in the supplemental material), and then the system reached
equilibrium. Figure 8B shows the final MD result structures ob-
tained for the WT protein in absence (left) or in the presence
(right) of ST-148. In the case of theWT capsid, ST-148 bound the
FIG 7 ST-148 increases DV capsid protein self-interaction. (A) Self-interac-
tion kinetics of WT and S43L capsid as determined by BRET. DSA were per-
formed in live 293T cells cotransfectedwith increasing amounts of YFP-tagged
and a constant amount of Rluc-tagged plasmids encoding WT or mutant
(S34L) capsid or NS4A, which served as negative controls. Forty-eight hours
later, energy transfer was induced by the addition of the Renilla luciferase
substrate coelenterazine H. The x axis shows the ratio between the normalized
fluorescence of the acceptor (netYFP) measured before coelenterazine addi-
tion and the luminescence of the donor. BRET50 values (netYFP/Renilla ratio
at which 50%ofmaximal BRET is occurring), which reflect the relative affinity
of the acceptor protein for the donor protein, are given in the top right of the
panel. Curves represent the means! standard deviations of results from one
representative experiment carried out in triplicate. The curves were fitted us-
ing a nonlinear regression equation inwhich a single binding site was assumed.
(B) Effect of ST-148 on capsid self interaction. 293T cells were transfected with
1 #g of YFP capsid and 20 ng of Rluc capsid (WT and S34L). Prior to trans-
fection, different concentrations of ST-148 or DMSO were added to the me-
dium, and 48 h later BRET was measured (***, P$ 0.001; *, P$ 0.01).
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FIG 8 Docking model of ST-148 and DV capsid and possible stabilization of interdimer capsid protein interaction. (A) Sequence comparison of capsid amino
acid sequences of DV serotypes 1 to 4 and selected flaviviruses. The position of serine 34 is highlighted in red. Sequence alignment was carried out using the
ClustalW algorithm, available at the Uniprot webserver, on the following isolates: DV-2 (Thailand/16681-PDK53), DV-1 (Brazil/97-11/1997), DV-3 (Martin-
ique/1243/1999), DV-4 (Thailand/0348/1991), West-Nile virus (WNV; H442), yellow fever virus (YFV; Ivory Coast/1999), Japanese encephalitis virus (JEV;
SA-14), Kunjin virus (KUNV; MRM61C), and St. Louis encephalitis virus (SLEV; MS1-7). UniprotKB accession numbers are given in Materials and Methods.
(B) Results from molecular dynamics (MD) simulations. Stable conformations of the WT capsid tetramer in the absence (left) or presence (right) of ST-148.
Capsid dimers are represented in blue and orange, with each monomer given in different shades of the same color. ST-148 is shown with green sticks, and the
serine residue at position 34 is represented with the Corey-Pauling-Koltun (CPK)model. Movies of theMD simulations are given in the supplemental material.
(C) Results of superimposition of theMD simulation of theWTC tetramer in the absence (red ribbon) or presence (blue ribbon) of ST-148 are presented at the
left. ST-148 is shown in greenwith the CPKmodel. A closer view of the same superimposition is presented in the right panel with the same color code. The dashed
arrows indicate the structural rearrangements, which occur at!2 and !3 helices upon ST-148 binding and allow accommodating the ligand. (D and E) Close-up
view of the docking pose of ST-148. (D)WT capsid dimer-dimer interface complexed with ST-148. (E) Same interface as that shown in panel D, with the serine
residue superimposed on Leu34. The dashed circle highlights the steric hindrance induced by the leucine residue at position 34, clarifying how the mutation
impedes this binding pose. In both panels one dimer is depicted in light blue, while the other capsid dimer is in red in the case of theWT or in yellow in the case
of the S34L resistance mutant. Protein residues are displayed as lines, while Ser34 and Leu34 are drawn with stick representations.
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complex in a cleft between the !1 helix of one dimer and !1 and
!3 helices of the other dimer and remained stable at this site for
the last 10 ns of the simulation (see Video S5 in the supplemental
material). It is worth noting that ST-148 induced a shift of the !3
and !2 helices (Fig. 8C, dashed arrows), creating the ligand cleft
and stabilizing further compound binding. Conversely, in the case
of the S34L mutant protein, the compound did not bind a cleft at
the dimer-dimer interface but explored more than one site in a
solvent-exposed area of one dimer (see Video S6 in the supple-
mental material).
To confirm this difference in ligand binding between the two
structures, we used the stableWT tetramer-ligand complex corre-
sponding to the equilibrium state and docked ST-148 into the
pocket identified during the MD by using a 20-Å grid (Fig. 8D).
This docking confirmed that ST-148 is able to bind the tetramer at
the dimer-dimer interface, and the same compound conforma-
tion obtained from theMDwas reproduced. In the case of theWT
structure, the binding site is formed primarily by residues Val26,
Leu29, Arg41, and Arg68 of one dimer and Ser34 of the other
dimer. As shown in Fig. 8D, the phenyl moiety of ST-148 binds
Phe33 with a "-" stacking interaction, while the thieno[2,3-b]
pyridine portion of ST-148 is tethered between Ser34 and Arg68,
where the positive charge interacts with the electron-dense aro-
matic system. Furthermore, as ST-148 is highly lipophilic, its
binding is enhanced by the large number of hydrophobic residues
forming the pocket. As the compound is in close contact with
Ser34, a leucine residue at this site creates a steric clash between the
protein and the ligand (Fig. 8E), confirming that the S34L resis-
tance mutation does not allow ST-148 to bind to the tetramer in
the same way, consistent with the MD simulations. In summary,
these results support the notion that ST-148 stabilizes capsid oli-
gomerization and reveal a plausiblemodel for compound binding
to the capsid protein as well as binding inhibition by a distinct
resistance mutation.
DISCUSSION
Capsid proteins of enveloped viruses have emerged as promising
targets for the design of antiviral agents. In fact, the processes
regulating both viral genome encapsidation and release during
entry proved extremely sensitive to even subtle molecular distur-
bances (reviewed in reference 50). In this study, we describe the
mechanism of action of ST-148, a recently identified small-mole-
cule inhibitor that binds to and induces resistance in DV capsid
(13). By using a combination of full-length reporter viruses and
DVTCP, we identified two distinct inhibitory effects: impaired DV
entry and reduced production of infectious virus particles. Based
on BRET assays, in silico docking, and MD simulations, we pro-
pose that these antiviral effects are the result of stabilized capsid
self-interaction.
With respect to inhibition of virus entry, the lack of virucidal
effects and the observed specific inhibitory effects of ST-148 on
virus entry up to 30minpostinfection point toward a block in viral
RNA uncoating. Although no detailed kinetics of nucleocapsid
disassembly have been reported to date, earlier studies suggested
that DV is internalized within 30 min after inoculation (51, 52).
While our data do not demonstrate inhibition of the uncoating
process, the observed increase of capsid self-interactionmakes this
assumption plausible. Nevertheless, additional experiments are
required to directly demonstrate that viral RNA release is blocked
at the nucleocapsid disassembly/RNA uncoating step.
In addition to impaired entry, ST-148 also reduced virus pro-
duction. This might occur at the level of particle assembly or their
release, but likely it is not due to alteration of specific infectivity of
DV particles, as suggested by the concomitant reduction in both
the released infectivity and the secreted viral RNA. Consistent
with this result, we note that in spite of the overall reduction of
electron-dense virus particles found within DV-infected cells
upon ST-148 treatment, particlemorphology appeared unaltered.
Interestingly, these particles accumulated in larger numbers
within ER stacks. Whether this phenomenon is a consequence of
altered nucleocapsid assembly or results from disturbed intracel-
lular transport of assembled virions remains to be determined. In
any case, the observed redistribution of capsid from the cytosol to
the nucleoli in ST-148-treated cells might contribute to the inter-
ference with virus production by reducing the amount of capsid
protein available for assembly. Although lower cytoplasmic capsid
levels also were observed for the DVS34L mutant, its ability to traf-
fic in and out of the nucleus likely is not compromised or is suffi-
cient to support virion morphogenesis. Conversely, in the case of
the WT capsid, the ST-148-induced nuclear retention correlated
with an alteration of the protein (or protein complex) solubility,
which might account for the observed reduction in virus produc-
tion.
The proposed mechanism of action for both the early- and
late-stage inhibition of ST-148 involves a direct effect on higher-
order structures of DV capsid. This assumption is supported by
the significant and dose-dependent increase in capsid self-inter-
action observed by BRET. Since we used conditions of BRETmax,
our results suggest that the compound induces the formation of
higher-order oligomeric capsid species or stabilizes further preex-
isting capsid dimers. This effect was specific for the WT capsid
protein and not due to pleiotropic effects caused by the com-
pound, because the interaction profile of the ST-148-resistant
mutant was unaltered.
By using MD, we generated a model of a capsid tetramer in
complex with ST-148. Obtained results confirmed that ST-148
stabilizes capsid self-interaction. Thus, ST-148 can be classified as
a direct protein-protein interaction (PPI) stabilizer, establishing
hydrophobic and electrostatic interactions in a cleft between the
capsid dimers. As shown by our MD simulations, ST-148 retains
the ability to bind the S34L-containing tetramer but in a less stable
conformation and involving only one dimer. Therefore, molecu-
lar modeling data are in agreement with the previously observed
binding of ST-148 to both theWTand the S34L-containing capsid
protein (13). Furthermore, our in silico results clarify the role of
S34L mutation in drug resistance, as the steric hindrance of leu-
cine at position 34 impedes the stable binding of the compound to
the tetrameric capsid protein complex.
Drug-induced modulation of capsid protein self-interactions
is not unique to DV and has been described as an applicable strat-
egy for several other enveloped viruses. For instance, in the case of
hepatitis B virus (HBV), several inhibitors targeting the core pro-
tein have been reported, and at least two classes of HBV assembly
effectors, the heteroaryldihydropyrimidines (HAPs) and phenyl-
propenamides, have been extensively characterized (53, 54, 55,
56). For the HAPs, elegant work from Zlotnick and colleagues
demonstrated that these compounds can increase the kinetics of
assembly and strengthen dimer-dimer association to stabilize cap-
sids (57, 58). Comparable to HAPs, certain phenylpropenamides
accelerate assembly and stabilize capsids, and some of these com-
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pounds, such as AT-130, were shown to block viral RNA packag-
ing without altering the geometry of nucleocapsids; they still
formed, but they were devoid of nucleic acids (59, 60). Interest-
ingly, molecules belonging to either class were shown to bind to
partially overlapping sites of the HBV core protein.
In the case of HIV, different series of capsid inhibitors have
been identified. For instance, the benzodiazepine (BD) and the
benzimidazole (BM) series were reported to inhibit virion release
or prevent virus maturation, respectively (61, 62). In the case of
the BD series, molecular studies, complemented by nuclear mag-
netic resonance and crystallography approaches, have shown that
compounds from this class inhibited HIV particle release by
blocking assembly of immature capsids (63). Conversely, mole-
cules of the BM series did not affect virus budding but prevented
capsid maturation. Similar to HBV, these two compound series
induced different biological phenotypes, although they both
shared the same binding site within the N-terminal domain of the
HIV capsid protein (64).
We note that Blair and colleagues characterized another series
of HIV-1 capsid-targeting compounds interfering with both viral
uncoating and formation of infectious particles (65). Similar to
those of ST-148, these effects appeared to be mediated by the
direct binding of the compound toHIV-1 capsid protein, increas-
ing the rate of capsid proteinmultimerization. Similar to the study
of Blair et al., a recent study reported the identification of a novel
class of HIV-1 capsid inhibitors accelerating HIV capsid-nucleo-
capsid assembly and stabilizing preassembled capsid-nucleocap-
sid tubes against dissociation (66). These reports strengthen the
concept of potent inhibition of viral replication via stabilization of
the viral capsid.
Comparable to what has been reported for the anti-HBV
HAPs, we hypothesize that the late-stage inhibitory effect of ST-
148 on DV results from the stabilization of capsid protein inter-
dimer association, which might reduce capsid plasticity and its
ability to package viral RNA. Additionally, ST-148 seems to share
selected features with the anti-HIV pyrrolopyrazolones, exerting
antiviral activity on the early steps of the viral replication cycle,
presumably by stabilizing preexisting capsid quaternary struc-
tures. However, the mechanism by which these HIV inhibitors
stabilize capsid complexes is uncertain, because the inhibitor
binding site does not reside within an inter- or intrahexameric
capsid interface stabilizing the capsid lattice, while in case of ST-
148, the putative binding site was identified between two DV cap-
sid dimers.
A growing list of studies supports the notion that the multi-
functional role of viral capsid protein, involving different protein
conformations and interactions with different protein surfaces
and host factors, represents a target that can be exploited for the
development of potent inhibitors. Our work supports this hy-
pothesis and argues that inhibitors targeting viral capsid proteins
also are applicable to flaviviruses. Given the lack of approved DV-
specific antiviral drugs, this target should be further investigated,
ideally to design combination therapies with a high genetic resis-
tance barrier.
In conclusion, we determined the mode of action of a DV cap-
sid inhibitor that affects both entry and assembly/release of infec-
tious virus particles. The antiviral effect appears to bemediated by
enhanced capsid protein interaction, eventually inducing struc-
tural rigidity and/or steric hindrance during nucleocapsid forma-
tion. These results, together with the first description of a robust
BRET-based assay to measure capsid self-interaction in live cells,
might serve as a starting point for optimization of more effective
therapeutics simultaneously targeting early and late stages of the
DV life cycle.
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A novel radiochemical approach to 1-(2’-
deoxy-2’-[18F]ﬂuoro-β-D-arabinofuranosyl)
cytosine (18F-FAC)†
Jan-Philip Meyer,a,b Katrin C. Probst,b Iuni M. L. Trist,a
Christopher McGuigan,a and Andrew D. Westwella*
18F-FAC (1-(2’-deoxy-2’-[18F]ﬂuoro-β-D-arabinofuranosyl)-cytosine) is an important 2’-ﬂuoro-nucleoside-based positron
emission tomography (PET) tracer that has been used for in vivo prediction of response to the widely used cancer
chemotherapy drug gemcitabine. Previously reported synthetic routes to 18F-FAC have relied on early introduction of the
18F radiolabel prior to attachment to protected cytosine base. Considering the 18F radiochemical half-life (110min) and
the technical challenges of multi-step syntheses on PET radiochemistry modular systems, late-stage radioﬂuorination is
preferred for reproducible and reliable radiosynthesis with in vivo applications. Herein, we report the ﬁrst late-stage
radiosynthesis of 18F-FAC. Cytidine derivatives with leaving groups at the 2’-position are particularly prone to undergo
anhydro side-product formation upon heating because of their electron density at the 2-carbonyl pyrimidone oxygen. Our
rationally developed ﬂuorination precursor showed an improved reactivity-to-stability ratio at elevated temperatures.
18F-FAC was obtained in radiochemical yields of 4.3–5.5% (n= 8, decay-corrected from end of bombardment), with
purities ≥98% and speciﬁc activities ≥63GBq/μmol. The synthesis time was 168min.
Keywords: nucleosides; positron emission tomography; radiochemistry; radiopharmaceuticals; computational chemistry
Introduction
Nucleoside derivatives represent an important emerging class
of biomarkers for positron emission tomography (PET)
imaging.1 For example, the clinically approved proliferation
biomarker 18F-FLT (3’-deoxy-3’-[18F]ﬂuoro-L-thymidine) is
accessible via an effective radiochemical synthesis in high
radiochemical yield and purity suitable for human production
under Good Manufacturing Practice guidelines.2 Hence,
18F-FLT is now commonly used for the early detection of
various cancers and the evaluation of treatment response.3
Especially in high-grade tumours, it appears to be more
powerful in predicting treatment response and survival than
18F-FDG, as measured by standard uptake values of 18F-FLT
directly corresponding to cell proliferation shown by the
Ki-67 proliferation index.4
Cytidine-based radiotracers for PET imaging such as 18F-FAC
(1, Figure 1) and 1-(2’-deoxy-2’-[18F]ﬂuoroarabinofuranosyl)-
5-methylcytosine (18F-FMAC, 2, Figure 1) have been previously
shown to be successful as predictors of response for
nucleoside analogue-based treatment of cancer5,6 as well as
local immune activation in mouse models.7 As such, 18F-FAC
has been used for response prediction to the widely used
chemotherapy drug gemcitabine.5 Gemcitabine is frequently
used for (combination) chemotherapy of a number of solid
tumours such as pancreatic, non-small cell lung, breast
and bladder cancer. Importantly, gemcitabine efﬁcacy is
compromised by poor cellular uptake by nucleoside
transporters, variable activity of the essential deoxycytidine
kinase (dCK) activating enzyme and rapid deactivating
metabolism by cytidine deaminase (CDA). In addition, serious
dose-limiting toxicities are associated with this chemotherapy
drug.8 Prediction of patient response to gemcitabine
chemotherapy would therefore be an important milestone
towards personalized patient chemotherapy in the cancer clinic.
Given the close structural resemblance to gemcitabine,
18F-FAC was found to have a comparably high afﬁnity for
deoxycytidine kinase (dCK), a rate-limiting enzyme in the
nucleoside salvage pathway. Hence, in vivo imaging
determined dCK-positive and dCK-negative tumours.
Furthermore, an additional study showed that 18F-FMAC PET
imaging provides information about cytidine deaminase
(CDA) enzymatic activity in vivo, which is related to
gemcitabine resistance.6 Together, cytidine-based PET
probes enable further conclusions towards personalized
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chemotherapy that, considering the low (≤20%) response
rates and severe side effects, could lead to signiﬁcantly
improved treatment efﬁcacy.8
2’-[18F]arabinocytidines such as 18F-FAC and 18F-FIAC
(3, Figure 1) have been synthesized in high purities using
an early stage 18F introduction strategy.9 However, this
synthetic approach limits reliable and reproducible
production on commercially available synthesis modules for
human application.10 For instance, multiple steps after 18F
introduction with an additional puriﬁcation step due to the
formation of the D- and L-isomers, as well as the use of toxic
substances such as hydrogen bromide, make the translation
to automated synthesizers difﬁcult. These challenges go hand
in hand with reproducibility issues when it comes to quality
control in clinical practice according to the British/European/
American Pharmacopeia. Furthermore, as the number and
space in hot cells is limited, multiple-step radiosyntheses
should preferably be replaced by shorter and less complex
synthetic procedures. Lazari et al. recently presented a newly
designed radiosynthesis module system that furnished the
nucleoside analogues 18F-FMAU and 18F-FAC in good overall
radiochemical yields (46% and 31%, respectively, decay-
corrected) and with acceptable reproducibility following early
stage ﬂuoride introduction.11 Overall synthesis times were
reported to be 165–170min in each case. The ﬂexible
radiosynthesizers developed are described as being suitable
for both the development and production of different
radiotracers for applications in PET.
The aim of this study was to develop a novel and
straightforward synthetic approach towards 18F-FAC that
could be applied to the radiosynthesis of related cytidine-
based radiotracers. A more straightforward radiosynthesis
similar to the 18F-FDG synthesis in combination with
innovative radiosynthesizers would enable a faster transition
from tracer development to clinical application. Late-stage
18F-introduction at the 2’-arabino position of an intact
nucleoside towards nucleoside-based radiotracers was
previously considered as difﬁcult.12 However, Alauddin and
co-workers recently developed a novel radiosynthesis of the
uridine analogue 18F-FMAU based on a late-stage
18F-introduction approach in order to increase possibilities
for making nucleoside-based PET tracer suitable for clinical
applications.10,12 The key towards a stable precursor that
would be less likely to undergo anhydro side-product
formation (e.g. Scheme 1) due to neighbouring group
participation was the introduction of a good electron-
withdrawing N-protecting group(s). Because the amino group
at the 4-position of cytidine derivatives likely enhances the
nucleophilicity of the 2-carbonyl oxygen, potential precursor
molecules containing a leaving group at the 2’-position are
even more prone to undergo anhydro formation especially
at high temperatures (≥75 °C). Thus, a reasonable
radioﬂuorination precursor must combine sufﬁcient reactivity
with stability towards heat as well as basic conditions. In this
study, we present for the ﬁrst time a late-stage
radioﬂuorination approach to the 18F-labelled cytidine
derivative 18F-FAC.
Experimental section
Radiosynthetic procedures
N4-bis-Boc-3’,5’-O-bis-tetrahydropyranyl-2’-deoxy-2’-[18F]
ﬂuoroarabinocytidine (25)
[18F]ﬂuoride was trapped on a QMA cartridge (equilibrated with 5%
NaHCO3 solution (5mL) and water (5mL)) before it was eluted with
an aqueous solution (0.7mL) of KHCO3 (22.6mg/mL) and kryptoﬁx
K222 (22.6mg/mL) in MeCN. The resulting
18F/KHCO3/K222-complex
was dried by co-evaporation under reduced pressure and a stream
of nitrogen. The drying process was repeated three times (3× 1mL
MeCN). A solution of precursor (23) (10mg, 14.5 μmol) in DMF
(0.3mL) was then added, and the resulting mixture was stirred at
110 °C for 20min. The crude mixture was either analysed directly
for determination of 18F-incorporation (radio-TLC) or passed through
an Alumina-Sep-Pak cartridge (equilibrated with water (5mL)) for
characterization (radio-HPLC). The 18F-labelled intermediate was
eluted with EtOAc (2mL), and an aliquot (0.2mL) of the mixture
was analysed by analytical HPLC using co-elution with the non-
radioactive reference compound (24). Rt = 17.2min, MeCN/H2O 9:1,
1mL/min, ≥87%, radio-TLC, Rf = 0.6 (4% MeOH/DCM).
18F-FAC (1)
After elution of the 18F-labelled intermediate (25) with EtOAc into a
new reaction V-vial, the solvent was removed under reduced
pressure and a stream of nitrogen at 80 °C. 2N HCl solution (0.3mL)
was added to the dried residue followed by stirring at 90 °C for
15min. The solution was then neutralized with 2N NaOH solution
(0.3mL). The resulting mixture was loaded onto a semi-preparative
HPLC column via a 10-mL injection loop. The fraction containing
18F-FAC was collected after 22.5min with 3% MeCN in H2O and a
ﬂow rate of 3.5mL/min. The appropriate fraction was ﬂushed through
a sterile ﬁlter and concentrated via evaporation on the module (100 °
C under a stream of nitrogen for 10min). The residue was taken up
in sterile saline. An aliquot (0.2mL) of the mixture was analysed by
analytical HPLC using co-elution with the non-radioactive reference
compound 27, Rt = 13.8min, 3% MeCN/H2O, 1mL/min, ≥98%. A
carrier-added synthesis was performed according to the previous
procedure, and the product 19F/18F-FAC was saved for decay for 20
half-lives (≈2 days) and subsequently analysed by mass spectrometry;
MS (70 eV): m/z (%): 245.4 (5) [(M +H)+], 267.7 (95) [(M +Na)+].
Scheme 1. Heat-mediated intramolecular cyclization towards 12 in d6-DMSO.Figure 1. Chemical structures of the cytidine-based biomarkers 18F-FAC, 18F-
FMAC and 18F-FIAC (1–3), and the anticancer drug gemcitabine.
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Computational methods
MOE 2010.10 software was used to design each compound and to
explore possible conformations. The searching method applied was
LowModMD that generates conformations using a short run of
molecular dynamics at constant temperature followed by an all-atom
energy minimization. Amongst the conformations, 16 of them
were selected for each compound for quantum mechanics (QM)
evaluation. QM calculations were executed for the selected
conformations with the GAMESS13 software. A geometry optimization
was performed in vacuo, using analytical energy gradients with the
restricted Hartree–Fock wave function. The 3-21G split valence basis
set was used, and diffuse sp shell was added to heavy atoms. The
initial hessian was guessed, and the convergence gradient tolerance
was set to 0.0005 Eh/bohr. The electrostatic potential was calculated
at points determined by Michael Connolly algorithm on the
surface of van der Waals fused spheres. Atomic charges were
consequently ﬁtted to this potential. The partial net charges of atoms
of interest were gathered from each molecule conformation, and
values were averaged.
Results and discussion
Precursor design
In order to develop a new precursor for radioﬂuorination of
the 2’-arabino position of cytidine derivatives, the idea of
radioﬂuorination of an intact nucleoside moiety was applied.
The main challenge of this new approach is the rational
design of precursors that combine reactivity and stability in
a way that the 18F-nucleophile can be incorporated at high
temperatures resulting in acceptable conversion rates whilst
heat-mediated anhydro formation is kept to a minimum. A
quantitative method for the characterization of precursor
stabilities was desirable prior to synthesis. The electric charge
density of the 2-carbonyl oxygen of the pyrimidone moiety
was determined using theoretical methods for the potential
to undergo an intramolecular nucleophilic attack at the
2’-position. Hence, the net electric charge of the 2-carbonyl
oxygen of a family containing N4-substituted cytidine
derivatives (4–8, Figure 2) was calculated using quantum
chemical calculations with restricted Hartree–Fock wave
function and the 3-21G basis set.
Additionally, selected uridine derivatives (9–11, Figure 2)
were included in this study, in order to obtain both a
reference value as well as a measurement of how the
substitution of the 4-carbonyl group (uridines) by an amino
group (cytidines) impacts the electric charge density at the
2-carbonyl oxygen. The N-substituents were chosen with
regard to both their synthetic accessibility and deprotection
mechanisms that would be suitable for radiochemical
syntheses in terms of subsequent efﬁcient removal. The
N3-nitro-2’-(methanesulfonyl)uridine (11) was considered as a
standard value as a N3-nitro-2’-(triﬂuoromethanesulfonyl)
uridine derivative was previously reported as
successfully synthesized and thermal stable.14 However, the
radioﬂuorination method could not be applied to a
N3-nitro-uridine-based precursor.
The results shown later (Table 1) indicate that the electron
density at the 2-carbonyl oxygen is reduced when
H-substitution at the N4 (N3 for uridine derivatives) with an
electron-withdrawing group is performed. Furthermore, it
shows that the stronger the electron-withdrawing effect of
the substituent(s), the lower the calculated electron density
Ω at the 2-carbonyl oxygen. For instance, double N4-Boc-
protection (7) decreases the electron density more than
single N4-Boc-protection (6) and N4-monoacetylation (5),
respectively.
Compounds 5 and 7 were synthesized (see Synthesis
section and Supporting information) and subsequently tested
for their ability to undergo heat-mediated decomposition by
forming the appropriate anhydro compounds 12 and 13.
First, an NMR sample of compound 5 in d6-DMSO was heated
up to 50 °C. 1H-NMR spectra were recorded hourly. Figure 3
shows that almost full conversion to anhydro compound 12
occurred after 2 h (Scheme 1).
Chemical shifts of the amino proton (11.5 to 12.25 ppm)
and the ribose protons clearly show the conversion into the
cyclic nucleoside compound (Figure 3). Furthermore, the
vanishing signal of the mesyl group at 3.5 ppm also indicates
decomposition as the free mesylate is expected to have a
different chemical shift that indeed could be observed at
around 2.3 ppm next to the methyl-signal of the acetamide.
13C-NMR data after 1-h incubation showed 24 instead of 12
signals of pure compound 5. Additionally, ESI-MS was
performed in order to show the change in the molecular
mass. The m/z-signal 268 [M+H]+ further conﬁrmed
generation of anhydro compound 12.
The double N4-Boc-protected compound (7), however,
showed signiﬁcantly increased thermal stability as shown in
Scheme 2 and Figure 4. Even though a tiny set of additional
Figure 2. Selected cytidine-based and uridine-based nucleosides for electric
charge density calculations at 2-carbonyl oxygen.
Table 1. Calculated electron density Ω of selected cytidine
(4–8) and uridine derivatives (9–11)
No. R1 R2 R3 [Ω±%]a
4 H H !0.911 ± 0.09
5 H Ac !0.901 ± 0.05
6 H Boc !0.860 ± 0.01
7 Boc Boc !0.825 ± 0.06
8 Phthalimide Phthalimide !0.814 ± 0.08
9 H !0.838 ± 0.02
10 Boc !0.770 ± 0.03
11 NO2 !0.589 ± 0.10
aQuantum chemically calculated net charge at the 2-carbonyl
oxygen.
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peaks appeared after 2 h at 80 °C, the observed stability of
compound 7 looked promising with regard to 18F-radiolabelling
reactions.
Hence, the calculated and experimental data lead to three
major conclusions: (1.) The electron density at the 2-carbonyl
oxygen of the pyrimidine moiety can be used as a measurement
for its ability to undergo intramolecular cyclization resulting
in the appropriate 2,2’-anhydro compounds. (2.) Electron-
withdrawing groups have a measurable/quantiﬁable effect on
the electron density at the 2-carbonyl oxygen. (3.) Depending on
the strength of its electron-withdrawing nature, a N4(N3)-protecting
Figure 3. Heat-mediated anhydro formation of 12. After only 2 h at 50 °C, nearly full conversion could be observed by 1H NMR analysis.
Scheme 2. Increased thermal stability of 7. No signiﬁcant formation of side
product (13) could be observed (in d4-MeOD).
Figure 4. Recorded 1H-NMR spectra of puriﬁed compound (7) after 0, 60 and 120min at 80 °C. The absence of additional peaks indicate no or minimal anhydro formation
through increased thermal stability.
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group inﬂuences the thermal stability of the nucleoside
analogue. Finally, an N,N-diBoc ﬂuorination precursor was
selected for radioﬂuorination studies.
Synthesis
The synthesis of test compound 5 was carried out with the
selective 3’- and 5’-protection of N-acetylcytidine (14) using
TIPDSCl2 in pyridine yielding compound 15 in good yield,
which was consecutively mesylated at the 2’-position using
an excess of MsCl and TEA in DCM furnishing compound
16. Subsequent removal of the silica-based protecting group
using TBAF in anhydrous THF at low temperatures gave test
compound 5 that was puriﬁed immediately and characterized
because of its high ability to undergo anhydro formation
(Scheme 3).
The synthesis of precursor (23) started with commercially
available cytidine (17), which was ﬁrst converted into the
3’- and 5’-protected nucleoside 18 using TIPDSCl2 and
pyridine at room temperature as previously described.8
Subsequent TMS-protection furnished 19 that was followed
by double N4-Boc-protection using excess of Boc2O (5–6 eq.)
and DMAP that gave compound 20 in good yield. Selective
removal of the TMS-group using p-TsOH was performed at
!5 °C to give intermediate 21. Subsequent mesylation of
the free 2’-hydroxy group was performed in high yield to
form compound 22. TBAF-mediated removal of the
bidentate-protecting group had to be carried out at lower
temperatures (approximately !10 °C) in order to avoid
signiﬁcant decrease in yield probably because of single Boc-
group removal. Puriﬁed compound 7 was then converted into
ﬂuorination precursor 23 using 3,4-dihydro-6H-pyran in
excess. Highly puriﬁed precursor 23 was obtained in 9%
overall yield from 17 (Scheme 4).
The choice of the leaving group as well as the protecting
group is based on a previous study10 that found that 3’/5’-
THP protection of uridine derivatives gave the best
radiochemical yields and a 2’-mesyl group an appropriate
balance between stability and leaving group abilities.
Furthermore, our pilot studies showed that the appropriate
tosyl-containing and nosyl-containing counterparts already
decomposed during puriﬁcation. Furthermore, even though
double THP protection makes NMR analysis complex
(mixture of diastereomers), the later removal of these groups
was straightforward.
Scheme 3. Reagents and conditions: (a) TIPDSCl2, pyridine, 0 °C – room
temperature (RT), 12 h, 87%; (b) MsCl, TEA, DCM, 0 °C – RT, 2 h, 81%; (c) TBAF,
THF, !10 °C, 30min, 53%.
Scheme 4. Reaction conditions: (a) TIPDSCl2, pyridine, 0 °C – RT, 18 h, 81%; (b)
TMSCl, TEA, DCM, 0 °C – RT, 2 h, 83%; (c) Boc2O, DMAP, DCM, RT, 5 h, 77%; (d) p-
TsOH, THF, !5 °C, 66–78%; (e) MsCl, TEA, DCM, 0 °C, 90%; (f) TBAF, THF, !10 °C,
70–80%; and (g) DHP, pTsOH, DCM, 0 °C – RT, 6–8 h, 45–56%.
Scheme 5. Reagents and conditions: (a) 1N TBAF/THF, DMF, 100 °C, 100min, 19%.
Scheme 6. Radioﬂuorination was performed using different reaction conditions
as outlined in the table later.
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Firstly, cold ﬂuorination reactions were carried out to assess
ﬂuoride incorporation for precursor (23). Amongst
ﬂuorination conditions tested, the best incorporation yield
was found at 100 °C for 100min in DMF using freshly
prepared 1N TBAF/THF-solution (Scheme 5). The ﬂuorinated
intermediate (24) was puriﬁed by column chromatography
on SiO2, and its identity and purity (≥97%) conﬁrmed by
1H/19F-NMR, HR-MS and analytical HPLC (Supporting
information). Notably, the 19F-spectrum showed a set of four
signals due to the four diastereomers that the THP protection
yields.
The obtained intermediate 24 was used as a cold reference
standard for co-elution on HPLC in order to identify the hot
intermediate.
Radiosynthesis of 18F-FAC
The 18F-incorporation to form intermediate (25) was carried
out using an Eckert & Ziegler modular system and
appropriate software for radiosynthesis. The reaction
parameters of solvent, temperature and reaction time were
varied in order to determine optimal 18F-incorporation
conditions, using KHCO3 as base (Scheme 6). [
18F]Fluoride
was eluted from the QMA cartridge using a K222/KHCO3
solution. Table 2 shows the calculated incorporation data,
and Figure 5 shows 18F-incorporation plotted against the
reaction temperature run in dry DMF as solvent. The highest
incorporation values were obtained using DMF at 110 °C for
20min. Although MeCN or tBuOH as solvent failed to show
any conversion, the use of an alternative base such as TBA–
OH or TBA–CO3 in MeCN or tBuOH might provide an
alternative strategy. However, higher temperatures and
longer reaction times led to decreased 18F-incorporation in
the arabino position because of the formation of the
anhydro intermediate. 18F-incorporation was calculated by
peak integration of the crude reaction mixture after
radioﬂuorination using radio-TLC (Supporting information).
The 18F-ﬂuorinated intermediate (25) was conﬁrmed by
radio-HPLC (Figure 6) and co-injection of the 19F-containing
reference standard (24) (Supporting information) after
trapping the majority of the unreacted 18F-ﬂuoride on a
Sep-Pak alumina cartridge. The intermediate was eluted with
2.5mL EtOAc into a new reaction vial.
The solvent was then removed at 90 °C under a stream of
nitrogen. 2N HCl solution was added to the dried residue
(25), which was then stirred at 95 °C for 20min (Scheme 7).
A shorter deprotection time was found to lead to decreased
ﬁnal yields of the product 18F-FAC.
After neutralization with 2N NaOH solution, the mixture
was loaded onto a semi-preparative HPLC column via a
10-mL injection loop. [18F]-FAC was eluted after 22.5min at
a ﬂow rate of 3.5mL/min using 3% MeCN in H2O as the
mobile phase. Following concentration on the module (100 °C
Table 2. [18F]-incorporation results obtained under different
conditions
No. Solvent T [°C] t [min] [18F]a [%]
1 MeCN 90 20 n/a
2 tBuOH 95 20 n/a
3 DMF 90 20 1.3 ± 0.3
4 DMF 95 20 2.6 ± 0.2
5 DMF 100 20 4.9 ± 0.6
6 DMF 105 20 7.7 ± 0.8
7 DMF 110 20 9.4 ± 0.8
8 DMF 110 30 7.9 ± 0.6
9 DMF 115 20 6.9 ± 0.5
10 DMF 120 20 4.1 ± 0.4
11 DMF 125 20 2.3 ± 0.2
12 DMF 130 20 1.8 ± 0.2
a[18F]-incorporation was calculated using radio-TLC. Each
reaction was repeated three times under identical conditions.
Figure 5. [18F]-incorporation plotted against the reaction temperature run in dry
DMF as solvent.
Figure 6. Radio-HPLC was performed in order to conﬁrm the formation of 25. The
ﬂuoridation product was co-eluted with reference compound 24 after 17.2min
(MeCN/H2O 10:1, ﬂow rate of 1mL/min). The proﬁle of the radio-HPLC diagram is
consistent with the radio-TLC diagram shown earlier.
Scheme 7. Subsequent deprotection of the hot intermediate 25 using (a) 2N HCl
at 95 °C for 20min. A shorter deprotection time results in decreased ﬁnal yields of
the product 18F-FAC (1).
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under a stream of nitrogen for 10min), the sample was taken
up in sterile saline, and an aliquot was co-eluted on an
analytical HPLC in combination with both possible
2’-19F-isomers FC (26) and FAC (27) as references (Figures 7
and 8). 18F-FAC was conﬁrmed, and its purity calculated to
≥98% with speciﬁc activity of ≥63GBq/μmol. The total
synthesis time was 168min, including the concentration and
saline formulation time. Finally, 0.75–0.86 GBq of 18F-FAC was
obtained resulting in radiochemical yields of 4.3–5.5% (n = 8,
decay-corrected from end of bombardment).
Additionally, a temperature study was performed to reveal why
the 18F-incorporation decreases when the reaction temperature
is increased. According to the mechanism, intramolecular
anhydro formation is expected at higher temperatures leading
to a lower yield of the correct stereoisomer. Figure 9 shows
radio-HPLC traces that were recorded after radioﬂuorination at
Figure 7. Radio-HPLC chromatogram of the puriﬁed fraction. Co-elution with
both cold 2’-[19F]-isomers 26 and 27 conﬁrms that the correct stereoisomer was
obtained.
Figure 8. Chemical structures of the two different ‘cold’ 2’-ﬂuoro-cytidines FC (26)
and FAC (27).
Figure 9. Radio-HPLC traces recorded after radioﬂuorinations performed at
different reaction temperatures.
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110, 120 and 130 °C (20 and 40min, bottom to top panel
respectively) and co-elution with both 2’-ﬂuoro stereoisomers FC
and FAC (bottom panel). The results show that higher
temperatures do lead to anhydro formation and radioﬂuorination
of the anhydro intermediate results in 18F-FC. The 18F-FAC/FC ratio
decreases as the reaction temperature and time increase.
Conclusions
A novel radiochemical approach to 18F-FAC is described. For the
ﬁrst time, 18F-FAC was synthesized via late-stage
radioﬂuorination of the intact pyrimidine nucleoside. Prior to
synthesis, a novel ﬂuorination precursor was designed using in
silico methods and stability studies monitored by NMR. Precursor
23 was found to be a promising candidate for further testing out
of the family of nucleosides that were investigated.
18F-incorporation studies led to optimal reaction conditions
(110 °C, 20min) that furnished 18F-FAC in 4.3–5.5% decay-
corrected radiochemical yield. Considering that this new process
involves late-stage ﬂuorination and labelling of a cytidine
derivative (more challenging than the equivalent uridine
derivative), our radiochemical yield is good. Our overall synthesis
time (168min) is similar to that reported previously for 18F-FAC.11
Even though early 18F-introduction gives a higher radiochemical
yield, its automation is more difﬁcult and the reliability and
reproducibility is less easy to maintain. In addition, the
radiochemical yield and overall radiosynthesis time of our
methods might be further improvable using other synthesizers;
alternatively, one could obtain the same amount of labelled
nucleoside product by starting with a higher 18F-activity. The
reaction time for the radiolabelling step (20min) is comparable
with that used in the related 18F-FMAU radiosynthesis,12
reﬂective of the similar steric hindrance around the 2’-position
in these nucleoside precursors. Shorter reaction times for this
radiolabelling step were found to lead to lower yields of product
through incomplete reaction.
Furthermore, it was shown that long reaction times and high
reaction temperatures led to intramolecular anhydro formation
identiﬁed by the detection of 18F-FC. This study shows that
rational precursor design can at least minimize the issue of
side-product formation and hence can offer synthetic access of
important PET radiotracer as a single stereoisomer. This
method should be transferable to GMP environments as it offers
a quick and reproducible two-step route towards 18F-FAC
comparable with the radiosynthesis of 18F-FDG. However,
further optimization is required in order to improve the
radiochemical yield and prepare for transfer to production of
clinical grade radiotracer.
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